0000097745-24-000007.txt : 20240222 0000097745-24-000007.hdr.sgml : 20240222 20240222130642 ACCESSION NUMBER: 0000097745-24-000007 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 117 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240222 DATE AS OF CHANGE: 20240222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: THERMO FISHER SCIENTIFIC INC. CENTRAL INDEX KEY: 0000097745 STANDARD INDUSTRIAL CLASSIFICATION: MEASURING & CONTROLLING DEVICES, NEC [3829] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042209186 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-08002 FILM NUMBER: 24663631 BUSINESS ADDRESS: STREET 1: 168 THIRD AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 7816221000 MAIL ADDRESS: STREET 1: 168 THIRD AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: THERMO ELECTRON CORP DATE OF NAME CHANGE: 19920703 10-K 1 tmo-20231231.htm 10-K tmo-20231231
0000097745FALSE2023FYhttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense
Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://thermofisher.com/20231231#RestructuringAndOtherCostsIncomeNet36633636000000977452023-01-012023-12-310000097745us-gaap:CommonStockMember2023-01-012023-12-310000097745tmo:SeniorNotes0.75Due2024Member2023-01-012023-12-310000097745tmo:SeniorNotes0.125Due2025Member2023-01-012023-12-310000097745tmo:SeniorNotes200Due2025Member2023-01-012023-12-310000097745tmo:SeniorNotes3200Due2026Member2023-01-012023-12-310000097745tmo:SeniorNotes1.40Due2026Member2023-01-012023-12-310000097745tmo:A1.45SeniorNotesDue2027Member2023-01-012023-12-310000097745tmo:SeniorNotes175Due2027Member2023-01-012023-12-310000097745tmo:SeniorNotes0.500Due2028Member2023-01-012023-12-310000097745tmo:SeniorNotes1.375Due2028Member2023-01-012023-12-310000097745tmo:SeniorNotes1.95Due2029Member2023-01-012023-12-310000097745tmo:SeniorNotes0.875Due2031Member2023-01-012023-12-310000097745tmo:SeniorNotes2375Due2032Member2023-01-012023-12-310000097745tmo:SeniorNotes3650Due2034Member2023-01-012023-12-310000097745tmo:SeniorNotes2.875Due2037Member2023-01-012023-12-310000097745tmo:SeniorNotes1.500Due2039Member2023-01-012023-12-310000097745tmo:SeniorNotes1.875Due2049Member2023-01-012023-12-3100000977452023-06-30iso4217:USD00000977452024-02-03xbrli:shares00000977452023-12-3100000977452022-12-31iso4217:USDxbrli:shares0000097745us-gaap:ProductMember2023-01-012023-12-310000097745us-gaap:ProductMember2022-01-012022-12-310000097745us-gaap:ProductMember2021-01-012021-12-310000097745us-gaap:ServiceMember2023-01-012023-12-310000097745us-gaap:ServiceMember2022-01-012022-12-310000097745us-gaap:ServiceMember2021-01-012021-12-3100000977452022-01-012022-12-3100000977452021-01-012021-12-3100000977452021-12-3100000977452020-12-310000097745us-gaap:CommonStockMember2020-12-310000097745us-gaap:AdditionalPaidInCapitalMember2020-12-310000097745us-gaap:RetainedEarningsMember2020-12-310000097745us-gaap:TreasuryStockCommonMember2020-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000097745us-gaap:ParentMember2020-12-310000097745us-gaap:NoncontrollingInterestMember2020-12-310000097745us-gaap:CommonStockMember2021-01-012021-12-310000097745us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000097745us-gaap:TreasuryStockCommonMember2021-01-012021-12-310000097745us-gaap:ParentMember2021-01-012021-12-310000097745us-gaap:RetainedEarningsMember2021-01-012021-12-310000097745us-gaap:NoncontrollingInterestMember2021-01-012021-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310000097745us-gaap:CommonStockMember2021-12-310000097745us-gaap:AdditionalPaidInCapitalMember2021-12-310000097745us-gaap:RetainedEarningsMember2021-12-310000097745us-gaap:TreasuryStockCommonMember2021-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000097745us-gaap:ParentMember2021-12-310000097745us-gaap:NoncontrollingInterestMember2021-12-310000097745us-gaap:CommonStockMember2022-01-012022-12-310000097745us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000097745us-gaap:TreasuryStockCommonMember2022-01-012022-12-310000097745us-gaap:ParentMember2022-01-012022-12-310000097745us-gaap:RetainedEarningsMember2022-01-012022-12-310000097745us-gaap:NoncontrollingInterestMember2022-01-012022-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000097745us-gaap:CommonStockMember2022-12-310000097745us-gaap:AdditionalPaidInCapitalMember2022-12-310000097745us-gaap:RetainedEarningsMember2022-12-310000097745us-gaap:TreasuryStockCommonMember2022-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000097745us-gaap:ParentMember2022-12-310000097745us-gaap:NoncontrollingInterestMember2022-12-310000097745us-gaap:CommonStockMember2023-01-012023-12-310000097745us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310000097745us-gaap:TreasuryStockCommonMember2023-01-012023-12-310000097745us-gaap:ParentMember2023-01-012023-12-310000097745us-gaap:RetainedEarningsMember2023-01-012023-12-310000097745us-gaap:NoncontrollingInterestMember2023-01-012023-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000097745us-gaap:CommonStockMember2023-12-310000097745us-gaap:AdditionalPaidInCapitalMember2023-12-310000097745us-gaap:RetainedEarningsMember2023-12-310000097745us-gaap:TreasuryStockCommonMember2023-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000097745us-gaap:ParentMember2023-12-310000097745us-gaap:NoncontrollingInterestMember2023-12-310000097745tmo:PPDSNBLKKMember2023-12-31xbrli:pure0000097745us-gaap:ChangeInAccountingPrincipleOtherMember2021-09-300000097745us-gaap:ProductMemberus-gaap:ChangeInAccountingPrincipleOtherMember2021-07-042021-10-020000097745us-gaap:ChangeInAccountingPrincipleOtherMember2021-10-020000097745tmo:LaboratoryProductsandServicesMemberus-gaap:ChangeInAccountingPrincipleOtherMember2021-10-020000097745tmo:LaboratoryProductsandServicesMemberus-gaap:ProductMemberus-gaap:ChangeInAccountingPrincipleOtherMember2021-07-042021-10-020000097745us-gaap:ProductMemberus-gaap:ChangeInAccountingPrincipleOtherMembertmo:SpecialtyDiagnosticsMember2021-07-042021-10-020000097745us-gaap:ChangeInAccountingPrincipleOtherMembertmo:SpecialtyDiagnosticsMember2021-10-020000097745srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2023-12-310000097745us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2023-12-310000097745srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2023-12-310000097745us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2023-12-310000097745us-gaap:LandMember2023-12-310000097745us-gaap:LandMember2022-12-310000097745us-gaap:BuildingAndBuildingImprovementsMember2023-12-310000097745us-gaap:BuildingAndBuildingImprovementsMember2022-12-310000097745us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember2023-12-310000097745us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember2022-12-310000097745us-gaap:ConstructionInProgressMember2023-12-310000097745us-gaap:ConstructionInProgressMember2022-12-310000097745srt:MaximumMember2023-12-310000097745us-gaap:CustomerRelationshipsMember2023-12-310000097745us-gaap:CustomerRelationshipsMember2022-12-310000097745us-gaap:DevelopedTechnologyRightsMember2023-12-310000097745us-gaap:DevelopedTechnologyRightsMember2022-12-310000097745us-gaap:TradeNamesMember2023-12-310000097745us-gaap:TradeNamesMember2022-12-310000097745us-gaap:OrderOrProductionBacklogMember2023-12-310000097745us-gaap:OrderOrProductionBacklogMember2022-12-310000097745us-gaap:TradeNamesMember2023-12-310000097745us-gaap:TradeNamesMember2022-12-310000097745tmo:LifeSciencesSolutionsMember2021-12-310000097745tmo:AnalyticalInstrumentsMember2021-12-310000097745tmo:SpecialtyDiagnosticsMember2021-12-310000097745tmo:LaboratoryProductsandServicesMember2021-12-310000097745tmo:LifeSciencesSolutionsMember2022-01-012022-12-310000097745tmo:AnalyticalInstrumentsMember2022-01-012022-12-310000097745tmo:SpecialtyDiagnosticsMember2022-01-012022-12-310000097745tmo:LaboratoryProductsandServicesMember2022-01-012022-12-310000097745tmo:LifeSciencesSolutionsMember2022-12-310000097745tmo:AnalyticalInstrumentsMember2022-12-310000097745tmo:SpecialtyDiagnosticsMember2022-12-310000097745tmo:LaboratoryProductsandServicesMember2022-12-310000097745tmo:LifeSciencesSolutionsMember2023-01-012023-12-310000097745tmo:AnalyticalInstrumentsMember2023-01-012023-12-310000097745tmo:SpecialtyDiagnosticsMember2023-01-012023-12-310000097745tmo:LaboratoryProductsandServicesMember2023-01-012023-12-310000097745tmo:LifeSciencesSolutionsMember2023-12-310000097745tmo:AnalyticalInstrumentsMember2023-12-310000097745tmo:SpecialtyDiagnosticsMember2023-12-310000097745tmo:LaboratoryProductsandServicesMember2023-12-310000097745tmo:TheBindingSiteGroupMember2023-01-032023-01-030000097745tmo:CorEvitasLLCMember2023-08-142023-08-140000097745us-gaap:CustomerRelationshipsMembertmo:TheBindingSiteGroupMember2023-01-030000097745tmo:CorEvitasLLCMemberus-gaap:CustomerRelationshipsMember2023-08-140000097745us-gaap:TechnologyBasedIntangibleAssetsMembertmo:TheBindingSiteGroupMember2023-01-030000097745us-gaap:TechnologyBasedIntangibleAssetsMembertmo:CorEvitasLLCMember2023-08-140000097745us-gaap:TradeNamesMembertmo:TheBindingSiteGroupMember2023-01-030000097745us-gaap:TradeNamesMembertmo:CorEvitasLLCMember2023-08-140000097745tmo:TheBindingSiteGroupMemberus-gaap:OrderOrProductionBacklogMember2023-01-030000097745tmo:CorEvitasLLCMemberus-gaap:OrderOrProductionBacklogMember2023-08-140000097745tmo:TheBindingSiteGroupMember2023-01-030000097745tmo:CorEvitasLLCMember2023-08-140000097745us-gaap:CustomerRelationshipsMember2023-01-012023-12-310000097745us-gaap:DevelopedTechnologyRightsMember2023-01-012023-12-310000097745us-gaap:TradeNamesMember2023-01-012023-12-310000097745us-gaap:OrderOrProductionBacklogMember2023-01-012023-12-310000097745tmo:OlinkHoldingABMember2023-10-170000097745tmo:OlinkHoldingABMember2023-10-172023-10-170000097745tmo:EuropeanViralVectorManufacturingBusinessMember2021-01-150000097745tmo:MesaBiotechMember2021-02-250000097745tmo:CSLMember2021-09-300000097745tmo:PPDIncMember2021-12-080000097745tmo:PeproTechIncMember2021-12-300000097745tmo:PPDIncMember2021-12-082021-12-080000097745tmo:PeproTechIncMember2021-12-302021-12-300000097745tmo:EuropeanViralVectorManufacturingBusinessMember2021-01-152021-01-150000097745tmo:MesaBiotechMember2021-02-252021-02-250000097745tmo:CSLMember2021-09-302021-09-300000097745us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-01-012021-12-310000097745us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-12-310000097745us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-12-310000097745us-gaap:CustomerRelationshipsMembertmo:PPDIncMember2021-12-080000097745us-gaap:CustomerRelationshipsMembertmo:PeproTechIncMember2021-12-300000097745tmo:EuropeanViralVectorManufacturingBusinessMemberus-gaap:CustomerRelationshipsMember2021-01-150000097745us-gaap:CustomerRelationshipsMembertmo:MesaBiotechMember2021-02-250000097745tmo:CSLMemberus-gaap:CustomerRelationshipsMember2021-09-300000097745us-gaap:CustomerRelationshipsMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-12-310000097745tmo:PPDIncMemberus-gaap:DevelopedTechnologyRightsMember2021-12-080000097745tmo:PeproTechIncMemberus-gaap:DevelopedTechnologyRightsMember2021-12-300000097745tmo:EuropeanViralVectorManufacturingBusinessMemberus-gaap:DevelopedTechnologyRightsMember2021-01-150000097745tmo:MesaBiotechMemberus-gaap:DevelopedTechnologyRightsMember2021-02-250000097745tmo:CSLMemberus-gaap:DevelopedTechnologyRightsMember2021-09-300000097745us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:DevelopedTechnologyRightsMember2022-12-310000097745us-gaap:TradeNamesMembertmo:PPDIncMember2021-12-080000097745us-gaap:TradeNamesMembertmo:PeproTechIncMember2021-12-300000097745us-gaap:TradeNamesMembertmo:EuropeanViralVectorManufacturingBusinessMember2021-01-150000097745us-gaap:TradeNamesMembertmo:MesaBiotechMember2021-02-250000097745us-gaap:TradeNamesMembertmo:CSLMember2021-09-300000097745us-gaap:TradeNamesMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-12-310000097745tmo:PPDIncMemberus-gaap:OrderOrProductionBacklogMember2021-12-080000097745us-gaap:CustomerRelationshipsMember2021-01-012021-12-310000097745us-gaap:DevelopedTechnologyRightsMember2021-01-012021-12-310000097745us-gaap:TradeNamesMember2021-01-012021-12-310000097745us-gaap:OrderOrProductionBacklogMember2021-01-012021-12-310000097745tmo:PPDIncMember2021-01-012021-12-310000097745us-gaap:AcquisitionRelatedCostsMembertmo:PPDIncMember2021-01-012021-12-310000097745tmo:ConsumablesMember2023-01-012023-12-310000097745tmo:ConsumablesMember2022-01-012022-12-310000097745tmo:ConsumablesMember2021-01-012021-12-310000097745tmo:InstrumentsMember2023-01-012023-12-310000097745tmo:InstrumentsMember2022-01-012022-12-310000097745tmo:InstrumentsMember2021-01-012021-12-310000097745srt:NorthAmericaMember2023-01-012023-12-310000097745srt:NorthAmericaMember2022-01-012022-12-310000097745srt:NorthAmericaMember2021-01-012021-12-310000097745srt:EuropeMember2023-01-012023-12-310000097745srt:EuropeMember2022-01-012022-12-310000097745srt:EuropeMember2021-01-012021-12-310000097745srt:AsiaPacificMember2023-01-012023-12-310000097745srt:AsiaPacificMember2022-01-012022-12-310000097745srt:AsiaPacificMember2021-01-012021-12-310000097745tmo:OtherRegionsMember2023-01-012023-12-310000097745tmo:OtherRegionsMember2022-01-012022-12-310000097745tmo:OtherRegionsMember2021-01-012021-12-3100000977452024-01-012023-12-31tmo:Segment0000097745tmo:LifeSciencesSolutionsMemberus-gaap:OperatingSegmentsMember2023-01-012023-12-310000097745tmo:LifeSciencesSolutionsMemberus-gaap:OperatingSegmentsMember2022-01-012022-12-310000097745tmo:LifeSciencesSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-12-310000097745tmo:AnalyticalInstrumentsMemberus-gaap:OperatingSegmentsMember2023-01-012023-12-310000097745tmo:AnalyticalInstrumentsMemberus-gaap:OperatingSegmentsMember2022-01-012022-12-310000097745tmo:AnalyticalInstrumentsMemberus-gaap:OperatingSegmentsMember2021-01-012021-12-310000097745us-gaap:OperatingSegmentsMembertmo:SpecialtyDiagnosticsMember2023-01-012023-12-310000097745us-gaap:OperatingSegmentsMembertmo:SpecialtyDiagnosticsMember2022-01-012022-12-310000097745us-gaap:OperatingSegmentsMembertmo:SpecialtyDiagnosticsMember2021-01-012021-12-310000097745tmo:LaboratoryProductsandServicesMemberus-gaap:OperatingSegmentsMember2023-01-012023-12-310000097745tmo:LaboratoryProductsandServicesMemberus-gaap:OperatingSegmentsMember2022-01-012022-12-310000097745tmo:LaboratoryProductsandServicesMemberus-gaap:OperatingSegmentsMember2021-01-012021-12-310000097745us-gaap:IntersegmentEliminationMember2023-01-012023-12-310000097745us-gaap:IntersegmentEliminationMember2022-01-012022-12-310000097745us-gaap:IntersegmentEliminationMember2021-01-012021-12-310000097745us-gaap:OperatingSegmentsMember2023-01-012023-12-310000097745us-gaap:OperatingSegmentsMember2022-01-012022-12-310000097745us-gaap:OperatingSegmentsMember2021-01-012021-12-310000097745us-gaap:MaterialReconcilingItemsMember2023-01-012023-12-310000097745us-gaap:MaterialReconcilingItemsMember2022-01-012022-12-310000097745us-gaap:MaterialReconcilingItemsMember2021-01-012021-12-310000097745tmo:LifeSciencesSolutionsMemberus-gaap:OperatingSegmentsMember2023-12-310000097745tmo:LifeSciencesSolutionsMemberus-gaap:OperatingSegmentsMember2022-12-310000097745tmo:LifeSciencesSolutionsMemberus-gaap:OperatingSegmentsMember2021-12-310000097745tmo:AnalyticalInstrumentsMemberus-gaap:OperatingSegmentsMember2023-12-310000097745tmo:AnalyticalInstrumentsMemberus-gaap:OperatingSegmentsMember2022-12-310000097745tmo:AnalyticalInstrumentsMemberus-gaap:OperatingSegmentsMember2021-12-310000097745us-gaap:OperatingSegmentsMembertmo:SpecialtyDiagnosticsMember2023-12-310000097745us-gaap:OperatingSegmentsMembertmo:SpecialtyDiagnosticsMember2022-12-310000097745us-gaap:OperatingSegmentsMembertmo:SpecialtyDiagnosticsMember2021-12-310000097745tmo:LaboratoryProductsandServicesMemberus-gaap:OperatingSegmentsMember2023-12-310000097745tmo:LaboratoryProductsandServicesMemberus-gaap:OperatingSegmentsMember2022-12-310000097745tmo:LaboratoryProductsandServicesMemberus-gaap:OperatingSegmentsMember2021-12-310000097745us-gaap:CorporateNonSegmentMember2023-12-310000097745us-gaap:CorporateNonSegmentMember2022-12-310000097745us-gaap:CorporateNonSegmentMember2021-12-310000097745us-gaap:CorporateNonSegmentMember2023-01-012023-12-310000097745us-gaap:CorporateNonSegmentMember2022-01-012022-12-310000097745us-gaap:CorporateNonSegmentMember2021-01-012021-12-310000097745country:US2023-01-012023-12-310000097745country:US2022-01-012022-12-310000097745country:US2021-01-012021-12-310000097745tmo:AllOtherCountriesMember2023-01-012023-12-310000097745tmo:AllOtherCountriesMember2022-01-012022-12-310000097745tmo:AllOtherCountriesMember2021-01-012021-12-310000097745country:US2023-12-310000097745country:US2022-12-310000097745country:US2021-12-310000097745tmo:AllOtherCountriesMember2023-12-310000097745tmo:AllOtherCountriesMember2022-12-310000097745tmo:AllOtherCountriesMember2021-12-310000097745srt:MinimumMemberus-gaap:EmployeeStockOptionMember2023-01-012023-12-310000097745us-gaap:EmployeeStockOptionMembersrt:MaximumMember2023-01-012023-12-310000097745us-gaap:EmployeeStockOptionMember2023-12-310000097745us-gaap:EmployeeStockOptionMember2023-01-012023-12-310000097745srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310000097745us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2023-01-012023-12-310000097745us-gaap:RestrictedStockUnitsRSUMember2023-12-310000097745us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310000097745srt:MinimumMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:US2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:US2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:US2021-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:US2023-01-012023-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:US2022-01-012022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2023-01-012023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-01-012022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-01-012021-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:US2021-01-012021-12-310000097745us-gaap:PensionPlansDefinedBenefitMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:UStmo:USEquityFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:UStmo:InternationalEquityFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:FixedIncomeFundsMember2023-12-310000097745srt:MinimumMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:EquityFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:EquityFundsMembersrt:MaximumMember2023-12-310000097745srt:MinimumMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FixedIncomeFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembersrt:MaximumMemberus-gaap:FixedIncomeFundsMember2023-12-310000097745srt:MinimumMembertmo:MultiassetFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2023-12-310000097745tmo:MultiassetFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembersrt:MaximumMember2023-12-310000097745srt:MinimumMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembertmo:AlternativeInvestmentsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembersrt:MaximumMembertmo:AlternativeInvestmentsMember2023-12-310000097745srt:MinimumMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembersrt:MaximumMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000097745srt:MinimumMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMembersrt:MaximumMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:UStmo:USEquityFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercountry:UStmo:USEquityFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membercountry:UStmo:USEquityFundsMember2023-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMembercountry:UStmo:USEquityFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:UStmo:InternationalEquityFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercountry:UStmo:InternationalEquityFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membercountry:UStmo:InternationalEquityFundsMember2023-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMembercountry:UStmo:InternationalEquityFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercountry:USus-gaap:FixedIncomeFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membercountry:USus-gaap:FixedIncomeFundsMember2023-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:FixedIncomeFundsMember2023-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2023-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:FairValueInputsLevel1Member2023-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercountry:US2023-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membercountry:US2023-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:MoneyMarketFundsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:FairValueInputsLevel1Member2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercountry:US2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membercountry:US2023-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:EquityFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:EquityFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:EquityFundsMember2023-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:EquityFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FixedIncomeFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:FixedIncomeFundsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:FixedIncomeFundsMember2023-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FixedIncomeFundsMember2023-12-310000097745tmo:MultiassetFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2023-12-310000097745tmo:MultiassetFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2023-12-310000097745tmo:MultiassetFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2023-12-310000097745tmo:MultiassetFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2023-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembertmo:MultiassetFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2023-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembertmo:AlternativeInvestmentsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembertmo:AlternativeInvestmentsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMembertmo:AlternativeInvestmentsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembertmo:AlternativeInvestmentsMember2023-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembertmo:AlternativeInvestmentsMember2023-12-310000097745tmo:InsuranceContractsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2023-12-310000097745tmo:InsuranceContractsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2023-12-310000097745tmo:InsuranceContractsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2023-12-310000097745tmo:InsuranceContractsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2023-12-310000097745tmo:InsuranceContractsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel1Member2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2023-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2023-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:UStmo:USEquityFundsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:UStmo:USEquityFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercountry:UStmo:USEquityFundsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membercountry:UStmo:USEquityFundsMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMembercountry:UStmo:USEquityFundsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:UStmo:InternationalEquityFundsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:UStmo:InternationalEquityFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercountry:UStmo:InternationalEquityFundsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membercountry:UStmo:InternationalEquityFundsMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMembercountry:UStmo:InternationalEquityFundsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:FixedIncomeFundsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercountry:USus-gaap:FixedIncomeFundsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membercountry:USus-gaap:FixedIncomeFundsMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:FixedIncomeFundsMember2022-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2022-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:FairValueInputsLevel1Member2022-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercountry:US2022-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membercountry:US2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:MoneyMarketFundsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:FairValueInputsLevel1Member2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercountry:US2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membercountry:US2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:EquityFundsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:EquityFundsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:EquityFundsMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:EquityFundsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FixedIncomeFundsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:FixedIncomeFundsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:FixedIncomeFundsMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FixedIncomeFundsMember2022-12-310000097745tmo:MultiassetFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-12-310000097745tmo:MultiassetFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2022-12-310000097745tmo:MultiassetFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2022-12-310000097745tmo:MultiassetFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembertmo:MultiassetFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMember2022-12-310000097745tmo:InsuranceContractsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-12-310000097745tmo:InsuranceContractsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2022-12-310000097745tmo:InsuranceContractsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2022-12-310000097745tmo:InsuranceContractsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2022-12-310000097745tmo:InsuranceContractsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-12-310000097745us-gaap:DomesticCountryMember2022-01-012022-12-310000097745us-gaap:DomesticCountryMember2022-12-310000097745tmo:DeferredTaxImplicationsMember2021-01-012021-12-310000097745tmo:CapitalLossMember2021-01-012021-12-310000097745us-gaap:DomesticCountryMember2023-12-310000097745us-gaap:StateAndLocalJurisdictionMember2023-12-310000097745us-gaap:ForeignCountryMember2023-12-310000097745tmo:DomesticNOLExpiresMember2023-12-310000097745tmo:StateNOLExpiresMember2023-12-310000097745tmo:ForeignCountryNolExpiresMember2023-12-310000097745tmo:ForeignTaxCreditCarryforwardsMember2023-12-310000097745tmo:DeferredTaxAssetInterestCarryforwardMember2023-12-310000097745tmo:DeferredTaxAssetInterestCarryforwardMembertmo:TaxYears20252033Member2023-12-310000097745tmo:ForeignTaxPositionsMember2023-01-012023-12-310000097745tmo:FederalAndStateMember2023-01-012023-12-310000097745tmo:ForeignTaxPositionsMember2022-01-012022-12-310000097745tmo:FederalAndStateMember2022-01-012022-12-310000097745tmo:ForeignTaxPositionsMember2021-01-012021-12-310000097745tmo:FederalAndStateMember2021-01-012021-12-310000097745us-gaap:CommercialPaperMember2023-12-310000097745us-gaap:CommercialPaperMember2022-12-310000097745tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:FloatingRateSOFR039SeniorNotesDue2023Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:FloatingRateSOFR039SeniorNotesDue2023Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:FloatingRateSOFR039SeniorNotesDue2023Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes0797Due2023Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes0797Due2023Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes0797Due2023Memberus-gaap:SeniorNotesMember2022-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRate2YearSeniorNotesDue2023Member2023-01-012023-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRate2YearSeniorNotesDue2023Member2023-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRate2YearSeniorNotesDue2023Member2022-12-310000097745tmo:SeniorNotes0000Due2023Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes0000Due2023Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes0000Due2023Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes0.75Due2024Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes0.75Due2024Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes0.75Due2024Memberus-gaap:SeniorNotesMember2022-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR053SeniorNotesDue2024Member2023-01-012023-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR053SeniorNotesDue2024Member2023-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR053SeniorNotesDue2024Member2022-12-310000097745tmo:SeniorNotes1215Due2024Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes1215Due2024Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes1215Due2024Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes0.125Due2025Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes0.125Due2025Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes0.125Due2025Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes200Due2025Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes200Due2025Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes200Due2025Memberus-gaap:SeniorNotesMember2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0853Due2025Member2023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0853Due2025Member2023-01-012023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0853Due2025Member2022-12-310000097745tmo:SeniorNotes0000Due2025Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes0000Due2025Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes0000Due2025Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes320Due2026Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes320Due2026Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes320Due2026Memberus-gaap:SeniorNotesMember2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.40Due2026Member2023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.40Due2026Member2023-01-012023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.40Due2026Member2022-12-310000097745tmo:SeniorNotes4953Due2026Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes4953Due2026Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes4953Due2026Memberus-gaap:SeniorNotesMember2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes5.000Due2026Member2023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes5.000Due2026Member2023-01-012023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes5.000Due2026Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:A1.45SeniorNotesDue2027Member2023-12-310000097745us-gaap:SeniorNotesMembertmo:A1.45SeniorNotesDue2027Member2023-01-012023-12-310000097745us-gaap:SeniorNotesMembertmo:A1.45SeniorNotesDue2027Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes175Due2027Member2023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes175Due2027Member2023-01-012023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes175Due2027Member2022-12-310000097745tmo:SeniorNotes1054Due2027Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes1054Due2027Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes1054Due2027Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes48Due2027Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes48Due2027Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes48Due2027Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes0.500Due2028Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes0.500Due2028Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes0.500Due2028Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes0.77Due2028Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes0.77Due2028Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes0.77Due2028Memberus-gaap:SeniorNotesMember2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.375Due2028Member2023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.375Due2028Member2023-01-012023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.375Due2028Member2022-12-310000097745tmo:SeniorNotes1750Due2028Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes1750Due2028Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes1750Due2028Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes5.000Due2029Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes5.000Due2029Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes5.000Due2029Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes1.95Due2029Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes1.95Due2029Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes1.95Due2029Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes2.60Due2029Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes2.60Due2029Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes2.60Due2029Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes1279Due2029Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes1279Due2029Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes1279Due2029Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes4977Due2030Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes4977Due2030Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes4977Due2030Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes080Due2030Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes080Due2030Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes080Due2030Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes0.875Due2031Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes0.875Due2031Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes0.875Due2031Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes2000Due2031Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes2000Due2031Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes2000Due2031Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes2375Due2032Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes2375Due2032Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes2375Due2032Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes149Due2032Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes149Due2032Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes149Due2032Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes495Due2032Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes495Due2032Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes495Due2032Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes5086Due2033Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes5086Due2033Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes5086Due2033Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes1125Due2033Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes1125Due2033Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes1125Due2033Memberus-gaap:SeniorNotesMember2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes5.200Due2034Member2023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes5.200Due2034Member2023-01-012023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes5.200Due2034Member2022-12-310000097745tmo:SeniorNotes365Due2034Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes365Due2034Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes365Due2034Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes1.50Due2035Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes1.50Due2035Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes1.50Due2035Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes2.875Due2037Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes2.875Due2037Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes2.875Due2037Memberus-gaap:SeniorNotesMember2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.500Due2039Member2023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.500Due2039Member2023-01-012023-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.500Due2039Member2022-12-310000097745tmo:SeniorNotes2800Due2041Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes2800Due2041Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes2800Due2041Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes1625Due2041Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes1625Due2041Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes1625Due2041Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes2069Due2042Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes2069Due2042Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes2069Due2042Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes5404Due2043Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes5404Due2043Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes5404Due2043Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes202Due2043Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes202Due2043Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes202Due2043Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes530Due2044Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes530Due2044Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes530Due2044Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes4.10Due2047Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes4.10Due2047Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes4.10Due2047Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes1.875Due2049Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes1.875Due2049Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes1.875Due2049Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes200Due2051Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes200Due2051Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes200Due2051Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes2382Due2052Memberus-gaap:SeniorNotesMember2023-12-310000097745tmo:SeniorNotes2382Due2052Memberus-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes2382Due2052Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:OtherDebtMember2023-12-310000097745tmo:OtherDebtMember2022-12-310000097745us-gaap:RevolvingCreditFacilityMember2023-12-310000097745us-gaap:RevolvingCreditFacilityMember2023-01-012023-12-310000097745tmo:U.S.CommercialPaperProgramMemberus-gaap:CommercialPaperMember2023-01-012023-12-310000097745tmo:EuroCommercialPaperProgramMemberus-gaap:CommercialPaperMember2023-01-012023-12-310000097745us-gaap:SeniorNotesMember2023-01-012023-12-310000097745tmo:SeniorNotes3.65Due2025Memberus-gaap:SeniorNotesMember2022-12-310000097745us-gaap:InterestRateSwapMember2021-01-012021-12-310000097745srt:MaximumMember2023-01-012023-12-31tmo:lease0000097745us-gaap:GuaranteeTypeOtherMember2023-12-310000097745us-gaap:StandbyLettersOfCreditMember2023-12-310000097745tmo:SuretyBondsAndOtherGuaranteesMember2023-12-310000097745tmo:PaymentGuaranteesInvestmentsMember2023-12-310000097745tmo:BusinessesSoldMemberus-gaap:FinancialGuaranteeMember2023-12-310000097745srt:MinimumMembertmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember2023-12-310000097745tmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMembersrt:MaximumMember2023-12-310000097745tmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember2023-12-310000097745us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000097745us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000097745us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000097745us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-310000097745us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310000097745us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-310000097745us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000097745us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000097745us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000097745us-gaap:SubsequentEventMember2024-01-012024-02-220000097745us-gaap:FairValueMeasurementsRecurringMember2023-12-310000097745us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310000097745us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310000097745us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310000097745us-gaap:FairValueMeasurementsRecurringMember2022-12-310000097745us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000097745us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000097745us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000097745tmo:ContingentConsiderationMember2022-12-310000097745tmo:ContingentConsiderationMember2021-12-310000097745tmo:ContingentConsiderationMember2023-01-012023-12-310000097745tmo:ContingentConsiderationMember2022-01-012022-12-310000097745tmo:ContingentConsiderationMember2023-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:EUR2023-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:EUR2022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMembercurrency:JPYus-gaap:NetInvestmentHedgingMember2023-12-310000097745us-gaap:CrossCurrencyInterestRateContractMembercurrency:JPYus-gaap:NetInvestmentHedgingMember2022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMembercurrency:CHFus-gaap:NetInvestmentHedgingMember2023-12-310000097745us-gaap:CrossCurrencyInterestRateContractMembercurrency:CHFus-gaap:NetInvestmentHedgingMember2022-12-310000097745us-gaap:ForeignExchangeContractMember2023-12-310000097745us-gaap:ForeignExchangeContractMember2022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-12-310000097745us-gaap:OtherExpenseMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000097745us-gaap:OtherExpenseMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310000097745us-gaap:OtherExpenseMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310000097745us-gaap:OtherExpenseMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000097745us-gaap:OtherExpenseMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310000097745us-gaap:OtherExpenseMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310000097745us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000097745us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310000097745us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310000097745us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2023-01-012023-12-310000097745us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2022-01-012022-12-310000097745us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2021-01-012021-12-310000097745us-gaap:OtherExpenseMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000097745us-gaap:OtherExpenseMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310000097745us-gaap:OtherExpenseMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310000097745tmo:ForeigncurrencydenominateddebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000097745tmo:ForeigncurrencydenominateddebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310000097745tmo:ForeigncurrencydenominateddebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:CostOfSalesMember2023-01-012023-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:CostOfSalesMember2022-01-012022-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:CostOfSalesMember2021-01-012021-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:OtherExpenseMemberus-gaap:NondesignatedMember2023-01-012023-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:OtherExpenseMemberus-gaap:NondesignatedMember2022-01-012022-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:OtherExpenseMemberus-gaap:NondesignatedMember2021-01-012021-12-310000097745us-gaap:OtherExpenseMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2021-01-012021-12-310000097745us-gaap:SeniorNotesMember2023-12-310000097745us-gaap:SeniorNotesMember2022-12-310000097745us-gaap:SubsequentEventMember2024-02-2200000977452023-10-012023-12-310000097745tmo:MichaelA.BoxerMember2023-01-012023-12-310000097745tmo:MichaelA.BoxerMember2023-10-012023-12-310000097745tmo:MichaelA.BoxerMember2023-12-310000097745tmo:LisaP.BrittMember2023-01-012023-12-310000097745tmo:LisaP.BrittMember2023-10-012023-12-310000097745tmo:LisaP.BrittMember2023-12-310000097745tmo:MarcN.CasperMember2023-01-012023-12-310000097745tmo:MarcN.CasperMember2023-10-012023-12-310000097745tmo:MarcN.CasperMember2023-12-31

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023 or
☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission file number 1-8002
THERMO FISHER SCIENTIFIC INC.
(Exact name of Registrant as specified in its charter)
Delaware04-2209186
(State of incorporation)(I.R.S. Employer Identification No.)
168 Third Avenue
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 622-1000
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $1.00 par valueTMONew York Stock Exchange
0.750% Notes due 2024TMO 24ANew York Stock Exchange
0.125% Notes due 2025TMO 25BNew York Stock Exchange
2.000% Notes due 2025TMO 25New York Stock Exchange
3.200% Notes due 2026TMO 26BNew York Stock Exchange
1.400% Notes due 2026TMO 26ANew York Stock Exchange
1.450% Notes due 2027TMO 27New York Stock Exchange
1.750% Notes due 2027TMO 27BNew York Stock Exchange
0.500% Notes due 2028TMO 28ANew York Stock Exchange
1.375% Notes due 2028TMO 28New York Stock Exchange
1.950% Notes due 2029TMO 29New York Stock Exchange
0.875% Notes due 2031TMO 31New York Stock Exchange
2.375% Notes due 2032TMO 32New York Stock Exchange
3.650% Notes due 2034TMO 34New York Stock Exchange
2.875% Notes due 2037TMO 37New York Stock Exchange
1.500% Notes due 2039TMO 39New York Stock Exchange
1.875% Notes due 2049TMO 49New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act:  None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒  No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐  No ☒ 
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months. Yes ☒  No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.      Large accelerated filer ☒             Accelerated filer ☐             Non-accelerated filer ☐         Smaller reporting company ☐        Emerging growth company ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒
As of June 30, 2023, the aggregate market value of the voting stock held by nonaffiliates of the Registrant was approximately $201,176,616,000 (based on the last reported sale of common stock on the New York Stock Exchange Composite Tape reporting system on June 30, 2023).
As of February 3, 2024, the Registrant had 381,312,268 shares of Common Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Sections of Thermo Fisher’s definitive Proxy Statement for the 2024 Annual Meeting of Shareholders (the “Proxy Statement”) are incorporated by reference into Part III of this report.


THERMO FISHER SCIENTIFIC INC.
ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023
TABLE OF CONTENTS
Page
PART I
PART II
PART III
PART IV

2
THERMO FISHER SCIENTIFIC INC.
PART I
Forward-looking Statements
Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 (the Exchange Act), are made throughout this Annual Report on Form 10-K. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, including without limitation statements regarding: projections of revenues, expenses, earnings, margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, and our liquidity position; cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions or divestitures; growth, declines and other trends in markets we sell into; new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; general economic and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; the COVID-19 pandemic; and any other statements that address events or developments that Thermo Fisher intends or believes will or may occur in the future. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company’s estimates change, and readers should not rely on those forward-looking statements as representing the company’s views as of any date subsequent to the date of the filing of this report. A number of important factors could cause the results of the company to differ materially from those indicated by such forward-looking statements, including those detailed under the heading, “Risk Factors” in Part I, Item 1A.
Item 1.    Business
Description of Business
Thermo Fisher Scientific Inc. (also referred to in this document as “Thermo Fisher,” “we,” the “company,” or the “registrant”) is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. We serve customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
We continuously increase our depth of capabilities across our broad portfolio of innovative products and services and leverage our extensive global channels to address our customers’ needs. We do this through organic investments in research and development, capacity and capabilities and through acquisitions. Our goal is to enable our customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their challenges and advance their important work.
Business Segments and Products
We report our business in four segments – Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Life Sciences Solutions Segment
Through our Life Sciences Solutions segment, we provide an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Life Sciences Solutions includes three primary businesses – Biosciences, Genetic Sciences, and BioProduction.
Our biosciences business includes reagents, instruments and consumables that help our customers conduct biological and medical research in areas such as molecular biology and protein biology, discover new drugs and vaccines, and enable the diagnosis of infection and disease. Our genetic sciences business combines a wide variety of instruments and related reagents used to provide high-value genomic solutions to assist customer decisions in the research, clinical, healthcare and applied markets. Our bioproduction business supports developers and manufacturers of biological-based therapeutics and vaccines with a portfolio of premium solutions and services focused on upstream cell culture, downstream purification, analytics for detection and quantitation of process/product impurities, and a suite of single-use solutions spanning the biologics workflow.
3
THERMO FISHER SCIENTIFIC INC.
Analytical Instruments Segment
Through our Analytical Instruments segment, we provide a broad offering of instruments and the supporting consumables, software and services that are used for a range of applications. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory. This segment includes three primary businesses – Chromatography and Mass Spectrometry, Chemical Analysis, and Electron Microscopy.
Our chromatography and mass spectrometry business develops and provides analytical instrumentation for organic and inorganic sample analysis across both applied technologies and scientific research. Our chemical analysis products fall into three main categories: production, process and analytics; field and safety instruments; and environmental and process instruments. Our electron microscopy business serves customers in the life sciences, materials sciences, and semiconductor markets providing leading research tools; and also, in the semiconductor market provides integrated workflows that power research development and production solutions.
Specialty Diagnostics Segment
Our Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of diagnoses, which improves patient care in a more cost-efficient manner. This segment has five primary businesses – Clinical Diagnostics, ImmunoDiagnostics, Microbiology, Transplant Diagnostics and our Healthcare Market Channel.
Our clinical diagnostics products include a broad offering of liquid, ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments. Such products are used for, among other things, drugs-of-abuse testing, therapeutic drug monitoring, thyroid hormone testing, sepsis screening, serum toxicity, first trimester screening, tumor markers testing, and the diagnosis and monitoring of multiple myeloma. Our immunodiagnostics offerings include developing, manufacturing and marketing complete blood-test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases. Our microbiology offerings include dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products and associated products for the microbiology laboratory. Our transplant diagnostics products include human leukocyte antigen typing and testing for the organ transplant market. Our healthcare market channel offerings include a broad array of consumables, diagnostic kits and reagents, equipment, instruments, solutions and services for hospitals, clinical laboratories, reference laboratories, physicians’ offices and other clinical testing facilities.
Laboratory Products and Biopharma Services Segment
Our Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more innovative, productive and cost-efficient. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing. We serve the pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory market through four key businesses: Laboratory Products, Research and Safety Market Channel, Pharma Services and Clinical Research.
Our laboratory products include lab consumables, equipment and chemicals that are used for life science research and drug discovery and development to advance the prevention and cure of diseases and enhance quality of life. Our research and safety market channel offers a mix of products that are manufactured by Thermo Fisher, by third parties for us on a private-label basis, and by third parties under their brands but offered for sale through us. Our pharma services business provides the entire spectrum of development, manufacturing and clinical trials services for both small-molecule and large-molecule pharmaceuticals. Our clinical research business offers comprehensive, integrated clinical development and analytical services including all phases of development (i.e., Phases I-IV), peri- and post-approval and site and patient access services.
Sales and Marketing
We market and sell our products and services through a direct sales force, customer-service professionals, electronic commerce and third-party distributors. Our global team delivers a combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
We have approximately 14,000 sales personnel including highly trained technical specialists who enable us to better meet the needs of our more technical end-users. We also provide customers with product standardization and other supply-chain-management services to reduce procurement costs.
4
THERMO FISHER SCIENTIFIC INC.
New Products and Research and Development
Our business includes the development and introduction of new products and may include entry into new business segments. We anticipate that we will continue to make significant expenditures for research and development as we seek to provide a continuing flow of innovative products to maintain and improve our competitive position.
Resources
Raw Materials
Our management team believes that we have a readily available supply of raw materials for all of our significant products from various sources. No single supplier is material, although for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design, certain materials components may be sourced from a single supplier or a limited number of suppliers that can readily provide such materials or components.
Raw material and fuel prices are subject to fluctuations due to market conditions. We employ many strategies, including the use of alternative materials, to mitigate the effect of these fluctuations on our results.
Patents, Licenses and Trademarks
Patents are important in many aspects of our business. No particular patent, or related group of patents, is so important, however, that its loss would significantly affect our operations as a whole. Where appropriate, we seek patent protection for inventions and developments made by our personnel that are incorporated into our products or otherwise fall within our fields of interest. Patent rights resulting from work sponsored by outside parties do not always accrue exclusively to the company and may be limited by agreements or contracts.
We protect some of our technology as trade secrets and, where appropriate, we use trademarks or register trademarks used in connection with products. We also enter into license agreements with others to grant and/or receive rights to intellectual property rights.
All trademarks, trade names, product names, graphics and logos of Thermo Fisher contained herein are trademarks or registered trademarks of Thermo Fisher or its subsidiaries, as applicable, in the United States and/or other countries. Solely for convenience, we may refer to trademarks in this Annual Report on Form 10-K without the ™ and ® symbols. Such references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted by law, our rights to our trademarks. To the extent other trademarks appear in this Annual Report on Form 10-K, they are the property of their respective owners.
Seasonal Influences
Revenues in the fourth quarter are historically stronger than in other quarters due to the capital spending patterns of industrial, pharmaceutical and government customers. Sales of seasonal products, such as allergy and flu tests and related diagnostic products, vary quarter to quarter and year to year.
Competition
The company encounters aggressive and able competition in virtually all of the markets we serve. Because of the diversity of our products and services, we face many different types of competitors and competition. Our competitors include a broad range of manufacturers, third-party distributors and service providers. Competitive climates in many of the markets we serve are characterized by changing technology and customer demands that require continuing research and development. Our success primarily depends on the following factors:
•technical performance and advances in technology that result in new products and improved price/performance ratios;
•product differentiation, availability and reliability;
•the depth of our capabilities;
•our reputation among customers as a quality provider of products and services;
•customer service and support;
•active research and application-development programs; and
•relative prices of our products and services.
5
THERMO FISHER SCIENTIFIC INC.
Government Regulation
Environmental Regulations
We are subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the United States and other countries. U.S. federal environmental legislation that affects us includes the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the Clean Air Act, the Clean Water Act, the Safe Drinking Water Act, and the Comprehensive Environmental Response Compensation and Liability Act (CERCLA). We are also subject to regulation by the Occupational Safety and Health Administration (OSHA) concerning employee safety and health matters. The United States Environmental Protection Agency (USEPA), OSHA, and other federal agencies have the authority to promulgate regulations that have an effect on our operations.
In addition to these federal laws and regulations, various states have been delegated certain authority under the aforementioned federal statutes and have authority over these matters under state laws. Many state and local governments have adopted environmental and employee safety and health laws and regulations, some of which are similar to federal requirements.
A number of our operations involve the handling, manufacturing, use or sale of substances that are or could be classified as toxic or hazardous materials within the meaning of applicable laws. Consequently, some risk of environmental harm is inherent in our operations and products, as it is with other companies engaged in similar businesses.
Our expenses for environmental requirements are incurred generally for ongoing compliance and historical remediation matters. Based on current information, we believe that these compliance costs are not material. For historical remediation obligations, our expenditures relate primarily to the cost of permitting, installing, and operating and maintaining groundwater-treatment systems and other remedial measures.
Our Fair Lawn and Somerville, New Jersey facilities entered into administrative consent orders with the New Jersey Department of Environmental Protection in 1984 to maintain groundwater-remediation activities at these sites, and are currently under the State’s Licensed Site Remediation Professional Program. As the owner of the Fair Lawn facility, we are listed as a potentially responsible party for remediation within an area called the Fair Lawn Wellfields Superfund Site, and, in 2008, the company and certain other parties entered into a consent order with the USEPA to complete a Remedial Investigation/Feasibility Study. In 2018, the USEPA issued a Record of Decision, setting forth the scope of required remediation work at the site, which includes upgrading a water treatment plant to address constituents such as chlorinated organic compounds, 1,4-dioxane, and perfluorooctanoic acid/perfluorooctane sulfonate (PFOA/PFOS). In 2020, the court approved a consent decree that requires the company and another responsible party to finance and perform the required remediation work with USEPA oversight. In 2023, the design of a groundwater treatment plant was fully approved by USEPA. Construction is expected to commence in 2024, and the plant is expected to be fully operating by April 2025.
In 2011, our Life Technologies subsidiary entered into a consent decree with the USEPA and other responsible parties to implement a groundwater remedy at the former Davis Landfill Superfund site in Smithfield, Rhode Island. After years of additional study, in September, 2020, USEPA revised its cleanup plan by selecting an interim remedial approach that includes groundwater treatment followed by additional monitoring of site conditions. Depending on the results of these treatment and monitoring activities over the next several years, USEPA anticipates selecting a final groundwater remedy for the site. In November 2021, the 2011 consent decree was amended to reflect the parties’ obligations to implement USEPA’s interim remedy, for which pre-design work commenced during 2022 and is ongoing.
We record accruals for environmental liabilities based on current interpretations of environmental laws and regulations when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. We calculate estimates based upon several factors, including reports prepared by environmental specialists and management’s knowledge and experience with these environmental matters. We include in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. Accrued liabilities for environmental matters totaled $75 million at December 31, 2023.
These environmental liabilities do not include third-party recoveries to which we may be entitled. We believe that our accrual is adequate for the environmental liabilities we currently expect to incur. As a result we believe that our ultimate liability with respect to environmental matters will not have a material adverse effect on our financial position, results of operations or cash flows. However, we may be subject to remedial or compliance costs due to future events, such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies, changes in the conduct of our operations, and the effect of changes in accounting rules, which could have a material adverse effect on our financial position, results of operations or cash flows. For a discussion of the environmental laws and regulations that the Company’s operations, products and services are subject to and other environmental contingencies, refer to Note 12 to our Consolidated Financial Statements.
6
THERMO FISHER SCIENTIFIC INC.
Other Laws and Regulations
Our operations, and some of the products and services we offer, are subject to a number of complex and stringent laws and regulations governing the development, testing, approval, production, handling, transportation and distribution of chemicals, drugs and other similar products, including the operating and security standards of the Food and Drug Administration, the Drug Enforcement Administration, the Bureau of Alcohol, Tobacco, Firearms and Explosives, and various state boards of pharmacy as well as comparable state and foreign agencies. As Thermo Fisher’s businesses also include export and import activities, we are subject to pertinent laws enforced by the U.S. Departments of Commerce, State and Treasury. In addition, our logistics activities must comply with the rules and regulations of the Department of Transportation, the Federal Aviation Administration and similar foreign agencies. While we believe we are in compliance in all material respects with such laws and regulations, any noncompliance could result in substantial fines or otherwise restrict our ability to provide competitive distribution services and thereby have an adverse effect on our financial condition. To date, no such laws or regulations have had a material impact on our operations.
We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenues associated with these customers. We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could also result in suspension of these contracts, criminal, civil and administrative penalties or debarment.
For a discussion of risks related to changes in governmental regulations, refer to “Risk Factors” in Part I, Item 1A.
Human Capital
The success of Thermo Fisher is fueled by colleagues who are highly engaged and feel empowered to achieve their goals. Everything we do starts with our Mission – to enable our customers to make the world healthier, cleaner and safer. Our colleagues understand the role they play in fulfilling that Mission and that inspires them to bring their best to work each day. Our Mission is not only a differentiator for us externally, but a motivator for us internally.
Our culture is rooted in our 4i Values of Integrity, Intensity, Innovation and Involvement. Within this framework, we strive to create a safe, fair and positive working environment for our colleagues around the world. We want our teams to feel they have a stake in our success, a voice in our direction and to be empowered to make a difference for the key stakeholders we serve.
Every year, we conduct an Employee Involvement Survey to solicit direct feedback from our colleagues on what we’re doing well and where we need to improve. We then compile the feedback to measure our progress using three key indices: Leadership, Involvement and Inclusion. Our continued focus on enhancing our culture helps position our company to be an even better place to work.
We are committed to maintaining the strongest team in our industry, focusing on developing and retaining our colleagues, while leveraging our leadership to attract new colleagues to our company. As of December 31, 2023, we employed approximately 122,000 colleagues globally, with an approximate regional distribution as follows: 61,000 based in the Americas, 20,000 in the Asia Pacific region, and nearly 41,000 in Europe, the Middle East and Africa (EMEA).
Culture of Inclusion
We recognize that the future aspirations outlined in our Vision for 2030, which serves as our long-term roadmap, will only be achievable if we have a culture that values diversity of backgrounds, experiences and viewpoints. When differences among colleagues are welcomed and supported, we create an inclusive workplace that unlocks the true benefits of diversity and promotes conditions for sustained success.
Diversity and Inclusion (D&I) is not an initiative at Thermo Fisher. It’s woven into the fabric of our culture, and our ways of working, embedded in every stage of our colleague lifecycle - from recruiting to onboarding, training, development and longer-term career planning. Our colleagues are encouraged to openly share the wide range of perspectives they represent. Progress is measured and reviewed on a range of D&I factors to help inform our efforts and initiatives, including those related to diversity within our workforce. We understand the critical role diversity plays in sustained business success, so we strive to have a workforce that represents the customers we serve. Further, to provide additional transparency to our U.S. workforce demographics, following our report submission to the U.S. Equal Employment Opportunity Commission, we disclose our EEO-1 report on our website each year.
Our inclusive culture is a competitive advantage, and we prioritize colleague engagement and empowerment to contribute, collaborate and innovate. For example, in 2023, Thermo Fisher was recognized as a Top Company for Women and Best Employer for Diversity by Forbes, a Best Place to Work for Disability Inclusion, and a top scorer on the Human Rights
7
THERMO FISHER SCIENTIFIC INC.
Campaign’s Corporate Equality Index for LGBTQ inclusion. Establishing this kind of environment is critical for our colleagues, where they can contribute their best ideas and bring their true selves to work each day.
We are also committed to ensuring our colleagues have access to resources, awareness training and internal networks that offer support and guidance. Our D&I strategy is greatly enabled by our Business Resource Groups (BRGs), which bring together individuals with similar interests to share experiences, learn from each other and collaborate to identify solutions to business challenges. Our BRGs reinforce that all colleagues can make a difference for our customers, for each other and for our company. As of December 31, 2023, we had 9 global BRGs, with more than 230 local BRG chapters.
Talent Development
Our overarching goal from a talent perspective is to create opportunities for our colleagues to achieve their full potential and career aspirations here at Thermo Fisher. We focus on the entire lifecycle of a colleague’s career, from their initial recruitment, to onboarding, through ongoing development. We encourage and support colleagues to enhance their skills so they are in the best position to deliver on their goals and achieve their career objectives.
In today’s environment, we know talent is a key differentiator, and that building the strongest team in the industry is critical to our future. From our colleague referral program, summer internships, university relations, to our Graduate Leadership Development Program, we continue to build strong internal and external sourcing channels.
Once on board, talent development at Thermo Fisher is a key organizational capability. We continue to make significant investments to support our colleagues along every step of their career journey to help support their success. Our talent development framework incorporates a multi-faceted approach, including formal and self-paced training, networking opportunities, on-the-job stretch learning, coaching, mentoring and manager training utilizing contemporary technology solutions to support the broad needs of our workforce.
We provide multiple programs at all career levels, from online learning for all colleagues through Thermo Fisher University, to focused trainings for managers at various experience levels, to our Global Leadership Program for executives. We also support our colleagues’ career advancement through our tuition reimbursement program.
In a company our size, we can also actively manage our talent through rotational opportunities across our businesses, functions and geographies that help our colleagues gain new experiences, share knowledge and broaden their skills. Our executives and leaders participate in frequent talent discussions as well as formal reviews, leveraging workforce data and predictive analytics to better anticipate the talent requirements of our business based on our growth opportunities and market demand.
Thermo Fisher is dedicated to talent development to meet our evolving business needs and to provide our colleagues with opportunities for long and fulfilling careers. Our colleagues are passionate about our company, and their role in our success, and it’s our responsibility to help them reach their full potential.
Total Rewards
We offer a comprehensive total rewards package that we regularly evaluate and measure against established benchmarks to ensure its effectiveness in recruiting and retention, and to position Thermo Fisher as an employer of choice.
Our health and wellness programs provide competitive, flexible programs that our global colleagues and their families can count on. For example, for U.S. colleagues, we offer a choice of comprehensive national medical, dental and vision plans; a wellness program, including valuable health incentive opportunities and tax-advantaged savings and spending accounts; as well as commuter benefits, employee assistance programs, optional group legal coverage, and company-paid disability, accident and life insurance. We also offer a company-paid proprietary program for cancer care called the Impact Program, which gives our colleagues and their families access to personalized support and direct lines of communication to experts in cancer genetics and genomics. Similar benefits are available in all countries around the world where we operate.
We also invest in our colleagues’ financial health, helping them to grow and protect their savings, plan for the future and share in the success of the company they are helping to build. We deliver comprehensive rewards, including competitive base pay, and also provide a variety of incentive and equity programs that, by design, directly link the impact of colleague contributions to the company’s overall success.
Available Information
The company files annual, quarterly and current reports, proxy statements and other documents with the Securities and Exchange Commission (SEC) under the Exchange Act. The SEC maintains a website that contains reports, proxy and information statements and other information that issuers, including the company, file electronically with the SEC. The public can obtain any documents that we file with the SEC at www.sec.gov. We also make available free of charge on or through our own website at www.thermofisher.com our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on
8
THERMO FISHER SCIENTIFIC INC.
Form 8-K and, if applicable, amendments to those reports filed or furnished pursuant to Section 13(a) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. In addition, paper copies of these documents may be obtained free of charge by writing to the company care of its Investor Relations Department at our principal executive office located at 168 Third Avenue, Waltham, Massachusetts 02451.
Information about Our Executive Officers
As of February 22, 2024, our executive officers were:
NameAgePresent Title
(Fiscal Year First Became Executive Officer)		Other Positions Held
Marc N. Casper55Chairman, President and Chief Executive Officer (2001)President and Chief Executive Officer (2009-2020)
Chief Operating Officer (2008-2009)
Executive Vice President (2006-2009)
Stephen Williamson57Senior Vice President and Chief Financial Officer (2015)Vice President, Financial Operations (2008-2015)
Michel Lagarde50Executive Vice President and Chief Operating Officer (2017)Executive Vice President (2019-2021)
Senior Vice President and President, Pharma Services (2017-2019)
President and Chief Operating Officer, Patheon N.V. (2016-2017)
Gianluca Pettiti45Executive Vice President (2021)Senior Vice President and President, Specialty Diagnostics (2019-2021)
President, Biosciences (2018-2019)
President, China (2015-2017)
Michael A. Boxer62Senior Vice President and General Counsel (2018)Senior Vice President, General Counsel and Secretary (2021-2022)
Lisa P. Britt55Senior Vice President and Chief Human Resources Officer (2017)
Joseph R. Holmes45Vice President and Chief Accounting Officer (2021)Senior Director, Technical Accounting (2017-2021)
Item 1A.    Risk Factors
Set forth below are the risks, some of which have occurred and any of which may occur in the future, that we believe are material to our investors. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements in Item 1. Business under the caption “Forward-looking Statements”.
Industry and Economic Risks
Our growth would suffer if the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality. Our growth depends in part on the growth of the markets which we serve. Any decline or lower than expected growth in our served markets would diminish demand for our products and services, which would adversely affect our financial statements. Certain of our businesses operate in industries that may experience periodic, cyclical downturns.
Our business is affected by general economic conditions and related uncertainties affecting markets in which we operate. Our business is affected by general economic conditions, both inside and outside the U.S. Both domestic and international markets experienced significant inflationary pressures in 2023 and inflation rates in the U.S., as well as in other countries in which we operate, continue at elevated levels. If the global economy and financial markets, or economic conditions in Europe, the U.S. or other key markets, continue to be unstable, they could adversely affect the business, results of operations and financial condition of the company and its customers, distributors, and suppliers, having the effect of:
•reducing demand for some of our products;
•increasing the rate of order cancellations or delays;
•increasing the risk of excess and obsolete inventories;
•increasing pressure on the prices for our products and services;
•causing supply interruptions, which could disrupt our ability to produce our products; and
•creating longer sales cycles, and greater difficulty in collecting sales proceeds and slower adoption of new technologies.
9
THERMO FISHER SCIENTIFIC INC.

Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations. International markets contribute a substantial portion of our revenues, and we intend to continue expanding our presence in these regions. The exposure to fluctuations in currency exchange rates takes on different forms. International revenues and costs are subject to the risk that fluctuations in exchange rates could adversely affect our reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. These fluctuations could also adversely affect the demand for products and services provided by us. As a multinational corporation, our businesses occasionally invoice third-party customers in currencies other than the one in which they primarily do business (which we refer to as the functional currency). Movements in the invoiced currency relative to the functional currency could adversely impact our cash flows and our results of operations. As our international sales grow, exposure to fluctuations in currency exchange rates could have a larger effect on our financial results. In 2023, currency translation had an unfavorable effect of $0.02 billion on revenues due to the strengthening of the U.S. dollar relative to other currencies in which the company sells products and services.
Some emerging market countries may be particularly vulnerable to periods of global and local political, legal, regulatory and financial instability, including issues of geopolitical relations, the imposition of international sanctions in response to certain state actions and/or sovereign debt issues, and may have a higher incidence of corruption and fraudulent business practices. As a result of these and other factors, our strategy to grow in emerging markets may not be successful, and growth rates in these markets may not be sustainable.
In addition, many of our employees, contract manufacturers, suppliers, job functions, outsourcing activities and manufacturing facilities are located outside the U.S. Accordingly, our future results could be harmed by a variety of factors, including:
•interruption to transportation flows for delivery of parts to us and finished goods to our customers;
•changes in a specific country's or region's political, economic, social or other conditions;
•changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes and sanctions and other trade barriers;
•tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, including the tariffs adopted by the U.S. government on various imports from China and by the Chinese government on certain U.S. goods;
•the impact of public health emergencies, pandemics, epidemics or other health outbreaks on the global economy, such as the COVID-19 pandemic;
•uncertainties regarding the collectability of accounts receivable;
•the imposition of governmental controls;
•diverse data privacy and protection requirements;
•supply interruptions, which could disrupt our ability to produce our products;
•increases in materials, energy, labor or other manufacturing-related costs or higher supply chain logistics costs;
•negative consequences from changes in or interpretation of laws and regulations, including those related to tax and import/export;
•difficulty in staffing and managing widespread operations;
•differing labor regulations;
•differing protection of intellectual property;
•unexpected changes in regulatory requirements; and
•geopolitical uncertainty or turmoil, including terrorism and war.
Demand for some of our products depends on capital spending policies of our customers and on government funding policies. Our customers include pharmaceutical and chemical companies, laboratories, universities, healthcare providers, government agencies and public and private research institutions. Many factors, including public policy spending priorities, available resources, and product and economic cycles, have a significant effect on the capital spending policies of these entities. Spending by some of these customers fluctuates based on budget allocations and the timely passage of the annual federal budget. An impasse in federal government budget decisions could lead to substantial delays or reductions in federal spending.
10
THERMO FISHER SCIENTIFIC INC.

We are subject to risks associated with public health emergencies, pandemics, epidemics, or other health outbreaks. Our global operations expose us to risks associated with public health emergencies, epidemics, pandemics and other health outbreaks, including the COVID-19 pandemic. COVID-19 had an adverse impact on certain of our operations, supply chains and distribution systems, and we may experience unpredictable reductions in supply and demand for certain of our products and services. National, state and local governments have implemented and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and shutdowns and other measures. These measures may disrupt normal business operations and may have significant negative impacts on businesses and financial markets worldwide. Our ability to continue to manufacture products is highly dependent on our ability to maintain the safety and health of our factory employees. The ability of our employees to work may be significantly impacted by future epidemics and pandemics. In addition, the duration and extent of future revenues from sales of products related to the COVID-19 response are uncertain and dependent primarily on customer testing demand as well as therapy and vaccine demand.
Business Risks
We must develop new products, adapt to rapid and significant technological change, respond to introductions of new products by competitors and maintain quality to remain competitive. Our growth strategy includes significant investment in and expenditures for product development. We sell our products in several industries that are characterized by rapid and significant technological changes, frequent new product and service introductions and enhancements and evolving industry standards. Competitive factors include technological innovation, price, service and delivery, breadth of product line, customer support, e-business capabilities and the ability to meet the special requirements of customers. Our competitors may adapt more quickly to new technologies and changes in customers’ requirements than we can. Without the timely introduction of new products, services and enhancements, our products and services will likely become technologically obsolete over time, in which case our revenues and operating results would suffer.
Many of our existing products and those under development are technologically innovative and require significant planning, design, development and testing at the technological, safety, quality, product and manufacturing-process levels. Our customers use many of our products to develop, test and manufacture their own products. As a result, we must anticipate industry trends and develop products in advance of the commercialization of our customers’ products. If we fail to adequately develop products or predict our customers’ needs and future activities, we may invest heavily in research and development of products and services that do not lead to significant revenues.
It may be difficult for us to implement our strategies for improving internal growth. Our growth depends in part on the growth of the markets which we serve. Any decline or lower than expected growth in our served markets could diminish demand for our products and services, which would adversely affect our results of operations and financial condition. To address this issue, we are pursuing a number of strategies to improve our internal growth, including:
•strengthening our presence in selected geographic markets;
•allocating research and development funding to products with higher growth prospects;
•developing new applications for our technologies;
•expanding our service offerings;
•continuing key customer initiatives;
•combining sales and marketing operations in appropriate markets to compete more effectively;
•finding new markets for our products; and
•continuing the development of commercial tools and infrastructure to increase and support cross-selling opportunities of products and services to take advantage of our depth in product offerings.
We may not be able to successfully implement these strategies, and these strategies may not result in the expected growth of our business.
Because we compete directly with certain of our larger customers and product suppliers, our results of operations could be adversely affected in the short term if these customers or suppliers abruptly discontinue or significantly modify their relationship with us. Our largest customer in the laboratory products business is also a significant competitor. Our business may be harmed in the short term if our competitive relationship in the marketplace with certain of our large customers results in a discontinuation of their purchases from us. In addition, we manufacture products that compete directly with products that we source from third-party suppliers. We also source competitive products from multiple suppliers. Our business could be adversely affected in the short term if any of our large third-party suppliers abruptly discontinues selling products to us.
11
THERMO FISHER SCIENTIFIC INC.

Our inability to complete any pending acquisitions or to successfully integrate any new or previous acquisitions could have a material adverse effect on our business. Our business strategy includes the acquisition of technologies and businesses that complement or augment our existing products and services. Certain acquisitions may be difficult to complete for a number of reasons, including the need for antitrust and/or other regulatory approvals, as well as disputes or litigation. Any acquisition we may complete may be made at a substantial premium over the fair value of the net identifiable assets of the acquired company. Further, we may not be able to integrate acquired businesses successfully into our existing businesses, make such businesses profitable, or realize anticipated cost savings or synergies, if any, from these acquisitions, which could adversely affect our business.
Moreover, we have acquired many companies and businesses. As a result of these acquisitions, we recorded significant goodwill and indefinite-lived intangible assets (primarily tradenames) on our balance sheet, which amount to approximately $44.02 billion and $1.24 billion, respectively, as of December 31, 2023. In addition, we have definite-lived intangible assets totaling $15.44 billion as of December 31, 2023. We assess the realizability of goodwill and indefinite-lived intangible assets annually as well as whenever events or changes in circumstances indicate that these assets may be impaired. We assess the realizability of definite-lived intangible assets whenever events or changes in circumstances indicate that these assets may be impaired. These events or circumstances would generally include operating losses or a significant decline in earnings associated with the acquired business or asset. Our ability to realize the value of the goodwill and intangible assets will depend on the future cash flows of these businesses. These cash flows in turn depend in part on how well we have integrated these businesses. If we are not able to realize the value of the goodwill and intangible assets, we may be required to incur material charges relating to the impairment of those assets.
Operational Risks
Our reliance upon sole or limited sources of supply for certain materials or components could cause production interruptions, delays and inefficiencies. Some of our businesses purchase certain materials from sole or limited source suppliers for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design. If these or other suppliers encounter financial, operating or other difficulties, or if our relationship with them changes, we might not be able to quickly establish or qualify replacement sources of supply. The supply chains for our businesses could also be disrupted by supplier capacity constraints, bankruptcy or exiting of the business for other reasons, decreased availability or increased cost of key raw materials or commodities, such as energy, and external events such as global economic downturns and macroeconomic trends, natural disasters, pandemic health issues such as COVID-19, war, terrorist actions, governmental actions and legislative or regulatory changes. Any of these factors could result in production interruptions, delays, extended lead times and inefficiencies.
A significant cyber-attack or other disruption in, or breach in security of, our information technology systems could adversely harm our operating results and financial condition, damage our reputation or otherwise materially harm our business. We rely on information technology systems to process, transmit and store electronic information (including sensitive data such as confidential business information, medical information, financial data and personally identifiable data relating to employees, customers and other business partners) and to manage or support a variety of critical business processes and activities (such as interacting with suppliers, selling our products and services, fulfilling orders and billing, collecting and making payments, shipping products, providing services and support to customers, tracking customer activity, fulfilling contractual obligations and otherwise conducting business). We use a risk-based approach to implementing security controls, reviewing the security controls of certain key business partners and third-party service providers and conducting due diligence on companies we propose to acquire. Despite our efforts, any particular system we operate or use may be susceptible to compromise of a vulnerability or a privileged account, damage or interruption from natural disasters, power loss, telecommunication failures, data center failure, third party provider failures (including failures at cloud services), hardware and software failures, human error or sabotage, terrorist attacks, geopolitical events, computer hackers, computer viruses, ransomware, phishing, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets, and other attempts to harm our systems and access our information.
We and our third-party providers experience cyber-attacks and other attempts to gain unauthorized access to our products, services, and systems and data on a regular basis, and we anticipate continuing to be subject to such attempts as cyber-attacks become increasingly sophisticated and more difficult to predict and protect against, particularly with the advancement of artificial intelligence. Despite our and our third-party providers’ implementation of security measures, our products, services, and systems and data, are vulnerable to cyber-attacks, data breaches, malware, inadvertent error, disruptions, tampering or other theft or misuse, including by employees, contingent workers, malicious actors, or nation-states or their agents. Although most of our systems leverage data backups, our disaster recovery planning is not sufficient for every eventuality. In addition, our customers rely upon our products (i.e. instruments, etc.) within their environments, which may be at risk of compromise. Risks affecting our products may include those associated with remote access solutions, system vulnerabilities, or delay of security updates, which may require customers to take action such as network isolation, password change, or manual update.
12
THERMO FISHER SCIENTIFIC INC.

Cyber-attacks, disruptions or other incidents described above, or breaches of security in our networks, in our customers’ or third-party providers’ networks, in third-party products we use, or in cloud-based services provided to us, regardless of whether the breach is attributable to a vulnerability in our products or services, a privileged account compromise, or a failure to maintain the digital security infrastructure or security tools that protect the integrity of our products, services, and systems and data, could materially interrupt our operations or our customer’s operations, delay production and shipments, impact quality, result in theft of our and our customers’ intellectual property and trade secrets, damage our reputation or key relationships, result in defective products or services, legal claims and proceedings, liability and penalties under privacy laws and increased cost for security and remediation, in each case resulting in an adverse effect on our business and financial results.
A violation of data privacy laws could adversely harm our operating results and financial condition, damage our reputation or otherwise materially harm our business. If we are unable to maintain reliable information technology systems and appropriate controls with respect to global data privacy and security requirements, we may suffer regulatory consequences in addition to business consequences. As a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of producing, collecting, processing, storing and transmitting confidential, personal and/or sensitive data in the course of our business. For example, in the U.S., individual states regulate data breach and security requirements and multiple governmental bodies assert authority over aspects of the protection of personal privacy. European laws require us to have an approved legal mechanism to transfer personal data out of Europe, and the EU General Data Protection Regulation imposes significantly stricter requirements in how we collect and process personal data. Several countries, such as China, have passed laws that require personal data relating to their citizens to be maintained on local servers and impose additional data transfer restrictions. Government enforcement actions can be costly and interrupt the regular operation of our business, and data breaches or violations of data privacy laws can result in fines, reputational damage and civil lawsuits, any of which may adversely affect our business, reputation and financial statements.
Our success is largely dependent upon our ability to attract and retain a highly qualified workforce, comprised of scientific, technical, clinical, and management talent. We have in the past, and may in the future, have difficulty in attracting and retaining such talent. Our success in doing so is largely dependent upon various factors, including a highly competitive market, sought-after skills, management changes, competitor recruitment, and maintaining an attractive workplace culture. Macroeconomic shifts such as increased competition for employees and wage inflation, have previously and could in the future affect our talent retention, turnover rates and operational costs. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the departure of any personnel will not have a material impact on our financial condition and results of operations.
We may incur unexpected costs from increases in fuel and raw material prices, which could reduce our earnings and cash flows. Our primary commodity exposures are for fuel, petroleum-based resins and steel. The costs for these commodities, as well as the costs of transportation, construction and services necessary for the production and distribution of our products, continue to increase and be volatile. While we may seek to minimize the impact of price increases through higher prices to customers and various cost-saving measures, our earnings and cash flows could be adversely affected in the event these measures are insufficient to cover our costs.
Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability. We ship a significant portion of our products to our customers through independent package delivery companies, such as Federal Express in the U.S. and DHL in Europe. We also maintain a small fleet of vehicles dedicated to the delivery of our products and ship our products through other carriers, including national and regional trucking firms, overnight carrier services and the U.S. Postal Service. If one or more of these third-party package-delivery providers were to experience a major work stoppage, preventing our products from being delivered in a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our relationships with certain of our customers could be adversely affected. In addition, if one or more of these third-party package-delivery providers were to increase prices, and we were not able to find comparable alternatives or make adjustments in our delivery network, our profitability could be adversely affected.
Natural disasters, public health crises, political crises, and other catastrophic events or other events outside of our control may disrupt our facilities or the facilities of third parties on which we depend, and could impact customer spending. We have significant operations in California, near major earthquake faults, which make us susceptible to earthquake risk. An earthquake or other natural disaster (including the effects of climate change such as sea level rise, drought, flooding, wildfires and more intense weather events), could disrupt our operations, including the ability to fulfill supply obligations to our customers, or impair our critical systems. Any of these disruptions or other events outside of our control, such as strikes or other labor unrest, could have an adverse effect on our results of operations. In addition, if any of our facilities, including our manufacturing or warehouse facilities, or the facilities of our suppliers, third-party service providers, or customers, is affected by natural disasters, such as earthquakes, tsunamis, power shortages or outages, fires, floods or monsoons, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability or other conflict, or other events
13
THERMO FISHER SCIENTIFIC INC.

outside of our control, such as trade protectionism, strikes or other labor unrest, our results of operations could be adversely affected. Moreover, these types of events could negatively impact customer spending in the impacted regions or depending upon the severity, globally, which could also adversely impact our operating results.
Increasing attention to environmental, social and governance matters may impact our business, financial results, stock price or reputation. We face increasing scrutiny from stakeholders related to our environmental, social and governance (ESG) practices and disclosures, including practices and disclosures related to climate change, diversity and inclusion and governance standards. Investor advocacy groups, certain institutional investors, lenders, investment funds and other influential investors are also increasingly focused on ESG practices and disclosures and in recent years have placed increasing importance on the implications and social cost of their investments. In addition, government organizations are enhancing or advancing legal and regulatory requirements specific to ESG matters. The heightened stakeholder focus on ESG issues related to our business requires the continuous monitoring of various and evolving laws, regulations, standards and expectations and the associated reporting requirements. A failure to adequately meet evolving stakeholder expectations may result in noncompliance, the loss of business, reputational impacts, diluted market valuation, an inability to attract customers and an inability to attract and retain top talent. In addition, if legislation or regulations are enacted or promulgated in the U.S. or in any other jurisdiction in which we do business that impose more stringent restrictions and requirements than our current legal or regulatory obligations, we and companies in our supply chain may experience increased compliance burdens and costs to meet the regulatory obligations, which could cause disruption in the sourcing, manufacturing and distribution of our products and adversely affect our business, financial condition or results of operations. In addition, our adoption of certain standards or mandated compliance to certain requirements could necessitate additional investments that could impact our profitability.
Legal, Quality and Regulatory Risks
New governmental regulations or changes in existing governmental regulations may reduce demand for our products or increase our expenses. We compete in many markets in which we and our customers must comply with federal, state, local and international regulations, such as environmental, health and safety and food and drug regulations. We develop, configure and market our products to meet customer needs created by those regulations. Any significant change in regulations, such as the Inflation Reduction Act of 2022 (IRA), which contains drug price negotiation provisions, or change in the interpretation of existing regulations, could reduce demand for our products or increase our expenses. For example, we manufacture pharmaceuticals and many of our instruments are marketed to the pharmaceutical industry for use in discovering and developing drugs. Changes in the U.S. Food and Drug Administration’s (the FDA) regulation of the drug discovery and development process could have an adverse effect on the demand for these products, and increased FDA regulation of laboratory-developed tests could delay and add to the cost of commercialization of these products, as well as subject us to additional regulatory controls.
We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenues associated with these customers. We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. The laws governing government contracts differ from the laws governing private contracts and government contracts may contain pricing terms and conditions that are not applicable to private contracts. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.
Our pharma services offerings are highly complex, and if we are unable to provide quality and timely offerings to our customers, our business could suffer. Our pharma services offerings are highly exacting and complex, due in part to strict quality and regulatory requirements. Our operating results in this business depend on our ability to execute and, when necessary, improve our quality management strategy and systems, and our ability to effectively train and maintain our employee base with respect to quality management. A failure of our quality control systems could result in problems with facility operations or preparation or provision of products. In each case, such problems could arise for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials or environmental factors and damage to, or loss of, manufacturing operations. Such problems could affect production of a particular batch or series of batches of products, requiring the destruction of such products or a halt of facility production altogether.
In addition, our failure to meet required quality standards may result in our failure to timely deliver products to our customers, which in turn could damage our reputation for quality and service. Any such failure could, among other things, lead to increased costs, lost revenues, reimbursement to customers for lost drug product, registered intermediates, registered starting materials, and active pharmaceutical ingredients, other customer claims, damage to and possibly termination of existing customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. Production problems in our drug and biologic manufacturing operations could be particularly
14
THERMO FISHER SCIENTIFIC INC.

significant because the cost of raw materials for such manufacturing is often high. If problems in preparation or manufacture of a product or failures to meet required quality standards for that product are not discovered before such product is released to the market, we may be subject to adverse regulatory actions, including product recalls, product seizures, injunctions to halt manufacture and distribution, restrictions on our operations, civil sanctions, including monetary sanctions, and criminal actions. In addition, such problems or failures could subject us to litigation claims, including claims from our customers for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of which could be significant.
We are subject to product and other liability risks for which we may not have adequate insurance coverage. We may be named as a defendant in product liability or errors and omissions lawsuits, which may allege that products or services we have provided have resulted or could result in an unsafe condition, property damage or injury to end users or financial loss for consumers. Additionally, products currently or previously sold by our environmental and process instruments and radiation measurement and security instruments businesses include fixed and portable instruments used for chemical, radiation and trace explosives detection. These products are used in airports, embassies, cargo facilities, border crossings and other high-threat facilities for the detection and prevention of terrorist acts. If any of these products were to malfunction, it is possible that explosive or radioactive material could fail to be detected by our product, which could lead to product liability claims. In addition, patients involved in our clinical services trials conducted by our clinical development services business or taking drugs approved on the basis of those trials may also bring personal injury claims against us. There are also many other factors beyond our control that could lead to liability claims, such as the reliability and competence of the customers’ operators and the training of such operators.
Any such product liability claims brought against us could be significant and any adverse determination may result in liabilities subject to insurance policy exclusions where insurance would not respond or in excess of our insurance coverage. Although we carry product liability and errors and omissions insurance, we cannot be certain that our current insurance will be sufficient to cover these claims or that it can be maintained on acceptable terms, if at all.
We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies. We are subject to various local, state, federal, foreign and transnational laws and regulations, which include the operating and security standards of the FDA, the U.S. Drug Enforcement Agency (the DEA), various state boards of pharmacy, state health departments, the U.S. Department of Health and Human Services (the DHHS), the European Medicines Agency (the EMA), the EU member states and other comparable agencies and, in the future, any changes to such laws and regulations could adversely affect us. In particular, we are subject to laws and regulations concerning current good manufacturing practices and drug safety. Our subsidiaries may be required to register for permits and/or licenses with, and may be required to comply with the laws and regulations of, the DEA, the FDA, the DHHS, foreign agencies including the EMA, and other various state boards of pharmacy, state health departments and/or comparable state agencies as well as certain accrediting bodies depending upon the type of operations and location of product distribution, manufacturing and sale.
The manufacture, distribution and marketing of many of our products and services, including medical devices, and our pharma and clinical development services, are subject to extensive ongoing regulation by the FDA, the DEA, the EMA, and other equivalent local, state, federal and non-U.S. regulatory authorities. In addition, we are subject to inspections by these regulatory authorities. Failure by us or by our customers to comply with the requirements of these regulatory authorities, including without limitation, remediating any inspectional observations to the satisfaction of these regulatory authorities, could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of existing or denial of pending approvals, including those relating to products or facilities. In addition, such a failure could expose us to contractual or product liability claims, contractual claims from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients or personal injury, as well as ongoing remediation and increased compliance costs, any or all of which could be significant. We are the sole manufacturer of a number of pharmaceuticals for many of our customers and a negative regulatory event could impact our customers’ ability to provide products to their customers.
We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the handling, transportation and manufacture of substances that could be classified as hazardous, and we are required to comply with various import laws and export control and economic sanctions laws, which may affect our transactions with certain customers. In certain circumstances, export control and economic sanctions regulations may prohibit the export of certain products, services and technologies. In other circumstances, we may be required to obtain an export license before exporting the controlled item. Compliance with the various import laws that apply to our businesses can restrict our access to, and increase the cost of obtaining, certain products and at times can interrupt our supply of imported inventory. Any noncompliance by us with applicable laws and regulations or the failure to maintain, renew or obtain necessary permits and licenses could result in criminal, civil and administrative penalties and could have an adverse effect on our results of operations.
15
THERMO FISHER SCIENTIFIC INC.

Our reputation, ability to do business and financial statements may be impaired by improper conduct by any of our employees, agents, business partners or other third parties. We have internal controls and compliance systems to protect the company against acts committed by employees, agents or businesses that we acquire that would violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks and false claims, pricing, sales and marketing practices, conflicts of interest, competition, employment practices and workplace behavior, export and import compliance, money laundering and data privacy, but these controls and systems may not be sufficient to prevent every such wrongful act. In particular, the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business, and we operate in many parts of the world that have experienced governmental corruption to some degree. Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in the U.S. and in other jurisdictions and related shareholder lawsuits, could lead to substantial civil and criminal, monetary and nonmonetary penalties and could cause us to incur significant legal and investigatory fees. In addition, the government may seek to hold us liable for violations committed by companies which we acquire. We also rely on our suppliers to adhere to our supplier standards of conduct, and material violations of such standards of conduct could occur that could have a material effect on our business, reputation and financial statements. In addition, any allegations of issues resulting from the misuse of our products could, even if untrue, adversely affect our reputation and our customers’ willingness to purchase products from us. Any such allegations could cause us to lose customers and divert our resources from other tasks, which could materially and adversely affect our business and operating results.
Our inability to protect our intellectual property could have a material adverse effect on our business. In addition, third parties may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result. We place considerable emphasis on obtaining patent and trade secret protection for significant new technologies, products and processes because of the length of time and expense associated with bringing new products through the development process and into the marketplace. Our success depends in part on our ability to develop patentable products and obtain, defend and enforce patent protection for our products both in the U.S. and in other countries. We own numerous U.S. and foreign patents, and we intend to file additional applications, as appropriate, for patents covering our products. Patents may not be issued for any pending or future patent applications owned by or licensed to us, and the claims allowed under any issued patents may not be sufficiently broad to protect our technology. Any issued patents owned by or licensed to us may be challenged, invalidated or circumvented, and the rights under these patents may not provide us with competitive advantages. In addition, competitors may design around our technology or develop competing technologies. Intellectual property rights may also be unavailable or limited in some foreign countries, which could make it easier for competitors to capture increased market position. We could incur substantial costs to defend ourselves in suits brought against us or in suits in which we may assert our patent rights against others. An unfavorable outcome of any such litigation could materially adversely affect our business and results of operations.
We also rely on trade secrets and proprietary know-how with which we seek to protect our products, in part, by confidentiality agreements with our collaborators, employees and consultants. These agreements may not adequately protect our trade secrets and other proprietary rights. These agreements may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently developed by our competitors.
We also depend in part on our trademarks and the strength of our proprietary brands, which we consider important to our business. If we are unable to protect or preserve the value of our intellectual property rights for any reason, including our inability to successfully defend against counterfeit, knock offs, grey-market, infringing or otherwise unauthorized products, our brand and reputation could be damaged, and our business may be harmed.
Third parties may assert claims against us to the effect that we are infringing on their intellectual property rights. In the event that a claim relating to intellectual property is asserted against us, or third parties not affiliated with us hold pending or issued patents that relate to our products or technology, we may seek licenses to such intellectual property or challenge those patents. However, we may be unable to obtain these licenses on commercially reasonable terms, if at all, and our challenge of the patents may be unsuccessful. Our failure to obtain the necessary licenses or other rights could prevent the sale, manufacture, or distribution of our products and, therefore, could have a material adverse effect on our business, financial condition and results of operations.
Risks Relating to Financial Profile
Fluctuations in our effective tax rate may adversely affect our results of operations and cash flows. As a global company, we are subject to taxation in numerous countries, states and other jurisdictions. In preparing our financial statements, we record the amount of tax that is payable in each of the countries, states and other jurisdictions in which we operate. Our future effective tax rate, however, may be lower or higher than experienced in the past due to numerous factors, including a change in the mix of our profitability from country to country, changes in accounting for income taxes, the results of examinations and audits of
16
THERMO FISHER SCIENTIFIC INC.

our tax filings and recently enacted and future changes in tax laws in jurisdictions in which we operate. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business, results of operations and cash flows.
In December 2021, the Organization for Economic Cooperation and Development (“OECD”) published a proposal for the establishment of a global minimum tax rate of 15% (the “Pillar Two rule”). The OECD has recommended that the Pillar Two rule become effective for fiscal years beginning after January 1, 2024. To date, member states are in various stages of implementation and the OECD continues to refine technical guidance. We are closely monitoring developments of the Pillar Two rule and are currently evaluating the potential impacts in each of the countries in which we operate; however, we currently do not expect the Pillar Two rule to have a material impact on our effective tax rate.
Our existing and future indebtedness may restrict our investment opportunities or limit our activities and negatively impact our credit ratings. As of December 31, 2023, we had approximately $34.92 billion in outstanding indebtedness. In addition, we have availability to borrow under a revolving credit facility that provides for up to $5.00 billion of unsecured multi-currency revolving credit (the Facility). We may also obtain additional long-term debt and lines of credit to meet future financing needs, which would have the effect of increasing our total leverage.
Our leverage could have negative consequences, including increasing our vulnerability to adverse economic and industry conditions, limiting our ability to obtain additional financing and limiting our ability to acquire new products and technologies through strategic acquisitions.
Our ability to make scheduled payments, refinance our obligations or obtain additional financing will depend on our future operating performance and on economic, financial, competitive and other factors beyond our control. Our business may not generate sufficient cash flow to meet our obligations. If we are unable to service our debt, refinance our existing debt or obtain additional financing, we may be forced to delay strategic acquisitions, capital expenditures or research and development expenditures.
Additionally, the agreements governing our debt require that we maintain a financial ratio, and contain affirmative and negative covenants that restrict our activities by, among other limitations, limiting our ability to incur additional indebtedness, merge or consolidate with other entities and create liens. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter.
Our ability to comply with these financial restrictions and covenants is dependent on our future performance, which is subject to prevailing economic conditions and other factors, including factors that are beyond our control such as the impact of foreign exchange rates and interest rates. Our failure to comply with any of these restrictions or covenants may result in an event of default under the applicable debt instrument, which could permit acceleration of the debt under that instrument and require us to prepay that debt before its scheduled due date. Also, an acceleration of the debt under certain of our debt instruments would trigger an event of default under other of our debt instruments.
Item 1B.    Unresolved Staff Comments
None.
Item 1C.    Cybersecurity
Cybersecurity Risk Management and Strategy
As is the case for most large global companies, we are regularly subject to cyberattacks and other cybersecurity incidents and, therefore, we incorporate cybersecurity into our overall risk management process. Our commitment to cybersecurity emphasizes using a risk-based, “defense in depth” approach to assess, educate, block, identify, respond to and recover from cybersecurity threats. Recognizing that no single technology, process or control can effectively prevent or mitigate all risks, we employ a strategy of technologies, processes and controls, all working independently but as part of a cohesive strategy to manage or reduce risk.
Our cybersecurity program assists in the management of risks associated with the confidentiality, integrity and availability of data and systems within the company environment to effectively support our business objectives and customer expectations. The program provides guidance to business stakeholders on cybersecurity risks as input into their risk management processes that balance cybersecurity risk with other important risks that may include strategic, regulatory, economic and financial considerations.
17
THERMO FISHER SCIENTIFIC INC.
We seek to routinely refine our cybersecurity approach to adapt to changes in the threat landscape and manage emerging security risks. In order to evaluate risks from cybersecurity threats associated with the company’s use of certain third-party technology providers, we have incorporated a risk-based assessment into the corporate information technology (IT) procurement process designed to assess the security risk of certain third parties providing new technology solutions to our environment.
We believe cybersecurity is the responsibility of every employee, and regularly educate and share best practices with our employees to raise awareness of cybersecurity threats through a security awareness training program, including regular exercises, periodic cyber-event simulations and annual attestation to our Technology Acceptable Use Policy.
We do not reasonably believe there are currently any cybersecurity incidents that have materially affected or are reasonably likely to materially affect the company or its business strategy, results of operations or financial condition. For more information on the risks related to our IT systems, see “A significant disruption in, or breach in security of, our IT systems or violation of data privacy laws could adversely affect our business or customers that use our products” under the heading “Risk Factors” in Part I, Item 1A.
Cybersecurity Governance and Oversight
The Board of Directors has delegated the oversight of cybersecurity risks to the Audit Committee. Our cybersecurity program is led by the company’s senior vice president, chief information officer, along with our vice president, chief information security officer. Management provides an operational update to the Audit Committee each quarter. In addition, the Audit Committee and our full Board of Directors receive an annual overview of the cybersecurity program, cybersecurity threat landscape, investments, and opportunities to enhance the company’s systems and security of products and operations.
The company’s corporate IT security team leads the company-wide cybersecurity strategy and advocates to protect the company systems, its employees and customers against cybersecurity risks. Through annual internal and external audits, we maintain an ISO/IEC 27001:2013 certification for the management of our cybersecurity program consisting of the following areas:
•cybersecurity program management and governance including risk management;
•cybersecurity operations including security operation centers;
•product security;
•security investigations;
•cybersecurity architecture and engineering; and
•security awareness and training.
Our senior vice president, chief information officer, vice president, chief information security officer (CISO), and vice president, chief product security officer have each served in various roles in IT and information security for over 20 years. These individuals’ knowledge and experience along with the culture and talent of the corporate IT security team organization are instrumental in developing and executing our cybersecurity strategies. The CISO meets with senior leadership to review and discuss the cybersecurity program, including emerging cybersecurity risks, threats and industry trends.
Cybersecurity is integrated into the risk management process for the company through various corporate mechanisms, including quarterly business reviews, annual budget planning, and targeted risk-based engagements.
Item 2.    Properties
The company owns and leases office, engineering, laboratory, production and warehouse space throughout the world.
Item 3.    Legal Proceedings
There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See Note 12 to our Consolidated Financial Statements – “Commitments and Contingencies”.
Item 4.    Mine Safety Disclosures
Not applicable.
18
THERMO FISHER SCIENTIFIC INC.
PART II
Item 5.    Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Price of Common Stock
Our common stock is traded on the New York Stock Exchange under the symbol TMO.
Holders of Common Stock
As of February 3, 2024, the company had 2,337 holders of record of its common stock. This does not include holdings in street or nominee names.
Issuer Purchases of Equity Securities
There was no share repurchase activity for the company’s fourth quarter of 2023. On November 14, 2023, the Board of Directors announced that it replaced the existing authorization to repurchase the company’s common stock, of which $1.00 billion was remaining, with a new authorization to repurchase up to $4.00 billion of the company’s common stock. Early in the first quarter of 2024, the company repurchased $3.00 billion (5.5 million shares) of the company's common stock. At February 22, 2024, $1.00 billion was available for future repurchases of the company’s common stock under this authorization.
Item 6.    Reserved
Not applicable.
Item 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
Reference is made throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations to Notes to the Consolidated Financial Statements, which begin on page 29 of this report. Management’s Discussion and Analysis of Financial Condition and Results of Operations for 2021 is included in Item 7 of the company’s 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission.
The company refers to various amounts or measures not prepared in accordance with generally accepted accounting principles (non-GAAP measures). These non-GAAP measures are further described and reconciled to their most directly comparable amount or measure under the section “Non-GAAP Measures” later in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Overview
Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The company’s operations fall into four segments (Note 4): Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.
Consolidated Results
(Dollars in millions except per share amounts)20232022Change
Revenues
$42,857 $44,915 (5)%
GAAP operating income$6,859 $8,393 (18)%
GAAP operating income margin16.0 %18.7 %(2.7) pt
Adjusted operating income (non-GAAP measure)
$9,810 $10,985 (11)%
Adjusted operating income margin (non-GAAP measure)
22.9 %24.5 %(1.6) pt
GAAP diluted earnings per share attributable to Thermo Fisher Scientific Inc.$15.45 $17.63 (12)%
Adjusted earnings per share (non-GAAP measure)
$21.55 $23.24 (7)%
19
THERMO FISHER SCIENTIFIC INC.
Organic Revenue Growth
Revenue growth(5)%
Impact of acquisitions1 %
Impact of currency translation0 %
Organic revenue growth* (non-GAAP measure)
(5)%
*    Results may not sum due to rounding.
Since 2020, the Life Sciences Solutions and Specialty Diagnostics segments as well as the laboratory products business have supported COVID-19 diagnostic testing, scaling and evolving their molecular diagnostics solutions and plastic consumables businesses to respond to the COVID-19 pandemic. The biosciences and bioproduction businesses have expanded their capacity to meet the needs of pharma and biotech customers as they have expanded their own production volumes to meet global vaccine manufacturing requirements. Additionally, our pharma services business has provided our pharma and biotech customers with the services they needed to develop and produce vaccines and therapies globally. Since the company’s acquisition of PPD in December 2021, the clinical research business has continued to play a leading role in supporting the clinical trials for COVID-19 vaccines and therapies. These positive impacts continued at much lower levels in 2023 as customer testing as well as therapy and vaccine demand declined. Sales of products related to COVID-19 testing were $0.33 billion and $3.11 billion in 2023 and 2022, respectively.
During 2023, growth from pharma and biotech customers slightly declined. Over the past few years, the company has played a meaningful role in the production of COVID-19 vaccines and therapies. In 2023, reduced demand for our products and services that support COVID-19 vaccines and therapies was partially offset through strong commercial execution as a result of our trusted partner status with customers in this market. We saw broad based strength across the academic and government market as we saw the benefits of our accelerated investments into high impact innovation with great customer adoption and strong demand globally. The industrial and applied market was strong, driven by the relevance of our analytical instrument technologies serving our semiconductor and materials science customers. The diagnostics and healthcare market declined due to decreased demand for COVID-19 testing products. During 2023, sales growth in all major regions declined due to decreased demand for COVID-19 related products, as well as a challenging macroeconomic environment and low economic activity in China. Contributions to organic revenue during 2023 from the Analytical Instruments and Laboratory Products and Biopharma Services segments were more than offset by declines in the Life Sciences Solutions and Specialty Diagnostics segments.
The company continues to execute its proven growth strategy which consists of three pillars:
•High-impact innovation,
•Our trusted partner status with customers, and
•Our unparalleled commercial engine.
GAAP operating income margin and adjusted operating income margin decreased in 2023 due primarily to lower COVID-19 related revenue. This was partially offset by strong productivity improvements and strong pricing realization to address higher inflation. GAAP operating income margin in 2023 was also impacted by restructuring and other charges incurred for headcount reductions and facility consolidations in an effort to streamline operations and limit the impact of expected lower revenue (Note 16). We estimate that restructuring actions resulting in charges of approximately $0.2 billion in 2023 will realize annual cost savings of approximately $0.5 billion, primarily due to reduced employee expenses.
The company’s references to strategic growth investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects and other expenditures to enhance the customer experience, as well as incentive compensation and recognition for employees. The company’s references throughout this discussion to productivity improvements generally refer to improved cost efficiencies from its Practical Process Improvement (PPI) business system including reduced costs resulting from implementing continuous improvement methodologies, global sourcing initiatives, a lower cost structure following restructuring actions including headcount reductions and consolidation of facilities, and low cost region manufacturing.
Notable Recent Acquisitions
On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma.
20
THERMO FISHER SCIENTIFIC INC.
On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment’s portfolio with the addition of highly complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development.
Segment Results
The company’s management evaluates segment operating performance using operating income before certain charges/credits as defined in Note 4. Accordingly, the following segment data are reported on this basis.
(Dollars in millions)20232022
Revenues
Life Sciences Solutions
$9,977 $13,532 
Analytical Instruments
7,263 6,624 
Specialty Diagnostics
4,405 4,763 
Laboratory Products and Biopharma Services
23,041 22,511 
Eliminations
(1,829)(2,515)
Consolidated revenues
$42,857 $44,915 
Life Sciences Solutions
Organic* (non-GAAP measure)
(Dollars in millions)20232022Total
Change		Currency
Translation		Acquisitions/ Divestitures
Revenues$9,977 $13,532 (26)%0 %0 %(26)%
Segment income3,420 5,582 (39)%
Segment income margin34.3 %41.2 %(6.9) pt
The decrease in organic revenues in 2023 was primarily due to moderation in COVID-19 related revenue. The decrease in segment income margin resulted primarily from significantly lower COVID-19 related revenue and unfavorable volume pull-through, partially offset by exceptionally strong productivity improvements and favorable price realization.
Analytical Instruments
Organic* (non-GAAP measure)
(Dollars in millions)20232022Total
Change		Currency
Translation		Acquisitions/ Divestitures
Revenues$7,263 $6,624 10 %(1)%0 %10 %
Segment income1,908 1,507 27 %
Segment income margin26.3 %22.8 %3.5  pt
The increase in organic revenues in 2023 was due to increased demand across all the segment’s businesses, with particular strength in the electron microscopy and chromatography and mass spectrometry businesses. The increase in segment income margin resulted primarily from strong productivity, strong pricing realization to address higher inflation and strong volume pull-through, offset in part by the effects of currency translation and strategic growth investments.
Specialty Diagnostics
Organic* (non-GAAP measure)
(Dollars in millions)20232022Total
Change		Currency
Translation		Acquisitions/ Divestitures
Revenues$4,405 $4,763 (8)%0 %5 %(13)%
Segment income1,124 1,024 10 %
Segment income margin25.5 %21.5 %4.0  pt
The decrease in organic revenues in 2023 was due to decreased demand, primarily driven by products addressing diagnosis of COVID-19, partially offset by underlying growth in the immunodiagnostics, microbiology, and transplant diagnostics businesses. The increase in segment income margin was due to favorable business mix, strong pricing realization to address higher inflation, and strong productivity improvements, partially offset by the impact of lower COVID-19 testing volume.
21
THERMO FISHER SCIENTIFIC INC.
Laboratory Products and Biopharma Services
Organic* (non-GAAP measure)
(Dollars in millions)20232022Total
Change		Currency
Translation		Acquisitions/ Divestitures
Revenues$23,041 $22,511 2 %0 %0 %2 %
Segment income3,358 2,872 17 %
Segment income margin14.6 %12.8 %1.8  pt
The increase in organic revenues in 2023 was primarily due to higher sales in the clinical research and pharma services businesses. The increase in segment income margin was primarily due to very strong productivity improvements and strong pricing realization to address higher inflation.
*    Results may not sum due to rounding
Non-operating Items
(Dollars in millions)20232022
Net interest expense
$496 $454 
GAAP other income/(expense)(65)(104)
Adjusted other income/(expense) (non-GAAP measure)
(15)13 
GAAP tax rate4.5 %9.0 %
Adjusted tax rate (non-GAAP measure)
10.0 %13.0 %
Weighted average diluted shares388 394 
Net interest expense (interest expense less interest income) increased due primarily to the increase in debt for general corporate purposes and the company’s capital deployment initiatives, which included financing stock buybacks, paying dividends and acquiring The Binding Site Group and CorEvitas, LLC (Note 2). These increases were partially offset by higher cash and cash equivalents balances as well as higher interest rates on these balances when compared to 2022. See additional discussion under the caption “Liquidity and Capital Resources” below. In 2023 and 2022 the company’s net interest expense was reduced by approximately $116 million and $16 million, respectively, as a result of its interest rate swap and cross-currency interest rate swap arrangements (Note 14).
GAAP other income/(expense) and adjusted other income/(expense) includes currency transaction gains/losses on non-operating monetary assets and liabilities, and net periodic pension benefit cost/income, excluding the service cost component. GAAP other income/(expense) in 2023 also includes $45 million of net losses on investments. GAAP other income/(expense) in 2022 also includes $160 million of net losses on investments and $26 million of losses on the early extinguishment of debt (Note 10), partially offset by $67 million of net gains on derivative instruments to address certain foreign currency risks.
The GAAP and adjusted tax rates in 2023 were impacted by changes in valuation allowances, including a $183 million release in a jurisdiction where the deferred tax assets are now expected to be realized, and, to a lesser extent, by a decrease in pre-tax earnings compared to 2022. The company’s GAAP and adjusted tax rates in 2023 were also impacted by tax planning initiatives, including a tax benefit of $127 million for U.S. tax credits and the revaluation of net operating loss carryforwards due to higher tax rates as a result of its tax return resubmissions, a tax benefit of $91 million, net of related tax expenses, from a foreign exchange loss on an intercompany debt refinancing transaction, and $233 million of tax benefits resulting from intra-entity transactions. The company’s GAAP and adjusted tax rates in 2022 were impacted by releases of valuation allowances of $189 million in jurisdictions where the deferred tax assets are now expected to be realized. The company’s 2022 GAAP tax rate was also impacted by a net benefit of $208 million resulting from tax audit settlements (Note 8). The effective tax rates in both 2023 and 2022 were also affected by relatively significant earnings in lower tax jurisdictions. Due primarily to the non-deductibility of intangible asset amortization for tax purposes, the company’s cash payments for income taxes were higher than its income tax expense for financial reporting purposes. See additional discussion under the caption “Liquidity and Capital Resources” below.
The company expects its GAAP effective tax rate in 2024 will be between 4% and 6% based on currently forecasted rates of profitability in the countries in which the company conducts business and expected generation of foreign tax credits. The effective tax rate can vary significantly from period to period as a result of discrete income tax factors and events. The company expects its adjusted tax rate will be approximately 10.5% in 2024.
The company has operations and a taxable presence in approximately 70 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the statutory tax rates in those countries. Based on the
22
THERMO FISHER SCIENTIFIC INC.
dispersion of the company’s non-U.S. income tax provision among many countries, the company believes that a change in the statutory tax rate in any individual country is not likely to materially affect the company’s income tax provision or net income, aside from any resulting one-time adjustment to the company’s deferred tax balances to reflect a new rate.
Weighted average diluted shares decreased in 2023 compared to 2022 due to share repurchases, net of option dilution.
Liquidity and Capital Resources
The company’s proven growth strategy has enabled it to generate free cash flow as well as access the capital markets. The company deploys its capital primarily via mergers and acquisitions and secondarily via share buybacks and dividends.
December 31,December 31,
(In millions)20232022
Cash and cash equivalents$8,077 $8,524 
Total debt34,917 34,488 
Approximately half of the company’s cash balances and cash flows from operations are from outside the U.S. The company uses its non-U.S. cash for needs outside of the U.S. including acquisitions, capacity expansion, and repayment of third-party foreign debt by foreign subsidiaries. In addition, the company also transfers cash to the U.S. using non-taxable intercompany transactions, including loans and returns of capital, as well as dividends where the related U.S. dividend received deduction or foreign tax credit equals any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company does not expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.
The company believes that its existing cash and cash equivalents and its future cash flow from operations together with available borrowing capacity under its revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24 months.
As of December 31, 2023, the company’s short-term debt totaled $3.61 billion. The company has a revolving credit facility with a bank group that provides up to $5.00 billion of unsecured multi-currency revolving credit (Note 10). If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of December 31, 2023, no borrowings were outstanding under the company’s revolving credit facility, although available capacity was reduced by immaterial outstanding letters of credit.
(In millions)20232022
Net cash provided by operating activities
$8,406 $9,154 
Net cash used in investing activities
(5,142)(2,159)
Net cash used in financing activities
(3,622)(2,810)
Free cash flow (non-GAAP measure)
7,014 6,935 
Operating Activities
During 2023, cash provided by income was offset in part by investments in working capital. A decrease in inventories provided cash of $0.60 billion. A decrease in accounts payable used cash of $0.50 billion, and changes in other assets and other liabilities used cash of $0.80 billion primarily due to the timing of payments for compensation and income taxes. Cash payments for income taxes were $1.48 billion during 2023.
During 2022, cash provided by income was offset in part by investments in working capital. Increases in accounts receivable and inventories used cash of $0.43 billion and $0.83 billion, respectively, primarily to support growth in sales. An increase in accounts payable provided cash of $0.65 billion. Cash payments for income taxes were $1.23 billion during 2022.
The company is contingently liable with respect to certain legal proceedings and related matters. An unfavorable outcome that differs materially from current accrual estimates, if any, for one or more of the matters described under the heading “Product Liability, Workers Compensation and Other Personal Injury Matters” in Note 12 could have a material adverse effect on the company’s financial position as well as its results of operations and cash flows.
23
THERMO FISHER SCIENTIFIC INC.
Investing Activities
During 2023, acquisitions of The Binding Site Group and CorEvitas, LLC used cash of $2.70 billion and $0.91 billion, respectively. The company’s investing activities also included purchases of $1.48 billion of property, plant and equipment for capacity and capability investments.
During 2022 the company’s investing activities were principally for the purchase of property, plant and equipment for capacity and capability investments.
The company expects that for all of 2024, expenditures for property, plant and equipment, net of disposals, will be between $1.3 billion and $1.5 billion.
Financing Activities
During 2023, issuance of senior notes provided $5.94 billion of cash. Repayment of senior notes and net commercial paper activity used cash of $5.78 billion and $0.32 billion, respectively. The company’s financing activities also included the repurchase of $3.00 billion of the company’s common stock (5.2 million shares) and the payment of $0.52 billion in cash dividends. On November 14, 2023, the Board of Directors announced that it replaced the existing authorization to repurchase the company’s common stock, of which $1.00 billion was remaining, with a new authorization to repurchase up to $4.00 billion of the company’s common stock.
Early in the first quarter of 2024, the company repurchased $3.00 billion (5.5 million shares) of the company's common stock. At February 22, 2024, $1.00 billion was available for future repurchases of the company’s common stock under this authorization.
During 2022, issuance of senior notes provided $3.19 billion of cash. Repayment of senior notes and net commercial paper activity used cash of $0.38 billion and $2.16 billion, respectively. The company’s financing activities also included the repurchase of $3.00 billion of the company's common stock (5.3 million shares) and the payment of $0.46 billion in cash dividends.
In addition to the obligations on the balance sheet at December 31, 2023, which include, but are not limited to pension obligations (Note 7), unrecognized tax benefits (Note 8), debt (Note 10), operating leases (Note 11), and contingent consideration (Note 14), the company has also entered into an agreement to acquire Olink (Note 2). The company also has unconditional purchase obligations in the ordinary course of business that include agreements to purchase goods, services or fixed assets, pay royalties, and fund capital commitments pursuant to investments held by the company (Note 12).
Non-GAAP Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the effects of currency translation. We report organic revenue growth because Thermo Fisher management believes that in order to understand the company’s short-term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures and foreign currency translation on revenues. Thermo Fisher management uses organic revenue growth to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.
We report adjusted operating income, adjusted operating income margin, adjusted other income/(expense), adjusted tax rate, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:
•Certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction/acquisition-related costs, including changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.
•Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities and large-scale abandonment of product lines are not indicative of our normal operating costs.
•Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on
24
THERMO FISHER SCIENTIFIC INC.
investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
•The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.
•The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.
We report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.
The non-GAAP financial measures of the company’s results of operations and cash flows included in this Form 10-K are not meant to be considered superior to or a substitute for the company’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth within the “Consolidated Results” and “Segment Results” sections and below.
(Dollars in millions except per share amounts)20232022
Reconciliation of adjusted operating income and adjusted operating income margin
GAAP operating income$6,859 16.0 %$8,393 18.7 %
Cost of revenues adjustments (a)
95 0.2 %46 0.1 %
Selling, general and administrative expenses adjustments (b)
59 0.1 %37 0.1 %
Restructuring and other costs (c)
459 1.1 %114 0.3 %
Amortization of acquisition-related intangible assets2,338 5.5 %2,395 5.3 %
Adjusted operating income (non-GAAP measure)
$9,810 22.9 %$10,985 24.5 %
Reconciliation of adjusted other income/(expense)
GAAP other income/(expense)$(65)$(104)
Adjustments (d)50 117 
Adjusted other income/(expense) (non-GAAP measure)
$(15)$13 
Reconciliation of adjusted tax rate
GAAP tax rate4.5 %9.0 %
Adjustments (e)5.5 %4.0 %
Adjusted tax rate (non-GAAP measure)
10.0 %13.0 %
Reconciliation of adjusted earnings per share
GAAP diluted earnings per share (EPS) attributable to Thermo Fisher Scientific Inc.$15.45 $17.63 
Cost of revenues adjustments (a)0.24 0.12 
Selling, general and administrative expenses adjustments (b)0.15 0.09 
Restructuring and other costs (c)1.18 0.29 
Amortization of acquisition-related intangible assets6.03 6.07 
Other income/expense adjustments (d)0.13 0.30 
Provision for income taxes adjustments (e)(1.66)(1.70)
Equity in earnings/losses of unconsolidated entities0.15 0.44 
Noncontrolling interests adjustments (f)(0.12)— 
Adjusted EPS (non-GAAP measure)
$21.55 $23.24 
25
THERMO FISHER SCIENTIFIC INC.
(Dollars in millions except per share amounts)20232022
Reconciliation of free cash flow
GAAP net cash provided by operating activities$8,406 $9,154 
Purchases of property, plant and equipment(1,479)(2,243)
Proceeds from sale of property, plant and equipment87 24 
Free cash flow (non-GAAP measure)
$7,014 $6,935 
(a) Adjusted results in 2023 and in 2022 exclude charges for the sale of inventories revalued at the date of acquisition and charges for inventory write-downs associated with large-scale abandonment of product lines. Adjusted results in 2023 also exclude $13 million of accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations.
(b) Adjusted results in 2023 and 2022 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges associated with product liability litigation.
(c) Adjusted results in 2023 and 2022 exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, charges for environmental-related matters, abandoned facility and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2023 also exclude $26 million of contract termination costs associated with facility closures, $19 million of net charges for pre-acquisition litigation and other matters, and $11 million of gains on the sale of real estate. Adjusted results in 2022 also exclude $14 million of gain on the sale of intellectual property.
(d) Adjusted results exclude net gains/losses on investments. Adjusted results in 2022 also exclude $67 million of net gains on derivative instruments to address certain foreign currency risks and $26 million of losses on the early extinguishment of debt.
(e) Adjusted results in 2023 and 2022 exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes and the tax impacts from audit settlements (including a $658 million benefit from an audit settlement in 2022). Adjusted results in 2023 also exclude $14 million of charges for pre-acquisition matters. Adjusted results in 2022 also exclude a $423 million charge for the impact of deferred tax realizability assessments as a result of audit settlements.
(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests.
Critical Accounting Policies and Estimates
The company’s discussion and analysis of its financial condition and results of operations is based upon its financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent liabilities. On an on-going basis, management evaluates its estimates, including those related to acquisition-related measurements and income taxes. Management believes the most complex and sensitive judgments, because of their significance to the consolidated financial statements, result primarily from the need to make estimates about the effects of matters that are inherently uncertain. Management bases its estimates on historical experience, current market and economic conditions and other assumptions that management believes are reasonable. The results of these estimates form the basis for judgments about the carrying value of assets and liabilities where the values are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
The company believes the following represent its critical accounting policies and estimates used in the preparation of its financial statements:
Acquisition-related Measurements
Business Combinations
The company uses assumptions and estimates in determining the fair value of assets acquired and liabilities assumed in a business combination. The determination of the fair value of intangible assets, which represent a significant portion of the purchase price in many of the company’s acquisitions, requires the use of significant judgment with regard to (i) the fair value and (ii) whether such intangibles are amortizable or non-amortizable and, if the former, the period and the method by which the intangible asset will be amortized. The company estimates the fair value of acquisition-related intangible assets principally based on projections of cash flows that will arise from identifiable intangible assets of acquired businesses, which include estimates of customer attrition and technology obsolescence rates. The projected cash flows are discounted to determine the present value of the assets at the dates of acquisition. See Note 2 for additional information about our recent business combinations.
26
THERMO FISHER SCIENTIFIC INC.
Goodwill and Indefinite-lived Intangible Assets
The company evaluates goodwill and indefinite-lived intangible assets for impairment annually and when events occur or circumstances change that would more likely than not reduce the fair value of an asset below its carrying amount. Events or circumstances that might require an interim evaluation include unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities, loss of key personnel and acts by governments and courts, among others. Goodwill and indefinite-lived intangible assets totaled $44.02 billion and $1.24 billion, respectively, at December 31, 2023 (see Note 1 for additional information). Estimates of discounted future cash flows require assumptions related to revenue and operating income growth rates, discount rates and other factors. For the goodwill impairment tests, the company also considers (i) peer revenues and earnings trading multiples from companies that have operational and financial characteristics that are similar to the respective reporting units and (ii) estimated weighted average costs of capital. Different assumptions from those made in the company’s analysis could materially affect projected cash flows and the company’s evaluation of goodwill and indefinite-lived intangible assets for impairment.
The company performed the quantitative goodwill impairment test for all of its reporting units and indefinite-lived intangible assets. Determinations of fair value based on projections of discounted cash flows, which decreased from the prior year projections primarily due to higher discount rates, and based on peer revenues and earnings trading multiples, which also decreased from the prior year, were sufficient to conclude that no impairments of goodwill or indefinite-lived intangible assets existed at the end of the tenth fiscal month of 2023, the date of the company’s annual impairment testing. There were no interim impairments of goodwill or indefinite-lived intangible assets in 2023. There can be no assurance, however, that adverse events or conditions will not cause the fair values of these assets to decline. Should the fair values of the company’s reporting units or indefinite-lived intangible assets decline because of reduced operating performance, market declines, or other indicators of impairment, or as a result of changes in the discount rates, charges for impairment may be necessary.
During its annual 2023 goodwill impairment assessments, the company determined that the excess of fair value over carrying value for one of the clinical research business’s reporting units had increased to 4%. Despite this favorable increase, given that the fair value of the reporting unit was not substantially in excess of its carrying value as of the annual 2023 assessment date, relatively small decreases in future cash flows versus anticipated results, decreases in peer trading multiples and/or increases in weighted average costs of capital could result in impairment of goodwill. The reporting unit had $3.95 billion of goodwill, and an overall carrying value of $5.54 billion as of December 31, 2023.
Definite-lived Intangible Assets
Definite-lived intangible assets totaled $15.44 billion at December 31, 2023 (see Note 1 for additional information). Certain definite-lived intangible assets have largely independent cash flows. The company reviews these definite-lived intangible assets for impairment individually when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. Actual cash flows arising from a particular intangible asset could vary from projected cash flows, which could imply different carrying values from those established at the dates of acquisition and which could result in impairment of such asset. Most of the company’s definite-lived intangible assets are used in conjunction with other assets, such as property, plant and equipment and operating lease right-of-use assets. In these situations, the company considers the asset groups to be the units of account for impairment testing. The company recorded definite-lived intangible asset impairments of $0.01 billion and $0.12 billion in 2023 and 2021, respectively (Note 16).
Income Taxes
Unrecognized Tax Benefits
In the ordinary course of business there is inherent uncertainty in quantifying the company’s income tax positions. The company assesses income tax positions and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the company has recorded the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Should tax return positions that the company expects are sustainable not be sustained upon audit, the company could be required to record an incremental tax provision for such taxes. The company’s liability for these unrecognized tax benefits totaled $0.54 billion at December 31, 2023, compared to $0.57 billion at December 31, 2022, primarily as a result of an audit settlement (Note 8).
The company operates in numerous countries under many legal forms and, as a result, is subject to the jurisdiction of numerous domestic and non-U.S. tax authorities, as well as to tax agreements and treaties among these governments. Determination of taxable income in any jurisdiction requires the company to interpret the related tax laws and regulations and the use of estimates and assumptions regarding significant future events, such as the amount, timing and character of deductions, permissible
27
THERMO FISHER SCIENTIFIC INC.
revenue recognition methods under the tax law and the sources and character of income and tax credits. Changes in tax laws, regulations, agreements and treaties, currency exchange restrictions or the company’s level of operations or profitability in each taxing jurisdiction could have an impact upon the amount of current and deferred tax balances and hence the company’s net income.
Valuation Allowances
The company estimates the degree to which tax assets will result in a benefit, after consideration of all positive and negative evidence, and provides a valuation allowance for tax assets that it believes will more likely than not go unused. In situations in which the company has been able to determine that its deferred tax assets will be realized, that determination generally relies on future reversals of taxable temporary differences and expected future taxable income. If it becomes more likely than not that a tax asset will be used, the company reverses the related valuation allowance. Any such reversals are recorded as a reduction of the company’s tax provision. The company’s tax valuation allowance totaled $1.32 billion at both December 31, 2023 and December 31, 2022 (Note 8). Should the company’s actual future taxable income by tax jurisdiction vary from estimates, additional allowances or reversals thereof may be necessary.
Recent Accounting Pronouncements
A description of recently issued accounting standards is included under the heading “Recent Accounting Pronouncements” in Note 1.
Item 7A.    Quantitative and Qualitative Disclosures About Market Risk
The company is exposed to market risk from changes in interest rates and currency exchange rates, which could affect its future results of operations and financial condition. The company manages its exposure to these risks through its regular operating and financing activities. The company has periodically hedged interest rate risks of fixed-rate instruments with offsetting interest rate swaps. Additionally, the company uses short-term forward and option contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates. Such exposures result from purchases, sales, cash and intercompany loans that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Canadian dollars, Singapore dollars, Czech koruna, Hong Kong dollars and Swedish krona. Income and losses arising from these derivative contracts are recognized as offsets to losses and income resulting from the underlying exposure being hedged. The company does not enter into speculative derivative agreements.
Interest Rates
The company is exposed to changes in interest rates while conducting normal business operations as a result of ongoing investing and financing activities, which affect the company’s debt as well as cash and cash equivalents. As of December 31, 2023, the company’s debt portfolio was comprised primarily of fixed rate borrowings. The fair market value of the company’s fixed interest rate debt is subject to interest rate risk. Generally, the fair market value of fixed interest rate debt will increase as interest rates fall and decrease as interest rates rise. The total estimated fair value of the company’s debt at December 31, 2023 was $32.27 billion (Note 14). Fair values were determined from available market prices using current interest rates and terms to maturity. If interest rates were to decrease by 100 basis points, the fair value of the company’s debt at December 31, 2023 would increase by approximately $2.33 billion. If interest rates were to increase by 100 basis points, the fair value of the company’s debt at December 31, 2023 would decrease by approximately $2.05 billion.
In addition, the fair value of the company’s cross-currency interest rate swap arrangements is subject to interest rate risk. If interest rates were to decrease by 100 basis points, the fair value of the company’s cross-currency interest rate swaps at December 31, 2023 would decrease by approximately $0.39 billion. If interest rates were to increase by 100 basis points, the fair value of the company’s cross-currency interest rate swaps at December 31, 2023 would increase by approximately $0.53 billion.
Currency Exchange Rates
The company views its investments in international subsidiaries with a functional currency other than the U.S. dollar as permanent. The company’s investment in international subsidiaries is sensitive to fluctuations in currency exchange rates. The functional currencies of the company’s international subsidiaries are principally denominated in British pounds sterling, euro, Swedish krona, Canadian dollars, Norwegian kroner and Danish kroner. The effect of a change in the period ending currency exchange rates on the company’s net investment in international subsidiaries is reflected in the “accumulated other comprehensive items” component of shareholders’ equity. The company also uses foreign currency-denominated debt to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A 10% depreciation in year-end 2023 functional currencies, relative to the U.S. dollar, would result in a reduction of shareholders’ equity of approximately $1.26 billion.
28
THERMO FISHER SCIENTIFIC INC.
The fair value of forward currency-exchange contracts is sensitive to changes in currency exchange rates. The fair value of forward currency-exchange contracts is the estimated amount that the company would pay or receive upon termination of the contract, taking into account the change in currency exchange rates. A 10% depreciation in year-end 2023 non-functional currency exchange rates related to the company’s contracts would result in an unrealized loss on forward currency-exchange contracts of $43 million. A 10% appreciation in year-end 2023 non-functional currency exchange rates related to the company’s contracts would result in an additional unrealized gain on forward currency-exchange contracts of $49 million. The unrealized gains or losses on forward currency-exchange contracts resulting from changes in currency exchange rates are expected to approximately offset losses or gains on the exposures being hedged.
Certain of the company’s cash and cash equivalents are denominated in currencies other than the functional currency of the depositor and are sensitive to changes in currency exchange rates. A 10% depreciation in the related year-end 2023 non-functional currency exchange rates applied to such cash balances would result in a negative impact of $13 million on the company’s net income.
Item 8.    Financial Statements and Supplementary Data
INDEX OF CONSOLIDATED FINANCIAL STATEMENTS
 Page

29

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of Thermo Fisher Scientific Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Thermo Fisher Scientific Inc. and its subsidiaries (the “Company”) as of December 31, 2023 and 2022, and the related consolidated statements of income, of comprehensive income, of redeemable noncontrolling interest and equity and of cash flows for each of the three years in the period ended December 31, 2023, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Annual Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely
30

detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Income taxes
As described in Note 8 to the consolidated financial statements, the Company’s provision for income taxes for the year ended December 31, 2023 was $284 million. The Company has deferred tax liabilities, net, of $1,091 million (including a valuation allowance of $1,317 million) and unrecognized tax benefits of $540 million as of December 31, 2023. As disclosed by management, the Company operates in numerous countries under many legal forms and, as a result, is subject to the jurisdiction of numerous domestic and non-U.S. tax authorities, as well as to tax agreements and treaties among these governments. Determination of taxable income in any jurisdiction requires management to interpret the related tax laws and regulations and to use estimates and assumptions regarding significant future events, such as the amount, timing and character of deductions, permissible revenue recognition methods under the tax law and the sources and character of income and tax credits. Management assesses income tax positions and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, management has recorded the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Management estimates the degree to which tax assets will result in a benefit, after consideration of all positive and negative evidence, and provides a valuation allowance for tax assets that it believes will more likely than not go unused. In situations in which management has been able to determine that the Company’s deferred tax assets will be realized, that determination generally relies on future reversals of taxable temporary differences and expected future taxable income. If it becomes more likely than not that a tax asset will be used, management reverses the related valuation allowance.
The principal considerations for our determination that performing procedures relating to income taxes is a critical audit matter are (i) the significant judgment by management when interpreting the numerous and complex tax laws and regulations as it relates to determining the provision for income taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits, (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to the provision for income taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits, and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the provision for income taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits. These procedures also included, among others (i) testing the accuracy of the provision for income taxes, including the rate reconciliation and permanent and temporary differences, (ii) evaluating whether the data utilized in the calculations of the provision for income taxes, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits were appropriate and consistent with evidence obtained in other areas of the audit, (iii) evaluating management’s assessment of the realizability of deferred tax assets on a jurisdictional basis, (iv) evaluating the identification of liabilities for unrecognized tax benefits and the reasonableness of the more likely than not
31

determination in consideration of court decisions, legislative actions, statutes of limitations, and developments in tax examinations by jurisdiction, (v) testing the calculation of the liability for unrecognized tax benefits by jurisdiction, including estimates of the amount of income tax benefit expected to be sustained, and (vi) evaluating the adequacy of the Company’s disclosures. Professionals with specialized skill and knowledge were used to assist in evaluating the reasonableness of management’s judgments and estimates related to the application of foreign and domestic tax laws and regulations.



/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 22, 2024

We have served as the Company’s auditor since 2002.
32

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED BALANCE SHEETS
 December 31,December 31,
(In millions except share and per share amounts)20232022
Assets
Current assets:
Cash and cash equivalents$8,077 $8,524 
Accounts receivable, less allowances of $193 and $189
8,221 8,115 
Inventories5,088 5,634 
Contract assets, net1,443 1,312 
Other current assets1,760 1,644 
Total current assets
24,589 25,229 
Property, plant and equipment, net9,448 9,280 
Acquisition-related intangible assets, net16,670 17,442 
Other assets3,999 4,007 
Goodwill44,020 41,196 
Total assets
$98,726 $97,154 
Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations$3,609 $5,579 
Accounts payable2,872 3,381 
Accrued payroll and employee benefits1,596 2,095 
Contract liabilities2,689 2,601 
Other accrued expenses3,246 3,354 
Total current liabilities
14,012 17,010 
Deferred income taxes1,922 2,849 
Other long-term liabilities4,642 4,238 
Long-term obligations31,308 28,909 
Commitments and contingencies (Note 12)
Redeemable noncontrolling interest118 116 
Equity:
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 442,188,634 and 440,668,112 shares issued
442 441 
Capital in excess of par value17,286 16,743 
Retained earnings47,364 41,910 
Treasury stock at cost, 55,541,290 and 50,157,275 shares
(15,133)(12,017)
Accumulated other comprehensive income/(loss)(3,224)(3,099)
Total Thermo Fisher Scientific Inc. shareholders’ equity46,735 43,978 
Noncontrolling interests(11)54 
Total equity
46,724 44,032 
Total liabilities, redeemable noncontrolling interest and equity
$98,726 $97,154 

The accompanying notes are an integral part of these consolidated financial statements.
33

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENTS OF INCOME
 Year Ended
 December 31,December 31,December 31,
(In millions except per share amounts)202320222021
Revenues
Product revenues
$25,243 $28,548 $30,361 
Service revenues
17,614 16,367 8,850 
Total revenues
42,857 44,915 39,211 
Costs and operating expenses:
Cost of product revenues
13,168 14,247 13,594 
Cost of service revenues
12,589 11,697 5,979 
Selling, general and administrative expenses
8,445 8,993 8,007 
Research and development expenses1,337 1,471 1,406 
Restructuring and other costs
459 114 197 
Total costs and operating expenses
35,998 36,522 29,183 
Operating income6,859 8,393 10,028 
Interest income879 272 43 
Interest expense(1,375)(726)(536)
Other income/(expense)
(65)(104)(694)
Income before income taxes
6,298 7,835 8,841 
Provision for income taxes
(284)(703)(1,109)
Equity in earnings/(losses) of unconsolidated entities(59)(172)(4)
Net income5,955 6,960 7,728 
Less: net (losses) income attributable to noncontrolling interests and redeemable noncontrolling interest(40)10 3 
Net income attributable to Thermo Fisher Scientific Inc.$5,995 $6,950 $7,725 
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic
$15.52 $17.75 $19.62 
Diluted
$15.45 $17.63 $19.46 
Weighted average shares
Basic
386 392 394 
Diluted
388 394 397 

The accompanying notes are an integral part of these consolidated financial statements.

34

THERMO FISHER SCIENTIFIC INC.
 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
 Year Ended
 December 31,December 31,December 31,
(In millions)202320222021
Comprehensive income
Net income
$5,955 $6,960 $7,728 
Other comprehensive income/(loss):
Currency translation adjustment:
Currency translation adjustment (net of tax provision (benefit) of $(134), $173 and $231)
(69)(822)373 
Unrealized gains and losses on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax benefit of $2, $1 and $17)
5 2 56 
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $(22), $9 and $11)
(69)38 36 
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $1, $3 and $6)
— 5 13 
Total other comprehensive income/(loss)
(133)(777)478 
Comprehensive income
5,822 6,183 8,206 
Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest
(48)3 2 
Comprehensive income attributable to Thermo Fisher Scientific Inc.
$5,870 $6,180 $8,204 

The accompanying notes are an integral part of these consolidated financial statements.

35

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended
December 31,December 31,December 31,
(In millions)202320222021
Operating activities
Net income
$5,955 $6,960 $7,728 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment
1,068 986 831 
Amortization of acquisition-related intangible assets
2,338 2,395 1,761 
Change in deferred income taxes
(1,300)(995)(647)
Stock-based compensation
278 307 230 
Loss on early extinguishment of debt— 26 767 
Other non-cash expenses
604 524 190 
Changes in assets and liabilities, excluding the effects of acquisitions:
Accounts receivable
(43)(430)(204)
Inventories
598 (825)(1,065)
Contract assets/liabilities252 (354)221 
Accounts payable
(500)648 479 
Contributions to retirement plans
(42)(41)(34)
Other(802)(47)(945)
Net cash provided by operating activities
8,406 9,154 9,312 
Investing activities
   
Acquisitions, net of cash acquired
(3,660)(39)(19,395)
Purchase of property, plant and equipment
(1,479)(2,243)(2,523)
Proceeds from sale of property, plant and equipment
87 24 20 
Proceeds from cross-currency interest rate swap interest settlements
70 15 8 
Other investing activities, net
(160)84 (42)
Net cash used in investing activities
(5,142)(2,159)(21,932)
Financing activities
Net proceeds from issuance of debt
5,942 3,193 18,137 
Repayment of debt
(5,782)(375)(11,738)
Proceeds from issuance of commercial paper
1,620 1,526 2,512 
Repayments of commercial paper
(1,935)(3,690)— 
Purchases of company common stock
(3,000)(3,000)(2,000)
Dividends paid
(523)(455)(395)
Other financing activities, net
56 (9)65 
Net cash (used in) provided by financing activities
(3,622)(2,810)6,581 
Exchange rate effect on cash
(82)(139)194 
(Decrease) increase in cash, cash equivalents and restricted cash
(440)4,046 (5,845)
Cash, cash equivalents and restricted cash at beginning of year
8,537 4,491 10,336 
Cash, cash equivalents and restricted cash at end of year
$8,097 $8,537 $4,491 
The accompanying notes are an integral part of these consolidated financial statements.
36

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY
 Redeemable Noncontrolling InterestCommon StockCapital in Excess of Par ValueRetained EarningsTreasury StockAccumulated Other Comprehensive ItemsTotal
Thermo Fisher Scientific Inc. Shareholders’ Equity		Noncontrolling InterestsTotal Equity
(In millions)SharesAmountSharesAmount
Balance at December 31, 2020$— 437 $437 $15,579 $28,116 40 $(6,818)$(2,807)$34,507 $10 $34,517 
Issuance of shares under stock plans
— 2 2 324 — 1 (104)— 222 — 222 
Stock-based compensation
— — — 230 — — — — 230 — 230 
Purchases of company common stock
— — — — — 4 (2,000)— (2,000)— (2,000)
Dividends declared ($1.04 per share)
— — — — (410)— — — (410)— (410)
Recognition upon acquisition122 — — — — — — — — — — 
Net income/(loss)
1 — — — 7,725 — — — 7,725 2 7,727 
Other comprehensive income/(loss)
(1)— — — — — — 478 478 — 478 
Contributions from (distributions to) noncontrolling interests— — — — — — — — — 50 50 
Other
— — — 41 — — — — 41 — 41 
Balance at December 31, 2021122 439 439 16,174 35,431 45 (8,922)(2,329)40,793 62 40,855 
Issuance of shares under stock plans
— 2 2 262 — — (95)— 169 — 169 
Stock-based compensation
— — — 307 — — — — 307 — 307 
Purchases of company common stock
— — — — — 5 (3,000)— (3,000)— (3,000)
Dividends declared ($1.20 per share)
— — — — (471)— — — (471)— (471)
Net income/(loss)
15 — — — 6,950 — — — 6,950 (5)6,945 
Other comprehensive income/(loss)
(6)— — — — — — (770)(770)(1)(771)
Contributions from (distributions to) noncontrolling interests(15)— — — — — — — — (2)(2)
Balance at December 31, 2022116 441 441 16,743 41,910 50 (12,017)(3,099)43,978 54 44,032 
Issuance of shares under stock plans
— 1 1 265 — 1 (88)— 178 — 178 
Stock-based compensation
— — — 278 — — — — 278 — 278 
Purchases of company common stock
— — — — — 5 (3,000)— (3,000)— (3,000)
Dividends declared ($1.40 per share)
— — — — (541)— — — (541)— (541)
Net income/(loss)
19 — — — 5,995 — — — 5,995 (59)5,936 
Other comprehensive income/(loss)
(3)— — — — — — (125)(125)(5)(130)
Contributions from (distributions to) noncontrolling interests(14)— — — — — — — — (1)(1)
Excise tax from stock repurchases— — — — — — (28)— (28)— (28)
Balance at December 31, 2023$118 442 $442 $17,286 $47,364 56 $(15,133)$(3,224)$46,735 $(11)$46,724 
The accompanying notes are an integral part of these consolidated financial statements.
37

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1.    Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.
Principles of Consolidation
The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. At December 31, 2023 and 2022, the company had such investments with carrying amounts of $489 million and $369 million, respectively. The company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity method. At December 31, 2023 and 2022, the fair value of such investments was $5 million and $7 million, respectively.
Redeemable Noncontrolling Interest
The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at a premium upon the occurrence of certain events.
Presentation
Certain reclassifications of prior year amounts have been made to conform to the current year presentation.
Revenue Recognition
Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year.
Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date. However, some modifications are distinct from existing services provided under the contract and recognized prospectively.
Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.
38
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Contract-related Balances
Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.
Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional.
Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract.
Warranty Obligations
The company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred.
Leases
Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations.
Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense.
Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option.
As a lessee, the company accounts for the lease and non-lease components as a single lease component.
Research and Development
The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred.
Restructuring Costs
Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of
39
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models.
From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to provide economic benefits to the company. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period.
Income Taxes
The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused.
The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money.
Earnings per Share
Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units.
Cash and Cash Equivalents
Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three months or less. These investments are carried at cost, which approximates market value.
Inventories
Inventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income. The components of inventories are as follows:
December 31,December 31,
(In millions)20232022
Raw materials$2,057 $2,405 
Work in process705 660 
Finished goods2,326 2,569 
Inventories$5,088 $5,634 
Prior to the third quarter of 2021, certain of the company’s businesses utilized the LIFO method of accounting for inventories. During the third quarter of 2021, these businesses, which comprised approximately 5% of consolidated inventories, changed from the LIFO method to the FIFO method. The company believes this change is preferable as it will provide a consistent, uniform costing method for all inventories across the company, better reflect the current value of inventories, and improve comparability with peers. Prior financial statements have not been retrospectively adjusted due to immateriality. The cumulative pre-tax effect of this change in accounting principle of $33 million was recorded as an increase to inventories and a decrease to cost of product revenues in the third quarter of 2021. This change was recorded in the Laboratory Products and Biopharma
40
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Services ($20 million) and Specialty Diagnostics ($13 million) segments. Reductions to cost of revenues as a result of the liquidation of LIFO inventories were nominal during the first half of 2021.
Property, Plant and Equipment
Property, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income. Property, plant and equipment consists of the following:
December 31,December 31,
(In millions)20232022
Land$458 $454 
Buildings and improvements3,593 3,153 
Machinery, equipment and leasehold improvements9,235 7,967 
Construction in progress2,238 2,695 
Property, plant and equipment, at cost15,524 14,269 
Less: Accumulated depreciation and amortization6,076 4,989 
Property, plant and equipment, net$9,448 $9,280 
Acquisition-related Intangible Assets
Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value.
In addition, the company has tradenames that have indefinite lives and which are not amortized. Intangible assets with indefinite lives are reviewed for impairment annually or whenever events or changes in circumstances indicate they may be impaired. The company may perform an optional qualitative assessment. If the company determines that the fair value of the indefinite-lived intangible asset is more likely than not greater than its carrying amount, no additional testing is necessary. If not, or if the company bypasses the optional qualitative assessment, it writes the carrying value down to the fair value, if applicable.
Acquisition-related intangible assets are as follows:
Balance at December 31, 2023Balance at December 31, 2022
(In millions)GrossAccumulated AmortizationNetGrossAccumulated AmortizationNet
Definite lived:
Customer relationships
$22,762 $(9,410)$13,352 $21,792 $(8,330)$13,462 
Product technology
5,894 (4,591)1,303 5,882 (4,360)1,522 
Tradenames
1,634 (1,079)555 1,635 (1,008)627 
Backlog
1,084 (859)225 1,038 (442)596 
31,374 (15,939)15,435 30,347 (14,140)16,207 
Indefinite lived:
Tradenames
1,235 N/A1,235 1,235 N/A1,235 
Acquisition-related intangible assets
$32,609 $(15,939)$16,670 $31,582 $(14,140)$17,442 
41
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2023 is as follows:
(In millions)
2024 $1,931 
2025 1,630 
2026 1,460 
2027 1,430 
2028 1,398 
2029 and thereafter7,586 
Estimated future amortization expense of definite-lived intangible assets$15,435 
Other Assets
Other assets in the accompanying balance sheet include operating lease right-of-use assets, investments, deferred tax assets, pension assets, insurance recovery receivables related to product liability matters, certain intangible assets and other assets.
At December 31, 2023 and 2022, the company had $37 million and $36 million, respectively, of intangible assets not derived from acquisitions, net of accumulated amortization, which are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years.
Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments. At December 31, 2023 and 2022, the company had such investments with carrying amounts of $12 million and $55 million, respectively, and investments measured at NAV of $28 million and $22 million, respectively, which are included in other assets.
Goodwill
The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2023, 2022 or 2021.
The changes in the carrying amount of goodwill by segment are as follows:
(In millions)Life Sciences
Solutions		Analytical
Instruments		Specialty
Diagnostics		Laboratory
Products and
Biopharma Services		Total
Balance at December 31, 2021
$10,143 $5,043 $3,277 $23,461 $41,924 
Acquisitions
— 24 — — 24 
Finalization of purchase price allocations for 2021 acquisitions
9 — — 168 177 
Currency translation
(6)(102)(186)(635)(929)
Balance at December 31, 2022
10,146 4,965 3,091 22,994 41,196 
Acquisitions
— 31 1,741 627 2,399 
Currency translation
5 55 91 274 425 
Balance at December 31, 2023
$10,151 $5,051 $4,923 $23,895 $44,020 
42
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Loss Contingencies
Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities acquired in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition.
Currency Translation
All assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period. Currency transaction gains/(losses) are included in the accompanying statement of income and in aggregate were $(67) million, $62 million and $25 million in 2023, 2022 and 2021, respectively.
Derivative Contracts
The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.
The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Canadian dollars, Singapore dollars, Czech koruna, Hong Kong dollars and Swedish krona. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management.
Cash flow hedges. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item.
Fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings.
Net investment hedges. The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
Government Assistance
From time to time, the company receives assistance from various governmental agencies generally in the form of cash or non-income tax credits. These programs help offset the costs of certain research and development activities, facility construction and expansion efforts, or hiring objectives. When the company believes that it is probable that it will meet the conditions tied to the assistance, it offsets the associated expense in the consolidated income statement. Such amounts were not material to the consolidated financial statements as of and for the years ended December 31, 2023 and 2022.
43
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.
Recent Accounting Pronouncements
The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures.
StandardDescriptionEffective date for Thermo Fisher and adoption approachImpact of adoption or other significant matters
Standards recently adopted
Accounting Standards Update (ASU) No. 2021-05, Leases (Topic 842): Lessors-Certain Leases with Variable Lease Payments
Amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. Third quarter of 2021 using a prospective methodNot material
ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance
New guidance to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model.
Fourth quarter of 2022 using a prospective method
Not material
ASU No. 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations
New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented.
Some aspects adopted in 2023 using a retrospective method and will adopt other aspects in 2024 using a prospective method
Not material
Standards not yet adopted
ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures
Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker.2024 annual report and interim periods thereafter using a retrospective methodWill increase disclosures in Note 4
ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures
Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid.2025 annual report and interim periods thereafter using a prospective or retrospective methodWill increase disclosures in Note 8
Note 2.    Acquisitions
The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.
44
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.
2023
On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not tax deductible.
On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment’s portfolio with the addition of highly complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development. The goodwill recorded as a result of this business combination is not tax deductible.
The components of the purchase price and net assets acquired are as follows:
(In millions)The Binding SiteCorEvitas
Purchase price
Cash paid
$2,412 $730 
Debt settled
307 184 
Cash acquired
(20)(4)
$2,699 $910 
Net assets acquired
Definite-lived intangible assets
Customer relationships
$868 $260 
Product technology
162 47 
Tradenames
42 — 
Backlog— 46 
Goodwill
1,741 627 
Net tangible assets
174 (2)
Deferred tax assets (liabilities)
(288)(68)
$2,699 $910 
In addition, in 2023, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Raman-based spectroscopy solutions for in-line measurement.
The weighted-average amortization periods for definite-lived intangible assets acquired in 2023 are 18 years for customer relationships, 14 years for product technology, 15 years for tradenames, and 13 years for backlog. The weighted-average amortization period for definite-lived intangible assets acquired in 2023 is 17 years.
Proposed Acquisition
On October 17, 2023, the company entered into a purchase agreement to acquire all of the issued and outstanding shares of Olink Holding AB (publ) at a price of $26.00 per share, or approximately $3.1 billion. Olink is a leading provider of next-generation proteomics solutions that will expand the company’s capabilities in this field. The company has commenced a tender offer to acquire all of the American Depositary Shares and common shares of Olink. The transaction is expected to close by mid-year 2024, subject to the satisfaction of customary closing conditions including receipt of applicable regulatory approvals, and completion of the tender offer. Upon completion, Olink will become part of the Life Sciences Solutions segment. The company intends to finance the purchase price with cash on hand and the net proceeds from issuances of debt.
2022
In 2022, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Fourier-transform infrared gas analysis technologies.
45
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
2021
On January 15, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, the Belgium-based European viral vector manufacturing business of Groupe Novasep SAS. The European viral vector manufacturing business provides manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities for cell and gene vaccines and therapies. The goodwill recorded as a result of this business combination is not tax deductible.
On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company. Mesa Biotech has developed and commercialized a polymerase chain reaction (PCR) based rapid point-of-care testing platform available for detecting infectious diseases including COVID-19. The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care. The goodwill recorded as a result of this business combination is not tax deductible.
On September 30, 2021, the company assumed operating responsibility, within the Laboratory Products and Biopharma Services segment, of a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland from CSL Limited to perform pharma services for CSL with capacity to serve other customers as well. The goodwill recorded as a result of this business combination is not tax deductible.
On December 8, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, PPD, Inc., a U.S.-based global provider of clinical research services to the pharma and biotech industry. The addition of PPD’s clinical research services enhances our offering to biotech and pharma customers by enabling them to accelerate innovation and increase their productivity within the drug development process. The goodwill recorded as a result of this business combination is not tax deductible.
On December 30, 2021, the company acquired, within the Life Sciences Solutions segment, PeproTech, Inc., a U.S.-based developer and manufacturer of recombinant proteins. PeproTech provides bioscience reagents known as recombinant proteins, including cytokines and growth factors. The acquisition expands the segment’s bioscience offerings. The goodwill recorded as a result of this business combination is not tax deductible.
In addition, in 2021, the company acquired, within the Life Sciences Solutions segment, cell sorting technology assets, an Ireland-based life sciences distributor and a developer of a digital PCR platform; within the Analytical Instruments segment, a Belgium-based developer of micro-chip based technology for liquid chromatography columns; and within the Specialty Diagnostics segment, a transplant diagnostics information system provider.
46
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The components of the purchase price and net assets acquired for 2021 acquisitions are as follows:
(In millions)PPDPeproTechEuropean Viral Vector BusinessMesa BiotechLengnau biologics manufacturing facilityOther
Purchase price
Cash paid
$17,237 $1,946 $848 $421 $17 $298 
Fair value of equity awards exchanged
43 — — — — — 
Fair value of contingent consideration
— — — 65 1 117 
Cash acquired
(1,244)(83)(18)(14)— (12)
$16,036 $1,863 $830 $472 $18 $403 
Net assets acquired
Current assets
$2,477 $58 $39 $54 $— $12 
Property, plant and equipment
527 18 59 2 93 2 
Definite-lived intangible assets:
Customer relationships
6,257 510 302 — — 2 
Product technology
— 282 25 279 — 224 
Tradenames
594 — — 2 — 2 
Backlog1,038 — — — — — 
Goodwill
13,949 1,198 600 237 18 198 
Other assets
1,060 11 3 3 364 2 
Contract liabilities(1,539)— (59)— — (1)
Deferred tax assets (liabilities)
(1,782)(192)(80)(72)— (27)
Finance lease liabilities
(90)— (24)— (82)— 
Debt assumed
(4,299)— — — — — 
Other liabilities assumed
(2,034)(22)(35)(33)(375)(11)
Redeemable noncontrolling interest(122)— — — — — 
$16,036 $1,863 $830 $472 $18 $403 
During 2022, we finalized the allocations of the purchase price for the Lengnau biologics manufacturing facility, PPD, Inc. and PeproTech, Inc., largely with respect to definite-lived intangible assets, property, plant and equipment, contract liabilities, equity method investments, asset retirement obligations, defined benefit pension plans, assumed contingent consideration and the related deferred taxes. The adjustments to the income statement recorded during 2022 were not material.
The weighted-average amortization periods for definite-lived intangible assets acquired in 2021 are 17 years for customer relationships, 11 years for product technology, 7 years for tradenames and 3 years for backlog. The weighted average amortization period for all definite-lived intangible assets acquired in 2021 is 14 years.
Unaudited Pro Forma Information
The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1, 2020:
47
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
 Year Ended
 December 31,
(In millions)2021
Revenues$44,886 
Net income attributable to Thermo Fisher Scientific Inc.$7,369 
The historical consolidated financial information of the company and PPD has been adjusted in the pro forma information to give effect to pro forma events that are directly attributable to the acquisitions and related financing arrangements and are factually supportable.
To reflect the acquisition of PPD as if it had occurred on January 1, 2020, the unaudited pro forma results include adjustments to reflect, among other things, the incremental intangible asset amortization to be incurred based on the values of each identifiable intangible asset and the interest expense from debt financings obtained to partially fund the cash consideration transferred. Pro forma adjustments were tax effected at the company's historical statutory rates in effect for the respective periods. The unaudited pro forma amounts are not necessarily indicative of the combined results of operations that would have been realized had the acquisitions and related financings occurred on the aforementioned dates nor are they meant to be indicative of any anticipated combined results of operations that the company will experience after the transaction. In addition, the amounts do not include any adjustments for actions that may be taken following the completion of the transaction, such as expected cost savings, operating synergies, or revenue enhancements that may be realized subsequent to the transaction.
Pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended December 31, 2021, excludes $312 million of transaction costs, initial restructuring costs, and debt extinguishment costs directly attributable to the PPD acquisition that were included in the determination of net income attributable to Thermo Fisher Scientific Inc. for that period.
The company’s results would not have been materially different from its pro forma results had the company’s other 2021 acquisitions occurred at the beginning of 2020.
PPD’s revenues and losses attributable to Thermo Fisher Scientific Inc. in 2021, subsequent to the acquisition date, were $378 million and $(60) million, respectively. The loss includes non-recurring transaction and compensation costs.
Note 3.    Revenues and Contract-related Balances
Disaggregated Revenues
Revenues by type are as follows:
(In millions)202320222021
Revenues
Consumables
$17,597 $20,624 $22,608 
Instruments
7,646 7,924 7,753 
Services
17,614 16,367 8,850 
Consolidated revenues
$42,857 $44,915 $39,211 
Revenues by geographic region based on customer location are as follows:
(In millions)202320222021
Revenues
North America
$22,764 $24,594 $19,659 
Europe
10,741 10,762 11,134 
Asia-Pacific
7,873 8,115 7,218 
Other regions
1,479 1,444 1,200 
Consolidated revenues
$42,857 $44,915 $39,211 
Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data.
48
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Remaining Performance Obligations
The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of December 31, 2023 was $26.92 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 53% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years.
Contract-related Balances
Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows:
December 31,December 31,
(In millions)20232022
Current contract assets, net$1,443 $1,312 
Noncurrent contract assets, net4 7 
Current contract liabilities2,689 2,601 
Noncurrent contract liabilities1,499 1,179 
Substantially all of the current contract liabilities balance at December 31, 2022 and 2021 was recognized in revenues during 2023 and 2022, respectively. Noncurrent contract liabilities increased during 2023 primarily due to advanced payments from a customer.
Note 4.    Business Segment and Geographical Information
The company’s financial performance is reported in four segments. A description of each segment follows.
Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Analytical Instruments: provides a broad offering of instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory.
Specialty Diagnostics: offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of diagnoses, which improves patient care in a more cost-efficient manner.
Laboratory Products and Biopharma Services: offers virtually everything needed for the laboratory. Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more innovative, productive and cost-efficient. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing.
The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation.
49
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Business Segment Information
(In millions)202320222021
Revenues
Life Sciences Solutions
$9,977 $13,532 $15,631 
Analytical Instruments
7,263 6,624 6,069 
Specialty Diagnostics
4,405 4,763 5,659 
Laboratory Products and Biopharma Services
23,041 22,511 14,862 
Eliminations
(1,829)(2,515)(3,010)
Consolidated revenues
42,857 44,915 39,211 
Segment Income
Life Sciences Solutions
3,420 5,582 7,817 
Analytical Instruments
1,908 1,507 1,197 
Specialty Diagnostics
1,124 1,024 1,280 
Laboratory Products and Biopharma Services
3,358 2,872 1,844 
Subtotal reportable segments
9,810 10,985 12,138 
Cost of revenues adjustments
(95)(46)(8)
Selling, general and administrative expenses adjustments
(59)(37)(144)
Restructuring and other costs
(459)(114)(197)
Amortization of acquisition-related intangible assets
(2,338)(2,395)(1,761)
Consolidated operating income
6,859 8,393 10,028 
Interest income879 272 43 
Interest expense(1,375)(726)(536)
Other income/(expense)
(65)(104)(694)
Consolidated income before taxes
$6,298 $7,835 $8,841 
Depreciation
Life Sciences Solutions
$220 $214 $197 
Analytical Instruments
93 83 83 
Specialty Diagnostics
86 75 128 
Laboratory Products and Biopharma Services
669 614 423 
Consolidated depreciation
$1,068 $986 $831 
Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of significant transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges related to product liability litigation.
50
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In millions)202320222021
Total assets
Life Sciences Solutions
$20,191 $21,848 $22,751 
Analytical Instruments
10,247 10,019 9,692 
Specialty Diagnostics
8,636 5,542 6,010 
Laboratory Products and Biopharma Services
51,091 51,281 52,639 
Corporate/other (a)
8,561 8,464 4,031 
Consolidated total assets
$98,726 $97,154 $95,123 
Capital expenditures
Life Sciences Solutions
$178 $490 $810 
Analytical Instruments
87 140 79 
Specialty Diagnostics
121 112 167 
Laboratory Products and Biopharma Services
1,013 1,403 1,327 
Corporate/other
80 98 140 
Consolidated capital expenditures
$1,479 $2,243 $2,523 
(a)Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.
Geographical Information
(In millions)202320222021
Revenues (b)
United States
$22,013 $23,820 $18,907 
Other
20,844 21,095 20,304 
Consolidated revenues
$42,857 $44,915 $39,211 
Long-lived Assets (c)
United States
$6,352 $6,308 $5,578 
Other
4,652 4,565 4,286 
Consolidated long-lived assets
$11,004 $10,873 $9,864 
(b)Revenues are attributed to countries based on customer location.
(c)Includes property, plant and equipment, net, and operating lease ROU assets.
Note 5.    Other Income/(Expense)
In all periods, other income/(expense) includes currency transaction gains/losses on non-operating monetary assets and liabilities and net periodic pension benefit cost/income, excluding the service cost component, which is included in operating expenses on the accompanying statements of income. In 2023, other income/(expense) includes $46 million of net losses on investments.
In 2022, other income/(expense) includes $161 million of net losses on investments, $67 million of net gains on derivative instruments to address certain foreign currency risks, and $26 million of losses on the early extinguishment of debt (Note 10).
In 2021, other income/(expense) includes $767 million of losses on the early extinguishment of debt (Note 10), $36 million of financing costs associated with obtaining bridge financing commitments in connection with the agreement to acquire PPD (Note 2), offset in part by $66 million of net gains on investments. The company had a cash outlay of $36 million in 2021 associated with obtaining the bridge financing commitments, included in other financing activities, net, in the accompanying statement of cash flows.
Note 6.    Stock-based Compensation Expense
The company has stock-based compensation plans for its key employees, directors and others. These plans permit the grant of a variety of stock and stock-based awards, including restricted stock units, stock options or performance-based shares, as determined by the compensation committee of the company’s Board of Directors or, for certain non-officer grants, by the company’s employee equity committee, which consists of its chief executive officer. The company generally issues new shares of its common stock to satisfy option exercises and restricted unit vesting. Grants of stock options and restricted units generally
51
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
provide that in the event of both a change in control of the company and a qualifying termination of an option or unit holder’s employment, all options and service-based restricted unit awards held by the recipient become immediately vested (unless an employment or other agreement with the employee provides for different treatment).
Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses.
Stock Options
The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate is calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures.
The weighted average assumptions used in the Black-Scholes option pricing model are as follows: 
202320222021
Expected stock price volatility
25 %26 %26 %
Risk free interest rate
4.2 %2.0 %0.8 %
Expected life of options (years)
4.74.74.3
Expected annual dividend
0.3 %0.2 %0.2 %
The weighted average per share grant-date fair values of options granted during 2023, 2022 and 2021 were $159.32, $135.07 and $123.97, respectively. The total intrinsic value of options exercised during the same periods was $320 million, $336 million and $501 million, respectively. The intrinsic value is the difference between the market value of the shares on the exercise date and the exercise price of the option.
A summary of the company’s option activity for the year ended December 31, 2023 is presented below:
Shares
(in millions)		Weighted average exercise priceWeighted average remaining contractual term
(in years)		Aggregate intrinsic
value
(in millions)
Outstanding at December 31, 2022
5.6 $359.27 
Granted
0.7 546.94 
Exercised
(1.0)218.82 
Canceled/expired
(0.3)543.25 
Outstanding at December 31, 2023
5.0 $401.30 3.9$714 
Vested and unvested expected to vest at December 31, 2023
4.8 $396.20 3.9$712 
Exercisable at December 31, 2023
2.8 $316.88 2.7$635 
As of December 31, 2023, there was $162 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to be recognized through 2027 with a weighted average amortization period of 2.2 years.
Restricted Share/Unit Awards
Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is
52
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.
A summary of the company’s restricted unit activity for the year ended December 31, 2023 is presented below:
 Units
(in millions)		Weighted
average
grant-date
fair value
Unvested at December 31, 2022
0.7 $495.39 
Granted
0.4 545.73 
Vested
(0.4)480.45 
Forfeited
(0.1)528.59 
Unvested at December 31, 2023
0.6 $533.65 
The weighted average per share grant-date fair values of restricted units granted during 2022 and 2021 were $520.83 and $444.61, respectively. The total fair value of shares vested during 2023, 2022 and 2021 was $207 million, $163 million and $151 million, respectively.
As of December 31, 2023, there was $179 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is expected to be recognized through 2027 with a weighted average amortization period of 1.9 years.
Employee Stock Purchase Plans
Qualifying employees are eligible to participate in an employee stock purchase plan sponsored by the company. Shares may be purchased under the program at 95% of the fair market value at the end of the purchase period and the shares purchased are not subject to a holding period. Shares are purchased through payroll deductions of up to 10% of each participating employee’s qualifying gross wages. The company issued 0.1 million, 0.2 million and 0.1 million shares, respectively, of its common stock in 2023, 2022 and 2021 under the employee stock purchase plan.
Note 7.    Pension and Other Postretirement Benefit Plans
401(k) Savings Plan and Other Defined Contribution Plans
The company’s 401(k) savings and other defined contribution plans cover the majority of the company’s eligible U.S. and certain non-U.S. employees. Contributions to the plans are made by both the employee and the company. Company contributions are based on the level of employee contributions, and are based on formulas determined by the company. In 2023, 2022 and 2021, the company charged to expense $468 million, $402 million and $299 million, respectively, related to its defined contribution plans.
Defined Benefit Pension Plans
Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented.
The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.
When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits.
53
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined. Contributions to the plans included in the following table are estimated at between $30 million and $50 million for 2024.
The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans:
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)2023202220232022
Accumulated benefit obligation
$1,005 $995 $1,166 $1,016 
Change in projected benefit obligations
Projected benefit obligation at beginning of year
$995 $1,260 $1,069 $1,552 
Acquisitions
— — 15 51 
Service costs
— — 26 34 
Interest costs
47 27 42 20 
Settlements
— — (37)(31)
Plan participants' contributions
— — 9 9 
Actuarial (gains) losses
42 (210)65 (447)
Benefits paid
(79)(82)(25)(19)
Currency translation and other
— — 57 (100)
Projected benefit obligation at end of year
$1,005 $995 $1,221 $1,069 
Change in fair value of plan assets
Fair value of plan assets at beginning of year
$937 $1,226 $868 $1,302 
Acquisitions— — 15 14 
Actual return on plan assets
84 (212)29 (347)
Employer contributions
5 5 36 36 
Settlements
— — (37)(31)
Plan participants' contributions
— — 9 9 
Benefits paid
(79)(82)(25)(19)
Currency translation and other
— — 49 (96)
Fair value of plan assets at end of year$947 $937 $944 $868 
Funded status
$(58)$(58)$(277)$(201)
Amounts recognized in balance sheet
Noncurrent assets
$— $— $65 $81 
Current liability
(6)(6)(11)(11)
Noncurrent liabilities
(52)(52)(331)(271)
Net amount recognized
$(58)$(58)$(277)$(201)
Amounts recognized in accumulated other comprehensive items
Net actuarial loss
$217 $200 $151 $74 
Prior service credits
— — (5)(4)
Net amount recognized
$217 $200 $146 $70 
For domestic pension plans, actuarial losses experienced in 2023 were driven by decreases in the weighted average discount rates used to determine the projected benefit obligation, as well as differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns. For non-U.S. pension plans, actuarial losses experienced in 2023 were principally driven by decreases in the weighted average discount rates used to determine the projected benefit obligation.
For domestic pension plans, actuarial gains experienced in 2022 were driven by increases in the weighted average discount rates used to determine the projected benefit obligation, as well as differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns. For non-U.S. pension plans, actuarial gains experienced in 2022 were principally driven by increases in the weighted average discount rates used to determine the projected benefit obligation.
54
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2023 and 2022 and are as follows:
 Domestic pension benefitsNon-U.S. pension benefits
 2023202220232022
Weighted average assumptions used to determine projected benefit obligations
Discount rate for determining benefit obligation
4.82 %5.01 %3.47 %3.91 %
Interest crediting rate for cash balance plans
4.76 %4.96 %2.06 %2.19 %
Average rate of increase in employee compensation
N/AN/A2.64 %2.78 %
The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year, as presented in the following table:
 Domestic pension benefitsNon-U.S. pension benefits
 202320222021202320222021
Weighted average assumptions used to determine net benefit cost (income)
Discount rate - service cost
N/AN/AN/A3.62 %1.00 %0.65 %
Discount rate - interest cost
5.01 %2.70 %2.33 %3.95 %1.36 %0.80 %
Average rate of increase in employee compensation
N/AN/AN/A2.77 %2.73 %2.30 %
Expected long-term rate of return on assets
6.25 %4.75 %4.25 %4.33 %2.33 %2.02 %
The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan.
The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows.
The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks.
Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements.
The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases.
The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows:
 Pension plans
(In millions)20232022
Pension plans with projected benefit obligations in excess of plan assets
Projected benefit obligation
$1,752 $1,636 
Fair value of plan assets
1,352 1,296 
55
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows:
 Pension plans
(In millions)20232022
Pension plans with accumulated benefit obligations in excess of plan assets
Accumulated benefit obligation
$1,695 $1,583 
Fair value of plan assets
1,349 1,294 
The measurement date used to determine benefit information is December 31 for all plan assets and benefit obligations.
The net periodic pension benefit cost (income) includes the following components:
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)202320222021202320222021
Components of net benefit cost (income)
Service cost
$— $— $— $26 $34 $27 
Interest cost on benefit obligation
47 27 23 42 20 11 
Expected return on plan assets
(59)(45)(40)(37)(26)(19)
Amortization of actuarial net loss
— 4 7 2 7 12 
Amortization of prior service cost (benefit)
— — — (1)(1)— 
Settlement/curtailment loss (gain)
— — — 1 (2)— 
Net periodic benefit cost (income)
$(12)$(14)$(10)$33 $32 $31 
Expected benefit payments are estimated using the same assumptions used in determining the company’s benefit obligation at December 31, 2023. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows:
(In millions)Domestic pension benefitsNon-U.S. pension benefits
Expected benefit payments
2024 $81 $52 
2025 79 55 
2026 80 59 
2027 79 60 
2028 79 65 
2029-2033374 354 
Domestic Pension Plan Assets
The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments.
Non-U.S. Pension Plan Assets
The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds,
56
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
multi-asset funds, alternative investments and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 30% - 90% for fixed income funds, 0% - 40% for multi-asset funds, 0% - 4% for alternative investments, 0% - 4% for real estate funds and 0% - 45% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments.
The fair values of the company’s plan assets at December 31, 2023 and 2022, by asset category are as follows:
 December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs		Not subject to leveling (a)
(In millions)2023(Level 1)(Level 2)(Level 3)
Domestic pension plan assets
U.S. equity funds
$93 $— $— $— $93 
International equity funds
93 — — — 93 
Fixed income funds
739 — — — 739 
Money market funds
22 — — — 22 
Total domestic pension plans
$947 $— $— $— $947 
Non-U.S. pension plan assets
Equity funds
$7 $— $— $— $7 
Fixed income funds
346 9 — — 337 
Multi-asset funds
66 — — — 66 
Derivative funds
184 — — — 184 
Alternative investments
1 — — — 1 
Insurance contracts
333 — 333 — — 
Real estate funds1 — — — 1 
Cash / money market funds
6 4 — — 2 
Total non-U.S. pension plans
$944 $13 $333 $— $598 
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
 December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs		Not subject to leveling (a)
(In millions)2022(Level 1)(Level 2)(Level 3)
Domestic pension plan assets
U.S. equity funds
$89 $— $— $— $89 
International equity funds
91 — — — 91 
Fixed income funds
739 — — — 739 
Money market funds
18 — — — 18 
Total domestic pension plans$937 $— $— $— $937 
Non-U.S. pension plan assets
Equity funds
$8 $— $— $— $8 
Fixed income funds
299 — — — 299 
Multi-asset funds
56 — — — 56 
Derivative funds
190 — — — 190 
Insurance contracts
306 — 306 — — 
Cash / money market funds
9 4 — — 5 
Total non-U.S. pension plans$868 $4 $306 $— $558 
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
57
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The tables above present the fair value of the company’s plan assets in accordance with the fair value hierarchy (Note 14). Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. The fair value amounts of these investments presented in the above tables are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension plan assets. These investments were also redeemable at the balance sheet date or within limited time restrictions.
Note 8.    Income Taxes
The components of income before provision for income taxes are as follows:
(In millions)202320222021
U.S.$2,431 $3,859 $3,340 
Non-U.S.3,867 3,976 5,501 
Income before income taxes
$6,298 $7,835 $8,841 
The components of the provision for income taxes are as follows:
(In millions)202320222021
Current income tax provision
Federal$228 $813 $446 
Non-U.S.1,206 633 1,148 
State150 254 160 
1,584 1,700 1,754 
Deferred income tax provision (benefit)
Federal$(551)$(611)$(227)
Non-U.S.(647)(314)(399)
State(102)(72)(19)
 (1,300)(997)(645)
Provision for income taxes
$284 $703 $1,109 
The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following:
(In millions)202320222021
Statutory federal income tax rate
21 %21 %21 %
Provision for income taxes at statutory rate
$1,323 $1,645 $1,857 
Increases (decreases) resulting from:
Foreign rate differential
(223)(329)(255)
Income tax credits
(276)(202)(315)
Global intangible low-taxed income
113 96 76 
Foreign-derived intangible income
(108)(149)(119)
Excess tax benefits from stock options and restricted stock units
(69)(80)(124)
Provision for (reversal of) tax reserves, net
13 (544)(17)
Intra-entity transfers
(233)(18)(284)
Foreign exchange loss on inter-company debt refinancing
(112)— — 
Provision for (reversal of) valuation allowances, net
(32)344 36 
Withholding taxes
33 84 164 
Tax return reassessments and settlements
(187)(210)1 
State income taxes, net of federal tax70 111 82 
Other, net
(28)(45)7 
Provision for income taxes
$284 $703 $1,109 
58
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate.
During 2023, the company released valuation allowances of $32 million in jurisdictions where the deferred tax assets are now expected to be realized. In 2023 the company also recorded a tax benefit of $127 million for U.S. tax credits and the revaluation of net operating loss carryforwards due to higher tax rates as a result of its tax return resubmissions, a $91 million tax benefit, net of related tax expenses, from a foreign exchange loss on an intercompany debt refinancing transaction, and $233 million of tax benefits resulting from intra-entity transactions.
During 2022, the company settled an IRS audit relating to the 2017 and 2018 tax years. The company recorded a $208 million net tax benefit primarily from this settlement and related impacts, which resulted in a decrease in the company’s unrecognized tax benefits of $658 million. The company recorded $49 million of charges for expired tax credits and other related components of the settlement. The company recorded a charge of $395 million to establish a valuation allowance against certain U.S. foreign tax credits which the company believes will more likely than not expire unutilized. The company also recorded $101 million of additional net unrecognized tax benefit liabilities related to other tax audits.
During 2021, the company recorded a $188 million income tax benefit related to the deferred tax implications of an intra-entity transfer of assets. Also in 2021, the company recorded a $96 million income tax benefit related to a capital loss resulting from certain intra-entity transactions.
The company generally receives a tax deduction upon the exercise of non-qualified stock options by employees, or the vesting of restricted stock units held by employees, for the difference between the exercise price and the market price of the underlying common stock on the date of exercise. The company uses the incremental tax benefit approach for utilization of tax attributes. These excess tax benefits reduce the tax provision. In 2023, 2022 and 2021, the company's tax provision was reduced by $69 million, $80 million and $124 million, respectively, of such benefits.
Net deferred tax asset/(liability) in the accompanying balance sheet consists of the following:
(In millions)20232022
Deferred tax asset/(liability)
Depreciation and amortization
$(4,286)$(4,277)
Net operating loss and credit carryforwards
2,385 1,951 
Reserves and accruals
157 140 
Accrued compensation
299 259 
Inventory basis difference
275 364 
Deferred interest753 445 
Research and development and other capitalized costs
380 220 
Unrealized (gains) losses on hedging instruments
(66)(199)
Other, net
329 435 
Deferred tax assets/(liabilities), net before valuation allowance
226 (662)
Less: Valuation allowance
1,317 1,322 
Deferred tax assets/(liabilities), net
$(1,091)$(1,984)
The company estimates the degree to which tax assets, losses and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2023, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense.
59
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The changes in the valuation allowance are as follows:
 Year Ended December 31,
(In millions)202320222021
Beginning balance
$1,322 $968 $933 
Additions (reductions) charged to income tax provision, net
(32)344 24 
Additions due to acquisitions
4 14 30 
Currency translation and other
23 (4)(19)
Ending balance$1,317 $1,322 $968 
At December 31, 2023, the company had net federal, state and non-U.S. net operating loss carryforwards of $70 million, $93 million and $1.42 billion, respectively. Use of the carryforwards is limited based on the future income of certain subsidiaries. Of the federal net operating loss carryforwards, $30 million expire in the years 2024 through 2037, and the remainder do not expire. Of the state net operating loss carryforwards, $83 million expire in the years 2024 through 2042, and the remainder do not expire. Of the net non-U.S. net operating loss carryforwards, $435 million expire in the years 2026 through 2043, and the remainder do not expire.
At December 31, 2023, the company had foreign tax credit carryforwards of $648 million and deferred interest carryforwards of $753 million. The foreign tax credit carryforwards will expire in the years 2025 through 2032. Of the deferred interest carryforwards, $149 million expire in the years 2025 through 2033 and the remainder do not expire.
U.S. federal taxes have been recorded on approximately $34 billion of undistributed foreign earnings as of December 31, 2023. A provision has not been made for certain U.S. state income taxes or additional non-U.S. taxes that would be due when cash is repatriated to the U.S. as the company’s undistributed foreign earnings are intended to be reinvested outside of the U.S. indefinitely. The determination of the amount of the unrecognized deferred tax liability related to the undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed. The company’s intent is to only make distributions from non-U.S. subsidiaries in the future when they can be made at no net tax cost.
Unrecognized Tax Benefits
As of December 31, 2023, the company had $0.54 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate.
A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:
(In millions)202320222021
Beginning balance
$572 $1,124 $1,091 
Additions due to acquisitions
— 15 26 
Additions for tax positions of current year
4 104 32 
Additions for tax positions of prior years
34 24 60 
Reductions for tax positions of prior years
(43)(659)(5)
Closure of tax years
(6)(4)(27)
Settlements
(21)(32)(53)
Ending balance
$540 $572 $1,124 
Substantially all of the unrecognized tax benefits are classified as long-term liabilities. The company does not expect its unrecognized tax benefits to change significantly over the next twelve months.
During 2023, the company’s unrecognized tax benefits decreased by $12 million as a result of uncertain tax positions relating to foreign tax positions and decreased $19 million relating to U.S. federal and state tax positions.
During 2022, the company’s unrecognized tax benefits increased by $143 million as a result of uncertain tax positions relating to foreign tax positions and decreased $610 million relating to U.S. federal and state tax positions which included $658 million from the settlement of the IRS audit of the 2017 and 2018 tax years. The company also assumed $15 million of uncertain tax benefits as part of the acquisition of PPD.
During 2021, the company’s unrecognized tax benefits increased by $80 million as a result of uncertain tax positions relating to foreign tax positions and decreased $75 million relating to U.S. federal and state tax positions. The company also assumed $26 million of uncertain tax benefits as part of the acquisition of PPD.
60
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The company classified interest and penalties related to unrecognized tax benefits as income tax expense. The total amount of interest and penalties related to uncertain tax positions and recognized in the balance sheet as of December 31, 2023 and 2022 was $95 million and $74 million, respectively.
The company conducts business globally and, as a result, Thermo Fisher or one or more of its subsidiaries files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the company is subject to examination by taxing authorities throughout the world, including such major jurisdictions as Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, the United Kingdom and the United States. With few exceptions, the company is no longer subject to U.S. state and local or non-U.S. income tax examinations for years before 2012 and no longer subject to U.S. federal income tax examinations for years before 2019.
Note 9.    Earnings per Share
(In millions except per share amounts)202320222021
Net income attributable to Thermo Fisher Scientific Inc.
$5,995 $6,950 $7,725 
Basic weighted average shares
386 392 394 
Plus effect of: stock options and restricted stock units
2 2 3 
Diluted weighted average shares
388 394 397 
Basic earnings per share
$15.52 $17.75 $19.62 
Diluted earnings per share
$15.45 $17.63 $19.46 
Antidilutive stock options excluded from diluted weighted average shares
2 2 1 
Note 10.    Debt and Other Financing Arrangements
Effective interest rate at December 31,December 31,December 31,
(Dollars in millions)202320232022
Commercial Paper$— $310 
Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023
— 1,000 
Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023
— 500 
0.797% 2-Year Senior Notes, Due 10/18/2023
— 1,350 
Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
— 1,819 
0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
— 589 
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
0.93 %1,104 1,071 
Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024
— 500 
1.215% 3-Year Senior Notes, Due 10/18/2024
1.42 %2,500 2,500 
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
0.41 %883 857 
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
2.10 %706 686 
0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated)
1.05 %158 170 
0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)
0.15 %607 589 
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)
3.39 %552 535 
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
1.53 %773 749 
4.953% 3-Year Senior Notes, Due 8/10/2026
5.19 %600 — 
5.000% 3-Year Senior Notes due 12/5/2026
5.00 %1,000 — 
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
1.65 %552 535 
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
1.97 %662 642 
1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)
1.18 %205 221 
4.80% 5-Year Senior Notes, Due 11/21/2027
5.00 %600 600 
61
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Effective interest rate at December 31,December 31,December 31,
(Dollars in millions)202320232022
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
0.77 %883 857 
0.77% 5-Year Senior Notes, Due 9/6/2028 (yen-denominated)
0.90 %206 — 
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
1.46 %662 642 
1.750% 7-Year Senior Notes, Due 10/15/2028
1.89 %700 700 
5.000% 5-Year Senior Notes due 1/31/2029
5.00 %1,000 — 
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
2.08 %773 749 
2.60% 10-Year Senior Notes, Due 10/1/2029
2.74 %900 900 
1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)
1.44 %33 36 
4.977% 7-Year Senior Notes, Due 8/10/2030
5.12 %750 — 
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)
0.89 %1,932 1,873 
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
1.13 %993 963 
2.00% 10-Year Senior Notes, Due 10/15/2031
2.23 %1,200 1,200 
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
2.55 %662 642 
1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)
1.60 %45 48 
4.95% 10-Year Senior Notes, Due 11/21/2032
5.09 %600 600 
5.086% 10-Year Senior Notes, Due 8/10/2033
5.20 %1,000 — 
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)
1.20 %1,656 1,606 
5.200% 10-Year Senior Notes due 1/31/2034
5.20 %500 — 
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)
3.76 %828 803 
1.50% 12-Year Senior Notes, due 9/6/2035 (yen-denominated)
1.58 %152 — 
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
2.94 %773 749 
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
1.73 %993 963 
2.80% 20-Year Senior Notes, Due 10/15/2041
2.90 %1,200 1,200 
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)
1.77 %1,380 1,339 
2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)
2.13 %104 111 
5.404% 20-Year Senior Notes, due 8/10/2043
5.50 %600 — 
2.02% 20-Year Senior Notes, due 9/6/2043 (yen-denominated)
2.06 %206 — 
5.30% 30-Year Senior Notes, Due 2/1/2044
5.37 %400 400 
4.10% 30-Year Senior Notes, Due 8/15/2047
4.23 %750 750 
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
1.98 %1,104 1,071 
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)
2.07 %828 803 
2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)
2.43 %236 254 
Other 77 79 
Total borrowings at par value
35,028 34,561 
Unamortized discount
(113)(112)
Unamortized debt issuance costs
(188)(171)
Total borrowings at carrying value
34,727 34,278 
Finance lease liabilities
190 210 
Less: Short-term obligations and current maturities
3,609 5,579 
Long-term obligations$31,308 $28,909 
SOFR - Secured Overnight Financing Rate
EURIBOR - Euro Interbank Offered Rate
62
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt issuance costs.
See Note 14 for fair value information pertaining to the company’s long-term borrowings.
As of December 31, 2023, the annual repayment requirements for debt obligations are as follows:
(In millions)BorrowingsFinance Lease Liabilities
2024 $3,604 $5 
2025 2,356 13 
2026 2,925 12 
2027 2,020 10 
2028 2,451 8 
2029 and thereafter21,672 142 
$35,028 $190 
In addition to available borrowings under the company’s revolving credit agreements, discussed below, the company had unused lines of credit of $69 million as of December 31, 2023. These unused lines of credit generally provide for short-term unsecured borrowings at various interest rates.
Credit Facilities
The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term SOFR, a EURIBOR-based rate (for funds drawn in euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of December 31, 2023, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit.
Commercial Paper Programs
The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis.
Senior Notes
Interest is payable quarterly on the floating rate senior notes, annually on the euro-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the U.S. dollar, euro-denominated fixed rate senior notes and yen-denominated private placement notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest, together with swap breakage costs payable to holders of yen-denominated private placement notes who have entered into cross-currency swap agreements. The company is subject to certain affirmative and negative covenants under the indentures and note purchase agreement governing the senior notes, the most restrictive of which limits the ability of the company to pledge certain property and assets as security under borrowing arrangements. The company was in compliance with all covenants at December 31, 2023.
In 2022 the company completed the full allocation of an amount equal to the net proceeds from the 0.000% senior notes due 2025 to finance or refinance, in whole or in part, certain COVID-19 response projects.
In 2022, the company redeemed all of its 3.650% Senior Notes due 2025. In connection with the redemption, the company incurred $26 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income.
63
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
In 2021, the company redeemed some of its existing senior notes. In connection with these redemptions, the company incurred $767 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income. Upon redemption of the senior notes, the company terminated the related fixed to floating rate interest rate swap arrangements and received $22 million, included in other financing activities, net, in the accompanying statement of cash flows.
Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the following notes outstanding as of December 31, 2023, included in the table above (collectively, the “Euronotes”) in registered public offerings: the 0.00% Senior Notes due 2025, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are consolidated in the financial statements of the company.
Note 11.    Leases
As a lessee, the company leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers, and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally for 1 to 10 years) or have options to terminate the arrangement within 1 year.
The company has guaranteed the residual value of three leased operating facilities with lease terms ending in 2024, 2025 and 2028. The company has agreed with the lessor to comply with certain financial covenants consistent with its other debt arrangements (Note 10). The aggregate maximum guarantee under these three lease arrangements is $147 million. Operating lease ROU assets and lease liabilities for these lease arrangements are recorded on the consolidated balance sheet as of December 31, 2023, but exclude any amounts for residual value guarantees.
As a lessee, the consolidated financial statements include the following relating to operating leases:
(Dollars in millions)202320222021
Statement of income
Operating lease costs
$355 $351 $254 
Variable lease costs
115 109 66 
Statement of cash flows
Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities$410 $289 $288 
Operating lease ROU assets obtained in exchange for new operating lease liabilities234 430 293 
Balance sheet
ROU assets - included in other assets$1,556 $1,593 
Operating lease liabilities - included in other accrued expenses263 272 
Operating lease liabilities - included in other long-term liabilities1,244 1,313 
Weighted average at end of year
Remaining operating lease term9.2 years9.4 years
Discount rate4.0 %3.2 %
Lease costs arising from finance leases, short-term leases, and sublease income are not material. See Note 10 for additional information relating to finance leases.
64
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
As of December 31, 2023, future payments of operating lease liabilities are as follows:
(In millions)
2024 $294 
2025 288 
2026 242 
2027 172 
2028 131 
2029 and thereafter723 
Total lease payments1,850 
Less: imputed interest
343 
Total operating lease liability$1,507 
As a lessor, operating leases, sales-type leases and direct financing leases are not material.
Note 12.    Commitments and Contingencies
Purchase Obligations
The company has entered into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods, services or fixed assets and to pay royalties that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable at any time without penalty. The aggregate amount of the company’s unconditional purchase obligations totaled $2.53 billion at December 31, 2023, the majority of which are expected to be settled during 2024.
Letters of Credit, Guarantees and Other Commitments
Outstanding letters of credit and bank guarantees totaled $315 million at December 31, 2023. Substantially all of these letters of credit and guarantees expire before 2040.
Outstanding surety bonds and other guarantees totaled $93 million at December 31, 2023. The expiration of these bonds and guarantees ranges through 2025.
The letters of credit, bank guarantees and surety bonds principally secure performance obligations, and allow the holder to draw funds up to the face amount of the letter of credit, bank guarantee or surety bond if the applicable business unit does not perform as contractually required.
The company has funding commitments totaling $164 million at December 31, 2023, related to investments.
The company is a guarantor of pension plan obligations of a divested business. The purchaser of the divested business has agreed to pay for the pension benefits, however the company was required to guarantee payment of these pension benefits should the purchaser fail to do so. The amount of the guarantee at December 31, 2023 was $24 million.
In connection with the sale of businesses of the company, the buyers have assumed certain contractual obligations of such businesses and have agreed to indemnify the company with respect to those assumed liabilities. In the event a third-party to a transferred contract does not recognize the transfer of obligations or a buyer defaults on its obligations under the transferred contract, the company could be liable to the third-party for such obligations. However, in such event, the company would be entitled to seek indemnification from the buyer.
Indemnifications
In conjunction with certain transactions, primarily divestitures, the company has agreed to indemnify the other parties with respect to certain liabilities related to the businesses that were sold or leased properties that were abandoned (e.g., retention of certain environmental, tax, employee and product liabilities). The scope and duration of such indemnity obligations vary from transaction to transaction. Where probable, an obligation for such indemnifications is recorded as a liability. Generally, a maximum obligation cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, historically the company has not made significant payments for these indemnifications.
In connection with the company’s efforts to reduce the number of facilities that it occupies, the company has vacated some of its leased facilities or sublet them to third parties. When the company sublets a facility to a third-party, it remains the primary obligor under the master lease agreement with the owner of the facility. As a result, if a third-party vacates the sublet facility,
65
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
the company would be obligated to make lease or other payments under the master lease agreement. The company believes that the financial risk of default by sublessors is individually and in the aggregate not material to the company’s financial position or results of operations.
In connection with the sale of products in the ordinary course of business, the company often makes representations affirming, among other things, that its products do not infringe on the intellectual property rights of others and agrees to indemnify customers against third-party claims for such infringement. The company has not been required to make material payments under such provisions.
Environmental Matters
The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including input from environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At December 31, 2023, the company’s total environmental liability was approximately $75 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows.
Litigation and Related Contingencies
The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows.
Product Liability, Workers Compensation and Other Personal Injury Matters
The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. The range of probable loss for product liability, workers compensation and other personal injury matters of the company’s continuing operations at December 31, 2023, was approximately $222 million to $379 million. The company’s accrual for these matters totaled $224 million at December 31, 2023. The accrual includes estimated defense costs and is gross of estimated amounts due from insurers of $88 million at December 31, 2023 that are included in other assets in the accompanying balance sheet. In addition, as of December 31, 2023, the company had a product liability accrual of $20 million relating to divested businesses.
66
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis.
Note 13.    Comprehensive Income/(Loss) and Shareholders' Equity
Comprehensive Income (Loss)
Changes in each component of accumulated other comprehensive items, net of tax are as follows:
(In millions)Currency
translation
adjustment		Unrealized
losses on
hedging
instruments		Pension and
other
postretirement
benefit
liability
adjustment		Total
Balance at December 31, 2022$(2,880)$(33)$(186)$(3,099)
Other comprehensive income/(loss) before reclassifications
(69)— (69)(138)
Amounts reclassified from accumulated other comprehensive income/(loss)
8 5 — 13 
Net other comprehensive income/(loss)
(61)5 (69)(125)
Balance at December 31, 2023$(2,941)$(28)$(255)$(3,224)
Shareholders’ Equity
At December 31, 2023, the company had reserved 39 million unissued shares of its common stock for possible issuance under stock-based compensation plans.
Early in the first quarter of 2024, the company repurchased $3.00 billion of the company's common stock (5.5 million shares).
Note 14.    Fair Value Measurements and Fair Value of Financial Instruments
Fair Value Measurements
The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2023. The company’s financial assets and liabilities carried at fair value are primarily comprised of investments in publicly traded securities, insurance contracts, investments in derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration.
Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access.
Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves.
Level 3: Inputs are unobservable data points that are not corroborated by market data.
67
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:
December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs
(In millions)2023(Level 1)(Level 2)(Level 3)
Assets
Cash equivalents
$5,021 $5,021 $— $— 
Bank time deposits3 3 — — 
Investments
20 20 — — 
Insurance contracts
210 — 210 — 
Derivative contracts
8 — 8 — 
Total assets
$5,262 $5,044 $218 $— 
Liabilities
Derivative contracts
$290 $— $290 $— 
Contingent consideration
87 — — 87 
Total liabilities
$377 $— $290 $87 
December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs
(In millions)2022(Level 1)(Level 2)(Level 3)
Assets
Cash equivalents
$5,804 $5,804 $— $— 
Investments
25 25 — — 
Warrants
12 — 12 — 
Insurance contracts
162 — 162 — 
Derivative contracts
79 — 79 — 
Total assets
$6,082 $5,829 $253 $— 
Liabilities
Derivative contracts
$101 $— $101 $— 
Contingent consideration
174 — — 174 
Total liabilities
$275 $— $101 $174 
The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense.
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration.
(In millions)20232022
Contingent consideration
Beginning balance
$174 $317 
Acquisitions (including assumed balances)
1 (18)
Payments
(63)(66)
Changes in fair value included in earnings
(25)(59)
Ending balance
$87 $174 
68
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Derivative Contracts
The following table provides the aggregate notional value of outstanding derivative contracts.
December 31,December 31,
(In millions)20232022
Cross-currency interest rate swaps designated as net investment hedge - euro$1,000 $900 
Cross-currency interest rate swaps designated as net investment hedge - Japanese yen4,650 1,200 
Cross-currency interest rate swaps designated as net investment hedge - Swiss franc2,500 — 
Currency exchange contracts
1,567 2,434 
While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income.
 Fair value – assetsFair value – liabilities
 December 31,December 31,December 31,December 31,
(In millions)2023202220232022
Derivatives designated as hedging instruments
Cross-currency interest rate swaps (a)
$5 $77 $287 $85 
Derivatives not designated as hedging instruments
Currency exchange contracts (b)
3 2 3 16 
Total derivatives
$8 $79 $290 $101 
(a)The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities.
(b)The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.
 Gain (loss) recognized
(In millions)202320222021
Fair value hedging relationships
Cross-currency interest rate swaps
Hedged long-term obligations - included in other income/(expense)
$— $77 $— 
Derivatives designated as hedging instruments - included in other income/(expense)
— (81)— 
Interest rate swaps
Hedged long-term obligations - included in other income/(expense)
— — 25 
Derivatives designated as hedging instruments - included in other income/(expense)
— — (3)
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to interest expense
(4)— — 
Amount reclassified from accumulated other comprehensive items to other income/(expense)(3)(3)(73)
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in currency translation adjustment within other comprehensive items
(356)695 922 
Cross-currency interest rate swaps
Included in currency translation adjustment within other comprehensive items
(222)52 71 
Included in interest expense
120 19 8 
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues
1 6 12 
Included in other income/(expense)
(29)102 162 
69
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the accompanying statements of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions.
The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
See Note 1 and Note 10 for additional information on the company’s risk management objectives and strategies.
Cash Flow Hedge Arrangements
During 2021, in connection with the extinguishment of debt (Note 10), the company reclassified $65 million from accumulated other comprehensive income/(loss) to other income/(expense).
Fair Value of Other Financial Instruments
The carrying value and fair value of the company’s debt instruments are as follows:
December 31, 2023December 31, 2022
CarryingFairCarryingFair
(In millions)valuevaluevaluevalue
Senior notes
$34,650 $32,191 $33,889 $29,901 
Commercial paper
— — 310 310 
Other
77 77 79 79 
$34,727 $32,268 $34,278 $30,290 
The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally developed pricing models and unobservable inputs, which represent level 3 measurements.
Note 15.    Supplemental Cash Flow Information
(In millions)202320222021
Cash paid for:
Interest
$1,385 $667 $555 
Income taxes
1,482 1,234 2,182 
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment
296 393 379 
Fair value of equity awards exchanged— — 43 
Fair value of acquisition contingent consideration— — 183 
Finance lease ROU assets obtained in exchange for new finance lease liabilities2 33 15 
Declared but unpaid dividends
137 119 104 
Issuance of stock upon vesting of restricted stock units
234 241 265 
Excise tax from stock repurchases28 — — 
70
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:
 December 31,December 31,
(In millions)20232022
Cash and cash equivalents$8,077 $8,524 
Restricted cash included in other current assets6 12 
Restricted cash included in other assets14 1 
Cash, cash equivalents and restricted cash$8,097 $8,537 
Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.
Note 16.    Restructuring and Other Costs
Restructuring and other costs in 2023 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2023, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the company’s workforce.
Restructuring and other costs in 2022 primarily included impairment of long-lived assets and continuing charges for headcount reductions and facility consolidations in an effort to streamline operations. In 2022, severance actions associated with facility consolidations and cost reduction measures affected less than 2% of the company’s workforce.
Restructuring and other costs in 2021 primarily included charges for impairments of an acquired technology asset and a tradename asset, and, to a lesser extent, compensation due to employees at acquired businesses on the date of acquisition. In 2021, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.
As of February 22, 2024, the company has identified restructuring actions that will result in additional charges of approximately $70 million, primarily in 2024, and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred.
Restructuring and other costs by segment are as follows:
(In millions)202320222021
Life Sciences Solutions
$105 $30 $129 
Analytical Instruments
33 1 6 
Specialty Diagnostics
11 68 18 
Laboratory Products and Biopharma Services
295 12 35 
Corporate
15 3 9 
$459 $114 $197 
71
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.
(In millions)Total (a)
Balance at December 31, 2020$21 
Net restructuring charges incurred in 2021 (b)
37 
Payments
(40)
Currency translation
(1)
Balance at December 31, 202117 
Net restructuring charges incurred in 2022 (c)
68 
Payments
(44)
Balance at December 31, 202241 
Net restructuring charges incurred in 2023 (d) (e)
194 
Payments
(175)
Balance at December 31, 2023$60 
(a)The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b)Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
(c)Excludes $46 million of net charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment.
(d)Excludes $264 million of net charges, principally $126 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments, $26 million of contract termination costs associated with facility closures in the Laboratory Products and Biopharma Services segment, and $19 million of net charges for pre-acquisition litigation and other matters in the Laboratory Products and Biopharma Services segment.
(e)Excludes $93 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $46 million attributable to a noncontrolling interest.
The company expects to pay accrued restructuring costs primarily through 2024.
72
THERMO FISHER SCIENTIFIC INC.
Item 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Not applicable.
Item 9A.    Controls and Procedures
Management’s Evaluation of Disclosure Controls and Procedures
The company’s management, with the participation of the company’s chief executive officer and chief financial officer, has evaluated the effectiveness of the company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, the company’s chief executive officer and chief financial officer concluded that, as of the end of such period, the company’s disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended December 31, 2023, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial reporting.
Management’s Annual Report on Internal Control Over Financial Reporting
The company’s management, including the company’s chief executive officer and chief financial officer, is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The company’s management conducted an assessment of the effectiveness of the company’s internal control over financial reporting as of December 31, 2023 based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, the company’s management concluded that, as of December 31, 2023, the company’s internal control over financial reporting was effective.
The company’s independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of the company’s internal control over financial reporting as of December 31, 2023, as stated in their report that appears on page 30 of this Annual Report on Form 10-K.
Item 9B.    Other Information
Amendment and Restatement of By-Laws
On February 21, 2024, the Board of Directors of the company amended and restated the company’s By-Laws, effective immediately, to remove the supermajority voting requirement for amending Article II or Article VI of the By-laws. Specifically, the amendments to the By-laws eliminate Article VI, Section 3 to remove the supermajority voting requirement, and update Article VI, Section 2 to remove the reference to Article VI, Section 3. The foregoing description of the amendments to the By-laws does not purport to be complete and is qualified in its entirety by reference to the full text of the By-laws, as amended and restated, a copy of which is attached as Exhibit 3.4 and incorporated by reference herein.
Director and Officer Trading Arrangements
On December 13, 2023, Michael A. Boxer, our senior vice president, general counsel, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Boxer’s plan is for the exercise of vested stock options and the associated sale of up to 20,566 shares of company common stock through December 13, 2024. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and December 13, 2024.
On December 12, 2023, Lisa P. Britt, our senior vice president, chief human resources officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Ms. Britt’s plan is for the exercise of vested stock options and the associated sale of up to 14,345 shares of company common stock through November 11, 2024. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and November 12, 2024.
On November 10, 2023, Marc N. Casper, our chairman, president and chief executive officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Casper’s plan is for the exercise of vested stock options
73
THERMO FISHER SCIENTIFIC INC.
and the associated sale of up to 202,150 shares of company common stock through November 1, 2024. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and November 4, 2024.
Item 9C.     Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
PART III
Item 10.    Directors, Executive Officers and Corporate Governance
The information with respect to directors required by this Item will be contained in our Proxy Statement to be filed with the SEC not later than 120 days after the close of business of the fiscal year including under “Corporate governance,” and is incorporated in this report by reference.
The information with respect to executive officers required by this Item is included in Item 1 of Part I of this report.
The other information required by this Item will be contained in our Proxy Statement including under “Corporate governance,” and is incorporated in this report by reference.
Item 11.    Executive Compensation
The information required by this Item will be contained in our Proxy Statement including under “Corporate governance,” and “Executive compensation,” and is incorporated in this report by reference.
Item 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item will be contained in our Proxy Statement including under “Information about stock ownership,” and is incorporated in this report by reference.
Item 13.    Certain Relationships and Related Transactions, and Director Independence
The information required by this Item will be contained in our Proxy Statement including under “Corporate governance,” and is incorporated in this report by reference.
Item 14.    Principal Accountant Fees and Services
The information required by this Item will be contained in our Proxy Statement including under “Audit matters,” and is incorporated in this report by reference.
PART IV
Item 15.    Exhibits and Financial Statement Schedules
(a) The following documents are filed as part of this report:
(1) Consolidated Financial Statements (see Index on page 29 of this report)
(2) All schedules are omitted because they are not applicable or not required, or because the required information is included either in the consolidated financial statements or in the notes thereto.
(b) Exhibits
Exhibit NumberDescription of Exhibit
2.1
Agreement and Plan of Merger, dated as of April 15, 2021, by and among Thermo Fisher Scientific Inc., Powder Acquisition Corp. and PPD, Inc. (filed as Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed April 16, 2021 [File No. 1-8002] and incorporated in this document by reference).
3.1
Amended and Restated Certificate of Incorporation of the Registrant (filed as Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2005 [File No. 1-8002] and incorporated in this document by reference).
3.2
Amendment to Thermo Fisher Scientific Inc.’s Third Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed November 14, 2006 [File No. 1-8002] and incorporated in this document by reference).
3.3
Certificate of Elimination of the Series B Junior Participating Preferred Stock of the Company, dated November 13, 2015 (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed November 16, 2015 [File No. 1-8002] and incorporated in this document by reference).
74

THERMO FISHER SCIENTIFIC INC.

Exhibit NumberDescription of Exhibit
3.4
The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each instrument with respect to long-term debt of the Registrant or its consolidated subsidiaries.
4.1
Indenture dated as of November 20, 2009 between the Company and The Bank of New York Mellon Trust Company, N.A. (filed as Exhibit 99.1 to the Registrant’s Current Report on Form 8-K filed November 20, 2009 [File No. 1-8002] and incorporated in this document by reference).
4.2
Sixth Supplemental Indenture, dated as of December 11, 2013, between the Company and The Bank of New York Mellon Trust Company, N.A. (filed as Exhibit 99.2 to the Registrant’s Current Report on Form 8-K filed December 11, 2013 [File No. 1-8002] and incorporated in this document by reference).
4.3
Eighth Supplemental Indenture, dated as of November 24, 2014, among the Company, The Bank of New York Mellon Trust Company, N.A., as trustee, and The Bank of New York Mellon, London Branch, as paying agent (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 24, 2014 [File No. 1-8002] and incorporated in this document by reference).
4.4
Thirteenth Supplemental Indenture, dated as of September 12, 2016, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed September 12, 2016 [File No. 1-8002] and incorporated in this document by reference).
4.5
Fifteenth Supplemental Indenture, dated as of March 16, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed March 16, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.6
Sixteenth Supplemental Indenture, dated as of July 24, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed July 24, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.7
Seventeenth Supplemental Indenture, dated as of August 14, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed August 14, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.8
Eighteenth Supplemental Indenture, dated as of September 30, 2019, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed September 30, 2019 [File No. 1-8002] and incorporated in this document by reference).
4.9
Nineteenth Supplemental Indenture, dated as of October 8, 2019, between the Company, and the Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 8, 2019 [File No. 1-8002] and incorporated in this document by reference).
4.10
Twenty-First Supplemental Indenture, dated as of April 2, 2020, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed April 2, 2020 [File No. 1-8002] and incorporated in this document by reference).
4.11
Twenty-Second Supplemental Indenture, dated as of August 23, 2021, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed August 23, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.12
Twenty-Third Supplemental Indenture, dated as of October 22, 2021, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 22, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.13
Twenty-Fourth Supplemental Indenture, dated as of October 20, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 20, 2022 [File No. 1-8002] and incorporated in this document by reference).
4.14
Twenty-Fifth Supplemental Indenture, dated as of November 21, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 21, 2022 [File No. 1-8002] and incorporated in this document by reference).
4.15
Twenty-Sixth Supplemental Indenture, dated as of November 21, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.3 to the Registrant’s Current Report on Form 8-K filed November 21, 2022 [File No. 1-8002] and incorporated in this document by reference).
4.16
Twenty-Seventh Supplemental Indenture, dated as of August 10, 2023, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed August 10, 2023 [File No. 1-8002] and incorporated in this document by reference).
4.17
Twenty-Eighth Supplemental Indenture, dated as of December 5, 2023, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K December 5, 2023 [File No. 1-8002] and incorporated in this document by reference).
4.18
Indenture, dated as of August 9, 2016, among Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), as issuer, the Company, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed August 9, 2016 [File No. 1-8002] and incorporated in this document by reference).
75

THERMO FISHER SCIENTIFIC INC.

Exhibit NumberDescription of Exhibit
4.19
Third Supplemental Indenture, dated as of October 18, 2021, among Thermo Fisher International, as issuer, the Company, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 18, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.20
Fourth Supplemental Indenture, dated as of November 18, 2021, among Thermo Fisher International, as issuer, the Company, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 18, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.21
Description of the Registrant’s Securities (filed as Exhibit 4.19 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 [File No. 1-8002] and incorporated in this document by reference).
10.1
10.2
Thermo Electron Corporation Deferred Compensation Plan, effective November 1, 2001 (filed as Exhibit 10.13 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 29, 2001 [File No. 1-8002] and incorporated in this document by reference).*
10.3
Form of Amended and Restated Indemnification Agreement between the Registrant and its directors and officers (filed as Exhibit 10.2 to the Registrant’s Registration Statement on Form S-4 [Reg. No. 333-90661] and incorporated in this document by reference).*
10.4
Summary of Thermo Fisher Scientific Inc. Annual Non-Management Director Compensation (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed February 24, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.5
Form of Noncompetition Agreement between the Registrant and certain key employees and executive officers, effective as of January 1, 2009 (filed as Exhibit 10.25 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.6Retirement Plan for Non-Employee Directors of Fisher Scientific International Inc. (filed as Exhibit 10.12 to Fisher Scientific International Inc.’s Annual Report on Form 10-K for the year ended December 31, 1992 [File No. 1-10920] and incorporated in this document by reference).*
10.7
First Amendment to the Fisher Scientific International Inc. Retirement Plan for Non-Employee Directors (filed as Exhibit 10.04 to Fisher Scientific International Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2005 [File No. 1-10920] and incorporated in this document by reference).*
10.8
Amendment to Retirement Plan for Non-Employee Directors of Fisher Scientific International Inc. (filed as Exhibit 10.02 to Fisher Scientific International Inc.’s Current Report on Form 8-K filed March 7, 2006 [File No. 1-10920] and incorporated in this document by reference).*
10.9
Thermo Fisher Scientific Inc. Amended and Restated 2005 Deferred Compensation Plan, effective January 1, 2020 (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 27, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.10
2009 Restatement of Executive Severance Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009 (filed as Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.11
Executive Change In Control Retention Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009 (filed as Exhibit 10.6 to the Registrant’s Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.12
Noncompetition Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009 (filed as Exhibit 10.7 to the Registrant’s Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.13
Amendment No. 1 to 2009 Restatement of Executive Severance Agreement, dated February 25, 2010, between the Registrant and Marc N. Casper (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed February 25, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.14
Amendment No. 2 to 2009 Restatement of Executive Severance Agreement, dated November 30, 2010, between the Registrant and Marc N. Casper (filed as Exhibit 10.55 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.15
Amendment No. 1 to Executive Change In Control Retention Agreement, dated November 30, 2010, between Marc N. Casper and the Registrant (filed as Exhibit 10.56 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.16
Amendment No. 2 to Executive Change in Control Retention Agreement, dated March 16, 2018, between Marc N. Casper and the Registrant (filed as Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 [File No. 1-8002] and incorporated in this document by reference).*
10.17
Form of Executive Change in Control Retention Agreement for Officers (other than Marc N. Casper) (filed as Exhibit 10.7 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.18
Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement for Directors (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended April 2, 2011 [File No. 1-8002] and incorporated in this document by reference).*
76

THERMO FISHER SCIENTIFIC INC.

Exhibit NumberDescription of Exhibit
10.19
Thermo Fisher Scientific Inc. Amended and Restated 2013 Stock Incentive Plan (filed as Exhibit 99.1 to the Registrant’s Form S-8 filed on May 24, 2023 [File No. 333-272173] and incorporated in this document by reference).*
10.20
Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement for Officers (filed as Exhibit 10.44 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2016 [File No. 1-8002] and incorporated in this document by reference).*
10.21
Patheon N.V. 2016 Omnibus Incentive Plan (filed as Exhibit 10.2 to the Current Report on Form 8-K filed by Patheon N.V. on July 26, 2016 [File No. 001-37837] and incorporated in this document by reference).*
10.22
Amendment to Patheon N.V. 2016 Omnibus Incentive Plan, dated March 7, 2017 (filed as Exhibit 4.5 to the Registrant's Registration Statement on Form S-8 filed August 29, 2017 [File No. 1-8002] and incorporated in this document by reference).*
10.23
Amendment to Patheon N.V. 2016 Omnibus Incentive Plan, dated August 23, 2017 (filed as Exhibit 4.6 to the Registrant's Registration Statement on Form S-8 filed August 29, 2017 [File No. 1-8002] and incorporated in this document by reference).*
10.24
10.25
Letter Agreement between the Registrant and Michel Lagarde dated August 28, 2017 (filed as Exhibit 10.39 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.26
Option Agreement Under the Patheon N.V. 2016 Omnibus Incentive Plan between Patheon N.V. and Michel Lagarde dated July 20, 2016 (filed as Exhibit 10.40 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.27
Option Agreement Under the Patheon N.V. 2016 Omnibus Incentive Plan between Patheon N.V. and Michel Lagarde dated March 23, 2017 (filed as Exhibit 10.42 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.28
Thermo Fisher Scientific Inc. Executive Severance Policy (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 29, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.29
Form of Noncompetition Agreement between the Registrant and certain key employees and executive officers (filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 29, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.30
Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement effective as of February 25, 2020 (filed as Exhibit 10.45 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.31
Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement effective as of February 25, 2020 (filed as Exhibit 10.46 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.32
Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement for Officers effective as of February 25, 2020 (filed as Exhibit 10.47 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.33
Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020 (filed as Exhibit 10.48 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.34
Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020 (filed as Exhibit 10.49 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.35
Form of Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020 (filed as Exhibit 10.50 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.36
Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.47 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.37
Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.48 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.38
Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement (filed as Exhibit 10.49 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.39
PPD, Inc. 2020 Omnibus Incentive Plan (filed as Exhibit 10.38 to PPD Inc.’s Form S-1/A filed January 27, 2020 [File No. 333-235860] and incorporated in this document by reference).*
77

THERMO FISHER SCIENTIFIC INC.

Exhibit NumberDescription of Exhibit
10.40
Amendment to Nonstatutory Stock Option Agreements between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.45 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.41
Amendment to Restricted Stock Unit Agreements between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.46 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.42
Amendment to Performance Restricted Stock Unit Agreements between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.47 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.43
Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement effective as of February 22, 2023 (filed as Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.44
Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement (filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.45
Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.46
Form of Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 22, 2023 (filed as Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.47
Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.48
Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.49
21
22
23.1
31.1
31.2
32.1
32.2
97
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema Document.
101.CALXBRL Taxonomy Calculation Linkbase Document.
101.DEFXBRL Taxonomy Definition Linkbase Document.
101.LABXBRL Taxonomy Label Linkbase Document.
101.PREXBRL Taxonomy Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
_______________________
*Indicates management contract or compensatory plan, contract or arrangement.
** Certification is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.
Item 16.    Form 10-K Summary
None.
78

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date:February 22, 2024THERMO FISHER SCIENTIFIC INC.
By:/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated, as of February 22, 2024.
By:
/s/ Marc N. Casper
By:
/s/ Jennifer M. Johnson
Marc N. Casper
Jennifer M. Johnson
Chairman, President and Chief Executive OfficerDirector
(Principal Executive Officer)
By:
/s/ Stephen Williamson
By:
/s/ R. Alexandra Keith
Stephen WilliamsonR. Alexandra Keith
Senior Vice President and Chief Financial OfficerDirector
(Principal Financial Officer)
By:
/s/ Joseph R. Holmes
By:
/s/ James C. Mullen
Joseph R. HolmesJames C. Mullen
Vice President and Chief Accounting OfficerDirector
(Principal Accounting Officer)
By:
/s/ Nelson J. Chai
By:
/s/ Lars R. Sørensen
Nelson J. Chai
Lars R. Sørensen
DirectorDirector
By:
/s/ Ruby R. Chandy
By:
/s/ Debora L. Spar
Ruby R. Chandy
Debora L. Spar
DirectorDirector
By:
/s/ C. Martin Harris
By:
/s/ Scott M. Sperling
C. Martin HarrisScott M. Sperling
DirectorDirector
By:
/s/ Tyler E. JacksBy:/s/ Dion J. Weisler
Tyler E. JacksDion J. Weisler
DirectorDirector

79
 EX-3.4 2 q4202310-kex34.htm AMENDED AND RESTATED BY-LAWS OF THE REGISTRANT Document
Exhibit 3.4
As amended and restated effective as of February 21, 2024

Thermo Fisher Scientific Inc.

BY-LAWS

TABLE OF CONTENTS
TitlePage
ARTICLE I - STOCKHOLDERS1
Section 1.Annual Meeting1
Section 2.Special Meetings1
Section 3.Notice of Meetings3
Section 4.Quorum; Adjournments4
Section 5.Voting; Proxies4
Section 6.Inspectors of Elections5
Section 7.Presiding Officer and Secretary5
Section 8.List of Stockholders6
Section 9.Advance Notice of Stockholder Nominations and Proposals6
Section 10.Proxy Access11
Section 11.Action Without Meeting17
Section 12.Meeting by Remote Communication17
Section 13.Delivery to the Corporation18
ARTICLE II - DIRECTORS18
Section 1.General Powers18
Section 2.Number and Qualification18
Section 3.Terms of Office18
Section 4.Removal18
Section 5.Vacancies19
Section 6.Resignations19
Section 7.Meetings19
Section 8.Notice of Meetings19
Section 9.Quorum19
Section 10.Action at Meeting19
Section 11.Action by Consent20
Section 12.Meetings by Telephone Conference Call20
Section 13.Compensation of Directors20
Section 14.Committees20
Section 15.Emergency Bylaws21
i



TitlePage
ARTICLE III - OFFICERS21
Section 1.General Provisions; Qualification21
Section 2.Election21
Section 3.Tenure21
Section 4.Resignation and Removal21
Section 5.Vacancies21
Section 6.The Chief Executive Officer22
Section 7.The President22
Section 8.Vice Presidents22
Section 9.Chief Financial Officer22
Section 10.General Counsel22
Section 11.The Treasurer22
Section 12.The Secretary22
Section 13.Assistant Treasurers23
Section 14.Assistant Secretaries23
Section 15.Other Officers23
Section 16.Delegation of Duties23
Section 17.Salaries23
ARTICLE IV - CAPITAL STOCK23
Section 1.Shares of Stock23
Section 2.Transfer of Shares of Stock23
Section 3.Lost, Stolen or Destroyed Certificates24
Section 4.Record Date24
Section 5.Regulations25
ARTICLE V - GENERAL PROVISIONS25
Section 1.Fiscal Year25
Section 2.Corporate Seal25
Section 3.Waiver of Notice25
Section 4.Voting of Securities25
Section 5.Evidence of Authority26
Section 6.Certificate of Incorporation26
Section 7.Transactions with Interested Parties26
Section 8.Severability26
Section 9.Limitation on Stock Option Repricing26
ARTICLE VI - AMENDMENTS27
Section 1.By the Board of Directors27
Section 2.By the Stockholders27
ii



THERMO FISHER SCIENTIFIC INC.
BY-LAWS
ARTICLE I - STOCKHOLDERS
Section 1. Annual Meeting. The annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, if any, on such date, and at such time as the Board of Directors may each year fix. The Board of Directors may postpone, reschedule or cancel any previously scheduled annual meeting.
Section 2. Special Meetings.
1.    Except as otherwise provided in paragraph 2 of Section 2 of this Article I, special meetings of stockholders may be called only by the Board of Directors, the Chairman of the Board of Directors, or the Chief Executive Officer. Business transacted at any special meeting of stockholders called pursuant to this paragraph 1 of Section 2 of Article I shall be limited to matters relating to the purpose or purposes stated in the notice of meeting.
2.    A special meeting of stockholders shall be called by the Secretary upon written request (a “Special Meeting Request”) of one or more holders of record representing not less than 15% of the outstanding shares of Common Stock of the Corporation (the “Requisite Percentage”), provided that such shares have been “Owned” (as defined in paragraphs 7 and 8 of Section 10 of this Article I) continuously by such holders for at least one year prior to the date of the Special Meeting Request (the “One Year Period”), who have complied in full with the requirements set forth in these By-laws.
(i)    A Special Meeting Request must be delivered to the attention of the Secretary at the principal executive offices of the Corporation. A Special Meeting Request shall be valid only if it is signed and dated by each stockholder of record submitting the Special Meeting Request and the beneficial owners, if any, on whose behalf the Special Meeting Request is being made, or such stockholder’s or beneficial owner’s duly authorized agent (each, a “Requesting Stockholder”) collectively representing the Requisite Percentage, and includes (A) a statement of the specific purpose(s) of the special meeting and the reasons for conducting such business at the special meeting; (B) as to any director nominations proposed to be presented at the special meeting and any matter (other than a director nomination) proposed to be conducted at the special meeting and as to each Requesting Stockholder, the information, statements, representations, agreements and other documents that would be required to be set forth in or included with a stockholder’s notice of a nomination pursuant to Section 9 of this Article I (including any nominee’s written consent to being named in the Corporation’s proxy statement as a nominee and to serving as a director if elected) and/or a stockholder’s notice of business proposed to be brought before a meeting pursuant to Section 9 of this Article I, as applicable; (C) a representation that a Requesting Stockholder or a qualified representative (as defined in Section 9 of this Article I) thereof intends to appear in person or by proxy at the special meeting to present the nomination(s) or business to be brought before the special meeting; (D) an agreement by each Requesting Stockholder to notify the Corporation promptly
1



in the event of any disposition prior to the date of the special meeting of shares of the Corporation owned beneficially or of record and an acknowledgement that any such disposition shall be deemed to be a revocation of such Special Meeting Request with respect to such disposed shares; and (E) documentary evidence that each Requesting Stockholder has Owned continuously for the One Year Period the Requisite Percentage; provided, however, that if the Requesting Stockholders are not the beneficial owners of the shares representing the Requisite Percentage, then to be valid, the Special Meeting Request must also include documentary evidence (or, if not simultaneously provided with the Special Meeting Request, such documentary evidence must be delivered to the Secretary within 10 days after the date on which the Special Meeting Request is delivered to the Secretary) that the beneficial owners on whose behalf the Special Meeting Request is made beneficially have Owned the Requisite Percentage continuously for the One Year Period. In addition, each Requesting Stockholder shall (x) further update and supplement the information provided in the Special Meeting Request, if necessary, so that the information provided or required to be provided therein shall be true and correct as of the record date for the special meeting and as of the date that is 10 business days prior to the special meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to the Secretary at the principal executive offices of the Corporation not later than five business days after the later of the record date for the meeting or the date notice of the record date is first publicly disclosed in the case of the update and supplement required to be made as of the record date and not later than 10 business days prior to the date of the special meeting or any adjournment or postponement thereof in the case of the update and supplement required to be made as of 10 business days prior to the special meeting or any adjournment or postponement thereof and (y) promptly provide any other information reasonably requested by the Corporation.
(ii)    A Special Meeting Request shall not be valid, and a special meeting requested by stockholders shall not be held, if (A) the Special Meeting Request does not comply with this Section 2; (B) the Special Meeting Request relates to an item of business that is not a proper subject for stockholder action under applicable law (as determined in good faith by the Board of Directors); (C) the Special Meeting Request is delivered during the period commencing 90 days prior to the first anniversary of the date of the immediately preceding annual meeting of stockholders and ending on the earlier of the date of the next annual meeting of stockholders and the date that is 90 days after the first anniversary of the date of the immediately preceding annual meeting of stockholders; (D) an identical or substantially similar item (as determined in good faith by the Board of Directors, a “Similar Item”), other than the election of directors, was presented at an annual or special meeting of stockholders held not more than 12 months before the Special Meeting Request is delivered; (E) a Similar Item was presented at an annual or special meeting of stockholders held not more than 120 days before the Special Meeting Request is delivered (and, for purposes of this clause (E), the election of directors shall be deemed to be a “Similar Item” with respect to all items of business involving the election or removal of directors, changing the size of the Board of Directors and the filling of vacancies and/or newly created directorships resulting from any increase in the authorized number of directors); (F) a Similar Item is included in the Corporation’s notice of meeting as an item of business to be brought before an annual or special meeting of stockholders that has been called but not yet held or that is called for a date within 90 days of the receipt by the Corporation of a Special Meeting Request; or (G) the Special Meeting Request was made in a manner that involved a violation of Regulation 14A under the Exchange Act or other applicable law.
2



(iii)    Special meetings of stockholders called pursuant to this Section 2 shall be held at such place, if any, on such date, and at such time as the Board of Directors shall fix; provided, however, that the special meeting shall not be held more than 90 days after receipt by the Corporation of a valid Special Meeting Request.
(iv)    The Requesting Stockholders may revoke a Special Meeting Request by written revocation delivered to the Secretary at the principal executive offices of the Corporation at any time prior to the special meeting. If, at any point after 60 days of the first date on which a Special Meeting Request is delivered to the Corporation the unrevoked requests from Requesting Stockholders (whether by specific written revocation or deemed revocation pursuant to clause (D) of paragraph 2(i) of this Section 2) represent in the aggregate less than the Requisite Percentage, the Board of Directors, in its discretion, may cancel the special meeting.
(v)    In determining whether a special meeting of stockholders has been requested by the Requesting Stockholders representing in the aggregate at least the Requisite Percentage, multiple Special Meeting Requests delivered to the Secretary of the Corporation will be considered together only if (A) each Special Meeting Request identifies substantially the same purpose or purposes of the special meeting and substantially the same matters proposed to be acted on at the special meeting, in each case as determined by the Board of Directors (which, if such purpose is the election or removal of directors, changing the size of the Board of Directors and/or the filling of vacancies and/or newly created directorships resulting from any increase in the authorized number of directors, will mean that the exact same person or persons are proposed for election or removal in each relevant Stockholder Meeting Request), and (B) such Special Meeting Requests have been dated and delivered to the Secretary of the Corporation within 60 days of the first date on which a Special Meeting Request is delivered to the Corporation.
(vi)    If none of the Requesting Stockholders appear or send a qualified representative (as defined in Section 9 of this Article I) to present the nomination and/or business to be presented for consideration as specified in the Special Meeting Request, the Corporation need not present such nomination and/or business for a vote at the special meeting, notwithstanding that proxies in respect of such nomination and/or business may have been received by the Corporation.
(vii)    Business transacted at any special meeting called pursuant to this paragraph 2 of Section 2 shall be limited to (A) the purpose(s) stated in the valid Special Meeting Request received from the Requisite Percentage of record holders and (B) any additional matters that the Board of Directors determines to include in the Corporation’s notice of the special meeting.
3.    The Board of Directors may postpone, reschedule or cancel any previously scheduled special meeting.
Section 3. Notice of Meetings. Notice of the place, date, and time of all meetings of the stockholders and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting shall be given, not less than ten (10) nor more than sixty (60) days before the date on which the meeting is to be held, to each stockholder entitled to vote at such meeting, except as otherwise required by the Delaware General Corporation Law (meaning, here and hereinafter, the General Corporation Law of the State of Delaware, as amended and in effect from time to time, the “Delaware General Corporation Law”).
3




Section 4. Quorum; Adjournments. At any meeting of the stockholders, the holders of a majority in voting power of all of the shares of the stock entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if any, authorized by the Board of Directors in its sole discretion, or represented by proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence of a larger number may be required by the Certificate of Incorporation or the Delaware General Corporation Law. Where a separate vote by a class or classes or series is required, a majority of the shares of such class or classes or series present in person, present by means of remote communication in a manner, if any, authorized by the Board of Directors in its sole discretion, or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. A quorum, once established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum.
Any meeting of stockholders may be adjourned from time to time to reconvene at any other time and to any other place at which a meeting of stockholders may be held under these Bylaws by the presiding officer. When a meeting is adjourned to another place or time (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), notice need not be given of the adjourned meeting if the place, if any, and time thereof and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting are (i) announced at the meeting at which the adjournment is taken, (ii) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication or (iii) set forth in the notice of meeting given in accordance with Section 3 hereof; provided, however, that if the date of any adjourned meeting is more than thirty (30) days after the date for which the meeting was originally noticed, or if a new record date is fixed for the adjourned meeting, notice of the place, if any, date, and time of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting shall be given in conformity herewith. At any adjourned meeting, any business may be transacted that could have been transacted at the original meeting.
Section 5. Voting; Proxies. Each stockholder shall have one vote for each share of stock entitled to vote held of record by such stockholder unless otherwise provided by the Delaware General Corporation Law or the Certificate of Incorporation. Each stockholder of record entitled to vote at a meeting of stockholders, or to express consent or dissent to corporate action in writing without a meeting, may vote or express such consent or dissent in person or may authorize another person or persons to vote or act for the stockholder by proxy authorized by an instrument in writing or by a transmission permitted by law, delivered in accordance with the procedure established for the meeting. No such proxy shall be voted or acted upon after three years from the date of its execution, unless the proxy expressly provides for a longer period.

4



When a quorum is present at any meeting, the affirmative vote of holders of a majority in voting power of the stock present or represented and entitled to vote and voting affirmatively or negatively on a matter (or if there are two or more classes or series of stock entitled to vote as separate classes, then in the case of each such class or series, the holders of a majority of the stock of that class present or represented and voting affirmatively or negatively on a matter) shall constitute stockholder action on any matter to be voted upon by the stockholders at such meeting, except when a different or minimum vote is required by the Delaware General Corporation Law, the Certificate of Incorporation, these By-laws, the rules and regulations of any stock exchange applicable to the Corporation, or any law or regulation application to the Corporation or its securities, in which case, such different or minimum vote shall be the applicable vote on the matter. Except as may be otherwise required by the Certificate of Incorporation, a nominee for director shall be elected to the Board of Directors if the votes cast for such nominee’s election exceed the votes cast against such nominee’s election (with “abstentions” and “broker nonvotes” not counted as a vote cast either “for” or “against” that director’s election), provided that if, on the tenth business day before the Corporation first mails its notice of meeting for such meeting to the stockholders, the number of nominees exceeds the number of directors to be elected, the directors shall be elected by the vote of a plurality of the shares represented in person or by proxy at any such meeting and entitled to vote on the election of directors. If directors are to be elected by a plurality of the votes cast, stockholders shall not be permitted to vote against a nominee.
Section 6. Inspectors of Elections. The Corporation shall, in advance of any meeting of the stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof and perform the other duties of inspectors at meetings of stockholders as set forth in the Delaware General Corporation Law. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting shall appoint one or more persons to act as inspector at the meeting. Each inspector, before entering the discharge of the inspector’s duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of the inspector’s ability.
Section 7. Presiding Officer and Secretary. The Chairman of the Board, or in the Chairman’s absence, the Chief Executive Officer, or in the Chief Executive Officer’s absence, the President, or in the President’s absence, the Chief Financial Officer, in such order, or, in the absence of all of them, any person designated by the Board of the Directors, shall call meetings of the stockholders to order, and shall act as presiding officer of such meeting. The Board of Directors may adopt by resolution such rules and regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the presiding officer shall have the power to convene and (for any or no reason) to recess or adjourn meetings to another place, if any, or time, to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such presiding officer, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by the presiding officer, may include, without limitation, the following: (i) the establishment of an agenda or order of business for the meeting; (ii) rules and procedures for maintaining order at the meeting and the safety of those present; (iii) limitations on attendance at or participation in the meeting to stockholders entitled to vote at the meeting, their duly authorized and constituted
5



proxies or such other persons as the presiding officer shall determine; (iv) restrictions on entry to the meeting after the time fixed for the commencement thereof; and (v) limitations on the time allotted to questions or comments by participants. The presiding officer, in addition to making any other determinations that may be appropriate to the conduct of the meeting, shall, if the facts warrant, determine and declare to the meeting that a matter or business was not properly brought before the meeting and if such presiding officer should so determine, such presiding officer shall so declare to the meeting and any such matter or business not properly brought before the meeting shall not be transacted or considered. Unless and to the extent determined by the Board of Directors or the presiding officer, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting. The Secretary of the Corporation, or in the Secretary’s absence, any Assistant Secretary, shall act as the secretary at all meetings of the stockholders, but in the absence of the Secretary and any Assistant Secretary, the presiding officer may appoint any person to act as secretary of the meeting.
Section 8. List of Stockholders. The Corporation shall prepare, at least 10 days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of 10 days ending on the day before the meeting date (i) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of meeting or (ii) during ordinary business hours at the principal place of business of the Corporation.
Section 9. Advance Notice of Stockholder Nominations and Proposals.
1.Nominations of persons for election to the Board of Directors and the proposal of business to be transacted by the stockholders may be made at an annual meeting of stockholders only (a) pursuant to the Corporation’s notice with respect to such meeting, (b) by or at the direction of the Board, (c) by any stockholder of record of the Corporation who was a stockholder of record at the time of the giving of the notice provided for in the following paragraph, who is entitled to vote at the meeting and who has complied with the notice procedures set forth in this Section 9 or (d) by an Eligible Stockholder (as defined in Section 10 of this Article I) whose Stockholder Nominee (as defined in Section 10 of this Article I) is included in the Corporation’s proxy materials for the relevant annual meeting of stockholders pursuant to Section 10 of this Article I.
2.For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to clause (c) of the foregoing paragraph, (1) the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation, (2) such business must be a proper matter for stockholder action under the Delaware General Corporation Law, (3) if the stockholder, or the beneficial owner on whose behalf any such proposal or nomination is made, and/or the respective affiliates and associates of, or others acting in concert with, such stockholder and such beneficial owner (each, a “Stockholder Associated Person”), has provided the Corporation with a Solicitation Notice, as that term is defined in subclause (c)(iii) of this paragraph, such stockholder, beneficial owner and/or Stockholder Associated Person must, in the case of a proposal, have delivered a proxy statement and form of proxy to holders of at least the percentage of the Corporation’s voting shares required under the Delaware General Corporation Law to carry any such proposal, or, in the case of a
6



nomination or nominations, have delivered a proxy statement and form of proxy to holders of a percentage of the Corporation’s voting shares reasonably believed by such stockholder, beneficial owner and/or Stockholder Associated Person to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder or such beneficial owner, and must, in either case, have included in such materials the Solicitation Notice, and (4) if no Solicitation Notice relating thereto has been timely provided pursuant to this Section 9, the stockholder or beneficial owner proposing such business or nomination must not have solicited a number of proxies or votes sufficient to have required the delivery of such a Solicitation Notice under this Section 9. To be timely, a stockholder’s notice shall be delivered to the Secretary at the principal executive offices of the Corporation not less than 60 or more than 75 days prior to the first anniversary (the “Anniversary”) of the date on which the Corporation first mailed its proxy materials for the preceding year’s annual meeting of stockholders; provided, however, that if the date of the annual meeting is advanced more than 30 days prior to or delayed (other than as a result of adjournment) by more than 30 days after the anniversary of the preceding year’s annual meeting, notice by the stockholder to be timely must be so delivered not later than the close of business on the later of (i) the 90th day prior to such annual meeting or (ii) the 10th day following the day on which public announcement of the date of such meeting is first made. In no event shall the adjournment or postponement of an annual meeting (or the public announcement thereof) commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described above. The number of nominees a stockholder may nominate for election at the annual meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the annual meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such annual meeting. Such stockholder’s notice shall set forth (a) as to each person whom the stockholder proposes to nominate for election or reelection as a director all information relating to such person as would be required to be disclosed in solicitations of proxies for the election of such nominees as directors pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and such person’s written consent to being named in the Corporation’s proxy statement as a nominee of the stockholder and to serve as a director if elected; (b) as to any other business that the stockholder proposes to bring before the meeting, a brief description of such business, the text of the proposal or business (including the exact text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend the By-laws, the exact text of the proposed amendment), the reasons for conducting such business at the meeting and any material interest in such business of such stockholder, such beneficial owner, and/or any Stockholder Associated Person; (c) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination is made (i) the name and address of such stockholder, as they appear on the Corporation’s books, and of such beneficial owner, (ii) the class, series and number of shares of the Corporation that are, directly or indirectly, owned beneficially and of record by such stockholder and such beneficial owner, (iii) whether either such stockholder, beneficial owner and/or Stockholder Associated Person intends to deliver a proxy statement and form of proxy to holders of, in the case of a proposal, at least the percentage of the Corporation’s voting shares required under the Delaware General Corporation Law to carry the proposal or, in the case of a nomination or nominations, a sufficient number of holders of the Corporation’s voting shares to elect such nominee or nominees (an affirmative statement of such intent, a “Solicitation Notice”), (iv) a representation as to whether or not such stockholder, such beneficial owner and/or any Stockholder Associated Person intends to solicit proxies in support of any director nominees other than the Corporation’s nominees in accordance with Rule 14a-19 promulgated under the Exchange Act, and, where such stockholder, beneficial owner, and/or Stockholder
7



Associated Person intends to so solicit proxies, the notice and information required by Rule 14a-19(b) under the Exchange Act, and a statement that such stockholder, beneficial owner, and/or Stockholder Associated Person has otherwise complied or will otherwise comply with the requirements of Rule 14a-19 under the Exchange Act, (v) a description of any agreement, arrangement or understanding with respect to the nomination or proposal between or among such stockholder, such beneficial owner, and/or any Stockholder Associated Person, including, in the case of a nomination, the nominee, (vi) a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, warrants, convertible securities, stock appreciation or similar rights, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of the stockholder’s notice by, or on behalf of, such stockholder, such beneficial owners, and/or any Stockholder Associated Person, whether or not such instrument or right shall be subject to settlement in underlying shares of capital stock of the Corporation, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of, such stockholder, such beneficial owner, and/or any Stockholder Associated Person, with respect to securities of the Corporation, (vii) a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to propose such business or nomination, (viii) a representation that such stockholder, such beneficial owner, and/or any Stockholder Associated Person has complied, and will comply, with all applicable requirements of state law and the Exchange Act with respect to matters set forth in this Section 9 and (ix) any other information relating to such stockholder, beneficial owner, and/or Stockholder Associated Person required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal and/or for the election of directors in an election contest pursuant to and in accordance with Section 14(a) of the Exchange Act and the rules and regulations promulgated thereunder. The foregoing notice requirements of this paragraph 2 of Section 9 shall be deemed satisfied by a stockholder with respect to business other than a nomination if the stockholder has notified the Corporation of his, her or its intention to present a proposal at an annual meeting in compliance with applicable rules and regulations promulgated under the Exchange Act and such stockholder’s proposal has been included in a proxy statement that has been prepared by the Corporation to solicit proxies for such annual meeting. The Corporation may require any proposed nominee to furnish such other information as the Corporation may reasonably require, to determine the eligibility of such proposed nominee to serve as a director of the Corporation.
3.Notwithstanding anything in the second sentence of the second paragraph of this Section 9 to the contrary, in the event that the number of directors to be elected to the Board at the annual meeting is increased effective after the time period for which nominations would otherwise be due under the second paragraph of this Section 9 and there is no public announcement naming the nominees for additional directorships at least 70 days prior to the Anniversary, a stockholder’s notice required by this By-law shall also be considered timely, but only with respect to nominees for the additional directorships, if it shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the 10th day following the day on which such public announcement is first made by the Corporation.
8




4.Only persons nominated in accordance with the procedures set forth in this Section 9 or Section 10, as applicable, shall be eligible to serve as directors and only such business shall be conducted at an annual meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Section 9. The presiding officer of the meeting (and, in advance of the meeting, the Board of Directors) shall have the power and the duty to determine whether a nomination or any business proposed to be brought before the meeting has been made in accordance with the procedures set forth in these By-laws (including whether the stockholder, beneficial owner and/or any Stockholder Associated Person did or did not solicit, as the case may be, proxies or votes in support of such stockholder’s nominee in compliance with the representations with respect thereto required by this Section 9), and, if any proposed nomination or business is not in compliance with these By-laws, to declare that such defective proposed business or nomination shall not be presented for stockholder action at the meeting and shall be disregarded. Notwithstanding the foregoing provisions of this Section 9, unless otherwise required by law, if the stockholder (or a qualified representative of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to present a nomination or proposed business, such nomination shall be disregarded and such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Section 9 and Section 10 of these By-laws, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders.
5.Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation’s notice of meeting. Nominations of persons for election to the Board may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation’s notice of meeting (a) by or at the direction of the Board or stockholders pursuant to Section 2 of this Article I or (b) provided that the Board or stockholders pursuant to Section 2 of this Article I have determined that directors shall be elected at such meeting, by any stockholder of record of the Corporation who is a stockholder of record at the time of giving of notice provided for in this paragraph, who shall be entitled to vote at the meeting and who complies with the procedures set forth in this Section 9, including, without limitation, the procedures regarding Solicitation Notices. The proposal by stockholders of other business to be conducted at a special meeting of stockholders may be made only in accordance with Section 2 of this Article I. The number of nominees a stockholder may nominate for election at the special meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the special meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such special meeting. In the event the Corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board, nominations by stockholders of persons for election to such positions as specified in the Corporation’s notice of meeting may be made at such a special meeting of stockholders if the stockholder’s notice required by Section 9 shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the later of the 90th day prior to such special
9



meeting or the 10th day following the day on which the Corporation first makes a public announcement of the date of the special meeting at which directors are to be elected. In no event shall the adjournment or postponement of a special meeting (or the public announcement thereof) commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described above.
6.For purposes of this Section 9 and Section 10 of this Article I, “public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or a comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.
7.Notwithstanding the foregoing provisions of this Section 9, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to matters set forth in this Section 9. Nothing in this Section 9 shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Exchange Act.
8.Notwithstanding anything to the contrary in these By-laws, unless otherwise required by law, (1) no stockholder, beneficial owner, and/or any Stockholder Associated Person shall solicit proxies in support of director nominees, other than the Corporation’s nominees, unless such stockholder, beneficial owner, and/or Stockholder Associated Person has complied with Rule 14a-19(b) promulgated under the Exchange Act in connection with the solicitation of such proxies, including the requirement to provide the Corporation with the notices required thereunder in a timely manner and (2) if any stockholder, beneficial owner, and/or Stockholder Associated Person (A) provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act and (B) subsequently fails to comply with the requirements of Rule 14a-19(a)(2) or Rule 14a-19(a)(3) promulgated under the Exchange Act or fails to timely provide reasonable evidence sufficient to satisfy the Corporation that such stockholder, beneficial owner, or Stockholder Associated Person has met the requirements of Rule 14a-19(a)(3) promulgated under the Exchange Act in accordance with the following sentence, then the nomination of each such director nominee shall be disregarded notwithstanding that proxies or votes in respect of the election of such proposed nominees may have been received by the Corporation (which proxies and votes shall be disregarded). If any stockholder, beneficial owner, and/or Stockholder Associated Person provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act, such stockholder, beneficial owner, or Stockholder Associated Person shall deliver to the Corporation, no later than five (5) business days prior to the applicable meeting, reasonable documentary evidence that such person has met the requirements of Rule 14a-19 promulgated under the Exchange Act, including clause (a)(3) thereof, together with a representation that such person has complied with the requirements of Rule 14a-19 promulgated under the Exchange Act.
9.Any person directly or indirectly soliciting proxies from stockholders of the Corporation must use a proxy card color other than white, which shall be reserved for exclusive use by the Board of Directors.
10




10.Unless the Corporation elects otherwise, a stockholder’s notice to the Corporation shall be in writing exclusively (and not in an electronic transmission) and shall be delivered exclusively by hand (including, without limitation, overnight courier service) or by certified or registered mail, return receipt requested, and the Corporation shall not be required to accept delivery of any document not in such written form or so delivered.
Section 10. Proxy Access.
1.Subject to the provisions of this Section 10, the Corporation shall include in its proxy statement (including its form of proxy) for an annual meeting of stockholders the name of any stockholder nominee for election to the Board of Directors submitted pursuant to this Section 10 (each a “Stockholder Nominee”) provided (a) timely written notice of such Stockholder Nominee satisfying this Section 10 (“Notice”) is delivered to the Corporation by or on behalf of a stockholder or stockholders that, at the time the Notice is delivered, satisfy the ownership and other requirements of this Section 10 (such stockholder or stockholders, and any person on whose behalf they are acting, the “Eligible Stockholder”), (b) the Eligible Stockholder expressly elects in writing at the time of providing the Notice to have its nominee included in the Corporation’s proxy statement pursuant to this Section 10, and (c) the Eligible Stockholder and the Stockholder Nominee otherwise satisfy the requirements of this Section 10 and the director qualifications requirements set forth in the Corporation’s Corporate Governance Guidelines and any other document(s) setting forth qualifications for directors.
2.To be timely, an Eligible Stockholder’s notice must be received in writing by the Secretary of the Corporation at the principal executive offices of the Corporation not less than 120 days nor more than 150 days prior to the first anniversary of the preceding year’s annual meeting; provided, however, that in the event that the date of the annual meeting is advanced by more than 30 days, or delayed (other than as a result of adjournment) by more than 60 days, from the first anniversary of the preceding year’s annual meeting, or if no annual meeting was held in the preceding year, a stockholder’s notice must be so received not earlier than the 150th day prior to such annual meeting and not later than the close of business on the later of (a) the 120th day prior to such annual meeting and (b) the tenth day following the day on which notice of the date of such annual meeting was mailed or public announcement (as defined in Section 9 of this Article I) of the date of such annual meeting was made, whichever first occurs. In no event shall the adjournment or postponement of an annual meeting (or the public announcement thereof) commence a new time period (or extend any time period) for the giving of an Eligible Stockholder’s notice as described above.
3.In addition to including the name of the Stockholder Nominee in the Corporation’s proxy statement for the annual meeting, the Corporation also shall include (a) the information concerning the Stockholder Nominee and the Eligible Stockholder that is required to be disclosed in the Corporation’s proxy statement pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder and (b) if the Eligible Stockholder so elects, a Statement (defined below) (collectively, the “Required Information”). Nothing in this Section 10 shall limit the Corporation’s ability to solicit against and include in its proxy statement its own statements relating to any Stockholder Nominee.
11




4.The number of Stockholder Nominees (including Stockholder Nominees that were submitted by an Eligible Stockholder for inclusion in the Corporation’s proxy statement pursuant to this Section 10 but either are subsequently withdrawn or that the Board of Directors decides to nominate (the latter a “Board Nominee”)) appearing in the Corporation’s proxy statement with respect to an annual meeting of stockholders shall not exceed the greater of (a) two or (b) 20% of the number of directors in office as of the last day on which notice of a nomination may be received pursuant to this Section 10 (the “Final Proxy Access Nomination Date”) or, if such amount is not a whole number, the closest whole number below 20% (such greater number the “Permitted Number”); provided, however, that the Permitted Number shall be reduced by (i) the number of director candidates for which the Corporation shall have received one or more valid notices that a stockholder intends to nominate director candidates at the annual meeting of stockholders pursuant to Section 9 of this Article I; provided further, that in no event shall the Permitted Number be less than one, (ii) any number of director candidates who will be included in the Corporation’s proxy materials with respect to the annual meeting as an unopposed (by the Corporation) nominee pursuant to any agreement, arrangement or other understanding with any stockholder or group of stockholders (other than any such agreement, arrangement or understanding entered into in connection with an acquisition of shares of capital stock of the Corporation, by such stockholder or group of stockholders, from the Corporation); provided, that in no event shall the Permitted Number be less than one, and (iii) any number of directors in office as of the nomination deadline who were included in the Corporation’s proxy statement as a Stockholder Nominee for any of the two preceding annual meetings and whom the Board of Directors decides to nominate for election to the Board of Directors. In the event that one or more vacancies for any reason occurs on the Board of Directors at any time after the Final Proxy Access Nomination Date and before the date of the applicable annual meeting of stockholders and the Board of Directors resolves to reduce the size of the Board of Directors in connection therewith, the Permitted Number shall be calculated based on the number of directors in office as so reduced.

5.In the event that the number of Stockholder Nominees submitted by Eligible Stockholders pursuant to this Section 10 exceeds the Permitted Number, each Eligible Stockholder shall select one Stockholder Nominee for inclusion in the Corporation’s proxy statement until the Permitted Number is reached, going in order of the amount (greatest to least) of the Corporation’s capital stock entitled to vote on the election of directors as disclosed in the Notice. If the Permitted Number is not reached after each Eligible Stockholder has selected one Stockholder Nominee, this selection process shall continue as many times as necessary, following the same order each time, until the Permitted Number is reached.

6.An Eligible Stockholder must have owned (as defined below) continuously for at least three years a number of shares that represents 3% or more of the Corporation’s outstanding shares of capital stock entitled to vote in the election of directors (the “Required Shares”) as of both the date the Notice is received by the Corporation in accordance with this Section 10 and the record date for determining stockholders entitled to vote at the annual meeting and must continue to own the Required Shares through the annual meeting date. For purposes of satisfying the ownership requirement under this Section 10, the shares of the Corporation’s capital stock owned by one or more stockholders, or by the person or persons who own shares of the Corporation’s capital stock and on whose behalf any stockholder is acting, may be aggregated, provided that (a) the number of stockholders and other persons whose ownership of shares is aggregated for such purpose shall not exceed 20, (b) each
12



stockholder or other person whose shares are aggregated shall have held such shares continuously for at least three years, and (c) a group of two or more funds that are (i) under common management and investment control, (ii) under common management and funded primarily by the same employer (or by a group of related employers that are under common control), or (iii) a “group of investment companies,” as such term is defined in Section 12(d)(1)(G)(ii) of the Investment Company Act of 1940, as amended, shall be treated as one stockholder or person for this purpose. Whenever an Eligible Stockholder consists of a group of stockholders and/or other persons, any and all requirements and obligations for an Eligible Stockholder set forth in this Section 10 must be satisfied by and as to each such stockholder or other person, except that shares may be aggregated to meet the Required Shares as provided in this Section 10. With respect to any one particular annual meeting, no stockholder or other person may be a member of more than one group of persons constituting an Eligible Stockholder under this Section 10.

7.For purposes of this Section 10, an Eligible Stockholder shall be deemed to “own” only those outstanding shares of the Corporation’s capital stock as to which the person possesses both (a) the full voting and investment rights pertaining to the shares and (b) the full economic interest in (including the opportunity for profit and risk of loss on) such shares; provided that the number of shares calculated in accordance with clauses (a) and (b) shall not include any shares (x) sold by such person or any of its affiliates in any transaction that has not been settled or closed, (y) borrowed by such person or any of its affiliates for any purposes or purchased by such person or any of its affiliates pursuant to an agreement to resell, or (z) subject to any option, warrant, forward contract, swap, contract of sale, other derivative or similar agreement entered into by such person or any of its affiliates, whether any such instrument or agreement is to be settled with shares or with cash based on the notional amount or value of outstanding shares of the Corporation’s capital stock, in any such case which instrument or agreement has, or is intended to have, the purpose or effect of (A) reducing in any manner, to any extent or at any time in the future, such person’s or affiliates’ full right to vote or direct the voting of any such shares, and/or (B) hedging, offsetting or altering to any degree gain or loss arising from the full economic ownership of such shares by such person or affiliate. A person shall “own” shares held in the name of a nominee or other intermediary so long as the person retains the right to instruct how the shares are voted with respect to the election of directors and possesses the full economic interest in the shares.
8.A person’s ownership of shares shall be deemed to continue during any period in which (a) the person has loaned such shares, provided that the person has the power to recall such loaned shares on five business days’ notice and provides a representation that it will promptly recall, and promptly recalls, such loaned shares upon being notified that any of its Stockholder Nominees will be included in the Corporation’s proxy statement, or (b) the person has delegated any voting power by means of a proxy, power of attorney or other instrument or arrangement that is revocable at any time by the person. The terms “owned,” “owning” and other variations of the word “own” shall have correlative meanings. For purposes of this Section 10, the term “affiliate” shall have the meaning ascribed thereto in the regulations promulgated under the Exchange Act.
9.An Eligible Stockholder must provide with its Notice the following in writing to the Secretary: (a) one or more written statements from the record holder of the shares (and from each intermediary through which the shares are or have been held during the requisite three-year holding period) verifying that, as of a date within seven calendar days prior to the date the Notice is received
13



by the Corporation, the Eligible Stockholder owns, and has owned continuously for the preceding three years, the Required Shares, and the Eligible Stockholder’s agreement to provide (i) within five business days after the record date for the annual meeting, written statements from the record holder and intermediaries verifying the Eligible Stockholder’s continuous ownership of the Required Shares through the record date and (ii) immediate notice if the Eligible Stockholder ceases to own any of the Required Shares prior to the date of the applicable annual meeting of stockholders; (b) documentation satisfactory to the Corporation demonstrating that a group of funds qualifies to be treated as one stockholder or person for purposes of this Section 10, if applicable; (c) a representation that the Eligible Stockholder (including each member of any group of stockholders and/or persons that together is an Eligible Stockholder hereunder) (i) intends to continue to own the Required Shares through the date of the annual meeting, (ii) acquired the Required Shares in the ordinary course of business and not with the intent to change or influence control of the Corporation, and does not presently have such intent, (iii) has not nominated and will not nominate for election to the Board of Directors at the annual meeting any person other than the Stockholder Nominee(s) being nominated pursuant to this Section 10, (iv) has not engaged and will not engage in, and has not and will not be, a “participant” in another person’s “solicitation” within the meaning of Rule 14a-1(l) under the Exchange Act in support of the election of any individual as a director at the annual meeting other than its Stockholder Nominee(s) or a Board Nominee, (v) will not distribute to any stockholder any form of proxy for the annual meeting other than the form distributed by the Corporation, and (vi) has provided and will provide facts, statements and other information in all communications with the Corporation and its stockholders that are or will be true and correct in all material respects and do not and will not omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading; (d) the written consent of each Stockholder Nominee to be named in the Corporation’s proxy statement as a nominee and to serve as a director if elected; (e) a copy of the Schedule 14N that has been filed with the Securities and Exchange Commission as required by Rule 14a-18 under the Exchange Act; (f) the information required to be provided by Section 9 of this Article I, as applicable; (g) in the case of a nomination by a group of stockholders that together is an Eligible Stockholder, the designation by all group members of one group member that is authorized to act on behalf of all members of the nominating stockholder group with respect to the nomination and matters related thereto, including withdrawal of the nomination; and (h) an undertaking that the Eligible Stockholder agrees to (i) assume all liability stemming from any legal or regulatory violation arising out of the Eligible Stockholder’s communications with the Corporation’s stockholders or out of the information that the Eligible Stockholder provides to the Corporation, (ii) indemnify and hold harmless the Corporation and each of its directors, officers and employees individually against any liability, loss or damages in connection with any threatened or pending action, suit or proceeding, whether legal, administrative or investigative, against the Corporation or any of its directors, officers or employees in connection with the Eligible Stockholder’s nomination and/or efforts to elect its Stockholder Nominee(s) pursuant to this Section 10, (iii) file with the Securities and Exchange Commission any solicitation or other communication with the Corporation’s stockholders relating to the annual meeting at which the Stockholder Nominee will be nominated, regardless of whether any such filing is required under Section 14 of the Exchange Act and the rules and regulations promulgated thereunder or whether any exemption from filing is available for such solicitation or other communication under Section 14 of the Exchange Act and the rules and regulations promulgated thereunder, and (iv) comply with all other applicable laws, rules, regulations and listing standards with respect to any solicitation in connection with the annual meeting.
14



10.The Eligible Stockholder may include with its Notice, a written statement for inclusion in the Corporation’s proxy statement for the annual meeting, not to exceed 500 words per Stockholder Nominee, in support of each Stockholder Nominee’s candidacy (the “Statement”). Notwithstanding anything to the contrary contained in this Section 10, the Corporation may omit from its proxy statement any information or Statement that it believes would violate any applicable law, rule, regulation or listing standard.
11.Each Stockholder Nominee must (a) provide within five business days of the Corporation’s request an executed agreement, in a form deemed satisfactory to the Corporation, that (i) the Stockholder Nominee has read and agrees to adhere to the Corporation’s Corporate Governance Guidelines and all other Corporation policies and guidelines applicable to directors, including with regard to securities trading, (ii) the Stockholder Nominee is not and will not become a party to (A) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation or (B) any Voting Commitment that could limit or interfere with such person’s ability to comply, if elected as a director of the Corporation, with such person’s fiduciary duties under applicable law, and (iii) the Stockholder Nominee is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification (a “Compensation Arrangement”) in connection with such person’s nomination or candidacy for director and/or service as a director that has not been disclosed to the Corporation; (b) complete, sign and submit all questionnaires required of the Corporation’s Board of Directors within five business days of receipt of each such questionnaire from the Corporation; and (c) provide within five business days of the Corporation’s request such additional information as the Corporation determines may be necessary to permit the Board of Directors to determine whether such Stockholder Nominee meets the requirements of this Section 10 and/or the Corporation’s requirements with regard to director qualifications and policies and guidelines applicable to directors, including whether (i) such Stockholder Nominee is independent under the listing standards of any U.S. exchange upon which the Corporation’s capital stock is listed, any applicable rules of the Securities and Exchange Commission, and any publicly disclosed standards used by the Board of Directors in determining and disclosing the independence of the directors (collectively, the “Independence Standards”), (ii) such Stockholder Nominee has any direct or indirect relationship with the Corporation, and (iii) such Stockholder Nominee has been subject to (A) any event specified in Item 401(f) of Regulation S-K under the Securities Act of 1933, as amended (the “Securities Act”) or (B) any order of the type specified in Rule 506(d) of Regulation D under the Securities Act.
12.In the event that any information or communications provided by the Eligible Stockholder or Stockholder Nominee to the Corporation or its stockholders ceases to be true and correct in any respect or omits a fact necessary to make the statements made, in light of the circumstances under which they were made, not misleading, each Eligible Stockholder or Stockholder Nominee, as the case may be, shall promptly notify the Secretary of any such inaccuracy or omission in such previously provided information and of the information that is required to make such information or communication true and correct; it being understood that
15



providing any such notification shall not be deemed to cure any defect or limit the Corporation’s right to omit a Stockholder Nominee from its proxy materials as provided in this Section 10.
13.The Corporation shall not be required to include, pursuant to this Section 10, a Stockholder Nominee in its proxy statement (or, if the proxy statement has already been filed, to allow the nomination of a Stockholder Nominee, notwithstanding that proxies in respect of such vote may have been received by the Corporation) (a) if the Eligible Stockholder who has nominated such Stockholder Nominee has nominated for election to the Board of Directors at the annual meeting any person other than pursuant to this Section 10, or has or is engaged in, or has been or is a “participant” in another person’s, “solicitation” within the meaning of Rule 14a-1(l) under the Exchange Act in support of the election of any individual as a director at the annual meeting other than its Stockholder Nominee(s) or a Board Nominee, (b) who is not independent under the Independence Standards, (c) whose election as a member of the Board of Directors would violate or cause the Corporation to be in violation of these By-laws, the Corporation’s certificate of incorporation, the Corporation’s Corporate Governance Guidelines or other document setting forth qualifications for directors, the listing standards of any U.S. exchange upon which the Corporation’s capital stock is listed, or any applicable state or federal law, rule or regulation, (d) if the Stockholder Nominee is or becomes a party to any undisclosed or prohibited Voting Commitment, (e) if the Stockholder Nominee is or becomes a party to any undisclosed Compensation Arrangement, (f) who is or has been, within the past three years, an officer or director of a competitor, as defined in Section 8 of the Clayton Antitrust Act of 1914, (g) whose then-current or prior business or personal interests place such Stockholder Nominee in a conflict of interest with the Corporation or any of its subsidiaries that would cause such Stockholder Nominee to violate any fiduciary duties of directors established pursuant to Delaware law, including but not limited to the duty of loyalty and duty of care, (h) who is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses) or has been convicted in such a criminal proceeding within the past ten years, (i) who is subject to any order of the type specified in Rule 506(d) of Regulation D under the Securities Act, or (j) if such Stockholder Nominee or the applicable Eligible Stockholder shall have provided information to the Corporation in respect of such nomination that was untrue in any material respect or omitted to state a material fact necessary in order to make the statement made, in light of the circumstances under which they were made, not misleading or shall have breached any of its or their agreements, representations, undertakings and/or obligations pursuant to this Section 10.
14.Notwithstanding anything to the contrary set forth herein, if (a) the Stockholder Nominee and/or the applicable Eligible Stockholder shall have breached its or their agreements, representations, undertakings and/or obligations pursuant to this Section 10, as determined by the Board of Directors or the person presiding at the annual meeting, or (b) the Eligible Stockholder (or a qualified representative thereof) does not appear at the annual meeting to present any nomination pursuant to this Section 10, (x) the Board of Directors or the person presiding at the annual meeting shall be entitled to declare a nomination by an Eligible Stockholder to be invalid, and such nomination shall be disregarded notwithstanding that proxies in respect of such vote may have been received by the Corporation and (y) the Corporation shall not be required to include in its proxy statement any successor or replacement nominee proposed by the applicable Eligible Stockholder or any other Eligible Stockholder.
16



15.Any Stockholder Nominee who is included in the Corporation’s proxy statement for a particular annual meeting of stockholders but either (a) withdraws from or becomes ineligible or unavailable for election at the annual meeting or (b) does not receive a number of votes cast in favor of his or her election at least equal to 25% of the shares present in person or represented by proxy at the annual meeting and entitled to vote on the Stockholder Nominee’s election, shall be ineligible to be included in the Corporation’s proxy statement as a Stockholder Nominee pursuant to this Section 10 for the next two annual meetings of stockholders following the annual meeting for which the Stockholder Nominee has been nominated for election. This Section 10 shall be the exclusive method for stockholders to include nominees for director election in the Corporation’s proxy materials, except to the extent required by Rule 14a-19 under the Exchange Act.
Section 11. Action Without Meeting. Unless otherwise provided in the Certificate of Incorporation, any action required or permitted to be taken by stockholders for or in connection with any corporate action may be taken without a meeting, without prior notice and without a vote, if a consent or consents, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation in accordance with Section 228 of the Delaware General Corporation Law. No consent shall be effective to take the corporate action referred to therein unless consents signed by a number of stockholders sufficient to take such action are delivered to the Corporation in the manner specified in this paragraph within sixty (60) days of the first date on which a consent is so delivered to the Corporation.
If action is taken by consent of stockholders and in accordance with the foregoing, there shall be filed with the records of the meetings of stockholders such consent or consents.
If action is taken by less than unanimous consent of stockholders, prompt notice of the taking of such action without a meeting shall be given to those who have not consented and a certificate signed and attested to by the Secretary of the Corporation that such notice was given shall be filed with the records of the meetings of stockholders.
In the event that the action consented to is such as would have required the filing of a certificate under any provision of the Delaware General Corporation Law, if such action had been voted upon by the stockholders at a meeting thereof, the certificate filed under such provision shall state, in lieu of any statement required by such provision concerning a vote of stockholders, that consent has been given under Section 228 of the Delaware General Corporation Law.
Section 12. Meetings by Remote Communication. If authorized by the Board of Directors, in its sole discretion, and subject to such guidelines and procedures as the Board of Directors may adopt, stockholders and proxy holders not physically present at a meeting of stockholders may by means of remote communication, to the fullest extent permitted by law: (a) participate in a meeting of stockholders, and (b) be deemed present in person and vote at a meeting of stockholders whether such meeting is to be held at a designated place or solely by means of remote communication.
17




Section 13. Delivery to the Corporation. Whenever Section 2, 9 or 10 of this Article I of these By-laws requires one or more persons (including a record or beneficial owner of stock of the Corporation) to deliver a document or information to the Corporation or any officer, employee or agent thereof (including any notice, request, questionnaire, revocation, representation or other document or agreement), such document or information shall be in writing exclusively (and not in an electronic transmission) and shall be delivered exclusively by hand (including, without limitation, overnight courier service) or by certified or registered mail, return receipt requested and the Corporation shall not be required to accept delivery of any document not in such written form or so delivered. For the avoidance of doubt, with respect to any notice from any stockholder of record or beneficial owner of the Corporation’s capital stock under the Certificate of Incorporation, these By-laws or the Delaware General Corporation Law, to the fullest extent permitted by law, the Corporation expressly opts out of Section 116 of the Delaware General Corporation Law.
ARTICLE II - DIRECTORS
Section 1. General Powers. The business and affairs of the Corporation shall be managed by or under the direction of a Board of Directors, who may exercise all of the powers of the Corporation except as otherwise provided by the Certificate of Incorporation or the Delaware General Corporation Law. In the event of a vacancy in the Board of Directors, the remaining directors, except as otherwise provided by the Certificate of Incorporation or the Delaware General Corporation Law, may exercise the powers of the full Board of Directors until the vacancy is filled. The Board of Directors may appoint a Chairman of the Board. The Chairman of the Board shall preside at all meetings of the Board of Directors and shall perform such duties and possess such powers as are assigned to the Chairman by the Board of Directors.
Section 2. Number and Qualification. Except as otherwise required by the Certificate of Incorporation, the number of directors that shall constitute the whole Board of Directors shall be determined by resolution of the Board of Directors, but in no event shall be less than three (3). The number of directors may be increased at any time by resolution of the Board of Directors. The number of directors may be decreased at any time and from time to time by a majority of the directors then in office (so long as a quorum is present), but only to eliminate vacancies existing by reason of the death, resignation, removal or expiration of the term of one or more directors. The Board of Directors shall be comprised of a majority of directors who are determined by the Board of Directors to be independent directors as such term is defined by Section 303A(2) of the New York Stock Exchange Listed Company Manual.
Section 3. Terms of Office. Each director shall be elected for a term expiring at the next annual meeting of stockholders following such director’s election and shall remain in office until a successor is elected and qualified, or until such director’s earlier death, resignation or removal; provided, however, that the foregoing shall not shorten the term of any incumbent director as of such date.
Section 4. Removal. Except as otherwise provided by the Certificate of Incorporation or the Delaware General Corporation Law, any one or more or all of the directors of the Corporation may be
18



removed, with or without cause, by the holders of a majority of the voting power of the shares entitled to vote thereon.
Section 5. Vacancies. Except as otherwise required by the Certificate of Incorporation or the Delaware General Corporation Law, any vacancy in the Board of Directors, however occurring, or any newly-created directorship resulting from an enlargement of the size of the Board of Directors, shall be filled only by vote of a majority of the directors then in office, even if less than a quorum, or by the sole remaining director and not by the stockholders. A director elected to fill a vacancy or a newly-created directorship shall serve for a term expiring at the next annual meeting of stockholders following such director’s election, and shall remain in office until the election and qualification of the director’s successor or the director’s earlier death, resignation or removal.
Section 6. Resignations. Any director may resign by delivering a resignation to the Corporation at its principal office or to the Chief Executive Officer or Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event.
Section 7. Meetings. Regular meetings of the Board of Directors may be held without notice at such time and place, either within or without the State of Delaware, as shall be determined from time to time by the Board of Directors. A regular meeting of the Board of Directors may be held without notice immediately after and at the same place as the annual meeting of stockholders. Special meetings of the Board of Directors may be called by the Chairman of the Board, the Chief Executive Officer, a majority of the total number of the whole Board of Directors, or by one director in the event that there is only a single director in office and may be held at any time and place, within or without the State of Delaware, as specified by the person(s) calling the meeting.
Section 8. Notice of Meetings. No notice of the annual or other regular meetings of the Board of Directors need be given. Notice of any special meeting of directors shall be given to each director by the Secretary. Notice to each director shall be duly given by mailing the same not later than the second business day before the meeting, or by giving notice in person, by fax, by telephone, or by any other electronic means not later than four hours before the meeting. No notice of a meeting need be given if all directors are present in person. Any business may be transacted at any meeting of the Board of Directors, whether or not specified in a notice of the meeting.
Section 9. Quorum. A majority of the total number of the whole Board of Directors shall constitute a quorum at all meetings of the Board of Directors. In the absence of a quorum at any such meeting, a majority of the directors present may adjourn the meeting from time to time to a different date, place, or time without further notice (or waiver of notice) other than announcement at the meeting, until a quorum shall be present.
Section 10. Action at Meeting. At any meeting of the Board of Directors at which a quorum is present, the vote of a majority of the directors present shall be sufficient to take any action, unless a different vote is specified by the Delaware General Corporation Law, the Certificate of Incorporation or these By-laws.


19



Section 11. Action by Consent. Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee of the Board of Directors may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent to the action in writing or by electronic transmission. After an action is taken, the consent or consents relating thereto shall be filed with the minutes of proceedings of the Board of Directors or committee in the same paper or electronic form as the minutes are maintained.
Section 12. Meetings by Telephone Conference Call. Directors or any members of any committee designated by the directors may participate in a meeting of the Board of Directors or such committee by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation by such means shall constitute presence in person at such meeting.
Section 13. Compensation of Directors. Directors may be paid such compensation for their services and such reimbursement for expenses of attendance at meetings of the Board of Directors or committees of the Board of Directors as the Board of Directors or any committee to which the Board has delegated responsibility for establishing director compensation may from time to time determine. No such payment shall preclude any director from serving the Corporation or any of its parent, subsidiary, or affiliate corporations in any other capacity and receiving compensation for such service.
Section 14. Committees. The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the Corporation. In addition to other committees that the Board of Directors may designate from time to time, the Board of Directors shall designate a Compensation Committee, an Audit Committee and a Nominating and Corporate Governance Committee each of which shall be comprised only of directors of the Corporation who are determined by the Board of Directors (i) to be “independent directors” as such term is defined by Section 303A(2) of the New York Stock Exchange Listed Company Manual and (ii) with respect to members of the Audit Committee only, to also be “independent” as such term is defined by Rule 10A-3(b)(1) of the Securities and Exchange Commission. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members of the committee present at any meeting and not disqualified from voting, whether or not the member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board of Directors and subject to the provisions of the Delaware General Corporation Law, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it. Each such committee shall keep minutes and make such reports as the Board of Directors may from time to time request. Except as the Board of Directors may otherwise determine, any committee may make rules for the conduct of its business, but unless otherwise provided by the directors or in such rules, its business shall be conducted as nearly as possible in the same manner as is provided in these By-laws for the Board of Directors. A majority of the members of a committee shall constitute a quorum unless the committee consist of one or two members, in which event, one member shall constitute a quorum. All matters shall be determined by a majority vote of the committee members present assuming a quorum is present.
20



Section 15. Emergency Bylaws. In the event of any emergency, disaster, catastrophe or other similar emergency condition of a type described in Section 110(a) of the Delaware General Corporation Law (an “Emergency”), notwithstanding any different or conflicting provisions in Delaware General Corporation Law, the Certificate of Incorporation or these By-laws, during such Emergency:
1.     Notice. A meeting of the Board of Directors or a committee thereof may be called by any director, the Chairman of the Board, the Chief Executive Officer, the President or the Secretary by such means as, in the judgment of the person calling the meeting, may be feasible at the time, and notice of any such meeting of the Board of Directors or any committee may be given, in the judgment of the person calling the meeting, only to such directors as it may be feasible to reach at the time and by such means as may be feasible at the time. Such notice shall be given at such time in advance of the meeting as, in the judgment of the person calling the meeting, circumstances permit.
2.     Quorum. The director or directors in attendance at a meeting called in accordance with Section 15 shall constitute a quorum.
3.     Liability. No officer, director or employee acting in accordance with this Section 15 shall be liable except for willful misconduct. No amendment, repeal or change to this Section 15 shall modify the prior sentence with regard to actions taken prior to the time of such amendment, repeal or change.
ARTICLE III - OFFICERS
Section 1. General Provisions; Qualification. The officers of the Corporation shall be a Chief Executive Officer, a President, a Chief Financial Officer, a General Counsel, a Treasurer and a Secretary, and may include one or more Vice Presidents, one or more Assistant Treasurers and one or more Assistant Secretaries and such other officers as the Board of Directors may deem appropriate. Any two or more offices may be held by the same person.
Section 2. Election. Officers of the Corporation shall be elected annually by the Board of Directors.
Section 3. Tenure. Except as otherwise provided by the Delaware General Corporation Law, by the Certificate of Incorporation or by these By-laws, each officer shall hold office until such officer’s successor is elected and qualified, unless a different term is specified in the vote choosing or appointing such officer, or until such officer’s earlier death, resignation or removal.
Section 4. Resignation and Removal. Any officer may resign by delivering a resignation to the Corporation at its principal office or to the Chief Executive Officer or the Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event. Any officer may be removed at any time, with or without cause by vote of the Board of Directors.
Section 5. Vacancies. The Board of Directors may at any time fill any vacancy occurring in any office for any reason. Each such successor shall hold office for the unexpired term of such successor’s predecessor and until such successor’s successor is elected and qualified, or until such successor’s earlier death, resignation or removal.
21



Section 6. The Chief Executive Officer. The Chief Executive Officer shall be the principal executive officer of the Corporation. Subject to the control of the Board of Directors, the Chief Executive Officer shall have general charge of the business and affairs of the Corporation. The Chief Executive Officer shall employ and discharge employees and agents of the Corporation, except such as shall hold their offices by appointment of the Board of Directors, but the Chief Executive Officer may delegate these powers to other officers as to employees under their immediate supervision. The Chief Executive Officer shall have such other powers and perform such other duties as may be prescribed by the Board of Directors.
Section 7. The President. The Board of Directors may appoint an officer of the Corporation to serve as the President of the Corporation. The President shall perform such of the duties of the Chief Executive Officer of the Corporation on behalf of the Corporation as may be assigned to the President from time to time by the Board of Directors or the Chief Executive Officer. In the absence or inability of the Chief Executive Officer to act, the President shall have and possess all of the powers and discharge all of the duties of the Chief Executive Officer, subject to the control of the Board of Directors.
Section 8. Vice Presidents. Each Vice President shall have such powers and perform such duties as the Board of Directors, the Chief Executive Officer, or the President may from time to time prescribe.
Section 9. Chief Financial Officer. The Board of Directors shall appoint an officer to serve as the Chief Financial Officer of the Corporation. The Chief Financial Officer shall be responsible for the Corporation’s public financial reporting obligations and shall have such further powers and duties as are incident to the position of Chief Financial Officer, subject to the direction of the Chief Executive Officer and the Board of Directors.
Section 10. General Counsel. The Board of Directors shall appoint an officer to serve as the General Counsel of the Corporation. The General Counsel shall be the chief legal officer of the Corporation and shall be responsible for all legal affairs of the Corporation, and shall have such further powers and duties as are incident to the position of General Counsel.
Section 11. The Treasurer. The Treasurer shall perform such duties and shall have such powers as may from time to time be assigned to the Treasurer by the Board of Directors, the Chief Executive Officer or the Chief Financial Officer. In addition, subject to the direction of the Board of Directors, the Treasurer shall perform such duties and have such powers as are incident to the office of treasurer, including, without limitation, the duty and power to keep and be responsible for all funds and securities of the Corporation, to deposit funds of the Corporation in depositories, to disburse such funds, to make proper accounts of such funds, and to render statements of all such transactions and of the financial condition of the Corporation.
Section 12. The Secretary. The Secretary shall keep the minutes of all meetings of the Board of Directors and of the stockholders and shall attend to the giving and serving of all notices of the Corporation.
22



The Secretary shall have custody of the seal of the Corporation and shall affix the seal to all certificates of shares of stock of the Corporation and to such other papers or documents as may be proper and, when the seal is so affixed, the Secretary shall attest the same by the Secretary’s signature wherever required. The Secretary shall have charge of the stock certificate book, transfer book, and stock ledger, and such other books and papers as the Board of Directors may direct. The Secretary shall, in general, perform all the duties of secretary, subject to the control of the Board of Directors.
Section 13. Assistant Treasurers. In the absence or inability of the Treasurer to act, any Assistant Treasurer may perform all the duties and exercise all of the powers of the Treasurer, subject to the control of the Board of Directors. An Assistant Treasurer shall also perform such other duties as the Board of Directors, the Chief Executive Officer, or the Treasurer may from time to time prescribe.
Section 14. Assistant Secretaries. In the absence or inability of the Secretary to act, any Assistant Secretary may perform all the duties and exercise all the powers of the Secretary, subject to the control of the Board of Directors. An Assistant Secretary shall also perform such other duties as the Board of Directors, the Chief Executive Officer, or the Secretary may from time to time prescribe.
Section 15. Other Officers. Other officers shall perform such duties and have such powers as may from time to time be assigned to them by the Board of Directors.
Section 16. Delegation of Duties. In case of the absence of any officer of the Corporation, or for any other reason that the Board of Directors may deem sufficient, the Board of Directors may confer, for the time being, the powers or duties, or any of them, of such officer upon any other officer, or upon any director.
Section 17. Salaries. Officers of the Corporation shall be entitled to such salaries, compensation, or reimbursement as shall be fixed or allowed from time to time by the Board of Directors.
ARTICLE IV - CAPITAL STOCK
Section 1. Shares of Stock. The shares of capital stock of the Corporation shall be uncertificated and shall not be represented by certificates, except to the extent as may be required by applicable law or as otherwise authorized by the Board of Directors. The preceding sentence shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation. Every holder of capital stock of the Corporation represented by certificates shall be entitled to have a certificate for shares of capital stock of the Corporation signed by, or in the name of the Corporation by two authorized officers of the Corporation (it being understood that each of the Chairman of the Board, the Vice-Chairman of the Board, the Chief Executive Officer, the President, any Vice President, the Secretary, any Assistant Secretary, the Treasurer and any Assistant Treasurer shall be an authorized person for these purposes), certifying the class and number of shares of record owned by such stockholder in the Corporation. Any or all of the signatures may be a facsimile.
Section 2. Transfer of Shares of Stock. Stock of the Corporation shall be transferable in the manner prescribed by applicable law and in these By-Laws. Transfers of stock shall be made on the books of the Corporation, and in the case of certificated shares of stock, only by the person named in the certificate or by such person’s attorney lawfully constituted in writing and upon the surrender of
23



the certificate therefor, properly endorsed for transfer and payment of all necessary transfer taxes; or, in the case of uncertificated shares of stock, upon receipt of proper transfer instructions from the registered holder of the shares or by such person’s attorney lawfully constituted in writing, and upon payment of all necessary transfer taxes and compliance with appropriate procedures for transferring shares in uncertificated form; provided, however, that such surrender and endorsement, compliance or payment of taxes shall not be required in any case in which the officers of the Corporation shall determine to waive such requirement. No transfer of stock shall be valid as against the Corporation for any purpose until it shall have been entered in the books of the Corporation by an entry showing from and to whom transferred.
Section 3. Lost, Stolen or Destroyed Certificates. In the event of the loss, theft or destruction of any certificate of stock, another may be issued in its place pursuant to such regulations as the Board of Directors or transfer agent may establish concerning proof of such loss, theft, or destruction and concerning the giving of a satisfactory bond or bonds of indemnity.
Section 4. Record Date.
(a)    In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders, or to receive payment of any dividend or other distribution or allotment of any rights or to exercise any rights in respect of any change, conversion, or exchange of stock or for the purpose of any other lawful action, the Board of Directors may, except as otherwise required by the Delaware General Corporation Law, fix a record date, which record date shall not precede the date on which the resolution fixing the record date is adopted and which record date shall not be more than sixty (60) nor less than ten (10) days before the date of any meeting of stockholders, nor more than sixty (60) days prior to the time for such other action as hereinbefore described; provided, however, that if no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held, and, for determining stockholders entitled to receive payment of any dividend or other distribution or allotment of rights or to exercise any rights of change, conversion, or exchange of stock or for any other purpose, the record date shall be at the close of business on the day on which the Board of Directors adopts a resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.
(b)    In order that the Corporation may determine the stockholders entitled to consent to corporate action without a meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which date shall not be more than ten (10) days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. Any stockholder of record seeking to have the stockholders authorize or take corporate action by consent shall, by written notice to the Secretary of the Corporation, request the Board of Directors to fix a record date.
24



The Board of Directors shall promptly, but in all events within ten (10) days after the date on which such a request is received by the Secretary, adopt a resolution fixing the record date. If no record date has been fixed by the Board of Directors within ten (10) days of the date on which such a request is received, the record date for determining stockholders entitled to consent to corporate action without a meeting, when no prior action by the Board of Directors is required by applicable law, shall be the first date on which a consent setting forth the action taken or proposed to be taken is delivered to the Corporation in accordance with Section 228 of the Delaware General Corporation Law. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by applicable law, the record date for determining stockholders entitled to consent to corporate action without a meeting shall be at the close of business on the date on which the Board of Directors adopts the resolution taking such prior action.
Section 5. Regulations. The issue, transfer, conversion and registration of shares of stock shall be governed by such other regulations as the Board of Directors may establish.
ARTICLE V - GENERAL PROVISIONS
Section 1. Fiscal Year. Except as from time to time otherwise designated by the Board of Directors, the fiscal year of the Corporation shall end on December 31.
Section 2. Corporate Seal. The corporate seal shall be in such form as may be approved by the Board of Directors. The corporate seal may be altered from time to time by the Board.
Section 3. Waiver of Notice. Whenever any notice whatsoever is required to be given by the Delaware General Corporation Law, by the Certificate of Incorporation or by these By-laws, a waiver of such notice given by the person entitled to such notice or such person’s duly authorized attorney, whether before or after the time of the event for which notice is to be given shall be deemed equivalent to the notice required to be given to such person. Neither the business nor the purpose of any meeting need be specified in such a waiver. The appearance of such person at such meeting in person or by proxy, shall constitute waiver of notice except attendance for the sole purpose of objecting at the beginning of the meeting to the timeliness or lack of notice.
Section 4. Voting of Securities. Unless otherwise provided by resolution adopted by the Board of Directors, the Chairman of the Board, the President, any Vice President or the Secretary may from time to time appoint an attorney or attorneys or agent or agents of the Corporation, in the name and on behalf of the Corporation, to cast the votes which the Corporation may be entitled to cast as the holder of stock or other securities in any other corporation or other entity, any of whose stock or other securities may be held by the Corporation, at meetings of the holders of the stock or other securities of such other corporation or other entity, or to consent in any manner permitted under applicable law, in the name of the Corporation as such holder, to any action by such other corporation or other entity, and may instruct the person or persons so appointed as to the manner of casting such votes or giving such consents, and may execute or cause to be executed in the name and on behalf of the Corporation and under its corporate seal or otherwise, all such proxies or other instruments as he or she may deem necessary or proper. Any of the rights set forth in this Section 4 which may be delegated to an attorney or agent may also be exercised directly by the Chairman of the Board, the President, any Vice President or the Secretary.
25




Section 5. Evidence of Authority. A certificate by the Secretary, or an Assistant Secretary as to any action taken by the stockholders, directors, a committee or any officer or representative of the Corporation shall as to all persons who rely on the certificate in good faith be conclusive evidence of such action.
Section 6. Certificate of Incorporation. All references in these By-laws to the Certificate of Incorporation shall be deemed to refer to the Third Amended and Restated Certificate of Incorporation of the Corporation, as amended, restated and in effect from time to time.
Section 7. Transactions with Interested Parties. No contract or transaction between the Corporation and one or more of the directors or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of the directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board of Directors or a committee of the Board of Directors that authorizes the contract or transaction or solely because the interested directors’ votes are counted for such purpose, if:
(1) The material facts as to the director’s or officer’s relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the Board of Directors or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum;
(2) The material facts as to the director’s or officer’s relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or
(3) The contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified, by the Board of Directors, a committee of the Board of Directors, or the stockholders.
Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee that authorizes the contract or transaction.
Section 8. Severability. Any determination that any provision of these By-laws is for any reason inapplicable, illegal, or ineffective shall not affect or invalidate any other provision of these By-laws.
Section 9. Limitation on Stock Option Repricing. No stock option granted to an officer or director of the Corporation shall, after issuance, be repriced to a lower exercise price (other than adjustments for stock splits, stock dividends, spinoffs, recapitalizations and like events), without the prior affirmative vote of the holders of a majority in voting power of the shares of capital stock of the Corporation present at a stockholders meeting in person or by proxy and entitled to vote thereon.
26




ARTICLE VI - AMENDMENTS
Section 1. By the Board of Directors. In furtherance and not in limitation of the powers conferred by the Delaware General Corporation Law and the Certificate of Incorporation, the Board of Directors is expressly authorized to alter, amend or repeal any provision of these By-laws or make new by-laws.
Section 2. By the Stockholders. The stockholders of the Corporation shall have the power to alter, amend or repeal any provision of these By-laws or make new by-laws by affirmative vote of the holders of a majority in voting power of the shares of capital stock of the Corporation issued and outstanding and entitled to vote, voting together as a single class.

27


 EX-10.1 3 q4202310-kex101.htm AMENDED AND RESTATED DEFERRED COMPENSATION PLAN FOR DIRECTORS Document
Exhibit 10.1
THERMO FISHER SCIENTIFIC INC.
DEFERRED COMPENSATION PLAN FOR DIRECTORS,
As amended and restated effective as of February 21, 2024
Section 1.Participation. Any director of Thermo Fisher Scientific Inc. (the “Company”) may elect to have such percentage as he or she may specify of the fees otherwise payable to him or her deferred and paid to him or her as provided in this Plan. A director who is also an employee of the Company or any subsidiary or parent of the Company shall not be eligible to participate in this Plan. Each election to defer fees to be paid in any calendar year shall be made by notice in writing delivered to the Secretary of the Company no later than December 31 of the preceding year, in such form as the Secretary shall designate, and each election shall be applicable only with respect to fees earned during the calendar year designated in the form. The term “participant” as used herein refers to any director who shall have made an election. No participant may defer the receipt of any fees to be earned after the date on which he or she shall cease to be a director of the Company (the “deferral termination date”).
Section 2.Establishment of Deferred Compensation Accounts. There shall be established for each participant an account to be designated as that participant’s deferred compensation account.
Section 3.Allocations to Deferred Compensation Accounts. There shall be allocated to each participant’s deferred compensation account, as of the end of each quarter, an amount equal to his or her fees for that quarter which that participant shall have elected to have deferred pursuant to Section 1.
Section 4.Stock Units and Stock Unit Accounts. All amounts allocated to a participant’s deferred compensation account pursuant to Section 3 shall be converted, at the end of each quarter, into stock units by dividing the accumulated balance in the deferred compensation account as of the end of that quarter by the last sale price per share of the Company’s common stock as reported in The Wall Street Journal, for the last trading day of that quarter. The number of stock units, so determined, rounded to the nearest one-hundredth of a share, shall be credited to a separate stock unit account to be established for the participant, and the aggregate value thereof as of the last business day of that quarter shall be charged to the participant’s deferred compensation account. No amounts credited to the participant’s deferred compensation account pursuant to Section 5 shall be converted into stock units. Any such amount shall be distributed in cash as provided in Section 8.
Section 5.Cash Dividend Credits. Additional credits shall be made to a participant’s deferred compensation account, until all distributions shall have been made from the participant’s stock unit account, in amounts equal to the cash dividends (or the fair market value of dividends paid in property other than dividends payable in common stock of the Company) which the participant would have received from time to time had he or she been the owner on the record dates for the payment of such dividends of the number of shares of the Company’s common stock equal to the number of units in his or her stock unit account on those dates.
    
1

Section 6.Stock Dividend Credits. Additional credits shall be made to a participant’s stock unit account, until all distributions shall have been made from the participant’s stock unit account, of a number of units equal to the number of shares of the Company’s common stock, rounded to the nearest one-hundredth share, which the participant would have received from time to time as stock dividends had he or she been the owner on the record dates for the payments of such stock dividends of the number of units of the Company’s common stock equal to the number of units credited to his or her stock unit account on those dates.
Section 7.Adjustments in the Event of Certain Transactions. In the event of a stock dividend, stock split or combination of shares, or other distribution with respect to holders of Common Stock other than normal cash dividends, the number of units then credited to a participant’s stock unit account shall be appropriately adjusted on the same basis. In the event of any recapitalization, merger or consolidation involving the Company, any transaction in which the Company becomes a subsidiary of another entity, any sale or other disposition of all or a substantial portion of the assets of the Company or any similar transaction, as determined by the Board, the Board in its discretion may terminate the Plan pursuant to Section 11.
Section 8.Distribution of Stock and Cash After Participant’s Deferral Termination Date. When a participant’s deferral termination date shall occur, the Company shall become obligated to make the distributions prescribed in the following paragraphs (a) and (b).
(a)The Company shall distribute to the participant the number of shares of the common stock of the Company which shall equal the total number of units accumulated in his or her stock unit account as of the close of the fiscal year in which the participant’s deferral termination date occurs. Such distribution of stock shall be made in a single distribution within 60 days after the close of the fiscal year in which the participant’s deferral termination date occurs. Distribution of stock made hereunder may be made from shares of common stock held in the treasury and/or from shares of authorized but previously unissued shares of common stock.
(b)The Company shall distribute to the participant sums in cash equal to the cash balance credited to his or her deferred compensation account as of the close of the fiscal year in which his or her deferral termination date occurs. The cash distribution shall be made on the same date as the distribution made pursuant to paragraph (a) above, and shall consist of the entire cash balance credited to the participant’s deferred compensation account at the time of the distribution.
(c)If a participant’s deferral termination date shall occur by reason of his or her death or if he or she shall die after his or her deferral termination date but prior to receipt of all distributions of stock and cash provided for in this Section 8, all stock and cash remaining distributable hereunder shall be distributed to such beneficiary as the participant shall have designated in writing and filed with the Secretary of the Company or, in the absence of designation, to the participant’s personal representative. Such distributions shall be made in the same manner and at the same intervals as they would have been made to the participant had he or she continued to live.
(d) A participant may change the time of payment of the distribution to be made
    
2

under Section 8(a) by submitting an election form to the Secretary of the Company. Such election shall not take effect until at least 12 months after the date on which the election is made, the new distribution shall take place at least 5 years after the distribution date that would otherwise been applicable, and the election must be made at least 12 months prior to such distribution date.
Section 9.Participant’s Rights Unsecured. The right of any participant to receive distributions under Section 8 shall be an unsecured claim against the general assets of the Company. The Company may but shall not be obligated to acquire shares of its outstanding common stock from time to time in anticipation of its obligation to make such distributions, but no participant shall have any rights in or against any shares of stock so acquired by the Company. All such stock shall constitute general assets of the Company and may be disposed of by the Company at such time and for such purposes as it may deem appropriate.
Section 10.Change in Control.
10.1Impact of Event
In the event of a “Change in Control” as defined in Section 10.2, the Plan shall terminate and full distribution shall be made from all participants’ deferred compensation accounts and stock unit accounts effective upon the Change of Control.
10.2Definition of “Change in Control”
"Change in Control" shall mean the occurrence of a "change in the ownership," a "change in the effective control" or a "change in the ownership of a substantial portion of the assets" of a corporation, as determined in accordance with this Section.
In order for an event described below to constitute a Change in Control with respect to a Participant, except as otherwise provided in part (b)(ii) of this Section, the applicable event must relate to the corporation for which the Participant is providing services, the corporation that is liable for payment of the Participant's Account Balance (or all corporations liable for payment if more than one), as identified by the Committee in accordance with Treas. Reg. § 1.409A-3(i)(5)(ii)(A)(2), or such other corporation identified by the Committee in accordance with Treas. Reg. § 1.409A-3(i)(5)(ii)(A)(3).
In determining whether an event shall be considered a "change in the ownership," a "change in the effective control" or a "change in the ownership of a substantial portion of the assets" of a corporation, the following provisions shall apply:
(a)A "change in the ownership" of the applicable corporation shall occur on the date on which any one person, or more than one person acting as a group, acquires ownership of stock of such corporation that, together with stock held by such person or group, constitutes more than 50% of the total fair market value or total voting power of the stock of such corporation, as determined in accordance with Treas. Reg. § 1.409A-3(i)(5)(v). If a person or group is considered either to own more than 50% of the total fair market value or total voting power of the stock of such corporation, or to have effective control of such corporation within the meaning
    
3

of part (b) of this Section, and such person or group acquires additional stock of such corporation, the acquisition of additional stock by such person or group shall not be considered to cause a "change in the ownership" of such corporation.
(b)A "change in the effective control" of the applicable corporation shall occur on either of the following dates:
(i)The date on which any one person, or more than one person acting as a group, acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons) ownership of stock of such corporation possessing 40% or more of the total voting power of the stock of such corporation, as determined in accordance with Treas. Reg. § 1.409A-3(i)(5)(vi). If a person or group is considered to possess 40% or more of the total voting power of the stock of a corporation, and such person or group acquires additional stock of such corporation, the acquisition of additional stock by such person or group shall not be considered to cause a "change in the effective control" of such corporation; or
(ii)The date on which a majority of the members of the applicable corporation's board of directors is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of such corporation's board of directors before the date of the appointment or election, as determined in accordance with Treas. Reg. § 1.409A-3(i)(5)(vi). In determining whether the event described in the preceding sentence has occurred, the applicable corporation to which the event must relate shall only include a corporation identified in accordance with Treas. Reg. § 1.409A-3(i)(5)(ii) for which no other corporation is a majority shareholder.
(c)A "change in the ownership of a substantial portion of the assets" of the applicable corporation shall occur on the date on which any one person, or more than one person acting as a group, acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons) assets from the corporation that have a total gross fair market value equal to or more than 40% of the total gross fair market value of all of the assets of the corporation immediately before such acquisition or acquisitions, as determined in accordance with Treas. Reg. § 1.409A-3(i)(5)(vii). A transfer of assets shall not be treated as a "change in the ownership of a substantial portion of the assets" when such transfer is made to an entity that is controlled by the shareholders of the transferor corporation, as determined in accordance with Treas. Reg. § 1.409A-3(i)(5)(vii)(B).
Section 11.Amendment and Termination of the Plan. The Board of Directors of the Company may amend or terminate the Plan at any time and from time to time, provided, however, that no amendment adversely affecting credits already made to any participant’s deferred compensation account or stock unit account may be made without the consent of that participant or, if that participant has died, that participant’s beneficiary. Upon termination of the Plan, the Company shall be obligated to distribute to the participant the following as the Board of Directors of the Company, in its sole discretion, may determine: (i) the number of shares of the common stock of the Company which shall equal the total number of units accumulated in the
    
4

participant’s stock unit account as of the effective date of termination of the Plan and/or (ii) a sum in cash equal to the balance credited to the participant’s deferred compensation account as of the effective date of termination of the Plan.
Section 12.Section 409A. This Plan is intended to comply with all applicable law, including Code Section 409A of the Internal Revenue Code and related Treasury guidance and regulations, and shall be operated and interpreted in accordance with this intention.
    
5
 EX-10.49 4 q4202310-kex1049.htm AMENDED AND RESTATED DEFERRED COMPENSATION PLAN Document
Exhibit 10.49











Thermo Fisher Scientific Inc.
Deferred Compensation Plan
Amended & Restated Effective January 1, 2024











IMPORTANT NOTE

This document has not been approved by the Department of Labor, Internal Revenue Service, or any other governmental entity. An adopting Employer must determine whether the Plan is subject to the federal securities laws and the securities laws of the various states. An adopting Employer may not rely on this document to ensure any particular tax consequences or to ensure that the Plan is “unfunded and maintained primarily for the purpose of providing deferred compensation to a select group of management or highly compensated employees” under Title I of the Employee Retirement Income Security Act of 1974, as amended, with respect to the Employer’s particular situation. FMR LLC, its affiliates and employees cannot provide you with legal advice in connection with the execution of this document. This document should be reviewed by the Employer’s attorney prior to execution.



Table of Contents
TOC-i

        


TOC-ii

        




TOC-iii

        


Preamble
The Plan is intended to be a “plan which is unfunded and is maintained by an employer primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees” within the meaning of Sections 201(2), 301(a)(3) and 401(a)(1) of the Employee Retirement Income Security Act of 1974, as amended, or an “excess benefit plan” within the meaning of Section 3(36) of the Employee Retirement Income Security Act of 1974, as amended, or a combination of both. The Plan is further intended to conform with the requirements of Internal Revenue Code Section 409A and the final regulations issued thereunder and shall be interpreted, implemented and administered in a manner consistent therewith.







Preamble 1



Article 1 - General
1.1.Plan
The Plan will be referred to by the name specified in the Adoption Agreement.

1.2.Effective Dates
(a)Original Effective Date. The Original Effective Date is the date as of which the Plan was initially adopted.

(b)Amendment Effective Date. The Amendment Effective Date is the date specified in the Adoption Agreement as of which the Plan is amended and restated. Except as otherwise provided in the Adoption Agreement, all amounts deferred under the Plan prior to the Amendment Effective Date shall be governed by the terms of the Plan as in effect on the day before the Amendment Effective Date.

(c)Special Effective Date. A Special Effective Date may apply to any given provision if so specified in Appendix A of the Adoption Agreement. A Special Effective Date will control over the Original Effective Date or Amendment Effective Date, whichever is applicable, with respect to such provision of the Plan.

1.3.Amounts Not Subject to Code Section 409A
Except as otherwise indicated by the Plan Sponsor in Section 1.01 of the Adoption Agreement, amounts deferred before January 1, 2005 that are earned and vested on December 31, 2004 will be separately accounted for and administered in accordance with the terms of the Plan as in effect on December 31, 2004.



Article 1-1


Article 2 - Definitions
Wherever used herein, the following terms have the meanings set forth below, unless a different meaning is clearly required by the context:

2.1.Account
“Account” means an account and any subaccounts established for the purpose of recording amounts credited on behalf of a Participant and any earnings, expenses, gains, losses or distributions included thereon. The Account shall be a bookkeeping entry only and shall be utilized solely as a device for the measurement and determination of the amounts to be paid to a Participant or to the Participant’s Beneficiary pursuant to the Plan.

2.2Administrator
“Administrator” means the person or persons designated by the Plan Sponsor in Section 1.05 of the Adoption Agreement to be responsible for the administration of the Plan. If no Administrator is designated in the Adoption Agreement, the Administrator is the Plan Sponsor.

2.3Adoption Agreement
“Adoption Agreement” means the agreement adopted by the Plan Sponsor that establishes the Plan.

2.4Beneficiary
“Beneficiary” means the persons, trusts, estates or other entities entitled under Section 8.2 to receive benefits under the Plan upon the death of a Participant. The Participant’s spouse, if living, otherwise the Participant’s estate, shall be the Beneficiary if: (i) the Participant has failed to properly designate a Beneficiary or (ii) all designated Beneficiaries have predeceased the Participant.

2.5Board or Board of Directors
“Board” or “Board of Directors” means the Board of Directors of the Plan Sponsor.

2.6.Bonus
“Bonus” means an amount of incentive remuneration payable by the Employer to a Participant.

2.7.Change in Control
“Change in Control” means the occurrence of an event involving the Plan Sponsor that is described in Section 9.7.

2.8.Code
“Code” means the Internal Revenue Code of 1986, as amended.

2.9.Committee
“Committee” means the Compensation Committee of the Board or such other committee as the Board may appoint from time to time.

2.10.Compensation
“Compensation” has the meaning specified in Section 3.01 of the Adoption Agreement.




































Article 2-1


2.11.Director
“Director” means a non-employee member of the Board.

2.12.Disability
“Disability” means that a Participant is disabled as defined in Section 6.01(i) of the Adoption Agreement.

2.13.Eligible Employee
“Eligible Employee” means an employee of the Employer who satisfies the requirements in Section 2.01 of the Adoption Agreement.

2.14.Employer
“Employer” means the Plan Sponsor and any other Related Employer that is listed in Section 1.04 of the Adoption Agreement and which is authorized by the Plan Sponsor to participate in and, in fact, does adopt the Plan.

2.15.ERISA
“ERISA” means the Employee Retirement Income Security Act of 1974, as amended.

2.16.Identification Date
“Identification Date” means the date as of which Key Employees are determined which is specified in Section 1.06 of the Adoption Agreement.

2.17.Key Employee
“Key Employee” means an employee who satisfies the conditions set forth in Section 9.6.

2.18.Match-Eligible Compensation
Match-Eligible Compensation for a given Plan Year means a Participant's Compensation that is in excess of the amount of Compensation treated as "compensation" for the applicable plan year under the Thermo Fisher Scientific Inc. 401(k) Retirement Plan. Match-Eligible Compensation includes a Participant's Compensation that is in excess of the IRS limit on covered compensation for qualified plans established in Code Section 401 (a)(17) in effect for that Plan Year and also includes any amount of a Participant's Compensation that was reduced below the Code Section 401(a)(17) limit for purposes of applying the Company match in the Company sponsored 401(k) plan due to deferrals in this Plan.

2.19.Participant
“Participant” means an Eligible Employee who commences participation in the Plan in accordance with Article 3.

2.20.Plan
“Plan” means the unfunded plan of deferred compensation set forth herein, including the Adoption Agreement and any trust agreement, as adopted by the Plan Sponsor, and as amended from time to time.

2.21.Plan Sponsor
“Plan Sponsor” means the entity identified in Section 1.03 of the Adoption Agreement or any successor by merger, consolidation or otherwise.

2.22.Plan Year
“Plan Year” means the period identified in Section 1.02 of the Adoption Agreement.




































Article 2-2



2.23.Related Employer
“Related Employer” means the Plan Sponsor and (a) any corporation that is a member of a controlled group of corporations as defined in Code Section 414(b) that includes the Plan Sponsor and (b) any trade or business that is under common control as defined in Code Section 414(c) that includes the Plan Sponsor.

2.24.Retirement
“Retirement” has the meaning specified in 6.01(f) of the Adoption Agreement.

2.25.Separation from Service
“Separation from Service” means the date that the Participant dies, retires or otherwise has a termination of employment with respect to all entities comprising the Related Employer. A Separation from Service does not occur if the Participant is on military leave, sick leave or other bona fide leave of absence if the period of leave does not exceed six months or such longer period during which the Participant’s right to re-employment is provided by statute or contract. If the period of leave exceeds six months and the Participant’s right to re-employment is not provided either by statute or contract, a Separation from Service will be deemed to have occurred on the first day following the six-month period. If the period of leave is due to any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than six months, where the impairment causes the Participant to be unable to perform the duties of his or her position of employment or any substantially similar position of employment, a 29 month period of absence may be substituted for the six month period.

Whether a termination of employment has occurred is based on whether the facts and circumstances indicate that the Related Employer and the Participant reasonably anticipated that no further services would be performed after a certain date or that the level of bona fide services the Participant would perform after such date (whether as an employee or as an independent contractor) would permanently decrease to no more than 20 percent of the average level of bona fide services performed (whether as an employee or an independent contractor) over the immediately preceding 36 month period (or the full period of services to the Related Employer if the employee has been providing services to the Related Employer for less than 36 months).

An independent contractor is considered to have experienced a Separation from Service with the Related Employer upon the expiration of the contract (or, in the case of more than one contract, all contracts) under which services are performed for the Related Employer if the expiration constitutes a good-faith and complete termination of the contractual relationship.

If a Participant provides services as both an employee and an independent contractor of the Related Employer, the Participant must separate from service both as an employee and as an independent contractor to be treated as having incurred a Separation from Service. If a Participant ceases providing services as an independent contractor and begins providing services as an employee, or ceases providing services as an employee and begins providing services as an independent contractor, the Participant will not be considered to have experienced a Separation from Service until the Participant has ceased providing services in both capacities.

If a Participant provides services both as an employee and as a member of the Board of Directors of a corporate Related Employer (or an analogous position with respect to a noncorporate Related Employer), the services provided as a Director are not taken into account in determining whether the Participant has incurred a Separation from Service as an employee for purposes of a nonqualified deferred compensation plan in which the Participant participates as an employee that is not aggregated under Code Section 409A with any plan in which the Participant participates as a Director.




































Article 2-3



For purposes of determining whether a Separation from Service has occurred, the Related Employer means the Related Employer as defined in Section 2.22 of the Plan, except that in applying Code Sections 1563(a)(1), (2) and (3) for purposes of determining whether another organization is a Related Employer of the Plan Sponsor under Code Section 414(b), and in applying Treas. Reg. § 1.414(c)-2 for purposes of determining whether another organization is a Related Employer of the Plan Sponsor under Code Section 414(c), "at least 50 percent" shall be used instead of "at least 80 percent" each place it appears in those Sections. The Plan Sponsor specifically reserves the right to determine whether a sale or other disposition of substantial assets to an unrelated party constitutes a Separation from Service with respect to a Participant providing services to the seller immediately prior to the transaction and providing services to the buyer after the transaction.

All determinations of whether a Separation from Service has occurred will be made in a manner consistent with Code Section 409A and the final regulations thereunder.

2.26.Unforeseeable Emergency
“Unforeseeable Emergency” means a severe financial hardship of the Participant resulting from an illness or accident of the Participant, the Participant’s spouse, the Participant’s Beneficiary or the Participant’s dependent (as defined in Code Section 152, without regard to Code Section 152(b)(1), (b)(2) and (d)(1)(B)); loss of the Participant’s property due to casualty; or other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Participant. The types of events which may qualify as an Unforeseeable Emergency may be limited by the Plan Sponsor.

2.27.Valuation Date
“Valuation Date” means each business day of the Plan Year that the New York Stock Exchange is open.

2.28.Years of Service
“Years of Service” means each one-year period for which the Participant receives service credit in accordance with the provisions of Section 7.01(d) of the Adoption Agreement.






































Article 2-4


Article 3 - Participation
3.1.Participation
The Participants in the Plan shall be those Eligible Employees of the Employer who satisfy the requirements of Section 2.01 of the Adoption Agreement.

3.2Termination of Participation
The Administrator may terminate a Participant’s participation in the Plan in a manner consistent with Code Section 409A. If the Employer terminates a Participant’s participation before the Participant experiences a Separation from Service, the Participant’s vested Accounts shall be paid in accordance with the provisions of Article 9.




Article 3-1


Article 4 - Participant Elections
4.1.Deferral Agreement
If permitted by the Plan Sponsor in accordance with Section 4.01 of the Adoption Agreement, each Eligible Employee may elect to defer his or her Compensation within the meaning of Section 3.01 of the Adoption Agreement by executing, in writing or electronically, a deferral agreement in accordance with rules and procedures established by the Administrator and the provisions of this Article 4.

A new deferral agreement must be timely executed for each Plan Year during which the Eligible Employee desires to defer Compensation. An Eligible Employee who does not timely execute a deferral agreement shall be deemed to have elected zero deferrals of Compensation for such Plan Year.

A deferral agreement may be changed or revoked during the period specified by the Administrator. Except as provided in Section 9.3, a deferral agreement becomes irrevocable at the close of the specified period.

The Plan Sponsor may modify any deferral agreement prior to the date the election becomes irrevocable under the rules of Section 4.3.

4.2.Amount of Deferral
An Eligible Employee may elect to defer Compensation in any amount permitted by Section 4.01(a) of the Adoption Agreement.

4.3.Timing of Election to Defer
Each Eligible Employee who desires to defer Compensation otherwise payable during a Plan Year must execute a deferral agreement within the period preceding the Plan Year during which the Compensation is earned that is specified by the Administrator. Each Eligible Employee who desires to defer Compensation that is a Bonus must execute a deferral agreement within the period preceding the Plan Year during which the Bonus is earned that is specified by the Administrator, except that if the Bonus can be treated as performance based compensation as described in Code Section 409A(a)(4)(B)(iii), the deferral agreement may be executed within the period specified by the Administrator, which period, in no event, shall end after the date which is six months prior to the end of the period during which the Bonus is earned, provided the Participant has performed services continuously from the later of the beginning of the performance period or the date the performance criteria are established through the date the Participant executed the deferral agreement and provided further that the compensation has not yet become ‘readily ascertainable’ within the meaning of Treas. Reg. § 1.409A-2(a)(8). Compensation that meets the definition of a "short-term deferral" described in Treas. Reg. § 1.409A-1(b)(4) may be deferred in accordance with the rules of Section 9.2, applied as if the date the substantial risk of forfeiture lapses is the date payments were originally scheduled to commence, provided, however, that the provisions requiring the delay of the payment date for a minimum period of 60 months from the originally scheduled date of payment shall not apply to payments attributable to a change in control (as defined in Treas. Reg. § 1.409A- 3(i)(5)). In addition, if the Compensation qualifies as ‘fiscal year compensation’ within the meaning of Treas. Reg. § 1.409A-2(a)(6), the deferral agreement may be made not later than the end of the Employer’s taxable year immediately preceding the first taxable year of the Employer in which any services are performed for which such Compensation is payable.


Article 4-1


Except as otherwise provided below, an employee who is classified or designated as an Eligible Employee during a Plan Year may elect to defer Compensation otherwise payable during the remainder of such Plan Year in accordance with the rules of this Section 4.3 by executing a deferral agreement within the thirty (30)-day period beginning on the date the employee is classified or designated as an Eligible Employee, if permitted by Section 4.01(b)(ii) of the Adoption Agreement. If Compensation is based on a specified performance period that begins before the Eligible Employee or Director executes his or her deferral agreement, the election will be deemed to apply to the portion of such Compensation equal to the total amount of Compensation for the performance period multiplied by the ratio of the number of days remaining in the performance period after the election becomes irrevocable and effective over the total number of days in the performance period. The rules of this paragraph shall not apply unless the Eligible Employee can be treated as initially eligible in accordance with Treas. Reg. § 1.409A-2(a)(7).

4.4.Election of Payment Schedule and Form of Payment
All elections of a payment schedule and a form of payment will be made in accordance with rules and procedures established by the Administrator and the provisions of this Section 4.4.

(a)If the Plan Sponsor has elected to permit annual distribution elections in accordance with Section 6.01(h) of the Adoption Agreement the following rules apply. At the time an Eligible Employee completes a deferral agreement, the Eligible Employee must elect a distribution event (which includes a specified time) and a form of payment for the Compensation subject to the deferral agreement from among the options the Plan Sponsor has made available for this purpose and which are specified in 6.01(b) of the Adoption Agreement. Prior to the time required by Treas. Reg. § 1.409A-2, the Eligible Employee shall elect a distribution event (which includes a specified time) and a form of payment for any Employer contributions that may be credited to the Participant’s Account during the Plan Year. If an Eligible Employee fails to elect a distribution event, he or she shall be deemed to have elected Separation from Service as the distribution event. If he or she fails to elect a form of payment, he or she shall be deemed to have elected a lump sum form of payment.

(b)If the Plan Sponsor has elected not to permit annual distribution elections in accordance with Section 6.01(h) of the Adoption Agreement the following rules apply. At the time an Eligible Employee first completes a deferral agreement but in no event later than the time required by Treas. Reg. § 1.409A-2, the Eligible Employee must elect a distribution event (which includes a specified time) and a form of payment for amounts credited to his or her Account from among the options the Plan Sponsor has made available for this purpose and which are specified in Section 6.01(b) of the Adoption Agreement. If an Eligible Employee fails to elect a distribution event, he or she shall be deemed to have elected Separation from Service in the distribution event. If the Participant fails to elect a form of payment, he or she shall be deemed to have elected a lump sum form of payment.


Article 4-2


Article 5 - Employer Contributions
5.1.Matching Contributions
If elected by the Plan Sponsor in Section 5.01(a) of the Adoption Agreement, the Employer will credit the Participant’s Account with a matching contribution determined in accordance with the formula specified in Section 5.01(a) of the Adoption Agreement. The matching contribution will be treated as allocated to the Participant’s Account at the time specified in Section 5.01(a)(iii) of the Adoption Agreement.

5.1.Other Contributions
If elected by the Plan Sponsor in Section 5.01(b) of the Adoption Agreement, the Employer will credit the Participant’s Account with a contribution or contributions determined in accordance with the formula or method specified in Section 5.01(b) of the Adoption Agreement. These contributions will be treated as allocated to the Participant’s Account at the time specified in Section 5.01(b)(iii) of the Adoption Agreement.



Article 5-1


Article 6 - Accounts and Credits
6.1.Establishment of Account
For accounting and computational purposes only, the Administrator will establish and maintain an Account on behalf of each Participant which will reflect the credits made pursuant to Section 6.2, distributions or withdrawals, along with the earnings, expenses, gains and losses allocated thereto, attributable to the hypothetical investments made with the amounts in the Account as provided in Article 7. The Administrator may establish and maintain such other records and accounts, as it decides in its discretion to be reasonably required or appropriate to discharge its duties under the Plan.

6.2.Credits to Account
A Participant’s Account will be credited for each Plan Year with the amount of his or her elective deferrals under Section 4.1 at the time the amount subject to the deferral election would otherwise have been payable to the Participant and the amount of Employer contributions, if any, treated as allocated on his or her behalf under Article 5.

Article 6-1


Article 7 - Investment of Contributions
7.2.Investment Options
The amount credited to each Account shall be treated as invested in the investment options designated for this purpose by the Administrator.

7.2.Adjustment of Accounts
The amount credited to each Account shall be adjusted for hypothetical investment earnings, expenses, gains or losses in an amount equal to the earnings, expenses, gains or losses attributable to the investment options selected by the party designated in Section 9.01 of the Adoption Agreement from among the investment options provided in Section 7.1. If permitted by Section 9.01 of the Adoption Agreement, a Participant (or the Participant’s Beneficiary after the death of the Participant) may, in accordance with rules and procedures established by the Administrator, select the investments from among the options provided in Section 7.1 to be used for the purpose of calculating future hypothetical investment adjustments to the Account or to future credits to the Account under Section 6.2 effective as of the Valuation Date coincident with or next following notice to the Administrator. Each Account shall be adjusted as of each Valuation Date to reflect: (a) the hypothetical earnings, expenses, gains and losses described above; (b) amounts credited pursuant to Section 6.2; and (c) distributions or withdrawals. In addition, each Account may be adjusted for its allocable share of the hypothetical costs and expenses associated with the maintenance of the hypothetical investments provided in Section 7.1.


Article 7-1


Article 8 - Right to Benefits
8.1.Vesting
A Participant, at all times, has a 100% nonforfeitable interest in the amounts credited to his or her Account attributable to his or her elective deferrals made in accordance with Section 4.1.

A Participant’s right to the amounts credited to his or her Account attributable to Employer contributions made in accordance with Article 5 shall be determined in accordance with the relevant schedule and provisions in Section 7.01 of the Adoption Agreement. Upon a Separation from Service and after application of the provisions of Section 7.01 of the Adoption Agreement, the Participant shall forfeit the nonvested portion of his or her Account.

8.2.Death
The Plan Sponsor may elect to accelerate vesting upon the death of the Participant in accordance with Section 7.01(c) of the Adoption Agreement and/or to accelerate distributions upon death in accordance with Section 6.01(b) or Section 6.01(d) of the Adoption Agreement. If the Plan Sponsor does not elect to accelerate distributions upon death in accordance with Section 6.01(b) or Section 6.01(d) of the Adoption Agreement, the vested amount credited to the Participant’s Account will be paid in accordance with the provisions of Article 9.

A Participant may designate a Beneficiary or Beneficiaries, or change any prior designation of Beneficiary or Beneficiaries in accordance with rules and procedures established by the Administrator. Whenever a Participant designates a new Beneficiary, all former Beneficiary designations by such Participant shall be revoked automatically. If a Participant and the Participant’s spouse divorce, any designations of the spouse as Beneficiary shall become null and void. The former spouse shall be treated as the Beneficiary under the Plan only if after the divorce is final, the Participant expressly re-designates the former spouse as the Participant’s Beneficiary.

A copy of the death notice or other sufficient documentation must be filed with and approved by the Administrator.

8.3.Disability
If the Plan Sponsor has elected to accelerate vesting upon the occurrence of a Disability in accordance with Section 7.01(c) of the Adoption Agreement and/or to permit distributions upon Disability in accordance with Section 6.01(b) or Section 6.01(d) of the Adoption Agreement, the determination of whether a Participant has incurred a Disability shall be based on the definition of Disability in Section 6.01(i) of the Adoption Agreement and in a manner consistent with the requirements of Code Section 409A.

Article 8-1


Article 9 - Distribution of Benefits
9.1.Amount of Benefits
The vested amount credited to a Participant’s Account as determined under Articles 6, 7 and 8 shall determine and constitute the basis for the value of benefits payable to the Participant under the Plan.

9.2.Method and Timing of Distributions
Except as otherwise provided in this Article 9, distributions under the Plan shall be made in accordance with the elections made or deemed made by the Participant under Article 4. Subject to the provisions of Section 9.6 requiring a six-month delay for certain distributions, payments following a distribution event described in Section 6.01(b) shall commence at the time specified in Section 6.01(a) and 6.01(b) of the Adoption Agreement. If permitted by Section 6.01(g) of the Adoption Agreement, a Participant may elect, at least twelve months before a scheduled distribution event, to delay the payment date for a minimum period of sixty months from the originally scheduled date of payment, provided the election does not take effect for at least twelve months from the date on which the election is made. The distribution election change must be made in accordance with procedures and rules established by the Administrator. The Participant may, at the same time the date of payment is deferred, change the form of payment but such change in the form of payment may not effect an acceleration of payment in violation of Code Section 409A or the provisions of Treas. Reg. § 1.409A-2(b). For purposes of this Section 9.2, a series of installment payments is always treated as a single payment and not as a series of separate payments.

Payments made on the payment date specified in the Plan, or on a later date within the same taxable year of the Participant or Beneficiary, or, if later, by the fifteenth (15th) day of the third (3rd) calendar month following the payment date specified in the Plan shall be treated as having been made on the payment date; provided, however, that the Participant or Beneficiary is not permitted, directly or indirectly, to designate the taxable year of the payment. In addition, payments made no earlier than thirty (30) days before the designated payment date will likewise be treated as having been made on the payment date so long as the Participant or Beneficiary is not permitted, directly or indirectly, to designate the taxable year of the payment. The foregoing shall be administered in compliance with the provisions of Treas. Reg. § l.409A- 3(d), which may authorize other instances in which payments made after the payment date shall be treated as having been made on the payment date.

9.3.Unforeseeable Emergency
A Participant may request a distribution of all or any portion of his or her vested Account due to an Unforeseeable Emergency if the Plan Sponsor has elected to permit Unforeseeable Emergency withdrawals under Section 8.01(a) of the Adoption Agreement. The request must be in writing and must be submitted to the Administrator along with evidence that the circumstances constitute an Unforeseeable Emergency. The Administrator has the discretion to require whatever evidence it deems necessary to determine whether a distribution is warranted, and may require the Participant to certify that the need cannot be met from other sources reasonably available to the Participant. Whether a Participant has incurred an Unforeseeable Emergency will be determined by the Administrator on the basis of the relevant facts and circumstances in its sole discretion, but, in no event, will an Unforeseeable Emergency be deemed to exist if the hardship can be relieved: (a) through reimbursement or compensation by insurance or otherwise, (b) by liquidation of the Participant’s assets to the extent such liquidation would not itself cause severe financial hardship or (c) by cessation of deferrals under the Plan. A distribution due to an Unforeseeable Emergency must be limited to the amount reasonably necessary to satisfy the emergency need, taking into account the additional compensation that is available to the Participant as the result of any cancellation of deferrals under the Plan, and may include any amounts necessary to pay any federal, state, foreign or local income taxes and penalties reasonably anticipated to result from the distribution. The distribution will be made in the
Article 9-1


form of a single lump sum cash payment. If permitted by Section 8.01(b) of the Adoption Agreement, a Participant’s deferral elections for the remainder of the Plan Year may be cancelled upon a withdrawal due to an Unforeseeable Emergency. If the payment of all or any portion of the Participant’s vested Account is being delayed in accordance with Section 9.6 at the time he or she experiences an Unforeseeable Emergency, the amount being delayed shall not be subject to the provisions of this Section 9.3 until the expiration of the six month period of delay required by Section 9.6.

9.4.Payment Election Overrides
If the Plan Sponsor has elected one or more payment election overrides in accordance with Section 6.01(d) of the Adoption Agreement, the following provisions apply. Upon the occurrence of the first event selected by the Plan Sponsor, the remaining vested amount credited to the Participant’s Account shall be paid in the form designated to the Participant or his or her Beneficiary regardless of whether the Participant had made different elections of time and/or form of payment or whether the Participant was receiving installment payments at the time of the event.

9.5.Cashouts of Amounts Not Exceeding Stated Limit
If the vested amount credited to the Participant’s Account does not exceed the limit established for this purpose by the Plan Sponsor in Section 6.01(e) of the Adoption Agreement at the time he or she incurs a Separation from Service for any reason, the Employer shall distribute such amount to the Participant at the time specified in Section 6.01(a) of the Adoption Agreement in a single lump sum cash payment following such Separation from Service regardless of whether the Participant had made different elections of time or form of payment as to the vested amount credited to his or her Account or whether the Participant was receiving installments at the time of such termination. A Participant’s Account, for purposes of this Section 9.5, shall include any amounts described in Section 1.3.

9.6.Required Delay in Payment (Including to Key Employees)
Except as otherwise provided in this Section 9.6, a distribution made on account of Separation from Service to any Participant (including to any Participant who is a Key Employee as of the date of his or her Separation from Service) shall not be made before the date which is six months after the Separation from Service.

The six-month delay does not apply to payments described in Section 9.9(a), (b) or (d) or to payments that occur after the death of the Participant. If the payment of all or any portion of the Participant’s vested Account is being delayed in accordance with this Section 9.6 at the time he or she incurs a Disability which would otherwise require a distribution under the terms of the Plan, no amount shall be paid until the expiration of the six month period of delay required by this Section 9.6.

Article 9-2


9.7.Change in Control
If the Plan Sponsor has elected to permit distributions upon a Change in Control, the following provisions shall apply. A distribution made upon a Change in Control will be made at the time specified in Section 6.01(a) of the Adoption Agreement in the form elected by the Participant in accordance with the procedures described in Article 4. Alternatively, if the Plan Sponsor has elected in accordance with Section 11.02 of the Adoption Agreement to require distributions upon a Change in Control, the Participant’s remaining vested Account shall be paid to the Participant or the Participant’s Beneficiary at the time specified in Section 6.01(a) of the Adoption Agreement as a single lump sum payment. A Change in Control, for purposes of the Plan, will occur upon a change in the ownership of the Plan Sponsor, a change in the effective control of the Plan Sponsor or a change in the ownership of a substantial portion of the assets of the Plan Sponsor, but only if elected by the Plan Sponsor in Section 11.03 of the Adoption Agreement. The Plan Sponsor, for this purpose, includes any corporation identified in this Section 9.7. However, an event constitutes a Change in Control with respect to a Participant only if the Participant performs services for the Plan Sponsor at the time of the Change in Control, or the Participant's relationship to the Plan Sponsor otherwise satisfies the requirements of Treas. Reg. § 1.409A-3(i)(5)(ii). All distributions made in accordance with this Section 9.7 are subject to the provisions of Section 9.6.

If a Participant continues to make deferrals in accordance with Article 4 after he or she has received a distribution due to a Change in Control, the residual amount payable to the Participant shall be paid at the time and in the form specified in the elections he or she makes in accordance with Article 4 or upon his or her death or Disability as provided in Article 8.

Whether a Change in Control has occurred will be determined by the Administrator in accordance with the rules and definitions set forth in this Section 9.7. The determination as to the occurrence of a Change in Control shall be based on objective facts and in accordance with the requirements of Code Section 409A. A distribution to the Participant will be treated as occurring upon a Change in Control if the Plan Sponsor terminates the Plan in accordance with Section 10.2 and distributes the Participant’s benefits within twelve (12) months of a Change in Control as provided in Section 10.3.

(a)Relevant Corporations. To constitute a Change in Control for purposes of the Plan, the event must relate to: (i) the corporation for whom the Participant is performing services at the time of the Change in Control, (ii) the corporation that is liable for the payment of the Participant’s benefits under the Plan (or all corporations liable if more than one corporation is liable) but only if either the deferred compensation is attributable to the performance of services by the Participant for such corporation (or corporations) or there is a bona fide business purpose for such corporation (or corporations) to be liable for such payment and, in either case, no significant purpose of making such corporation (or corporations) liable for such payment is the avoidance of federal income tax, or (iii) a corporation that is a majority shareholder of a corporation identified in (i) or (ii), or any corporation in a chain of corporations in which each corporation is a majority shareholder of another corporation in the chain, ending in a corporation identified in (i) or (ii). A majority shareholder is defined as a shareholder owning more than fifty percent (50%) of the total fair market value and voting power of such corporation.

(b)Stock Ownership. Code Section 318(a) applies for purposes of determining stock ownership. Stock underlying a vested option is considered owned by the individual who owns the vested option (and the stock underlying an unvested option is not considered owned by the individual who holds the unvested option). If, however, a vested option is exercisable for stock that is not substantially vested (as defined by Treas. Reg. § 1.83-3(b) and (j)) the stock underlying the option is not treated as owned by the individual who holds the option.

(c)Change in the Ownership of a Corporation. A change in the ownership of a corporation occurs on the date that any one person, or more than one person acting
Article 9-3


as a group, acquires ownership of stock of the corporation that, together with stock held by such person or group, constitutes more than fifty percent (50%) of the total fair market value or total voting power of the stock of such corporation. If any one person or more than one person acting as a group is considered to own more than fifty percent (50%) of the total fair market value or total voting power of the stock of a corporation, the acquisition of additional stock by the same person or persons is not considered to cause a change in the ownership of the corporation (or to cause a change in the effective control of the corporation as discussed below in Section 9.7(d)). An increase in the percentage of stock owned by any one person, or persons acting as a group, as a result of a transaction in which the corporation acquires its stock in exchange for property will be treated as an acquisition of stock. Section 9.7(c) applies only when there is a transfer of stock of a corporation (or issuance of stock of a corporation) and stock in such corporation remains outstanding after the transaction. For purposes of this Section 9.7(c), persons will not be considered to be acting as a group solely because they purchase or own stock of the same corporation at the same time or as a result of a public offering. Persons will, however, be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock or similar business transaction with the corporation. If a person, including an entity, owns stock in both corporations that enter into a merger, consolidation, purchase or acquisition of stock or similar transaction, such shareholder is considered to be acting as a group with other shareholders in a corporation only with respect to ownership in that corporation prior to the transaction giving rise to the change and not with respect to the ownership interest in the other corporation.

(d)Change in the Effective Control of a Corporation. A change in the effective control of a corporation occurs on the date that either (i) any one person, or more than one person acting as a group, acquires (or has acquired during the twelve month-period ending on the date of the most recent acquisition by such person or persons) ownership of stock of the corporation possessing forty percent (40%) or more of the total voting power of the stock of such corporation or (ii) a majority of members of the corporation’s Board of Directors is replaced during any twelve month period by Directors whose appointment or election is not endorsed by a majority of the members of the corporation’s Board of Directors prior to the date of the appointment or election, provided that for purposes of this paragraph (ii), the term corporation refers solely to the relevant corporation identified in Section 9.7(a) for which no other corporation is a majority shareholder for purposes of Section 9.7(a). In the absence of an event described in Section 9.7(d)(i) or (ii), a change in the effective control of a corporation will not have occurred. A change in effective control may also occur in any transaction in which either of the two corporations involved in the transaction has a change in the ownership of such corporation as described in Section 9.7(c) or a change in the ownership of a substantial portion of the assets of such corporation as described in Section 9.7(e). If any one person, or more than one person acting as a group, is considered to effectively control a corporation within the meaning of this Section 9.7(d), the acquisition of additional control of the corporation by the same person or persons is not considered to cause a change in the effective control of the corporation or to cause a change in the ownership of the corporation within the meaning of Section 9.7(c). For purposes of this Section 9.7(d), persons will or will not be considered to be acting as a group in accordance with rules similar to those set forth in Section 9.7(c) with the following exception. If a person, including an entity, owns stock in both corporations that enter into a merger, consolidation, purchase or acquisition of stock or similar transaction, such shareholder is considered to be acting as a group with other shareholders in a corporation only with respect to the ownership in that corporation prior to the transaction giving rise to the change and not with respect to the ownership interest in the other corporation.

Article 9-4


(e)Change in the Ownership of a Substantial Portion of a Corporation’s Assets. A change in the ownership of a substantial portion of a corporation’s assets occurs on the date that any one person, or more than one person acting as a group (as determined in accordance with rules similar to those set forth in Section 9.7(d)), acquires (or has acquired during the twelve month period ending on the date of the most recent acquisition by such person or persons) assets from the corporation that have a total gross fair market value equal to or more than forty percent (40%) of the total gross fair market value of all of the assets of the corporation immediately prior to such acquisition or acquisitions. For this purpose, gross fair market value means the value of the assets of the corporation or the value of the assets being disposed of determined without regard to any liabilities associated with such assets. There is no Change in Control event under this Section 9.7(e) when there is a transfer to an entity that is controlled by the shareholders of the transferring corporation immediately after the transfer. A transfer of assets by a corporation is not treated as a change in ownership of such assets if the assets are transferred to (i) a shareholder of the corporation (immediately before the asset transfer) in exchange for or with respect to its stock, (ii) an entity, fifty percent (50%) or more of the total value or voting power of which is owned, directly or indirectly, by the corporation, (iii) a person, or more than one person acting as a group, that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power of all the outstanding stock of the corporation, or (iv) an entity, at least fifty (50%) of the total value or voting power of which is owned, directly or indirectly, by a person described in Section 9.7(e)(iii). For purposes of the foregoing, and except as otherwise provided, a person’s status is determined immediately after the transfer of assets.

Article 9-5


9.8.Permissible Delays in Payment
Distributions may be delayed beyond the date payment would otherwise occur in accordance with the provisions of Articles 8 and 9, provided such delay would be permitted by the provisions of Treas. Reg. § 1.409A-2(b)(7), including the following events (as long as the Employer treats all payments to similarly situated Participants on a reasonably consistent basis):

(a)The Employer may delay payment if it reasonably anticipates that its deduction with respect to such payment would be limited or eliminated by the application of Code Section 162(m). Payment must be made during the Participant’s first taxable year in which the Employer reasonably anticipates, or should reasonably anticipate, that if the payment is made during such year the deduction of such payment will not be barred by the application of Code Section 162(m) or during the period beginning with the Participant’s Separation from Service and ending on the later of the last day of the Employer’s taxable year in which the Participant separates from service or the 15th day of the third month following the Participant’s Separation from Service. If a scheduled payment to a Participant is delayed in accordance with this Section 9.8(a), all scheduled payments to the Participant that could be delayed in accordance with this Section 9.8(a) will also be delayed.

(b)The Employer may also delay payment if it reasonably anticipates that the making of the payment will violate federal securities laws or other applicable laws provided payment is made at the earliest date on which the Employer reasonably anticipates that the making of the payment will not cause such violation.

(c)The Employer reserves the right to amend the Plan to provide for a delay in payment upon such other events and conditions as the Secretary of the Treasury may prescribe in generally applicable guidance published in the Internal Revenue Bulletin.

9.9.Permitted Acceleration of Payment
The Employer may permit acceleration of the time or schedule of any payment or amount scheduled to be paid pursuant to a payment under the Plan provided such acceleration would be permitted by the provisions of Treas. Reg. § 1.409A-3(j)(4), including the following events:

(a)Domestic Relations Order. A payment may be accelerated if such payment is made to an alternate payee pursuant to and following the receipt and qualification of a domestic relations order as defined in Code Section 414(p).

(b)Compliance with Ethics Agreement and Legal Requirements. A payment may be accelerated as may be necessary to comply with ethics agreements with the federal government or as may be reasonably necessary to avoid the violation of federal, state, local or foreign ethics law or conflicts of laws, in accordance with the requirements of Code Section 409A.

(c)De Minimis Amounts. A payment may be accelerated if (i) the amount of the payment is not greater than the applicable dollar amount under Code Section 402(g)(1)(B) and (ii) at the time the payment is made, the amount constitutes the Participant’s entire interest under the Plan and all other plans that are aggregated with the Plan under Treas. Reg. § 1.409A-1(c)(2).

(d)FICA Tax. A payment may be accelerated to the extent required to pay the Federal Insurance Contributions Act tax imposed under Code Sections 3101, 3121(a) and 3121(v)(2) of the Code with respect to compensation deferred under the Plan (the “FICA Amount”). Additionally, a payment may be accelerated to pay the income tax on wages imposed under Code Section 3401 of the Code on the FICA Amount and to pay the additional income tax at source on wages attributable to the pyramiding
Article 9-6


Code Section 3401 wages and taxes. The total payment under this subsection (d) may not exceed the aggregate of the FICA Amount and the income tax withholding related to the FICA Amount.

(e)Section 409A Additional Tax. A payment may be accelerated if the Plan fails to meet the requirements of Code Section 409A; provided that such payment may not exceed the amount required to be included in income as a result of the failure to comply with the requirements of Code Section 409A.

(f)Offset. A payment may be accelerated in the Employer’s discretion as satisfaction of a debt of the Participant to the Employer, where such debt is incurred in the ordinary course of the service relationship between the Participant and the Employer, the entire amount of the reduction in any of the Employer’s taxable years does not exceed $5,000 and the reduction is made at the same time and in the same amount as the debt otherwise would have been due and collected from the Participant.

(g)Other Events. A payment may be accelerated in the Administrator’s discretion in connection with such other events and conditions as permitted by Code Section 409A.

Article 9-7


Article 10 - Amendment and Termination
10.1.Amendment by Plan Sponsor
The Plan Sponsor reserves the right to amend the Plan (for itself and each Employer) through action of its Board of Directors or other authorized person or body. No amendment can directly or indirectly deprive any current or former Participant or Beneficiary of all or any portion of his or her Account which had accrued and vested prior to the amendment.

10.2.Plan Termination Following Change in Control or Corporate     Dissolution
If so elected by the Plan Sponsor in 11.01 of the Adoption Agreement, the Plan Sponsor reserves the right to terminate the Plan and distribute all amounts credited to all Participant Accounts within the 30 days preceding or the twelve months following a Change in Control as determined in accordance with the rules set forth in Section 9.7 through action of its Board of Directors or other authorized person or body. For this purpose, the Plan will be treated as terminated only if all agreements, methods, programs and other arrangements sponsored by the Related Employer immediately after the Change in Control which are treated as a single plan under Treas. Reg. § 1.409A-1(c)(2) are also terminated so that all Participants under the Plan and all similar arrangements are required to receive all amounts deferred under the terminated arrangements within twelve months of the date the Plan Sponsor irrevocably takes all necessary action to terminate the arrangements. In addition, the Plan Sponsor reserves the right to terminate the Plan within twelve months of a corporate dissolution taxed under Code Section 331 or with the approval of a bankruptcy court pursuant to Section 503(b)(1)(A) of Title 11of the United States Code provided that amounts deferred under the Plan are included in the gross incomes of Participants in the latest of (a) the calendar year in which the termination and liquidation occurs, (b) the first calendar year in which the amount is no longer subject to a substantial risk of forfeiture or (c) the first calendar year in which payment is administratively practicable.

10.3.Other Plan Terminations
The Plan Sponsor retains the discretion to terminate the Plan through action of its Board of Directors or other authorized person or body if (a) all arrangements sponsored by the Plan Sponsor that would be aggregated with any terminated arrangement under Code Section 409A and Treas. Reg. § 1.409A-1(c)(2) are terminated, (b) no payments other than payments that would be payable under the terms of the arrangements if the termination had not occurred are made within twelve months of the termination of the arrangements, (c) all payments are made within twenty-four months of the date the Plan Sponsor takes all necessary action to irrevocably terminate and liquidate the arrangements, (d) the Plan Sponsor does not adopt a new arrangement that would be aggregated with any terminated arrangement under Code Section 409A and the regulations thereunder at any time within the three year period following the date of termination of the arrangement and (e) the termination does not occur proximate to a downturn in the financial health of the Plan Sponsor. The Plan Sponsor also reserves the right to amend the Plan to provide that termination of the Plan will occur under such conditions and events as may be prescribed by the Secretary of the Treasury in generally applicable guidance published in the Internal Revenue Bulletin.



Article 10-1


Article 11 - The Trust
11.1.Establishment of Trust
The Plan Sponsor may but is not required to establish a trust to hold amounts which the Plan Sponsor may contribute from time to time to correspond to some or all amounts credited to Participants under Section 6.2. In the event that the Plan Sponsor wishes to establish a trust to provide a source of funds for the payment of Plan benefits, any such trust shall be constructed to constitute an unfunded arrangement that does not affect the status of the Plan as an unfunded plan for purposes of Title I of ERISA and the Code. If the Plan Sponsor elects to establish a trust in accordance with Section 10.01 of the Adoption Agreement, the provisions of Sections 11.2 and 11.3 shall become operative.

11.2.Trust
Any trust established by the Plan Sponsor shall be between the Plan Sponsor and a trustee pursuant to a separate written agreement under which assets are held, administered and managed, subject to the claims of the Plan Sponsor’s creditors in the event of the Plan Sponsor’s insolvency. The Plan Sponsor must notify the trustee in the event of a bankruptcy or insolvency.

11.3.Investment of Trust Funds
Any amounts contributed to the trust by the Plan Sponsor shall be invested by the trustee in accordance with the provisions of the trust and the instructions of the Administrator. Trust investments need not reflect the hypothetical investments selected by Participants under Section 7.1 for the purpose of adjusting Accounts and the earnings or investment results of the trust need not affect the hypothetical investment adjustments to Participant Accounts under the Plan.
Article 11-1



Article 12 - Plan Administration
12.1.Powers and Responsibilities of the Administrator
The Administrator has the full power and the full responsibility to administer the Plan in all of its details, subject, however, to the applicable requirements of ERISA. The Administrator’s powers and responsibilities include, but are not limited to, the following:

(a)To make and enforce such rules and procedures as it deems necessary or proper for the efficient administration of the Plan;

(b)To interpret the Plan, its interpretation thereof to be final, except as provided in Section 12.2, on all persons claiming benefits under the Plan;

(c)To decide all questions concerning the Plan and the eligibility of any person to participate in the Plan;

(d)To administer the claims and review procedures specified in Section 12.2;

(e)To compute the amount of benefits which will be payable to any Participant, former Participant or Beneficiary in accordance with the provisions of the Plan;

(f)To determine the person or persons to whom such benefits will be paid;

(g)To authorize the payment of benefits;

(h)To make corrections and recover the overpayment of any benefits;

(i)To comply with the reporting and disclosure requirements of Part 1 of Subtitle B of Title I of ERISA;

(j)To appoint such agents, counsel, accountants and consultants as may be required to assist in administering the Plan;

(k)To sever from the Plan or any deferral agreement any provision or exercise of a right that otherwise would result in a violation of Code Section 409A; and

(l)By written instrument, to allocate and delegate its responsibilities, including the formation of an administrative committee to administer the Plan.

Within one hundred and twenty (120) days following a Change in Control, the individuals who comprised the Committee (as defined in the Adoption Agreement) immediately prior to the Change in Control (whether or not such individuals are members of the Committee following the Change in Control) may, by written consent of the majority of such individuals, appoint an independent third party administrator to perform any or all of the Plan Sponsor's duties as Administrator as described in this Section, including, without limitation, the power to determine any questions arising in connection with the administration or interpretation of the Plan and the power to make benefit entitlement determinations. Upon and after the effective date of such appointment, (i) the Plan Sponsor must pay all reasonable administrative expenses and fees of such new administrator and (ii) such new administrator may only be terminated with the written consent of the majority of Participants with an Account balance in the Plan as of the date of such proposed termination.

The decision or action of the Plan Sponsor, or in the event of a Change in Control and actions pursuant to any new administrator, in respect of any question arising out of or in connection with the administration, interpretation and application of the Plan and the rules and regulations thereunder shall be final and conclusive and binding upon all persons having any interest in the Plan.
Article 12-1



12.2.Claims and Review Procedures
(a)Claims Procedure. If any person believes he or she is being denied any rights or benefits under the Plan, such person may file a claim in writing with the Administrator. Notice of a claim for payments shall be delivered to the Administrator within 90 days of the latest date upon which the payment could have been timely made in accordance with the terms of the Plan and Code Section 409A, and if not paid, such person must file a claim under this Article 12 not later than 180 days after such latest date.

If any such claim is wholly or partially denied, the Administrator will notify such person of its decision in writing. Such notification will contain (i) specific reasons for the denial, (ii) specific reference to pertinent Plan provisions, (iii) a description of any additional material or information necessary for such person to perfect such claim and an explanation of why such material or information is necessary and (iv) a description of the Plan’s review procedures and the time limits applicable to such procedures, including a statement of the person’s right to bring a civil action under Section 502(a) of ERISA following an adverse decision on review. If the claim involves a Disability, the denial must also include (i) a statement that the Administrator will provide to such person, upon request and free of charge, a copy of any internal rule, guideline, protocol or other similar criterion that was relied upon in making the decision and (ii) a discussion of the decision, including an explanation of the basis for disagreeing with or not following (a) the views of health care professionals treating such person or vocational professionals who evaluated such person that were presented by such person to the Plan, (b) the views of medical or vocational experts whose advice was obtained on behalf of the Plan in connection with the adverse benefit determination, regardless of whether the advice was relied on in making the determination or (c) a disability determination regarding such person made by the Social Security Administration that was presented by such person to the Plan.

Such notification will be given within 90 days (45 days in the case of a claim regarding Disability) after the claim is received by the Administrator. The Administrator may extend the period for providing the notification by 90 days (30 days in the case of a claim regarding Disability, which may be extended an additional 30 days) if special circumstances require an extension of time for processing the claim and if written notice of such extension, the circumstances requiring the extension and the date by which the Administrator expects to make a decision is given to such person within the initial 90 day period (45 day period in the case of a claim regarding Disability). Further, in the case of a claim regarding Disability, if the Administrator determines that a decision cannot be made within the first extension period due to matters beyond the control of the Administrator, the Administrator may extend the period for providing the notification by an additional 30 days if written notice of such extension, the circumstances requiring the extension, the date by which the Administrator expects to make a decision, the specific standards on which such entitlement to a benefit is based, the unresolved issues that prevent a decision on the claim and any additional information needed to resolve those issues is given to such person within the initial 30-day extension. Such person will be provided a minimum of 45 days to submit any necessary additional information to the Administrator. In the event that a 30-day extension is necessary due to such person’s failure to submit information necessary to decide a claim, the period for furnishing a notice of decision shall be tolled from the date on which the notice of the extension is sent to such person until the earlier of the date such person responds to the request for additional information or the response deadline. If such notification is not given within the proper period, the claim will be considered denied as of the last day of such period and such person may request a review of his or her claim.

(b)Review Procedure. Within 60 days (180 days in the case of a claim regarding Disability) after the date on which a person receives a written notification of
Article 12-2


complete or partial denial of claim (or, if written notification is not provided, within 60 days (180 days in the case of a claim regarding Disability) of the date denial is considered to have occurred), such person (or his or her duly authorized representative) may file a written request with the Administrator (but in the case of a claim regarding Disability, the Committee exclusive of the person who made the initial adverse decision or such person’s subordinate) for a review of his or her denied claim. If such person timely requests a review of the denied claim, such person may review, upon request and free of charge, copies of all documents, records and other information relevant to the denial and may submit written comments, documents, records and other information relevant to the claim to the Committee . All written comments, document, records and other information shall be considered “relevant” if the information (i) was relied upon in making a benefits determination, (ii) was submitted, considered or generated in the course of making a benefits decision regardless of whether it was relied upon to make the decision or (iii) demonstrates compliance with administrative processes and safeguards established for making benefit decisions. The Committee may, in its sole discretion and if it deems appropriate or necessary, decide to hold a hearing with respect to the claim appeal.

The Committee will take into account comments, documents, records and other information submitted by the person relating to the claim without regard to whether such information was submitted or considered in the initial benefit determination. In the case of a claim regarding Disability, the Committee will (i) not afford deference to the initial denial of the claim, (ii) consult a medical professional who has appropriate training and experience in the field of medicine relating to such person’s Disability and who was neither consulted as part of the initial denial nor is the subordinate of such individual and (iii) identify the medical or vocational experts whose advice was obtained with respect to the initial benefit denial, without regard to whether the advice was relied upon in making the decision.

The Committee will notify such person of its decision in writing. Such notification will be written in a manner calculated to be understood by such person and will contain (i) specific reasons for the decision, (ii) specific references to pertinent Plan provisions, (iii) a statement that the person is entitled to receive, upon request and free of charge, reasonable access to and copies of all documents, records or other information relevant (as defined above) to such person’s claim and (iv) a statement describing any voluntary appeals procedures offered by the Plan and a statement of such person’s right to bring a civil action under Section 502(a) of ERISA following an adverse decision on review. In the case of a claim regarding Disability, the notification will also contain a statement that the Committee will provide, upon request and free of charge, (i) any internal rule, guideline, protocol or other similar criterion relied upon in making the decision, (ii) any medical opinion relied upon to make the decision, (iii) the required statement under Section 2560.503-1(i)(5)(iii) of the Department of Labor regulations and (iv) a discussion of the decision, including an explanation of the basis for disagreeing with or not following (a) the views of health care professionals treating such person, or vocational professionals who evaluated such person, that were presented by such person to the Plan, (b) the views of medical or vocational experts whose advice was obtained on behalf of the Plan in connection with the appeal of the adverse benefit determination, regardless of whether the advice was relied upon in making the determination or (c) a disability determination regarding such person made by the Social Security Administration that was presented by such person to the Plan.

The decision on review will be made within 60 days (45 days in the case of a claim regarding Disability) following receipt of the appeal. The Committee may extend the period for making the decision on review by 60 days (45 days in the case of a claim regarding Disability) if special circumstances require an extension of time for processing the request such as an election by the Committee to hold a hearing, and if written notice of such extension, the circumstances requiring the extension and the date by which the Committee expects to make a decision is given to such person
Article 12-3


within the initial 60-day period (45 days in the case of a claim regarding Disability). If the decision on review is not made within such period, the claim will be considered denied.

Before issuing any decision with respect to a claim involving Disability, the Committee will provide to the person, free of charge, the following information as soon as possible and sufficiently in advance of the date on which the response is required to be provided to the person to allow the person a reasonable opportunity to respond prior to the due date of the response:

(i)Any new or additional evidence considered, relied upon, or generated by the Committee or other person making the decision; and

(ii)A new or additional rationale if the decision will be based on that rationale.

(c)Review Procedure Upon Change in Control. Upon a Change in Control, the Committee, as constituted immediately prior to such Change in Control, shall continue to act as the Committee. Upon such Change in Control, the Plan Sponsor may not remove any member of the Committee but may replace resigning members if 2/3rds of the members of the Committee, as constituted immediately prior to such Change in Control, and a majority of Participants and Beneficiaries with Account balances consent to the replacement. The Committee shall have the exclusive authority at the appeals stage to interpret the terms of the Plan and resolve appeals under the claims procedures.

(d)Exhaustion of Claims Procedures and Right to Bring Legal Claim. A claimant may not bring any legal action, including commencement of any arbitration, relating to a claim for benefits under the Plan unless and until the claimant has followed the claims procedures under the Plan and exhausted his or her administrative remedies under such claims procedures. No such action at law or equity shall be brought more than one year after the Committee’s affirmation of a denial of a claim, or, if no appeal is filed by the applicable appeals deadline, 12 months following the appeals deadline.

If a Participant or Beneficiary prevails in a legal proceeding brought under the Plan to enforce the rights of such Participant or any other similarly situated Participant or Beneficiary, in whole or in part, the Plan Sponsor shall reimburse such Participant or Beneficiary for all reasonable legal costs, expenses, attorneys' fees and such other reasonable liabilities incurred as a result of such proceedings. If the legal proceeding is brought in connection with a Change in Control, or a "change in control" as defined in a trust described in Section 11.1 (if applicable), the Participant or Beneficiary may file a claim directly with the trustee for reimbursement of such costs, expenses and fees. For purposes of the preceding sentence, the amount of the claim shall be treated as if it were an addition to the Participant's or Beneficiary's Account balance.

(e)Discretion of Committee. All interpretations, determinations and decisions of the Committee with respect to any claim shall be made in its sole discretion, and shall be final and conclusive.

(f)Arbitration. If, prior to a Change in Control, any claim or controversy between the Plan Sponsor and a Participant or Beneficiary is not resolved through the claims procedure set forth in this Article 12, such claim shall be submitted to and resolved exclusively by expedited binding arbitration by a single arbitrator. Arbitration shall be conducted in accordance with the following procedures.

The complaining party shall promptly send written notice to the other party identifying the matter in dispute and the proposed remedy. Following the giving of such notice, the parties shall meet and attempt in good faith to resolve the matter. In the event the parties are unable to resolve the matter within 21 days, the parties
Article 12-4


shall meet and attempt in good faith to select a single arbitrator acceptable to both parties. If a single arbitrator is not selected by mutual consent within ten business days following the giving of the written notice of dispute, an arbitrator shall be selected from a list of nine persons each of whom shall be an attorney who is either engaged in the active practice of law or a recognized arbitrator and who, in either event, is experienced in serving as an arbitrator in disputes between employers and employees, which list shall be provided by the main office of either Judicial Arbitration and Mediation Services, Inc. (“JAMS”), the American Arbitration Association ("AAA") or the Federal Mediation and Conciliation Service. If, within three business days of the parties' receipt of such list, the parties are unable to agree on an arbitrator from the list, then the parties shall each strike names alternatively from the list, with the first to strike being determined by the flip of a coin. After each party has had four strikes, the remaining name on the list shall be the arbitrator. If such person is unable to serve for any reason, the parties shall repeat this process until an arbitrator is selected.

Unless the parties agree otherwise, within 60 days of the selection of the arbitrator, a hearing shall be conducted before such arbitrator at a time and a place agreed upon by the parties. In the event the parties are unable to agree upon the time or place of the arbitration, the time and place shall be designated by the arbitrator after consultation with the parties. Within 30 days of the conclusion of the arbitration hearing, the arbitrator shall issue an award, accompanied by a written decision explaining the basis for the arbitrator's award.

In any arbitration hereunder, the Plan Sponsor shall pay all administrative fees of the arbitration and all fees of the arbitrator. Each party shall pay its own attorneys’ fees, cost and expenses, unless the arbitrator orders otherwise. The prevailing party in such arbitration, as determined by the arbitrator, and in any enforcement or other court proceedings, shall be entitled, to the extent permitted by law, to reimbursement from the other party for all of the prevailing party’s costs (including but not limited to the arbitrator’s compensation), expenses and attorneys’ fees. The arbitrator shall have no authority to add to or to modify this Plan, shall apply all applicable law and shall have no lesser and no greater remedial authority than would a court of law resolving the same claim or controversy. The arbitrator shall, upon an appropriate motion, dismiss any claim without an evidentiary hearing if the party bringing the motion establishes that it would be entitled to summary judgment if the matter had been pursued in court litigation.

The parties shall be entitled to discovery as follows: Each party may take no more than three depositions. The Plan Sponsor may depose the Participant or Beneficiary plus two other witnesses, and the Participant or Beneficiary may depose the Plan Sponsor, pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure, plus two other witnesses. Each party may make such reasonable document discovery requests as are allowed in the discretion of the arbitrator.

The decision of the arbitrator shall be final, binding, and non-appealable, and may be enforced as a final judgment in any court of competent jurisdiction.

This arbitration provision of the Plan shall extend to claims against any parent, subsidiary or affiliate of each party, and, when acting within such capacity, any officer, director, shareholder, Participant, Beneficiary or agent of any party or of any of the above and shall apply as well to claims arising out of state and federal statutes and local ordinances as well as to claims arising under the common law or under this Plan.

Notwithstanding the foregoing, and unless otherwise agreed between the parties, either party may apply to a court for provisional relief, including a temporary restraining order or preliminary injunction, on the grounds that the arbitration award to which the applicant may be entitled may be rendered ineffectual without provisional relief.

Article 12-5


Any arbitration hereunder shall be conducted in accordance with the Federal Arbitration Act, provided, however, that, in the event of any inconsistency between the rules and procedures of the Act and the terms of this Plan, the terms of this Plan shall prevail.

If any of the provisions of this Section are determined to be unlawful or otherwise unenforceable, in the whole part, such determination shall not affect the validity of the remainder of this Section and this Section shall be reformed to the extent necessary to carry out its provisions to the greatest extent possible and to insure that the resolution of all conflicts between the parties, including those arising out of statutory claims, shall be resolved by neutral, binding arbitration. If a court should find that the provisions of this Section are not absolutely binding, then the parties intend any arbitration decision and award to be fully admissible in evidence in any subsequent action, given great weight by any finder of fact and treated as determinative to the maximum extent permitted by law.

The parties do not agree to arbitrate any putative class action or any other representative action. The parties agree to arbitrate only the claims(s) of a single Participant or Beneficiary.

(g)Arbitration Upon Change in Control. If, upon the occurrence of a Change in Control, any dispute, controversy or claim arises between a Participant or Beneficiary and the Plan Sponsor out of or relating to or concerning the provisions of the Plan, such dispute, controversy or claim shall be finally settled by a court of competent jurisdiction which, notwithstanding any other provision of the Plan, shall apply a de novo standard of review to any determination made by the Plan Sponsor or the Committee.

12.3.Plan Administrative Costs
All reasonable costs and expenses (including legal, accounting and employee communication fees) incurred by the Administrator in administering the Plan shall be paid by the Plan to the extent not paid by the Employer.

Article 12-6


Article 13 - Miscellaneous
13.1.Unsecured General Creditor of the Employer
Participants and their Beneficiaries, heirs, successors and assigns shall have no legal or equitable rights, interests or claims in any property or assets of the Employer. For purposes of the payment of benefits under the Plan, any and all of the Employer’s assets shall be, and shall remain, the general, unpledged, unrestricted assets of the Employer. Each Employer's obligation under the Plan shall be merely that of an unfunded and unsecured promise to pay money in the future.

13.2.Employer’s Liability
Each Employer’s liability for the payment of benefits under the Plan shall be defined only by the Plan and by the deferral agreements entered into between a Participant and the Employer. An Employer shall have no obligation or liability to a Participant under the Plan except as provided by the Plan and a deferral agreement or agreements. An Employer shall have no liability to Participants employed by other Employers.

13.3.Limitation of Rights
Neither the establishment of the Plan, nor any amendment thereof, nor the creation of any fund or account, nor the payment of any benefits, will be construed as giving to the Participant or any other person any legal or equitable right against the Employer, the Plan or the Administrator, except as provided herein; and in no event will the terms of employment or service of the Participant be modified or in any way affected hereby.

13.4.Anti-Assignment
Except as may be necessary to fulfill a domestic relations order within the meaning of Code Section 414(p), none of the benefits or rights of a Participant or any Beneficiary of a Participant shall be subject to the claim of any creditor. In particular, to the fullest extent permitted by law, all such benefits and rights shall be free from attachment, garnishment or any other legal or equitable process available to any creditor of the Participant and his or her Beneficiary. Neither the Participant nor his or her Beneficiary shall have the right to alienate, anticipate, commute, pledge, encumber or assign any of the payments which he or she may expect to receive, contingently or otherwise, under the Plan, except the right to designate a Beneficiary to receive death benefits provided hereunder. Notwithstanding the preceding, the benefit payable from a Participant’s Account may be reduced, at the discretion of the Administrator, to satisfy any debt or liability to the Employer.

However, the Employer may assign any or all of its liabilities under this Plan in connection with any restructuring, recapitalization, sale of assets or other similar transactions affecting the Employer without the consent of the Participant.

Article 13-1


13.5.Facility of Payment
If the Administrator determines, on the basis of medical reports or other evidence satisfactory to the Administrator, that the recipient of any benefit payments under the Plan is incapable of handling his or her affairs by reason of minority, illness, infirmity or other incapacity, the Administrator may direct the Employer to disburse such payments (i) to the legal guardian, or if none, to a parent of a minor payee with whom the payee maintains his or her residence or (ii) to the conservator or, if none, to the person having custody of an incompetent payee. The receipt by such person or institution of any such payments therefore, and any such payment to the extent thereof, shall discharge the liability of the Employer, the Plan and the Administrator for the payment of benefits hereunder to such recipient.

13.6.Notices
Any notice or other communication to the Employer or Administrator in connection with the Plan shall be deemed delivered in writing, in person, or through such electronic means as is established by the Employer or Administrator. Notice shall be deemed given as of the date it is actually delivered or, in the case delivery is made by mail, as of the date shown on the postmark on the receipt for registration or certification. Written transmission shall be addressed to the Plan Sponsor at the address specified in Section 1.03 of the Adoption Agreement.

Any notice or filing required or permitted to be given to a Participant under this Plan shall be sufficient if in writing or hand-delivered or sent by mail to the last known address of the Participant.

13.7.Tax Withholding
If the Employer concludes that tax is owing with respect to any deferral or payment hereunder, the Employer shall withhold such amounts from any payments due the Participant or from amounts deferred, as permitted by law, or otherwise make appropriate arrangements with the Participant or his or her Beneficiary for satisfaction of such obligation. Tax, for purposes of this Section 13.7 means any federal, state, local or any other governmental income tax, employment or payroll tax, excise tax or any other tax or assessment owing with respect to amounts deferred, any earnings thereon and any payments made to Participants under the Plan.

13.8.Indemnification
(a)Each Indemnitee (as defined in Section 13.8(d)) shall be indemnified and held harmless by the Employer for all actions taken by him or her and for all failures to take action (regardless of the date of any such action or failure to take action) in connection with the operation and administration of the Plan, to the fullest extent permitted by the law of the jurisdiction in which the Employer is incorporated and to the extent that the claim, fine or penalty, expense or liability is not paid for by liability insurance purchased or paid for by the Employer, against all claims, fines and penalties, expenses and liabilities (including, without limitation, reasonable attorneys’ fees) reasonably incurred or suffered by the Indemnitee. No indemnification pursuant to this Section shall be made, however, in any case where (1) the act or failure to act are due to gross negligence or willful misconduct or (2) for any such amount incurred through any settlement or compromise of any action unless the Employer consents in writing to such settlement or compromise.

(b)Indemnification pursuant to this Section shall continue as to an Indemnitee who has ceased to be such and shall inure to the benefit of his or her heirs, executors and administrators. The Employer agrees that the undertakings made in this Section shall be binding on its successors or assigns and shall survive the termination, amendment or restatement of the Plan.

Article 13-2


(c)The foregoing right to indemnification shall be in addition to such other rights as the Indemnitee may enjoy as a matter of law or by reason of insurance coverage of any kind and is in addition to and not in lieu of any rights to indemnification to which the Indemnitee may be entitled pursuant to the by-laws of the Employer.

(d)“Indemnitee” shall mean each person serving as an Administrator (or any other person who is an employee, Director, agent, organization or officer of the Employer) to whom or to which are delegated duties, responsibilities and authority under the Plan or otherwise with respect to administration of the Plan.

13.9.Successors
The provisions of the Plan shall bind and inure to the benefit of the Plan Sponsor, the Employer and their successors and assigns and the Participant and the Participant’s designated Beneficiaries.

13.10.Lost Participant or Beneficiaries
Any Participant or Beneficiary who is entitled to a benefit from the Plan has the duty to keep the Employer advised of his or her current mailing address. If benefit payments are returned to the Plan or are not presented for payment after a reasonable amount of time, the Employer shall presume that the payee is missing. The Employer, after making such efforts as in its discretion it deems reasonable and appropriate to locate the payee, shall stop payment on any uncashed checks and may discontinue making future payments until contact with the payee is restored.

13.11.Headings
The headings of Sections are included solely for convenience of reference, and if there is any conflict between such headings and the text of this Plan, the text shall control.

13.12.Invalid or Unenforceable Provisions
If any provision of this Plan shall be held invalid or unenforceable, such invalidity or unenforceability shall not affect any other provisions hereof and the Employer may elect in its sole discretion to construe such invalid or unenforceable provisions in a manner that conforms to applicable law or as if such provisions, to the extent invalid or unenforceable, had not been included.

13.13.Disclaimer
It is the Plan Sponsor’s intention that the Plan comply with the requirements of Code Section 409A. Neither the Plan Sponsor nor the Employer shall have any liability to any Participant should any provision of the Plan fail to satisfy the requirements of Code Section 409A.

13.14.Governing Law
The Plan will be construed, administered and enforced according to the laws of the State specified by the Plan Sponsor in Section 12.01 of the Adoption Agreement.




Article 13-3







Thermo Fisher Scientific Inc.
Deferred Compensation Plan
Adoption Agreement













Table of Contents


    

i
Adoption Agreement

1.01    Preamble
By the execution of this Adoption Agreement the Plan Sponsor hereby [complete (a) or (b)]

(1)☐    adopts a new plan as of [month, day, year]

(2)☒    amends and restates its existing plan as of January 1, 2024 which is the Amendment Effective Date. All amounts deferred under the Plan prior to the Amendment Effective Date shall be governed by the terms of the Plan as in effect on the day before the Amendment Effective Date.

Originally effective November 1, 2001; Amounts deferred under the Plan prior to January 1, 2005 that were vested as of December 31, 2004 shall be subject to the provisions of the Plan as in effect on October 3, 2004.

Previously Amended & Restated effective January 1, 2009 and executed on January 27, 2009 for amounts deferred on or after January 1, 2005; and previously Restated effective January 1, 2020 with subsequent First Amendment effective January 1, 2022 and Second Amendment effective March 1, 2023.
Pre-409A Grandfathering: ☒ Yes    ☐ No

By executing this Adoption Agreement, the Plan Sponsor (as defined below) has adopted the Plan (as defined below) consisting of the Basic Plan Document along with this Adoption Agreement (and any exhibits or scheduled attached hereto).  The Plan Sponsor, by completing this Adoption Agreement has made the specific choices regarding plan design as set forth in the Adoption Agreement together with the detailed additional provisions set out in the Basic Plan Document.  All capitalized terms used in this Adoption Agreement have the same meaning given in the Basic Plan Document.

1.02    Plan
Plan Name:Thermo Fisher Scientific Inc. Deferred Compensation Plan

Plan Year:Calendar Year (1/1 – 12/31)

















    1


1.03    Plan Sponsor
Name:Thermo Fisher Scientific Inc. (also referred to herein as the “Company”)

Address:
168 3rd Avenue, Waltham MA 02451

Phone #:781-622-1000

EIN #:04-2209186

Fiscal Year:Calendar Year (1/1 – 12/31)

Is stock of the Plan Sponsor, any Employer or any Related Employer publicly traded on an established securities market?    ☒ Yes    ☐ No

1.04    Employer
The following entities have been authorized by the Plan Sponsor to participate in and have adopted the Plan [insert “Not Applicable” if none have been authorized]:

EntityPublicly Traded on Est. Securities Market
YesNo
Not Applicable☐☐
☐☐

1.05    Administrator
The Plan Sponsor has designated the following party or parties to be responsible for the administration of the Plan:

Name:
Thermo Fisher Scientific Inc. Management Pension Committee (the “Committee”)

Address:
168 3rd Avenue, Waltham MA 02451

Note: The Administrator is the person or persons designated by the Plan Sponsor to be responsible for the administration of the Plan. Neither Fidelity Employer Services Company nor any other Fidelity affiliate can be the Administrator.




















2


1.06    Key Employee Determination Dates
Key Employee identification will not be applicable given distribution events other than those based on Specified Date or Specified Age, Death, Disability, or Change in Control will be treated as not having occurred for six (6) months (i.e., 6-month delay applies to all Participants. The remainder of this section is retained for information purposes only.

The Employer has designated [month, day, year] as the Identification Date for purposes of determining Key Employees.

In the absence of a designation, the Identification Date is December 31.

The Employer has designated [month, day, year] as the effective date for purposes of applying the six month delay in distributions to Key Employees.

In the absence of a designation, the effective date is the first day of the fourth month following the Identification Date.

















3


2.01    Participation
(a)☒    Employees [complete (i), (ii) or (iii)]

(i)☐    Eligible Employees are selected by the Employer.

(ii)☒    Eligible Employees are those employees of the Employer who satisfy the following criteria:

Eligible Employee means a member of a "select group of management or highly compensated employees" of the Company within the meaning of Sections 201(2), 30l(a)(3) and 401 (a)(l) of ERISA, as determined by the Committee from time to time in its sole discretion. Employees become Eligible Employees upon notification by the Company of their eligibility to become Participants in the Plan.

An Eligible Employee becomes a Participant upon the earlier to occur of: (i) the notification of eligibility to participate and the timely submission of a deferral agreement on which an election to make a deferral is made; or (ii) a credit of a Company contribution.

Further, a Participant shall become eligible to earn Matching Contributions under the Plan when they become eligible to earn matching contributions in the Thermo Fisher Scientific Inc. 401(k) Retirement Plan (without consideration of any limitations imposed by the Code).

(iii)☐    Employees are not eligible to participate.


















4


3.01    Compensation
For purposes of determining Participant contributions under Article 4 and Employer contributions under Article 5, Compensation shall be defined in the following manner [complete (a) or (b) and select (c) and/or (d), if applicable]:

(a)☒    Compensation is defined as:

Compensation means the amount paid in the year of the deferral as the Participant's base salary, bonus and such other remuneration for services rendered as an employee (if any) approved by the Company as Compensation that may be deferred under this Plan. Compensation shall not include any Compensation that has been previously deferred under this Plan or any other arrangement subject to Code Section 409A. The Company has the authority to determine the payroll practices under which Compensation subject to a deferral agreement will be deducted from a Participant's Compensation.

“Match-Eligible Compensation” for a given Plan Year means a Participant's Compensation that is in excess of the amount of Compensation treated as "compensation" for the applicable plan year under the Thermo Fisher Scientific Inc. 401(k) Retirement Plan. Match-Eligible Compensation includes a Participant's Compensation that is in excess of the Internal Revenue Service (“IRS”) limit on covered compensation for qualified plans established in Code Section 401(a)(17) in effect for that Plan Year and also includes any amount of a Participant's Compensation that was reduced below the Code Section 401(a)(17) limit for purposes of applying the Company match in the Company sponsored 401(k) plan due to deferrals in this Plan.

(b)☐    Compensation as defined in [insert name of qualified plan] without regard to the limitation in Section 401(a)(17) of the Code for such Plan Year.

(c)☐    Compensation shall, for all Plan purposes, be limited to $         .

(d)☐    Not Applicable.



















5


3.02    Bonuses
Compensation, as defined in Section 3.01 of the Adoption Agreement, includes the following type of bonuses that will be the subject of a separate deferral election:

Type
[Will be treated as]
Performance Based Compensation
YesNo
Annual Incentive Plan (AIP)☒☐
☐☐
☐☐
☐☐
☐☐

☐    Not Applicable.

















6


4.01    Participant Contributions
If Participant contributions are permitted, complete (a) and (b). Otherwise complete (c).

(a)Amount of Deferrals

A Participant may elect within the period specified in Section 4.01(b) of the Adoption Agreement to defer the following amounts of remuneration. For each type of remuneration listed, complete “dollar amount” and/or “percentage amount”.

(i)Compensation other than Bonuses [do not complete if you complete (iii)]

Type of RemunerationDollar Amount% AmountIncrement
MinMaxMinMax
Base Salary1%75%1%
Match-Eligible Compensation6%6%N/A


Note: The increment is required to determine the permissible deferral amounts. For example, a minimum of 0% and maximum of 20% with a 5% increment would allow an individual to defer 0%, 5%, 10%, 15% or 20%.

(ii)Bonuses [do not complete if you complete (iii)]

Type of BonusDollar Amount% AmountIncrement
MinMaxMinMax
Annual Incentive Plan1%75%1%

Note: (If Match-Eligible Compensation is elected by Participant in Section 4.01(a)(i) and (ii) for deferral, Participants are prohibited from making separate base salary or Annual Incentive Plan bonus elections and vice versa (i.e., Participants may only defer Match-Eligible Compensation or separate base salary and/or Annual Incentive Plan).

(iii)Compensation [do not complete if you completed (i) and (ii)]

Type of RemunerationDollar Amount% AmountIncrement
MinMaxMinMax
























7


(b)Election Period

(i)Performance Based Compensation

A special election period

☐    Does

☒    Does Not

apply to each eligible type of performance based compensation referenced in Section 3.02 of the Adoption Agreement.

The special election period, if applicable, will be determined by the Employer.

(ii)Newly Eligible Participants

An employee who is classified or designated as an Eligible Employee during a Plan Year

☒    May

☐    May Not

elect to defer Compensation earned during the remainder of the Plan Year by completing a deferral agreement within the 30 day period beginning on the date he or she is eligible to participate in the Plan.

The special election period, if applicable, will be determined by the Employer.

(c)No Participant Contributions

☐    Participant contributions are not permitted under the Plan.
















8


5.01    Employer Contributions
If Employer contributions are permitted, complete (a) and/or (b). Otherwise complete (c).

(a)Matching Contributions

(i)Amount

For each Plan Year, the Employer shall make a matching contribution on behalf of each Participant who defers Compensation for the Plan Year and satisfies the requirements of Section 5.01(a)(ii) of the Adoption Agreement equal to [complete the ones that are applicable]:

(A)☐    [insert percentage]% of the Compensation the Participant has elected to defer for the Plan Year

(B)☐    An amount determined by the Employer in its sole discretion

(C)☐    Matching contributions for each Participant shall be limited to $         and/or [insert percentage]% of Compensation

(D)☒    Other:
In each Plan Year, with respect to each Participant determined eligible for the Plan, the Plan Sponsor shall make a matching contribution equal to 100% of the first six percent (6%) of Match-Eligible Compensation that such Participant elected to defer for that Plan Year.

(E)☐    Not Applicable [Proceed to Section 5.01(b)]

(ii)Eligibility for matching contribution

A Participant who defers Compensation for the Plan Year shall receive an allocation of matching contributions determined in accordance with Section 5.01(a)(i) provided he or she satisfies the following requirements [complete the ones that are applicable]:

(A)☐    Describe requirements:

















9



(B)☒    Is selected by the Employer in its sole discretion to receive an allocation of matching contributions

(C)☐    No requirements

(iii)Time of Allocation

Matching contributions, if made, shall be treated as allocated [select one]:

(A)☐    As of the last day of the Plan Year

(B)☒    At such times as the Employer shall determine in its sole discretion


(C)☐    At the time the Compensation on account of which the matching contribution is being made would otherwise have been paid to the Participant

(D)☐    Other:


(b)Other Contributions

(i)Amount

The Employer shall make a contribution on behalf of each Participant who satisfies the requirements of Section 5.01(b)(ii) equal to [complete the ones that are applicable]:

(A)☐    An amount equal to [insert percentage]% of the Participant’s Compensation

(B)☒    An amount determined by the Employer in its sole discretion

(C)☐    Contributions for each Participant shall be limited to $        

















10



(D)☐    Other:

(E)☐    Not Applicable [Proceed to Section 6.01]

(ii)Eligibility for Other Contribution

A Participant shall receive an allocation of other Employer contributions determined in accordance with Section 5.01(b)(i) for the Plan Year if he or she satisfies the following requirements [complete the one that is applicable]:

(A)☐    Describe requirements:


(B)☒    Is selected by the Employer in its sole discretion to receive an allocation of other Employer contributions

(C)☐    No requirements


(iii)Time of Allocation

Employer contributions, if made, shall be treated as allocated [select one]:

(A)☐    As of the last day of the Plan Year

(B)☒    At such times or times as the Employer shall determine in its sole discretion

(C)☐    Other:


(c)No Employer Contributions

☐    Employer contributions are not permitted under the Plan.
















11


6.01    Distributions
The timing and form of payment of distributions made from the Participant’s vested Account shall be made in accordance with the elections made in this Section 6.01 of the Adoption Agreement except when Section 9.6 of the Plan requires a six month delay for certain distributions to Key Employees of publicly traded companies.

(a)Timing of Distributions

(i)All distributions shall commence in accordance with the following [choose one]:

(A)☐    As soon as administratively feasible following the distribution event but in no event later than the time prescribed by Treas. Reg. Sec. 1.409A-3(d).

(B)☒    Monthly on the first business day of the month.

(C)☐    Annually on specified month and day [insert month and day]

(D)☐    Calendar quarter on specified month and day [insert month and day] [insert numerical quarter 1, 2, 3, or 4]

(ii)The timing of distributions as determined in Section 6.01(a)(i) shall be modified by the adoption of:

(A)☒    Event Delay – Distribution events other than those based on Specified Date or Specified Age, Death, Disability, or Change in Control will be treated as not having occurred for six (6) months

(B)☐    Hold Until Next Year – Distribution events other than those based on Specified Date or Specified Age will be treated as not having occurred for twelve months from the date of the event if payment pursuant to Section 6.01(a)(i) will thereby occur in the next calendar year or on the first payment date in the next calendar year in all other cases

(C)☐    Immediate Processing – The timing method selected by the Plan Sponsor under Section 6.01(a)(i) shall be overridden for the following distribution events [insert events]:


(D)☐    Not applicable
















12


(b)Distribution Events

(i)Participant Contributions under Section 4.01(a)

Participants may elect the following payment events and the associated form or forms of payment. If multiple events for each year are selected, the earliest to occur will trigger payment. For installments, insert the range of available periods (e.g., 5-15) or insert the periods available (e.g., 5, 7, 9).


Lump SumInstallments
(A)☒    Specified Date (MM/YYYY)
☒
2-5 years
(B)☐    Specified Age
☐
       years
(C)☒    Separation from Service
☒
2-15 years; (25 years with respect to contributions to the Plan made prior to 1/1/2022)
(D)☐    Separation from Service plus 6 months
☐
       years
(E)☐    Separation from Service plus ___ months [not to exceed ___ months]
☐
       years
(F)☐    Retirement
☐
       years
(G)☐    Retirement plus 6 months
☐
       years
(H)☐    Retirement plus 12 months
☐
       years
(I)☐    Disability
☐
       years
(J)☐    Death
☐
       years
(K)☒Change in Control**
☒
2-15 years
** Change in Control benefit only available to amounts deferred under Compensation Deferral Agreements that became irrevocable prior to October 1, 2019 for those Participants who have elected prior to October 1, 2019 to receive a Change in Control Benefit and shall be paid within ninety (90) days following the date upon which the Change in Control occurred,
The minimum deferral period for Specified Date or Specified Age event shall be 2 year(s).

















13



Installments may be paid [select each that applies]

☐    Monthly

☐    Quarterly

☐    Semi-Annually

☒    Annually

(ii)Employer Contributions under Section 5.01(a) and (b).

Participants may elect the following payment events and the associated form or forms of payment. If multiple events for each year are selected, the earliest to occur will trigger payment. For installments, insert the range of available periods (e.g., 5-15) or insert the periods available (e.g., 5, 7, 9).


Lump SumInstallments
(A)☐    Specified Date (MM/YYYY)
☐
       years
(B)☐    Specified Age
☐
       years
(C)☒    Separation from Service
☒
2-15 years
(D)☐    Separation from Service plus 6 months
☐
       years
(E)☐    Separation from Service plus ___ months [not to exceed ___ months]
☐
       years
(F)☐    Retirement
☐
       years
(G)☐    Retirement plus 6 months
☐
       years
(H)☐    Retirement plus 12 months
☐
       years
(I)☐    Disability
☐
       years
(J)☐    Death
☐
       years
(K)☐    Change in Control
☐
       years

















14


The minimum deferral period for Specified Date or Specified Age event shall be Not Applicable year(s).

Installments may be paid [select each that applies]

☐    Monthly

☐    Quarterly

☐    Semi-Annually

☒    Annually

(c)Specified Date and Specified Age elections may not extend beyond age Not Applicable.

(d)Payment Election Override

Payment of the remaining vested balance of the Participant’s Account will automatically occur at the time specified in Section 6.01(a) of the Adoption Agreement in the form indicated upon the earliest to occur of the following events [check each event that applies and for each event include only a single form of payment]:

EventsForm of Payment
Lump SumInstallments
☒    Separation from Service/Change in Control**
☒   
** Upon a Separation from Service or, with respect to any Participant who has elected (prior to October 1, 2019) a Change in Control benefit pursuant to Section 6.01(b), upon a Change in Control, the unpaid balance of a Specified Date account shall be paid as follows: (i) Specified Date payments that have commenced (i.e. in “pay status) shall continue to be paid separately; and (ii) Specified Date payments that have not commenced shall be paid in accordance with the form of payment applicable to the Separation from Service or Change in Control Benefit, as applicable. If such benefit is payable in a single lump sum, the unpaid balance of all Specified Date Accounts (including those in pay status) will be paid in a lump sum."
☐    Separation from Service before Retirement
☐   
☒    Separation from Service within 24 months following a Change in Control
☒   
☒    Death
☒   
☐    Disability
☐   
☐    Not Applicable
☐   
















15


(e)Involuntary Cashouts

☒    If the Participant’s vested Account at the time of his or her Separation from Service does not exceed the applicable dollar amount under Code Section 402(g)(1)(B), distribution of the vested Account shall automatically be made in the form of a single lump sum in accordance with Section 9.5 of the Plan.

☐    There are no involuntary cashouts.

(f)Retirement

☐    Retirement shall be defined as a Separation from Service that occurs on or after the Participant [insert description of requirements]:


☒    No special definition of Retirement applies.

(g)Distribution Election Change

A Participant

☒    Shall

☐    Shall Not

be permitted to modify a scheduled distribution date and/or payment option in accordance with Section 9.2 of the Plan.

The Plan Sponsor, in its sole and absolute discretion, reserves the right to limit the number of times a Participant may be permitted to modify distribution elections.

Administratively, allowable distribution events will be modified to reflect all options necessary to fulfill the distribution change election provision.

















16



(h)Frequency of Elections

The Plan Sponsor

☒    Has

☐    Has Not

elected to permit annual elections of a time and form of payment for amounts deferred under the Plan. If a single election of a time and/or form of payment is required, the Participant will make such election at the time he or she first completes a deferral agreement which, in all cases, will be no later than the time required by Reg. Sec. 1.409A-2.

(i)Disability

For Purposes of Section 2.11 of the Plan, Disability shall be defined as

☐    Total disability as determined by the Social Security Administration or the Railroad Retirement Board.

☐    As determined by the Employer’s long term disability insurance policy.

☐    As follows [insert description of requirements]:


☒    Not applicable.

















17


7.01    Vesting
(a)Matching Contributions

The Participant’s vested interest in the amount credited to his or her Account attributable to matching contributions shall be based on the following schedule:

☒Years of ServiceVesting %
0100%[insert “100” if there is immediate vesting]
1
        %
2
        %
3
        %
4
        %
5
        %
6
        %
7
        %
8
        %
9
        %

☐    Other:


☐    Class year vesting applies:


☐    Not applicable.

















18



(b)Other Employer Contributions

The Participant’s vested interest in the amount credited to his or her Account attributable to Employer contributions other than matching contributions shall be based on the following schedule:

☐Years of ServiceVesting %
0
        %
[insert “100” if there is immediate vesting]
1
        %
2
        %
3
        %
4
        %
5
        %
6
        %
7
        %
8
        %
9
        %

☒    Other:

Vesting determined by the Employer in its sole discretion at the time the contribution is made.

☐    Class year vesting applies:


☐    Not applicable.

(c)Acceleration of Vesting

The Participant’s vested interest in his or her Account will automatically be 100% upon the occurrence of the following events [select the ones that are applicable]:

















19


(i)☒    Death.

(ii)☐    Disability.

(iii)☐    Change in Control.

(iv)☐    Eligibility for Retirement.

(v)☒    Other:

The Plan Sponsor may, at any time, in its sole discretion, increase a Participant's vested interest in a Plan Sponsor discretionary contribution.

(vi)☐    Not applicable.

(d)Years of Service

(i)A Participant’s Years of Service shall include all service performed for the Employer and

☐    Shall

☐    Shall Not

include service performed for the Related Employer.

















20



(ii)Years of Service shall also include service performed for the following entities:






(iii)Years of Service shall be determined in accordance with [select one]:

(A)☐    The elapsed time method in Treas. Reg. Sec. 1.410(a)-7

(B)☐    The general method in DOL Reg. Sec. 2530.200b-1 through b-4

(C)☐    Participant’s Years of Service credited under:

[insert name of plan]

(D)☐    Other:





(iv)☒    Not applicable.

















21


8.01    Unforeseeable Emergency
(a)A withdrawal due to an Unforeseeable Emergency as defined in Section 2.24:

☒    Will

☐    Will Not [if Unforeseeable Emergency withdrawals are not permitted, proceed to Section 9.01]

be allowed.

(b)Upon (i) a withdrawal due to an Unforeseeable Emergency, or (ii) during periods in which the Participant is unable to perform the duties of his or her position or any substantially similar position due to a mental or physical impairment that can be expected to result in death or last for a continuous period of at least six (6) months, provided cancellation occurs by the later of the end of the taxable year of the Participant or the fifteenth (15th) day of the third (3rd) month following the date the Participant incurs the Disability (as defined here), a Participant’s deferral election for the remainder of the Plan Year:

☒    May

☐    Will Not

be cancelled. If cancellation occurs, the Participant may resume participation in accordance with Article 4 of the Plan.

















22


9.01    Investment Decisions
Investment decisions regarding the hypothetical amounts credited to a Participant’s Account shall be made by [select one]:

(a)☒    The Participant or his or her Beneficiary

(b)☐    The Employer

















23


10.01    Trust
The Employer [select one]:

☒    Does

☐    Does Not

intend to establish a trust as provided in Article 11 of the Plan.

















24


11.01    Termination Upon Change In Control
The Plan Sponsor

☒    Reserves

☐    Does Not Reserves

the right to terminate the Plan and distribute all vested amounts credited to Participant Accounts upon a Change in Control as described in Section 9.7.

11.02    Automatic Distribution Upon Change In Control
Distribution of the remaining vested balance of each Participant’s Account

☐    Shall

☒    Shall Not

automatically be paid as a lump sum payment upon the occurrence of a Change in Control as provided in Section 9.7.

11.03    Change In Control
A Change in Control for Plan purposes includes the following [select each definition that applies]:

(a)☒    A change in the ownership of the Employer as described in Section 9.7(c) of the Plan.

(b)☒    A change in the effective control of the Employer as described in Section 9.7(d) of the Plan.

(c)☒    A change in the ownership of a substantial portion of the assets of the Employer as described in Section 9.7(e) of the Plan.

(d)☐    Not Applicable.

















25


12.01    Governing State Law
The laws of Massachusetts shall apply in the administration of the Plan to the extent not preempted by ERISA.

















26


The Plan Sponsor has caused this Adoption Agreement to be executed this 20 day of December, 2023.


Plan Sponsor:Thermo Fisher Scientific Inc.
By:/s/ Lisa P. Britt
Title:SVP & Chief Human Resources Officer



















27

 EX-21 5 q4202310-kex21.htm SUBSIDIARIES OF THE REGISTRANT Document
Exhibit 21
 THERMO FISHER SCIENTIFIC INC. 
NAME
STATE OR JURISDICTION OF ORGANIZATION
0972792 B.C. LTDCanada
236 Perinton Parkway, LLCNew York
27 Forge Parkway LLCDelaware
Abgene Inc.Delaware
Abgene LimitedEngland
ABII 2 LimitedEngland
ACI Holdings Inc.New York
Acoustic Cytometry Systems, Inc.Delaware
AcroMetrix LLC
California
Acros Organics BVBelgium
Acurian, Inc.Delaware
Advanced Biotechnologies LimitedEngland
Advanced Scientifics International, Inc.Pennsylvania
Advanced Scientifics, Inc.Pennsylvania
Affymetrix Biotech Shanghai LtdChina
Affymetrix Japan K.K.Japan
Affymetrix UK LtdEngland
Affymetrix, IncDelaware
Alchematrix LLCDelaware
Alchematrix, Inc.Delaware
Alfa Aesar (China) Chemical Co. Ltd.China
Alfa Aesar (Hong Kong) LimitedHong Kong
Allergon ABSweden
Ambion, Inc.
Delaware
APBI Finance CorporationDelaware
Apogent Finance CompanyDelaware
Apogent Holding CompanyDelaware
Apogent Technologies Inc.Wisconsin
Apogent Transition Corp.Delaware
Apogent U.K. LimitedEngland
Applied Bioscience International, LLCDelaware
Applied Biosystems B.V.Netherlands
1

NAME
STATE OR JURISDICTION OF ORGANIZATION
Applied Biosystems de Mexico S. de R.L. de C.V.Mexico
Applied Biosystems International Inc.Delaware
Applied Biosystems Taiwan LLCDelaware
Applied Biosystems Trading (Shanghai) Company Ltd.China
Applied Biosystems, LLCDelaware
Applied Scientific CorporationCalifornia
App-Tek International Pty LtdAustralia
ARG Services LLCDelaware
ASPEX CorporationPennsylvania
ATP, LLCNorth Carolina
Avances Cientificos de Mexico, S. de R.L. de C.V.Mexico
Avocado Research Chemicals LimitedEngland
B.R.A.H.M.S. Biotech GmbHGermany
B.R.A.H.M.S. GmbHGermany
B.R.A.H.M.S. UK LtdEngland
BAC BVNetherlands
BAC IP BVNetherlands
Barnstead Thermolyne LLCDelaware
Beijing Phadia Diagnostics Co LtdChina
Bender MedSystems GmbHAustria
Biochemical Sciences LLCDelaware
Bio-Sciences LtdIreland
BioTrove CorporationDelaware
BioTrove International, Inc.Delaware
BmT GmbH LaborprodukteGermany
Brammer Bio Holding Company, LLCDelaware
Brammer Bio MA, LLCDelaware
Brammer Bio, LLCDelaware
Bumi-Sans Sendirian BerhadMalaysia
CAC LimitedEngland
Capitol Scientific Products, Inc.New York
Capitol Vial, Inc.Alabama
2

NAME
STATE OR JURISDICTION OF ORGANIZATION
CB Diagnostics ABSweden
CB Diagnostics Holding ABSweden
CB Diagnostics I ABSweden
CCBR (Beijing) Company LimitedChina
Cellomics, Inc.Delaware
CellzDirect, Inc.Delaware
Center for Clinical and Basic Research A/SDenmark
CEPH International CorporationPuerto Rico
Cezanne S.A.S.France
Chase Scientific Glass, Inc.Wisconsin
CHK Holdings Inc.
Delaware
Chromacol LimitedEngland
Clinical Technology Centre (International) LimitedEngland
Clinical Technology Centre (Ireland) LimitedIreland
Clintrak Clinical Labeling Services, LLCDelaware
Clintrak Pharmaceutical Services, LLCDelaware
Cohesive Technologies (UK) LimitedEngland
Cohesive Technologies Inc.Delaware
Columbia Diagnostics, Inc.Delaware
Combinati IncorporatedDelaware
Compass NeuroHealth, LLCFlorida
Compass Research, LLCFlorida
Compendia Bioscience, Inc.
Michigan
Comtest LimitedEngland
Consolidated Technologies, Inc.Wisconsin
Consultores Fisher Scientific Chile LtdChile
Core Informatics UK Ltd.England
Core Informatics, LLCConnecticut
CorEvitas, LLCDelaware
Corrona Intermediate Holdings, Inc.Delaware
Corrona UK Holdings LimitedEngland
CTPS LLCDelaware
3

NAME
STATE OR JURISDICTION OF ORGANIZATION
DCG Systems G.K.Japan
D-finitive Technologies, Inc.South Carolina
Diagnostix Ltd.Canada
Dionex (Switzerland) AGSwitzerland
Dionex (UK) LimitedEngland
Dionex Austria GmbHAustria
Dionex Benelux B.V.Netherlands
Dionex Canada Ltd.Canada
Dionex China LimitedHong Kong
Dionex CorporationDelaware
Dionex Denmark A/SDenmark
Dionex Holding GmbHGermany
Dionex I, LLCDelaware
Dionex S.A.France
Dionex S.p.A.Italy
Dionex Softron GmbHGermany
Dionex Sweden ABSweden
Distribution Solutions International, Inc.Michigan
Doe & Ingalls Investors, Inc.Delaware
Doe & Ingalls LimitedIreland
Doe & Ingalls Management, LLCDelaware
Doe & Ingalls of California Operating LLCNorth Carolina
Doe & Ingalls of Florida Operating LLCFlorida
Doe & Ingalls of Maryland Operating LLCNorth Carolina
Doe & Ingalls of Massachusetts Operating LLCNorth Carolina
Doe & Ingalls of North Carolina Operating LLCNorth Carolina
Doe & Ingalls Properties II, LLCNorth Carolina
Doe & Ingalls Properties, LLCNorth Carolina
Doublecape Holding LimitedEngland
Doublecape LimitedEngland
DPI Newco LLCDelaware
Drakeside Real Estate Holding Company LLCDelaware
4

NAME
STATE OR JURISDICTION OF ORGANIZATION
DSM Pharmaceutical Products, Inc.Delaware
Duke Scientific CorporationCalifornia
Dynal Biotech Beijing LimitedChina
Eagle Holding Company II, LLCDelaware
eBioscience SASFrance
eBioscience, LtdEngland
EGS Gauging Ltd.England
EGS Gauging Technical Services CompanyDelaware
EP Scientific Products LLCDelaware
Epsom Glass Industries LimitedEngland
Erie (GC) Holding LimitedEngland
Erie Finance 1 LimitedEngland
Erie Finance 2 LimitedEngland
Erie Finance Holding LimitedEngland
Erie Finance LimitedEngland
Erie Finance LLCDelaware
Erie GC Holding LLCDelaware
Erie GC LimitedEngland
Erie LP Holding LLCDelaware
Erie Luxembourg LLCDelaware
Erie N10 LLCDelaware
Erie N2 LLCDelaware
Erie N2 UK LimitedEngland
Erie Scientific Company of Puerto RicoDelaware
Erie Scientific Hungary Ipari és Szolgáltató KftHungary
Erie Scientific LLCDelaware
Erie U.K. LimitedEngland
Erie UK 1 Limited                           England
Erie UK 1 LLCDelaware
Erie UK 2 LimitedEngland
Erie UK 3 LimitedEngland
Erie UK 4 LimitedEngland
5

NAME
STATE OR JURISDICTION OF ORGANIZATION
Erie UK 5 LimitedEngland
Erie UK 6 LimitedEngland
Erie UK Holding CompanyDelaware
Erie UK Senior Holding LimitedEngland
Erie US II LLCDelaware
Erie US III LLCDelaware
European Laboratory Holdings LimitedIreland
Eutech Instruments Pte Ltd.Singapore
Ever Ready Thermometer Co., Inc.Wisconsin
Evidera Access Consulting LtdEngland
Evidera Holdings LtdEngland
Evidera LtdEngland
Evidera, Inc.Delaware
Excel PharmaStudies Inc.Cayman Islands
FB2 Blocker, LLCDelaware
FEI Asia Pacific Co., Ltd.China
FEI Australia Pty LtdAustralia
FEI CompanyOregon
FEI Company Japan Ltd.Japan
FEI Company of USA (S.E.A.) Pte Ltd.Singapore
FEI CPD B.V.Netherlands
FEI Deutschland GmbHGermany
FEI EFA International Pte. Ltd.Singapore
FEI EFA, Inc.Delaware
FEI Electron Optics B.V.Netherlands
FEI Electron Optics International B.V.Netherlands
FEI Europe B.V.Netherlands
FEI France SASFrance
FEI Hong Kong Company LimitedHong Kong
FEI Houston, Inc.Delaware
FEI Italia SrlItaly
FEI Korea Ltd.Korea
6

NAME
STATE OR JURISDICTION OF ORGANIZATION
FEI Melbourne Pty Ltd.Australia
FEI Microscopy Solutions LtdIsrael
FEI SASFrance
FEI Saudi Arabia LLCSaudi Arabia
FEI Technologies, Inc.Oregon
FEI Technology de Mexico S.A. de C.V.Mexico
FEI Trading (Shanghai) Co., Ltd.China
FEI UK LimitedEngland
Fermentas China Co., LtdChina
Fermentas Inc.Maryland
FHP LLCDelaware
Fiberlite Centrifuge LLCDelaware
Finesse Scientific Equipment (Shanghai) Co., Ltd.China
Finesse Solutions, Inc.Delaware
Fisher Alder S. de R.L. de C.V.Mexico
Fisher Bermuda Holdings LimitedBermuda
Fisher Bioblock Holding II SNCFrance
Fisher BioPharma Services (India) Private Limited
India
Fisher BioSciences Japan G.K.Japan
Fisher BioServices Inc.Virginia
Fisher Bioservices Netherlands B.V.Netherlands
Fisher Canada Holding ULC 1Canada
Fisher Canada Holding ULC 2Canada
Fisher Canada Holding ULC 3
Canada
Fisher Clinical Logistics LLCDelaware
Fisher Clinical Services (Beijing) Co., Ltd.China
Fisher Clinical Services (Bristol), LLCDelaware
Fisher Clinical Services (Colombia) LLCDelaware
Fisher Clinical Services (Korea) Co., LtdKorea
Fisher Clinical Services (Mexico) LLCDelaware
Fisher Clinical Services (Peru) LLCDelaware
Fisher Clinical Services (Suzhou) Co., Ltd.China
7

NAME
STATE OR JURISDICTION OF ORGANIZATION
Fisher Clinical Services Colombia S.A.S.Colombia
Fisher Clinical Services GmbHGermany
Fisher Clinical Services GmbHSwitzerland
Fisher Clinical Services Inc.Pennsylvania
Fisher Clinical Services Japan K.K.Japan
Fisher Clinical Services Latin America S.R.L.Argentina
Fisher Clinical Services Limited Liability CompanyRussia
Fisher Clinical Services Mexico, S. de R.L. de C.V.
Mexico
Fisher Clinical Services Peru S.R.LPeru
Fisher Clinical Services Pte Ltd.Singapore
Fisher Clinical Services Rheinfelden GmbHGermany
Fisher Clinical Services U.K. LimitedEngland
Fisher CLP Holding Limited PartnershipCanada
Fisher Emergo B.V.Netherlands
Fisher Hamilton China Inc.Delaware
Fisher Hamilton Mexico LLCDelaware
Fisher Internet Minority Holdings L.L.C.Delaware
Fisher Luxembourg Danish Holdings SARLLuxembourg
Fisher Manufacturing (Malaysia) Sdn BhdMalaysia
Fisher Maybridge Holdings LimitedEngland
Fisher Mexico, S. de R.L. de C.V.Mexico
Fisher Scientific (Austria) GmbHAustria
Fisher Scientific (Hong Kong) LimitedHong Kong
Fisher Scientific (M) Sdn BhdMalaysia
Fisher Scientific (SEA) Pte. Ltd.Singapore
Fisher Scientific A/SNorway
Fisher Scientific AGSwitzerland
Fisher Scientific Australia Pty LimitedAustralia
Fisher Scientific Biotech Line ApSDenmark
Fisher Scientific Brazil Inc.Delaware
Fisher Scientific Central America Inc.Delaware
Fisher Scientific Chile Inc.Delaware
8

NAME
STATE OR JURISDICTION OF ORGANIZATION
Fisher Scientific Colombia Inc.Delaware
Fisher Scientific CompanyCanada
Fisher Scientific Company L.L.C.Delaware
Fisher Scientific Costa Rica Sociedad de Responsabilidad LimitadaCosta Rica
Fisher Scientific de Mexico S.A.Mexico
Fisher Scientific Europe Holdings B.V.Netherlands
Fisher Scientific Germany Beteiligungs GmbHGermany
Fisher Scientific GmbHGermany
Fisher Scientific GTF ABSweden
Fisher Scientific Holding Company LLCDelaware
Fisher Scientific Holding HK LimitedHong Kong
Fisher Scientific Holding U.K., LimitedEngland
Fisher Scientific Holdings (S) Pte LtdSingapore
Fisher Scientific International LLCDelaware
Fisher Scientific Investments (Cayman), Ltd.Cayman Islands
Fisher Scientific Ireland Investments UnlimitedIreland
Fisher Scientific Ireland LimitedIreland
Fisher Scientific Japan, Ltd.Japan
Fisher Scientific Jersey Island LimitedJersey
Fisher Scientific Korea LtdKorea
Fisher Scientific Latin America Inc.Delaware
Fisher Scientific Luxembourg S.a.r.l.Luxembourg
Fisher Scientific Mexicana, S. de R.L. de C.V.Mexico
Fisher Scientific Mexico Inc.Delaware
Fisher Scientific Middle East and Africa Inc.Delaware
Fisher Scientific Norway ASNorway
Fisher Scientific Operating CompanyDelaware
Fisher Scientific Oxoid Holdings Ltd.England
Fisher Scientific OyFinland
Fisher Scientific Pte. Ltd.Singapore
Fisher Scientific S.A.S.France
Fisher Scientific S.L.Spain
9

NAME
STATE OR JURISDICTION OF ORGANIZATION
Fisher Scientific SRLBelgium
Fisher Scientific The Hague II B.V.Netherlands
Fisher Scientific The Hague III B.V.Netherlands
Fisher Scientific The Hague V B.V.Netherlands
Fisher Scientific U.K., LimitedEngland
Fisher Scientific UK Holding Company 2England
Fisher Scientific UK Holding Company LimitedEngland
Fisher Scientific Venezuela Inc.Delaware
Fisher Scientific Worldwide (Shanghai) Co., Ltd.China
Fisher Scientific Worldwide Holdings I C.V.Netherlands
Fisher Scientific Worldwide Inc.Delaware
Fisher Scientific, spol. S.r.o
Czech Republic
Fisher Scientific, Unipessoal, Lda.Portugal
Fisher Servicios Clinicos (Chile) LLCDelaware
Fisher Servicios Clinicos Chile LtdaChile
Fisher Worldwide Gene Distribution SPVCayman Islands
Fisher WWD Holding L.L.C.Delaware
FRC Holding Inc., VDelaware
FS Casa Rocas Holdings LLCDelaware
FS Mexicana Holdings LLCDelaware
FSI Receivables Company LLCDelaware
FSII Sweden Holdings ABSweden
FSII Sweden Holdings I ABSweden
FSII Sweden Holdings II ABSweden
FSIR Holdings (UK) LimitedEngland
FSIR Holdings (US) Inc.Delaware
FSUK Holdings LimitedEngland
FSWH Company LLCDelaware
FSWH I LLCDelaware
FSWH II LLCDelaware
FSWH International Holdings LLCDelaware
Fuji PartnershipJapan
10

NAME
STATE OR JURISDICTION OF ORGANIZATION
G & M Procter LimitedScotland
G V Instruments LimitedEngland
General Scientific Company Sdn Bhd (M)Malaysia
Ginkgo Parc SABelgium
Gold Cattle Standard Testing Labs, Inc.Texas
Golden West Indemnity Company LimitedBermuda
Goring Kerr Detection LimitedEngland
Greenbird LimitedCyprus
GV Instruments IncDelaware
Hangar 215, Inc.Delaware
Health iQ LimitedEngland
HealthUnlocked Holdings LimitedEngland
Helmet Securities LimitedEngland
Henogen SRLBelgium
HighChem s.r.o.Slovakia
Hybaid LimitedEngland
HyClone International Trade (Tianjin) Co., LtdChina
I.Q. (BIO) LimitedEngland
Indigo Merger Subsidiary Inc.Delaware
Inel Inc.Delaware
Inel SASFrance
InnaPhase LimitedEngland
IntegenX LtdEngland
IntegenX, Inc.California
Intrinsic BioProbes, Inc.Arizona
Invitrogen (Shanghai) Investment Co., Ltd.China
Invitrogen Argentina SAArgentina
Invitrogen BioServices India Private LimitedIndia
Invitrogen Europe LimitedScotland
Invitrogen Finance CorporationDelaware
Invitrogen Holdings LimitedScotland
Invitrogen Holdings LLCDelaware
11

NAME
STATE OR JURISDICTION OF ORGANIZATION
Invitrogen Hong Kong LimitedHong Kong
Invitrogen IP Holdings, Inc.Delaware
Invitrogen Trading (Shanghai) Co., Ltd.China
Ion Torrent Systems, Inc.Delaware
Jaguar (Barbados) Finance SRLBarbados
Jaguar Holding Company I, LLCDelaware
Jaguar Holding Company IIDelaware
Jouan LimitedEngland
Jouan LLCDelaware
Kendro Containment & Services LimitedEngland
Kendro Laboratory Products LtdEngland
Kettlebrook Insurance Co. ltd.Hawaii
Kyle Jordan Investments LLCDelaware
Lab-Chrom-Pack LLCNew York
Lab-Line Instruments, Inc.Delaware
Labomex MBP, S. de R. L. De C.V.Mexico
Laboratoire Service International - L.S.IFrance
Laboratory Management Systems, Inc.Delaware
Laboratory Specialties Proprietary Ltd.South Africa
LambTrack LimitedEngland
La-Pha-Pack GmbHGermany
Laser Analytical Systems, Inc.California
Liberty Lane Investment LLCDelaware
Liberty Lane Real Estate Holding Company LLCDelaware
Life Sciences International Holdings BVNetherlands
Life Sciences International LimitedEngland
Life Sciences International LLCDelaware
Life Technologies ASNorway
Life Technologies BPD UK LimitedEngland
Life Technologies Brasil Comercio e Industria de Produtos para Biotecnologia LtdaBrazil
Life Technologies Chile SpAChile
Life Technologies Clinical Services Lab, Inc.Delaware
12

NAME
STATE OR JURISDICTION OF ORGANIZATION
Life Technologies Co., Ltd.Taiwan
Life Technologies CorporationDelaware
Life Technologies Czech Republic s.r.o.Czech Republic
Life Technologies Europe B.V.Netherlands
Life Technologies Finance Ltd.Scotland
Life Technologies GmbHGermany
Life Technologies Holdings PTE Ltd.Singapore
Life Technologies Inc.Canada
Life Technologies Japan Ltd.Japan
Life Technologies LimitedScotland
Life Technologies LimitedHong Kong
Life Technologies Magyarorszag KftHungary
Life Technologies Norway Investments US LLCDelaware
Life Technologies Polska Sp z.o.o.Poland
Life Technologies s.r.oSlovakia
Life Technologies SASpain
Life Technologies SASFrance
Limited Liability Company Contract Research Organisation InnopharmUkraine
Limited Liability Company PPD Development (Smolensk)Russia
LLC PPD UkraineUkraine
Loftus Furnace CompanyPennsylvania
Lomb Scientific (Aust) Pty LimitedAustralia
LTC Tech South Africa PTY Ltd.South Africa
Marketbase International LimitedHong Kong
MarqMetrix, IncWashington
Matrix MicroScience Inc.Delaware
Matrix Microscience LimitedEngland
Matrix Technologies Corporation LimitedEngland
Matrix Technologies LLCDelaware
Maybridge Chemical Holdings LimitedEngland
Maybridge LimitedEngland
Medical Analysis Systems International, Inc.California
13

NAME
STATE OR JURISDICTION OF ORGANIZATION
Medical Analysis Systems, Inc.Delaware
Medical Centre Synexus Sofia EOODBulgaria
Medical Diagnostics Systems, Inc.California
MediciGroup, Inc.Pennsylvania
Medimix Latam Pesquisa de Mercado LtdaBrazil
Mesa Biotech LLCDelaware
Metavac LLCDelaware
Microgenics B.V. & Co. KGGermany
Microgenics CorporationDelaware
MLS ACQ, Inc.Delaware
Molecular BioProducts, Inc.California
Molecular Probes, Inc.Oregon
Molecular Transfer, Inc.Delaware
Nalge Nunc International (Monterrey) LLCDelaware
Nalge Nunc International CorporationDelaware
NanoDrop Technologies LLCDelaware
NAPCO, Inc.Connecticut
National Scientific CompanyWisconsin
Navaho Acquisition Corp.Delaware
NERL Diagnostics LLCWisconsin
NeuroHealth, Inc.Florida
New FS Holdings Inc.Delaware
NewcoGen PE, LLCDelaware
Niton Asia LimitedHong Kong
NovaWave Technologies, Inc.California
Nunc A/SDenmark
Odyssey Holdings CorporationDelaware
Odyssey Holdings LLCDelaware
Odyssey Luxembourg IP Holdings 1 S.à r.l.Luxembourg
Odyssey Luxembourg IP Holdings 2 S.à r.l.Luxembourg
Odyssey Venture CorporationDelaware
Oncomine India Private LimitedIndia
14

NAME
STATE OR JURISDICTION OF ORGANIZATION
Oncomine K.K.Japan
Oncomine LimitedEngland
Oncomine LLCDelaware
Oncomine Molecular Inc.Delaware
Oncomine Molecular, S.LSpain
Oncomine Pte. LtdSingapore
Oncomine S.r.lItaly
Oncomine ULCCanada
One Lambda, IncCalifornia
Onix Holdings LimitedEngland
ONIX Systems Inc.Delaware
Optimal Research, LLCMaryland
Orion Acquisition ABSweden
Owl Separation Systems LLCWisconsin
Oxoid (ELY) LimitedEngland
Oxoid 2000 LimitedEngland
Oxoid Australia Pty. LimitedAustralia
Oxoid CompanyCanada
Oxoid Deutschland GmbHGermany
Oxoid Holding SASFrance
Oxoid Holdings LimitedEngland
Oxoid Inc.Delaware
Oxoid International LimitedEngland
Oxoid Investments GmbHGermany
Oxoid LimitedEngland
Oxoid LimitedIreland
Oxoid NVBelgium
Oxoid Pension Trustees LimitedEngland
Oxoid Senior Holdings LimitedEngland
Oxoid UKH LLCDelaware
Pacific Rim Far East Industries LLCDelaware
Pacific Rim Investment, LLCDelaware
15

NAME
STATE OR JURISDICTION OF ORGANIZATION
Panomics, L.L.C.California
Pasteur U.S. CorporationDelaware
Patheon API Inc.South Carolina
Patheon API Manufacturing Inc.South Carolina
Patheon API Services Inc.South Carolina
Patheon Austria GmbH & Co. KGAustria
Patheon B.V.
Netherlands
Patheon Banner U.S. Holdings Inc.Delaware
Patheon Biologics (NJ) LLCDelaware
Patheon Biologics Australia Pty LtdAustralia
Patheon Biologics B.V.Netherlands
Patheon Biologics LLCDelaware
Patheon Calculus Merger LLCDelaware
Patheon Development Services Inc.Delaware
Patheon France SASFrance
Patheon Holdings B.V.Netherlands
Patheon Holdings I B.V.Netherlands
Patheon Holdings II B.V.Netherlands
Patheon Holdings SASFrance
Patheon I B.V.Netherlands
Patheon I Holding GmbHAustria
Patheon Inc.Canada
Patheon Italia S.p.A.Italy
Patheon KKJapan
Patheon Life Science Products International GmbHAustria
Patheon Logistics Switzerland GmbHSwitzerland
Patheon Manufacturing Services LLCDelaware
Patheon Pharmaceuticals Inc.Delaware
Patheon Pharmaceuticals Services Inc.Delaware
Patheon Puerto Rico Acquisitions CorporationPuerto Rico
Patheon Puerto Rico, Inc.Puerto Rico
Patheon Regensburg GmbHGermany
16

NAME
STATE OR JURISDICTION OF ORGANIZATION
Patheon Softgels B.V.Netherlands
Patheon Softgels Inc.Delaware
Patheon U.S. Holdings Inc.Delaware
Patheon U.S. Holdings LLCDelaware
Patheon UK LimitedEngland
Patheon UK Pension Trustees LimitedEngland
PAX – DSI Acquisition LLCDelaware
Pelican Acquisition CorporationDelaware
PeproTech Asia LtdIsrael
PeproTech BioTech (Suzhou) Co., Ltd.China
PeproTech EC Ltd.England
PeproTech FranceFrance
PeproTech GmbHGermany
PeproTech KoreaKorea
PeproTech, Inc.New Jersey
Perbio Science (Canada) CompanyCanada
Perbio Science ABSweden
Perbio Science France SASFrance
Perbio Science International Netherlands B.V.Netherlands
Perbio Science Sweden Holdings ABSweden
Perbio Science UK LimitedEngland
Perbio Science, Inc.Delaware
Percivia LLCDelaware
Phadia ABSweden
Phadia Diagnosticos LtdaBrazil
Phadia GmbHGermany
Phadia Holding ABSweden
Phadia International Holdings LPEngland
Phadia International LLCDelaware
Phadia Real Property ABSweden
Phadia s.r.o.Czech Republic
Phadia Taiwan Inc.Taiwan
17

NAME
STATE OR JURISDICTION OF ORGANIZATION
Phadia US Inc.Delaware
Phadia US Market Holdings LLCDelaware
Pharmacaps Mexicana S.A. de C.V.Mexico
Pharmaceutical Product Development South Africa (Proprietary) LtdSouth Africa
Pharmaceutical Product Development Spain SLSpain
Pharmaceutical Product Development, LLCDelaware
Pharmaco Investments, Inc.Delaware
PharmaFluidics NVBelgium
Phitonex, Inc.North Carolina
picoSpin, LLCColorado
Pierce Biotechnology, Inc.Delaware
Pierce Milwaukee Holding Corp.Delaware
Pierce Milwaukee, Inc.Delaware
Power Sweden Holdings I ABSweden
Power Sweden Holdings II ABSweden
PPD (Netherlands) B.V.Netherlands
PPD (Netherlands) LLCDelaware
PPD Aeronautics CorporationDelaware
PPD Aeronautics, LLCNorth Carolina
PPD Argentina S.A.Argentina
PPD Australia Pty LimitedAustralia
PPD Bulgaria EOODBulgaria
PPD CanadaCanada
PPD Colombia S.A.SColombia
PPD CT Investments LLPEngland
PPD Czech Republic S.R.O.Czech Republic
PPD Development (HK) LimitedHong Kong
PPD Development (S) Pte. Ltd.Singapore
PPD Development (Thailand) Co., Ltd.Thailand
PPD Development Ireland LimitedIreland
PPD Development, L.P.Delaware
PPD do Brasil- Suporte a Pesquisa Clinica LtdBrazil
18

NAME
STATE OR JURISDICTION OF ORGANIZATION
PPD France SASFrance
PPD Germany GmbHGermany
PPD Germany GmbH & Co. KGGermany
PPD Global Central Labs (S) Pte. Ltd.Singapore
PPD Global Central Labs BVBelgium
PPD Global Central Labs, LLCKentucky
PPD Global Ltd.England
PPD GP, LLCDelaware
PPD Holdings, LLCDelaware
PPD Hrvatska d.o.o.Croatia
PPD Hungary Research and Development Ltd.Hungary
PPD International Holdings (UK) LtdEngland
PPD International Holdings GmbHGermany
PPD International Holdings, Inc. y Compania LimitadaChile
PPD International Holdings, LLCDelaware
PPD International Investments LimitedEngland
PPD Investigator Services, LLCDelaware
PPD Italy S.r.lItaly
PPD Laboratories (Suzhou) Co., Ltd.
China
PPD Latvia SIALatvia
PPD Mexico S.A. de C.V.Mexico
PPD Netherlands International LLCDelaware
PPD Peru S.A.C.Peru
PPD Pharmaceutical Development (Beijing) Co., Ltd.China
PPD Pharmaceutical Development India Private LimitedIndia
PPD Pharmaceutical Development Japan K.K.Japan
PPD Pharmaceutical Development Philippines Corp.Philippines
PPD Pharmaceutical Development Vietnam Company LimitedVietnam
PPD Poland Sp.Z o.o.Poland
PPD Romania SRLRomania
PPD Scandinavia ABSweden
PPD Serbia D.O.O. BeogradSerbia
19

NAME
STATE OR JURISDICTION OF ORGANIZATION
PPD Services, Inc.North Carolina
PPD Slovak Republic s.r.o.Slovak Republic
PPD Switzerland GmbHSwitzerland
PPD UK Holdings LimitedEngland
PPD Vaccines and Biologics, LLCPennsylvania
PPD, Inc.Delaware
PPD-SNBL K.K.Japan
Pregistry Holdings LimitedEngland
Pregistry, LLCDelaware
Princeton Gamma-Tech Instruments LLCDelaware
Prionics France SASFrance
Prionics Lelystad B.V.Netherlands
Prionics USA Inc.Delaware
Priority Air Express Pte. Ltd.Singapore
Priority Air Express UK LimitedEngland
Priority Air Express, LLCDelaware
Priority Air Holdings CorpDelaware
Proxeon Biosystems ApSDenmark
Quebec B.V.Netherlands
Quebec Court B.V.Netherlands
Remel Europe LimitedEngland
Remel Inc.Wisconsin
REP GBP I-B Blocker, Inc.Delaware
River Ventures, LLCNorth Carolina
Robbins Scientific LLCCalifornia
Robocon Labor- und Industrieroboter Gesellschaft m.b.HAustria
S.C.I. du 10 rue Dugay TrouinFrance
Samco Scientific (Monterrey) LLCDelaware
Samco Scientific LLC
Delaware
Saroph Sweden ABSweden
Schantz Road LLCPennsylvania
SCI Inno 92France
20

NAME
STATE OR JURISDICTION OF ORGANIZATION
Seradyn Inc.
Delaware
Shanghai Life Technologies Biotechnology Co. LimitedChina
Shanghai Thermo Fisher (C-I) Trading Co. LtdChina
Shanghai Thermo Fisher (S) Trading Co. LtdChina
Shorecloud CorporationPhilippines
Southern Trials (Pty) Ltd.South Africa
Specialty (SMI) Inc.California
Spectra-Physics AB
Sweden
Spectra-Physics Holdings LimitedEngland
Spectra-Physics Holdings USA, LLCDelaware
Staten Island Cogeneration CorporationNew York
STC Bio Manufacturing, Inc.Illinois
Sterilin LimitedEngland
Stokes Bio Ltd.Ireland
SwissAnalytic Group GmbHSwitzerland
Synexus Bulgaria EOODBulgaria
Synexus Clinical Research Acquisitions LimitedEngland
Synexus Clinical Research GmbHGermany
Synexus Clinical Research LimitedEngland
Synexus Clinical Research Midco No1 LimitedEngland
Synexus Clinical Research South Africa (Pty) LimitedSouth Africa
Synexus Clinical Research Topco LimitedEngland
Synexus Clinical Research US, Inc.Arizona
Synexus Compass, Inc. (fmr. Synarc Inc.)Delaware
Synexus Czech s.r.o.Czech Republic
Synexus LimitedEngland
Synexus Magyarorszg Egszsggyi Szolgltat Korltolt Felelssg TrsasgHungary
Synexus Polska Sp. Z o.oPoland
Synexus Ukraine Limited Liability CompanyUkraine
SystemLink, Inc.Virginia
Systems Manufacturing CorporationDelaware
TBS Howard Hill LLCVermont
21

NAME
STATE OR JURISDICTION OF ORGANIZATION
Technology Design Solutions Pty LtdAustralia
TFLP LLCDelaware
TFS (Barbados) I SrlBarbados
TFS Brammer Holding CorporationDelaware
TFS Breda B.V.Netherlands
TFS FEI Holding LLCDelaware
TFS Group Holding I LLCDelaware
TFS Group Holding II LLCDelaware
TFS Group Holdings III LLCDelaware
TFS Group Holdings IV LLC
Delaware
TFS Life Holding LLCDelaware
TFS LLCMassachusetts
TFS Singapore HK LimitedHong Kong
TFS Venture Holdings I LLCDelaware
TFS Venture Holdings III S.C.S.Luxembourg
The Binding Site Benelux BVBelgium
The Binding Site Brasil Comercio De Produtos Para Laboratorio Ltda.Brazil
The Binding Site Corporation LimitedEngland
The Binding Site Denmark ApSDenmark
The Binding Site France SASFrance
The Binding Site GmbHGermany
The Binding Site Group (Shanghai) Trading Co., Ltd.China
The Binding Site Group LimitedEngland
The Binding Site Group LimitedJordan
The Binding Site Holding GmbHGermany
The Binding Site Holding Inc.Delaware
The Binding Site Ireland LimitedIreland
The Binding Site KKJapan
The Binding Site LimitedNew Zealand
The Binding Site Portugal, Specialist Protein Company, Unip LdaPortugal
The Binding Site Pte Ltd.Singapore
The Binding Site Pty LimitedAustralia
22

NAME
STATE OR JURISDICTION OF ORGANIZATION
The Binding Site S. de R.L. de C.V.Mexico
The Binding Site S.r.l.Italy
The Binding Site s.r.o.Czech Republic
The Binding Site Spain (Specialist Protein Company) S.L.Spain
The Binding Site VT, Inc.Vermont
The Binding Site, Inc.California
The Compass Clinic, LLCFlorida
The Nettleton Gate LimitedEngland
The Thermo Fisher Scientific Phambili TrustSouth Africa
Thermedics Detection de Argentina S.R.LArgentina
Thermo Asset Management Services Inc.Delaware
Thermo BioAnalysis LimitedEngland
Thermo BioAnalysis LLCDelaware
Thermo BioSciences Holdings LLCDelaware
Thermo Cambridge LimitedEngland
Thermo Cayman Holdings Ltd.Cayman Islands
Thermo CIDTEC Inc.New York
Thermo CN Luxembourg LLCDelaware
Thermo CorporationDelaware
Thermo CRS Holdings Ltd.Canada
Thermo CRS Ltd.Canada
Thermo Detection de Mexico S. de R.L. de C.V.Mexico
Thermo DMA Inc.Texas
Thermo Eberline Holdings I LLCDelaware
Thermo Eberline Holdings II LLCDelaware
Thermo Eberline LLCDelaware
Thermo EGS Gauging LLCDelaware
Thermo Electron (Calgary) LimitedCanada
Thermo Electron (Chile) S.p.A.Chile
Thermo Electron (Karlsruhe) GmbHGermany
Thermo Electron (Management Services) LimitedEngland
Thermo Electron (Proprietary) LimitedSouth Africa
23

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo Electron A/SDenmark
Thermo Electron Australia Pty LimitedAustralia
Thermo Electron Export Inc.Barbados
Thermo Electron Holdings SASFrance
Thermo Electron IndustriesFrance
Thermo Electron LED GmbHGermany
Thermo Electron LED S.A.S.France
Thermo Electron LimitedEngland
Thermo Electron Manufacturing LimitedEngland
Thermo Electron Metallurgical Services, Inc.Texas
Thermo Electron North America LLCDelaware
Thermo Electron Pension Trust GmbHGermany
Thermo Electron Puerto Rico, Inc.Puerto Rico
Thermo Electron SASFrance
Thermo Electron Scientific Instruments LLCDelaware
Thermo Electron Sweden ABSweden
Thermo Electron Sweden Forvaltning AB
Sweden
Thermo Electron Weighing & Inspection LimitedEngland
Thermo Environmental Instruments LLCCalifornia
Thermo Finland Holdings MT1 B.V.Netherlands
Thermo Finland Holdings MT2 B.V.Netherlands
Thermo Finnigan LLCDelaware
Thermo Fisher (Cayman) Holdings I Ltd.Cayman Islands
Thermo Fisher (Cayman) Holdings II Ltd.Cayman Islands
Thermo Fisher (China) Analytical Ltd.China
Thermo Fisher (CN) Luxembourg Holding S.a.r.l.
[Domesticated in the State of Delaware under the name of Thermo Fisher (CN) Luxembourg Holding S.a.r.l. LLC]
Luxembourg
Thermo Fisher (CN) Luxembourg S.a.r.l.Luxembourg
Thermo Fisher (CN) Malta Holdings LimitedMalta
Thermo Fisher (CN-I) Luxembourg LLCDelaware
Thermo Fisher (CN-II) Luxembourg LLCDelaware
Thermo Fisher (FEI) Ireland LtdIreland
Thermo Fisher (Gibraltar) II LimitedGibraltar
24

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher (Gibraltar) LimitedGibraltar
Thermo Fisher (Heysham) LimitedEngland
Thermo Fisher (Kandel) GmbHGermany
Thermo Fisher Biopharma Services (Hangzhou) Ltd.China
Thermo Fisher Biopharma Services Pte. Ltd.Singapore
Thermo Fisher Bioprocessing Research and Development (Shanghai) Co., Ltd.China
Thermo Fisher China Business TrustChina
Thermo Fisher CHK Holding LLCDelaware
Thermo Fisher Clinical Switzerland Holding LLCDelaware
Thermo Fisher CM II LLCDelaware
Thermo Fisher Detection Mexico LLCDelaware
Thermo Fisher Diagnostics (Ireland) LimitedIreland
Thermo Fisher Diagnostics ABSweden
Thermo Fisher Diagnostics AGSwitzerland
Thermo Fisher Diagnostics ApsDenmark
Thermo Fisher Diagnostics ASNorway
Thermo Fisher Diagnostics Austria GmbHAustria
Thermo Fisher Diagnostics B.V.Netherlands
Thermo Fisher Diagnostics CZ s.r.o.Czech Republic
Thermo Fisher Diagnostics GmbHGermany
Thermo Fisher Diagnostics K.K.Japan
Thermo Fisher Diagnostics LimitedEngland
Thermo Fisher Diagnostics NVBelgium
Thermo Fisher Diagnostics OyFinland
Thermo Fisher Diagnostics S.p.A. Italy
Thermo Fisher Diagnostics SASFrance
Thermo Fisher Diagnostics sp. z o.oPoland
Thermo Fisher Diagnostics, S.L.U.Spain
Thermo Fisher Diagnostics, Sociedade Unipessoal LdaPortugal
Thermo Fisher Electronic Technology Research and Development (Shanghai) Co., LtdChina
Thermo Fisher Eurobonds Ltd.Cayman Islands
Thermo Fisher Financial Services B.V.Netherlands
25

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Financial Services Inc.Delaware
Thermo Fisher German Holdings LLCDelaware
Thermo Fisher Germany B.V.Netherlands
Thermo Fisher GP LLCDelaware
Thermo Fisher India Holding B.V.Netherlands
Thermo Fisher Insurance Holdings Inc.Delaware
Thermo Fisher Insurance Holdings LLCDelaware
Thermo Fisher Investments (Cayman) LLCDelaware
Thermo Fisher Investments (Cayman) Ltd.Cayman Islands
Thermo Fisher Israel Ltd.Israel
Thermo Fisher Project Cyprus LLCDelaware
Thermo Fisher RE I CorporationDelaware
Thermo Fisher RE II CorporationDelaware
Thermo Fisher Scientific (Asheville) LLCDelaware
Thermo Fisher Scientific (Breda) Holding BVNetherlands
Thermo Fisher Scientific (Bremen) GmbHGermany
Thermo Fisher Scientific (Cayman) LLCDelaware
Thermo Fisher Scientific (CH EQ) LLCDelaware
Thermo Fisher Scientific (CH) 1 LLCDelaware
Thermo Fisher Scientific (CH) 2 LLCDelaware
Thermo Fisher Scientific (China) Co., Ltd.
China
Thermo Fisher Scientific (China) Holding LimitedEngland
Thermo Fisher Scientific (China-HK) Holding LimitedHong Kong
Thermo Fisher Scientific (CP1) LimitedEngland
Thermo Fisher Scientific (CP2) LimitedEngland
Thermo Fisher Scientific (DE) Holding S.a.r.l.Luxembourg
Thermo Fisher Scientific (DPI) Limited PartnershipCanada
Thermo Fisher Scientific (Ecublens) SARLSwitzerland
Thermo Fisher Scientific (FCS) Holding LLCDelaware
Thermo Fisher Scientific (Finance I) B.V.Netherlands
Thermo Fisher Scientific (Finance I) S.a.r.l.Luxembourg
Thermo Fisher Scientific (Finance II) S.a.r.l.Luxembourg
26

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific (Finance III) LLCDelaware
Thermo Fisher Scientific (Finance III) S.a.r.l.Luxembourg
Thermo Fisher Scientific (Fuji) LLCDelaware
Thermo Fisher Scientific (Guangzhou) Biotechnology Co., Ltd.China
Thermo Fisher Scientific (Guangzhou) Co., Ltd  China
Thermo Fisher Scientific (Holding II) B.V. & Co. KGGermany
Thermo Fisher Scientific (Hong Kong) LimitedHong Kong
Thermo Fisher Scientific (IVGN) B.V.Netherlands
Thermo Fisher Scientific (IVGN) Holding LLCDelaware
Thermo Fisher Scientific (IVGN) LimitedHong Kong
Thermo Fisher Scientific (IVGN) Luxembourg S.a.r.l.Luxembourg
Thermo Fisher Scientific (Johannesburg) (Proprietary) LimitedSouth Africa
Thermo Fisher Scientific (Luxembourg) II Holdings S.a.r.l.Luxembourg
Thermo Fisher Scientific (Luxembourg) II S.a.r.l.Luxembourg
Thermo Fisher Scientific (Mexico City) LLCDelaware
Thermo Fisher Scientific (Milwaukee) LLCDelaware
Thermo Fisher Scientific (Mississauga) Inc.Canada
Thermo Fisher Scientific (Monterrey), S. De R.L. De C.V.Mexico
Thermo Fisher Scientific (NK) LLCDelaware
Thermo Fisher Scientific (OLI) 1 LimitedEngland
Thermo Fisher Scientific (OLI) 2 LimitedEngland
Thermo Fisher Scientific (OLI) 3 LimitedEngland
Thermo Fisher Scientific (OLI) 3 LLCDelaware
Thermo Fisher Scientific (OLI) LimitedEngland
Thermo Fisher Scientific (OLI) LLCDelaware
Thermo Fisher Scientific (OLI) LPCanada
Thermo Fisher Scientific (OLI) UK Limited
England
Thermo Fisher Scientific (Panama) B.V.Netherlands
Thermo Fisher Scientific (Panama) Dutch LLCDelaware
Thermo Fisher Scientific (Panama) II B.V.Netherlands
Thermo Fisher Scientific (PN) UK Limited PartnershipEngland
Thermo Fisher Scientific (PN) UK LLCDelaware
27

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific (PN1) UK LtdEngland
Thermo Fisher Scientific (PN-I) SRLBarbados
Thermo Fisher Scientific (PN-II) SRLBarbados
Thermo Fisher Scientific (PN-III) SRLBarbados
Thermo Fisher Scientific (Praha) s.r.o.Czech Republic
Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG
Germany
Thermo Fisher Scientific (Real Estate 1) S.a.r.l.Luxembourg
Thermo Fisher Scientific (Schweiz) AGSwitzerland
Thermo Fisher Scientific (Shanghai) Instruments Co., Ltd.China
Thermo Fisher Scientific (Shanghai) Management Co., Ltd.China
Thermo Fisher Scientific (Shanghai) Supply Chain Management Co., LtdChina
Thermo Fisher Scientific (Suzhou) Instruments Co., LtdChina
Thermo Fisher Scientific (Suzhou) Research and Development Co., Ltd.China
Thermo Fisher Scientific (Thailand) Co., Ltd.Thailand
Thermo Fisher Scientific Africa Proprietary LtdSouth Africa
Thermo Fisher Scientific AL-1 LLCDelaware
Thermo Fisher Scientific Aquasensors LLCDelaware
Thermo Fisher Scientific Asset Management 1 GmbHGermany
Thermo Fisher Scientific Asset Management 2 GmbHGermany
Thermo Fisher Scientific AU C.V.Netherlands
Thermo Fisher Scientific AU II Limited
England
Thermo Fisher Scientific AU LimitedEngland
Thermo Fisher Scientific AU LLCDelaware
Thermo Fisher Scientific Australia Pty LtdAustralia
Thermo Fisher Scientific B.V.Netherlands
Thermo Fisher Scientific Baltics UABLithuania
Thermo Fisher Scientific Beteiligungsverwaltungs GmbHGermany
Thermo Fisher Scientific BHK (I) LimitedHong Kong
Thermo Fisher Scientific BHK (II) LimitedHong Kong
Thermo Fisher Scientific Biosciences Corp.Canada
Thermo Fisher Scientific Blade I LimitedEngland
Thermo Fisher Scientific Blade II LimitedEngland
28

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific Blade III LimitedEngland
Thermo Fisher Scientific Blade IV LimitedEngland
Thermo Fisher Scientific Blade V LimitedEngland
Thermo Fisher Scientific Blade VI LimitedEngland
Thermo Fisher Scientific Blade VII LimitedEngland
Thermo Fisher Scientific BLG LimitedEngland
Thermo Fisher Scientific Brahms LLCDelaware
Thermo Fisher Scientific Brasil Instrumentos de Processo Ltda.Brazil
Thermo Fisher Scientific Brasil Serviços de Logística LtdaBrazil
Thermo Fisher Scientific Brno s.r.o.Czech Republic
Thermo Fisher Scientific Brussels BVBelgium
Thermo Fisher Scientific BVBelgium
Thermo Fisher Scientific C.F. GmbHGermany
Thermo Fisher Scientific C.V.Netherlands
Thermo Fisher Scientific Canada Financing 1 ULCCanada
Thermo Fisher Scientific Canada Financing 2 ULCCanada
Thermo Fisher Scientific Canada Holdings LLCDelaware
Thermo Fisher Scientific Cayman Investments LLCDelaware
Thermo Fisher Scientific Chemicals Inc.Delaware
Thermo Fisher Scientific China (C-I) LLCDelaware
Thermo Fisher Scientific China (S) LLCDelaware
Thermo Fisher Scientific China Holdings I B.V.Netherlands
Thermo Fisher Scientific China Holdings II B.V.Netherlands
Thermo Fisher Scientific China Holdings III B.V.Netherlands
Thermo Fisher Scientific China Holdings IV B.V.Netherlands
Thermo Fisher Scientific CHK Senior Holdings LLCDelaware
Thermo Fisher Scientific CHN Holding LimitedEngland
Thermo Fisher Scientific Chromatography Holdings ApsDenmark
Thermo Fisher Scientific Chromatography Holdings S.à r.l.Luxembourg
Thermo Fisher Scientific Clinical Services Ireland LimitedIreland
Thermo Fisher Scientific CMN LLCDelaware
Thermo Fisher Scientific CN Holding LLCDelaware
29

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific Colombia S.A.S.Colombia
Thermo Fisher Scientific Cork LtdIreland
Thermo Fisher Scientific Cyprus I LtdCayman Islands
Thermo Fisher Scientific Cyprus II LtdCayman Islands
Thermo Fisher Scientific Cyprus III LtdCayman Islands
Thermo Fisher Scientific Denmark Senior Holdings ApSDenmark
Thermo Fisher Scientific Dutch Holdings B.V.Netherlands
Thermo Fisher Scientific Dutch Holdings II B.V.Netherlands
Thermo Fisher Scientific Dutch Senior Holdings B.V.Netherlands
Thermo Fisher Scientific eCommerce Solutions, LLC Delaware
Thermo Fisher Scientific EMEA LimitedIreland
Thermo Fisher Scientific Erie 1 Financing (Barbados) SRLBarbados
Thermo Fisher Scientific Erie Financing (Barbados) SRLBarbados
Thermo Fisher Scientific Erie Financing S.a r.lLuxembourg
Thermo Fisher Scientific Falcon Senior Holdings Inc.Delaware
Thermo Fisher Scientific FCS LimitedEngland
Thermo Fisher Scientific FCS Switzerland Holdings GmbHSwitzerland
Thermo Fisher Scientific Flagship I LLCDelaware
Thermo Fisher Scientific Flagship II LLCDelaware
Thermo Fisher Scientific FLC B.V.Netherlands
Thermo Fisher Scientific FLC Hong Kong LimitedHong Kong
Thermo Fisher Scientific FLC II B.V.
[Domesticated in the State of Delaware under the name of Thermo Fisher Scientific FLC II B.V.]
Netherlands
Thermo Fisher Scientific FLC LLCDelaware
Thermo Fisher Scientific FSIR Financing (Barbados) SRLBarbados
Thermo Fisher Scientific FSIR Financing S.a.r.l.Luxembourg
Thermo Fisher Scientific FSIR Holdings (UK) Financing LimitedEngland
Thermo Fisher Scientific FSUKHCO Financing (Barbados) SRL
Barbados
Thermo Fisher Scientific GCL LimitedEngland
Thermo Fisher Scientific GCL LLCDelaware
Thermo Fisher Scientific GCL2 LimitedDelaware
Thermo Fisher Scientific GENEART GmbHGermany
Thermo Fisher Scientific Germany BV & Co. KG
Germany
30

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific GmbHGermany
Thermo Fisher Scientific Holdings (Cayman) ICayman Islands
Thermo Fisher Scientific Holdings (Cayman) II Cayman Islands
Thermo Fisher Scientific Holdings Europe LimitedEngland
Thermo Fisher Scientific HR Services Mexico, S. de R.L. de C.V.Mexico
Thermo Fisher Scientific India Holding LLCDelaware
Thermo Fisher Scientific India Pvt LtdIndia
Thermo Fisher Scientific Investments (Luxembourg) II S.a.r.l.Luxembourg
Thermo Fisher Scientific Investments (Luxembourg) S.a.r.l.Luxembourg
Thermo Fisher Scientific Investments (Sweden) II LLCDelaware
Thermo Fisher Scientific Investments (Sweden) S.a.r.l.Luxembourg
Thermo Fisher Scientific Invitrogen Financing (Barbados) SRLBarbados
Thermo Fisher Scientific Invitrogen Holding 2 LLCDelaware
Thermo Fisher Scientific IT Services GmbHGermany
Thermo Fisher Scientific Japan 1 LLCDelaware
Thermo Fisher Scientific Japan 2 LLCDelaware
Thermo Fisher Scientific Japan Holdings I B.V.Netherlands
Thermo Fisher Scientific Japan Holdings I LLCDelaware
Thermo Fisher Scientific Japan Holdings I LPDelaware
Thermo Fisher Scientific Japan Holdings II B.V.Netherlands
Thermo Fisher Scientific Japan Holdings II LLCDelaware
Thermo Fisher Scientific Japan Holdings II LPDelaware
Thermo Fisher Scientific Japan Holdings III B.V.Netherlands
Thermo Fisher Scientific Japan Holdings III LLCDelaware
Thermo Fisher Scientific Japan Holdings IV LLC
Delaware
Thermo Fisher Scientific Japan Holdings V LLCDelaware
Thermo Fisher Scientific K.K.Japan
Thermo Fisher Scientific Korea Ltd.Korea
Thermo Fisher Scientific Life Canada Holding ULCCanada
Thermo Fisher Scientific Life Financing (Barbados) SRLBarbados
Thermo Fisher Scientific Life Financing (Cayman)Cayman Islands
Thermo Fisher Scientific Life Financing 2 LimitedEngland
31

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific Life Financing LimitedEngland
Thermo Fisher Scientific Life Holding MRP LLCDelaware
Thermo Fisher Scientific Life Holdings 1 LimitedEngland
Thermo Fisher Scientific Life Holdings 2 LimitedEngland
Thermo Fisher Scientific Life Holdings III C.V. LLCDelaware
Thermo Fisher Scientific Life Holdings LimitedEngland
Thermo Fisher Scientific Life International Holdings II LPEngland
Thermo Fisher Scientific Life Investments II S.à r.l.Luxembourg
Thermo Fisher Scientific Life Investments IV S.a.r.lLuxembourg
Thermo Fisher Scientific Life Investments US Financing I LLCDelaware
Thermo Fisher Scientific Life Investments US Financing II LLCDelaware
Thermo Fisher Scientific Life Sciences COE CorporationDelaware
Thermo Fisher Scientific Life Senior Holdings MRP LLCDelaware
Thermo Fisher Scientific Life Senior Holdings, Inc.Delaware
Thermo Fisher Scientific Life Tech Korea Holdings LLCDelaware
Thermo Fisher Scientific Life Technologies Enterprise Holding LimitedEngland
Thermo Fisher Scientific Life Technologies Investment I LLCDelaware
Thermo Fisher Scientific Life Technologies Investment II LLCDelaware
Thermo Fisher Scientific Life Technologies Investment UK I LimitedEngland
Thermo Fisher Scientific Life Technologies Investment UK II LimitedEngland
Thermo Fisher Scientific Life Technologies Israel Investment I LimitedEngland
Thermo Fisher Scientific Life Technologies Israel Investment II Limited
England
Thermo Fisher Scientific Life Technologies Luxembourg Holding LLCDelaware
Thermo Fisher Scientific Life UK Holdings 2 LPEngland
Thermo Fisher Scientific Life UK Holdings LPEngland
Thermo Fisher Scientific LSI Financing (Barbados) SRLBarbados
Thermo Fisher Scientific Luxembourg Enterprise Holdings S.à r.l.Luxembourg
Thermo Fisher Scientific Luxembourg German Holdings S.a.r.l.Luxembourg
Thermo Fisher Scientific Luxembourg Life Technologies UK Holding S.à r.lLuxembourg
Thermo Fisher Scientific Luxembourg Sweden Holdings I S.à r.lLuxembourg
Thermo Fisher Scientific Luxembourg Sweden Holdings II S.à r.l.Luxembourg
Thermo Fisher Scientific Luxembourg Venture Holdings I S.a.r.l.Luxembourg
32

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific Luxembourg Venture Holdings II S.a.r.l.
Luxembourg
Thermo Fisher Scientific Malaysia Sdn. Bhd.Malaysia
Thermo Fisher Scientific Matrix Holding LimitedEngland
Thermo Fisher Scientific Messtechnik GmbHGermany
Thermo Fisher Scientific Middle East Holdings Inc.Delaware
Thermo Fisher Scientific Milano SrlItaly
Thermo Fisher Scientific MRP 1 LLCDelaware
Thermo Fisher Scientific New Zealand HoldingsNew Zealand
Thermo Fisher Scientific New Zealand LimitedNew Zealand
Thermo Fisher Scientific NHK LimitedHong Kong
Thermo Fisher Scientific Norway Holdings ASNorway
Thermo Fisher Scientific Norway Senior Holding ASNorway
Thermo Fisher Scientific Norway US Investments LLC
Delaware
Thermo Fisher Scientific Odyssey Financing (Barbados) SRLBarbados
Thermo Fisher Scientific Odyssey Holding LLCDelaware
Thermo Fisher Scientific Odyssey Holdings LimitedEngland
Thermo Fisher Scientific One LimitedEngland
Thermo Fisher Scientific Operating Company LLCDelaware
Thermo Fisher Scientific OyFinland
Thermo Fisher Scientific Pakistan (Private) LimitedPakistan
Thermo Fisher Scientific Panama I Cayman LtdCayman Islands
Thermo Fisher Scientific Peprotech Holding LLCDelaware
Thermo Fisher Scientific Peru S.R.L.
Peru
Thermo Fisher Scientific PN LLCDelaware
Thermo Fisher Scientific PN2 (Luxembourg) S.à.r.lLuxembourg
Thermo Fisher Scientific PN2 C.VNetherlands
Thermo Fisher Scientific PN2 LLCDelaware
Thermo Fisher Scientific PNM Limited Liability Partnership  England
Thermo Fisher Scientific PNM S.a.r.lLuxembourg
Thermo Fisher Scientific Powder Finance LLCDelaware
Thermo Fisher Scientific Powder Financing 2 LLCDelaware
Thermo Fisher Scientific Powder Holdings 4 LLCDelaware
33

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific Powder Holdings ICayman Islands
Thermo Fisher Scientific Powder Holdings IICayman Islands
Thermo Fisher Scientific Powder Holdings IIICayman Islands
Thermo Fisher Scientific Powder Holdings IVCayman Islands
Thermo Fisher Scientific Powder LLCDelaware
Thermo Fisher Scientific Powder SRLBarbados
Thermo Fisher Scientific Powder UK Holdings LimitedEngland
Thermo Fisher Scientific Powder UK Senior Holdings LimitedEngland
Thermo Fisher Scientific Powder US Holdings Corp.Delaware
Thermo Fisher Scientific Powder US Holdings LimitedEngland
Thermo Fisher Scientific PPD (OLI) LLCDelaware
Thermo Fisher Scientific PRB S.a.r.l.
Luxembourg
Thermo Fisher Scientific PSG CorporationDelaware
Thermo Fisher Scientific Pte. Ltd.Singapore
Thermo Fisher Scientific Re Ltd.Bermuda
Thermo Fisher Scientific Remel Luxembourg S.a.r.l.Luxembourg
Thermo Fisher Scientific Senior Financing LLCDelaware
Thermo Fisher Scientific Senior Holdings Australia LLC
Delaware
Thermo Fisher Scientific Senior Holdings LPCanada
Thermo Fisher Scientific Singapore Holdings LLCDelaware
Thermo Fisher Scientific SLSpain
Thermo Fisher Scientific Solutions LLCKorea
Thermo Fisher Scientific South Africa Proprietary Ltd
South Africa
Thermo Fisher Scientific SpAItaly
Thermo Fisher Scientific Spectra S.a.r.l.Luxembourg
Thermo Fisher Scientific Spectra-Physics Holdings Luxembourg I S.à r.l.Luxembourg
Thermo Fisher Scientific Spectra-Physics Holdings Luxembourg II S.à r.l.Luxembourg
Thermo Fisher Scientific Sweden 2 LLCDelaware
Thermo Fisher Scientific Sweden Holdings LLCDelaware
Thermo Fisher Scientific Sweden Holdings S.a.r.lLuxembourg
Thermo Fisher Scientific Switzerland B.V.Netherlands
Thermo Fisher Scientific Taiwan Co., Ltd.Taiwan
34

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific TDI 2 S.a.r.l.Luxembourg
Thermo Fisher Scientific TDI S.a.r.lLuxembourg
Thermo Fisher Scientific TR LimitedHong Kong
Thermo Fisher Scientific TX LLCTexas
Thermo Fisher Scientific UK Holding Company Financing LimitedEngland
Thermo Fisher Scientific US 1 LLCDelaware
Thermo Fisher Scientific Vector Holdings 2 LLCDelaware
Thermo Fisher Scientific Vector Holdings LLCDelaware
Thermo Fisher Scientific Vector Holdings UABLithuania
Thermo Fisher Scientific Vector Senior Holdings I UABLithuania
Thermo Fisher Scientific Vector Senior Holdings II UABLithuania
Thermo Fisher Scientific West Palm Holdings LLCDelaware
Thermo Fisher Scientific Wissenschaftliche Geräte GmbHAustria
Thermo Fisher Scientific Worldwide Investments (Cayman)Cayman Islands
Thermo Fisher Scientific Worldwide Investments (Luxembourg) S.a.r.l.Luxembourg
Thermo Fisher Scientific Worldwide Investments LLCDelaware
Thermo Fisher Senior Canada Holdings LLCDelaware
Thermo Fisher TDI Holding LLCDelaware
Thermo FLC LPDelaware
Thermo Foundation, Inc.Massachusetts
Thermo Gamma-Metrics Holdings Pty Ltd.Australia
Thermo Gamma-Metrics LLCDelaware
Thermo Gamma-Metrics Pty LtdAustralia
Thermo Holding European Operations LLCDelaware
Thermo Hypersil-Keystone LLCDelaware
Thermo Instrument Controls de Mexico, S.A. de C.V.Mexico
Thermo Kevex X-Ray LLCDelaware
Thermo Keytek LLCDelaware
Thermo LabSystems Inc.Massachusetts
Thermo Life Science International Trading (Tianjin) Co., Ltd.China
Thermo Life Sciences ABSweden
Thermo Luxembourg Holding S.a.r.l.
[Domesticated in the State of Delaware under the name of Thermo Luxembourg Holding LLC]
Luxembourg
35

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo Luxembourg S.a.r.l.Luxembourg
Thermo Luxembourg U.S. S.a.r.l.Luxembourg
Thermo Measuretech Canada Inc.Canada
Thermo MF Physics LLCDelaware
Thermo Neslab LLCNew Hampshire
Thermo Onix LimitedEngland
Thermo Optek LimitedEngland
Thermo Orion Inc.Massachusetts
Thermo Patheon Holdings LLCDelaware
Thermo Portable Holdings LLCDelaware
Thermo Power CorporationMassachusetts
Thermo Process Instruments GP, LLCDelaware
Thermo Process Instruments, L.P.Texas
Thermo Projects LimitedEngland
Thermo Ramsey Italia S.r.l.Italy
Thermo Ramsey LLCMassachusetts
Thermo Ramsey S.A.Spain
Thermo Re, Ltd.Bermuda
Thermo Scientific Microbiology Pte Ltd.Singapore
Thermo Scientific Microbiology Sdn BhdMalaysia
Thermo Scientific Portable Analytical Instruments Inc.Delaware
Thermo Scientific Services, Inc.California
Thermo Securities CorporationDelaware
Thermo Sentron Canada Inc.Canada
Thermo Services (Hungary) KftHungary
Thermo Suomi Holding B.V.Netherlands
Thermo TLH (UK) LimitedEngland
Thermo TLH L.P.Delaware
Thermo TLH Luxembourg S.a.r.l.Luxembourg
Thermo Trace Pty Ltd.
Australia
Thermo USC I LLCDelaware
Thermo USC II LLCDelaware
36

NAME
STATE OR JURISDICTION OF ORGANIZATION
Thermo-Fisher Biochemical Product (Beijing) Co., Ltd.China
ThermoLase LLCDelaware
TK Partnership (aka Silent PartnershipJapan
TMOI Inc.Delaware
TPI Real Estate Holdings LLCDelaware
Trek Diagnostic Systems LLCDelaware
Trek Diagnostic Systems Ltd.England
Trek Holding Company II Ltd.England
Trek Holding Company Ltd.England
Trex Medical CorporationDelaware
TSP Holdings I LLCDelaware
TWX, LLCMassachusetts
United Diagnostics, Inc.Delaware
USB CorporationOhio
Vestrum Health Inc.Canada
Vestrum Health, LLCDelaware
VG Systems LimitedEngland
Westover Scientific, Inc.Washington
Wildcat Acquisition Holdings (UK) LimitedEngland

37
 EX-22 6 q4202310-kex22.htm SUBSIDIARY ISSUER OF GUARANTEED SECURITIES Document

Exhibit 22


Subsidiary Issuer of Guaranteed Securities

Thermo Fisher Scientific Inc. (the “Registrant”) is the guarantor of the senior secured registered notes listed below issued by Thermo Fisher Scientific (Finance I) B.V., a wholly-owned finance subsidiary of the Registrant.

Thermo Fisher Scientific (Finance I) B.V.
0.800% Senior Notes due 2030
1.125% Senior Notes due 2033
1.625% Senior Notes due 2041
2.000% Senior Notes due 2051
0.000% Senior Notes due 2025


 EX-23.1 7 q4202310-kex231pwcconsent.htm CONSENT OF PRICEWATERHOUSECOOPERS LLP Document

Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-263034) and Form S-8 (Nos. 033-51189, 033-54347, 333-188846, 333-220231, 333-261548, 333-272173, and 333-275438) of Thermo Fisher Scientific Inc. of our report dated February 22, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.


/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts
February 22, 2024


 EX-31.1 8 q4202310-kex311.htm CERTIFICATION Document

Exhibit 31.1

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Marc N. Casper, certify that:
1.I have reviewed this Annual Report on Form 10-K of Thermo Fisher Scientific Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 22, 2024
/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer


 EX-31.2 9 q4202310-kex312.htm CERTIFICATION Document

Exhibit 31.2

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen Williamson, certify that:
1.I have reviewed this Annual Report on Form 10-K of Thermo Fisher Scientific Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 22, 2024
/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer


 EX-32.1 10 q4202310-kex321.htm CERTIFICATION Document

Exhibit 32.1

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Thermo Fisher Scientific Inc. (the “Company”) for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Marc N. Casper, Chairman, President and Chief Executive Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:  February 22, 2024

/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer






























A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-32.2 11 q4202310-kex322.htm CERTIFICATION Document

Exhibit 32.2

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Thermo Fisher Scientific Inc. (the “Company”) for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Stephen Williamson, Senior Vice President and Chief Financial Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:  February 22, 2024

/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer






























A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-97 12 q4202310-kex97.htm CLAWBACK POLICY Document
Exhibit 97
Policies & Procedures

    
image_0.jpg    
     EFFECTIVE DATE: October 2, 2023
                                



Title: CLAWBACK POLICY

Supersedes: February 25, 2019

Total Pages: 3

POLICY

This Clawback Policy (this “Policy”), relates to the Company’s right to recover compensation previously paid to specified employees in certain circumstances, including the recovery of Erroneously Awarded Compensation (as defined below) in accordance with Section 303A.14 of the New York Stock Exchange (“NYSE”) Listed Company Manual (“Section 303A.14”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (collectively, the “Applicable Rules”). This Policy is effective as of October 2, 2023 (the “Effective Date”).

This Policy is applicable to current or former Executive Officers (as defined in 16a-1(f) under the Exchange Act), and such other employees of the Company as may be determined from time to time by the Compensation Committee of the Board of Directors (the “Committee”).

In the event the Company is required, on or after the Effective Date, to prepare an Accounting Restatement, the Company will use reasonable efforts to recover reasonably promptly from each Covered Person, any Erroneously Awarded Compensation that was Received by such Covered Person from the Company during the three completed fiscal years immediately preceding the date on which the Company is required to prepare an Accounting Restatement (or such other period as may be required by Applicable Rules in the event of a change in the Company’s fiscal year).

This Policy does not apply to Incentive-Based Compensation that was Received before the Effective Date. With respect to any Covered Person, this Policy does not apply to Incentive--Based Compensation that was Received by such Covered Person before beginning service as an Executive Officer.

INTERPRETATION AND ADMINISTRATION

This Policy will be interpreted in a manner that is consistent with the Applicable Rules and any other applicable law and this Policy will otherwise be interpreted in the business judgment of the Committee. All decisions and interpretations of the Committee will be final and binding; provided that such decisions must be consistent with the Applicable Rules.

The Company is not required to recover Erroneously Awarded Compensation under this Policy if a determination is made by the Committee that either (A) after the Company has made and documented a reasonable attempt to recover such Erroneously Awarded Compensation, the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered or (B) recovery of such Erroneously Awarded Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or 411(a) of the Internal Revenue Code and regulations thereunder.



The Company will not indemnify any Covered Person against the loss of Erroneously Awarded Compensation and will not pay or reimburse any Covered Person for the purchase of a third-party insurance policy to fund potential recovery obligations.

The Committee will determine the appropriate means of any recovery of Erroneously Awarded Compensation under this Policy, which may vary between Covered Persons or based on the nature of the applicable Incentive-Based Compensation. Such recovery may involve, establishing a deferred repayment plan, setting off against current or future compensation otherwise payable to the Covered Person, or other appropriate means.

The Company may have other rights or remedies available to the Company under any agreement with a Covered Person (such as an equity award agreement) or applicable law, and nothing in this Policy will limit the Company’s right to pursue these rights or remedies.

DEFINITIONS

“Accounting Restatement” means a requirement that the Company prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the U.S. federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. Changes to the Company’s financial statements that do not represent error corrections are not an Accounting Restatement, including: (A) retrospective application of a change in accounting principle; (B) retrospective revision to reportable segment information due to a change in the structure of the Company’s internal organization; (C) retrospective reclassification due to a discontinued operation; (D) retrospective application of a change in reporting entity, such as from a reorganization of entities under common control; and (E) retrospective revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure.

“Covered Person” means a person who served as an Executive Officer (and any other employee of the Company as may be determined from time to time by the Committee as subject to this Policy) at any time during the performance period for the applicable Incentive-Based Compensation.

“Erroneously Awarded Compensation” means the amount of Incentive-Based Compensation that was Received that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received had the amount of Incentive-Based Compensation been determined based on the restated amounts, computed without regard to any taxes paid by the Covered Person or by the Company on the Covered Person’s behalf. For Incentive-Based Compensation based on stock price or total shareholder return (“TSR”), where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the amount of Erroneously Awarded Compensation will be based on a reasonable estimate by the Committee of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive-Based Compensation was Received.

“Incentive-Based Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of (A) measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures that are derived wholly or in part from such measures (whether or not such measures are presented within the Company’s financial statements or included in a filing made with the U.S. Securities and Exchange Commission), (B) stock price and (C) TSR.

2



Incentive-Based Compensation is deemed to be “Received” in the Company’s fiscal period during which the financial reporting measure specified in the applicable Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period or is subject to additional time-based vesting requirements.
3


 EX-101.SCH 13 tmo-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheet link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statement of Income link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statement of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statement of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Consolidated Statement of Redeemable Noncontrolling Interest and Equity link:presentationLink link:calculationLink link:definitionLink 0000010 - Statement - Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Revenue and Contract-related Balances link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Business Segment and Geographical Information link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Other Income/Expense link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Stock-based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Pension and Other Postretirement Benefit Plans link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Debt and Other Financing Arrangements link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Comprehensive Income and Shareholders Equity link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Restructuring and Other Costs link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Revenue and Contract-related Balances (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Business Segment and Geographical Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Stock-based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Debt and Other Financing Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Comprehensive Income and Shareholders Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Restructuring and Other Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Additional Accounting Policy and Balance Sheet Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Acquisitions - Schedule of Components of Purchase Price (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Acquisitions - Schedule of Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Revenue & Contract-related Balances - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Revenue & Contract-related Balances - Revenue Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Revenue & Contract-related Balances - Revenue Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Revenue & Contract-related Balances - Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Business Segment and Geographical Information - Schedule of Revenue by Geographical Areas (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Other Income/Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Stock-based Compensation Expense - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Stock-based Compensation Expense - Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Stock-based Compensation Expense - Summary of the Company's Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Stock-based Compensation Expense - Summary of the Company's Restricted Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Pensions and Other Postretirement Benefit Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Pensions and Other Postretirement Benefit Plans - Reconciliation of Benefit Obligations and Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Pensions and Other Postretirement Benefit Plans - Actuarial Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation and Fair Value of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Pension and Other Postretirement Benefit Plans - Schedule of Estimated Future Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Pension and Other Postretirement Benefit Plans - Schedule of Fair Value of the Company's Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Income Taxes - Components of Income Before Provision for Income Taxes and Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Income Taxes - Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Debt and Other Financing Arrangements - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Debt and Other Financing Arrangements - Schedule of Annual Repayment Requirements for Debt Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Debt and Other Financing Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Leases- Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Leases - Schedule of Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Leases - Schedule of Future Payments of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Leases - Schedule of Future Payments of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Comprehensive Income and Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Rollforward of the Fair Value of Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Aggregate Notional Value and Fair Value of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Derivative Instruments, Gain (Loss) Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of the Company's Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9954532 - Disclosure - Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) link:presentationLink link:calculationLink link:definitionLink 9954533 - Disclosure - Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 14 tmo-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 15 tmo-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 16 tmo-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Revolving credit facility capacity Line of Credit Facility, Maximum Borrowing Capacity 5.30% 30-Year Senior Notes, Due 2/1/2044 Senior Notes 5.30% Due 2044 [Member] 5.30% 30-Year Senior Notes, Due 2/1/2044 [Member] Research and development expenses Research and Development Expense Changes in assets and liabilities, excluding the effects of acquisitions: Increase (Decrease) in Operating Capital [Abstract] 1.450% Notes due 2027 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.45% Senior Notes Due 2027 [Member] 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) Term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Expected timing of satisfaction of remaining performance obligation Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Contract-related Balances Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Impairment of intangible assets Impairment of Intangible Assets (Excluding Goodwill) Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Plans, Policy [Policy Text Block] Cash paid Payments to Acquire Businesses, Gross Performance Guarantee Performance Guarantee [Member] 5.000% 5-Year Senior Notes due 1/31/2029 Senior Notes 5.000% Due 2029 [Member] Senior Notes 5.000% Due 2029 Deferred income taxes Deferred Income Tax Liabilities, Net Insider Trading Policies and Procedures [Line Items] Exercisable (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Net Assets Acquired [Abstract] Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Currency translation Restructuring Reserve, Foreign Currency Translation Gain (Loss) Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] 2028  Lessee, Operating Lease, Liability, to be Paid, Year Five Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Comprehensive Income and Shareholders' Equity Equity [Text Block] Options vested and expected to vest, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Schedule of Revenue by Geographical Areas Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Pension plans with projected benefit obligations in excess of plan assets Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract] Surety Bonds and Other Guarantees Surety Bonds and Other Guarantees [Member] Surety Bonds and Other Guarantees Ownership [Axis] Ownership [Axis] Expected annual dividend Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Schedule of Actuarial Assumptions Defined Benefit Plan, Assumptions [Table Text Block] Current liabilities: Liabilities, Current [Abstract] Noncontrolling Interest [Table] Noncontrolling Interest [Table] Federal Deferred Federal Income Tax Expense (Benefit) Preferred stock, $100 par value, 50,000 shares authorized; none issued Preferred Stock, Value, Issued Intersegment Eliminations Intersegment Eliminations [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Canceled/expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Dividends paid Payments of Ordinary Dividends, Common Stock Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Impairment of long-lived assets Impairment, Long-Lived Asset, Held-for-Use Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration] Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration] Diluted (in dollars per share) Diluted Earnings Per Share (in dollars per share) Earnings Per Share, Diluted Acquisition-related Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Accounts receivable, less allowances of $193 and $189 Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Reclassification adjustment for losses included in net income (net of tax benefit of $2, $1 and $17) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Average rate of increase in employee compensation Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Schedule of Net Benefit Costs Schedule of Net Benefit Costs [Table Text Block] 1.875% Notes due 2049 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) Senior Notes 1.875% Due 2049 [Member] Senior Notes 1.875% Due 2049 [Member] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Redeemable noncontrolling interest Redeemable noncontrolling interest, beginning balance Redeemable noncontrolling interest, ending balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Entity Stock Trading Symbol Trading Symbol Guarantor Obligations, Nature [Domain] Guarantor Obligations, Nature [Domain] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 2029 and thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Investments measured at NAV Alternative Investment Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Machinery and Equipment Machinery and Equipment [Member] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Acquisition-related intangible assets Intangible Assets, Gross (Excluding Goodwill) All Currencies [Domain] All Currencies [Domain] 1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated) Senior Notes 1.279% Due 2029 [Member] Senior Notes 1.279% Due 2029 Other liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Specialty Diagnostics Specialty Diagnostics [Member] Specialty Diagnostics Segment Thermo Fisher Scientific Inc. shareholders’ equity: Equity, Attributable to Parent [Abstract] Derivative funds Defined Benefit Plan, Derivative [Member] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Service costs Service cost Defined Benefit Plan, Service Cost Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Executive Category: Executive Category [Axis] Exchange rate effect on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Unvested Restricted Units [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Prior service credits Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Unrealized gains and losses on hedging instruments: Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Maximum guarantee under lease arrangements Guarantor Obligations, Maximum Exposure, Undiscounted Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] 2025  Long-Term Debt, Maturity, Year Two Granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Multi-asset funds Multi-asset Funds [Member] Multi-asset Funds Entity Small Business Entity Small Business 0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated) Senior Notes 0.000% Due 2025 [Member] Senior Notes 0.000% Due 2025 2027  Finite-Lived Intangible Asset, Expected Amortization, Year Four Foreign exchange loss on inter-company debt refinancing Effective Income Tax Rate Reconciliation, Foreign Exchange Loss On Debt Refinancing Effective Income Tax Rate Reconciliation, Foreign Exchange Loss On Debt Refinancing Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] 2028  Finance Lease, Liability, to be Paid, Year Five Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] Notional amount Derivative, Notional Amount Option to terminate, term Lessee, Operating Lease, Option to Terminate, Term Term of lessee's operating lease if an option to terminate is available and executed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Repayments of commercial paper Repayments of Commercial Paper Measurement Frequency [Axis] Measurement Frequency [Axis] Machinery, equipment and leasehold improvements Other Capitalized Property Plant and Equipment [Member] Nature of Operations and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Restricted cash included in other current assets Restricted Cash and Cash Equivalents, Current Retirement Plan Type [Domain] Retirement Plan Type [Domain] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation of property, plant and equipment Depreciation Retirement Benefits [Abstract] Retirement Benefits [Abstract] Provision for (reversal of) tax reserves, net Effective Income Tax Rate Reconciliation, Provision For (Reversal Of) Tax Reserves, Net Effective Income Tax Rate Reconciliation, Provision For (Reversal Of) Tax Reserves, Net Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible Enumeration] Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration] Schedule of Components of Purchase Price Schedule of Business Acquisitions, by Acquisition [Table Text Block] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Short-term Financing [Line Items] Short-Term Debt [Line Items] Contributions from (distributions to) noncontrolling interests Noncontrolling interest, contribution from (distributions to) noncontrolling interests Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders net of decreases in noncontrolling interest balance from payment of dividends or other distributions. Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Domestic Plan Domestic Plan [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Beginning balance Ending balance Restructuring Reserve Excise tax from stock repurchases Excise tax from stock repurchases Share Repurchase Program, Excise Tax Share Repurchase Program, Excise Tax 1.750% Notes due 2027 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) Senior Notes 1.75% Due 2027 [Member] Senior Notes 1.75% Due 2027 Antidilutive stock options excluded from diluted weighted averages shares (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Non-cash investing and financing activities Noncash Investing and Financing Items [Abstract] 1.750% 7-Year Senior Notes, Due 10/15/2028 Senior Notes 1.750% Due 2028 [Member] Senior Notes 1.750% Due 2028 Reconciliation of Unrecognized Tax Benefits [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Hedging Designation [Axis] Hedging Designation [Axis] Goodwill [Line Items] Goodwill [Line Items] Property, plant and equipment, at cost Property, Plant and Equipment, Gross Operating lease ROU assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) Senior Notes 1.625% Due 2041 [Member] Senior Notes 1.625% Due 2041 Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Contract assets/liabilities Increase (Decrease) In Contract With Customer Assets And Liabilities Increase (Decrease) In Contract With Customer Assets And Liabilities Employer contributions Defined Benefit Plan, Plan Assets, Contributions by Employer PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Components of the Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Net operating loss and credit carryforwards Deferred Tax Assets, Other Tax Carryforwards Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Operating lease liabilities - current Operating Lease, Liability, Current Other Expense Other Expense [Member] Proceeds from cross-currency interest rate swap interest settlements Proceeds From (Payments For) Cross-Currency Interest Rate Swap Interest Settlements The cash inflow (outflow) provided by (paid for) cross-currency interest rate swap interest rate settlements, which are classified as investing activities, for hedging instruments designated as net investment hedges. Shares issued under ESPP (shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans 2026  Lessee, Operating Lease, Liability, to be Paid, Year Three Audit Information [Abstract] Audit Information Estimated future amortization expense of definite-lived intangible assets Finite-Lived Intangible Assets, Net Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Estimated contributions to plan Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Accrued compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Senior Notes 3.65% Due 2025 [Member] Senior Notes 3.65% Due 2025 [Member] 3.65% 10-Year Senior Notes, Due 12/15/2025 [Member] 2025  Lessee, Operating Lease, Liability, to be Paid, Year Two Fair value Debt Instrument, Fair Value Disclosure Components of Income Before Provision for Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Non-U.S. Income (Loss) from Continuing Operations before Income Taxes, Foreign Weighted Average Assumptions Used to Determine Benefit Obligation [Abstract] Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Total purchase price Business Combination, Consideration Transferred Contract liabilities Contract with Customer, Liability, Current Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name 1.215% 3-Year Senior Notes, Due 10/18/2024 Senior Notes 1.215% Due 2024 [Member] Senior Notes 1.215% Due 2024 Stock-based Compensation Expense Share-Based Payment Arrangement [Policy Text Block] Selling, general and administrative expenses Selling, General and Administrative Expense Accumulated other comprehensive income/(loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Cross-currency interest rate swaps designated as net investment hedge - Swiss franc Switzerland, Francs Other comprehensive income/(loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Options Employee Stock Option [Member] Investments Investment, Policy [Policy Text Block] Total costs and operating expenses Costs and Expenses Maximum Maximum [Member] Schedule of Restructuring and Other Costs by Segment Restructuring and Related Costs [Table Text Block] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Acquisitions Goodwill, Acquired During Period Settlements Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Tabular List, Table Tabular List [Table Text Block] Purchases of company common stock Treasury Stock, Value, Acquired, Cost Method 2029 and thereafter Long-Term Debt, Maturity, after Year Five Inventories Inventory, Policy [Policy Text Block] Other comprehensive income/(loss) Temporary Equity, Foreign Currency Translation Adjustments 2026  Finance Lease, Liability, to be Paid, Year Three Analytical Instruments Analytical Instruments [Member] Analytical Instruments Segment Defined Benefit Plan, Information about Plan Assets [Abstract] Defined Benefit Plan, Information about Plan Assets [Abstract] Stock-based Compensation Expense Share-Based Payment Arrangement [Text Block] Federal Current Federal Tax Expense (Benefit) Other non-cash expenses Other Noncash Income (Expense) Purchase Price Business Combination, Consideration Transferred [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Accounts Receivable Allowances Accounts Receivable, Allowance for Credit Loss, Current State Deferred State and Local Income Tax Expense (Benefit) Nonrecurring Adjustment [Domain] Nonrecurring Adjustment [Domain] Raw materials Inventory, Raw Materials, Net of Reserves Costs and operating expenses: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Actuarial (gains) losses Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Ownership interest, noncontrolling owners Subsidiary, Ownership Percentage, Noncontrolling Owner Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] 5.404% 20-Year Senior Notes, due 8/10/2043 Senior Notes 5.404% Due 2043 [Member] Senior Notes 5.404% Due 2043 U.S. equity funds U S Equity Funds [Member] U.S. Equity Funds Total Reportable Segments Operating Segments [Member] Unvested, weighted average grant-date fair value, beginning (in dollars per share) Unvested, weighted average grant-date fair value, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Investments Payment Guarantees, Investments [Member] Payment Guarantees, Investments Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Domestic NOL Expires Domestic NOL Expires [Member] Domestic NOL Expires Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Currency translation Goodwill, Foreign Currency Translation Gain (Loss) Inventory basis difference Deferred Tax Assets, Inventory Statistical Measurement [Axis] Statistical Measurement [Axis] Operating Activities [Domain] Operating Activities [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Laboratory Products and Biopharma Services Laboratory Products and Services [Member] Laboratory Products and Services Segment Product revenues Product [Member] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Other non-cash restructuring costs Restructuring and Related Costs, Non-Cash Costs Restructuring and other costs which consist principally of gains and losses resulting from changes in estimates for significant litigation-related matters, and, in some periods, may also include gains and losses on the sale of businesses, product lines and real estate, and asset impairment charges. Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible List] Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Settlement/curtailment loss (gain) Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Entity Listings [Line Items] Entity Listings [Line Items] Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Carrying Value and Fair Value of the Company's Debt Instruments Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Derivatives Contracts Derivatives, Policy [Policy Text Block] Settlements Defined Benefit Plan, Plan Assets, Payment for Settlement 2024  Finite-Lived Intangible Asset, Expected Amortization, Year One Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities Operating Lease, Payments Cost of revenues adjustments Cost Of Revenues Charges Certain charges to cost of revenues primarily for 1) the sale of inventories revalued at fair value at the date of acquisition and 2) accelerated depreciation at facilities closing due to facility consolidations. Balance (in shares) Balance (in shares) Common Stock, Shares, Outstanding Discount rate - service cost Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate Service Cost Weighted average rate for present value of future retirement benefits cash flows, used to determine service cost component of net periodic benefit cost of defined benefit plan. Interest costs Interest cost on benefit obligation Defined Benefit Plan, Interest Cost 3.200% Notes due 2026 Senior Notes 3.200% Due 2026 [Member] Senior Notes 3.200% Due 2026 Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] PEO PEO [Member] Range of probable loss Loss Contingency, Estimate of Possible Loss Auditor Location Auditor Location Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Pension and Other Postretirement Benefit Plans Retirement Benefits [Text Block] Change in fair value of plan assets Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Debt assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt Noncurrent contract assets, net Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent Cash / money market funds Defined Benefit Plan, Cash and Cash Equivalents [Member] 2.000% Notes due 2025 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) Senior Notes 2.00% Due 2025 [Member] 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro denominated) [Member] State income taxes, net of federal tax Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Common Stock, $1 Par Value - Par Value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Amount reclassified from accumulated other comprehensive items to interest expense Amount reclassified from accumulated other comprehensive items to interest expense Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Interest rate swaps - fair value hedges Interest Rate Swap [Member] 3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated) Senior Notes 3.20% Due 2026 [Member] Senior Notes 3.20% Due 2026 Debt Instrument [Axis] Debt Instrument [Axis] Pro forma revenues Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Credit Facility [Axis] Credit Facility [Axis] Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024 Floating Rate SOFR +0.53% Senior Notes Due 2024 [Member] Floating Rate SOFR +0.53% Senior Notes Due 2024 Schedule of Annual Repayment Requirements for Debt Obligations Schedule of Maturities of Long-Term Debt [Table Text Block] Current income tax provision Current Income Tax Expense (Benefit) Expected stock price volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 1.950% Notes due 2029 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) Senior Notes 1.95% Due 2029 [Member] 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) [Member] Measurement Frequency [Domain] Measurement Frequency [Domain] Unissued shares of common stock (in shares) Common Stock, Capital Shares Reserved for Future Issuance Valuation Allowance [Roll Forward] Valuation Allowance [Roll Forward] Valuation Allowance [Roll Forward] Undiscounted product liability accrual Loss Contingency Accrual, Product Liability, Gross, Divested Business The estimated aggregate undiscounted amount of the accrual for damages arising from third-party use of product(s) or process(es) of divested businesses as of the balance sheet date. Cash acquired Cash Acquired in Excess of Payments to Acquire Business Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Operating Activities [Axis] Operating Activities [Axis] Research and development and other capitalized costs Deferred Tax Assets, in Process Research and Development North America North America [Member] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost (Income) [Abstract] Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] 2025  Defined Benefit Plan, Expected Future Benefit Payment, Year Two Mesa Biotech Mesa Biotech [Member] Mesa Biotech Intra-Entity [Axis] Intra-Entity [Axis] Intra-Entity Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) Senior Notes 0.80% Due 2030 [Member] Senior Notes 0.80% Due 2030 State Current State and Local Tax Expense (Benefit) 2.80% 20-Year Senior Notes, Due 10/15/2041 Senior Notes 2.800% Due 2041 [Member] Senior Notes 2.800% Due 2041 Total current assets Assets, Current Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Net periodic benefit cost (income) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Fair value of contingent consideration Business Combination, Contingent Consideration, Liability Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Information [Abstract] Fair value of plan assets Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets Deferred Interest Carryforward Deferred Tax Asset, Interest Carryforward [Member] Deferred Tax Asset, Interest Carryforward Michael A. Boxer [Member] Michael A. Boxer Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Earnings per Share Earnings Per Share, Policy [Policy Text Block] Excess tax benefits from stock options and restricted stock units Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount PPD PPD, Inc [Member] PPD, Inc Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Change in Accounting Principle, Other Change in Accounting Principle, Other [Member] Current income tax provision Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Schedule of Change in Each Component of Accumulated Other Comprehensive Items Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Insurance contracts Cash Surrender Value, Fair Value Disclosure Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 2028  Finite-Lived Intangible Asset, Expected Amortization, Year Five Life Sciences Solutions Life Sciences Solutions [Member] Life Sciences Solutions Segment 2027  Finance Lease, Liability, to be Paid, Year Four Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Options exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Schedule of Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Class of Stock [Axis] Class of Stock [Axis] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Amortization of prior service cost (benefit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) U.S. Commercial Paper Program U.S. Commercial Paper Program [Member] Borrowings under the company's U.S. commercial paper program Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023 Floating Rate SOFR +0.35% 18 Month Senior Notes Due 2023 [Member] Floating Rate SOFR +0.35% 18 Month Senior Notes Due 2023 Fair Value Measurements and Fair Value of Financial Instruments Derivatives and Fair Value [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Consumables Consumables [Member] Consumable, single-use products Business Combination and Asset Acquisition [Abstract] Commercial Paper Programs Commercial Paper [Member] Consolidation Items [Axis] Consolidation Items [Axis] Revenues Business Acquisition, Pro Forma Revenue Long-lived Assets Long-Lived Assets Valuation Allowance Beginning Balance Ending Balance Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Unrealized losses on hedging instruments Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Reconciliation of Benefit Obligations and Plan Assets Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Long-term obligations Long-Term Debt and Lease Obligation Deferred tax assets (liabilities) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Cost method investments Equity Securities without Readily Determinable Fair Value, Amount Portion of Non- U.S. with expiration dates Foreign Country NOL Expires [Member] Portion of Non- U.S. with expiration dates Tax benefit on amortization of net loss and prior service benefit included in net periodic pension cost Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] European Viral Vector Business European Viral Vector Manufacturing Business [Member] European Viral Vector Manufacturing Business Preferred Stock, $100 Par Value - Shares Issued (in shares) Preferred Stock, Shares Issued Entity Emerging Growth Company Entity Emerging Growth Company Unamortized debt issuance costs Debt Issuance Costs, Net Defined Benefit Plan, Expected Future Benefit Payments [Abstract] Defined Benefit Plan, Expected Future Benefit Payment [Abstract] Intra-entity transfers Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount Acquisition-related intangible assets, net Acquisition-related intangible assets Intangible Assets, Net (Excluding Goodwill) Real estate funds Real Estate Funds [Member] Warranty Obligations Standard Product Warranty, Policy [Policy Text Block] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Definite-lived intangible assets: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 2024  Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Common Stock, $1.00 par value Common Stock [Member] Individual: Individual [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Closure of tax years Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Income Statement Location [Domain] Income Statement Location [Domain] Unamortized discount Debt Instrument, Unamortized Discount (Premium), Net Rollforward of the Fair Value of Investments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Other regions Other Regions [Member] All geographical regions not separately disclosed Finance lease liabilities Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation Total equity Balance Balance Equity, Including Portion Attributable to Noncontrolling Interest Contributions from (distributions to) noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Minimum Minimum [Member] 2.00% 10-Year Senior Notes, Due 10/15/2031 Senior Notes 2.000% Due 2031 [Member] Senior Notes 2.000% Due 2031 Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible List] Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Total other comprehensive income/(loss) Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Projected benefit obligation at beginning of year Projected benefit obligation at end of year Defined Benefit Plan, Benefit Obligation Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Net proceeds from issuance of debt Proceeds from Issuance of Long-Term Debt 2026  Defined Benefit Plan, Expected Future Benefit Payment, Year Three Currency transaction gains (losses) Gain (Loss), Foreign Currency Transaction, before Tax Schedule of Fair Value of Derivative Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Other, net Deferred Tax Assets, Other Accumulated benefit obligation Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Retirement Plan Type [Axis] Retirement Plan Type [Axis] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Other investing activities, net Payments for (Proceeds from) Other Investing Activities Retained Earnings Retained Earnings [Member] 2.60% 10-Year Senior Notes, Due 10/1/2029 Senior Notes 2.60% Due 2029 [Member] Senior Notes 2.60% Due 2029 [Member] Goodwill recorded Business Acquisition, Goodwill, Expected Tax Deductible Amount Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Currency translation and other Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Basic (in dollars per share) Basic Earnings Per Share (in dollars per share) Earnings Per Share, Basic Unrealized (gains) losses on hedging instruments Deferred Tax Assets (Liabilities), Hedging Transactions Amount before allocation of valuation allowances of deferred tax asset (liability) attributable to unrealized losses (gains) from hedging transactions. Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Fair value of plan assets at beginning of year Fair value of plan assets at end of year Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Lease Residual Value Guarantee Guarantee Type, Other [Member] Total intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Schedule of Cash, Cash Equivalents and Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $1, $3 and $6) Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Issuance of stock upon vesting of restricted stock units Stock Issued Leased operating facilities Lessee, Operating Lease, Number Of Leases With Guaranteed Residual Value Lessee, Operating Lease, Number Of Leases With Guaranteed Residual Value Income taxes Income Taxes Paid Principles of Consolidation Consolidation, Policy [Policy Text Block] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Finalization of purchase price allocations for 2022 acquisitions Goodwill, Purchase Accounting Adjustments Interest Expense Interest Expense [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Technology-Based Intangible Assets Technology-Based Intangible Assets [Member] Intra-Entity [Domain] Intra-Entity [Domain] Intra-Entity [Domain] Alternative investments Alternative Investments [Member] Alternative Investments [Member] Accounts payable Increase (Decrease) in Accounts Payable Tax benefit on reclassification adjustment for losses on hedging instruments recognized in net income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Reconciliation of Unrecognized Tax Benefits Summary of Income Tax Contingencies [Table Text Block] Valuation Allowance by Deferred Tax Asset [Axis] Valuation Allowance by Deferred Tax Asset [Axis] Entity Public Float Entity Public Float Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 3.650% Notes due 2034 Senior Notes 3.650% Due 2034 [Member] Senior Notes 3.650% Due 2034 Derivative Instrument [Axis] Derivative Instrument [Axis] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Total borrowings at par value Total borrowings at par value Long-Term Debt, Gross Expected acquisition price Business Combination, Price of Acquisition, Expected Liability Class [Axis] Liability Class [Axis] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] 1.400% Notes due 2026 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) Senior Notes 1.40% Due 2026 [Member] 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) [Member] Compensation Amount Outstanding Recovery Compensation Amount Minimum consolidated net interest coverage ratio Debt, Covenant, Minimum Consolidated Interest Coverage Ratio Minimum permitted Consolidated Interest Coverage Ratio (the ratio of Consolidated EBITDA to Consolidated Interest Expense) as defined in the debt or line of credit facility agreements. Other comprehensive income/(loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Derivative contracts Fair value – assets Derivative Asset Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Deferred income tax provision (benefit) Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] 4.80% 5-Year Senior Notes, Due 11/21/2027 Senior Notes 4.8% Due 2027 [Member] Senior Notes 4.8% Due 2027 Backlog Order or Production Backlog [Member] Finance lease liabilities Finance Lease, Liability Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Amounts recognized in balance sheet Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] Forfeited (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Acquisitions Defined Benefit Plan, Plan Assets, Business Combination Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] 2024  Long-Term Debt, Maturity, Year One Interest crediting rate for cash balance plans Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Pre-acquisition litigation costs Restructuring and Related Costs, Non-Cash Costs, Pre-Acquisition Litigation Costs Restructuring and Related Costs, Non-Cash Costs, Pre-Acquisition Litigation Costs Plus effect of: stock options and restricted stock units (shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Environmental liability Accrual for Environmental Loss Contingencies Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Documents Incorporated by Reference [Text Block] Documents Incorporated by Reference [Text Block] Schedule of Guarantor Obligations [Table] Schedule of Guarantor Obligations [Table] Payments Payments for Restructuring Document Period End Date Document Period End Date Contract liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Adoption Date Trading Arrangement Adoption Date PeproTech PeproTech, Inc. [Member] PeproTech, Inc. 5.000% 3-Year Senior Notes due 12/5/2026 Senior Notes 5.000% Due 2026 [Member] Senior Notes 5.000% Due 2026 Schedule of Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Treasury Stock Treasury Stock, Common [Member] PPD-SNBL K.K. PPD-SNBL K.K. [Member] PPD-SNBL K.K. (Consolidated subsidiary with a noncontrolling interest) Loss accrual Loss Contingency Accrual Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] International equity funds International Equity Funds [Member] International Equity Funds Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Derivatives designated as hedging instruments Designated as Hedging Instrument [Member] Amounts reclassified from accumulated other comprehensive income/(loss) Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Redeemable Noncontrolling Interest [Roll Forward] Redeemable Noncontrolling Interest [Roll Forward] Redeemable Noncontrolling Interest Accrual for Environmental Loss Contingencies Disclosure [Abstract] Accrual for Environmental Loss Contingencies Disclosure [Abstract] Impairment of disposal group Impairment of Long-Lived Assets to be Disposed of Remaining operating lease term Operating Lease, Weighted Average Remaining Lease Term Total net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Deferred Tax Implications Deferred Tax Implications [Member] Deferred Tax Implications 2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated) Senior Notes 2.382% Due 2052 [Member] Senior Notes 2.382% Due 2052 Additions due to acquisitions Deferred Tax Assets Valuation Allowance, Increase Resulting from Acquisition Amount of increase in deferred tax valuation allowance resulting from acquisitions. Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Depreciation and amortization Deferred Tax Liabilities, Depreciation and Amortization The amount as of the balance sheet date of the estimated future tax effects attributable to the difference between the tax basis of long-lived assets, including property, plant and equipment and intangible assets, and the basis of long-lived assets computed in accordance with generally accepted accounting principles. The basis difference, whether due to impairment charges or other reasons, will increase future taxable income when it reverses. Money market funds Money Market Funds [Member] Amortization of actuarial net loss Defined Benefit Plan, Amortization of Gain (Loss) Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Tax credit carryforward Tax Credit Carryforward, Amount Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Revenue, Performance Obligation, Description of Timing Revenue, Performance Obligation, Description of Timing Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Expected long-term rate of return on assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Credit Facility [Domain] Credit Facility [Domain] Purchases of company common stock (in shares) Treasury Stock, Shares, Acquired Variable rate Debt Instrument, Basis Spread on Variable Rate Useful lives Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] 0.125% Notes due 2025 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) Senior Notes 0.125% Due 2025 [Member] Senior Notes 0.125% Due 2025 [Member] Insurance contracts Insurance Contracts [Member] Insurance Contracts Tax return reassessments and settlements Tax return reassessments and settlements Effective Income Tax Rate Reconciliation, Tax Settlement, Amount Schedule of Contract-related Balances Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Finance lease ROU assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Revenue and Contract-related Balances Revenue from Contract with Customer [Text Block] Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Capital in excess of par value Additional Paid in Capital, Common Stock Capital in Excess of Par Value Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Equity in earnings/(losses) of unconsolidated entities Income (Loss) from Equity Method Investments Loss Contingencies [Line Items] Loss Contingencies [Line Items] 3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated) Senior Notes 3.65% Due 2034 [Member] Senior Notes 3.65% Due 2034 Cover page. Cover [Abstract] Tax Period [Axis] Tax Period [Axis] United States UNITED STATES Fair Value, Recurring Fair Value, Recurring [Member] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Other long-term liabilities Other Liabilities, Noncurrent Total lease payments Lessee, Operating Lease, Liability, to be Paid Canceled/expired (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Schedule of Supplemental Cash Flow Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Transaction price allocated to remaining performance obligation Revenue, Remaining Performance Obligation, Amount Non-recurring Pro Forma Adjustments, Transaction Costs Acquisition-related Costs [Member] Cash Flow Hedging Cash Flow Hedging [Member] Business Segment and Geographical Information Segment Reporting Disclosure [Text Block] (Decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Options to extend, renewal term Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] State State and Local Jurisdiction [Member] Withholding taxes Effective Income Tax Rate Reconciliation, Foreign Withholding Taxes Amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign withholding taxes. Work in process Inventory, Work in Process, Net of Reserves Contributions to retirement plans Cash contributions to retirement plans Payment for Pension and Other Postretirement Benefits Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Current Reporting Status Entity Current Reporting Status Recognition upon acquisition Noncontrolling Interest, Increase from Business Combination Operating income Subtotal reportable segments Consolidated operating income Operating Income (Loss) Average rate of increase in employee compensation Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Cash compensation charges Charges For Cash Compensation Due To Employees Of Acquired Businesses Charges For Cash Compensation Due To Employees Of Acquired Businesses LIFO Method Inventories [Abstract] LIFO Method Related Items [Abstract] Plan participants' contributions Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Segments [Axis] Segments [Axis] State NOL Expires State NOL Expires [Member] State NOL Expires Contingent Consideration Contingent Consideration [Member] Contingent Consideration [Member] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Borrowings outstanding Long-Term Line of Credit Customer relationships Customer Relationships [Member] Components of Income From Continuing Operations Before Income Taxes [Abstract] Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Change in Accounting Principle, Type [Axis] Change in Accounting Principle, Type [Axis] Changes in fair value included in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Less: net (losses) income attributable to noncontrolling interests and redeemable noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Statistical Measurement [Domain] Statistical Measurement [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Cash acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Remaining lease term Lessee, Operating Lease, Remaining Lease Term Unvested, beginning balance (shares) Unvested, ending balance (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Debt and Other Financing Arrangements Debt Disclosure [Text Block] Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible List] Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Research and Development Research and Development Expense, Policy [Policy Text Block] Cross-currency interest rate swaps - designated as net investment hedges Cross Currency Interest Rate Contract [Member] Revolving Credit Facility Revolving Credit Facility [Member] Other Debt Other Debt [Member] Other Debt MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Eliminated workforce percentage Restructuring and Related Cost, Percentage of Total Workforce Eliminated The maximum number of positions eliminated in connection with restructuring plans during the period as a percentage of the company's total workforce. Options exercisable, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Real estate funds Defined Benefit Plan, Real Estate [Member] Pro forma losses Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Restatement Determination Date: Restatement Determination Date [Axis] Statutory federal income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 1.50% 12-Year Senior Notes, due 9/6/2035 (yen-denominated) Senior Notes 1.50% Due 2035 [Member] Senior Notes 1.50% Due 2035 Commitments and Contingencies Commitments and Contingencies Capital expenditures Segment, Expenditure, Addition to Long-Lived Assets Schedule of Goodwill [Table] Schedule of Goodwill [Table] 0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated) Senior Notes 0.853% Due 2025 [Member] Senior Notes 0.853% Due 2025 Geographical [Axis] Geographical [Axis] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Foreign Plan Foreign Plan [Member] Income Taxes Income Tax Disclosure [Text Block] 2028  Defined Benefit Plan, Expected Future Benefit Payment, Year Five Restricted cash included in other assets Restricted Cash and Cash Equivalents, Noncurrent Leases Lessee, Leases [Policy Text Block] Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Loss attributable to noncontrolling interest Restructuring and Related Costs, Non-Cash Costs, Amount Attributable To Noncontrolling Interest Restructuring and Related Costs, Non-Cash Costs, Amount Attributable To Noncontrolling Interest Guarantor Obligations, Nature [Axis] Guarantor Obligations, Nature [Axis] Provision for (reversal of) valuation allowances, net Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Preferred Stock, $100 Par Value - Par Value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Business Acquisition [Line Items] Business Acquisition [Line Items] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) Senior Notes 2.00% Due 2051 [Member] Senior Notes 2.00% Due 2051 1.500% Notes due 2039 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) Senior Notes 1.500% Due 2039 [Member] Senior Notes 1.500% Due 2039 [Member] PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Goodwill [Roll Forward] Goodwill [Roll Forward] Vested and unvested expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Schedule of Fair Value of the Company's Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Treasury Stock at Cost (in shares) Balance, treasury stock (in shares) Balance, treasury stock (in shares) Treasury Stock, Common, Shares 2024  Defined Benefit Plan, Expected Future Benefit Payment, Year One Outstanding, beginning balance (shares) Outstanding, ending balance (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Buildings and improvements Building and Building Improvements [Member] 0.797% 2-Year Senior Notes, Due 10/18/2023 Senior Notes 0.797% Due 2023 [Member] Senior Notes 0.797% Due 2023 Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Investments Investments, Fair Value Disclosure Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net Income (Loss) Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Schedule of Aggregate Notional Value of Outstanding Derivative Contracts Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Projected Benefit Obligation and Fair Value of Plan Assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] 2025  Finance Lease, Liability, to be Paid, Year Two Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leases Lessee, Operating Leases [Text Block] Liabilities, redeemable noncontrolling interest and equity Liabilities and Equity [Abstract] Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Currency translation and other Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Marc N. Casper [Member] Marc N. Casper Exercised (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period U.S. Income (Loss) from Continuing Operations before Income Taxes, Domestic Cost of revenues Cost of goods and services sold Cost of Goods and Services Sold Net amount recognized Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Weighted-average amortization period Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Schedule of Indefinite-Lived Acquisition-related Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Net gains on derivative instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Currency exchange contracts Foreign Exchange Contract [Member] Name Measure Name Name Forgone Recovery, Individual Name 2.375% Notes due 2032 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) Senior Notes 2.375% Due 2032 [Member] Senior Notes 2.375% Due 2032 The Binding Site Group The Binding Site Group [Member] The Binding Site Group Goodwill Beginning balance Ending balance Goodwill Additions for tax positions of prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Euro Commercial Paper Program Euro Commercial Paper Program [Member] Borrowings under the company's euro commercial paper program Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Underlying Securities Award Underlying Securities Amount Accounts receivable Increase (Decrease) in Accounts Receivable Tax provision (benefit) on currency translation adjustment OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax Cash dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated) Senior Notes 1.054% Due 2027 [Member] Senior Notes 1.054% Due 2027 Operating lease liabilities - noncurrent Operating Lease, Liability, Noncurrent Term Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Currency translation and other Deferred Tax Assets Valuation Allowance, Increase (Decrease) Resulting From Currency Translation And Other Amount of increase (decrease) in deferred tax valuation allowance resulting from currency translation and other. 0.500% Notes due 2028 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) Senior Notes 0.500% Due 2028 [Member] Senior Notes 0.500% Due 2028 [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Income Statement Location [Axis] Income Statement Location [Axis] 2.875% Notes due 2037 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) Senior Notes 2.875% Due 2037 [Member] 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) [Member] Noncurrent liabilities Liability, Defined Benefit Plan, Noncurrent Tax benefit from foreign exchange loss on an intercompany debt refinancing transaction Effective Income Tax Rate Reconciliation, Foreign Exchange Loss On Debt Refinancing, Net Of Expenses Effective Income Tax Rate Reconciliation, Foreign Exchange Loss On Debt Refinancing, Net Of Expenses Loss Contingencies Commitments and Contingencies, Policy [Policy Text Block] 4.10% 30-Year Senior Notes, Due 8/15/2047 Senior Notes 4.10% Due 2047 [Member] 4.10% 30-Year Senior Notes, Due 8/15/2047 [Member] Schedule of Future Payments of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Change in projected benefit obligations Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Europe Europe [Member] Foreign currency-denominated debt Foreign currency-denominated debt [Member] Foreign currency-denominated debt [Member] Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023 Floating Rate SOFR +0.39% Senior Notes Due 2023 [Member] Floating Rate SOFR +0.39% Senior Notes Due 2023 Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Undistributed earnings Undistributed Earnings of Foreign Subsidiaries Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Reserves and accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals 0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated) Senior Notes 0.000% Due 2023 [Member] Senior Notes 0.000% Due 2023 Discount rate - interest cost Defined Benefit Plan Assumptions Used Calculating Periodic Benefit Cost Discount Rate Interest Cost Weighted average rate for present value of future retirement benefits cash flows, used to determine interest cost component of net periodic benefit cost of defined benefit plan. Schedule of Operating Leases Lease, Cost [Table Text Block] Inventories Increase (Decrease) in Inventories Contract assets, net Contract with Customer, Asset, after Allowance for Credit Loss, Current Letters of Credit / Bank Guarantees Standby Letters of Credit [Member] Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Unconditional Purchase Obligations [Abstract] Unconditional Purchase Obligations (Excluding Capital Stock Redemptions) [Abstract] Interest expense Interest Expense Acquired but unpaid property, plant and equipment Capital Expenditures Incurred but Not yet Paid Loss on early extinguishment of debt Loss on early extinguishment of debt Gain (Loss) on Extinguishment of Debt Federal and State Federal and State [Member] Federal and State [Member] Options outstanding, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Other Adjustments to Additional Paid in Capital, Other Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Trading Arrangement: Trading Arrangement [Axis] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Use of Estimates Use of Estimates, Policy [Policy Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] 2029 and thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Summary of the Company's Restricted Unit Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] 2026  Long-Term Debt, Maturity, Year Three Government Assistance Government Assistance [Policy Text Block] Reductions for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Auditor Firm ID Auditor Firm ID Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] 2.02% 20-Year Senior Notes, due 9/6/2043 (yen-denominated) Senior Notes 2.02% Due 2043 [Member] Senior Notes 2.02% Due 2043 Amortization of acquisition-related intangible assets Amortization of acquisition-related intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Restatement Determination Date Restatement Determination Date Additions for tax positions of current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash, cash equivalents and restricted cash at beginning of year Cash, cash equivalents and restricted cash at end of year Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 0.750% Notes due 2024 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) Senior Notes 0.75% Due 2024 [Member] Senior Notes 0.75% Due 2024 [Member] Variable lease costs Variable Lease, Cost Accumulated Benefit Obligation and Fair Value of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Operating lease costs Operating Lease, Cost Common Stock, $1 Par Value - Shares Issued (in shares) Common Stock, Shares, Issued Net actuarial loss Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Vested (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Treasury stock at cost, 55,541,290 and 50,157,275 shares Treasury Stock, Common, Value Research credits and incentives Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Total assets Assets, Fair Value Disclosure Total borrowings at carrying value Carrying value Long-Term Debt 2027  Long-Term Debt, Maturity, Year Four Currency translation adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Weighted average amortization period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 5.086% 10-Year Senior Notes, Due 8/10/2033 Senior Notes 5.086% Due 2033 [Member] Senior Notes 5.086% Due 2033 Other financing activities, net Proceeds from (Payments for) Other Financing Activities Comprehensive income attributable to Thermo Fisher Scientific Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Estimated Future Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Funded status Defined Benefit Plan, Funded (Unfunded) Status of Plan Provision for (reversal of) tax reserves, net Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Federal Domestic Tax Authority [Member] Entity Address, Address Line One Entity Address, Address Line One 1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated) Senior Notes 1.49% Due 2032 [Member] Senior Notes 1.49% Due 2032 Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Deferred Tax Assets (Liabilities) [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Ownership percentage, parent Subsidiary, Ownership Percentage, Parent 2024  Finance Lease, Liability, to be Paid, Year One Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Net amount recognized Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Remaining performance obligation percentage Revenue, Remaining Performance Obligation, Percentage Subsequent Event Subsequent Event [Member] UTB, interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued NOL carryforwards Operating Loss Carryforwards Payroll deductions Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Net income/(loss) Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Schedule of Acquisition-related Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Other accrued expenses Other Liabilities, Current Deferred interest Deferred Tax Asset, Interest Carryforward Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible List] Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Income Statement [Abstract] Income Statement [Abstract] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Goodwill Goodwill, Gross Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Schedule of the Company's Accrued Restructuring Balance Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Components of Net Periodic Benefit Cost (Income) [Abstract] Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Derivative contracts Fair value – liabilities Derivative Liability Net income attributable to Thermo Fisher Scientific Inc. Business Acquisition, Pro Forma Net Income (Loss) Capital Loss Capital Loss [Member] Capital Loss Issuance of shares under stock plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Other current assets Other Assets, Current CorEvitas, LLC CorEvitas, LLC [Member] CorEvitas, LLC Provision for income taxes at statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Noncurrent assets Assets for Plan Benefits, Defined Benefit Plan Equity method investments Equity Method Investments Inventories Inventories Inventory, Net Acquisitions (including assumed balances) Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances, Net Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances, Net Land Land [Member] Pension and other postretirement benefit liability adjustments: Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract] Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total Shareholder Return Amount Total Shareholder Return Amount Purchases of company common stock Purchases of company common stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Non-U.S. Deferred Foreign Income Tax Expense (Benefit) Acquisitions Mergers, Acquisitions and Dispositions Disclosures [Text Block] Cross-currency interest rate swaps designated as net investment hedge - Japanese yen Japan, Yen Fixed income funds Fixed Income Funds [Member] Total Thermo Fisher Scientific Inc. Shareholders’ Equity Parent [Member] Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Guarantor Obligations [Line Items] Guarantor Obligations [Line Items] Other Series of Individually Immaterial Business Acquisitions [Member] Contingent consideration Contingent Consideration Liabilities, Fair Value Disclosures Fair value of contingent consideration liability. Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Unrecognized tax benefits reclassed to accrued income taxes in connection with IRS settlement Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority Class of Stock [Domain] Class of Stock [Domain] Schedule of Components of Inventories Schedule of Inventory, Current [Table Text Block] Net income attributable to Thermo Fisher Scientific Inc. Net income Net Income (Loss) Available to Common Stockholders, Basic Options Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Total operating lease liability Operating Lease, Liability Service revenues Service [Member] Lengnau biologics manufacturing facility CSL [Member] CSL Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accumulated Other Comprehensive Items AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Defined contribution plan expense Defined Contribution Plan, Cost All Executive Categories All Executive Categories [Member] 0.77% 5-Year Senior Notes, Due 9/6/2028 (yen-denominated) Senior Notes 0.77% Due 2028 [Member] Senior Notes 0.77% Due 2028 Noncurrent contract liabilities Contract with Customer, Liability, Noncurrent Other, net Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Pension Obligation Guarantee Financial Guarantee [Member] Pension and other postretirement benefit liability adjustment Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Reportable segments Number of Reportable Segments Earnings per share attributable to Thermo Fisher Scientific Inc. Earnings Per Share [Abstract] Currency translation adjustment: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract] Hedged long-term obligations - included in other income/(expense) Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge 4.977% 7-Year Senior Notes, Due 8/10/2030 Senior Notes 4.977% Due 2030 [Member] Senior Notes 4.977% Due 2030 Common stock, $1 par value, 1,200,000,000 shares authorized; 442,188,634 and 440,668,112 shares issued Common Stock, Value, Issued Redemption price Debt Instrument, Redemption Price, Percentage Unconditional purchase obligations Unrecorded Unconditional Purchase Obligation Fair Value Measured at Net Asset Value Per Share Fair Value Measured at Net Asset Value Per Share [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Tradenames Trade Names [Member] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Loss Contingency [Abstract] Loss Contingency [Abstract] Included in currency translation adjustment within other comprehensive items Derivatives used in Net Investment Hedge, Increase (Decrease), Gross of Tax Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Senior Notes Senior Notes [Member] Net tangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Tangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Tangible Assets Other intangible assets Other Intangible Assets, Net Deferred income tax provision (benefit) Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Recent Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Table Text Block] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Equity funds Equity Funds [Member] Other income/(expense) Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Additions due to acquisitions Unrecognized Tax Benefits, Increase Resulting from Acquisition Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Unrecognized tax benefits Beginning balance Ending balance Unrecognized Tax Benefits Income Tax Authority [Axis] Income Tax Authority [Axis] PEO Name PEO Name Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Asia-Pacific Asia Pacific [Member] Preferred Stock, $100 Par Value - Shares Authorized (in shares) Preferred Stock, Shares Authorized Acquisitions Defined Benefit Plan, Benefit Obligation, Business Combination 2029-2033 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Schedule of Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Entity Listings [Table] Entity Listings [Table] Expected price per share (dollars per share) Business Acquisition, Share Price, Expected Business Acquisition, Share Price, Expected 1.375% Notes due 2028 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) Senior Notes 1.375% Due 2028 [Member] Senior Notes 1.375% Due 2028 [Member] Corporate Corporate, Non-Segment [Member] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Businesses Sold Businesses Sold [Member] Businesses Sold Cross-currency interest rate swaps designated as net investment hedge - euro Euro Member Countries, Euro Interest rate Debt Instrument, Interest Rate, Stated Percentage Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total Thermo Fisher Scientific Inc. shareholders’ equity Equity, Attributable to Parent Total other comprehensive income/(loss) Other Comprehensive Income (Loss) Net of Tax Including Redeemable and NonRedeemable NCI Other Comprehensive Income (Loss) Net of Tax Including Redeemable and NonRedeemable NCI Schedule of Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Expected life of options (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated) Senior Notes 2.069% Due 2042 [Member] Senior Notes 2.069% Due 2042 Other Income/Expense Other Income and Other Expense Disclosure [Text Block] Instruments Instruments [Member] Instruments (longer-lived products) Charge for expired tax credits Charge for Expired Tax Credits due to Audit Settlement Charge for Expired Tax Credits due to Audit Settlement Derivatives not designated as hedging instruments Not Designated as Hedging Instrument [Member] Percentage of LIFO inventory Percentage of LIFO Inventory Foreign Tax Credit Carryforwards Foreign Tax Credit Carryforwards [Member] Foreign Tax Credit Carryforwards Restructuring and Other Costs Restructuring and Related Activities Disclosure [Text Block] 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) Senior Notes 1.125% Due 2033 [Member] Senior Notes 1.125% Due 2033 Hedging Designation [Domain] Hedging Designation [Domain] Current liability Liability, Defined Benefit Plan, Current Product Liability, Workers Compensation and Other Personal Injury Matters Product Liability, Workers Compensation and Other Personal Injury Matters [Member] Amount charged to earnings in the current period for product liability, workers compensation and other personal injury matters. Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible List] Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible Enumeration] Net Investment Hedging Net Investment Hedging [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Guarantees [Abstract] Guarantees [Abstract] Proceeds from interest rate swap Proceeds from Hedge, Financing Activities Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Schedule of Derivative Instruments, Gain (Loss) Recognized Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Increase (decrease) in UTB Unrecognized Tax Benefits, Period Increase (Decrease) Document Fiscal Period Focus Document Fiscal Period Focus Estimated useful life Finite-Lived Intangible Asset, Useful Life Unused lines of credit Line of Credit Facility, Remaining Borrowing Capacity 2027  Lessee, Operating Lease, Liability, to be Paid, Year Four Purchase price percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date Outstanding, beginning of period (in dollars per share) Outstanding, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Non- U.S. Foreign Tax Authority [Member] City Area Code City Area Code Earnings Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Bank time deposits Time Deposits, at Carrying Value Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Document Fiscal Year Focus Document Fiscal Year Focus Restricted Units, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Geographical [Domain] Geographical [Domain] Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $(22), $9 and $11) Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated) Floating Rate 2 Year Senior Notes Due 2023 [Member] Floating Rate 2 Year Senior Notes Due 2023 Summary of the Company's Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Dividends declared Dividends, Common Stock, Cash Total liabilities Liabilities, Fair Value Disclosure Fair value of investments Equity Securities, FV-NI, Noncurrent Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Tax Years 2025-2033 Tax Years 2025-2033 [Member] Tax Years 2025-2033 Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Currency translation adjustment (net of tax provision (benefit) of $(134), $173 and $231) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Product technology Developed Technology Rights [Member] Lisa P. Britt [Member] Lisa P. Britt 0.875% Notes due 2031 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) Senior Notes 0.875% Due 2031 [Member] Senior Notes 0.875% Due 2031 [Member] Total liabilities, redeemable noncontrolling interest and equity Liabilities and Equity Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] ROU assets Operating Lease, Right-of-Use Asset Risk free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Restructuring Costs Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Additions (reductions) charged to income tax provision, net Deferred Tax Assets Valuation Allowance, Increase Charged To Income Tax Provision Amount of increase in deferred tax valuation allowance resulting from amounts charged to income tax expense. Non-U.S. Current Foreign Tax Expense (Benefit) Other All Other Countries [Member] All Other Countries Currency [Axis] Currency [Axis] Future restructuring costs Restructuring and Related Cost, Expected Cost Discount rate for determining benefit obligation Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Plan participants' contributions Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Schedule of Segment Reporting Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Options vested and expected to vest, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Income tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount Net restructuring charges incurred Restructuring Charges Projected benefit obligation Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Termination Date Trading Arrangement Termination Date Change in Accounting Principle, Type [Domain] Change in Accounting Principle, Type [Domain] Common Stock, $1 Par Value - Shares Authorized (in shares) Common Stock, Shares Authorized Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Warrants Other Assets, Fair Value Disclosure Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Award Timing Disclosures [Line Items] Declared but unpaid dividends Dividends Payable Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Selling, general and administrative expenses adjustments Selling General And Administrative Charges Net Certain charges/credits to selling, general and administrative expenses principally associated with acquisition accounting. Gain (loss) on investments Gain (Loss) on Investments Net income/(loss) Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Debt settled Business Combination, Consideration Transferred, Liabilities Incurred 4.95% 10-Year Senior Notes, Due 11/21/2032 Senior Notes 4.95% Due 2032 [Member] Senior Notes 4.95% Due 2032 Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Supplemental Cash Flow Information Cash Flow, Supplemental Disclosures [Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Short-term obligations and current maturities of long-term obligations Less: Short-term obligations and current maturities Debt, Current 2026  Finite-Lived Intangible Asset, Expected Amortization, Year Three Insider Trading Arrangements [Line Items] Options outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Amounts recognized in accumulated other comprehensive items Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract] Maximum period prior to maturity Maximum Period to Maturity Allowed Under Program Maximum maturity period allowed under U.S. commercial paper program Issuance of shares under employees' and directors' stock plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] 2025  Finite-Lived Intangible Asset, Expected Amortization, Year Two Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of Sales Cost of Sales [Member] Noncontrolling interests Equity, Attributable to Noncontrolling Interest Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Auditor Name Auditor Name Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Financial Assets and Liabilities Measured at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Repayment of debt Repayments of Long-Term Debt Entity Central Index Key Entity Central Index Key Liabilities [Abstract] Liabilities, Fair Value Disclosure [Abstract] Foreign Foreign Tax Positions [Member] Foreign Tax Positions [Member] Included in interest expense Derivative, Gain (Loss) on Derivative, Net Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Definite-lived intangible assets, gross Finite-Lived Intangible Assets, Gross Finished goods Inventory, Finished Goods, Net of Reserves Income Tax Authority [Domain] Income Tax Authority [Domain] Accrued payroll and employee benefits Employee-related Liabilities, Current Cash outlay Payments of Financing Costs Name Trading Arrangement, Individual Name Weighted average shares Weighted Average Shares [Abstract] Weighted Average Shares Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, Tax Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Revenues Revenue from Contract with Customer, Excluding Assessed Tax Olink Holding AB Olink Holding AB [Member] Olink Holding AB Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Fair Value Hedging Fair Value Hedging [Member] Discount rate Operating Lease, Weighted Average Discount Rate, Percent Tax Period [Domain] Tax Period [Domain] Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Assets [Abstract] Assets, Fair Value Disclosure [Abstract] Estimated amounts due from insurers Loss Contingency, Receivable Business Combinations Business Combinations Policy [Policy Text Block] Deferred tax assets/(liabilities), net Deferred Tax Liabilities, Net Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Diluted (in shares) Diluted weighted average shares (shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Global intangible low-taxed income Effective Income Tax Rate Reconciliation, GILTI, Amount Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Purchase of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount 2027  Defined Benefit Plan, Expected Future Benefit Payment, Year Four Total assets Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Business Acquisition, Pro Forma Information [Abstract] Business Acquisition, Pro Forma Information [Abstract] 2029 and thereafter Finance Lease, Liability, to be Paid, after Year Five Proceeds from issuance of commercial paper Proceeds from Issuance of Commercial Paper Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition 2028  Long-Term Debt, Maturity, Year Five Segment Reconciling Items Segment Reconciling Items [Member] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Loss on contract termination Loss on Contract Termination Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Deferred tax assets/(liabilities), net before valuation allowance Deferred Tax Assets (Liabilities) Before Valuation Allowance For entities that net deferred tax assets and tax liabilities, represents the unclassified net amount of deferred tax assets, before any related valuation allowance, and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities. A temporary difference is a difference between the tax basis of an asset or liability and its carrying amount in the financial statements prepared in accordance with generally accepted accounting principles that will reverse in ensuing periods. Construction in progress Construction in Progress [Member] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Restructuring and other costs Restructuring and other costs Restructuring And Other Costs (Income) Net Amount of restructuring charges, remediation costs and assets impairment loss; and, in some periods, may also include gains and losses on the sale of businesses, product lines and real estate. Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible Enumeration] Restricted Cash and Cash Equivalents, Current, Statement of Financial Position [Extensible Enumeration] Pension Plans, Defined Benefit Pension Plan [Member] Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Income before income taxes Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Non-PEO NEO Non-PEO NEO [Member] Target allocations for investments Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Adjustment to Compensation: Adjustment to Compensation [Axis] Fair value of equity awards exchanged Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Schedule of Short-term Debt [Table] Schedule of Short-Term Debt [Table] Presentation Reclassification, Comparability Adjustment [Policy Text Block] Redeemable noncontrolling interest Business Combination, Redeemable noncontrolling interest Redeemable noncontrolling interest assumed in a business combination Revenues Revenues [Abstract] Pension plans with accumulated benefit obligations in excess of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Foreign-derived intangible income Effective Income Tax Rate Reconciliation, FDII, Amount Vested and unvested expected to vest (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Schedule of Debt Schedule of Debt [Table Text Block] 4.953% 3-Year Senior Notes, Due 8/10/2026 Senior Notes 4.953% Due 2026 [Member] Senior Notes 4.953% Due 2026 Noncontrolling Interests Noncontrolling Interest [Member] 5.200% 10-Year Senior Notes due 1/31/2034 Senior Notes 5.200% Due 2034 [Member] Senior Notes 5.200% Due 2034 Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] EX-101.PRE 17 tmo-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 18 image_0.jpg begin 644 image_0.jpg M_]C_X 02D9)1@ ! 0$ W #< #_VP!# (! 0$! 0(! 0$" @(" @0# @(" M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_ MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P 1" !? <$# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#@ 3W'W:4! MM_S5^X'_ [._8>SS\ -,_\ B?_ ..5YC^V5^P#^R-\//V7O'/CCP7\%]/L M=4TOPW=3V-W'/,6AD6,E7&YR,@^QK\EK<$YC1HRJ.<;13;U?17[']NY?](SA M?'XVEAH82LG4E&*;Y+)MI*_O;:ZZ'Y'9 /-(2XZ=*3W>OM'_ ((Z?LW?!?\ M:(USQ[:_&/P-;:Y'I5GISV"7,CKY1D:XWD;&'78O7/2OFLNP%3,L9'#0:3E> MU]M$WTOV/V+BOB;"\)\/U/P ^$?[/? M_!.[XD>'O@_X,M]%L[V2RN+J"W9R))?MELN\ER3G:H'7'%?:8?A;'953JUZD MXM*G-:-WUBUU2/YVSCQHR/CC%8#+,+0J0D\30:XD"*BBQL>23P!BO,X+?+G&O\K_0^X^D)&4^ 5&*O^]A^I]V'!YS1R1N->(: MU_P46_8UT+4FTV]^/GAYI%;:Q@OA(H/H2N0/?GBO1_AG\8_AA\8-*_MSX:^. MM*UJUSCSM-ODF"GK@[3QP17ZI3QF%J5.2%2+?9--G\2XK);&,IRY8J[+I/;- ..E>*>(O^"AO['/AB^.G:G\??#C2KPZVNH+-L]CLS@_6 MM3P'^V[^RU\2M0CTKP?\;O#MU=3.%AM?[3197/LC$$_AFN../P,JG(JD;]KJ M_P!USUY\.<04\/[>6$J*&_,X2M]]K'K&SN&11EASBN(_X:+^"*G:/BMX?_\ !M%_\570WOBWP_INE?VW MJ.KVL%F(?,^TRW"K&$QG.[..G/TJ(UJ,K\LD[>9M4P6,HM*I3DK[735_0UCE MJ;7'^%OCS\(?&]IJ5_X/^).BZE!HRJ^K36>I1R):*=V#(5)V9V-C.,[3Z&H_ M^&BO@CN_Y*GX?_\ !K%_C2^L4+7YE]Z*CEV8.;BJ,KK=,]/FU7PKXFL+^VMY-DTUI=+(J-C."5)P<8/T-<'XS_;:_99^ M'^J3:+XL^./ANSO+=RDUK)JT7F(<]"N<@TJF)P\(\\II+NVDOO*P^69EBJSI M4:,I26Z46VODD>K[MRT$]^]<=\-?CQ\)?C#8MJ'PQ^(.CZW$IQ(VFZ@DVSZA M3P:Z#Q%XFT3POILFL>(-6M[.VA1GDN+J81HB@9))/'2KC5I5*?/%IKOT,:F% MQ5&M[&I!J=[6::=_3_%+X?_ !4T1?$/P\\8Z;K-D[86ZTV\29/IE216-/%X6M)Q MIU(R:Z)ILZ\5DN;8&BJN)P\X1>SE&23]&TKG2T9HR/6J.JZSINBV[7FIW\-O M#&NYI)Y BKCW-=-TM6>=&,I2M%79<)..*$SW->*^)/\ @H1^Q[X3NC8ZO\>_ M#GF*V&CM]128HWH=F_A6 MXMITDC;E7C;(/Y58!!Z5V'C-.+LS\]_^"^G_ ")/PZ_["E]_Z+CK\S\]Z_3# M_@OI_P B3\.O^PI??^BXZ_,T\+C-?C/%W_(]J>D?R1_?_@+_ ,FVPO\ BJ?^ MG)"GFFJOJM?JG_P34_8N_9C^+7[&'@_Q]\1?@_I.K:Q?-J NK^YC;S)/+O[B M-<\]D51TZ"O=V_X)R_L5'C_AG[0_^_3?_%5UX7@O'8G#PK1J1M))J][V:OV/ MG\W^D-P[D^;5\!4PM5RI3E!M2=FUI?H?G-_P1P^#LGQ%_:Q7Q]> M6C-I_@K2YKYY H,?VF4-#"C9[X:5QCO%^?D/[;/QB_X7Q^U-XT^(UO<1RV<^ MKM;:6T6=K6L $,; 'IO1 Y]W-?M%\./V=/@-^S]IVK7'PR\":;X<@U"%6U:: MU4IYB1JV"[$]%#/CD8W$UY2OP'_X)D9P?"/P[_[^0_\ Q5>U6X7K0RJG@_:Q MB^9RE=NS>RMIT7D?GN6^,N7UN.,5G\L'5J)TXTJ:BDW"-^:7-K:[EJM=C\Y_ M^"6?P;C^,7[9_AF*_M5FT_PV6UV^5G*D>05\DC'<7#P$CNH:OVP4!0$ ]J\F M^ ?PW_96\&ZM?7_[/.@^&;6XDBC34IM!\LN4W$H'*G(&<_7'?''INK:WINB6 MK7^J7T-O#&I9IKB8(JX]2:^AX?RN.48%PR5Y!H#$\YKQ7Q'_P %"/V._"ET;/5/CYX<,P;: MT=OJ23%3[["I_ M:&!YN3VL;]KJ_P"9\:^&^((T/;/"5.3^;DE;[[6/8Y/N-]*_)'_@N(RU&TU*T-U9W,?^9$ MM/\ TLO:\'C#7))>J/U#P#3CXCT4_P"2?_I)\=V.?ML./^>R_P Z_HJTW(LH MQ_LK_*OYUK+B^A)_YZK_ #K]_?B#\#P+4ITZ>(E-V2Y=7\S])^DQAZ^*Q>54J47*356R2;;_ (>R6IVV M5)^[0,[:\3\/?\%#_P!CKQ1J:Z/I7Q[\/^=(VV-9KX1[CZ M@$_C7L6F:C:: MG:K?V5U'-#)S')&X96'KFOT*CB,/7UIS4O1I_D?RWCLJS++)*.,HSIM[*47& M_P!Z1:/6@LQVGK[5C2QN M#KRY:=2+?9-,]'%Y#G6 I^TQ.&J07>4))?>T=D02.M(<@Y-(TGEQEB?N\UQM MS\?O@U9W,ME>_$_0H9H9&CECDU2)61@<$$9X(-;3J4Z?Q-+U//HX;$8FZI0< MK=DW^1V08G@&G9P,'K7*:#\9OAEXKU1=&\+^.M)U"Z92RV]GJ"2.5'4X!)P! M7/?%+]KG]G7X+WW]F?$SXN:'I-U@-]CN-03SBOKLSNQ64TH]VU;[ MSHI97F5;$*A3H3'C9_R;'&>E/_ -.0/TQ_"OG7_@J[_P F%^// M^N=C_P"EMO7T57SK_P %7?\ DPOQX?\ IG9?^EUO7ZUFW_(KK_X)?^DL_AO@ MO_DL,N_Z_P!+_P!+B?B?D[GZQJ>ER:D^JWVD: M/"Q#RLL47F38XV@1IC=P#D]<5YX7)XVU^H__ 0A\,Z.?@!XN\2_8(_MUQXQ M:VFN?+&]HX[2V=$)]%,LA ]6)K\>X?R^699A[#G<4T[M=ET^9_>WBEQ-3X1X M5_M%T(U91G'D4E=*3VEWT5[6UOH?FY\3OA#\2_@SKX\,_%#P5?Z+?/'YD<%_ M;LGF)G&Y21\PSP2,\]ZM_!#XZ?$S]GCQ_9_$?X7^()K&]M'4R1ACY-W'G+12 MKD;T/X8Z@@@$?HW_ ,%V?!VB2? 'PIXO>T4ZA8^+EM8+C'S"*6UN'=/Q:&,_ M\!K\MB1ZT\VP4LCS3DI3>EFGUU_R,^ N(L/XE\&?6,=0BN9RA.-KQ=NU^Z:= MNC/WD\,_M.>!;W]F*S_:?UJY^QZ'-X9CU>Z\QMS0@Q;C%Q]YPWR8'5N!DU^0 M'[7'[<'Q?_:S\875SKNMW-AX:69^?>#?A[D^6XS,,QJP4YTZ]6E3YE?EC3E:ZOU M;T;Z):=3V[]EW_@G[^T%^UAHDWBWX?Z7:V>C13-"-5U68QQR2KMRB LW7D@ M8!!!P>*XO]H/]G3XI?LQ?$"3X=_%/1A:W0B$UK/%)NANH2Q DC8=1D$$<$$< MC-?9?[*O_!7#X"?LZ? 3PS\'H/A1XBDDT734CNYK=H-DUR^7FD7,@.&E9VY] M:\H_X*/?MX?"']L_PSX;7PGX#UG3=8T'4)2MUJ'E;&MY4^=/D.(\C^$] M._'BL#D=/*U.E7O6LFUT=[72TZ=SV\EXF\2L5QU+#XW+G'+Y2E%/ELXI7Y9- MW=[V5U:VNAU7_!+C_@H/XU\!_$S2?V??BQXEN-1\,Z]<1V>C7-Y(TDFFW3$" M&,,>3$YPF#D*2N,#-=Y_P7^*O?\ PIE7I]GUH_K8U^=EMV@:*/7?#NH7Z1M_")HM M/DQ^ :NC!YE6Q7#.)H5)7Y.5QOO9R6GRMIZG#G/!^7Y+XR91F6$IJ*K^V4XI M67-&E)IV[R3UMU5]V?"?(WAQS&.&.U;F-Y"O+,RX<8( !'4D@>/D^$S',JDL-AG:ZO+6R MLN_S>W^1]YQYGW"/"-&CFV;T^:<'*--**;O)*_*G9+1;O;;KKY9_P3L9A^Q_ M^U H/RGP1!G_ ,!=1KX\9LG"U^S/QR_93^!/[-7['OQ>/P8\#QZ+_;/@F\&I M;+F63SO*M9]F=['&/,?IC.><\5^,S$]Q7?Q%@ZV6X?#8>(M8-_J2Z*K-<31")(_+RO*)\@+G.2, G&X'COBO\ ?XP_ R_@T_XL> - M2T62[R;5KZW*I-C&=C=#C(!&>,X-?=?_ 00\,:3=-\1O$\UC&U]$=-MH[AD M!=(SY[,H/8$JI([[1Z"O:/\ @M#X*T/7OV,+_P 27MDIO-"UJQN+"0#YD=YA M WX%96]LX/:NRGD,L9P[]=G5=U%N*Z)1;NOG:YX&*\2J7#_BJ^'L-@X*G5J0 MC4FK\\ISC'WK[67,E;LNA^3WPR^*'CWX.^,[+Q_\./$UQI>J6,@>*XMFP& . M=CCHZ'H5(((ZBO=/C3\>OVMO^"D_C)=,\(^$-5N=)TVWCV^'M%5WMX7Q\TLQ M'WF9E)7=T& .Y/S=A?NFOUL_X(G>$]%L?V0V\06EI&MUJGB2\>\F\L;GV;8U M&>N H&!T!)]37GR3MU5W9J[/RN^(GPR\?_ E\1MX1^)'A*^T74D7?]DU" QL5 M)(##/53@X(KI?V:?VD_B3^RY\2K/X@> M9FCC29?[4TOS3Y&H0@_-&Z],X)P MV,J3D=P?N#_@O3X.T:W\/_#_ ,91VZB^6]O+)IE3#/$R(^TGN R9'IN/J<_F M\,GY&%;.G1F_=::>SU2:_.Q[?!^<87Q(X%ABL?0C:JI1E#>-XMQ; M5^CM==5?<_?3Q)^T;\/?"?P ;]HW6-0\OP__ &#'JBS;?F>.2,/&H'=VW*H' M*;FZ\3:]<6'A\3'^S?#=K,5MXH\\>8!CS7QR6;@'. M*^COV[?B'J.A?\$Q_@7\.K*Z:./7]'T^>[Y/[V&VLT.P^V^2)O\ @(KX-?D; M,_PU[O%6=8FM4AAHNRY8N275M)Z^236A^9^"/A_E.#P^(SFO!3J>TG"GS)/E MC"3C==FVGKO9:;N_H'P*_9:^.O[25[=6?P<\!7&K+8K_ *5<;ECAB8]%,CD* M&_V7OC6X7*3)Q\R.,AQGC()YXZU^P M7_!+3X=:1\/_ -B?P;]@M%6XUBS;4[R8)AII)W+@MZD(44>R"O./^"W/PWTO MQ+^RM:^/I+2/[;X;UZW>&XV_/Y:QX'EF6/4-)NI6D:SC)_P!;!G)4KUV9VD= "^._V M*-%T_4;EIIO#^H76F%V;/R*_F1K]%CE11[**[."\VQ%2I+!U975KQOTM:Z]- M;GB_2(X)RO!X6EGV#@H2<^2HHJRE=-J5EI=--/O?78\B_P""^?\ R)/PZ_[" ME]_Z+CK\S,GI7Z9_\%]#CP3\.O\ L*7W_HN.OS-)&WD5\_Q=_P CVIZ1_)'Z MAX"_\FUPO^*I_P"G)'Z+?L"_\%/?V:_V=?V5/#/P?^(-WJT>JZ2]]]J6VTV2 M1!YM[/,F& YRKCZ'CM7N/AK_ (+"_LH>,/$^G>$O#L^N3WVJ7T5I9P_V/(/, MFD<(J].[,*_+#P7^S'^T-\1/#=OXP\"_!KQ!JNEW6\6M]8Z<\D4FUBK88#LP M93Z%<5](?\$U/V(?C-%^UQH'BSXM_"C5M(T?P[%+J7FZMIS)'-<* L* G@.) M)!(/^N1KULISKB"4J.&C#W/=2?*]M%>_IJ? \<>'OA7AZ>89K5Q;>(_>3<%5 MC=U&VW'EM=>\[6W1^GGQYF-Q\"?%[E=O_%-7W_I.]?S]G&_D5_01^T& OP+\ M7 ?]"S??^D[U_/OG+\"MN/&U5H^C_-'-]&6,983,;J_O4_RD?H5_P01D$.H_ M%24M]RSTEOUO*^9_VV/VX/B9^U?\0]0=O$%W9^$+>Z9-#T&&8K%Y(.%DE .) M)&'SI:5=M#,DBD"0 _+(G]Y&'((X((->7C:^+APSA8P;46Y@-9/Q>^#7Q)^ _C6;X>_ M%7PU)I.JPQ+*;>1@P>-NCJRDAE.#R"1D$9R"*]"_8R_;9^('[&'B?4]8\'Z# M9:I8ZTD"ZMI]V2C2B'S/+*N,["/-;L<@U]$^(_VT?^">?[7OC&S\7_M2_"C7 M-'UJWTN.R^V0SO+!M61W"#RCN^](_) ]ZX<+@\KQ>!C:MRU[Z\VD;7Z.W:W7 MN?19UQ'QMD7$L^?+_;Y=9ZVVMK+O$%S?>$/$U_'86]K<2-(=.NY&V0O%U*JSE59.%&_=P0:.1T_X0.S(_\#+VOK/X _L-_P#!.?QW-IOQ4^!PAU.32=0AN[.ZL=;>0P3Q MLLBEESP0P'6ODK_@N'&(OVNM'0D_+X!LP/\ P-O:^@QN$QF#X7G3KS4U=--. M^G:_Y>I^4<-YYP[Q#XT4,7EF&E0DZ=15(SBHMR2>MD]VM'YJY\@ 'M7 MD\,Y+'.%5C*HXQC9M+JW>WW:_>?=^,/B%4X"J8*IAL-"K5J<]I37PQ7)S)-: MWDVNMM-C^>"6.6&5[>>)HW5MKJP(*D<$'\:^V_\ @CU^V)XR\)_&/3_V:/%^ MORW?AS7U==%6YDW?V?=JC2!4)/".%9=O3>5( RV?%O\ @I3X4T7P9^W%\0M" MT&Q2WMO[4@N?+C7CS)[6&>0_C)(S?C7.?L4LR?M G7RO/8TX2VGROLU>S7S/HN*,/EG&WAG4Q6(I+]Y0]K'JXRY.96?=/3S M6FS/U!_X*;_MS_\ #)7@"UT#P0\,WC#Q$CKI:R+N6SA7[]RXZ<$@*#U/J :_ M(GQ5XP^(/Q?\8MKWB_7=0U[6M2N OFW4K322R,W"*.V6P%50 . !@5[M_P5 MH\9ZKXL_;@\4:=J$^ZWT.UL;#3U ^Y']F28CZ^9-(?QQVKR?]F?XC^$/A!\> M_"_Q.\>Z)<:EI>AZB+R>RLPOF/(BL8L;B!\LNQCD\8]<5V<09E4S#.'1J3Y: M<9G0=-^T+;>>V@+?!KO;UP.-A;'.W=GMUXKYP\*^+_&WPR\4P^) M?!^OWVBZO83?N[BTD:*2)E/*G'OP5(((X((XK],?^'['P*2W:!?A'XHV[2.M MOQQ_UTK\[?VC_B!X0^*WQQ\3?$GP'H4^F:7KNIO>V]C<;=\32 -)G:2.9-[< M' R*C.,-D^#ITZF7UKN^NNO=/R_X8Z/#W../L]Q6)PG%. 4*3C>+<$EJ[.#5 MW?1W5^SO<_6+_@FC^VO<_M2XKWS_@C)XYNO#/[8:^%XY6$'B/ MP[=VTD6>"\>)U;'J!$X]@QKP?]I[C]I;XB'_ *GG5_\ TMEKIS7,*F83P-PM@^%?%3,\+AX6I3I0J0CTBI2LTO)-22[(9\ /CGXF M_9W\;W7Q"\'-LU5M$NK&QGX_<23(%\WD$?+G< 006"Y&,UQVK:MJNOZG<:UK M>I7%Y>74S275W=2EY)7)R6+')))ZDFNH^ GP@UKX^_&/P_\ ![P]-Y=UKVHK M ;@KN\F, O))COM16;'?%?L'\)_^"9G[(/PX\,PZ5_PJ>SU:Z6-4NM0U?=-+ M.P_C()VJ2?[H'%<>49+F.>4'&G-*G%]6[7=KV2ZV2/>X[\0N$_#G-%4K4'/% M5HKX4KJ";Y;MV25V[):O4_$[]W17[O?\,*?LE?\ 1!?#W_@"M%>Q_J)C/^?L M?Q_R/@_^)EL@_P"@&I]\?\SUOO\ C_2O'/V__P#DS'XD?]BG>_\ HHU[%D9K MQW]O\@?L8?$@$_\ ,IWG_HHU^B9A_N%7_"_R9_*/#?\ R46$_P"OM/\ ]*1^ M%/S;<8K]"O\ @@;_ ,C1\3/^O'2?_0[NOSU4D'!%?H3_ ,$"^?$WQ.R?^7'2 MO_0[NOR'A7_D>4O5_DS^\/&S_DV.,]*?_IR!^F-?.O\ P5#_IE9?^ MET%?161G%?.O_!5Q@/V"/'G/_+*R_P#2Z"OUG-O^177_ ,,OR9_#?!?_ "6& M7?\ 7^E_Z5^3X7YOFK]7O^"ZQ'_#+/AWG_ )GJV_\ 2.\K\H=S9J>- M/^1T_P#"@^CO_P D"_\ K[/_ -M/L3XU:8UU_P $9/A'J20$FV\>7FYA_"K7 M.J#^>W_)KX[;TS^5?J3^S%\!_P#AIG_@CGI?PDMF1;Z\AU273)GQ\EU%JUS+ M%S_""RA2?[I-?F+XK\+>(O OB2^\(>,-(GT_4M.N'@OK.ZC*R12 \J<_F.QZ MC(-8\082I3IX6NU[LJ<=?-)77K:QZ7A7GF#Q&,S?+.>U:GBZ\N7KRRF[->5[ MI_\ !/N_X#_\$7?!_P 9?@UX5^*LWQWU"T?Q#H%IJ$EI'H\;+"TT*.4!W\X) MVYQVJS\1O^".7P ^$=E;ZE\2?VNI=&ANI3%;2WVEPQK(X&<#,G/ S]*X+]B# M_@K3JG[,?PK@^$'Q"\"7&O:;IC-_8UU9W02:)&?=Y3;^"H9FVGJ 0.BBO*/V MY_VY?%W[:'B_3K[4-$CTG1=#$R:3IJR;F)D*EI)#W8A47 X&#CJ:]"MB.%:> M6QG3I*55I>[>2UTO=WV6OJ?(X'*?&[&<7U,)B,;.EA%*355*F_=UY>56NWLF MGMJ>SG_@G'^Q+C_D_FQ_\!(/_CE6/^"OOA71_ OPE_9^\%^'=>_M33])\*WM MG8ZD%V_:XHX=.1)<#@;E /''-?,_[*/[-'C7]JGXQ:;\-?"UA<"T>99-D66@0_"'2=.@6*WM[/6(H(47"QHHL MJCV& !4T_9UN'\36IT%37NJZ;U?,K[WV-JT<;E_BOD^7XO-)8NE*WPI:RUT?;S/SWS]C.,)^RG\.0OW?\ A!]*^7_MSBK\$]GO7[W_ M +'##_AE7X=\_P#,DZ5_Z1Q5V< _QZWHOS/)^DY_R+\O_P 4_P HE#]NK'_# M'OQ,'_4DZE_Z325^#^/^6E?O!^W4R_\ #'WQ*.?^9+U+_P!)GK\'U)!P:CCS M_>Z7H_S1K]&;_D3X_P#QQ_\ 23]*/^"!'_(O_$PX_P"7S3?_ $&XKW#_ (+# MC_C!+Q1_U_:;_P"EL->'_P#! C_D ?$P ?\ +YIO_H-Q7N'_ 6'/_&"/B@_ M]/VF_P#I;#7MY?\ \D7_ -N3_-GYUQ1_RD''_L(H?E3/QFPO]ZOV#_X(M_\ M)D]E_P!AZ^_]&"OQ]R5YVU^P7_!%D_\ &$]B/^H]??\ HP5\KP3_ ,CA_P"% M_H?LWTC/^2%A_P!?H?\ I,CS7_@OCG_A6O@$_P#4=N?_ $37YC_+][%?IQ_P M7Q/_ !;7P#_V';G_ -$U^9.1ZUCQ?_R/9^D?_24>OX#_ /)M[<9%O>P1+L/L"5*G'.UFK\F_'O@+Q?\,/%M M]X%\>:#/INJ:?,8KBUN(RI&#C(_O#T/0T<38*K2JTL2E[LXQU\TDK?#7 M$>"Q>7XO)IR2K4*U7W>KC*;E?Y-M/M\S]L/^"7-9LXRZH3\I5F^8@]#DCK7 M,_MU?M\>,_VT=8T^QFT-=&\.Z/*\NGZ:LF]Y)"-OFR-T+!?E ' &[^]7T&(X MEP%3A[V*?[QQ4>6W6R3=]K=3\OROP?XIPOBLL9*G;"QK.LJEUK'F]D M]//8\ +97I7Z\?\ !$SPQ?Z)^QJNL7?^KUCQ-?7=M[HNR _^/0M7Y;_ CX&? M$+]HCXC6/PT^'.CR75W=S*)IMA\NTCS\TLA_A51S[XP*_=?X"?";P_\ OX1 MZ#\)?#"L;+0].CMHY&7#2,!\TA]V;+'U+&N/@;!598N>)DO=2:OYNWZ;GT7T MD.),#'):&30DG5E-3DEO&,4TK]KMZ>C/BO\ X+YG_BB/AU_V%+[_ -%QU^9I M/R8-?IE_P7S(_P"$)^'()_YBE]_Z*CK\S7P1SZ5Y?&'_ "/JGI'\D?<^ O\ MR;?"_P"*I_Z_^D[U_/NI M^0XKX7C[^/0])?H?TC]&'_=V*^I/VC?AI^PK^U#IWD?%3Q1X=FO(X?*M=6M=6BBNH%ST5 MP>1GLP(&20,FODS_ ((D>$].\=^'_C1X*UC=]EU;0]/L[A5Z^7(M\C?H37Q% M\1OA[XJ^$_CS5OAOXVTYK/5-'O)+:\A;LRM]X>JL,,IZ$$&HHYI++N'C[)QY%JTZ<;M.ZV>C]3[:\?'+]GWXL?LW^-#X" M^+GA>33;\PK-"0V^*>/^]'(.&&C^[K7^!7:W\_+4_0.&:?BAD_ M%SRW'S6)P"5U6DHQE\-UHGJ^;1IIZ:W.+_97_:-\9?LO_&71_B9X8U*X6UM[ MM%UK3TD_=WUH3AXV&<%MN=I/W6P?4'Z _P""WTWG_M;:++G[W@&S/_DY>U\W M_LY_ [Q1^T5\9=!^$_A>UF9M3OHUO+F.,L+2V!S+.WLJ;CSU.!U-?1W_ 6Z M3R_VM=%C'.WP!9C_ ,F[VGA98F7#5?G^#FC;UZ_H&<4\ICXQ98Z"2KNC5]I; M>UER7_\ )K=?E8^/['_C]A/_ $U7^=?T6Z=Q91C/_+-?_0:_G4L<_;(7_P"F MJ_SK^BJP(^PQG/\ RS7_ -!KZ'P_^#$?]N_J?E?TGOXV5^E;_P!QGXI_\%5O M^3^OB%_U\:?_ .FZUKB_V*L?\-;?#M=I_P55(/[?7Q S_S\ M:?\ ^FZUKA_V+Y?*_:Y^&Q;^+QKIJ_G<**^7Q'_)2R_Z^_\ MQ^T9=_R9^E_ MV!1_],G:?\%2]-N=._;M\=^? RK<2V,T+$??4V%OR/7D,/J#7#_LC? S2OVE M/VA= ^"FM>)WT>WUHW*_VA'")&C:.WEE "D@'=LV]>]?9W_!;;]E?7M2NM'_ M &H/".F374-M8+I_B>.&/=Y$:NS17''1#=>NO#'BG]N*WL-0LGV75K<6,"O$V <$>9QP1753_\ M%X<_#[[+9_!&3_A(VM]KR/?C[&)#U(_CQWZ9K\__ !MXR\0?$+QAJOCOQ7>> M=J6KW\MW?3$?>E=BS8_V>>G;IVKU_8E_8J_9C^%'[2>A^/_AI^UK;^*M6 MTV&Z:WT2&UB5IE>VDB8Y5R<*K;NG:O@C]I\;?VF/B(,?\SSJ_P#Z6RU]M_\ M!%G]DKQ3HVIZA^U'XVTJ:S@N-/:Q\,Q7$>UID9@9;C!Z+\JHI[Y?M7Q+^T]_ MRAX?XBI4\4,PHSQK MQ;I480=1J*U4FW%OQ?_X)"G_C/+PGS_RZZA_Z1RU^T&1ZU]1P-_R*)?XW^2/QGZ1W_)>4 M_P#KQ#_TNH%%%%?:'X"-[XKF?BY\,M"^,OPYUGX8>*3*NGZUI\EG>>0VU_+< M;3@]CBNFR13=P+,!6(/_!D?\*];_93_84^$/[(5]K-]\,+C4G;78H$OOMUT9.(BY7' MI_K&SZU[7D'HU*S87K7GX?)\LPU95*5)1DMG\O\ (^FS#C?BW-<'+"8S&5)T MY6O%NZ=K-?L+&MU]EDV2?)*DJX;M\R M#/M79;@3@&@=N:]&I3A4IN$E=---=T]SYO#XBMA<1"O1ERS@TTUNFFFG\FKG MQS_PY(_9,'6\\0?^#(_X5[M^RQ^RE\.OV1O ]]X ^&,U\UC?:JVH3?;KCS&\ MYHXXS@^FV)>/7/K7J1!QG--*MC-<6%RG+<'4]I0I*,MKH^@S3C#BC.\+]6Q^ M+G5IW3Y9.ZNMG\CR_P#:F_95^'7[7'@:S\ ?$N6\2QL=42_A^PS>6_G+')&, MGTQ*W'T]*\)/_!$K]DLC'VSQ!_X,S_A7V, >GZ4 @_QC\Z6*RG+L94]I6IJ3 MVN_(65\8\49)A?JV Q#OV;?A5IOP?\!/<-I>FM M.UN;N7?(3+,\S9/?YG/X5Q'[2/[ /[.7[4$O]J_$7PCY>K84+K6GOY-P0H( M9A]X#=T/]T>E>W$CU'%&1GBMYX/"U,.J$H)Q222>MK:+[CSL/GF<87,GF%&O M*-9MR6T^E.VG;TKRX\,Y+&IS*BO MQ/M*GB[XC5<.Z4LQG9_X4_O2O]VIP_P9_9^^%'P \*Q^#_A3X0M=)M551(T$ M8\R=E_B=NK,3DY/^$G[9$F@O\49]1C;P[]J%C]ANO+R)_+W[ MO7_5+CTKVDXSUI P/(/2O4J8/"U,/["4%R::=-'?\SXO#YYFV#S-9C2KR5>[ M?/=N5VFGJ]=4VCXZ_P"')/[)6,_:_$'_ (,C_A7U3\.? ND?#+P-H_P_\/>8 M;'1=,@L+4S-N?RHHQ&N3W.%&36[\Q.V@#YQKY;_X0?LG_L7?"K]CVUUJR^%\M^RZY)"]Y]NN3)S$'" MX]/OG]*Z7]HGX!>#_P!I;X6WWPD^(#W"Z7J$D,DQLY=D@,4JRK@]OF09]J[I M&^KJ%H6:MY/?\SDK9UFV(S19E4K2==-/GO[UXV2=_*R M^X^.1_P1)_9,Q\U]X@_\&1_PKZ$_9J_9Q\#_ ++?PWC^%WP]ENWTZ*ZEN%^V M3>8^^0Y;GTKT(G"XQ2C@\"L<+E>7X.I[2A347:UTNAZ&:\8<39YAOJ^/Q)?\ M#D?]DQEYOO$'_@R/^%?8[=LT(<#!;MWJ<1E.6XRI[2M34I/J_+0TRWC3BK)L M&L)@L9.G35VHQ=DKN[^]NYR7P3^#_AOX$?"_2?A/X0GN'TW1X##:M=2;I-FX MM@GO][\JY/\ :*_8L^ /[3VG^3\4?!45Q=QKM@U2W;RKJ)NVWW'D4$O\ @A-\&-.U*WN_ M%?Q7U_4H4;_2+-8(X5E_V=R\BOO;ME?RI""0!_%7DQX9R53YO8K\?\S[>7B[ MXBSH>R>83MM]F_WJ-SSKX#_LP_!G]F[PXOAGX4>#;?3E;;]JNE7=-,^F><5Z(O(Z4$;>*!C&17M4Z5.C!0II)+9)61^?XO%XK'XB5?$S62S@ Y]> *\6/_ 1( M_9-(P+[Q!_X,C_A7V0P)XQ2D8&,UPXC*,MQ=1U:M)2D[7;\CZ#+>-.*LGP<< M+@L9.G35[1B[)7=W][;9P_[/OP)\(?LW_"32_@YX$>Y;2]):=K9KJ3?)F6=Y MVR>_S2-CVXKM\G;S2,0O!-&,C@5W4J<*4%""LDDDNR6Q\[B<3B,9B)UZTN:< MVW)O=MN[;]6[F;XK\,V/C'PQJ/A34P_V?4K&6UN"APP61"K8/K@U\EI_P1(_ M9*09-WX@_P#!F?\ "OL@$J>:;D \FN7&9=@LG^M; M/KQ2?M+?L$?L\?M3'^T_B1X4*:LD86/6M/D\JYPJD*K,/OJ,YP?0>E>VCD8S M2#.,XI_V?@_JWU?D7(ME;1:WT$^)<^EFSS/ZS/ZP[7G=J3LDE=KR27R/S\O_ M /@@S\-70MI7QQUY?FZ3:?"0!Z7-QSGYY#R>W' X'I7$?M M.?\ !.7X%_M6?$"#XC_$F?5%O[72X["(6-X8U\E9))!QCKNE;GTQ7T)Z'% R MW%>C4R_!5,.J$J:Y%]GH?'X?B//<+F;S&GB)JN[WG=N6NF[N]M/0^.4_X(F_ MLE1NK+=^(/E.?^0F?\*^P(+<6]O]G5CC&*FX#X-!;!R*6#R_!X&_L*:C>U[= M;;?F5G'$F><0332Y6ZSJNDN:][^=[W^\] M"GQUQA3P*P<<;45)1Y%&^G+:W+;M;2Q1U71-.UVPDTO5[*.XMIH_+GAFC#)( MI'*D'@@C((Z$&ODOXV?\$9_V8?B5K$FM>#Y-0\)S7$BO-'I)#PC P0L;\+GJ M<=S7V%G(R#2GVKHQ>7X/'14:\%+M?IZ'GY+Q+GW#M?VV6XF5*3WY7H_5;/YH M_/8_\$&? $MYM'QRUL6_?=I\.[&/\?TKT[X#_P#!'']F/X1ZM#XB\4M?>+KZ MWFWP_P!L;5@!P-I,2_*<'D9[U]=XZ8-(W6N&AP[DU"ISQHJ_G=_F?29CXJ.]9N]<%YK>J7%_=B/4"%\V:5I7P,<#+' KZT/!P306!X M]Z[L5@<)C(J-:"DEM?H?,Y1Q%G>159U^OS/FO]G[_@E_\ ML^_LV_%:P^+W@.ZU%&#C8"H/MGB'_ ((>?\%GO 6BMKGPA_X*\:MJFL;1_H5Q-?6* M-R./-\Z7_P!!KX9_X)_?\%$/VL?^"!7Q>\7? ;X^?LW7EQI6M7\<^M>&]69K M.=9XMT8NK.YVO'(C# + 2(P08(/-?JI\!/\ @Z#_ ."9OQ(M%,ML&;' EMC(Q )ZLBCO06SH_^"0H_P""S^B^._&'PV_X*2_V3>>% MO#MC##X=UZ012WFJ7)(D=M.\,Z!>ZMJ"QCYC!;0/,^/?:AH ^%_^"PO_ 7>^'7_ 3DO(_@ MC\*_#=MXT^+%]#'+_8[R-]DT>)P#&]SL.XR/D;(5()!#D@%0WRQ\-?V7?^#D MK_@H!9V7QE^)_P"U;&U_:'N='E\;_V3"?$\GA^) MUL_MFWYQ%O.=HZ9XR*OB9^PS\ M&?B3XYUF?4M;\0?"?P[J>L:C6:5CW9G=F/UK\GO\ @\KQN_9Q MS_U-_P#[A*_5'_@F8?\ C7!^S^?^J(^%/_3/:T%?9/<****"3Q7_ (**^._& M'PJ_8)^,_P 3OA_KDVEZ[X?^&.MZCH^I6K;9+6ZAL99(Y4/9E=01Z&OP\_X) MR?$S_@O?_P %/=,\7:O^SY^W7=6&?BMI?[ M3&K:U:S>+;[1Y='_ +'TK[3N6WCO!)N^==O,J8ZYYH*7PW/JG_AWO_P= ?\ M2031?_"RN?\ Y&K[ _X).?LV?\%._@9?^.-3_P""C?[2$/CEM0BT^+P?;6.L MR7<=H%-P;IG#Q)AFS;@$9X#=*\^/_!T3_P $JQU\6^,O_"6_^VU]P_ 'XW>! M_P!I+X,>&OCQ\-)[B3P_XKTF+4-(DO(?*E:"094LF3M/MDT$G:4444 ?*_\ MP6E^,GQ._9]_X)C_ !6^,7P=\77F@^)=#T[3Y-+U>QDVRV[/J=I&VT^Z.RGV M8U^0'_!)C_@X(_:<^&'[3NE>&_V]_BWK'B3X=^-HTM?[6US+'1I/-:..]C8C MF$2!XY0., GDQ@']7?\ @X,/_&GGXU?]@G3/_3O95^4G['O_ 3"3_@H_P#\ M$'[CQ-\-M(5OBA\-?B)KLWA-E55;4K8P6DTVF%NX?=NC)QB4#D!F)"HG]#]C M?6FI6<>H6-U'-!-&LD,T,@99$(R&!'!!!R"."*_)C_@Z._;=_:J_8V_X4;_P MS/\ &C6/"'_"1_\ "3?VW_9-QL^U_9_[*\G?Z[//EQ_OFL'_ (-K?^"M.H^. M-&C_ .";?[36MS0>+/#<3Q?#^^U9BLMY:Q9\S2Y-_P PF@ )0'DQJR<&, \1 M_P 'E)!/[.)4_P#0X?\ N$H!+WK,_83]F#7];\7_ +-GP_\ %WB34);S4M5\ M#Z3>:A=3'+3SR6<3O(?=F8DUWU><_L=_\FC_ M_[)SHG_I!#7HU!(-TYK\F M_P!H;]AG_@XN\7?M ^//%7P0_;ATG2?!>I>,=4N_".ER^*KB)K/2Y+N5[6 H M+U^6=52!XU?>7C3!S(N <\]*^H=&_8._X.<]=TBTUNR_X* Z1Y-Y; MQSQ;_%]P&"LH8"Y[O4K72KG8D\RW;H'/OMX_"OVAK^?\ _P"#P;G]JKX2?]D_NO\ MTN>@J.Y^^6@,TNAV<\C;FDM8V9O4E035ZJ?AS_D7K'_KSB_] %7*"0KY&_X+ ME_&SXJ?LX?\ !+7XH?&GX)^,;SP[XHT7^Q?[-UC3Y-LUOYNMV%O)M/O%+(I] MF-?7-?#_ /P<=?\ *&7XR?3P_P#^I#IE UN?FK_P3S/_ <#?\%*O@KJ?QU^ M!'[?$EGI.D^*)M!N(M?\0313&YBM[:X8@)$P*;+F, YSG(QQS[U_P[U_X.?3Z@JCHNJ6^NZ1;:S:;O(NH$FAW+@[&4$9_ U>H)#\* M_(__ (.B?VX?VK/V-;OX()^S/\:=9\(+XCC\2?VU_9-QL^U^0=,\G?Z[?.DQ MZ;S7ZX5^'/\ P>3_ /'_ /L['_IGXL_GH]!4=S]^%^@:AJVH7#;I+FZFTZ"665CW9G8D^I->K5XW_P3L_Y1]_ G_LCG MAC_TTVU>R4$A6)X^\=>$/AAX,U;XB>/_ !%:Z3HNAV,E[JFI7T@2*V@C4LTC M'T !^OUK;K\DO^#MK]I[Q)\,/V4/ 7[-OAC4YK4?$KQ%=7.M-"V//L--6%S MW^RT]S;OVSY..F: /-OC/_P76_;\_P""BG[0-U^S!_P1\^%,EKI\#L)O&%Y9 MH]S- -RMW4>[T\WOX(?M/1_" M?]LWXFZ+XN^%5II>)M1NQ?3W$K8\N"WF(2<2 ]0X,:KNQN.,?I=1102% M%%% !2%U7JU+7@?_ 4D\"_MF?$O]DKQ%X&_8,\::3X>^(6H>5'9ZSJFH26K MVUN&W3?9Y41]EPZCRU9@ ['Q(KXG_:L_X-LO\ @FE^T#H5\_@#X:S?#7Q!<*[6FL># M[IHX89". UHY,!CS@E55&QD!ESFOAWQ3_P %L/\ @N7_ ,$V7'P__;9^#'@7 MQ,]J O\ :6LRVS7DB9PK>;IET(R#ZM%NZ$\YSEG_ (.*/^"L'[>H;X&?L;? M;P7X;U_5E^RC4M-O U]&SC&89+^X2",]0&9&(Z@J0#05RR1YO_P07^)GQU_8 ME_X++S_L-?\ "6M?:+JGB/7?"7C#3K>9FL[BYTZ.Z9;R)-?TC5^6_P#P0Z_X(3^,/V'?B!>?M@_M>^(K'6/BEJ-K-%I6EV-Q]JBT07 _ MTB>2X(_?W<@)C+*-J*TF'E\S(_4B@);A7*_&WX;6/QE^#WBOX0:K^)#7544$G\W_\ P;9_%ZU_8N_X*G^)OV;?CXZ^'M1\ M5:1>^$3;Z@JIY.O6UY&T5N[$@*6,5Q$HYW2-&HR2*_H_5E?H:_,[_@L;_P & M_?AG]O7Q;)^T]^S1XNL?!?Q8VQG4/MV]=/U]H@%C>5XP7M[A555$RJP(50R] M''R==?\ !6G_ (+L?\$LM/A^$/[9/P=\'^-H=-A5+76?$6J03W\L(7Y&-S8W M8\P8YW2Q&4_Q'/4*^+4_>(N@ZM0KJW0U^%?A;_@MK_P6X_X*.-_PK/\ 8=_9 MT\"^&KR\C^;6+.^MWO+=& )D5M1NA$N$.?\ 5,WISBOUY_8@T+]JKPQ^S#X3 M\.?MI^(O#^L?$BPT\0>(-5\-R2-;W94D1R,71,SF/9YI50ADW%!M( !6/7** M**!'X?\ _!Y4?G_9Q_[F_P#]PE?JA_P3/('_ 3=_9^'_5$?"G_IGM:_.3_@ M[&_9R^,WQ^/P#/PB\&_VO_9)\4_VA_Q,;>W\KS?[(\O_ %TB;L^6_3.,?AO6O!W[ 7P-\)>(K/[/J&E_!_PS:7T'F*_E31Z7;HZ;E)5L,I&02# MU!(H*^RCV:BBB@D\!_X*K_\ *,W]H#_LCOB+_P!-T]?DE_P:E?LL_LU_M&># M_C;=?'_X"^$?&DFDZEH*Z6_B?P_;WIM%DCO_ #!&95;;N*)NQUVKGH*_7G_@ MI9X7USQI_P $\OCAX/\ #-C]JU'5/A3KUI8VWF*GG2R6$RHNYR%7).,D@#J: M_G]_X)X?%/\ X*X_\$R--\5:5^SA\$_#,T/C"XLYM6/B*[L;HAK99A'LVWJ; M?]<^>N>,8H+C\+/W^_X=@?\ !.;_ *,:^%'_ (0=C_\ &J]=\%^!O!_PU\)V M'@7X?^&+'1=%TJV6WTW2=,M5AM[6%1@)&B@*BCT Q7X;?\/H_P#@X,_Z(3\, M_P#P&M/_ )85];?\$ /%_Q1_X)5_%SP%X M%TG[=JVH:;IZV=KY\<7F,NJ6;GYI&51\JD\D=,5XS_P;#?"'XF_!+_@GEKW@ MOXJ^'O[-U!OBIJ5Q#:_;(9\0M8Z>H.Z%V7[ROP3GCW%!7V3Y._X.+?\ @EOX MM^ ?Q%A_X*O_ +&]I=://::O!>^/(=$!CDTN_5P8M9BV"(;A;9Y$[*5D3)\LM7]'OBKPOX>\;^&]0\(>+M$M=2TK5+*:SU+3[V%9(;F M"1-LD3HW#*REE((P0>:_F:_X*J?\$0/CU^R1^U%JOA/]G;P\VO?#?Q$?[6\* ME]=MXI;.,LZFSF6>56=H2659.0T;*=VXNJA4=3^C3]CPX_9(^%H/_1.=$_\ M2"&O1J\]_94TG4-!_9?^&^A:M;^3=6?@'1X+B'7(ME"K+E>#@\<<'M7H5 M!F%%%% 'X._\'B^/^%M_ T_]2[KG_H^TK]Q_AN?^+=Z!_P!@:U_]$K7XW_\ M!UK^S1\;/CY\4/@W>_"7P7_:L6F:#J\=\W]I6UOY;-/:[1B:11G'>OV1 M^'T,EOX#T2WF7#1Z3;*RYS@B):"Y?"C:HHHH("OY_P#_ (/!O^3J?A(?^J?W M7_I<]?T 5^'7_!U)^R_\<_CW^TI\+];^%'@;^U;:P\#W$-U)_:5K!Y_\ 4BTRON"OC?\ X+Y?#CQI\6?^"3'Q8^'OP_T; M^T-6U#^P_L=G]ICB\S9KNGR/\TC*HPB,>2,XP.2*!Q^(^,?^#6_]DG]EWX^? M\$_?&'C#XV_L\^#/%FJ6OQBU"SM]1\0^'+>[FBMUTK2G6(/*K$(&D=L9QEV/ M4FOTH/\ P35_X)\D8_X8I^%O_A#V/_QNOD+_ (-;_@M\3/@7_P $_P#QAX0^ M*?AO^R]0N/C%J%W#;_;(9]T)TK24#[H791\T;C!.?EST(K]*Z!RW(+2TM[&V MCM+6!8XXT"1Q(N%50!QCV%3T44$A7X<_\'E'_']^SM_US\6?ST>OW&K\;_\ M@[!_9R^,OQ_O/@.?A)X._M?^R8_$W]H?\3"WM_*\PZ3L_P!=(N[/EOTSC'/: M@J/Q'Z5_\$ZR/^'?7P)Y_P":.>&/_33;5[+7D?[!GA_5_"W[#7P9\+:]:_9[ M[3?A1X=M+ZW\Q7\N:/3+=776N1;V^I)!LG?T436<<7^]<*.]?L"IR,URWQ@^$ M7P]^/7PRUSX/?%GPM;:UX<\1:;)8ZQIEV#LGA<8(X.5/1@P(96 92" 0 CY$ M_P"#>K]J7P3^T=_P3#^'^@Z1K\$NO?#W3AX9\3::K_O+1[_\$4?^"G'_ 2?^.&I_M+_ /!)WXOP^(O#]%D&WFWNXKHI:WL2#D2*R29Y5%;YCE?\11W_!1'P%>Q_#WXE?L@ M?#>?Q'EHEDM=0N88WD4#.5%U(.GHX'/&.E!7+V/WF5U;[K4M?D_^P!\&X *M&TKI 4&K#GAG5OU>A9V7+T$CJ*** /_]D! end XML 19 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Feb. 03, 2024
Jun. 30, 2023
Entity Listings [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 1-8002    
Entity Registrant Name THERMO FISHER SCIENTIFIC INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 04-2209186    
Entity Address, Address Line One 168 Third Avenue    
Entity Address, City or Town Waltham    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02451    
City Area Code 781    
Local Phone Number 622-1000    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 201,176,616
Entity Common Stock, Shares Outstanding   381,312,268  
Documents Incorporated by Reference [Text Block] Sections of Thermo Fisher’s definitive Proxy Statement for the 2024 Annual Meeting of Shareholders (the “Proxy Statement”) are incorporated by reference into Part III of this report.    
Entity Central Index Key 0000097745    
Amendment Flag false    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Common Stock, $1.00 par value      
Entity Listings [Line Items]      
Title of 12(b) Security Common Stock, $1.00 par value    
Entity Stock Trading Symbol TMO    
Security Exchange Name NYSE    
0.750% Notes due 2024      
Entity Listings [Line Items]      
Title of 12(b) Security 0.750% Notes due 2024    
Entity Stock Trading Symbol TMO 24A    
Security Exchange Name NYSE    
0.125% Notes due 2025      
Entity Listings [Line Items]      
Title of 12(b) Security 0.125% Notes due 2025    
Entity Stock Trading Symbol TMO 25B    
Security Exchange Name NYSE    
2.000% Notes due 2025      
Entity Listings [Line Items]      
Title of 12(b) Security 2.000% Notes due 2025    
Entity Stock Trading Symbol TMO 25    
Security Exchange Name NYSE    
3.200% Notes due 2026      
Entity Listings [Line Items]      
Title of 12(b) Security 3.200% Notes due 2026    
Entity Stock Trading Symbol TMO 26B    
Security Exchange Name NYSE    
1.400% Notes due 2026      
Entity Listings [Line Items]      
Title of 12(b) Security 1.400% Notes due 2026    
Entity Stock Trading Symbol TMO 26A    
Security Exchange Name NYSE    
1.450% Notes due 2027      
Entity Listings [Line Items]      
Title of 12(b) Security 1.450% Notes due 2027    
Entity Stock Trading Symbol TMO 27    
Security Exchange Name NYSE    
1.750% Notes due 2027      
Entity Listings [Line Items]      
Title of 12(b) Security 1.750% Notes due 2027    
Entity Stock Trading Symbol TMO 27B    
Security Exchange Name NYSE    
0.500% Notes due 2028      
Entity Listings [Line Items]      
Title of 12(b) Security 0.500% Notes due 2028    
Entity Stock Trading Symbol TMO 28A    
Security Exchange Name NYSE    
1.375% Notes due 2028      
Entity Listings [Line Items]      
Title of 12(b) Security 1.375% Notes due 2028    
Entity Stock Trading Symbol TMO 28    
Security Exchange Name NYSE    
1.950% Notes due 2029      
Entity Listings [Line Items]      
Title of 12(b) Security 1.950% Notes due 2029    
Entity Stock Trading Symbol TMO 29    
Security Exchange Name NYSE    
0.875% Notes due 2031      
Entity Listings [Line Items]      
Title of 12(b) Security 0.875% Notes due 2031    
Entity Stock Trading Symbol TMO 31    
Security Exchange Name NYSE    
2.375% Notes due 2032      
Entity Listings [Line Items]      
Title of 12(b) Security 2.375% Notes due 2032    
Entity Stock Trading Symbol TMO 32    
Security Exchange Name NYSE    
3.650% Notes due 2034      
Entity Listings [Line Items]      
Title of 12(b) Security 3.650% Notes due 2034    
Entity Stock Trading Symbol TMO 34    
Security Exchange Name NYSE    
2.875% Notes due 2037      
Entity Listings [Line Items]      
Title of 12(b) Security 2.875% Notes due 2037    
Entity Stock Trading Symbol TMO 37    
Security Exchange Name NYSE    
1.500% Notes due 2039      
Entity Listings [Line Items]      
Title of 12(b) Security 1.500% Notes due 2039    
Entity Stock Trading Symbol TMO 39    
Security Exchange Name NYSE    
1.875% Notes due 2049      
Entity Listings [Line Items]      
Title of 12(b) Security 1.875% Notes due 2049    
Entity Stock Trading Symbol TMO 49    
Security Exchange Name NYSE    
XML 20 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audit Information
 12 Months Ended
Dec. 31, 2023
Audit Information [Abstract]  
Auditor Firm ID 238
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Boston, Massachusetts
XML 21 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheet - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 8,077 $ 8,524
Accounts receivable, less allowances of $193 and $189 8,221 8,115
Inventories 5,088 5,634
Contract assets, net 1,443 1,312
Other current assets 1,760 1,644
Total current assets 24,589 25,229
Property, plant and equipment, net 9,448 9,280
Acquisition-related intangible assets, net 16,670 17,442
Other assets 3,999 4,007
Goodwill 44,020 41,196
Total assets 98,726 97,154
Current liabilities:    
Short-term obligations and current maturities of long-term obligations 3,609 5,579
Accounts payable 2,872 3,381
Accrued payroll and employee benefits 1,596 2,095
Contract liabilities 2,689 2,601
Other accrued expenses 3,246 3,354
Total current liabilities 14,012 17,010
Deferred income taxes 1,922 2,849
Other long-term liabilities 4,642 4,238
Long-term obligations 31,308 28,909
Commitments and Contingencies
Redeemable noncontrolling interest 118 116
Thermo Fisher Scientific Inc. shareholders’ equity:    
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 442,188,634 and 440,668,112 shares issued 442 441
Capital in excess of par value 17,286 16,743
Retained earnings 47,364 41,910
Treasury stock at cost, 55,541,290 and 50,157,275 shares (15,133) (12,017)
Accumulated other comprehensive income/(loss) (3,224) (3,099)
Total Thermo Fisher Scientific Inc. shareholders’ equity 46,735 43,978
Noncontrolling interests (11) 54
Total equity 46,724 44,032
Total liabilities, redeemable noncontrolling interest and equity $ 98,726 $ 97,154
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheet (Parenthetical) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Accounts Receivable Allowances $ 193 $ 189
Preferred Stock, $100 Par Value - Par Value (in dollars per share) $ 100 $ 100
Preferred Stock, $100 Par Value - Shares Authorized (in shares) 50,000 50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares) 0 0
Common Stock, $1 Par Value - Par Value (in dollars per share) $ 1 $ 1
Common Stock, $1 Par Value - Shares Authorized (in shares) 1,200,000,000 1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares) 442,188,634 440,668,112
Treasury Stock at Cost (in shares) 55,541,290 50,157,275
XML 23 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statement of Income - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues      
Revenues $ 42,857 $ 44,915 $ 39,211
Costs and operating expenses:      
Selling, general and administrative expenses 8,445 8,993 8,007
Research and development expenses 1,337 1,471 1,406
Restructuring and other costs 459 114 197
Total costs and operating expenses 35,998 36,522 29,183
Operating income 6,859 8,393 10,028
Interest income 879 272 43
Interest expense (1,375) (726) (536)
Other income/(expense) (65) (104) (694)
Income before income taxes 6,298 7,835 8,841
Provision for income taxes (284) (703) (1,109)
Equity in earnings/(losses) of unconsolidated entities (59) (172) (4)
Net income 5,955 6,960 7,728
Less: net (losses) income attributable to noncontrolling interests and redeemable noncontrolling interest (40) 10 3
Net income attributable to Thermo Fisher Scientific Inc. $ 5,995 $ 6,950 $ 7,725
Earnings per share attributable to Thermo Fisher Scientific Inc.      
Basic (in dollars per share) $ 15.52 $ 17.75 $ 19.62
Diluted (in dollars per share) $ 15.45 $ 17.63 $ 19.46
Weighted average shares      
Basic (in shares) 386 392 394
Diluted (in shares) 388 394 397
Product revenues      
Revenues      
Revenues $ 25,243 $ 28,548 $ 30,361
Costs and operating expenses:      
Cost of revenues 13,168 14,247 13,594
Service revenues      
Revenues      
Revenues 17,614 16,367 8,850
Costs and operating expenses:      
Cost of revenues $ 12,589 $ 11,697 $ 5,979
XML 24 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statement of Comprehensive Income - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Comprehensive income      
Net income $ 5,955 $ 6,960 $ 7,728
Currency translation adjustment:      
Currency translation adjustment (net of tax provision (benefit) of $(134), $173 and $231) (69) (822) 373
Unrealized gains and losses on hedging instruments:      
Reclassification adjustment for losses included in net income (net of tax benefit of $2, $1 and $17) 5 2 56
Pension and other postretirement benefit liability adjustments:      
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $(22), $9 and $11) (69) 38 36
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $1, $3 and $6) 0 5 13
Total other comprehensive income/(loss) (133) (777) 478
Comprehensive income 5,822 6,183 8,206
Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest (48) 3 2
Comprehensive income attributable to Thermo Fisher Scientific Inc. $ 5,870 $ 6,180 $ 8,204
XML 25 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statement of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]      
Tax provision (benefit) on currency translation adjustment $ (134) $ 173 $ 231
Tax benefit on reclassification adjustment for losses on hedging instruments recognized in net income 2 1 17
Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period (22) 9 11
Tax benefit on amortization of net loss and prior service benefit included in net periodic pension cost $ 1 $ 3 $ 6
XML 26 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statement of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating activities      
Net income $ 5,955 $ 6,960 $ 7,728
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation of property, plant and equipment 1,068 986 831
Amortization of acquisition-related intangible assets 2,338 2,395 1,761
Change in deferred income taxes (1,300) (995) (647)
Stock-based compensation 278 307 230
Loss on early extinguishment of debt 0 26 767
Other non-cash expenses 604 524 190
Changes in assets and liabilities, excluding the effects of acquisitions:      
Accounts receivable (43) (430) (204)
Inventories 598 (825) (1,065)
Contract assets/liabilities 252 (354) 221
Accounts payable (500) 648 479
Contributions to retirement plans (42) (41) (34)
Other (802) (47) (945)
Net cash provided by operating activities 8,406 9,154 9,312
Investing activities      
Acquisitions, net of cash acquired (3,660) (39) (19,395)
Purchase of property, plant and equipment (1,479) (2,243) (2,523)
Proceeds from sale of property, plant and equipment 87 24 20
Proceeds from cross-currency interest rate swap interest settlements 70 15 8
Other investing activities, net (160) 84 (42)
Net cash used in investing activities (5,142) (2,159) (21,932)
Financing activities      
Net proceeds from issuance of debt 5,942 3,193 18,137
Repayment of debt (5,782) (375) (11,738)
Proceeds from issuance of commercial paper 1,620 1,526 2,512
Repayments of commercial paper (1,935) (3,690) 0
Purchases of company common stock (3,000) (3,000) (2,000)
Dividends paid (523) (455) (395)
Other financing activities, net 56 (9) 65
Net cash (used in) provided by financing activities (3,622) (2,810) 6,581
Exchange rate effect on cash (82) (139) 194
(Decrease) increase in cash, cash equivalents and restricted cash (440) 4,046 (5,845)
Cash, cash equivalents and restricted cash at beginning of year 8,537 4,491 10,336
Cash, cash equivalents and restricted cash at end of year $ 8,097 $ 8,537 $ 4,491
XML 27 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statement of Redeemable Noncontrolling Interest and Equity - USD ($)
$ in Millions
Total
Total Thermo Fisher Scientific Inc. Shareholders’ Equity
Common Stock, $1.00 par value
Capital in Excess of Par Value
Retained Earnings
Treasury Stock
Accumulated Other Comprehensive Items
Noncontrolling Interests
Redeemable noncontrolling interest, beginning balance at Dec. 31, 2020 $ 0              
Redeemable Noncontrolling Interest [Roll Forward]                
Recognition upon acquisition 122              
Net income/(loss) 1              
Other comprehensive income/(loss) (1)              
Redeemable noncontrolling interest, ending balance at Dec. 31, 2021 122              
Balance (in shares) at Dec. 31, 2020     437,000,000          
Balance at Dec. 31, 2020 34,517 $ 34,507 $ 437 $ 15,579 $ 28,116 $ (6,818) $ (2,807) $ 10
Balance, treasury stock (in shares) at Dec. 31, 2020           40,000,000    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of shares under employees' and directors' stock plans (in shares)     2,000,000     1,000,000    
Issuance of shares under stock plans 222 222 $ 2 324   $ (104)    
Stock-based compensation 230 230   230        
Purchases of company common stock (in shares)           4,000,000    
Purchases of company common stock (2,000) (2,000)       $ (2,000)    
Dividends declared (410) (410)     (410)      
Net income/(loss) 7,727 7,725     7,725     2
Total other comprehensive income/(loss) 478 478         478  
Contributions from (distributions to) noncontrolling interests 50             50
Excise tax from stock repurchases 0              
Other 41 41   41        
Balance (in shares) at Dec. 31, 2021     439,000,000          
Balance at Dec. 31, 2021 40,855 40,793 $ 439 16,174 35,431 $ (8,922) (2,329) 62
Balance, treasury stock (in shares) at Dec. 31, 2021           45,000,000    
Redeemable Noncontrolling Interest [Roll Forward]                
Net income/(loss) 15              
Other comprehensive income/(loss) (6)              
Contributions from (distributions to) noncontrolling interests (15)              
Redeemable noncontrolling interest, ending balance at Dec. 31, 2022 116              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of shares under employees' and directors' stock plans (in shares)     2,000,000          
Issuance of shares under stock plans 169 169 $ 2 262   $ (95)    
Stock-based compensation 307 307   307        
Purchases of company common stock (in shares)           5,000,000    
Purchases of company common stock (3,000) (3,000)       $ (3,000)    
Dividends declared (471) (471)     (471)      
Net income/(loss) 6,945 6,950     6,950     (5)
Total other comprehensive income/(loss) (771) (770)         (770) (1)
Contributions from (distributions to) noncontrolling interests (2)             (2)
Excise tax from stock repurchases 0              
Balance (in shares) at Dec. 31, 2022     441,000,000          
Balance at Dec. 31, 2022 $ 44,032 43,978 $ 441 16,743 41,910 $ (12,017) (3,099) 54
Balance, treasury stock (in shares) at Dec. 31, 2022 50,157,275         50,000,000    
Redeemable Noncontrolling Interest [Roll Forward]                
Net income/(loss) $ 19              
Other comprehensive income/(loss) (3)              
Contributions from (distributions to) noncontrolling interests (14)              
Redeemable noncontrolling interest, ending balance at Dec. 31, 2023 118              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of shares under employees' and directors' stock plans (in shares)     1,000,000     1,000,000    
Issuance of shares under stock plans 178 178 $ 1 265   $ (88)    
Stock-based compensation 278 278   278        
Purchases of company common stock (in shares)           5,000,000    
Purchases of company common stock (3,000) (3,000)       $ (3,000)    
Dividends declared (541) (541)     (541)      
Net income/(loss) 5,936 5,995     5,995     (59)
Total other comprehensive income/(loss) (130) (125)         (125) (5)
Contributions from (distributions to) noncontrolling interests (1)             (1)
Excise tax from stock repurchases (28) (28)       (28)    
Balance (in shares) at Dec. 31, 2023     442,000,000          
Balance at Dec. 31, 2023 $ 46,724 $ 46,735 $ 442 $ 17,286 $ 47,364 $ (15,133) $ (3,224) $ (11)
Balance, treasury stock (in shares) at Dec. 31, 2023 55,541,290         56,000,000    
XML 28 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Parenthetical) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]      
Cash dividends declared per common share (in dollars per share) $ 1.40 $ 1.20 $ 1.04
XML 29 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
Nature of Operations and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations and Summary of Significant Accounting Policies Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.
Principles of Consolidation
The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. At December 31, 2023 and 2022, the company had such investments with carrying amounts of $489 million and $369 million, respectively. The company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity method. At December 31, 2023 and 2022, the fair value of such investments was $5 million and $7 million, respectively.
Redeemable Noncontrolling Interest
The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at a premium upon the occurrence of certain events.
Presentation
Certain reclassifications of prior year amounts have been made to conform to the current year presentation.
Revenue Recognition
Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year.
Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date. However, some modifications are distinct from existing services provided under the contract and recognized prospectively.
Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.
Contract-related Balances
Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.
Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional.
Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract.
Warranty Obligations
The company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred.
Leases
Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations.
Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense.
Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option.
As a lessee, the company accounts for the lease and non-lease components as a single lease component.
Research and Development
The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred.
Restructuring Costs
Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of
an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models.
From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to provide economic benefits to the company. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period.
Income Taxes
The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused.
The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money.
Earnings per Share
Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units.
Cash and Cash Equivalents
Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three months or less. These investments are carried at cost, which approximates market value.
Inventories
Inventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income. The components of inventories are as follows:
December 31,December 31,
(In millions)20232022
Raw materials$2,057 $2,405 
Work in process705 660 
Finished goods2,326 2,569 
Inventories$5,088 $5,634 
Prior to the third quarter of 2021, certain of the company’s businesses utilized the LIFO method of accounting for inventories. During the third quarter of 2021, these businesses, which comprised approximately 5% of consolidated inventories, changed from the LIFO method to the FIFO method. The company believes this change is preferable as it will provide a consistent, uniform costing method for all inventories across the company, better reflect the current value of inventories, and improve comparability with peers. Prior financial statements have not been retrospectively adjusted due to immateriality. The cumulative pre-tax effect of this change in accounting principle of $33 million was recorded as an increase to inventories and a decrease to cost of product revenues in the third quarter of 2021. This change was recorded in the Laboratory Products and Biopharma
Services ($20 million) and Specialty Diagnostics ($13 million) segments. Reductions to cost of revenues as a result of the liquidation of LIFO inventories were nominal during the first half of 2021.
Property, Plant and Equipment
Property, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income. Property, plant and equipment consists of the following:
December 31,December 31,
(In millions)20232022
Land$458 $454 
Buildings and improvements3,593 3,153 
Machinery, equipment and leasehold improvements9,235 7,967 
Construction in progress2,238 2,695 
Property, plant and equipment, at cost15,524 14,269 
Less: Accumulated depreciation and amortization6,076 4,989 
Property, plant and equipment, net$9,448 $9,280 
Acquisition-related Intangible Assets
Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value.
In addition, the company has tradenames that have indefinite lives and which are not amortized. Intangible assets with indefinite lives are reviewed for impairment annually or whenever events or changes in circumstances indicate they may be impaired. The company may perform an optional qualitative assessment. If the company determines that the fair value of the indefinite-lived intangible asset is more likely than not greater than its carrying amount, no additional testing is necessary. If not, or if the company bypasses the optional qualitative assessment, it writes the carrying value down to the fair value, if applicable.
Acquisition-related intangible assets are as follows:
Balance at December 31, 2023Balance at December 31, 2022
(In millions)GrossAccumulated AmortizationNetGrossAccumulated AmortizationNet
Definite lived:
Customer relationships
$22,762 $(9,410)$13,352 $21,792 $(8,330)$13,462 
Product technology
5,894 (4,591)1,303 5,882 (4,360)1,522 
Tradenames
1,634 (1,079)555 1,635 (1,008)627 
Backlog
1,084 (859)225 1,038 (442)596 
31,374 (15,939)15,435 30,347 (14,140)16,207 
Indefinite lived:
Tradenames
1,235 N/A1,235 1,235 N/A1,235 
Acquisition-related intangible assets
$32,609 $(15,939)$16,670 $31,582 $(14,140)$17,442 
The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2023 is as follows:
(In millions)
2024 $1,931 
2025 1,630 
2026 1,460 
2027 1,430 
2028 1,398 
2029 and thereafter7,586 
Estimated future amortization expense of definite-lived intangible assets$15,435 
Other Assets
Other assets in the accompanying balance sheet include operating lease right-of-use assets, investments, deferred tax assets, pension assets, insurance recovery receivables related to product liability matters, certain intangible assets and other assets.
At December 31, 2023 and 2022, the company had $37 million and $36 million, respectively, of intangible assets not derived from acquisitions, net of accumulated amortization, which are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years.
Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments. At December 31, 2023 and 2022, the company had such investments with carrying amounts of $12 million and $55 million, respectively, and investments measured at NAV of $28 million and $22 million, respectively, which are included in other assets.
Goodwill
The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2023, 2022 or 2021.
The changes in the carrying amount of goodwill by segment are as follows:
(In millions)Life Sciences
Solutions		Analytical
Instruments		Specialty
Diagnostics		Laboratory
Products and
Biopharma Services		Total
Balance at December 31, 2021
$10,143 $5,043 $3,277 $23,461 $41,924 
Acquisitions
— 24 — — 24 
Finalization of purchase price allocations for 2021 acquisitions
9 — — 168 177 
Currency translation
(6)(102)(186)(635)(929)
Balance at December 31, 2022
10,146 4,965 3,091 22,994 41,196 
Acquisitions
— 31 1,741 627 2,399 
Currency translation
5 55 91 274 425 
Balance at December 31, 2023
$10,151 $5,051 $4,923 $23,895 $44,020 
Loss Contingencies
Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities acquired in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition.
Currency Translation
All assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period. Currency transaction gains/(losses) are included in the accompanying statement of income and in aggregate were $(67) million, $62 million and $25 million in 2023, 2022 and 2021, respectively.
Derivative Contracts
The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.
The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Canadian dollars, Singapore dollars, Czech koruna, Hong Kong dollars and Swedish krona. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management.
Cash flow hedges. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item.
Fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings.
Net investment hedges. The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
Government Assistance
From time to time, the company receives assistance from various governmental agencies generally in the form of cash or non-income tax credits. These programs help offset the costs of certain research and development activities, facility construction and expansion efforts, or hiring objectives. When the company believes that it is probable that it will meet the conditions tied to the assistance, it offsets the associated expense in the consolidated income statement. Such amounts were not material to the consolidated financial statements as of and for the years ended December 31, 2023 and 2022.
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.
Recent Accounting Pronouncements
The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures.
StandardDescriptionEffective date for Thermo Fisher and adoption approachImpact of adoption or other significant matters
Standards recently adopted
Accounting Standards Update (ASU) No. 2021-05, Leases (Topic 842): Lessors-Certain Leases with Variable Lease Payments
Amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. Third quarter of 2021 using a prospective methodNot material
ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance
New guidance to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model.
Fourth quarter of 2022 using a prospective method
Not material
ASU No. 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations
New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented.
Some aspects adopted in 2023 using a retrospective method and will adopt other aspects in 2024 using a prospective method
Not material
Standards not yet adopted
ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures
Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker.2024 annual report and interim periods thereafter using a retrospective methodWill increase disclosures in Note 4
ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures
Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid.2025 annual report and interim periods thereafter using a prospective or retrospective methodWill increase disclosures in Note 8
XML 30 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions
 12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Acquisitions Acquisitions
The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.
Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.
2023
On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not tax deductible.
On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment’s portfolio with the addition of highly complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development. The goodwill recorded as a result of this business combination is not tax deductible.
The components of the purchase price and net assets acquired are as follows:
(In millions)The Binding SiteCorEvitas
Purchase price
Cash paid
$2,412 $730 
Debt settled
307 184 
Cash acquired
(20)(4)
$2,699 $910 
Net assets acquired
Definite-lived intangible assets
Customer relationships
$868 $260 
Product technology
162 47 
Tradenames
42 — 
Backlog— 46 
Goodwill
1,741 627 
Net tangible assets
174 (2)
Deferred tax assets (liabilities)
(288)(68)
$2,699 $910 
In addition, in 2023, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Raman-based spectroscopy solutions for in-line measurement.
The weighted-average amortization periods for definite-lived intangible assets acquired in 2023 are 18 years for customer relationships, 14 years for product technology, 15 years for tradenames, and 13 years for backlog. The weighted-average amortization period for definite-lived intangible assets acquired in 2023 is 17 years.
Proposed Acquisition
On October 17, 2023, the company entered into a purchase agreement to acquire all of the issued and outstanding shares of Olink Holding AB (publ) at a price of $26.00 per share, or approximately $3.1 billion. Olink is a leading provider of next-generation proteomics solutions that will expand the company’s capabilities in this field. The company has commenced a tender offer to acquire all of the American Depositary Shares and common shares of Olink. The transaction is expected to close by mid-year 2024, subject to the satisfaction of customary closing conditions including receipt of applicable regulatory approvals, and completion of the tender offer. Upon completion, Olink will become part of the Life Sciences Solutions segment. The company intends to finance the purchase price with cash on hand and the net proceeds from issuances of debt.
2022
In 2022, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Fourier-transform infrared gas analysis technologies.
2021
On January 15, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, the Belgium-based European viral vector manufacturing business of Groupe Novasep SAS. The European viral vector manufacturing business provides manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities for cell and gene vaccines and therapies. The goodwill recorded as a result of this business combination is not tax deductible.
On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company. Mesa Biotech has developed and commercialized a polymerase chain reaction (PCR) based rapid point-of-care testing platform available for detecting infectious diseases including COVID-19. The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care. The goodwill recorded as a result of this business combination is not tax deductible.
On September 30, 2021, the company assumed operating responsibility, within the Laboratory Products and Biopharma Services segment, of a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland from CSL Limited to perform pharma services for CSL with capacity to serve other customers as well. The goodwill recorded as a result of this business combination is not tax deductible.
On December 8, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, PPD, Inc., a U.S.-based global provider of clinical research services to the pharma and biotech industry. The addition of PPD’s clinical research services enhances our offering to biotech and pharma customers by enabling them to accelerate innovation and increase their productivity within the drug development process. The goodwill recorded as a result of this business combination is not tax deductible.
On December 30, 2021, the company acquired, within the Life Sciences Solutions segment, PeproTech, Inc., a U.S.-based developer and manufacturer of recombinant proteins. PeproTech provides bioscience reagents known as recombinant proteins, including cytokines and growth factors. The acquisition expands the segment’s bioscience offerings. The goodwill recorded as a result of this business combination is not tax deductible.
In addition, in 2021, the company acquired, within the Life Sciences Solutions segment, cell sorting technology assets, an Ireland-based life sciences distributor and a developer of a digital PCR platform; within the Analytical Instruments segment, a Belgium-based developer of micro-chip based technology for liquid chromatography columns; and within the Specialty Diagnostics segment, a transplant diagnostics information system provider.
The components of the purchase price and net assets acquired for 2021 acquisitions are as follows:
(In millions)PPDPeproTechEuropean Viral Vector BusinessMesa BiotechLengnau biologics manufacturing facilityOther
Purchase price
Cash paid
$17,237 $1,946 $848 $421 $17 $298 
Fair value of equity awards exchanged
43 — — — — — 
Fair value of contingent consideration
— — — 65 1 117 
Cash acquired
(1,244)(83)(18)(14)— (12)
$16,036 $1,863 $830 $472 $18 $403 
Net assets acquired
Current assets
$2,477 $58 $39 $54 $— $12 
Property, plant and equipment
527 18 59 2 93 2 
Definite-lived intangible assets:
Customer relationships
6,257 510 302 — — 2 
Product technology
— 282 25 279 — 224 
Tradenames
594 — — 2 — 2 
Backlog1,038 — — — — — 
Goodwill
13,949 1,198 600 237 18 198 
Other assets
1,060 11 3 3 364 2 
Contract liabilities(1,539)— (59)— — (1)
Deferred tax assets (liabilities)
(1,782)(192)(80)(72)— (27)
Finance lease liabilities
(90)— (24)— (82)— 
Debt assumed
(4,299)— — — — — 
Other liabilities assumed
(2,034)(22)(35)(33)(375)(11)
Redeemable noncontrolling interest(122)— — — — — 
$16,036 $1,863 $830 $472 $18 $403 
During 2022, we finalized the allocations of the purchase price for the Lengnau biologics manufacturing facility, PPD, Inc. and PeproTech, Inc., largely with respect to definite-lived intangible assets, property, plant and equipment, contract liabilities, equity method investments, asset retirement obligations, defined benefit pension plans, assumed contingent consideration and the related deferred taxes. The adjustments to the income statement recorded during 2022 were not material.
The weighted-average amortization periods for definite-lived intangible assets acquired in 2021 are 17 years for customer relationships, 11 years for product technology, 7 years for tradenames and 3 years for backlog. The weighted average amortization period for all definite-lived intangible assets acquired in 2021 is 14 years.
Unaudited Pro Forma Information
The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1, 2020:
 Year Ended
 December 31,
(In millions)2021
Revenues$44,886 
Net income attributable to Thermo Fisher Scientific Inc.$7,369 
The historical consolidated financial information of the company and PPD has been adjusted in the pro forma information to give effect to pro forma events that are directly attributable to the acquisitions and related financing arrangements and are factually supportable.
To reflect the acquisition of PPD as if it had occurred on January 1, 2020, the unaudited pro forma results include adjustments to reflect, among other things, the incremental intangible asset amortization to be incurred based on the values of each identifiable intangible asset and the interest expense from debt financings obtained to partially fund the cash consideration transferred. Pro forma adjustments were tax effected at the company's historical statutory rates in effect for the respective periods. The unaudited pro forma amounts are not necessarily indicative of the combined results of operations that would have been realized had the acquisitions and related financings occurred on the aforementioned dates nor are they meant to be indicative of any anticipated combined results of operations that the company will experience after the transaction. In addition, the amounts do not include any adjustments for actions that may be taken following the completion of the transaction, such as expected cost savings, operating synergies, or revenue enhancements that may be realized subsequent to the transaction.
Pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended December 31, 2021, excludes $312 million of transaction costs, initial restructuring costs, and debt extinguishment costs directly attributable to the PPD acquisition that were included in the determination of net income attributable to Thermo Fisher Scientific Inc. for that period.
The company’s results would not have been materially different from its pro forma results had the company’s other 2021 acquisitions occurred at the beginning of 2020.
PPD’s revenues and losses attributable to Thermo Fisher Scientific Inc. in 2021, subsequent to the acquisition date, were $378 million and $(60) million, respectively. The loss includes non-recurring transaction and compensation costs.
XML 31 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue and Contract-related Balances
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue and Contract-related Balances Revenues and Contract-related Balances
Disaggregated Revenues
Revenues by type are as follows:
(In millions)202320222021
Revenues
Consumables
$17,597 $20,624 $22,608 
Instruments
7,646 7,924 7,753 
Services
17,614 16,367 8,850 
Consolidated revenues
$42,857 $44,915 $39,211 
Revenues by geographic region based on customer location are as follows:
(In millions)202320222021
Revenues
North America
$22,764 $24,594 $19,659 
Europe
10,741 10,762 11,134 
Asia-Pacific
7,873 8,115 7,218 
Other regions
1,479 1,444 1,200 
Consolidated revenues
$42,857 $44,915 $39,211 
Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data.
Remaining Performance Obligations
The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of December 31, 2023 was $26.92 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 53% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years.
Contract-related Balances
Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows:
December 31,December 31,
(In millions)20232022
Current contract assets, net$1,443 $1,312 
Noncurrent contract assets, net4 7 
Current contract liabilities2,689 2,601 
Noncurrent contract liabilities1,499 1,179 
Substantially all of the current contract liabilities balance at December 31, 2022 and 2021 was recognized in revenues during 2023 and 2022, respectively. Noncurrent contract liabilities increased during 2023 primarily due to advanced payments from a customer.
XML 32 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Business Segment and Geographical Information
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Business Segment and Geographical Information Business Segment and Geographical Information
The company’s financial performance is reported in four segments. A description of each segment follows.
Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Analytical Instruments: provides a broad offering of instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory.
Specialty Diagnostics: offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of diagnoses, which improves patient care in a more cost-efficient manner.
Laboratory Products and Biopharma Services: offers virtually everything needed for the laboratory. Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more innovative, productive and cost-efficient. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing.
The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation.
Business Segment Information
(In millions)202320222021
Revenues
Life Sciences Solutions
$9,977 $13,532 $15,631 
Analytical Instruments
7,263 6,624 6,069 
Specialty Diagnostics
4,405 4,763 5,659 
Laboratory Products and Biopharma Services
23,041 22,511 14,862 
Eliminations
(1,829)(2,515)(3,010)
Consolidated revenues
42,857 44,915 39,211 
Segment Income
Life Sciences Solutions
3,420 5,582 7,817 
Analytical Instruments
1,908 1,507 1,197 
Specialty Diagnostics
1,124 1,024 1,280 
Laboratory Products and Biopharma Services
3,358 2,872 1,844 
Subtotal reportable segments
9,810 10,985 12,138 
Cost of revenues adjustments
(95)(46)(8)
Selling, general and administrative expenses adjustments
(59)(37)(144)
Restructuring and other costs
(459)(114)(197)
Amortization of acquisition-related intangible assets
(2,338)(2,395)(1,761)
Consolidated operating income
6,859 8,393 10,028 
Interest income879 272 43 
Interest expense(1,375)(726)(536)
Other income/(expense)
(65)(104)(694)
Consolidated income before taxes
$6,298 $7,835 $8,841 
Depreciation
Life Sciences Solutions
$220 $214 $197 
Analytical Instruments
93 83 83 
Specialty Diagnostics
86 75 128 
Laboratory Products and Biopharma Services
669 614 423 
Consolidated depreciation
$1,068 $986 $831 
Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of significant transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges related to product liability litigation.
(In millions)202320222021
Total assets
Life Sciences Solutions
$20,191 $21,848 $22,751 
Analytical Instruments
10,247 10,019 9,692 
Specialty Diagnostics
8,636 5,542 6,010 
Laboratory Products and Biopharma Services
51,091 51,281 52,639 
Corporate/other (a)
8,561 8,464 4,031 
Consolidated total assets
$98,726 $97,154 $95,123 
Capital expenditures
Life Sciences Solutions
$178 $490 $810 
Analytical Instruments
87 140 79 
Specialty Diagnostics
121 112 167 
Laboratory Products and Biopharma Services
1,013 1,403 1,327 
Corporate/other
80 98 140 
Consolidated capital expenditures
$1,479 $2,243 $2,523 
(a)Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.
Geographical Information
(In millions)202320222021
Revenues (b)
United States
$22,013 $23,820 $18,907 
Other
20,844 21,095 20,304 
Consolidated revenues
$42,857 $44,915 $39,211 
Long-lived Assets (c)
United States
$6,352 $6,308 $5,578 
Other
4,652 4,565 4,286 
Consolidated long-lived assets
$11,004 $10,873 $9,864 
(b)Revenues are attributed to countries based on customer location.
(c)Includes property, plant and equipment, net, and operating lease ROU assets.
XML 33 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Income/Expense
 12 Months Ended
Dec. 31, 2023
Other Income and Expenses [Abstract]  
Other Income/Expense Other Income/(Expense)
In all periods, other income/(expense) includes currency transaction gains/losses on non-operating monetary assets and liabilities and net periodic pension benefit cost/income, excluding the service cost component, which is included in operating expenses on the accompanying statements of income. In 2023, other income/(expense) includes $46 million of net losses on investments.
In 2022, other income/(expense) includes $161 million of net losses on investments, $67 million of net gains on derivative instruments to address certain foreign currency risks, and $26 million of losses on the early extinguishment of debt (Note 10).
In 2021, other income/(expense) includes $767 million of losses on the early extinguishment of debt (Note 10), $36 million of financing costs associated with obtaining bridge financing commitments in connection with the agreement to acquire PPD (Note 2), offset in part by $66 million of net gains on investments. The company had a cash outlay of $36 million in 2021 associated with obtaining the bridge financing commitments, included in other financing activities, net, in the accompanying statement of cash flows.
XML 34 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation Expense
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation Expense Stock-based Compensation Expense
The company has stock-based compensation plans for its key employees, directors and others. These plans permit the grant of a variety of stock and stock-based awards, including restricted stock units, stock options or performance-based shares, as determined by the compensation committee of the company’s Board of Directors or, for certain non-officer grants, by the company’s employee equity committee, which consists of its chief executive officer. The company generally issues new shares of its common stock to satisfy option exercises and restricted unit vesting. Grants of stock options and restricted units generally
provide that in the event of both a change in control of the company and a qualifying termination of an option or unit holder’s employment, all options and service-based restricted unit awards held by the recipient become immediately vested (unless an employment or other agreement with the employee provides for different treatment).
Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses.
Stock Options
The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate is calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures.
The weighted average assumptions used in the Black-Scholes option pricing model are as follows: 
202320222021
Expected stock price volatility
25 %26 %26 %
Risk free interest rate
4.2 %2.0 %0.8 %
Expected life of options (years)
4.74.74.3
Expected annual dividend
0.3 %0.2 %0.2 %
The weighted average per share grant-date fair values of options granted during 2023, 2022 and 2021 were $159.32, $135.07 and $123.97, respectively. The total intrinsic value of options exercised during the same periods was $320 million, $336 million and $501 million, respectively. The intrinsic value is the difference between the market value of the shares on the exercise date and the exercise price of the option.
A summary of the company’s option activity for the year ended December 31, 2023 is presented below:
Shares
(in millions)		Weighted average exercise priceWeighted average remaining contractual term
(in years)		Aggregate intrinsic
value
(in millions)
Outstanding at December 31, 2022
5.6 $359.27 
Granted
0.7 546.94 
Exercised
(1.0)218.82 
Canceled/expired
(0.3)543.25 
Outstanding at December 31, 2023
5.0 $401.30 3.9$714 
Vested and unvested expected to vest at December 31, 2023
4.8 $396.20 3.9$712 
Exercisable at December 31, 2023
2.8 $316.88 2.7$635 
As of December 31, 2023, there was $162 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to be recognized through 2027 with a weighted average amortization period of 2.2 years.
Restricted Share/Unit Awards
Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is
generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.
A summary of the company’s restricted unit activity for the year ended December 31, 2023 is presented below:
 Units
(in millions)		Weighted
average
grant-date
fair value
Unvested at December 31, 2022
0.7 $495.39 
Granted
0.4 545.73 
Vested
(0.4)480.45 
Forfeited
(0.1)528.59 
Unvested at December 31, 2023
0.6 $533.65 
The weighted average per share grant-date fair values of restricted units granted during 2022 and 2021 were $520.83 and $444.61, respectively. The total fair value of shares vested during 2023, 2022 and 2021 was $207 million, $163 million and $151 million, respectively.
As of December 31, 2023, there was $179 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is expected to be recognized through 2027 with a weighted average amortization period of 1.9 years.
Employee Stock Purchase Plans
Qualifying employees are eligible to participate in an employee stock purchase plan sponsored by the company. Shares may be purchased under the program at 95% of the fair market value at the end of the purchase period and the shares purchased are not subject to a holding period. Shares are purchased through payroll deductions of up to 10% of each participating employee’s qualifying gross wages. The company issued 0.1 million, 0.2 million and 0.1 million shares, respectively, of its common stock in 2023, 2022 and 2021 under the employee stock purchase plan.
XML 35 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pension and Other Postretirement Benefit Plans
 12 Months Ended
Dec. 31, 2023
Retirement Benefits [Abstract]  
Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans
401(k) Savings Plan and Other Defined Contribution Plans
The company’s 401(k) savings and other defined contribution plans cover the majority of the company’s eligible U.S. and certain non-U.S. employees. Contributions to the plans are made by both the employee and the company. Company contributions are based on the level of employee contributions, and are based on formulas determined by the company. In 2023, 2022 and 2021, the company charged to expense $468 million, $402 million and $299 million, respectively, related to its defined contribution plans.
Defined Benefit Pension Plans
Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented.
The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.
When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits.
The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined. Contributions to the plans included in the following table are estimated at between $30 million and $50 million for 2024.
The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans:
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)2023202220232022
Accumulated benefit obligation
$1,005 $995 $1,166 $1,016 
Change in projected benefit obligations
Projected benefit obligation at beginning of year
$995 $1,260 $1,069 $1,552 
Acquisitions
— — 15 51 
Service costs
— — 26 34 
Interest costs
47 27 42 20 
Settlements
— — (37)(31)
Plan participants' contributions
— — 9 9 
Actuarial (gains) losses
42 (210)65 (447)
Benefits paid
(79)(82)(25)(19)
Currency translation and other
— — 57 (100)
Projected benefit obligation at end of year
$1,005 $995 $1,221 $1,069 
Change in fair value of plan assets
Fair value of plan assets at beginning of year
$937 $1,226 $868 $1,302 
Acquisitions— — 15 14 
Actual return on plan assets
84 (212)29 (347)
Employer contributions
5 5 36 36 
Settlements
— — (37)(31)
Plan participants' contributions
— — 9 9 
Benefits paid
(79)(82)(25)(19)
Currency translation and other
— — 49 (96)
Fair value of plan assets at end of year$947 $937 $944 $868 
Funded status
$(58)$(58)$(277)$(201)
Amounts recognized in balance sheet
Noncurrent assets
$— $— $65 $81 
Current liability
(6)(6)(11)(11)
Noncurrent liabilities
(52)(52)(331)(271)
Net amount recognized
$(58)$(58)$(277)$(201)
Amounts recognized in accumulated other comprehensive items
Net actuarial loss
$217 $200 $151 $74 
Prior service credits
— — (5)(4)
Net amount recognized
$217 $200 $146 $70 
For domestic pension plans, actuarial losses experienced in 2023 were driven by decreases in the weighted average discount rates used to determine the projected benefit obligation, as well as differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns. For non-U.S. pension plans, actuarial losses experienced in 2023 were principally driven by decreases in the weighted average discount rates used to determine the projected benefit obligation.
For domestic pension plans, actuarial gains experienced in 2022 were driven by increases in the weighted average discount rates used to determine the projected benefit obligation, as well as differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns. For non-U.S. pension plans, actuarial gains experienced in 2022 were principally driven by increases in the weighted average discount rates used to determine the projected benefit obligation.
The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2023 and 2022 and are as follows:
 Domestic pension benefitsNon-U.S. pension benefits
 2023202220232022
Weighted average assumptions used to determine projected benefit obligations
Discount rate for determining benefit obligation
4.82 %5.01 %3.47 %3.91 %
Interest crediting rate for cash balance plans
4.76 %4.96 %2.06 %2.19 %
Average rate of increase in employee compensation
N/AN/A2.64 %2.78 %
The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year, as presented in the following table:
 Domestic pension benefitsNon-U.S. pension benefits
 202320222021202320222021
Weighted average assumptions used to determine net benefit cost (income)
Discount rate - service cost
N/AN/AN/A3.62 %1.00 %0.65 %
Discount rate - interest cost
5.01 %2.70 %2.33 %3.95 %1.36 %0.80 %
Average rate of increase in employee compensation
N/AN/AN/A2.77 %2.73 %2.30 %
Expected long-term rate of return on assets
6.25 %4.75 %4.25 %4.33 %2.33 %2.02 %
The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan.
The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows.
The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks.
Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements.
The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases.
The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows:
 Pension plans
(In millions)20232022
Pension plans with projected benefit obligations in excess of plan assets
Projected benefit obligation
$1,752 $1,636 
Fair value of plan assets
1,352 1,296 
The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows:
 Pension plans
(In millions)20232022
Pension plans with accumulated benefit obligations in excess of plan assets
Accumulated benefit obligation
$1,695 $1,583 
Fair value of plan assets
1,349 1,294 
The measurement date used to determine benefit information is December 31 for all plan assets and benefit obligations.
The net periodic pension benefit cost (income) includes the following components:
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)202320222021202320222021
Components of net benefit cost (income)
Service cost
$— $— $— $26 $34 $27 
Interest cost on benefit obligation
47 27 23 42 20 11 
Expected return on plan assets
(59)(45)(40)(37)(26)(19)
Amortization of actuarial net loss
— 4 7 2 7 12 
Amortization of prior service cost (benefit)
— — — (1)(1)— 
Settlement/curtailment loss (gain)
— — — 1 (2)— 
Net periodic benefit cost (income)
$(12)$(14)$(10)$33 $32 $31 
Expected benefit payments are estimated using the same assumptions used in determining the company’s benefit obligation at December 31, 2023. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows:
(In millions)Domestic pension benefitsNon-U.S. pension benefits
Expected benefit payments
2024 $81 $52 
2025 79 55 
2026 80 59 
2027 79 60 
2028 79 65 
2029-2033374 354 
Domestic Pension Plan Assets
The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments.
Non-U.S. Pension Plan Assets
The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds,
multi-asset funds, alternative investments and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 30% - 90% for fixed income funds, 0% - 40% for multi-asset funds, 0% - 4% for alternative investments, 0% - 4% for real estate funds and 0% - 45% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments.
The fair values of the company’s plan assets at December 31, 2023 and 2022, by asset category are as follows:
 December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs		Not subject to leveling (a)
(In millions)2023(Level 1)(Level 2)(Level 3)
Domestic pension plan assets
U.S. equity funds
$93 $— $— $— $93 
International equity funds
93 — — — 93 
Fixed income funds
739 — — — 739 
Money market funds
22 — — — 22 
Total domestic pension plans
$947 $— $— $— $947 
Non-U.S. pension plan assets
Equity funds
$7 $— $— $— $7 
Fixed income funds
346 9 — — 337 
Multi-asset funds
66 — — — 66 
Derivative funds
184 — — — 184 
Alternative investments
1 — — — 1 
Insurance contracts
333 — 333 — — 
Real estate funds1 — — — 1 
Cash / money market funds
6 4 — — 2 
Total non-U.S. pension plans
$944 $13 $333 $— $598 
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
 December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs		Not subject to leveling (a)
(In millions)2022(Level 1)(Level 2)(Level 3)
Domestic pension plan assets
U.S. equity funds
$89 $— $— $— $89 
International equity funds
91 — — — 91 
Fixed income funds
739 — — — 739 
Money market funds
18 — — — 18 
Total domestic pension plans$937 $— $— $— $937 
Non-U.S. pension plan assets
Equity funds
$8 $— $— $— $8 
Fixed income funds
299 — — — 299 
Multi-asset funds
56 — — — 56 
Derivative funds
190 — — — 190 
Insurance contracts
306 — 306 — — 
Cash / money market funds
9 4 — — 5 
Total non-U.S. pension plans$868 $4 $306 $— $558 
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
The tables above present the fair value of the company’s plan assets in accordance with the fair value hierarchy (Note 14). Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. The fair value amounts of these investments presented in the above tables are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension plan assets. These investments were also redeemable at the balance sheet date or within limited time restrictions.
XML 36 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The components of income before provision for income taxes are as follows:
(In millions)202320222021
U.S.$2,431 $3,859 $3,340 
Non-U.S.3,867 3,976 5,501 
Income before income taxes
$6,298 $7,835 $8,841 
The components of the provision for income taxes are as follows:
(In millions)202320222021
Current income tax provision
Federal$228 $813 $446 
Non-U.S.1,206 633 1,148 
State150 254 160 
1,584 1,700 1,754 
Deferred income tax provision (benefit)
Federal$(551)$(611)$(227)
Non-U.S.(647)(314)(399)
State(102)(72)(19)
 (1,300)(997)(645)
Provision for income taxes
$284 $703 $1,109 
The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following:
(In millions)202320222021
Statutory federal income tax rate
21 %21 %21 %
Provision for income taxes at statutory rate
$1,323 $1,645 $1,857 
Increases (decreases) resulting from:
Foreign rate differential
(223)(329)(255)
Income tax credits
(276)(202)(315)
Global intangible low-taxed income
113 96 76 
Foreign-derived intangible income
(108)(149)(119)
Excess tax benefits from stock options and restricted stock units
(69)(80)(124)
Provision for (reversal of) tax reserves, net
13 (544)(17)
Intra-entity transfers
(233)(18)(284)
Foreign exchange loss on inter-company debt refinancing
(112)— — 
Provision for (reversal of) valuation allowances, net
(32)344 36 
Withholding taxes
33 84 164 
Tax return reassessments and settlements
(187)(210)1 
State income taxes, net of federal tax70 111 82 
Other, net
(28)(45)7 
Provision for income taxes
$284 $703 $1,109 
The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate.
During 2023, the company released valuation allowances of $32 million in jurisdictions where the deferred tax assets are now expected to be realized. In 2023 the company also recorded a tax benefit of $127 million for U.S. tax credits and the revaluation of net operating loss carryforwards due to higher tax rates as a result of its tax return resubmissions, a $91 million tax benefit, net of related tax expenses, from a foreign exchange loss on an intercompany debt refinancing transaction, and $233 million of tax benefits resulting from intra-entity transactions.
During 2022, the company settled an IRS audit relating to the 2017 and 2018 tax years. The company recorded a $208 million net tax benefit primarily from this settlement and related impacts, which resulted in a decrease in the company’s unrecognized tax benefits of $658 million. The company recorded $49 million of charges for expired tax credits and other related components of the settlement. The company recorded a charge of $395 million to establish a valuation allowance against certain U.S. foreign tax credits which the company believes will more likely than not expire unutilized. The company also recorded $101 million of additional net unrecognized tax benefit liabilities related to other tax audits.
During 2021, the company recorded a $188 million income tax benefit related to the deferred tax implications of an intra-entity transfer of assets. Also in 2021, the company recorded a $96 million income tax benefit related to a capital loss resulting from certain intra-entity transactions.
The company generally receives a tax deduction upon the exercise of non-qualified stock options by employees, or the vesting of restricted stock units held by employees, for the difference between the exercise price and the market price of the underlying common stock on the date of exercise. The company uses the incremental tax benefit approach for utilization of tax attributes. These excess tax benefits reduce the tax provision. In 2023, 2022 and 2021, the company's tax provision was reduced by $69 million, $80 million and $124 million, respectively, of such benefits.
Net deferred tax asset/(liability) in the accompanying balance sheet consists of the following:
(In millions)20232022
Deferred tax asset/(liability)
Depreciation and amortization
$(4,286)$(4,277)
Net operating loss and credit carryforwards
2,385 1,951 
Reserves and accruals
157 140 
Accrued compensation
299 259 
Inventory basis difference
275 364 
Deferred interest753 445 
Research and development and other capitalized costs
380 220 
Unrealized (gains) losses on hedging instruments
(66)(199)
Other, net
329 435 
Deferred tax assets/(liabilities), net before valuation allowance
226 (662)
Less: Valuation allowance
1,317 1,322 
Deferred tax assets/(liabilities), net
$(1,091)$(1,984)
The company estimates the degree to which tax assets, losses and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2023, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense.
The changes in the valuation allowance are as follows:
 Year Ended December 31,
(In millions)202320222021
Beginning balance
$1,322 $968 $933 
Additions (reductions) charged to income tax provision, net
(32)344 24 
Additions due to acquisitions
4 14 30 
Currency translation and other
23 (4)(19)
Ending balance$1,317 $1,322 $968 
At December 31, 2023, the company had net federal, state and non-U.S. net operating loss carryforwards of $70 million, $93 million and $1.42 billion, respectively. Use of the carryforwards is limited based on the future income of certain subsidiaries. Of the federal net operating loss carryforwards, $30 million expire in the years 2024 through 2037, and the remainder do not expire. Of the state net operating loss carryforwards, $83 million expire in the years 2024 through 2042, and the remainder do not expire. Of the net non-U.S. net operating loss carryforwards, $435 million expire in the years 2026 through 2043, and the remainder do not expire.
At December 31, 2023, the company had foreign tax credit carryforwards of $648 million and deferred interest carryforwards of $753 million. The foreign tax credit carryforwards will expire in the years 2025 through 2032. Of the deferred interest carryforwards, $149 million expire in the years 2025 through 2033 and the remainder do not expire.
U.S. federal taxes have been recorded on approximately $34 billion of undistributed foreign earnings as of December 31, 2023. A provision has not been made for certain U.S. state income taxes or additional non-U.S. taxes that would be due when cash is repatriated to the U.S. as the company’s undistributed foreign earnings are intended to be reinvested outside of the U.S. indefinitely. The determination of the amount of the unrecognized deferred tax liability related to the undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed. The company’s intent is to only make distributions from non-U.S. subsidiaries in the future when they can be made at no net tax cost.
Unrecognized Tax Benefits
As of December 31, 2023, the company had $0.54 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate.
A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:
(In millions)202320222021
Beginning balance
$572 $1,124 $1,091 
Additions due to acquisitions
— 15 26 
Additions for tax positions of current year
4 104 32 
Additions for tax positions of prior years
34 24 60 
Reductions for tax positions of prior years
(43)(659)(5)
Closure of tax years
(6)(4)(27)
Settlements
(21)(32)(53)
Ending balance
$540 $572 $1,124 
Substantially all of the unrecognized tax benefits are classified as long-term liabilities. The company does not expect its unrecognized tax benefits to change significantly over the next twelve months.
During 2023, the company’s unrecognized tax benefits decreased by $12 million as a result of uncertain tax positions relating to foreign tax positions and decreased $19 million relating to U.S. federal and state tax positions.
During 2022, the company’s unrecognized tax benefits increased by $143 million as a result of uncertain tax positions relating to foreign tax positions and decreased $610 million relating to U.S. federal and state tax positions which included $658 million from the settlement of the IRS audit of the 2017 and 2018 tax years. The company also assumed $15 million of uncertain tax benefits as part of the acquisition of PPD.
During 2021, the company’s unrecognized tax benefits increased by $80 million as a result of uncertain tax positions relating to foreign tax positions and decreased $75 million relating to U.S. federal and state tax positions. The company also assumed $26 million of uncertain tax benefits as part of the acquisition of PPD.
The company classified interest and penalties related to unrecognized tax benefits as income tax expense. The total amount of interest and penalties related to uncertain tax positions and recognized in the balance sheet as of December 31, 2023 and 2022 was $95 million and $74 million, respectively.
The company conducts business globally and, as a result, Thermo Fisher or one or more of its subsidiaries files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the company is subject to examination by taxing authorities throughout the world, including such major jurisdictions as Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, the United Kingdom and the United States. With few exceptions, the company is no longer subject to U.S. state and local or non-U.S. income tax examinations for years before 2012 and no longer subject to U.S. federal income tax examinations for years before 2019.
XML 37 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Earnings Per Share
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Earnings Per Share Earnings per Share
(In millions except per share amounts)202320222021
Net income attributable to Thermo Fisher Scientific Inc.
$5,995 $6,950 $7,725 
Basic weighted average shares
386 392 394 
Plus effect of: stock options and restricted stock units
2 2 3 
Diluted weighted average shares
388 394 397 
Basic earnings per share
$15.52 $17.75 $19.62 
Diluted earnings per share
$15.45 $17.63 $19.46 
Antidilutive stock options excluded from diluted weighted average shares
2 2 1 
XML 38 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt and Other Financing Arrangements
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Debt and Other Financing Arrangements Debt and Other Financing Arrangements
Effective interest rate at December 31,December 31,December 31,
(Dollars in millions)202320232022
Commercial Paper$— $310 
Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023
— 1,000 
Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023
— 500 
0.797% 2-Year Senior Notes, Due 10/18/2023
— 1,350 
Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
— 1,819 
0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
— 589 
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
0.93 %1,104 1,071 
Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024
— 500 
1.215% 3-Year Senior Notes, Due 10/18/2024
1.42 %2,500 2,500 
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
0.41 %883 857 
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
2.10 %706 686 
0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated)
1.05 %158 170 
0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)
0.15 %607 589 
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)
3.39 %552 535 
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
1.53 %773 749 
4.953% 3-Year Senior Notes, Due 8/10/2026
5.19 %600 — 
5.000% 3-Year Senior Notes due 12/5/2026
5.00 %1,000 — 
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
1.65 %552 535 
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
1.97 %662 642 
1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)
1.18 %205 221 
4.80% 5-Year Senior Notes, Due 11/21/2027
5.00 %600 600 
Effective interest rate at December 31,December 31,December 31,
(Dollars in millions)202320232022
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
0.77 %883 857 
0.77% 5-Year Senior Notes, Due 9/6/2028 (yen-denominated)
0.90 %206 — 
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
1.46 %662 642 
1.750% 7-Year Senior Notes, Due 10/15/2028
1.89 %700 700 
5.000% 5-Year Senior Notes due 1/31/2029
5.00 %1,000 — 
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
2.08 %773 749 
2.60% 10-Year Senior Notes, Due 10/1/2029
2.74 %900 900 
1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)
1.44 %33 36 
4.977% 7-Year Senior Notes, Due 8/10/2030
5.12 %750 — 
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)
0.89 %1,932 1,873 
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
1.13 %993 963 
2.00% 10-Year Senior Notes, Due 10/15/2031
2.23 %1,200 1,200 
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
2.55 %662 642 
1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)
1.60 %45 48 
4.95% 10-Year Senior Notes, Due 11/21/2032
5.09 %600 600 
5.086% 10-Year Senior Notes, Due 8/10/2033
5.20 %1,000 — 
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)
1.20 %1,656 1,606 
5.200% 10-Year Senior Notes due 1/31/2034
5.20 %500 — 
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)
3.76 %828 803 
1.50% 12-Year Senior Notes, due 9/6/2035 (yen-denominated)
1.58 %152 — 
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
2.94 %773 749 
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
1.73 %993 963 
2.80% 20-Year Senior Notes, Due 10/15/2041
2.90 %1,200 1,200 
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)
1.77 %1,380 1,339 
2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)
2.13 %104 111 
5.404% 20-Year Senior Notes, due 8/10/2043
5.50 %600 — 
2.02% 20-Year Senior Notes, due 9/6/2043 (yen-denominated)
2.06 %206 — 
5.30% 30-Year Senior Notes, Due 2/1/2044
5.37 %400 400 
4.10% 30-Year Senior Notes, Due 8/15/2047
4.23 %750 750 
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
1.98 %1,104 1,071 
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)
2.07 %828 803 
2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)
2.43 %236 254 
Other 77 79 
Total borrowings at par value
35,028 34,561 
Unamortized discount
(113)(112)
Unamortized debt issuance costs
(188)(171)
Total borrowings at carrying value
34,727 34,278 
Finance lease liabilities
190 210 
Less: Short-term obligations and current maturities
3,609 5,579 
Long-term obligations$31,308 $28,909 
SOFR - Secured Overnight Financing Rate
EURIBOR - Euro Interbank Offered Rate
The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt issuance costs.
See Note 14 for fair value information pertaining to the company’s long-term borrowings.
As of December 31, 2023, the annual repayment requirements for debt obligations are as follows:
(In millions)BorrowingsFinance Lease Liabilities
2024 $3,604 $5 
2025 2,356 13 
2026 2,925 12 
2027 2,020 10 
2028 2,451 8 
2029 and thereafter21,672 142 
$35,028 $190 
In addition to available borrowings under the company’s revolving credit agreements, discussed below, the company had unused lines of credit of $69 million as of December 31, 2023. These unused lines of credit generally provide for short-term unsecured borrowings at various interest rates.
Credit Facilities
The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term SOFR, a EURIBOR-based rate (for funds drawn in euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of December 31, 2023, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit.
Commercial Paper Programs
The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis.
Senior Notes
Interest is payable quarterly on the floating rate senior notes, annually on the euro-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the U.S. dollar, euro-denominated fixed rate senior notes and yen-denominated private placement notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest, together with swap breakage costs payable to holders of yen-denominated private placement notes who have entered into cross-currency swap agreements. The company is subject to certain affirmative and negative covenants under the indentures and note purchase agreement governing the senior notes, the most restrictive of which limits the ability of the company to pledge certain property and assets as security under borrowing arrangements. The company was in compliance with all covenants at December 31, 2023.
In 2022 the company completed the full allocation of an amount equal to the net proceeds from the 0.000% senior notes due 2025 to finance or refinance, in whole or in part, certain COVID-19 response projects.
In 2022, the company redeemed all of its 3.650% Senior Notes due 2025. In connection with the redemption, the company incurred $26 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income.
In 2021, the company redeemed some of its existing senior notes. In connection with these redemptions, the company incurred $767 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income. Upon redemption of the senior notes, the company terminated the related fixed to floating rate interest rate swap arrangements and received $22 million, included in other financing activities, net, in the accompanying statement of cash flows.
Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the following notes outstanding as of December 31, 2023, included in the table above (collectively, the “Euronotes”) in registered public offerings: the 0.00% Senior Notes due 2025, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are consolidated in the financial statements of the company.
XML 39 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Leases Leases
As a lessee, the company leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers, and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally for 1 to 10 years) or have options to terminate the arrangement within 1 year.
The company has guaranteed the residual value of three leased operating facilities with lease terms ending in 2024, 2025 and 2028. The company has agreed with the lessor to comply with certain financial covenants consistent with its other debt arrangements (Note 10). The aggregate maximum guarantee under these three lease arrangements is $147 million. Operating lease ROU assets and lease liabilities for these lease arrangements are recorded on the consolidated balance sheet as of December 31, 2023, but exclude any amounts for residual value guarantees.
As a lessee, the consolidated financial statements include the following relating to operating leases:
(Dollars in millions)202320222021
Statement of income
Operating lease costs
$355 $351 $254 
Variable lease costs
115 109 66 
Statement of cash flows
Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities$410 $289 $288 
Operating lease ROU assets obtained in exchange for new operating lease liabilities234 430 293 
Balance sheet
ROU assets - included in other assets$1,556 $1,593 
Operating lease liabilities - included in other accrued expenses263 272 
Operating lease liabilities - included in other long-term liabilities1,244 1,313 
Weighted average at end of year
Remaining operating lease term9.2 years9.4 years
Discount rate4.0 %3.2 %
Lease costs arising from finance leases, short-term leases, and sublease income are not material. See Note 10 for additional information relating to finance leases.
As of December 31, 2023, future payments of operating lease liabilities are as follows:
(In millions)
2024 $294 
2025 288 
2026 242 
2027 172 
2028 131 
2029 and thereafter723 
Total lease payments1,850 
Less: imputed interest
343 
Total operating lease liability$1,507 
As a lessor, operating leases, sales-type leases and direct financing leases are not material.
XML 40 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Purchase Obligations
The company has entered into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods, services or fixed assets and to pay royalties that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable at any time without penalty. The aggregate amount of the company’s unconditional purchase obligations totaled $2.53 billion at December 31, 2023, the majority of which are expected to be settled during 2024.
Letters of Credit, Guarantees and Other Commitments
Outstanding letters of credit and bank guarantees totaled $315 million at December 31, 2023. Substantially all of these letters of credit and guarantees expire before 2040.
Outstanding surety bonds and other guarantees totaled $93 million at December 31, 2023. The expiration of these bonds and guarantees ranges through 2025.
The letters of credit, bank guarantees and surety bonds principally secure performance obligations, and allow the holder to draw funds up to the face amount of the letter of credit, bank guarantee or surety bond if the applicable business unit does not perform as contractually required.
The company has funding commitments totaling $164 million at December 31, 2023, related to investments.
The company is a guarantor of pension plan obligations of a divested business. The purchaser of the divested business has agreed to pay for the pension benefits, however the company was required to guarantee payment of these pension benefits should the purchaser fail to do so. The amount of the guarantee at December 31, 2023 was $24 million.
In connection with the sale of businesses of the company, the buyers have assumed certain contractual obligations of such businesses and have agreed to indemnify the company with respect to those assumed liabilities. In the event a third-party to a transferred contract does not recognize the transfer of obligations or a buyer defaults on its obligations under the transferred contract, the company could be liable to the third-party for such obligations. However, in such event, the company would be entitled to seek indemnification from the buyer.
Indemnifications
In conjunction with certain transactions, primarily divestitures, the company has agreed to indemnify the other parties with respect to certain liabilities related to the businesses that were sold or leased properties that were abandoned (e.g., retention of certain environmental, tax, employee and product liabilities). The scope and duration of such indemnity obligations vary from transaction to transaction. Where probable, an obligation for such indemnifications is recorded as a liability. Generally, a maximum obligation cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, historically the company has not made significant payments for these indemnifications.
In connection with the company’s efforts to reduce the number of facilities that it occupies, the company has vacated some of its leased facilities or sublet them to third parties. When the company sublets a facility to a third-party, it remains the primary obligor under the master lease agreement with the owner of the facility. As a result, if a third-party vacates the sublet facility,
the company would be obligated to make lease or other payments under the master lease agreement. The company believes that the financial risk of default by sublessors is individually and in the aggregate not material to the company’s financial position or results of operations.
In connection with the sale of products in the ordinary course of business, the company often makes representations affirming, among other things, that its products do not infringe on the intellectual property rights of others and agrees to indemnify customers against third-party claims for such infringement. The company has not been required to make material payments under such provisions.
Environmental Matters
The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including input from environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At December 31, 2023, the company’s total environmental liability was approximately $75 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows.
Litigation and Related Contingencies
The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows.
Product Liability, Workers Compensation and Other Personal Injury Matters
The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. The range of probable loss for product liability, workers compensation and other personal injury matters of the company’s continuing operations at December 31, 2023, was approximately $222 million to $379 million. The company’s accrual for these matters totaled $224 million at December 31, 2023. The accrual includes estimated defense costs and is gross of estimated amounts due from insurers of $88 million at December 31, 2023 that are included in other assets in the accompanying balance sheet. In addition, as of December 31, 2023, the company had a product liability accrual of $20 million relating to divested businesses.
Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis.
XML 41 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Comprehensive Income and Shareholders Equity
 12 Months Ended
Dec. 31, 2023
Stockholders' Equity Note [Abstract]  
Comprehensive Income and Shareholders' Equity Comprehensive Income/(Loss) and Shareholders' Equity
Comprehensive Income (Loss)
Changes in each component of accumulated other comprehensive items, net of tax are as follows:
(In millions)Currency
translation
adjustment		Unrealized
losses on
hedging
instruments		Pension and
other
postretirement
benefit
liability
adjustment		Total
Balance at December 31, 2022$(2,880)$(33)$(186)$(3,099)
Other comprehensive income/(loss) before reclassifications
(69)— (69)(138)
Amounts reclassified from accumulated other comprehensive income/(loss)
8 5 — 13 
Net other comprehensive income/(loss)
(61)5 (69)(125)
Balance at December 31, 2023$(2,941)$(28)$(255)$(3,224)
Shareholders’ Equity
At December 31, 2023, the company had reserved 39 million unissued shares of its common stock for possible issuance under stock-based compensation plans.
Early in the first quarter of 2024, the company repurchased $3.00 billion of the company's common stock (5.5 million shares).
XML 42 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements and Fair Value of Financial Instruments
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements and Fair Value of Financial Instruments Fair Value Measurements and Fair Value of Financial Instruments
Fair Value Measurements
The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2023. The company’s financial assets and liabilities carried at fair value are primarily comprised of investments in publicly traded securities, insurance contracts, investments in derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration.
Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access.
Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves.
Level 3: Inputs are unobservable data points that are not corroborated by market data.
The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:
December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs
(In millions)2023(Level 1)(Level 2)(Level 3)
Assets
Cash equivalents
$5,021 $5,021 $— $— 
Bank time deposits3 3 — — 
Investments
20 20 — — 
Insurance contracts
210 — 210 — 
Derivative contracts
8 — 8 — 
Total assets
$5,262 $5,044 $218 $— 
Liabilities
Derivative contracts
$290 $— $290 $— 
Contingent consideration
87 — — 87 
Total liabilities
$377 $— $290 $87 
December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs
(In millions)2022(Level 1)(Level 2)(Level 3)
Assets
Cash equivalents
$5,804 $5,804 $— $— 
Investments
25 25 — — 
Warrants
12 — 12 — 
Insurance contracts
162 — 162 — 
Derivative contracts
79 — 79 — 
Total assets
$6,082 $5,829 $253 $— 
Liabilities
Derivative contracts
$101 $— $101 $— 
Contingent consideration
174 — — 174 
Total liabilities
$275 $— $101 $174 
The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense.
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration.
(In millions)20232022
Contingent consideration
Beginning balance
$174 $317 
Acquisitions (including assumed balances)
1 (18)
Payments
(63)(66)
Changes in fair value included in earnings
(25)(59)
Ending balance
$87 $174 
Derivative Contracts
The following table provides the aggregate notional value of outstanding derivative contracts.
December 31,December 31,
(In millions)20232022
Cross-currency interest rate swaps designated as net investment hedge - euro$1,000 $900 
Cross-currency interest rate swaps designated as net investment hedge - Japanese yen4,650 1,200 
Cross-currency interest rate swaps designated as net investment hedge - Swiss franc2,500 — 
Currency exchange contracts
1,567 2,434 
While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income.
 Fair value – assetsFair value – liabilities
 December 31,December 31,December 31,December 31,
(In millions)2023202220232022
Derivatives designated as hedging instruments
Cross-currency interest rate swaps (a)
$5 $77 $287 $85 
Derivatives not designated as hedging instruments
Currency exchange contracts (b)
3 2 3 16 
Total derivatives
$8 $79 $290 $101 
(a)The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities.
(b)The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.
 Gain (loss) recognized
(In millions)202320222021
Fair value hedging relationships
Cross-currency interest rate swaps
Hedged long-term obligations - included in other income/(expense)
$— $77 $— 
Derivatives designated as hedging instruments - included in other income/(expense)
— (81)— 
Interest rate swaps
Hedged long-term obligations - included in other income/(expense)
— — 25 
Derivatives designated as hedging instruments - included in other income/(expense)
— — (3)
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to interest expense
(4)— — 
Amount reclassified from accumulated other comprehensive items to other income/(expense)(3)(3)(73)
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in currency translation adjustment within other comprehensive items
(356)695 922 
Cross-currency interest rate swaps
Included in currency translation adjustment within other comprehensive items
(222)52 71 
Included in interest expense
120 19 8 
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues
1 6 12 
Included in other income/(expense)
(29)102 162 
Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the accompanying statements of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions.
The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
See Note 1 and Note 10 for additional information on the company’s risk management objectives and strategies.
Cash Flow Hedge Arrangements
During 2021, in connection with the extinguishment of debt (Note 10), the company reclassified $65 million from accumulated other comprehensive income/(loss) to other income/(expense).
Fair Value of Other Financial Instruments
The carrying value and fair value of the company’s debt instruments are as follows:
December 31, 2023December 31, 2022
CarryingFairCarryingFair
(In millions)valuevaluevaluevalue
Senior notes
$34,650 $32,191 $33,889 $29,901 
Commercial paper
— — 310 310 
Other
77 77 79 79 
$34,727 $32,268 $34,278 $30,290 
The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally developed pricing models and unobservable inputs, which represent level 3 measurements.
XML 43 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Supplemental Cash Flow Information
 12 Months Ended
Dec. 31, 2023
Supplemental Cash Flow Information [Abstract]  
Supplemental Cash Flow Information Supplemental Cash Flow Information
(In millions)202320222021
Cash paid for:
Interest
$1,385 $667 $555 
Income taxes
1,482 1,234 2,182 
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment
296 393 379 
Fair value of equity awards exchanged— — 43 
Fair value of acquisition contingent consideration— — 183 
Finance lease ROU assets obtained in exchange for new finance lease liabilities2 33 15 
Declared but unpaid dividends
137 119 104 
Issuance of stock upon vesting of restricted stock units
234 241 265 
Excise tax from stock repurchases28 — — 
Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:
 December 31,December 31,
(In millions)20232022
Cash and cash equivalents$8,077 $8,524 
Restricted cash included in other current assets6 12 
Restricted cash included in other assets14 1 
Cash, cash equivalents and restricted cash$8,097 $8,537 
Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.
XML 44 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Other Costs
 12 Months Ended
Dec. 31, 2023
Restructuring and Related Activities [Abstract]  
Restructuring and Other Costs Restructuring and Other Costs
Restructuring and other costs in 2023 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2023, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the company’s workforce.
Restructuring and other costs in 2022 primarily included impairment of long-lived assets and continuing charges for headcount reductions and facility consolidations in an effort to streamline operations. In 2022, severance actions associated with facility consolidations and cost reduction measures affected less than 2% of the company’s workforce.
Restructuring and other costs in 2021 primarily included charges for impairments of an acquired technology asset and a tradename asset, and, to a lesser extent, compensation due to employees at acquired businesses on the date of acquisition. In 2021, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.
As of February 22, 2024, the company has identified restructuring actions that will result in additional charges of approximately $70 million, primarily in 2024, and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred.
Restructuring and other costs by segment are as follows:
(In millions)202320222021
Life Sciences Solutions
$105 $30 $129 
Analytical Instruments
33 1 6 
Specialty Diagnostics
11 68 18 
Laboratory Products and Biopharma Services
295 12 35 
Corporate
15 3 9 
$459 $114 $197 
The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.
(In millions)Total (a)
Balance at December 31, 2020$21 
Net restructuring charges incurred in 2021 (b)
37 
Payments
(40)
Currency translation
(1)
Balance at December 31, 202117 
Net restructuring charges incurred in 2022 (c)
68 
Payments
(44)
Balance at December 31, 202241 
Net restructuring charges incurred in 2023 (d) (e)
194 
Payments
(175)
Balance at December 31, 2023$60 
(a)The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b)Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
(c)Excludes $46 million of net charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment.
(d)Excludes $264 million of net charges, principally $126 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments, $26 million of contract termination costs associated with facility closures in the Laboratory Products and Biopharma Services segment, and $19 million of net charges for pre-acquisition litigation and other matters in the Laboratory Products and Biopharma Services segment.
(e)Excludes $93 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $46 million attributable to a noncontrolling interest.
The company expects to pay accrued restructuring costs primarily through 2024.
XML 45 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
 3 Months Ended 12 Months Ended
Dec. 31, 2023
shares
Dec. 31, 2023
shares
Trading Arrangements, by Individual    
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Michael A. Boxer [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
On December 13, 2023, Michael A. Boxer, our senior vice president, general counsel, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Boxer’s plan is for the exercise of vested stock options and the associated sale of up to 20,566 shares of company common stock through December 13, 2024. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and December 13, 2024.
Name Michael A. Boxer  
Title senior vice president, general counsel  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date December 13, 2023  
Arrangement Duration 366 days  
Aggregate Available 20,566 20,566
Lisa P. Britt [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
On December 12, 2023, Lisa P. Britt, our senior vice president, chief human resources officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Ms. Britt’s plan is for the exercise of vested stock options and the associated sale of up to 14,345 shares of company common stock through November 11, 2024. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and November 12, 2024.
Name Lisa P. Britt  
Title senior vice president, chief human resources officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date December 12, 2023  
Arrangement Duration 336 days  
Aggregate Available 14,345 14,345
Marc N. Casper [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
On November 10, 2023, Marc N. Casper, our chairman, president and chief executive officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Casper’s plan is for the exercise of vested stock options
and the associated sale of up to 202,150 shares of company common stock through November 1, 2024. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and November 4, 2024.
Name Marc N. Casper  
Title chairman, president and chief executive officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date November 10, 2023  
Arrangement Duration 360 days  
Aggregate Available 202,150 202,150
XML 46 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Nature of Operations and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Principles of Consolidation
Principles of Consolidation
The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. At December 31, 2023 and 2022, the company had such investments with carrying amounts of $489 million and $369 million, respectively. The company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity method. At December 31, 2023 and 2022, the fair value of such investments was $5 million and $7 million, respectively.
Redeemable Noncontrolling Interest
The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at a premium upon the occurrence of certain events.
Presentation
Presentation
Certain reclassifications of prior year amounts have been made to conform to the current year presentation.
Revenue Recognition
Revenue Recognition
Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year.
Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date. However, some modifications are distinct from existing services provided under the contract and recognized prospectively.
Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.
Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional.
Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract.
Contract-related Balances
Contract-related Balances
Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.
Warranty Obligations
Warranty Obligations
The company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred.
Leases
Leases
Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations.
Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense.
Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option.
As a lessee, the company accounts for the lease and non-lease components as a single lease component.
Research and Development
Research and Development
The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred.
Restructuring Costs
Restructuring Costs
Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of
an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models.
From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to provide economic benefits to the company. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period.
Income Taxes
Income Taxes
The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused.
The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money.
Earnings per Share
Earnings per Share
Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units.
Cash and Cash Equivalents
Cash and Cash Equivalents
Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three months or less. These investments are carried at cost, which approximates market value.
Inventories
Inventories
Inventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income.
Property, Plant and Equipment
Property, Plant and Equipment
Property, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income.
Acquisition-related Intangible Assets
Acquisition-related Intangible Assets
Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value.
Investments Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments.
Goodwill
Goodwill
The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2023, 2022 or 2021.
Loss Contingencies
Loss Contingencies
Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities acquired in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition.
Currency Translation
Currency Translation
All assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period.
Derivatives Contracts
Derivative Contracts
The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.
The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Canadian dollars, Singapore dollars, Czech koruna, Hong Kong dollars and Swedish krona. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management.
Cash flow hedges. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item.
Fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings.
Net investment hedges. The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
Government Assistance
Government Assistance
From time to time, the company receives assistance from various governmental agencies generally in the form of cash or non-income tax credits. These programs help offset the costs of certain research and development activities, facility construction and expansion efforts, or hiring objectives. When the company believes that it is probable that it will meet the conditions tied to the assistance, it offsets the associated expense in the consolidated income statement. Such amounts were not material to the consolidated financial statements as of and for the years ended December 31, 2023 and 2022.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures.
StandardDescriptionEffective date for Thermo Fisher and adoption approachImpact of adoption or other significant matters
Standards recently adopted
Accounting Standards Update (ASU) No. 2021-05, Leases (Topic 842): Lessors-Certain Leases with Variable Lease Payments
Amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. Third quarter of 2021 using a prospective methodNot material
ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance
New guidance to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model.
Fourth quarter of 2022 using a prospective method
Not material
ASU No. 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations
New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented.
Some aspects adopted in 2023 using a retrospective method and will adopt other aspects in 2024 using a prospective method
Not material
Standards not yet adopted
ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures
Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker.2024 annual report and interim periods thereafter using a retrospective methodWill increase disclosures in Note 4
ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures
Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid.2025 annual report and interim periods thereafter using a prospective or retrospective methodWill increase disclosures in Note 8
Business Combinations
The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.
Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.
Stock-based Compensation Expense
Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses.
Stock Options
The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate is calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures.
Restricted Share/Unit Awards
Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is
generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.
Pension and Other Postretirement Benefit Plans
Defined Benefit Pension Plans
Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented.
The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.
When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits.
The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined.
The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan.
The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows.
The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks.
Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements.
The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases.
Domestic Pension Plan Assets
The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments.
Non-U.S. Pension Plan Assets
The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds,
multi-asset funds, alternative investments and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 30% - 90% for fixed income funds, 0% - 40% for multi-asset funds, 0% - 4% for alternative investments, 0% - 4% for real estate funds and 0% - 45% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments.
XML 47 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
Nature of Operations and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Components of Inventories The components of inventories are as follows:
December 31,December 31,
(In millions)20232022
Raw materials$2,057 $2,405 
Work in process705 660 
Finished goods2,326 2,569 
Inventories$5,088 $5,634 
Schedule of Property, Plant and Equipment Property, plant and equipment consists of the following:
December 31,December 31,
(In millions)20232022
Land$458 $454 
Buildings and improvements3,593 3,153 
Machinery, equipment and leasehold improvements9,235 7,967 
Construction in progress2,238 2,695 
Property, plant and equipment, at cost15,524 14,269 
Less: Accumulated depreciation and amortization6,076 4,989 
Property, plant and equipment, net$9,448 $9,280 
Schedule of Acquisition-related Intangible Assets
Acquisition-related intangible assets are as follows:
Balance at December 31, 2023Balance at December 31, 2022
(In millions)GrossAccumulated AmortizationNetGrossAccumulated AmortizationNet
Definite lived:
Customer relationships
$22,762 $(9,410)$13,352 $21,792 $(8,330)$13,462 
Product technology
5,894 (4,591)1,303 5,882 (4,360)1,522 
Tradenames
1,634 (1,079)555 1,635 (1,008)627 
Backlog
1,084 (859)225 1,038 (442)596 
31,374 (15,939)15,435 30,347 (14,140)16,207 
Indefinite lived:
Tradenames
1,235 N/A1,235 1,235 N/A1,235 
Acquisition-related intangible assets
$32,609 $(15,939)$16,670 $31,582 $(14,140)$17,442 
Schedule of Indefinite-Lived Acquisition-related Intangible Assets
Acquisition-related intangible assets are as follows:
Balance at December 31, 2023Balance at December 31, 2022
(In millions)GrossAccumulated AmortizationNetGrossAccumulated AmortizationNet
Definite lived:
Customer relationships
$22,762 $(9,410)$13,352 $21,792 $(8,330)$13,462 
Product technology
5,894 (4,591)1,303 5,882 (4,360)1,522 
Tradenames
1,634 (1,079)555 1,635 (1,008)627 
Backlog
1,084 (859)225 1,038 (442)596 
31,374 (15,939)15,435 30,347 (14,140)16,207 
Indefinite lived:
Tradenames
1,235 N/A1,235 1,235 N/A1,235 
Acquisition-related intangible assets
$32,609 $(15,939)$16,670 $31,582 $(14,140)$17,442 
Schedule of Future Amortization Expense
The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2023 is as follows:
(In millions)
2024 $1,931 
2025 1,630 
2026 1,460 
2027 1,430 
2028 1,398 
2029 and thereafter7,586 
Estimated future amortization expense of definite-lived intangible assets$15,435 
Schedule of Changes in Carrying Amount of Goodwill
The changes in the carrying amount of goodwill by segment are as follows:
(In millions)Life Sciences
Solutions		Analytical
Instruments		Specialty
Diagnostics		Laboratory
Products and
Biopharma Services		Total
Balance at December 31, 2021
$10,143 $5,043 $3,277 $23,461 $41,924 
Acquisitions
— 24 — — 24 
Finalization of purchase price allocations for 2021 acquisitions
9 — — 168 177 
Currency translation
(6)(102)(186)(635)(929)
Balance at December 31, 2022
10,146 4,965 3,091 22,994 41,196 
Acquisitions
— 31 1,741 627 2,399 
Currency translation
5 55 91 274 425 
Balance at December 31, 2023
$10,151 $5,051 $4,923 $23,895 $44,020 
Recent Accounting Pronouncements
The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures.
StandardDescriptionEffective date for Thermo Fisher and adoption approachImpact of adoption or other significant matters
Standards recently adopted
Accounting Standards Update (ASU) No. 2021-05, Leases (Topic 842): Lessors-Certain Leases with Variable Lease Payments
Amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. Third quarter of 2021 using a prospective methodNot material
ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance
New guidance to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model.
Fourth quarter of 2022 using a prospective method
Not material
ASU No. 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations
New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented.
Some aspects adopted in 2023 using a retrospective method and will adopt other aspects in 2024 using a prospective method
Not material
Standards not yet adopted
ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures
Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker.2024 annual report and interim periods thereafter using a retrospective methodWill increase disclosures in Note 4
ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures
Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid.2025 annual report and interim periods thereafter using a prospective or retrospective methodWill increase disclosures in Note 8
XML 48 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions (Tables)
 12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of Components of Purchase Price
The components of the purchase price and net assets acquired are as follows:
(In millions)The Binding SiteCorEvitas
Purchase price
Cash paid
$2,412 $730 
Debt settled
307 184 
Cash acquired
(20)(4)
$2,699 $910 
Net assets acquired
Definite-lived intangible assets
Customer relationships
$868 $260 
Product technology
162 47 
Tradenames
42 — 
Backlog— 46 
Goodwill
1,741 627 
Net tangible assets
174 (2)
Deferred tax assets (liabilities)
(288)(68)
$2,699 $910 
The components of the purchase price and net assets acquired for 2021 acquisitions are as follows:
(In millions)PPDPeproTechEuropean Viral Vector BusinessMesa BiotechLengnau biologics manufacturing facilityOther
Purchase price
Cash paid
$17,237 $1,946 $848 $421 $17 $298 
Fair value of equity awards exchanged
43 — — — — — 
Fair value of contingent consideration
— — — 65 1 117 
Cash acquired
(1,244)(83)(18)(14)— (12)
$16,036 $1,863 $830 $472 $18 $403 
Net assets acquired
Current assets
$2,477 $58 $39 $54 $— $12 
Property, plant and equipment
527 18 59 2 93 2 
Definite-lived intangible assets:
Customer relationships
6,257 510 302 — — 2 
Product technology
— 282 25 279 — 224 
Tradenames
594 — — 2 — 2 
Backlog1,038 — — — — — 
Goodwill
13,949 1,198 600 237 18 198 
Other assets
1,060 11 3 3 364 2 
Contract liabilities(1,539)— (59)— — (1)
Deferred tax assets (liabilities)
(1,782)(192)(80)(72)— (27)
Finance lease liabilities
(90)— (24)— (82)— 
Debt assumed
(4,299)— — — — — 
Other liabilities assumed
(2,034)(22)(35)(33)(375)(11)
Redeemable noncontrolling interest(122)— — — — — 
$16,036 $1,863 $830 $472 $18 $403 
During 2022, we finalized the allocations of the purchase price for the Lengnau biologics manufacturing facility, PPD, Inc. and PeproTech, Inc., largely with respect to definite-lived intangible assets, property, plant and equipment, contract liabilities, equity method investments, asset retirement obligations, defined benefit pension plans, assumed contingent consideration and the related deferred taxes. The adjustments to the income statement recorded during 2022 were not material.
Schedule of Pro Forma Information
The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1, 2020:
 Year Ended
 December 31,
(In millions)2021
Revenues$44,886 
Net income attributable to Thermo Fisher Scientific Inc.$7,369 
XML 49 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue and Contract-related Balances (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
Disaggregated Revenues
Revenues by type are as follows:
(In millions)202320222021
Revenues
Consumables
$17,597 $20,624 $22,608 
Instruments
7,646 7,924 7,753 
Services
17,614 16,367 8,850 
Consolidated revenues
$42,857 $44,915 $39,211 
Revenues by geographic region based on customer location are as follows:
(In millions)202320222021
Revenues
North America
$22,764 $24,594 $19,659 
Europe
10,741 10,762 11,134 
Asia-Pacific
7,873 8,115 7,218 
Other regions
1,479 1,444 1,200 
Consolidated revenues
$42,857 $44,915 $39,211 
Schedule of Contract-related Balances
Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows:
December 31,December 31,
(In millions)20232022
Current contract assets, net$1,443 $1,312 
Noncurrent contract assets, net4 7 
Current contract liabilities2,689 2,601 
Noncurrent contract liabilities1,499 1,179 
XML 50 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Business Segment and Geographical Information (Tables)
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information
Business Segment Information
(In millions)202320222021
Revenues
Life Sciences Solutions
$9,977 $13,532 $15,631 
Analytical Instruments
7,263 6,624 6,069 
Specialty Diagnostics
4,405 4,763 5,659 
Laboratory Products and Biopharma Services
23,041 22,511 14,862 
Eliminations
(1,829)(2,515)(3,010)
Consolidated revenues
42,857 44,915 39,211 
Segment Income
Life Sciences Solutions
3,420 5,582 7,817 
Analytical Instruments
1,908 1,507 1,197 
Specialty Diagnostics
1,124 1,024 1,280 
Laboratory Products and Biopharma Services
3,358 2,872 1,844 
Subtotal reportable segments
9,810 10,985 12,138 
Cost of revenues adjustments
(95)(46)(8)
Selling, general and administrative expenses adjustments
(59)(37)(144)
Restructuring and other costs
(459)(114)(197)
Amortization of acquisition-related intangible assets
(2,338)(2,395)(1,761)
Consolidated operating income
6,859 8,393 10,028 
Interest income879 272 43 
Interest expense(1,375)(726)(536)
Other income/(expense)
(65)(104)(694)
Consolidated income before taxes
$6,298 $7,835 $8,841 
Depreciation
Life Sciences Solutions
$220 $214 $197 
Analytical Instruments
93 83 83 
Specialty Diagnostics
86 75 128 
Laboratory Products and Biopharma Services
669 614 423 
Consolidated depreciation
$1,068 $986 $831 
Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of significant transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges related to product liability litigation.
(In millions)202320222021
Total assets
Life Sciences Solutions
$20,191 $21,848 $22,751 
Analytical Instruments
10,247 10,019 9,692 
Specialty Diagnostics
8,636 5,542 6,010 
Laboratory Products and Biopharma Services
51,091 51,281 52,639 
Corporate/other (a)
8,561 8,464 4,031 
Consolidated total assets
$98,726 $97,154 $95,123 
Capital expenditures
Life Sciences Solutions
$178 $490 $810 
Analytical Instruments
87 140 79 
Specialty Diagnostics
121 112 167 
Laboratory Products and Biopharma Services
1,013 1,403 1,327 
Corporate/other
80 98 140 
Consolidated capital expenditures
$1,479 $2,243 $2,523 
(a)Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.
Schedule of Revenue by Geographical Areas
Geographical Information
(In millions)202320222021
Revenues (b)
United States
$22,013 $23,820 $18,907 
Other
20,844 21,095 20,304 
Consolidated revenues
$42,857 $44,915 $39,211 
Long-lived Assets (c)
United States
$6,352 $6,308 $5,578 
Other
4,652 4,565 4,286 
Consolidated long-lived assets
$11,004 $10,873 $9,864 
(b)Revenues are attributed to countries based on customer location.
(c)Includes property, plant and equipment, net, and operating lease ROU assets.
XML 51 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation Expense (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model
The weighted average assumptions used in the Black-Scholes option pricing model are as follows: 
202320222021
Expected stock price volatility
25 %26 %26 %
Risk free interest rate
4.2 %2.0 %0.8 %
Expected life of options (years)
4.74.74.3
Expected annual dividend
0.3 %0.2 %0.2 %
Summary of the Company's Option Activity
A summary of the company’s option activity for the year ended December 31, 2023 is presented below:
Shares
(in millions)		Weighted average exercise priceWeighted average remaining contractual term
(in years)		Aggregate intrinsic
value
(in millions)
Outstanding at December 31, 2022
5.6 $359.27 
Granted
0.7 546.94 
Exercised
(1.0)218.82 
Canceled/expired
(0.3)543.25 
Outstanding at December 31, 2023
5.0 $401.30 3.9$714 
Vested and unvested expected to vest at December 31, 2023
4.8 $396.20 3.9$712 
Exercisable at December 31, 2023
2.8 $316.88 2.7$635 
Summary of the Company's Restricted Unit Activity
A summary of the company’s restricted unit activity for the year ended December 31, 2023 is presented below:
 Units
(in millions)		Weighted
average
grant-date
fair value
Unvested at December 31, 2022
0.7 $495.39 
Granted
0.4 545.73 
Vested
(0.4)480.45 
Forfeited
(0.1)528.59 
Unvested at December 31, 2023
0.6 $533.65 
XML 52 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pension and Other Postretirement Benefit Plans (Tables)
 12 Months Ended
Dec. 31, 2023
Retirement Benefits [Abstract]  
Reconciliation of Benefit Obligations and Plan Assets The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans:
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)2023202220232022
Accumulated benefit obligation
$1,005 $995 $1,166 $1,016 
Change in projected benefit obligations
Projected benefit obligation at beginning of year
$995 $1,260 $1,069 $1,552 
Acquisitions
— — 15 51 
Service costs
— — 26 34 
Interest costs
47 27 42 20 
Settlements
— — (37)(31)
Plan participants' contributions
— — 9 9 
Actuarial (gains) losses
42 (210)65 (447)
Benefits paid
(79)(82)(25)(19)
Currency translation and other
— — 57 (100)
Projected benefit obligation at end of year
$1,005 $995 $1,221 $1,069 
Change in fair value of plan assets
Fair value of plan assets at beginning of year
$937 $1,226 $868 $1,302 
Acquisitions— — 15 14 
Actual return on plan assets
84 (212)29 (347)
Employer contributions
5 5 36 36 
Settlements
— — (37)(31)
Plan participants' contributions
— — 9 9 
Benefits paid
(79)(82)(25)(19)
Currency translation and other
— — 49 (96)
Fair value of plan assets at end of year$947 $937 $944 $868 
Funded status
$(58)$(58)$(277)$(201)
Amounts recognized in balance sheet
Noncurrent assets
$— $— $65 $81 
Current liability
(6)(6)(11)(11)
Noncurrent liabilities
(52)(52)(331)(271)
Net amount recognized
$(58)$(58)$(277)$(201)
Amounts recognized in accumulated other comprehensive items
Net actuarial loss
$217 $200 $151 $74 
Prior service credits
— — (5)(4)
Net amount recognized
$217 $200 $146 $70 
Schedule of Actuarial Assumptions
The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2023 and 2022 and are as follows:
 Domestic pension benefitsNon-U.S. pension benefits
 2023202220232022
Weighted average assumptions used to determine projected benefit obligations
Discount rate for determining benefit obligation
4.82 %5.01 %3.47 %3.91 %
Interest crediting rate for cash balance plans
4.76 %4.96 %2.06 %2.19 %
Average rate of increase in employee compensation
N/AN/A2.64 %2.78 %
The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year, as presented in the following table:
 Domestic pension benefitsNon-U.S. pension benefits
 202320222021202320222021
Weighted average assumptions used to determine net benefit cost (income)
Discount rate - service cost
N/AN/AN/A3.62 %1.00 %0.65 %
Discount rate - interest cost
5.01 %2.70 %2.33 %3.95 %1.36 %0.80 %
Average rate of increase in employee compensation
N/AN/AN/A2.77 %2.73 %2.30 %
Expected long-term rate of return on assets
6.25 %4.75 %4.25 %4.33 %2.33 %2.02 %
Projected Benefit Obligation and Fair Value of Plan Assets
The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows:
 Pension plans
(In millions)20232022
Pension plans with projected benefit obligations in excess of plan assets
Projected benefit obligation
$1,752 $1,636 
Fair value of plan assets
1,352 1,296 
Accumulated Benefit Obligation and Fair Value of Plan Assets
The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows:
 Pension plans
(In millions)20232022
Pension plans with accumulated benefit obligations in excess of plan assets
Accumulated benefit obligation
$1,695 $1,583 
Fair value of plan assets
1,349 1,294 
Schedule of Net Benefit Costs
The net periodic pension benefit cost (income) includes the following components:
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)202320222021202320222021
Components of net benefit cost (income)
Service cost
$— $— $— $26 $34 $27 
Interest cost on benefit obligation
47 27 23 42 20 11 
Expected return on plan assets
(59)(45)(40)(37)(26)(19)
Amortization of actuarial net loss
— 4 7 2 7 12 
Amortization of prior service cost (benefit)
— — — (1)(1)— 
Settlement/curtailment loss (gain)
— — — 1 (2)— 
Net periodic benefit cost (income)
$(12)$(14)$(10)$33 $32 $31 
Schedule of Estimated Future Benefit Payments Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows:
(In millions)Domestic pension benefitsNon-U.S. pension benefits
Expected benefit payments
2024 $81 $52 
2025 79 55 
2026 80 59 
2027 79 60 
2028 79 65 
2029-2033374 354 
Schedule of Fair Value of the Company's Plan Assets
The fair values of the company’s plan assets at December 31, 2023 and 2022, by asset category are as follows:
 December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs		Not subject to leveling (a)
(In millions)2023(Level 1)(Level 2)(Level 3)
Domestic pension plan assets
U.S. equity funds
$93 $— $— $— $93 
International equity funds
93 — — — 93 
Fixed income funds
739 — — — 739 
Money market funds
22 — — — 22 
Total domestic pension plans
$947 $— $— $— $947 
Non-U.S. pension plan assets
Equity funds
$7 $— $— $— $7 
Fixed income funds
346 9 — — 337 
Multi-asset funds
66 — — — 66 
Derivative funds
184 — — — 184 
Alternative investments
1 — — — 1 
Insurance contracts
333 — 333 — — 
Real estate funds1 — — — 1 
Cash / money market funds
6 4 — — 2 
Total non-U.S. pension plans
$944 $13 $333 $— $598 
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
 December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs		Not subject to leveling (a)
(In millions)2022(Level 1)(Level 2)(Level 3)
Domestic pension plan assets
U.S. equity funds
$89 $— $— $— $89 
International equity funds
91 — — — 91 
Fixed income funds
739 — — — 739 
Money market funds
18 — — — 18 
Total domestic pension plans$937 $— $— $— $937 
Non-U.S. pension plan assets
Equity funds
$8 $— $— $— $8 
Fixed income funds
299 — — — 299 
Multi-asset funds
56 — — — 56 
Derivative funds
190 — — — 190 
Insurance contracts
306 — 306 — — 
Cash / money market funds
9 4 — — 5 
Total non-U.S. pension plans$868 $4 $306 $— $558 
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
XML 53 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Components of Income Before Provision for Income Taxes
The components of income before provision for income taxes are as follows:
(In millions)202320222021
U.S.$2,431 $3,859 $3,340 
Non-U.S.3,867 3,976 5,501 
Income before income taxes
$6,298 $7,835 $8,841 
Components of the Provision for Income Taxes
The components of the provision for income taxes are as follows:
(In millions)202320222021
Current income tax provision
Federal$228 $813 $446 
Non-U.S.1,206 633 1,148 
State150 254 160 
1,584 1,700 1,754 
Deferred income tax provision (benefit)
Federal$(551)$(611)$(227)
Non-U.S.(647)(314)(399)
State(102)(72)(19)
 (1,300)(997)(645)
Provision for income taxes
$284 $703 $1,109 
Schedule of Effective Income Tax Rate Reconciliation
The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following:
(In millions)202320222021
Statutory federal income tax rate
21 %21 %21 %
Provision for income taxes at statutory rate
$1,323 $1,645 $1,857 
Increases (decreases) resulting from:
Foreign rate differential
(223)(329)(255)
Income tax credits
(276)(202)(315)
Global intangible low-taxed income
113 96 76 
Foreign-derived intangible income
(108)(149)(119)
Excess tax benefits from stock options and restricted stock units
(69)(80)(124)
Provision for (reversal of) tax reserves, net
13 (544)(17)
Intra-entity transfers
(233)(18)(284)
Foreign exchange loss on inter-company debt refinancing
(112)— — 
Provision for (reversal of) valuation allowances, net
(32)344 36 
Withholding taxes
33 84 164 
Tax return reassessments and settlements
(187)(210)1 
State income taxes, net of federal tax70 111 82 
Other, net
(28)(45)7 
Provision for income taxes
$284 $703 $1,109 
Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance
Net deferred tax asset/(liability) in the accompanying balance sheet consists of the following:
(In millions)20232022
Deferred tax asset/(liability)
Depreciation and amortization
$(4,286)$(4,277)
Net operating loss and credit carryforwards
2,385 1,951 
Reserves and accruals
157 140 
Accrued compensation
299 259 
Inventory basis difference
275 364 
Deferred interest753 445 
Research and development and other capitalized costs
380 220 
Unrealized (gains) losses on hedging instruments
(66)(199)
Other, net
329 435 
Deferred tax assets/(liabilities), net before valuation allowance
226 (662)
Less: Valuation allowance
1,317 1,322 
Deferred tax assets/(liabilities), net
$(1,091)$(1,984)
The company estimates the degree to which tax assets, losses and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2023, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense.
The changes in the valuation allowance are as follows:
 Year Ended December 31,
(In millions)202320222021
Beginning balance
$1,322 $968 $933 
Additions (reductions) charged to income tax provision, net
(32)344 24 
Additions due to acquisitions
4 14 30 
Currency translation and other
23 (4)(19)
Ending balance$1,317 $1,322 $968 
Reconciliation of Unrecognized Tax Benefits
A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:
(In millions)202320222021
Beginning balance
$572 $1,124 $1,091 
Additions due to acquisitions
— 15 26 
Additions for tax positions of current year
4 104 32 
Additions for tax positions of prior years
34 24 60 
Reductions for tax positions of prior years
(43)(659)(5)
Closure of tax years
(6)(4)(27)
Settlements
(21)(32)(53)
Ending balance
$540 $572 $1,124 
XML 54 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Earnings Per Share (Tables)
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
(In millions except per share amounts)202320222021
Net income attributable to Thermo Fisher Scientific Inc.
$5,995 $6,950 $7,725 
Basic weighted average shares
386 392 394 
Plus effect of: stock options and restricted stock units
2 2 3 
Diluted weighted average shares
388 394 397 
Basic earnings per share
$15.52 $17.75 $19.62 
Diluted earnings per share
$15.45 $17.63 $19.46 
Antidilutive stock options excluded from diluted weighted average shares
2 2 1 
XML 55 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt and Other Financing Arrangements (Tables)
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Debt
Effective interest rate at December 31,December 31,December 31,
(Dollars in millions)202320232022
Commercial Paper$— $310 
Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023
— 1,000 
Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023
— 500 
0.797% 2-Year Senior Notes, Due 10/18/2023
— 1,350 
Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
— 1,819 
0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
— 589 
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
0.93 %1,104 1,071 
Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024
— 500 
1.215% 3-Year Senior Notes, Due 10/18/2024
1.42 %2,500 2,500 
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
0.41 %883 857 
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
2.10 %706 686 
0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated)
1.05 %158 170 
0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)
0.15 %607 589 
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)
3.39 %552 535 
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
1.53 %773 749 
4.953% 3-Year Senior Notes, Due 8/10/2026
5.19 %600 — 
5.000% 3-Year Senior Notes due 12/5/2026
5.00 %1,000 — 
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
1.65 %552 535 
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
1.97 %662 642 
1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)
1.18 %205 221 
4.80% 5-Year Senior Notes, Due 11/21/2027
5.00 %600 600 
Effective interest rate at December 31,December 31,December 31,
(Dollars in millions)202320232022
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
0.77 %883 857 
0.77% 5-Year Senior Notes, Due 9/6/2028 (yen-denominated)
0.90 %206 — 
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
1.46 %662 642 
1.750% 7-Year Senior Notes, Due 10/15/2028
1.89 %700 700 
5.000% 5-Year Senior Notes due 1/31/2029
5.00 %1,000 — 
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
2.08 %773 749 
2.60% 10-Year Senior Notes, Due 10/1/2029
2.74 %900 900 
1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)
1.44 %33 36 
4.977% 7-Year Senior Notes, Due 8/10/2030
5.12 %750 — 
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)
0.89 %1,932 1,873 
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
1.13 %993 963 
2.00% 10-Year Senior Notes, Due 10/15/2031
2.23 %1,200 1,200 
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
2.55 %662 642 
1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)
1.60 %45 48 
4.95% 10-Year Senior Notes, Due 11/21/2032
5.09 %600 600 
5.086% 10-Year Senior Notes, Due 8/10/2033
5.20 %1,000 — 
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)
1.20 %1,656 1,606 
5.200% 10-Year Senior Notes due 1/31/2034
5.20 %500 — 
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)
3.76 %828 803 
1.50% 12-Year Senior Notes, due 9/6/2035 (yen-denominated)
1.58 %152 — 
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
2.94 %773 749 
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
1.73 %993 963 
2.80% 20-Year Senior Notes, Due 10/15/2041
2.90 %1,200 1,200 
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)
1.77 %1,380 1,339 
2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)
2.13 %104 111 
5.404% 20-Year Senior Notes, due 8/10/2043
5.50 %600 — 
2.02% 20-Year Senior Notes, due 9/6/2043 (yen-denominated)
2.06 %206 — 
5.30% 30-Year Senior Notes, Due 2/1/2044
5.37 %400 400 
4.10% 30-Year Senior Notes, Due 8/15/2047
4.23 %750 750 
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
1.98 %1,104 1,071 
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)
2.07 %828 803 
2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)
2.43 %236 254 
Other 77 79 
Total borrowings at par value
35,028 34,561 
Unamortized discount
(113)(112)
Unamortized debt issuance costs
(188)(171)
Total borrowings at carrying value
34,727 34,278 
Finance lease liabilities
190 210 
Less: Short-term obligations and current maturities
3,609 5,579 
Long-term obligations$31,308 $28,909 
SOFR - Secured Overnight Financing Rate
EURIBOR - Euro Interbank Offered Rate
Schedule of Annual Repayment Requirements for Debt Obligations
As of December 31, 2023, the annual repayment requirements for debt obligations are as follows:
(In millions)BorrowingsFinance Lease Liabilities
2024 $3,604 $5 
2025 2,356 13 
2026 2,925 12 
2027 2,020 10 
2028 2,451 8 
2029 and thereafter21,672 142 
$35,028 $190 
XML 56 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Schedule of Operating Leases
As a lessee, the consolidated financial statements include the following relating to operating leases:
(Dollars in millions)202320222021
Statement of income
Operating lease costs
$355 $351 $254 
Variable lease costs
115 109 66 
Statement of cash flows
Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities$410 $289 $288 
Operating lease ROU assets obtained in exchange for new operating lease liabilities234 430 293 
Balance sheet
ROU assets - included in other assets$1,556 $1,593 
Operating lease liabilities - included in other accrued expenses263 272 
Operating lease liabilities - included in other long-term liabilities1,244 1,313 
Weighted average at end of year
Remaining operating lease term9.2 years9.4 years
Discount rate4.0 %3.2 %
Schedule of Future Payments of Operating Lease Liabilities
As of December 31, 2023, future payments of operating lease liabilities are as follows:
(In millions)
2024 $294 
2025 288 
2026 242 
2027 172 
2028 131 
2029 and thereafter723 
Total lease payments1,850 
Less: imputed interest
343 
Total operating lease liability$1,507 
XML 57 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Comprehensive Income and Shareholders Equity (Tables)
 12 Months Ended
Dec. 31, 2023
Stockholders' Equity Note [Abstract]  
Schedule of Change in Each Component of Accumulated Other Comprehensive Items
Changes in each component of accumulated other comprehensive items, net of tax are as follows:
(In millions)Currency
translation
adjustment		Unrealized
losses on
hedging
instruments		Pension and
other
postretirement
benefit
liability
adjustment		Total
Balance at December 31, 2022$(2,880)$(33)$(186)$(3,099)
Other comprehensive income/(loss) before reclassifications
(69)— (69)(138)
Amounts reclassified from accumulated other comprehensive income/(loss)
8 5 — 13 
Net other comprehensive income/(loss)
(61)5 (69)(125)
Balance at December 31, 2023$(2,941)$(28)$(255)$(3,224)
XML 58 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements and Fair Value of Financial Instruments (Tables)
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Measured at Fair Value
The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:
December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs
(In millions)2023(Level 1)(Level 2)(Level 3)
Assets
Cash equivalents
$5,021 $5,021 $— $— 
Bank time deposits3 3 — — 
Investments
20 20 — — 
Insurance contracts
210 — 210 — 
Derivative contracts
8 — 8 — 
Total assets
$5,262 $5,044 $218 $— 
Liabilities
Derivative contracts
$290 $— $290 $— 
Contingent consideration
87 — — 87 
Total liabilities
$377 $— $290 $87 
December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs
(In millions)2022(Level 1)(Level 2)(Level 3)
Assets
Cash equivalents
$5,804 $5,804 $— $— 
Investments
25 25 — — 
Warrants
12 — 12 — 
Insurance contracts
162 — 162 — 
Derivative contracts
79 — 79 — 
Total assets
$6,082 $5,829 $253 $— 
Liabilities
Derivative contracts
$101 $— $101 $— 
Contingent consideration
174 — — 174 
Total liabilities
$275 $— $101 $174 
Rollforward of the Fair Value of Investments
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration.
(In millions)20232022
Contingent consideration
Beginning balance
$174 $317 
Acquisitions (including assumed balances)
1 (18)
Payments
(63)(66)
Changes in fair value included in earnings
(25)(59)
Ending balance
$87 $174 
Schedule of Aggregate Notional Value of Outstanding Derivative Contracts
The following table provides the aggregate notional value of outstanding derivative contracts.
December 31,December 31,
(In millions)20232022
Cross-currency interest rate swaps designated as net investment hedge - euro$1,000 $900 
Cross-currency interest rate swaps designated as net investment hedge - Japanese yen4,650 1,200 
Cross-currency interest rate swaps designated as net investment hedge - Swiss franc2,500 — 
Currency exchange contracts
1,567 2,434 
Schedule of Fair Value of Derivative Instruments
While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income.
 Fair value – assetsFair value – liabilities
 December 31,December 31,December 31,December 31,
(In millions)2023202220232022
Derivatives designated as hedging instruments
Cross-currency interest rate swaps (a)
$5 $77 $287 $85 
Derivatives not designated as hedging instruments
Currency exchange contracts (b)
3 2 3 16 
Total derivatives
$8 $79 $290 $101 
(a)The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities.
(b)The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.
Schedule of Derivative Instruments, Gain (Loss) Recognized
 Gain (loss) recognized
(In millions)202320222021
Fair value hedging relationships
Cross-currency interest rate swaps
Hedged long-term obligations - included in other income/(expense)
$— $77 $— 
Derivatives designated as hedging instruments - included in other income/(expense)
— (81)— 
Interest rate swaps
Hedged long-term obligations - included in other income/(expense)
— — 25 
Derivatives designated as hedging instruments - included in other income/(expense)
— — (3)
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to interest expense
(4)— — 
Amount reclassified from accumulated other comprehensive items to other income/(expense)(3)(3)(73)
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in currency translation adjustment within other comprehensive items
(356)695 922 
Cross-currency interest rate swaps
Included in currency translation adjustment within other comprehensive items
(222)52 71 
Included in interest expense
120 19 8 
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues
1 6 12 
Included in other income/(expense)
(29)102 162 
Schedule of Carrying Value and Fair Value of the Company's Debt Instruments
The carrying value and fair value of the company’s debt instruments are as follows:
December 31, 2023December 31, 2022
CarryingFairCarryingFair
(In millions)valuevaluevaluevalue
Senior notes
$34,650 $32,191 $33,889 $29,901 
Commercial paper
— — 310 310 
Other
77 77 79 79 
$34,727 $32,268 $34,278 $30,290 
The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally developed pricing models and unobservable inputs, which represent level 3 measurements.
XML 59 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Supplemental Cash Flow Information (Tables)
 12 Months Ended
Dec. 31, 2023
Supplemental Cash Flow Information [Abstract]  
Schedule of Supplemental Cash Flow Disclosures
(In millions)202320222021
Cash paid for:
Interest
$1,385 $667 $555 
Income taxes
1,482 1,234 2,182 
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment
296 393 379 
Fair value of equity awards exchanged— — 43 
Fair value of acquisition contingent consideration— — 183 
Finance lease ROU assets obtained in exchange for new finance lease liabilities2 33 15 
Declared but unpaid dividends
137 119 104 
Issuance of stock upon vesting of restricted stock units
234 241 265 
Excise tax from stock repurchases28 — — 
Schedule of Cash, Cash Equivalents and Restricted Cash
Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:
 December 31,December 31,
(In millions)20232022
Cash and cash equivalents$8,077 $8,524 
Restricted cash included in other current assets6 12 
Restricted cash included in other assets14 1 
Cash, cash equivalents and restricted cash$8,097 $8,537 
XML 60 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Other Costs (Tables)
 12 Months Ended
Dec. 31, 2023
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring and Other Costs by Segment
Restructuring and other costs by segment are as follows:
(In millions)202320222021
Life Sciences Solutions
$105 $30 $129 
Analytical Instruments
33 1 6 
Specialty Diagnostics
11 68 18 
Laboratory Products and Biopharma Services
295 12 35 
Corporate
15 3 9 
$459 $114 $197 
Schedule of the Company's Accrued Restructuring Balance
The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.
(In millions)Total (a)
Balance at December 31, 2020$21 
Net restructuring charges incurred in 2021 (b)
37 
Payments
(40)
Currency translation
(1)
Balance at December 31, 202117 
Net restructuring charges incurred in 2022 (c)
68 
Payments
(44)
Balance at December 31, 202241 
Net restructuring charges incurred in 2023 (d) (e)
194 
Payments
(175)
Balance at December 31, 2023$60 
(a)The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b)Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
(c)Excludes $46 million of net charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment.
(d)Excludes $264 million of net charges, principally $126 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments, $26 million of contract termination costs associated with facility closures in the Laboratory Products and Biopharma Services segment, and $19 million of net charges for pre-acquisition litigation and other matters in the Laboratory Products and Biopharma Services segment.
(e)Excludes $93 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $46 million attributable to a noncontrolling interest.
XML 61 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Nature of Operations and Summary of Significant Accounting Policies - Additional Accounting Policy and Balance Sheet Disclosures (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Noncontrolling Interest [Line Items]      
Equity method investments $ 489 $ 369  
Fair value of investments 5 7  
Cost method investments 12 55  
Investments measured at NAV 28 22  
Currency transaction gains (losses) $ (67) $ 62 $ 25
PPD-SNBL K.K.      
Noncontrolling Interest [Line Items]      
Ownership percentage, parent 60.00%    
Ownership interest, noncontrolling owners 40.00%    
XML 62 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
Nature of Operations and Summary of Significant Accounting Policies - Inventories (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Oct. 02, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Raw materials   $ 2,057 $ 2,405    
Work in process   705 660    
Finished goods   2,326 2,569    
Inventories   5,088 5,634    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Inventories   5,088 5,634    
Product revenues          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cost of goods and services sold   $ (13,168) $ (14,247) $ (13,594)  
Change in Accounting Principle, Other          
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Inventories $ 33        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Percentage of LIFO inventory         5.00%
Inventories 33        
Change in Accounting Principle, Other | Product revenues          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cost of goods and services sold 33        
Change in Accounting Principle, Other | Laboratory Products and Biopharma Services          
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Inventories 20        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Inventories 20        
Change in Accounting Principle, Other | Laboratory Products and Biopharma Services | Product revenues          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cost of goods and services sold 20        
Change in Accounting Principle, Other | Specialty Diagnostics          
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Inventories 13        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Inventories 13        
Change in Accounting Principle, Other | Specialty Diagnostics | Product revenues          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cost of goods and services sold $ 13        
XML 63 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Nature of Operations and Summary of Significant Accounting Policies - Property, Plant and Equipment (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, at cost $ 15,524 $ 14,269
Less: Accumulated depreciation and amortization 6,076 4,989
Property, plant and equipment, net 9,448 9,280
Land    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, at cost 458 454
Buildings and improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, at cost $ 3,593 3,153
Buildings and improvements | Minimum    
Property, Plant and Equipment [Line Items]    
Useful lives 25 years  
Buildings and improvements | Maximum    
Property, Plant and Equipment [Line Items]    
Useful lives 40 years  
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, at cost $ 2,238 2,695
Machinery, equipment and leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, at cost $ 9,235 $ 7,967
Machinery and Equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Useful lives 3 years  
Machinery and Equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Useful lives 10 years  
XML 64 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Intangible Assets [Line Items]    
Definite-lived intangible assets, gross $ 31,374 $ 30,347
Accumulated Amortization (15,939) (14,140)
Estimated future amortization expense of definite-lived intangible assets 15,435 16,207
Acquisition-related intangible assets 32,609 31,582
Acquisition-related intangible assets 16,670 17,442
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]    
2024  1,931  
2025  1,630  
2026  1,460  
2027  1,430  
2028  1,398  
2029 and thereafter 7,586  
Estimated future amortization expense of definite-lived intangible assets 15,435 16,207
Other intangible assets $ 37 36
Maximum    
Intangible Assets [Line Items]    
Estimated useful life 20 years  
Tradenames    
Intangible Assets [Line Items]    
Indefinite-lived intangible assets $ 1,235 1,235
Customer relationships    
Intangible Assets [Line Items]    
Definite-lived intangible assets, gross 22,762 21,792
Accumulated Amortization (9,410) (8,330)
Estimated future amortization expense of definite-lived intangible assets 13,352 13,462
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]    
Estimated future amortization expense of definite-lived intangible assets 13,352 13,462
Product technology    
Intangible Assets [Line Items]    
Definite-lived intangible assets, gross 5,894 5,882
Accumulated Amortization (4,591) (4,360)
Estimated future amortization expense of definite-lived intangible assets 1,303 1,522
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]    
Estimated future amortization expense of definite-lived intangible assets 1,303 1,522
Tradenames    
Intangible Assets [Line Items]    
Definite-lived intangible assets, gross 1,634 1,635
Accumulated Amortization (1,079) (1,008)
Estimated future amortization expense of definite-lived intangible assets 555 627
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]    
Estimated future amortization expense of definite-lived intangible assets 555 627
Backlog    
Intangible Assets [Line Items]    
Definite-lived intangible assets, gross 1,084 1,038
Accumulated Amortization (859) (442)
Estimated future amortization expense of definite-lived intangible assets 225 596
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]    
Estimated future amortization expense of definite-lived intangible assets $ 225 $ 596
XML 65 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
Nature of Operations and Summary of Significant Accounting Policies - Goodwill (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Goodwill [Roll Forward]    
Beginning balance $ 41,196 $ 41,924
Acquisitions 2,399 24
Finalization of purchase price allocations for 2022 acquisitions   177
Currency translation 425 (929)
Ending balance 44,020 41,196
Life Sciences Solutions    
Goodwill [Roll Forward]    
Beginning balance 10,146 10,143
Acquisitions 0 0
Finalization of purchase price allocations for 2022 acquisitions   9
Currency translation 5 (6)
Ending balance 10,151 10,146
Analytical Instruments    
Goodwill [Roll Forward]    
Beginning balance 4,965 5,043
Acquisitions 31 24
Finalization of purchase price allocations for 2022 acquisitions   0
Currency translation 55 (102)
Ending balance 5,051 4,965
Specialty Diagnostics    
Goodwill [Roll Forward]    
Beginning balance 3,091 3,277
Acquisitions 1,741 0
Finalization of purchase price allocations for 2022 acquisitions   0
Currency translation 91 (186)
Ending balance 4,923 3,091
Laboratory Products and Biopharma Services    
Goodwill [Roll Forward]    
Beginning balance 22,994 23,461
Acquisitions 627 0
Finalization of purchase price allocations for 2022 acquisitions   168
Currency translation 274 (635)
Ending balance $ 23,895 $ 22,994
XML 66 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
Nature of Operations and Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accounts receivable $ 8,221 $ 8,115
Retained earnings $ 47,364 $ 41,910
XML 67 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Oct. 17, 2023
Dec. 31, 2023
Dec. 31, 2021
Dec. 30, 2021
Dec. 08, 2021
Sep. 30, 2021
Feb. 25, 2021
Jan. 15, 2021
Business Acquisition [Line Items]                
Weighted-average amortization period   17 years 14 years          
European Viral Vector Business                
Business Acquisition [Line Items]                
Goodwill recorded               $ 0
Mesa Biotech                
Business Acquisition [Line Items]                
Goodwill recorded             $ 0  
Lengnau biologics manufacturing facility                
Business Acquisition [Line Items]                
Goodwill recorded           $ 0    
PPD                
Business Acquisition [Line Items]                
Goodwill recorded         $ 0      
Net income attributable to Thermo Fisher Scientific Inc.     $ 7,369          
Pro forma revenues     378          
Pro forma losses     (60)          
PPD | Non-recurring Pro Forma Adjustments, Transaction Costs                
Business Acquisition [Line Items]                
Net income attributable to Thermo Fisher Scientific Inc.     $ 312          
PeproTech                
Business Acquisition [Line Items]                
Goodwill recorded       $ 0        
Olink Holding AB                
Business Acquisition [Line Items]                
Expected price per share (dollars per share) $ 26.00              
Expected acquisition price $ 3,100              
Customer relationships                
Business Acquisition [Line Items]                
Weighted-average amortization period   18 years 17 years          
Product technology                
Business Acquisition [Line Items]                
Weighted-average amortization period   14 years 11 years          
Tradenames                
Business Acquisition [Line Items]                
Weighted-average amortization period   15 years 7 years          
Backlog                
Business Acquisition [Line Items]                
Weighted-average amortization period   13 years 3 years          
XML 68 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions - Schedule of Components of Purchase Price (Details) - USD ($)
$ in Millions
 12 Months Ended
Aug. 14, 2023
Jan. 03, 2023
Dec. 30, 2021
Dec. 08, 2021
Sep. 30, 2021
Feb. 25, 2021
Jan. 15, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Purchase Price                    
Fair value of equity awards exchanged               $ 0 $ 0 $ 43
Fair value of contingent consideration               $ 0 0 183
The Binding Site Group                    
Purchase Price                    
Cash paid   $ 2,412                
Debt settled   307                
Cash acquired   20                
Total purchase price   2,699                
Net Assets Acquired [Abstract]                    
Goodwill   1,741                
Net tangible assets   174                
Deferred tax assets (liabilities)   (288)                
Total net assets acquired   2,699                
The Binding Site Group | Customer relationships                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:   868                
The Binding Site Group | Tradenames                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:   42                
The Binding Site Group | Backlog                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:   0                
The Binding Site Group | Technology-Based Intangible Assets                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:   $ 162                
PPD                    
Purchase Price                    
Cash paid       $ 17,237            
Fair value of equity awards exchanged       43            
Fair value of contingent consideration       0            
Cash acquired       (1,244)            
Total purchase price       16,036            
Net Assets Acquired [Abstract]                    
Current assets       2,477            
Property, plant and equipment       527            
Goodwill       13,949            
Other assets       1,060            
Contract liabilities       (1,539)            
Deferred tax assets (liabilities)       (1,782)            
Finance lease liabilities       (90)            
Debt assumed       (4,299)            
Other liabilities assumed       (2,034)            
Redeemable noncontrolling interest       (122)            
Total net assets acquired       16,036            
PPD | Customer relationships                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:       6,257            
PPD | Product technology                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:       0            
PPD | Tradenames                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:       594            
PPD | Backlog                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:       $ 1,038            
PeproTech                    
Purchase Price                    
Cash paid     $ 1,946              
Fair value of contingent consideration     0              
Cash acquired     (83)              
Total purchase price     1,863              
Net Assets Acquired [Abstract]                    
Current assets     58              
Property, plant and equipment     18              
Goodwill     1,198              
Other assets     11              
Contract liabilities     0              
Deferred tax assets (liabilities)     (192)              
Finance lease liabilities     0              
Debt assumed     0              
Other liabilities assumed     (22)              
Total net assets acquired     1,863              
PeproTech | Customer relationships                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:     510              
PeproTech | Product technology                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:     282              
PeproTech | Tradenames                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:     $ 0              
European Viral Vector Business                    
Purchase Price                    
Cash paid             $ 848      
Fair value of contingent consideration             0      
Cash acquired             (18)      
Total purchase price             830      
Net Assets Acquired [Abstract]                    
Current assets             39      
Property, plant and equipment             59      
Goodwill             600      
Other assets             3      
Contract liabilities             (59)      
Deferred tax assets (liabilities)             (80)      
Finance lease liabilities             (24)      
Debt assumed             0      
Other liabilities assumed             (35)      
Total net assets acquired             830      
European Viral Vector Business | Customer relationships                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:             302      
European Viral Vector Business | Product technology                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:             25      
European Viral Vector Business | Tradenames                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:             $ 0      
Mesa Biotech                    
Purchase Price                    
Cash paid           $ 421        
Fair value of contingent consideration           65        
Cash acquired           (14)        
Total purchase price           472        
Net Assets Acquired [Abstract]                    
Current assets           54        
Property, plant and equipment           2        
Goodwill           237        
Other assets           3        
Contract liabilities           0        
Deferred tax assets (liabilities)           (72)        
Finance lease liabilities           0        
Debt assumed           0        
Other liabilities assumed           (33)        
Total net assets acquired           472        
Mesa Biotech | Customer relationships                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:           0        
Mesa Biotech | Product technology                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:           279        
Mesa Biotech | Tradenames                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:           $ 2        
Lengnau biologics manufacturing facility                    
Purchase Price                    
Cash paid         $ 17          
Fair value of contingent consideration         1          
Cash acquired         0          
Total purchase price         18          
Net Assets Acquired [Abstract]                    
Current assets         0          
Property, plant and equipment         93          
Goodwill         18          
Other assets         364          
Contract liabilities         0          
Deferred tax assets (liabilities)         0          
Finance lease liabilities         (82)          
Debt assumed         0          
Other liabilities assumed         (375)          
Total net assets acquired         18          
Lengnau biologics manufacturing facility | Customer relationships                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:         0          
Lengnau biologics manufacturing facility | Product technology                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:         0          
Lengnau biologics manufacturing facility | Tradenames                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:         $ 0          
Other                    
Purchase Price                    
Cash paid                   298
Fair value of contingent consideration                   117
Cash acquired                   (12)
Total purchase price                   $ 403
Net Assets Acquired [Abstract]                    
Current assets                 12  
Property, plant and equipment                 2  
Goodwill                 198  
Other assets                 2  
Contract liabilities                 (1)  
Deferred tax assets (liabilities)                 (27)  
Finance lease liabilities                 0  
Debt assumed                 0  
Other liabilities assumed                 (11)  
Total net assets acquired                 403  
Other | Customer relationships                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:                 2  
Other | Product technology                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:                 224  
Other | Tradenames                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets:                 $ 2  
CorEvitas, LLC                    
Purchase Price                    
Cash paid $ 730                  
Debt settled 184                  
Cash acquired 4                  
Total purchase price 910                  
Net Assets Acquired [Abstract]                    
Net tangible assets (2)                  
Deferred tax assets (liabilities) (68)                  
Total net assets acquired 910                  
CorEvitas, LLC | Customer relationships                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets: 260                  
CorEvitas, LLC | Tradenames                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets: 0                  
CorEvitas, LLC | Backlog                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets: 46                  
Goodwill 627                  
CorEvitas, LLC | Technology-Based Intangible Assets                    
Net Assets Acquired [Abstract]                    
Definite-lived intangible assets: $ 47                  
XML 69 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions - Schedule of Pro Forma Information (Details) - PPD
$ in Millions
 12 Months Ended
Dec. 31, 2021
USD ($)
Business Acquisition, Pro Forma Information [Abstract]  
Revenues $ 44,886
Net income attributable to Thermo Fisher Scientific Inc. $ 7,369
XML 70 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue & Contract-related Balances - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]      
Revenues $ 42,857 $ 44,915 $ 39,211
North America      
Disaggregation of Revenue [Line Items]      
Revenues 22,764 24,594 19,659
Europe      
Disaggregation of Revenue [Line Items]      
Revenues 10,741 10,762 11,134
Asia-Pacific      
Disaggregation of Revenue [Line Items]      
Revenues 7,873 8,115 7,218
Other regions      
Disaggregation of Revenue [Line Items]      
Revenues 1,479 1,444 1,200
Consumables      
Disaggregation of Revenue [Line Items]      
Revenues 17,597 20,624 22,608
Instruments      
Disaggregation of Revenue [Line Items]      
Revenues 7,646 7,924 7,753
Service revenues      
Disaggregation of Revenue [Line Items]      
Revenues $ 17,614 $ 16,367 $ 8,850
XML 71 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue & Contract-related Balances - Revenue Performance Obligations (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Transaction price allocated to remaining performance obligation $ 26,920
Revenue, Performance Obligation, Description of Timing Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years.
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Remaining performance obligation percentage 53.00%
Expected timing of satisfaction of remaining performance obligation 12 months
XML 72 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue & Contract-related Balances - Contract Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]    
Contract assets, net $ 1,443 $ 1,312
Noncurrent contract assets, net 4 7
Contract liabilities 2,689 2,601
Noncurrent contract liabilities $ 1,499 $ 1,179
XML 73 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
Segment
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Segment Reporting Information [Line Items]      
Reportable segments | Segment 4    
Revenues $ 42,857 $ 44,915 $ 39,211
Subtotal reportable segments 6,859 8,393 10,028
Restructuring and other costs (459) (114) (197)
Amortization of acquisition-related intangible assets (2,338) (2,395) (1,761)
Consolidated operating income 6,859 8,393 10,028
Interest income 879 272 43
Interest expense (1,375) (726) (536)
Other income/(expense) (65) (104) (694)
Income before income taxes 6,298 7,835 8,841
Depreciation of property, plant and equipment 1,068 986 831
Total assets 98,726 97,154 95,123
Capital expenditures 1,479 2,243 2,523
Total Reportable Segments      
Segment Reporting Information [Line Items]      
Subtotal reportable segments 9,810 10,985 12,138
Consolidated operating income 9,810 10,985 12,138
Total Reportable Segments | Life Sciences Solutions      
Segment Reporting Information [Line Items]      
Revenues 9,977 13,532 15,631
Subtotal reportable segments 3,420 5,582 7,817
Restructuring and other costs (105) (30) (129)
Consolidated operating income 3,420 5,582 7,817
Depreciation of property, plant and equipment 220 214 197
Total assets 20,191 21,848 22,751
Capital expenditures 178 490 810
Total Reportable Segments | Analytical Instruments      
Segment Reporting Information [Line Items]      
Revenues 7,263 6,624 6,069
Subtotal reportable segments 1,908 1,507 1,197
Restructuring and other costs (33) (1) (6)
Consolidated operating income 1,908 1,507 1,197
Depreciation of property, plant and equipment 93 83 83
Total assets 10,247 10,019 9,692
Capital expenditures 87 140 79
Total Reportable Segments | Specialty Diagnostics      
Segment Reporting Information [Line Items]      
Revenues 4,405 4,763 5,659
Subtotal reportable segments 1,124 1,024 1,280
Restructuring and other costs (11) (68) (18)
Consolidated operating income 1,124 1,024 1,280
Depreciation of property, plant and equipment 86 75 128
Total assets 8,636 5,542 6,010
Capital expenditures 121 112 167
Total Reportable Segments | Laboratory Products and Biopharma Services      
Segment Reporting Information [Line Items]      
Revenues 23,041 22,511 14,862
Subtotal reportable segments 3,358 2,872 1,844
Restructuring and other costs (295) (12) (35)
Consolidated operating income 3,358 2,872 1,844
Depreciation of property, plant and equipment 669 614 423
Total assets 51,091 51,281 52,639
Capital expenditures 1,013 1,403 1,327
Intersegment Eliminations      
Segment Reporting Information [Line Items]      
Revenues (1,829) (2,515) (3,010)
Segment Reconciling Items      
Segment Reporting Information [Line Items]      
Cost of revenues adjustments (95) (46) (8)
Selling, general and administrative expenses adjustments (59) (37) (144)
Restructuring and other costs (459) (114) (197)
Amortization of acquisition-related intangible assets (2,338) (2,395) (1,761)
Corporate      
Segment Reporting Information [Line Items]      
Restructuring and other costs (15) (3) (9)
Total assets [1] 8,561 8,464 4,031
Capital expenditures $ 80 $ 98 $ 140
[1] Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.
XML 74 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
Business Segment and Geographical Information - Schedule of Revenue by Geographical Areas (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenues $ 42,857 $ 44,915 $ 39,211
Long-lived Assets [1] 11,004 10,873 9,864
United States      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenues [2] 22,013 23,820 18,907
Long-lived Assets [1] 6,352 6,308 5,578
Other      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenues [2] 20,844 21,095 20,304
Long-lived Assets [1] $ 4,652 $ 4,565 $ 4,286
[1] Includes property, plant and equipment, net, and operating lease ROU assets.
[2] Revenues are attributed to countries based on customer location.
XML 75 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other Income/Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]      
Gain (loss) on investments $ (46) $ (161) $ 66
Net gains on derivative instruments   67  
Loss on early extinguishment of debt $ 0 $ (26) (767)
Cash outlay     36
Interest rate swaps - fair value hedges | Cash Flow Hedging | Other Expense      
Schedule of Equity Method Investments [Line Items]      
Amount reclassified from accumulated other comprehensive items to interest expense     $ 65
XML 76 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation Expense - Narrative (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted average grant date fair value (in dollars per share) $ 159.32 $ 135.07 $ 123.97
Total intrinsic value $ 320 $ 336 $ 501
Fair value of shares vested $ 207 $ 163 $ 151
Purchase price percentage 95.00%    
Payroll deductions 10.00%    
Shares issued under ESPP (shares) 0.1 0.2 0.1
Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized compensation cost $ 162    
Weighted average amortization period 2 years 2 months 12 days    
Restricted Stock Units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized compensation cost $ 179    
Weighted average amortization period 1 year 10 months 24 days    
Minimum | Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years    
Term 7 years    
Minimum | Restricted Stock Units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years    
Maximum | Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 5 years    
Term 10 years    
Maximum | Restricted Stock Units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 4 years    
XML 77 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation Expense - Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model (Details)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]      
Expected stock price volatility 25.00% 26.00% 26.00%
Risk free interest rate 4.20% 2.00% 0.80%
Expected life of options (years) 4 years 8 months 12 days 4 years 8 months 12 days 4 years 3 months 18 days
Expected annual dividend 0.30% 0.20% 0.20%
XML 78 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation Expense - Summary of the Company's Option Activity (Details)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
shares
Options Outstanding [Roll Forward]  
Outstanding, beginning balance (shares) | shares 5.6
Granted (shares) | shares 0.7
Exercised (shares) | shares (1.0)
Canceled/expired (shares) | shares (0.3)
Outstanding, ending balance (shares) | shares 5.0
Vested and unvested expected to vest (shares) | shares 4.8
Exercisable (shares) | shares 2.8
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]  
Outstanding, beginning of period (in dollars per share) | $ / shares $ 359.27
Granted (in dollars per share) | $ / shares 546.94
Exercised (in dollars per share) | $ / shares 218.82
Canceled/expired (in dollars per share) | $ / shares 543.25
Outstanding, end of period (in dollars per share) | $ / shares 401.30
Vested and unvested expected to vest (in dollars per share) | $ / shares 396.20
Exercisable (in dollars per share) | $ / shares $ 316.88
Options, Additional Disclosures [Abstract]  
Options outstanding, weighted average remaining contractual term 3 years 10 months 24 days
Options vested and expected to vest, weighted average remaining contractual term 3 years 10 months 24 days
Options exercisable, weighted average remaining contractual term 2 years 8 months 12 days
Options outstanding, aggregate intrinsic value | $ $ 714
Options vested and expected to vest, aggregate intrinsic value | $ 712
Options exercisable, aggregate intrinsic value | $ $ 635
XML 79 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation Expense - Summary of the Company's Restricted Unit Activity (Details) - $ / shares
shares in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Unvested Restricted Units [Roll Forward]      
Unvested, beginning balance (shares) 0.7    
Granted (shares) 0.4    
Vested (shares) (0.4)    
Forfeited (shares) (0.1)    
Unvested, ending balance (shares) 0.6 0.7  
Restricted Units, Additional Disclosures [Abstract]      
Unvested, weighted average grant-date fair value, beginning (in dollars per share) $ 495.39    
Granted (in dollars per share) 545.73 $ 520.83 $ 444.61
Vested (in dollars per share) 480.45    
Forfeited (in dollars per share) 528.59    
Unvested, weighted average grant-date fair value, ending (in dollars per share) $ 533.65 $ 495.39  
Restricted Stock Units (RSUs) | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years    
Restricted Stock Units (RSUs) | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 4 years    
XML 80 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pensions and Other Postretirement Benefit Plans - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]      
Defined contribution plan expense $ 468 $ 402 $ 299
Cash contributions to retirement plans $ 42 $ 41 $ 34
U.S. equity funds | United States | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 10.00%    
International equity funds | United States | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 10.00%    
Fixed income funds | United States | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 80.00%    
Minimum      
Defined Benefit Plan Disclosure [Line Items]      
Estimated contributions to plan $ 30    
Minimum | Fixed income funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 30.00%    
Minimum | Equity funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 0.00%    
Minimum | Multi-asset funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 0.00%    
Minimum | Alternative investments | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 0.00%    
Minimum | Derivative funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 0.00%    
Minimum | Real estate funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 0.00%    
Maximum      
Defined Benefit Plan Disclosure [Line Items]      
Estimated contributions to plan $ 50    
Maximum | Fixed income funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 90.00%    
Maximum | Equity funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 25.00%    
Maximum | Multi-asset funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 40.00%    
Maximum | Alternative investments | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 4.00%    
Maximum | Derivative funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 45.00%    
Maximum | Real estate funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 4.00%    
XML 81 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pensions and Other Postretirement Benefit Plans - Reconciliation of Benefit Obligations and Plan Assets (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
United States      
Defined Benefit Plan Disclosure [Line Items]      
Accumulated benefit obligation $ 1,005 $ 995  
Change in projected benefit obligations      
Projected benefit obligation at beginning of year 995 1,260  
Acquisitions 0 0  
Service costs 0 0 $ 0
Interest costs 47 27 23
Settlements 0 0  
Plan participants' contributions 0 0  
Actuarial (gains) losses 42 (210)  
Benefits paid (79) (82)  
Currency translation and other 0 0  
Projected benefit obligation at end of year 1,005 995 1,260
Change in fair value of plan assets      
Fair value of plan assets at beginning of year 937 1,226  
Acquisitions 0 0  
Actual return on plan assets 84 (212)  
Employer contributions 5 5  
Settlements 0 0  
Plan participants' contributions 0 0  
Benefits paid (79) (82)  
Currency translation and other 0 0  
Fair value of plan assets at end of year 947 937 1,226
Funded status (58) (58)  
Amounts recognized in balance sheet      
Noncurrent assets 0 0  
Current liability (6) (6)  
Noncurrent liabilities (52) (52)  
Net amount recognized (58) (58)  
Amounts recognized in accumulated other comprehensive items      
Net actuarial loss 217 200  
Prior service credits 0 0  
Net amount recognized 217 200  
Foreign Plan      
Defined Benefit Plan Disclosure [Line Items]      
Accumulated benefit obligation 1,166 1,016  
Change in projected benefit obligations      
Projected benefit obligation at beginning of year 1,069 1,552  
Acquisitions 15 51  
Service costs 26 34 27
Interest costs 42 20 11
Settlements (37) (31)  
Plan participants' contributions 9 9  
Actuarial (gains) losses 65 (447)  
Benefits paid (25) (19)  
Currency translation and other 57 (100)  
Projected benefit obligation at end of year 1,221 1,069 1,552
Change in fair value of plan assets      
Fair value of plan assets at beginning of year 868 1,302  
Acquisitions 15 14  
Actual return on plan assets 29 (347)  
Employer contributions 36 36  
Settlements (37) (31)  
Plan participants' contributions 9 9  
Benefits paid (25) (19)  
Currency translation and other 49 (96)  
Fair value of plan assets at end of year 944 868 $ 1,302
Funded status (277) (201)  
Amounts recognized in balance sheet      
Noncurrent assets 65 81  
Current liability (11) (11)  
Noncurrent liabilities (331) (271)  
Net amount recognized (277) (201)  
Amounts recognized in accumulated other comprehensive items      
Net actuarial loss 151 74  
Prior service credits (5) (4)  
Net amount recognized $ 146 $ 70  
XML 82 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pensions and Other Postretirement Benefit Plans - Actuarial Assumptions (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Components of Net Periodic Benefit Cost (Income) [Abstract]      
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible List] Other income/(expense)    
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible List] Other income/(expense)    
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible List] Other income/(expense)    
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible List] Other income/(expense)    
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible List] Other income/(expense)    
Pension Plans, Defined Benefit | United States      
Weighted Average Assumptions Used to Determine Benefit Obligation [Abstract]      
Discount rate for determining benefit obligation 4.82% 5.01%  
Interest crediting rate for cash balance plans 4.76% 4.96%  
Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost (Income) [Abstract]      
Discount rate - interest cost 5.01% 2.70% 2.33%
Expected long-term rate of return on assets 6.25% 4.75% 4.25%
Components of Net Periodic Benefit Cost (Income) [Abstract]      
Service cost $ 0 $ 0 $ 0
Interest cost on benefit obligation 47 27 23
Expected return on plan assets (59) (45) (40)
Amortization of actuarial net loss 0 4 7
Amortization of prior service cost (benefit) 0 0 0
Settlement/curtailment loss (gain) 0 0 0
Net periodic benefit cost (income) $ (12) $ (14) $ (10)
Pension Plans, Defined Benefit | Foreign Plan      
Weighted Average Assumptions Used to Determine Benefit Obligation [Abstract]      
Discount rate for determining benefit obligation 3.47% 3.91%  
Interest crediting rate for cash balance plans 2.06% 2.19%  
Average rate of increase in employee compensation 2.64% 2.78%  
Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost (Income) [Abstract]      
Discount rate - service cost 3.62% 1.00% 0.65%
Discount rate - interest cost 3.95% 1.36% 0.80%
Average rate of increase in employee compensation 2.77% 2.73% 2.30%
Expected long-term rate of return on assets 4.33% 2.33% 2.02%
Components of Net Periodic Benefit Cost (Income) [Abstract]      
Service cost $ 26 $ 34 $ 27
Interest cost on benefit obligation 42 20 11
Expected return on plan assets (37) (26) (19)
Amortization of actuarial net loss 2 7 12
Amortization of prior service cost (benefit) (1) (1) 0
Settlement/curtailment loss (gain) 1 (2) 0
Net periodic benefit cost (income) $ 33 $ 32 $ 31
XML 83 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation and Fair Value of Plan Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Pension plans with projected benefit obligations in excess of plan assets    
Projected benefit obligation $ 1,752 $ 1,636
Fair value of plan assets 1,352 1,296
Pension Plans, Defined Benefit    
Defined Benefit Plan Disclosure [Line Items]    
Accumulated benefit obligation 1,695 1,583
Fair value of plan assets $ 1,349 $ 1,294
XML 84 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pension and Other Postretirement Benefit Plans - Schedule of Estimated Future Benefit Payments (Details) - Pension Plans, Defined Benefit
$ in Millions
Dec. 31, 2023
USD ($)
United States  
Defined Benefit Plan, Expected Future Benefit Payments [Abstract]  
2024  $ 81
2025  79
2026  80
2027  79
2028  79
2029-2033 374
Foreign Plan  
Defined Benefit Plan, Expected Future Benefit Payments [Abstract]  
2024  52
2025  55
2026  59
2027  60
2028  65
2029-2033 $ 354
XML 85 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pension and Other Postretirement Benefit Plans - Schedule of Fair Value of the Company's Plan Assets (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
United States      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 947 $ 937 $ 1,226
United States | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 947 937 [1]  
United States | U.S. equity funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 93 89  
United States | U.S. equity funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | U.S. equity funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | U.S. equity funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | U.S. equity funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 93 89 [1]  
United States | International equity funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 93 91  
United States | International equity funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | International equity funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | International equity funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | International equity funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 93 91 [1]  
United States | Fixed income funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 739 739  
United States | Fixed income funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Fixed income funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Fixed income funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Fixed income funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 739 739 [1]  
United States | Money market funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 22 18  
United States | Money market funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Money market funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Money market funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Money market funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 22 18 [1]  
Foreign Plan      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 944 868 $ 1,302
Foreign Plan | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 13 4  
Foreign Plan | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 333 306  
Foreign Plan | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 598 558 [1]  
Foreign Plan | Fixed income funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 346 299  
Foreign Plan | Fixed income funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 9 0  
Foreign Plan | Fixed income funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Fixed income funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Fixed income funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 337 299 [1]  
Foreign Plan | Equity funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 7 8  
Foreign Plan | Equity funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Equity funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Equity funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Equity funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 7 8 [1]  
Foreign Plan | Multi-asset funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 66 56  
Foreign Plan | Multi-asset funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Multi-asset funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Multi-asset funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Multi-asset funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 66 56 [1]  
Foreign Plan | Derivative funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 184 190  
Foreign Plan | Derivative funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Derivative funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Derivative funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Derivative funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 184 190 [1]  
Foreign Plan | Alternative investments      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1    
Foreign Plan | Alternative investments | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0    
Foreign Plan | Alternative investments | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0    
Foreign Plan | Alternative investments | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0    
Foreign Plan | Alternative investments | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1    
Foreign Plan | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 333 306  
Foreign Plan | Insurance contracts | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Insurance contracts | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 333 306  
Foreign Plan | Insurance contracts | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Insurance contracts | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0 [1]  
Foreign Plan | Real estate funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1    
Foreign Plan | Real estate funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0    
Foreign Plan | Real estate funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0    
Foreign Plan | Real estate funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0    
Foreign Plan | Real estate funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1    
Foreign Plan | Cash / money market funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 6 9  
Foreign Plan | Cash / money market funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4 4  
Foreign Plan | Cash / money market funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Cash / money market funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Cash / money market funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 2 $ 5 [1]  
[1]
Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
XML 86 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Components of Income Before Provision for Income Taxes and Provision for Income Taxes (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Components of Income From Continuing Operations Before Income Taxes [Abstract]      
U.S. $ 2,431 $ 3,859 $ 3,340
Non-U.S. 3,867 3,976 5,501
Income before income taxes 6,298 7,835 8,841
Current income tax provision      
Federal 228 813 446
Non-U.S. 1,206 633 1,148
State 150 254 160
Current income tax provision 1,584 1,700 1,754
Deferred income tax provision (benefit)      
Federal (551) (611) (227)
Non-U.S. (647) (314) (399)
State (102) (72) (19)
Deferred income tax provision (benefit) (1,300) (997) (645)
Provision for income taxes $ 284 $ 703 $ 1,109
XML 87 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
Statutory federal income tax rate 21.00% 21.00% 21.00%
Provision for income taxes at statutory rate $ 1,323 $ 1,645 $ 1,857
Foreign rate differential (223) (329) (255)
Income tax credits (276) (202) (315)
Global intangible low-taxed income 113 96 76
Foreign-derived intangible income (108) (149) (119)
Excess tax benefits from stock options and restricted stock units (69) (80) (124)
Provision for (reversal of) tax reserves, net 13 (544) (17)
Intra-entity transfers (233) (18) (284)
Foreign exchange loss on inter-company debt refinancing (112) 0 0
Provision for (reversal of) valuation allowances, net (32) 344 36
Withholding taxes 33 84 164
Tax return reassessments and settlements (187) (210) 1
State income taxes, net of federal tax 70 111 82
Other, net (28) (45) 7
Provision for income taxes $ 284 $ 703 $ 1,109
XML 88 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Operating Loss Carryforwards [Line Items]        
Provision for (reversal of) valuation allowances, net $ (32) $ 344 $ 36  
Tax benefit from foreign exchange loss on an intercompany debt refinancing transaction 91      
Research credits and incentives 127      
Intra-entity transfers (233) (18) (284)  
Tax return reassessments and settlements 187 210 (1)  
Excess tax benefits from stock options and restricted stock units (69) (80) (124)  
Undistributed earnings 34,000      
Unrecognized tax benefits 540 572 1,124 $ 1,091
Additions due to acquisitions 0 15 26  
UTB, interest and penalties 95 74    
Foreign Tax Credit Carryforwards        
Operating Loss Carryforwards [Line Items]        
Tax credit carryforward 648      
Deferred Interest Carryforward        
Operating Loss Carryforwards [Line Items]        
Tax credit carryforward 753      
Deferred Interest Carryforward | Tax Years 2025-2033        
Operating Loss Carryforwards [Line Items]        
Tax credit carryforward 149      
Federal        
Operating Loss Carryforwards [Line Items]        
NOL carryforwards 70      
Domestic NOL Expires        
Operating Loss Carryforwards [Line Items]        
NOL carryforwards 30      
State        
Operating Loss Carryforwards [Line Items]        
NOL carryforwards 93      
State NOL Expires        
Operating Loss Carryforwards [Line Items]        
NOL carryforwards 83      
Non- U.S.        
Operating Loss Carryforwards [Line Items]        
NOL carryforwards 1,420      
Portion of Non- U.S. with expiration dates        
Operating Loss Carryforwards [Line Items]        
NOL carryforwards 435      
Federal        
Operating Loss Carryforwards [Line Items]        
Provision for (reversal of) valuation allowances, net   395    
Tax return reassessments and settlements   208    
Provision for (reversal of) tax reserves, net   658    
Charge for expired tax credits   49    
Unrecognized tax benefits reclassed to accrued income taxes in connection with IRS settlement   101    
Foreign        
Operating Loss Carryforwards [Line Items]        
Increase (decrease) in UTB 12 (143) (80)  
Federal and State        
Operating Loss Carryforwards [Line Items]        
Increase (decrease) in UTB $ 19 $ 610 75  
Deferred Tax Implications        
Operating Loss Carryforwards [Line Items]        
Intra-entity transfers     188  
Capital Loss        
Operating Loss Carryforwards [Line Items]        
Intra-entity transfers     $ 96  
XML 89 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Deferred Tax Assets (Liabilities) [Abstract]      
Depreciation and amortization $ (4,286) $ (4,277)  
Net operating loss and credit carryforwards 2,385 1,951  
Reserves and accruals 157 140  
Accrued compensation 299 259  
Inventory basis difference 275 364  
Deferred interest 753 445  
Research and development and other capitalized costs 380 220  
Unrealized (gains) losses on hedging instruments (66) (199)  
Other, net 329 435  
Deferred tax assets/(liabilities), net before valuation allowance 226 (662)  
Valuation Allowance 1,317 1,322 $ 968
Deferred tax assets/(liabilities), net (1,091) (1,984)  
Valuation Allowance [Roll Forward]      
Beginning Balance 1,322 968 933
Additions (reductions) charged to income tax provision, net (32) 344 24
Additions due to acquisitions 4 14 30
Currency translation and other 23 (4) (19)
Ending Balance $ 1,317 $ 1,322 $ 968
XML 90 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Reconciliation of Unrecognized Tax Benefits [Roll Forward]      
Beginning balance $ 572 $ 1,124 $ 1,091
Additions due to acquisitions 0 15 26
Additions for tax positions of current year 4 104 32
Additions for tax positions of prior years 34 24 60
Reductions for tax positions of prior years (43) (659) (5)
Closure of tax years (6) (4) (27)
Settlements (21) (32) (53)
Ending balance $ 540 $ 572 $ 1,124
XML 91 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Earnings Per Share [Abstract]      
Net income $ 5,995 $ 6,950 $ 7,725
Basic (in shares) 386 392 394
Plus effect of: stock options and restricted stock units (shares) 2 2 3
Diluted weighted average shares (shares) 388 394 397
Basic Earnings Per Share (in dollars per share) $ 15.52 $ 17.75 $ 19.62
Diluted Earnings Per Share (in dollars per share) $ 15.45 $ 17.63 $ 19.46
Antidilutive stock options excluded from diluted weighted averages shares (shares) 2 2 1
XML 92 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt and Other Financing Arrangements - Schedule of Debt (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Total borrowings at par value $ 35,028 $ 34,561
Unamortized discount (113) (112)
Unamortized debt issuance costs (188) (171)
Total borrowings at carrying value 34,727 34,278
Finance lease liabilities 190 210
Less: Short-term obligations and current maturities 3,609 5,579
Long-term obligations $ 31,308 $ 28,909
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Long-term obligations Long-term obligations
Commercial Paper Programs    
Debt Instrument [Line Items]    
Total borrowings at par value $ 0 $ 310
Total borrowings at carrying value 0 310
Senior Notes    
Debt Instrument [Line Items]    
Total borrowings at carrying value $ 34,650 33,889
Senior Notes | Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023    
Debt Instrument [Line Items]    
Variable rate 0.35%  
Term 1 year 6 months  
Total borrowings at par value $ 0 1,000
Senior Notes | Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023    
Debt Instrument [Line Items]    
Variable rate 0.39%  
Term 2 years  
Total borrowings at par value $ 0 500
Senior Notes | 0.797% 2-Year Senior Notes, Due 10/18/2023    
Debt Instrument [Line Items]    
Interest rate 0.797%  
Term 2 years  
Total borrowings at par value $ 0 1,350
Senior Notes | Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)    
Debt Instrument [Line Items]    
Variable rate 0.20%  
Term 2 years  
Total borrowings at par value $ 0 1,819
Senior Notes | 0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.00%  
Term 2 years  
Total borrowings at par value $ 0 589
Senior Notes | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.75%  
Term 8 years  
Effective interest rate 0.93%  
Total borrowings at par value $ 1,104 1,071
Senior Notes | Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024    
Debt Instrument [Line Items]    
Variable rate 0.53%  
Term 3 years  
Total borrowings at par value $ 0 500
Senior Notes | 1.215% 3-Year Senior Notes, Due 10/18/2024    
Debt Instrument [Line Items]    
Interest rate 1.215%  
Term 3 years  
Effective interest rate 1.42%  
Total borrowings at par value $ 2,500 2,500
Senior Notes | 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.125%  
Term 5 years 6 months  
Effective interest rate 0.41%  
Total borrowings at par value $ 883 857
Senior Notes | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 2.00%  
Term 10 years  
Effective interest rate 2.10%  
Total borrowings at par value $ 706 686
Senior Notes | 0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.853%  
Term 3 years  
Effective interest rate 1.05%  
Total borrowings at par value $ 158 170
Senior Notes | 0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.00%  
Term 4 years  
Effective interest rate 0.15%  
Total borrowings at par value $ 607 589
Senior Notes | 3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 3.20%  
Term 3 years  
Effective interest rate 3.39%  
Total borrowings at par value $ 552 535
Senior Notes | 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.40%  
Term 8 years 6 months  
Effective interest rate 1.53%  
Total borrowings at par value $ 773 749
Senior Notes | 4.953% 3-Year Senior Notes, Due 8/10/2026    
Debt Instrument [Line Items]    
Interest rate 4.953%  
Term 3 years  
Effective interest rate 5.19%  
Total borrowings at par value $ 600 0
Senior Notes | 5.000% 3-Year Senior Notes due 12/5/2026    
Debt Instrument [Line Items]    
Interest rate 5.00%  
Term 3 years  
Effective interest rate 5.00%  
Total borrowings at par value $ 1,000 0
Senior Notes | 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.45%  
Term 10 years  
Effective interest rate 1.65%  
Total borrowings at par value $ 552 535
Senior Notes | 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.75%  
Term 7 years  
Effective interest rate 1.97%  
Total borrowings at par value $ 662 642
Senior Notes | 1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.054%  
Term 5 years  
Effective interest rate 1.18%  
Total borrowings at par value $ 205 221
Senior Notes | 4.80% 5-Year Senior Notes, Due 11/21/2027    
Debt Instrument [Line Items]    
Interest rate 4.80%  
Term 5 years  
Effective interest rate 5.00%  
Total borrowings at par value $ 600 600
Senior Notes | 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.50%  
Term 8 years 6 months  
Effective interest rate 0.77%  
Total borrowings at par value $ 883 857
Senior Notes | 0.77% 5-Year Senior Notes, Due 9/6/2028 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.77%  
Term 5 years  
Effective interest rate 0.90%  
Total borrowings at par value $ 206 0
Senior Notes | 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.375%  
Term 12 years  
Effective interest rate 1.46%  
Total borrowings at par value $ 662 642
Senior Notes | 1.750% 7-Year Senior Notes, Due 10/15/2028    
Debt Instrument [Line Items]    
Interest rate 1.75%  
Term 7 years  
Effective interest rate 1.89%  
Total borrowings at par value $ 700 700
Senior Notes | 5.000% 5-Year Senior Notes due 1/31/2029    
Debt Instrument [Line Items]    
Interest rate 5.00%  
Term 5 years  
Effective interest rate 5.00%  
Total borrowings at par value $ 1,000 0
Senior Notes | 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.95%  
Term 12 years  
Effective interest rate 2.08%  
Total borrowings at par value $ 773 749
Senior Notes | 2.60% 10-Year Senior Notes, Due 10/1/2029    
Debt Instrument [Line Items]    
Interest rate 2.60%  
Term 10 years  
Effective interest rate 2.74%  
Total borrowings at par value $ 900 900
Senior Notes | 1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.279%  
Term 7 years  
Effective interest rate 1.44%  
Total borrowings at par value $ 33 36
Senior Notes | 4.977% 7-Year Senior Notes, Due 8/10/2030    
Debt Instrument [Line Items]    
Interest rate 4.977%  
Term 7 years  
Effective interest rate 5.12%  
Total borrowings at par value $ 750 0
Senior Notes | 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.80%  
Term 9 years  
Effective interest rate 0.89%  
Total borrowings at par value $ 1,932 1,873
Senior Notes | 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.875%  
Term 12 years  
Effective interest rate 1.13%  
Total borrowings at par value $ 993 963
Senior Notes | 2.00% 10-Year Senior Notes, Due 10/15/2031    
Debt Instrument [Line Items]    
Interest rate 2.00%  
Term 10 years  
Effective interest rate 2.23%  
Total borrowings at par value $ 1,200 1,200
Senior Notes | 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 2.375%  
Term 12 years  
Effective interest rate 2.55%  
Total borrowings at par value $ 662 642
Senior Notes | 1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.49%  
Term 10 years  
Effective interest rate 1.60%  
Total borrowings at par value $ 45 48
Senior Notes | 4.95% 10-Year Senior Notes, Due 11/21/2032    
Debt Instrument [Line Items]    
Interest rate 4.95%  
Term 10 years  
Effective interest rate 5.09%  
Total borrowings at par value $ 600 600
Senior Notes | 5.086% 10-Year Senior Notes, Due 8/10/2033    
Debt Instrument [Line Items]    
Interest rate 5.086%  
Term 10 years  
Effective interest rate 5.20%  
Total borrowings at par value $ 1,000 0
Senior Notes | 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.125%  
Term 12 years  
Effective interest rate 1.20%  
Total borrowings at par value $ 1,656 1,606
Senior Notes | 5.200% 10-Year Senior Notes due 1/31/2034    
Debt Instrument [Line Items]    
Interest rate 5.20%  
Term 10 years  
Effective interest rate 5.20%  
Total borrowings at par value $ 500 0
Senior Notes | 3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 3.65%  
Term 12 years  
Effective interest rate 3.76%  
Total borrowings at par value $ 828 803
Senior Notes | 1.50% 12-Year Senior Notes, due 9/6/2035 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.50%  
Term 12 years  
Effective interest rate 1.58%  
Total borrowings at par value $ 152 0
Senior Notes | 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 2.875%  
Term 20 years  
Effective interest rate 2.94%  
Total borrowings at par value $ 773 749
Senior Notes | 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.50%  
Term 20 years  
Effective interest rate 1.73%  
Total borrowings at par value $ 993 963
Senior Notes | 2.80% 20-Year Senior Notes, Due 10/15/2041    
Debt Instrument [Line Items]    
Interest rate 2.80%  
Term 20 years  
Effective interest rate 2.90%  
Total borrowings at par value $ 1,200 1,200
Senior Notes | 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.625%  
Term 20 years  
Effective interest rate 1.77%  
Total borrowings at par value $ 1,380 1,339
Senior Notes | 2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 2.069%  
Term 20 years  
Effective interest rate 2.13%  
Total borrowings at par value $ 104 111
Senior Notes | 5.404% 20-Year Senior Notes, due 8/10/2043    
Debt Instrument [Line Items]    
Interest rate 5.404%  
Term 20 years  
Effective interest rate 5.50%  
Total borrowings at par value $ 600 0
Senior Notes | 2.02% 20-Year Senior Notes, due 9/6/2043 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 2.02%  
Term 20 years  
Effective interest rate 2.06%  
Total borrowings at par value $ 206 0
Senior Notes | 5.30% 30-Year Senior Notes, Due 2/1/2044    
Debt Instrument [Line Items]    
Interest rate 5.30%  
Term 30 years  
Effective interest rate 5.37%  
Total borrowings at par value $ 400 400
Senior Notes | 4.10% 30-Year Senior Notes, Due 8/15/2047    
Debt Instrument [Line Items]    
Interest rate 4.10%  
Term 30 years  
Effective interest rate 4.23%  
Total borrowings at par value $ 750 750
Senior Notes | 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.875%  
Term 30 years  
Effective interest rate 1.98%  
Total borrowings at par value $ 1,104 1,071
Senior Notes | 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 2.00%  
Term 30 years  
Effective interest rate 2.07%  
Total borrowings at par value $ 828 803
Senior Notes | 2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 2.382%  
Term 30 years  
Effective interest rate 2.43%  
Total borrowings at par value $ 236 254
Other Debt    
Debt Instrument [Line Items]    
Total borrowings at par value 77 79
Total borrowings at carrying value $ 77 $ 79
XML 93 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt and Other Financing Arrangements - Schedule of Annual Repayment Requirements for Debt Obligations (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
2024  $ 3,604  
2025  2,356  
2026  2,925  
2027  2,020  
2028  2,451  
2029 and thereafter 21,672  
Total borrowings at par value 35,028 $ 34,561
2024  5  
2025  13  
2026  12  
2027  10  
2028  8  
2029 and thereafter 142  
Finance lease liabilities $ 190 $ 210
XML 94 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt and Other Financing Arrangements - Narrative (Details)
 12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Short-term Financing [Line Items]      
Unused lines of credit $ 69,000,000    
Loss on early extinguishment of debt $ 0 $ 26,000,000 $ 767,000,000
Senior Notes      
Short-term Financing [Line Items]      
Redemption price 100.00%    
Interest rate swaps - fair value hedges      
Short-term Financing [Line Items]      
Proceeds from interest rate swap     $ 22,000,000
U.S. Commercial Paper Program | Commercial Paper Programs      
Short-term Financing [Line Items]      
Maximum period prior to maturity 397 days    
Euro Commercial Paper Program | Commercial Paper Programs      
Short-term Financing [Line Items]      
Maximum period prior to maturity 183 days    
Senior Notes 3.65% Due 2025 [Member] | Senior Notes      
Short-term Financing [Line Items]      
Interest rate   3.65%  
0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated) | Senior Notes      
Short-term Financing [Line Items]      
Interest rate 0.00%    
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) | Senior Notes      
Short-term Financing [Line Items]      
Interest rate 0.80%    
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) | Senior Notes      
Short-term Financing [Line Items]      
Interest rate 1.125%    
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) | Senior Notes      
Short-term Financing [Line Items]      
Interest rate 1.625%    
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) | Senior Notes      
Short-term Financing [Line Items]      
Interest rate 2.00%    
Revolving Credit Facility      
Short-term Financing [Line Items]      
Revolving credit facility capacity $ 5,000,000,000    
Minimum consolidated net interest coverage ratio 3.5    
Borrowings outstanding $ 0    
XML 95 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases- Narrative (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
lease
Lessee, Lease, Description [Line Items]  
Leased operating facilities | lease 3
Lease Residual Value Guarantee  
Lessee, Lease, Description [Line Items]  
Maximum guarantee under lease arrangements | $ $ 147
Minimum  
Lessee, Lease, Description [Line Items]  
Remaining lease term 1 month
Options to extend, renewal term 1 year
Maximum  
Lessee, Lease, Description [Line Items]  
Remaining lease term 30 years
Options to extend, renewal term 10 years
Option to terminate, term 1 year
XML 96 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Schedule of Operating Leases (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Leases [Abstract]      
Operating lease costs $ 355 $ 351 $ 254
Variable lease costs 115 109 66
Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities 410 289 288
Operating lease ROU assets obtained in exchange for new operating lease liabilities 234 430 $ 293
ROU assets 1,556 1,593  
Operating lease liabilities - current 263 272  
Operating lease liabilities - noncurrent $ 1,244 $ 1,313  
Remaining operating lease term 9 years 2 months 12 days 9 years 4 months 24 days  
Discount rate 4.00% 3.20%  
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other assets Other assets  
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other accrued expenses Other accrued expenses  
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other long-term liabilities Other accrued expenses  
XML 97 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Schedule of Future Payments of Operating Lease Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
2024  $ 294  
2025  288  
2026  242  
2027  172  
2028  131  
2029 and thereafter 723  
Total lease payments 1,850  
Less: imputed interest $ 343  
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Other accrued expenses, Other long-term liabilities Other accrued expenses, Other long-term liabilities
Total operating lease liability $ 1,507  
XML 98 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies (Details)
$ in Millions
Dec. 31, 2023
USD ($)
Unconditional Purchase Obligations [Abstract]  
Unconditional purchase obligations $ 2,530
Accrual for Environmental Loss Contingencies Disclosure [Abstract]  
Environmental liability $ 75
Loss Contingency [Abstract]  
Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration] Other accrued expenses, Other long-term liabilities
Letters of Credit / Bank Guarantees  
Guarantor Obligations [Line Items]  
Maximum guarantee under lease arrangements $ 315
Surety Bonds and Other Guarantees  
Guarantor Obligations [Line Items]  
Maximum guarantee under lease arrangements 93
Investments  
Guarantor Obligations [Line Items]  
Maximum guarantee under lease arrangements 164
Businesses Sold | Pension Obligation Guarantee  
Guarantor Obligations [Line Items]  
Maximum guarantee under lease arrangements 24
Product Liability, Workers Compensation and Other Personal Injury Matters  
Loss Contingency [Abstract]  
Loss accrual 224
Estimated amounts due from insurers 88
Undiscounted product liability accrual 20
Product Liability, Workers Compensation and Other Personal Injury Matters | Minimum  
Loss Contingency [Abstract]  
Range of probable loss 222
Product Liability, Workers Compensation and Other Personal Injury Matters | Maximum  
Loss Contingency [Abstract]  
Range of probable loss $ 379
XML 99 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
Comprehensive Income and Shareholders' Equity (Details) - USD ($)
shares in Millions, $ in Millions
 2 Months Ended 12 Months Ended
Feb. 22, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Balance $ 46,724 $ 44,032 $ 40,855 $ 34,517
Total other comprehensive income/(loss)   (133) (777) 478
Balance   $ 46,724 44,032 40,855
Unissued shares of common stock (in shares)   39.0    
Purchases of company common stock   $ 3,000 3,000 2,000
Currency translation adjustment        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Balance (2,941) (2,880)    
Other comprehensive income/(loss) before reclassifications   (69)    
Amounts reclassified from accumulated other comprehensive income/(loss)   8    
Total other comprehensive income/(loss)   (61)    
Balance   (2,941) (2,880)  
Unrealized losses on hedging instruments        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Balance (28) (33)    
Other comprehensive income/(loss) before reclassifications   0    
Amounts reclassified from accumulated other comprehensive income/(loss)   5    
Total other comprehensive income/(loss)   5    
Balance   (28) (33)  
Pension and other postretirement benefit liability adjustment        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Balance (255) (186)    
Other comprehensive income/(loss) before reclassifications   (69)    
Amounts reclassified from accumulated other comprehensive income/(loss)   0    
Total other comprehensive income/(loss)   (69)    
Balance   (255) (186)  
Accumulated Other Comprehensive Items        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Balance (3,224) (3,099) (2,329) (2,807)
Other comprehensive income/(loss) before reclassifications   (138)    
Amounts reclassified from accumulated other comprehensive income/(loss)   13    
Total other comprehensive income/(loss)   (125)    
Balance   $ (3,224) $ (3,099) $ (2,329)
Subsequent Event        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Purchases of company common stock $ 3,000      
Purchases of company common stock (in shares) 5.5      
XML 100 R82.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Liabilities [Abstract]    
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other long-term liabilities  
Fair Value, Recurring    
Assets [Abstract]    
Cash equivalents $ 5,021 $ 5,804
Bank time deposits 3  
Investments 20 25
Warrants   12
Insurance contracts 210 162
Derivative contracts 8 79
Total assets 5,262 6,082
Liabilities [Abstract]    
Derivative contracts 290 101
Contingent consideration 87 174
Total liabilities 377 275
Fair Value, Recurring | Quoted Prices in Active Markets (Level 1)    
Assets [Abstract]    
Cash equivalents 5,021 5,804
Bank time deposits 3  
Investments 20 25
Warrants   0
Insurance contracts 0 0
Derivative contracts 0 0
Total assets 5,044 5,829
Liabilities [Abstract]    
Derivative contracts 0 0
Contingent consideration 0 0
Total liabilities 0 0
Fair Value, Recurring | Significant Other Observable Inputs (Level 2)    
Assets [Abstract]    
Cash equivalents 0 0
Bank time deposits 0  
Investments 0 0
Warrants   12
Insurance contracts 210 162
Derivative contracts 8 79
Total assets 218 253
Liabilities [Abstract]    
Derivative contracts 290 101
Contingent consideration 0 0
Total liabilities 290 101
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)    
Assets [Abstract]    
Cash equivalents 0 0
Bank time deposits 0  
Investments 0 0
Warrants   0
Insurance contracts 0 0
Derivative contracts 0 0
Total assets 0 0
Liabilities [Abstract]    
Derivative contracts 0 0
Contingent consideration 87 174
Total liabilities $ 87 $ 174
XML 101 R83.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements and Fair Value of Financial Instruments - Rollforward of the Fair Value of Investments (Details) - Contingent Consideration - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance $ 174 $ 317
Acquisitions (including assumed balances) 1 (18)
Payments (63) (66)
Changes in fair value included in earnings (25) (59)
Ending balance $ 87 $ 174
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, general and administrative expenses Selling, general and administrative expenses
XML 102 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Aggregate Notional Value and Fair Value of Derivative Instruments (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Derivatives, Fair Value [Line Items]    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets, Other assets  
Cross-currency interest rate swaps - designated as net investment hedges | Derivatives designated as hedging instruments    
Derivatives, Fair Value [Line Items]    
Fair value – assets $ 5 $ 77
Fair value – liabilities 287 85
Cross-currency interest rate swaps - designated as net investment hedges | Net Investment Hedging | Cross-currency interest rate swaps designated as net investment hedge - euro    
Derivatives, Fair Value [Line Items]    
Notional amount 1,000 900
Cross-currency interest rate swaps - designated as net investment hedges | Net Investment Hedging | Cross-currency interest rate swaps designated as net investment hedge - Japanese yen    
Derivatives, Fair Value [Line Items]    
Notional amount 4,650 1,200
Cross-currency interest rate swaps - designated as net investment hedges | Net Investment Hedging | Cross-currency interest rate swaps designated as net investment hedge - Swiss franc    
Derivatives, Fair Value [Line Items]    
Notional amount 2,500 0
Currency exchange contracts    
Derivatives, Fair Value [Line Items]    
Notional amount 1,567 2,434
Currency exchange contracts | Derivatives not designated as hedging instruments    
Derivatives, Fair Value [Line Items]    
Fair value – assets 3 2
Fair value – liabilities 3 16
Fair Value, Recurring    
Derivatives, Fair Value [Line Items]    
Fair value – assets 8 79
Fair value – liabilities $ 290 $ 101
XML 103 R85.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Derivative Instruments, Gain (Loss) Recognized (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Currency exchange contracts | Other Expense | Derivatives not designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Included in interest expense $ (29) $ 102 $ 162
Currency exchange contracts | Cost of Sales | Derivatives not designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Included in interest expense 1 6 12
Fair Value Hedging | Interest rate swaps - fair value hedges | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Included in interest expense 0 0 (3)
Fair Value Hedging | Interest rate swaps - fair value hedges | Other Expense | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Hedged long-term obligations - included in other income/(expense) 0 0 25
Fair Value Hedging | Cross-currency interest rate swaps - designated as net investment hedges | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Included in interest expense 0 (81) 0
Fair Value Hedging | Cross-currency interest rate swaps - designated as net investment hedges | Other Expense | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Hedged long-term obligations - included in other income/(expense) 0 77 0
Cash Flow Hedging | Interest rate swaps - fair value hedges | Other Expense      
Derivative Instruments, Gain (Loss) [Line Items]      
Amount reclassified from accumulated other comprehensive items to interest expense     (65)
Cash Flow Hedging | Interest rate swaps - fair value hedges | Other Expense | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Amount reclassified from accumulated other comprehensive items to interest expense 3 3 73
Cash Flow Hedging | Interest rate swaps - fair value hedges | Interest Expense | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Amount reclassified from accumulated other comprehensive items to interest expense 4 0 0
Net Investment Hedging | Foreign currency-denominated debt | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Included in currency translation adjustment within other comprehensive items (356) 695 922
Net Investment Hedging | Cross-currency interest rate swaps - designated as net investment hedges | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Included in interest expense 120 19 8
Included in currency translation adjustment within other comprehensive items $ (222) $ 52 $ 71
XML 104 R86.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of the Company's Debt Instruments (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Carrying value $ 34,727 $ 34,278
Fair value 32,268 30,290
Senior Notes    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Carrying value 34,650 33,889
Fair value 32,191 29,901
Commercial Paper Programs    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Carrying value 0 310
Fair value 0 310
Other Debt    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Carrying value 77 79
Fair value $ 77 $ 79
XML 105 R87.htm IDEA: XBRL DOCUMENT v3.24.0.1
Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Disclosures (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Supplemental Cash Flow Information [Abstract]      
Interest $ 1,385 $ 667 $ 555
Income taxes 1,482 1,234 2,182
Non-cash investing and financing activities      
Acquired but unpaid property, plant and equipment 296 393 379
Fair value of equity awards exchanged 0 0 43
Fair value of contingent consideration 0 0 183
Finance lease ROU assets obtained in exchange for new finance lease liabilities 2 33 15
Declared but unpaid dividends 137 119 104
Issuance of stock upon vesting of restricted stock units 234 241 265
Excise tax from stock repurchases $ 28 $ 0 $ 0
XML 106 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Supplemental Cash Flow Information [Abstract]        
Cash and cash equivalents $ 8,077 $ 8,524    
Restricted cash included in other current assets 6 12    
Restricted cash included in other assets 14 1    
Cash, cash equivalents and restricted cash $ 8,097 $ 8,537 $ 4,491 $ 10,336
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible Enumeration] Other current assets      
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible Enumeration] Other assets      
XML 107 R89.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Feb. 22, 2024
Restructuring Cost and Reserve [Line Items]        
Eliminated workforce percentage 5.00% 2.00% 1.00%  
Restructuring and other costs $ 459 $ 114 $ 197  
Subsequent Event        
Restructuring Cost and Reserve [Line Items]        
Future restructuring costs       $ 70
Corporate        
Restructuring Cost and Reserve [Line Items]        
Restructuring and other costs 15 3 9  
Life Sciences Solutions | Total Reportable Segments        
Restructuring Cost and Reserve [Line Items]        
Restructuring and other costs 105 30 129  
Analytical Instruments | Total Reportable Segments        
Restructuring Cost and Reserve [Line Items]        
Restructuring and other costs 33 1 6  
Specialty Diagnostics | Total Reportable Segments        
Restructuring Cost and Reserve [Line Items]        
Restructuring and other costs 11 68 18  
Laboratory Products and Biopharma Services | Total Reportable Segments        
Restructuring Cost and Reserve [Line Items]        
Restructuring and other costs $ 295 $ 12 $ 35  
XML 108 R90.htm IDEA: XBRL DOCUMENT v3.24.0.1
Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Restructuring Reserve [Roll Forward]      
Beginning balance $ 41 $ 17 $ 21
Net restructuring charges incurred 194 68 37
Payments (175) (44) (40)
Currency translation     (1)
Ending balance 60 41 17
Other non-cash restructuring costs 264 $ 46 160
Impairment of intangible assets     122
Cash compensation charges     $ 35
Impairment of long-lived assets 126    
Loss on contract termination 26    
Pre-acquisition litigation costs 19    
Impairment of disposal group 93    
Loss attributable to noncontrolling interest $ 46    
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring and other costs    
EXCEL 110 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 119 tmo-20231231_htm.xml IDEA: XBRL DOCUMENT 0000097745 2023-01-01 2023-12-31 0000097745 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes0.75Due2024Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes0.125Due2025Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes200Due2025Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes3200Due2026Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1.40Due2026Member 2023-01-01 2023-12-31 0000097745 tmo:A1.45SeniorNotesDue2027Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes175Due2027Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes0.500Due2028Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1.375Due2028Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1.95Due2029Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes0.875Due2031Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes2375Due2032Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes3650Due2034Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes2.875Due2037Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1.500Due2039Member 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1.875Due2049Member 2023-01-01 2023-12-31 0000097745 2023-06-30 0000097745 2024-02-03 0000097745 2023-12-31 0000097745 2022-12-31 0000097745 us-gaap:ProductMember 2023-01-01 2023-12-31 0000097745 us-gaap:ProductMember 2022-01-01 2022-12-31 0000097745 us-gaap:ProductMember 2021-01-01 2021-12-31 0000097745 us-gaap:ServiceMember 2023-01-01 2023-12-31 0000097745 us-gaap:ServiceMember 2022-01-01 2022-12-31 0000097745 us-gaap:ServiceMember 2021-01-01 2021-12-31 0000097745 2022-01-01 2022-12-31 0000097745 2021-01-01 2021-12-31 0000097745 2021-12-31 0000097745 2020-12-31 0000097745 us-gaap:CommonStockMember 2020-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000097745 us-gaap:RetainedEarningsMember 2020-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2020-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000097745 us-gaap:ParentMember 2020-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2020-12-31 0000097745 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-12-31 0000097745 us-gaap:ParentMember 2021-01-01 2021-12-31 0000097745 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000097745 us-gaap:CommonStockMember 2021-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000097745 us-gaap:RetainedEarningsMember 2021-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2021-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000097745 us-gaap:ParentMember 2021-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2021-12-31 0000097745 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0000097745 us-gaap:ParentMember 2022-01-01 2022-12-31 0000097745 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000097745 us-gaap:CommonStockMember 2022-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000097745 us-gaap:RetainedEarningsMember 2022-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2022-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000097745 us-gaap:ParentMember 2022-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2022-12-31 0000097745 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0000097745 us-gaap:ParentMember 2023-01-01 2023-12-31 0000097745 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0000097745 us-gaap:CommonStockMember 2023-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000097745 us-gaap:RetainedEarningsMember 2023-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2023-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000097745 us-gaap:ParentMember 2023-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2023-12-31 0000097745 tmo:PPDSNBLKKMember 2023-12-31 0000097745 us-gaap:ChangeInAccountingPrincipleOtherMember 2021-09-30 0000097745 us-gaap:ProductMember us-gaap:ChangeInAccountingPrincipleOtherMember 2021-07-04 2021-10-02 0000097745 us-gaap:ChangeInAccountingPrincipleOtherMember 2021-10-02 0000097745 us-gaap:ChangeInAccountingPrincipleOtherMember tmo:LaboratoryProductsandServicesMember 2021-10-02 0000097745 us-gaap:ProductMember us-gaap:ChangeInAccountingPrincipleOtherMember tmo:LaboratoryProductsandServicesMember 2021-07-04 2021-10-02 0000097745 us-gaap:ProductMember us-gaap:ChangeInAccountingPrincipleOtherMember tmo:SpecialtyDiagnosticsMember 2021-07-04 2021-10-02 0000097745 us-gaap:ChangeInAccountingPrincipleOtherMember tmo:SpecialtyDiagnosticsMember 2021-10-02 0000097745 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0000097745 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0000097745 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0000097745 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0000097745 us-gaap:LandMember 2023-12-31 0000097745 us-gaap:LandMember 2022-12-31 0000097745 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0000097745 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0000097745 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2023-12-31 0000097745 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2022-12-31 0000097745 us-gaap:ConstructionInProgressMember 2023-12-31 0000097745 us-gaap:ConstructionInProgressMember 2022-12-31 0000097745 srt:MaximumMember 2023-12-31 0000097745 us-gaap:CustomerRelationshipsMember 2023-12-31 0000097745 us-gaap:CustomerRelationshipsMember 2022-12-31 0000097745 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000097745 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000097745 us-gaap:TradeNamesMember 2023-12-31 0000097745 us-gaap:TradeNamesMember 2022-12-31 0000097745 us-gaap:OrderOrProductionBacklogMember 2023-12-31 0000097745 us-gaap:OrderOrProductionBacklogMember 2022-12-31 0000097745 us-gaap:TradeNamesMember 2023-12-31 0000097745 us-gaap:TradeNamesMember 2022-12-31 0000097745 tmo:LifeSciencesSolutionsMember 2021-12-31 0000097745 tmo:AnalyticalInstrumentsMember 2021-12-31 0000097745 tmo:SpecialtyDiagnosticsMember 2021-12-31 0000097745 tmo:LaboratoryProductsandServicesMember 2021-12-31 0000097745 tmo:LifeSciencesSolutionsMember 2022-01-01 2022-12-31 0000097745 tmo:AnalyticalInstrumentsMember 2022-01-01 2022-12-31 0000097745 tmo:SpecialtyDiagnosticsMember 2022-01-01 2022-12-31 0000097745 tmo:LaboratoryProductsandServicesMember 2022-01-01 2022-12-31 0000097745 tmo:LifeSciencesSolutionsMember 2022-12-31 0000097745 tmo:AnalyticalInstrumentsMember 2022-12-31 0000097745 tmo:SpecialtyDiagnosticsMember 2022-12-31 0000097745 tmo:LaboratoryProductsandServicesMember 2022-12-31 0000097745 tmo:LifeSciencesSolutionsMember 2023-01-01 2023-12-31 0000097745 tmo:AnalyticalInstrumentsMember 2023-01-01 2023-12-31 0000097745 tmo:SpecialtyDiagnosticsMember 2023-01-01 2023-12-31 0000097745 tmo:LaboratoryProductsandServicesMember 2023-01-01 2023-12-31 0000097745 tmo:LifeSciencesSolutionsMember 2023-12-31 0000097745 tmo:AnalyticalInstrumentsMember 2023-12-31 0000097745 tmo:SpecialtyDiagnosticsMember 2023-12-31 0000097745 tmo:LaboratoryProductsandServicesMember 2023-12-31 0000097745 tmo:TheBindingSiteGroupMember 2023-01-03 2023-01-03 0000097745 tmo:CorEvitasLLCMember 2023-08-14 2023-08-14 0000097745 tmo:TheBindingSiteGroupMember us-gaap:CustomerRelationshipsMember 2023-01-03 0000097745 tmo:CorEvitasLLCMember us-gaap:CustomerRelationshipsMember 2023-08-14 0000097745 tmo:TheBindingSiteGroupMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-03 0000097745 tmo:CorEvitasLLCMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-08-14 0000097745 tmo:TheBindingSiteGroupMember us-gaap:TradeNamesMember 2023-01-03 0000097745 tmo:CorEvitasLLCMember us-gaap:TradeNamesMember 2023-08-14 0000097745 tmo:TheBindingSiteGroupMember us-gaap:OrderOrProductionBacklogMember 2023-01-03 0000097745 tmo:CorEvitasLLCMember us-gaap:OrderOrProductionBacklogMember 2023-08-14 0000097745 tmo:TheBindingSiteGroupMember 2023-01-03 0000097745 tmo:CorEvitasLLCMember 2023-08-14 0000097745 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0000097745 us-gaap:DevelopedTechnologyRightsMember 2023-01-01 2023-12-31 0000097745 us-gaap:TradeNamesMember 2023-01-01 2023-12-31 0000097745 us-gaap:OrderOrProductionBacklogMember 2023-01-01 2023-12-31 0000097745 tmo:OlinkHoldingABMember 2023-10-17 0000097745 tmo:OlinkHoldingABMember 2023-10-17 2023-10-17 0000097745 tmo:EuropeanViralVectorManufacturingBusinessMember 2021-01-15 0000097745 tmo:MesaBiotechMember 2021-02-25 0000097745 tmo:CSLMember 2021-09-30 0000097745 tmo:PPDIncMember 2021-12-08 0000097745 tmo:PeproTechIncMember 2021-12-30 0000097745 tmo:PPDIncMember 2021-12-08 2021-12-08 0000097745 tmo:PeproTechIncMember 2021-12-30 2021-12-30 0000097745 tmo:EuropeanViralVectorManufacturingBusinessMember 2021-01-15 2021-01-15 0000097745 tmo:MesaBiotechMember 2021-02-25 2021-02-25 0000097745 tmo:CSLMember 2021-09-30 2021-09-30 0000097745 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-01-01 2021-12-31 0000097745 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-12-31 0000097745 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2022-12-31 0000097745 tmo:PPDIncMember us-gaap:CustomerRelationshipsMember 2021-12-08 0000097745 tmo:PeproTechIncMember us-gaap:CustomerRelationshipsMember 2021-12-30 0000097745 tmo:EuropeanViralVectorManufacturingBusinessMember us-gaap:CustomerRelationshipsMember 2021-01-15 0000097745 tmo:MesaBiotechMember us-gaap:CustomerRelationshipsMember 2021-02-25 0000097745 tmo:CSLMember us-gaap:CustomerRelationshipsMember 2021-09-30 0000097745 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:CustomerRelationshipsMember 2022-12-31 0000097745 tmo:PPDIncMember us-gaap:DevelopedTechnologyRightsMember 2021-12-08 0000097745 tmo:PeproTechIncMember us-gaap:DevelopedTechnologyRightsMember 2021-12-30 0000097745 tmo:EuropeanViralVectorManufacturingBusinessMember us-gaap:DevelopedTechnologyRightsMember 2021-01-15 0000097745 tmo:MesaBiotechMember us-gaap:DevelopedTechnologyRightsMember 2021-02-25 0000097745 tmo:CSLMember us-gaap:DevelopedTechnologyRightsMember 2021-09-30 0000097745 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000097745 tmo:PPDIncMember us-gaap:TradeNamesMember 2021-12-08 0000097745 tmo:PeproTechIncMember us-gaap:TradeNamesMember 2021-12-30 0000097745 tmo:EuropeanViralVectorManufacturingBusinessMember us-gaap:TradeNamesMember 2021-01-15 0000097745 tmo:MesaBiotechMember us-gaap:TradeNamesMember 2021-02-25 0000097745 tmo:CSLMember us-gaap:TradeNamesMember 2021-09-30 0000097745 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:TradeNamesMember 2022-12-31 0000097745 tmo:PPDIncMember us-gaap:OrderOrProductionBacklogMember 2021-12-08 0000097745 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0000097745 us-gaap:DevelopedTechnologyRightsMember 2021-01-01 2021-12-31 0000097745 us-gaap:TradeNamesMember 2021-01-01 2021-12-31 0000097745 us-gaap:OrderOrProductionBacklogMember 2021-01-01 2021-12-31 0000097745 tmo:PPDIncMember 2021-01-01 2021-12-31 0000097745 tmo:PPDIncMember us-gaap:AcquisitionRelatedCostsMember 2021-01-01 2021-12-31 0000097745 tmo:ConsumablesMember 2023-01-01 2023-12-31 0000097745 tmo:ConsumablesMember 2022-01-01 2022-12-31 0000097745 tmo:ConsumablesMember 2021-01-01 2021-12-31 0000097745 tmo:InstrumentsMember 2023-01-01 2023-12-31 0000097745 tmo:InstrumentsMember 2022-01-01 2022-12-31 0000097745 tmo:InstrumentsMember 2021-01-01 2021-12-31 0000097745 srt:NorthAmericaMember 2023-01-01 2023-12-31 0000097745 srt:NorthAmericaMember 2022-01-01 2022-12-31 0000097745 srt:NorthAmericaMember 2021-01-01 2021-12-31 0000097745 srt:EuropeMember 2023-01-01 2023-12-31 0000097745 srt:EuropeMember 2022-01-01 2022-12-31 0000097745 srt:EuropeMember 2021-01-01 2021-12-31 0000097745 srt:AsiaPacificMember 2023-01-01 2023-12-31 0000097745 srt:AsiaPacificMember 2022-01-01 2022-12-31 0000097745 srt:AsiaPacificMember 2021-01-01 2021-12-31 0000097745 tmo:OtherRegionsMember 2023-01-01 2023-12-31 0000097745 tmo:OtherRegionsMember 2022-01-01 2022-12-31 0000097745 tmo:OtherRegionsMember 2021-01-01 2021-12-31 0000097745 2024-01-01 2023-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LifeSciencesSolutionsMember 2023-01-01 2023-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LifeSciencesSolutionsMember 2022-01-01 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LifeSciencesSolutionsMember 2021-01-01 2021-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:AnalyticalInstrumentsMember 2023-01-01 2023-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:AnalyticalInstrumentsMember 2022-01-01 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:AnalyticalInstrumentsMember 2021-01-01 2021-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:SpecialtyDiagnosticsMember 2023-01-01 2023-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:SpecialtyDiagnosticsMember 2022-01-01 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:SpecialtyDiagnosticsMember 2021-01-01 2021-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LaboratoryProductsandServicesMember 2023-01-01 2023-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LaboratoryProductsandServicesMember 2022-01-01 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LaboratoryProductsandServicesMember 2021-01-01 2021-12-31 0000097745 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-12-31 0000097745 us-gaap:IntersegmentEliminationMember 2022-01-01 2022-12-31 0000097745 us-gaap:IntersegmentEliminationMember 2021-01-01 2021-12-31 0000097745 us-gaap:OperatingSegmentsMember 2023-01-01 2023-12-31 0000097745 us-gaap:OperatingSegmentsMember 2022-01-01 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0000097745 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-12-31 0000097745 us-gaap:MaterialReconcilingItemsMember 2022-01-01 2022-12-31 0000097745 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LifeSciencesSolutionsMember 2023-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LifeSciencesSolutionsMember 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LifeSciencesSolutionsMember 2021-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:AnalyticalInstrumentsMember 2023-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:AnalyticalInstrumentsMember 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:AnalyticalInstrumentsMember 2021-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:SpecialtyDiagnosticsMember 2023-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:SpecialtyDiagnosticsMember 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:SpecialtyDiagnosticsMember 2021-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LaboratoryProductsandServicesMember 2023-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LaboratoryProductsandServicesMember 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LaboratoryProductsandServicesMember 2021-12-31 0000097745 us-gaap:CorporateNonSegmentMember 2023-12-31 0000097745 us-gaap:CorporateNonSegmentMember 2022-12-31 0000097745 us-gaap:CorporateNonSegmentMember 2021-12-31 0000097745 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-12-31 0000097745 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0000097745 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-12-31 0000097745 country:US 2023-01-01 2023-12-31 0000097745 country:US 2022-01-01 2022-12-31 0000097745 country:US 2021-01-01 2021-12-31 0000097745 tmo:AllOtherCountriesMember 2023-01-01 2023-12-31 0000097745 tmo:AllOtherCountriesMember 2022-01-01 2022-12-31 0000097745 tmo:AllOtherCountriesMember 2021-01-01 2021-12-31 0000097745 country:US 2023-12-31 0000097745 country:US 2022-12-31 0000097745 country:US 2021-12-31 0000097745 tmo:AllOtherCountriesMember 2023-12-31 0000097745 tmo:AllOtherCountriesMember 2022-12-31 0000097745 tmo:AllOtherCountriesMember 2021-12-31 0000097745 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000097745 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000097745 us-gaap:EmployeeStockOptionMember 2023-12-31 0000097745 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000097745 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0000097745 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0000097745 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000097745 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0000097745 srt:MinimumMember 2023-12-31 0000097745 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000097745 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000097745 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000097745 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000097745 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000097745 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000097745 us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:USEquityFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:InternationalEquityFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FixedIncomeFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 srt:MinimumMember us-gaap:EquityFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 srt:MaximumMember us-gaap:EquityFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 srt:MinimumMember us-gaap:FixedIncomeFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 srt:MaximumMember us-gaap:FixedIncomeFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 srt:MinimumMember tmo:MultiassetFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 srt:MaximumMember tmo:MultiassetFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 srt:MinimumMember tmo:AlternativeInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 srt:MaximumMember tmo:AlternativeInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 srt:MinimumMember us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 srt:MaximumMember us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 srt:MinimumMember us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 srt:MaximumMember us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:MoneyMarketFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:AlternativeInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:AlternativeInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:AlternativeInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:AlternativeInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:AlternativeInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000097745 tmo:USEquityFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InternationalEquityFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:MoneyMarketFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0000097745 us-gaap:DomesticCountryMember 2022-12-31 0000097745 tmo:DeferredTaxImplicationsMember 2021-01-01 2021-12-31 0000097745 tmo:CapitalLossMember 2021-01-01 2021-12-31 0000097745 us-gaap:DomesticCountryMember 2023-12-31 0000097745 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0000097745 us-gaap:ForeignCountryMember 2023-12-31 0000097745 tmo:DomesticNOLExpiresMember 2023-12-31 0000097745 tmo:StateNOLExpiresMember 2023-12-31 0000097745 tmo:ForeignCountryNolExpiresMember 2023-12-31 0000097745 tmo:ForeignTaxCreditCarryforwardsMember 2023-12-31 0000097745 tmo:DeferredTaxAssetInterestCarryforwardMember 2023-12-31 0000097745 tmo:DeferredTaxAssetInterestCarryforwardMember tmo:TaxYears20252033Member 2023-12-31 0000097745 tmo:ForeignTaxPositionsMember 2023-01-01 2023-12-31 0000097745 tmo:FederalAndStateMember 2023-01-01 2023-12-31 0000097745 tmo:ForeignTaxPositionsMember 2022-01-01 2022-12-31 0000097745 tmo:FederalAndStateMember 2022-01-01 2022-12-31 0000097745 tmo:ForeignTaxPositionsMember 2021-01-01 2021-12-31 0000097745 tmo:FederalAndStateMember 2021-01-01 2021-12-31 0000097745 us-gaap:CommercialPaperMember 2023-12-31 0000097745 us-gaap:CommercialPaperMember 2022-12-31 0000097745 tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:FloatingRateSOFR039SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:FloatingRateSOFR039SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:FloatingRateSOFR039SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0797Due2023Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes0797Due2023Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes0797Due2023Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:FloatingRate2YearSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:FloatingRate2YearSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:FloatingRate2YearSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0000Due2023Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes0000Due2023Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes0000Due2023Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0.75Due2024Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes0.75Due2024Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes0.75Due2024Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:FloatingRateSOFR053SeniorNotesDue2024Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:FloatingRateSOFR053SeniorNotesDue2024Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:FloatingRateSOFR053SeniorNotesDue2024Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1215Due2024Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes1215Due2024Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1215Due2024Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0.125Due2025Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes0.125Due2025Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes0.125Due2025Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes200Due2025Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes200Due2025Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes200Due2025Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0853Due2025Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes0853Due2025Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes0853Due2025Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0000Due2025Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes0000Due2025Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes0000Due2025Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes320Due2026Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes320Due2026Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes320Due2026Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1.40Due2026Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes1.40Due2026Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1.40Due2026Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes4953Due2026Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes4953Due2026Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes4953Due2026Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes5.000Due2026Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes5.000Due2026Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes5.000Due2026Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:A1.45SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:A1.45SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:A1.45SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes175Due2027Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes175Due2027Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes175Due2027Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1054Due2027Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes1054Due2027Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1054Due2027Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes48Due2027Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes48Due2027Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes48Due2027Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0.500Due2028Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes0.500Due2028Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes0.500Due2028Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0.77Due2028Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes0.77Due2028Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes0.77Due2028Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1.375Due2028Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes1.375Due2028Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1.375Due2028Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1750Due2028Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes1750Due2028Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1750Due2028Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes5.000Due2029Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes5.000Due2029Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes5.000Due2029Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1.95Due2029Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes1.95Due2029Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1.95Due2029Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2.60Due2029Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes2.60Due2029Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes2.60Due2029Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1279Due2029Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes1279Due2029Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1279Due2029Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes4977Due2030Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes4977Due2030Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes4977Due2030Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes080Due2030Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes080Due2030Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes080Due2030Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0.875Due2031Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes0.875Due2031Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes0.875Due2031Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2000Due2031Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes2000Due2031Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes2000Due2031Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2375Due2032Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes2375Due2032Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes2375Due2032Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes149Due2032Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes149Due2032Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes149Due2032Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes495Due2032Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes495Due2032Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes495Due2032Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes5086Due2033Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes5086Due2033Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes5086Due2033Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1125Due2033Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes1125Due2033Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1125Due2033Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes5.200Due2034Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes5.200Due2034Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes5.200Due2034Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes365Due2034Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes365Due2034Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes365Due2034Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1.50Due2035Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes1.50Due2035Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1.50Due2035Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2.875Due2037Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes2.875Due2037Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes2.875Due2037Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1.500Due2039Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes1.500Due2039Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1.500Due2039Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2800Due2041Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes2800Due2041Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes2800Due2041Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1625Due2041Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes1625Due2041Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1625Due2041Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2069Due2042Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes2069Due2042Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes2069Due2042Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes5404Due2043Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes5404Due2043Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes5404Due2043Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes202Due2043Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes202Due2043Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes202Due2043Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes530Due2044Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes530Due2044Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes530Due2044Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes4.10Due2047Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes4.10Due2047Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes4.10Due2047Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1.875Due2049Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes1.875Due2049Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes1.875Due2049Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes200Due2051Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes200Due2051Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes200Due2051Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2382Due2052Member us-gaap:SeniorNotesMember 2023-12-31 0000097745 tmo:SeniorNotes2382Due2052Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes2382Due2052Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:OtherDebtMember 2023-12-31 0000097745 tmo:OtherDebtMember 2022-12-31 0000097745 us-gaap:RevolvingCreditFacilityMember 2023-12-31 0000097745 us-gaap:RevolvingCreditFacilityMember 2023-01-01 2023-12-31 0000097745 tmo:U.S.CommercialPaperProgramMember us-gaap:CommercialPaperMember 2023-01-01 2023-12-31 0000097745 tmo:EuroCommercialPaperProgramMember us-gaap:CommercialPaperMember 2023-01-01 2023-12-31 0000097745 us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0000097745 tmo:SeniorNotes3.65Due2025Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 us-gaap:InterestRateSwapMember 2021-01-01 2021-12-31 0000097745 srt:MaximumMember 2023-01-01 2023-12-31 0000097745 us-gaap:GuaranteeTypeOtherMember 2023-12-31 0000097745 us-gaap:StandbyLettersOfCreditMember 2023-12-31 0000097745 tmo:SuretyBondsAndOtherGuaranteesMember 2023-12-31 0000097745 tmo:PaymentGuaranteesInvestmentsMember 2023-12-31 0000097745 us-gaap:FinancialGuaranteeMember tmo:BusinessesSoldMember 2023-12-31 0000097745 srt:MinimumMember tmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember 2023-12-31 0000097745 srt:MaximumMember tmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember 2023-12-31 0000097745 tmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember 2023-12-31 0000097745 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000097745 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000097745 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000097745 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-12-31 0000097745 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-12-31 0000097745 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-12-31 0000097745 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000097745 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000097745 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000097745 us-gaap:SubsequentEventMember 2024-01-01 2024-02-22 0000097745 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000097745 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000097745 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000097745 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000097745 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000097745 tmo:ContingentConsiderationMember 2022-12-31 0000097745 tmo:ContingentConsiderationMember 2021-12-31 0000097745 tmo:ContingentConsiderationMember 2023-01-01 2023-12-31 0000097745 tmo:ContingentConsiderationMember 2022-01-01 2022-12-31 0000097745 tmo:ContingentConsiderationMember 2023-12-31 0000097745 currency:EUR us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2023-12-31 0000097745 currency:EUR us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2022-12-31 0000097745 currency:JPY us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2023-12-31 0000097745 currency:JPY us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2022-12-31 0000097745 currency:CHF us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2023-12-31 0000097745 currency:CHF us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2022-12-31 0000097745 us-gaap:ForeignExchangeContractMember 2023-12-31 0000097745 us-gaap:ForeignExchangeContractMember 2022-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2023-01-01 2023-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2022-01-01 2022-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2021-01-01 2021-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2023-01-01 2023-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2022-01-01 2022-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2021-01-01 2021-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-01-01 2023-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2023-01-01 2023-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2022-01-01 2022-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2021-01-01 2021-12-31 0000097745 tmo:ForeigncurrencydenominateddebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-12-31 0000097745 tmo:ForeigncurrencydenominateddebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000097745 tmo:ForeigncurrencydenominateddebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherExpenseMember 2023-01-01 2023-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherExpenseMember 2022-01-01 2022-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherExpenseMember 2021-01-01 2021-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:OtherExpenseMember 2021-01-01 2021-12-31 0000097745 us-gaap:SeniorNotesMember 2023-12-31 0000097745 us-gaap:SeniorNotesMember 2022-12-31 0000097745 us-gaap:SubsequentEventMember 2024-02-22 0000097745 2023-10-01 2023-12-31 0000097745 tmo:MichaelA.BoxerMember 2023-01-01 2023-12-31 0000097745 tmo:MichaelA.BoxerMember 2023-10-01 2023-12-31 0000097745 tmo:MichaelA.BoxerMember 2023-12-31 0000097745 tmo:LisaP.BrittMember 2023-01-01 2023-12-31 0000097745 tmo:LisaP.BrittMember 2023-10-01 2023-12-31 0000097745 tmo:LisaP.BrittMember 2023-12-31 0000097745 tmo:MarcN.CasperMember 2023-01-01 2023-12-31 0000097745 tmo:MarcN.CasperMember 2023-10-01 2023-12-31 0000097745 tmo:MarcN.CasperMember 2023-12-31 iso4217:USD shares iso4217:USD shares pure tmo:Segment tmo:lease 0000097745 false 2023 FY http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://thermofisher.com/20231231#RestructuringAndOtherCostsIncomeNet P366D P336D P360D 10-K true 2023-12-31 --12-31 false 1-8002 THERMO FISHER SCIENTIFIC INC. DE 04-2209186 168 Third Avenue Waltham MA 02451 781 622-1000 Common Stock, $1.00 par value TMO NYSE 0.750% Notes due 2024 TMO 24A NYSE 0.125% Notes due 2025 TMO 25B NYSE 2.000% Notes due 2025 TMO 25 NYSE 3.200% Notes due 2026 TMO 26B NYSE 1.400% Notes due 2026 TMO 26A NYSE 1.450% Notes due 2027 TMO 27 NYSE 1.750% Notes due 2027 TMO 27B NYSE 0.500% Notes due 2028 TMO 28A NYSE 1.375% Notes due 2028 TMO 28 NYSE 1.950% Notes due 2029 TMO 29 NYSE 0.875% Notes due 2031 TMO 31 NYSE 2.375% Notes due 2032 TMO 32 NYSE 3.650% Notes due 2034 TMO 34 NYSE 2.875% Notes due 2037 TMO 37 NYSE 1.500% Notes due 2039 TMO 39 NYSE 1.875% Notes due 2049 TMO 49 NYSE Yes No Yes Yes Large Accelerated Filer false false true false false 201176616000 381312268 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sections of Thermo Fisher’s definitive Proxy Statement for the 2024 Annual Meeting of Shareholders (the “Proxy Statement”) are incorporated by reference into Part III of this report.</span> 238 PricewaterhouseCoopers LLP Boston, Massachusetts 8077000000 8524000000 193000000 189000000 8221000000 8115000000 5088000000 5634000000 1443000000 1312000000 1760000000 1644000000 24589000000 25229000000 9448000000 9280000000 16670000000 17442000000 3999000000 4007000000 44020000000 41196000000 98726000000 97154000000 3609000000 5579000000 2872000000 3381000000 1596000000 2095000000 2689000000 2601000000 3246000000 3354000000 14012000000 17010000000 1922000000 2849000000 4642000000 4238000000 31308000000 28909000000 118000000 116000000 100 100 50000 50000 0 0 1 1 1200000000 1200000000 442188634 440668112 442000000 441000000 17286000000 16743000000 47364000000 41910000000 55541290 50157275 15133000000 12017000000 -3224000000 -3099000000 46735000000 43978000000 -11000000 54000000 46724000000 44032000000 98726000000 97154000000 25243000000 28548000000 30361000000 17614000000 16367000000 8850000000 42857000000 44915000000 39211000000 13168000000 14247000000 13594000000 12589000000 11697000000 5979000000 8445000000 8993000000 8007000000 1337000000 1471000000 1406000000 459000000 114000000 197000000 35998000000 36522000000 29183000000 6859000000 8393000000 10028000000 879000000 272000000 43000000 1375000000 726000000 536000000 -65000000 -104000000 -694000000 6298000000 7835000000 8841000000 284000000 703000000 1109000000 -59000000 -172000000 -4000000 5955000000 6960000000 7728000000 -40000000 10000000 3000000 5995000000 6950000000 7725000000 15.52 17.75 19.62 15.45 17.63 19.46 386000000 392000000 394000000 388000000 394000000 397000000 5955000000 6960000000 7728000000 -134000000 173000000 231000000 -69000000 -822000000 373000000 -2000000 -1000000 -17000000 -5000000 -2000000 -56000000 -22000000 9000000 11000000 69000000 -38000000 -36000000 -1000000 -3000000 -6000000 0 5000000 13000000 -133000000 -777000000 478000000 5822000000 6183000000 8206000000 -48000000 3000000 2000000 5870000000 6180000000 8204000000 5955000000 6960000000 7728000000 1068000000 986000000 831000000 2338000000 2395000000 1761000000 1300000000 995000000 647000000 278000000 307000000 230000000 0 -26000000 -767000000 -604000000 -524000000 -190000000 43000000 430000000 204000000 -598000000 825000000 1065000000 -252000000 354000000 -221000000 -500000000 648000000 479000000 42000000 41000000 34000000 802000000 47000000 945000000 8406000000 9154000000 9312000000 3660000000 39000000 19395000000 1479000000 2243000000 2523000000 87000000 24000000 20000000 70000000 15000000 8000000 160000000 -84000000 42000000 -5142000000 -2159000000 -21932000000 5942000000 3193000000 18137000000 5782000000 375000000 11738000000 1620000000 1526000000 2512000000 1935000000 3690000000 0 3000000000 3000000000 2000000000 523000000 455000000 395000000 56000000 -9000000 65000000 -3622000000 -2810000000 6581000000 -82000000 -139000000 194000000 -440000000 4046000000 -5845000000 8537000000 4491000000 10336000000 8097000000 8537000000 4491000000 0 437000000 437000000 15579000000 28116000000 40000000 -6818000000 -2807000000 34507000000 10000000 34517000000 2000000 2000000 324000000 1000000 -104000000 222000000 222000000 230000000 230000000 230000000 4000000 2000000000 2000000000 2000000000 1.04 410000000 410000000 410000000 122000000 1000000 7725000000 7725000000 2000000 7727000000 -1000000 478000000 478000000 478000000 50000000 50000000 41000000 41000000 41000000 122000000 439000000 439000000 16174000000 35431000000 45000000 -8922000000 -2329000000 40793000000 62000000 40855000000 2000000 2000000 262000000 -95000000 169000000 169000000 307000000 307000000 307000000 5000000 3000000000 3000000000 3000000000 1.20 471000000 471000000 471000000 15000000 6950000000 6950000000 -5000000 6945000000 -6000000 -770000000 -770000000 -1000000 -771000000 15000000 -2000000 -2000000 116000000 441000000 441000000 16743000000 41910000000 50000000 -12017000000 -3099000000 43978000000 54000000 44032000000 1000000 1000000 265000000 1000000 -88000000 178000000 178000000 278000000 278000000 278000000 5000000 3000000000 3000000000 3000000000 1.40 541000000 541000000 541000000 19000000 5995000000 5995000000 -59000000 5936000000 -3000000 -125000000 -125000000 -5000000 -130000000 14000000 -1000000 -1000000 28000000 28000000 28000000 118000000 442000000 442000000 17286000000 47364000000 56000000 -15133000000 -3224000000 46735000000 -11000000 46724000000 Nature of Operations and Summary of Significant Accounting Policies <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. At December 31, 2023 and 2022, the company had such investments with carrying amounts of $489 million and $369 million, respectively. The company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity method. At December 31, 2023 and 2022, the fair value of such investments was $5 million and $7 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interest</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at a premium upon the occurrence of certain events.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications of prior year amounts have been made to conform to the current year presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date. However, some modifications are distinct from existing services provided under the contract and recognized prospectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract-related Balances</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warranty Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessee, the company accounts for the lease and non-lease components as a single lease component. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to provide economic benefits to the company. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three months or less. These investments are carried at cost, which approximates market value.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income. The components of inventories are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,057 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,569 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,088 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,634 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the third quarter of 2021, certain of the company’s businesses utilized the LIFO method of accounting for inventories. During the third quarter of 2021, these businesses, which comprised approximately 5% of consolidated inventories, changed from the LIFO method to the FIFO method. The company believes this change is preferable as it will provide a consistent, uniform costing method for all inventories across the company, better reflect the current value of inventories, and improve comparability with peers. Prior financial statements have not been retrospectively adjusted due to immateriality. The cumulative pre-tax effect of this change in accounting principle of $33 million was recorded as an increase to inventories and a decrease to cost of product revenues in the third quarter of 2021. This change was recorded in the Laboratory Products and Biopharma </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services ($20 million) and Specialty Diagnostics ($13 million) segments. Reductions to cost of revenues as a result of the liquidation of LIFO inventories were nominal during the first half of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income. Property, plant and equipment consists of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery, equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,448 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,280 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-related Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the company has tradenames that have indefinite lives and which are not amortized. Intangible assets with indefinite lives are reviewed for impairment annually or whenever events or changes in circumstances indicate they may be impaired. The company may perform an optional qualitative assessment. If the company determines that the fair value of the indefinite-lived intangible asset is more likely than not greater than its carrying amount, no additional testing is necessary. If not, or if the company bypasses the optional qualitative assessment, it writes the carrying value down to the fair value, if applicable. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related intangible assets are as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Definite lived:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product technology</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,894 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backlog</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,374 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,939)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,435 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,347 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,140)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,207 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Indefinite lived:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related intangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,609 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,939)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,582 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,442 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2023 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,931 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated future amortization expense of definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,435 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets in the accompanying balance sheet include operating lease right-of-use assets, investments, deferred tax assets, pension assets, insurance recovery receivables related to product liability matters, certain intangible assets and other assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023 and 2022, the company had $37 million and $36 million, respectively, of intangible assets not derived from acquisitions, net of accumulated amortization, which are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments. At December 31, 2023 and 2022, the company had such investments with carrying amounts of $12 million and $55 million, respectively, and investments measured at NAV of $28 million and $22 million, respectively, which are included in other assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2023, 2022 or 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill by segment are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.658%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences<br/>Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical<br/>Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory<br/>Products and<br/>Biopharma Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,043 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,461 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,924 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finalization of purchase price allocations for 2021 acquisitions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(929)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,965 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,051 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,923 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,895 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,020 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities acquired in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Currency Translation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period. Currency transaction gains/(losses) are included in the accompanying statement of income and in aggregate were $(67) million, $62 million and $25 million in 2023, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Canadian dollars, Singapore dollars, Czech koruna, Hong Kong dollars and Swedish krona. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value hedges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment hedges. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the company receives assistance from various governmental agencies generally in the form of cash or non-income tax credits. These programs help offset the costs of certain research and development activities, facility construction and expansion efforts, or hiring objectives. When the company believes that it is probable that it will meet the conditions tied to the assistance, it offsets the associated expense in the consolidated income statement. Such amounts were not material to the consolidated financial statements as of and for the years ended December 31, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective date for Thermo Fisher and adoption approach</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Impact of adoption or other significant matters</span></td></tr><tr><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Standards recently adopted</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Standards Update (ASU) No. 2021-05,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Leases (Topic 842): Lessors-Certain Leases with Variable Lease Payments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third quarter of 2021 using a prospective method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not material</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU No. 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New guidance to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth quarter of 2022 using a prospective method</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not material</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU No. 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented. </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Some aspects adopted in 2023 using a retrospective method and will adopt other aspects in 2024 using a prospective method </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not material</span></div></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Standards not yet adopted</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Segment Reporting (Topic 280): Improving Reportable Segment Disclosures </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 annual report and interim periods thereafter using a retrospective method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Will increase disclosures in Note 4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 annual report and interim periods thereafter using a prospective or retrospective method</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Will increase disclosures in Note 8</span></td></tr></table> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. At December 31, 2023 and 2022, the company had such investments with carrying amounts of $489 million and $369 million, respectively. The company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity method. At December 31, 2023 and 2022, the fair value of such investments was $5 million and $7 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interest</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at a premium upon the occurrence of certain events.</span></div> 489000000 369000000 5000000 7000000 0.60 0.40 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications of prior year amounts have been made to conform to the current year presentation.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date. However, some modifications are distinct from existing services provided under the contract and recognized prospectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract-related Balances</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warranty Obligations</span></div>The company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. </span></div>As a lessee, the company accounts for the lease and non-lease components as a single lease component. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to provide economic benefits to the company. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three months or less. These investments are carried at cost, which approximates market value.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div>Inventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income. The components of inventories are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,057 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,569 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,088 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,634 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2057000000 2405000000 705000000 660000000 2326000000 2569000000 5088000000 5634000000 0.05 -33000000 33000000 20000000 -20000000 -13000000 13000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment</span></div>Property, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income. P25Y P40Y P3Y P10Y Property, plant and equipment consists of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery, equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,448 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,280 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 458000000 454000000 3593000000 3153000000 9235000000 7967000000 2238000000 2695000000 15524000000 14269000000 6076000000 4989000000 9448000000 9280000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-related Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value.</span></div> P20Y <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related intangible assets are as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Definite lived:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product technology</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,894 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backlog</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,374 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,939)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,435 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,347 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,140)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,207 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Indefinite lived:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related intangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,609 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,939)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,582 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,442 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related intangible assets are as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Definite lived:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product technology</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,894 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backlog</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,374 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,939)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,435 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,347 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,140)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,207 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Indefinite lived:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related intangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,609 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,939)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,582 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,442 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 22762000000 9410000000 13352000000 21792000000 8330000000 13462000000 5894000000 4591000000 1303000000 5882000000 4360000000 1522000000 1634000000 1079000000 555000000 1635000000 1008000000 627000000 1084000000 859000000 225000000 1038000000 442000000 596000000 31374000000 15939000000 15435000000 30347000000 14140000000 16207000000 1235000000 1235000000 1235000000 1235000000 32609000000 15939000000 16670000000 31582000000 14140000000 17442000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2023 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,931 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated future amortization expense of definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,435 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1931000000 1630000000 1460000000 1430000000 1398000000 7586000000 15435000000 37000000 36000000 P20Y Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments. 12000000 55000000 28000000 22000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2023, 2022 or 2021.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill by segment are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.658%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences<br/>Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical<br/>Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory<br/>Products and<br/>Biopharma Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,043 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,461 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,924 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finalization of purchase price allocations for 2021 acquisitions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(929)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,965 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,051 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,923 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,895 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,020 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10143000000 5043000000 3277000000 23461000000 41924000000 0 24000000 0 0 24000000 9000000 0 0 168000000 177000000 -6000000 -102000000 -186000000 -635000000 -929000000 10146000000 4965000000 3091000000 22994000000 41196000000 0 31000000 1741000000 627000000 2399000000 5000000 55000000 91000000 274000000 425000000 10151000000 5051000000 4923000000 23895000000 44020000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities acquired in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Currency Translation</span></div>All assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period. -67000000 62000000 25000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Canadian dollars, Singapore dollars, Czech koruna, Hong Kong dollars and Swedish krona. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value hedges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment hedges. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.</span> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the company receives assistance from various governmental agencies generally in the form of cash or non-income tax credits. These programs help offset the costs of certain research and development activities, facility construction and expansion efforts, or hiring objectives. When the company believes that it is probable that it will meet the conditions tied to the assistance, it offsets the associated expense in the consolidated income statement. Such amounts were not material to the consolidated financial statements as of and for the years ended December 31, 2023 and 2022.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div>The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective date for Thermo Fisher and adoption approach</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Impact of adoption or other significant matters</span></td></tr><tr><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Standards recently adopted</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Standards Update (ASU) No. 2021-05,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Leases (Topic 842): Lessors-Certain Leases with Variable Lease Payments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third quarter of 2021 using a prospective method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not material</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU No. 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New guidance to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth quarter of 2022 using a prospective method</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not material</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU No. 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented. </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Some aspects adopted in 2023 using a retrospective method and will adopt other aspects in 2024 using a prospective method </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not material</span></div></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Standards not yet adopted</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Segment Reporting (Topic 280): Improving Reportable Segment Disclosures </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 annual report and interim periods thereafter using a retrospective method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Will increase disclosures in Note 4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 annual report and interim periods thereafter using a prospective or retrospective method</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Will increase disclosures in Note 8</span></td></tr></table> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective date for Thermo Fisher and adoption approach</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Impact of adoption or other significant matters</span></td></tr><tr><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Standards recently adopted</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Standards Update (ASU) No. 2021-05,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Leases (Topic 842): Lessors-Certain Leases with Variable Lease Payments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third quarter of 2021 using a prospective method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not material</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU No. 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New guidance to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth quarter of 2022 using a prospective method</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not material</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU No. 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented. </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Some aspects adopted in 2023 using a retrospective method and will adopt other aspects in 2024 using a prospective method </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not material</span></div></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Standards not yet adopted</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Segment Reporting (Topic 280): Improving Reportable Segment Disclosures </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 annual report and interim periods thereafter using a retrospective method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Will increase disclosures in Note 4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 annual report and interim periods thereafter using a prospective or retrospective method</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Will increase disclosures in Note 8</span></td></tr></table> Acquisitions<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not tax deductible. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment’s portfolio with the addition of highly complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development. The goodwill recorded as a result of this business combination is not tax deductible.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the purchase price and net assets acquired are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Binding Site</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CorEvitas</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt settled</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash acquired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product technology</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net tangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,699 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2023, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Raman-based spectroscopy solutions for in-line measurement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average amortization periods for definite-lived intangible assets acquired in 2023 are 18 years for customer relationships, 14 years for product technology, 15 years for tradenames, and 13 years for backlog. The weighted-average amortization period for definite-lived intangible assets acquired in 2023 is 17 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proposed Acquisition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 17, 2023, the company entered into a purchase agreement to acquire all of the issued and outstanding shares of Olink Holding AB (publ) at a price of $26.00 per share, or approximately $3.1 billion. Olink is a leading provider of next-generation proteomics solutions that will expand the company’s capabilities in this field. The company has commenced a tender offer to acquire all of the American Depositary Shares and common shares of Olink. The transaction is expected to close by mid-year 2024, subject to the satisfaction of customary closing conditions including receipt of applicable regulatory approvals, and completion of the tender offer. Upon completion, Olink will become part of the Life Sciences Solutions segment. The company intends to finance the purchase price with cash on hand and the net proceeds from issuances of debt.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Fourier-transform infrared gas analysis technologies. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 15, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, the Belgium-based European viral vector manufacturing business of Groupe Novasep SAS. The European viral vector manufacturing business provides manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities for cell and gene vaccines and therapies. The goodwill recorded as a result of this business combination is not tax deductible.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company. Mesa Biotech has developed and commercialized a polymerase chain reaction (PCR) based rapid point-of-care testing platform available for detecting infectious diseases including COVID-19. The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care. The goodwill recorded as a result of this business combination is not tax deductible.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2021, the company assumed operating responsibility, within the Laboratory Products and Biopharma Services segment, of a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland from CSL Limited to perform pharma services for CSL with capacity to serve other customers as well. The goodwill recorded as a result of this business combination is not tax deductible.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, PPD, Inc., a U.S.-based global provider of clinical research services to the pharma and biotech industry. The addition of PPD’s clinical research services enhances our offering to biotech and pharma customers by enabling them to accelerate innovation and increase their productivity within the drug development process. The goodwill recorded as a result of this business combination is not tax deductible.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2021, the company acquired, within the Life Sciences Solutions segment, PeproTech, Inc., a U.S.-based developer and manufacturer of recombinant proteins. PeproTech provides bioscience reagents known as recombinant proteins, including cytokines and growth factors. The acquisition expands the segment’s bioscience offerings. The goodwill recorded as a result of this business combination is not tax deductible. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2021, the company acquired, within the Life Sciences Solutions segment, cell sorting technology assets, an Ireland-based life sciences distributor and a developer of a digital PCR platform; within the Analytical Instruments segment, a Belgium-based developer of micro-chip based technology for liquid chromatography columns; and within the Specialty Diagnostics segment, a transplant diagnostics information system provider. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the purchase price and net assets acquired for 2021 acquisitions are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PPD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PeproTech</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Viral Vector Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mesa Biotech</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lengnau biologics manufacturing facility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of equity awards exchanged</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash acquired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,036 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product technology</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt assumed</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities assumed</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,034)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redeemable noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,036 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we finalized the allocations of the purchase price for the Lengnau biologics manufacturing facility, PPD, Inc. and PeproTech, Inc., largely with respect to definite-lived intangible assets, property, plant and equipment, contract liabilities, equity method investments, asset retirement obligations, defined benefit pension plans, assumed contingent consideration and the related deferred taxes. The adjustments to the income statement recorded during 2022 were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average amortization periods for definite-lived intangible assets acquired in 2021 are 17 years for customer relationships, 11 years for product technology, 7 years for tradenames and 3 years for backlog. The weighted average amortization period for all definite-lived intangible assets acquired in 2021 is 14 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Unaudited Pro Forma Information</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1, 2020:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Thermo Fisher Scientific Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The historical consolidated financial information of the company and PPD has been adjusted in the pro forma information to give effect to pro forma events that are directly attributable to the acquisitions and related financing arrangements and are factually supportable. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reflect the acquisition of PPD as if it had occurred on January 1, 2020, the unaudited pro forma results include adjustments to reflect, among other things, the incremental intangible asset amortization to be incurred based on the values of each identifiable intangible asset and the interest expense from debt financings obtained to partially fund the cash consideration transferred. Pro forma adjustments were tax effected at the company's historical statutory rates in effect for the respective periods. The unaudited pro forma amounts are not necessarily indicative of the combined results of operations that would have been realized had the acquisitions and related financings occurred on the aforementioned dates nor are they meant to be indicative of any anticipated combined results of operations that the company will experience after the transaction. In addition, the amounts do not include any adjustments for actions that may be taken following the completion of the transaction, such as expected cost savings, operating synergies, or revenue enhancements that may be realized subsequent to the transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended December 31, 2021, excludes $312 million of transaction costs, initial restructuring costs, and debt extinguishment costs directly attributable to the PPD acquisition that were included in the determination of net income attributable to Thermo Fisher Scientific Inc. for that period. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s results would not have been materially different from its pro forma results had the company’s other 2021 acquisitions occurred at the beginning of 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PPD’s revenues and losses attributable to Thermo Fisher Scientific Inc. in 2021, subsequent to the acquisition date, were $378 million and $(60) million, respectively. The loss includes non-recurring transaction and compensation costs.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the purchase price and net assets acquired are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Binding Site</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CorEvitas</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt settled</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash acquired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product technology</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net tangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,699 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the purchase price and net assets acquired for 2021 acquisitions are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PPD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PeproTech</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Viral Vector Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mesa Biotech</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lengnau biologics manufacturing facility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of equity awards exchanged</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash acquired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,036 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product technology</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt assumed</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities assumed</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,034)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redeemable noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,036 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we finalized the allocations of the purchase price for the Lengnau biologics manufacturing facility, PPD, Inc. and PeproTech, Inc., largely with respect to definite-lived intangible assets, property, plant and equipment, contract liabilities, equity method investments, asset retirement obligations, defined benefit pension plans, assumed contingent consideration and the related deferred taxes. The adjustments to the income statement recorded during 2022 were not material.</span></div> 2412000000 730000000 307000000 184000000 20000000 4000000 2699000000 910000000 868000000 260000000 162000000 47000000 42000000 0 0 46000000 1741000000 627000000 174000000 -2000000 288000000 68000000 2699000000 910000000 P18Y P14Y P15Y P13Y P17Y 26.00 3100000000 0 0 0 0 0 17237000000 1946000000 848000000 421000000 17000000 298000000 43000000 0 0 0 65000000 1000000 117000000 1244000000 83000000 18000000 14000000 0 12000000 16036000000 1863000000 830000000 472000000 18000000 403000000 2477000000 58000000 39000000 54000000 0 12000000 527000000 18000000 59000000 2000000 93000000 2000000 6257000000 510000000 302000000 0 0 2000000 0 282000000 25000000 279000000 0 224000000 594000000 0 0 2000000 0 2000000 1038000000 13949000000 1198000000 600000000 237000000 18000000 198000000 1060000000 11000000 3000000 3000000 364000000 2000000 1539000000 0 59000000 0 0 1000000 1782000000 192000000 80000000 72000000 0 27000000 90000000 0 24000000 0 82000000 0 4299000000 0 0 0 0 0 2034000000 22000000 35000000 33000000 375000000 11000000 122000000 16036000000 1863000000 830000000 472000000 18000000 403000000 P17Y P11Y P7Y P3Y P14Y <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1, 2020:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Thermo Fisher Scientific Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 44886000000 7369000000 312000000 378000000 -60000000 Revenues and Contract-related Balances <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregated Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by type are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumables</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,646 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,614 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,857 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region based on customer location are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North America</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia-Pacific</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other regions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,857 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of December 31, 2023 was $26.92 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 53% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract-related Balances</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:70.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current contract assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,312 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent contract assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the current contract liabilities balance at December 31, 2022 and 2021 was recognized in revenues during 2023 and 2022, respectively. Noncurrent contract liabilities increased during 2023 primarily due to advanced payments from a customer.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregated Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by type are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumables</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,646 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,614 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,857 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region based on customer location are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North America</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia-Pacific</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other regions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,857 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17597000000 20624000000 22608000000 7646000000 7924000000 7753000000 17614000000 16367000000 8850000000 42857000000 44915000000 39211000000 22764000000 24594000000 19659000000 10741000000 10762000000 11134000000 7873000000 8115000000 7218000000 1479000000 1444000000 1200000000 42857000000 44915000000 39211000000 26920000000 0.53 P12M Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:70.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current contract assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,312 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent contract assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1443000000 1312000000 4000000 7000000 2689000000 2601000000 1499000000 1179000000 Business Segment and Geographical Information <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s financial performance is reported in four segments. A description of each segment follows. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analytical Instruments: provides a broad offering of instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specialty Diagnostics: offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of diagnoses, which improves patient care in a more cost-efficient manner. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory Products and Biopharma Services: offers virtually everything needed for the laboratory. Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more innovative, productive and cost-efficient. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segment Information</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,405 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,857 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Segment Income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal reportable segments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,810 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,985 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues adjustments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses adjustments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring and other costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(459)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated operating income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(726)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated income before taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,841 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated depreciation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,068 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">986 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of significant transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges related to product liability litigation. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,091 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate/other (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,154 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate/other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated capital expenditures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,479 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,243 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,523 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geographical Information</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,857 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,578 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,565 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated long-lived assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,004 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,873 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,864 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Revenues are attributed to countries based on customer location.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Includes property, plant and equipment, net, and operating lease ROU assets.</span></div> 4 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segment Information</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,405 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,857 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Segment Income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal reportable segments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,810 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,985 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues adjustments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses adjustments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring and other costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(459)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated operating income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(726)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated income before taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,841 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated depreciation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,068 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">986 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of significant transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges related to product liability litigation. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,091 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate/other (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,154 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate/other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated capital expenditures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,479 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,243 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,523 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.</span></div> 9977000000 13532000000 15631000000 7263000000 6624000000 6069000000 4405000000 4763000000 5659000000 23041000000 22511000000 14862000000 -1829000000 -2515000000 -3010000000 42857000000 44915000000 39211000000 3420000000 5582000000 7817000000 1908000000 1507000000 1197000000 1124000000 1024000000 1280000000 3358000000 2872000000 1844000000 9810000000 10985000000 12138000000 95000000 46000000 8000000 59000000 37000000 144000000 459000000 114000000 197000000 2338000000 2395000000 1761000000 6859000000 8393000000 10028000000 879000000 272000000 43000000 1375000000 726000000 536000000 -65000000 -104000000 -694000000 6298000000 7835000000 8841000000 220000000 214000000 197000000 93000000 83000000 83000000 86000000 75000000 128000000 669000000 614000000 423000000 1068000000 986000000 831000000 20191000000 21848000000 22751000000 10247000000 10019000000 9692000000 8636000000 5542000000 6010000000 51091000000 51281000000 52639000000 8561000000 8464000000 4031000000 98726000000 97154000000 95123000000 178000000 490000000 810000000 87000000 140000000 79000000 121000000 112000000 167000000 1013000000 1403000000 1327000000 80000000 98000000 140000000 1479000000 2243000000 2523000000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geographical Information</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,857 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,578 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,565 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated long-lived assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,004 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,873 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,864 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Revenues are attributed to countries based on customer location.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Includes property, plant and equipment, net, and operating lease ROU assets.</span></div> 22013000000 23820000000 18907000000 20844000000 21095000000 20304000000 42857000000 44915000000 39211000000 6352000000 6308000000 5578000000 4652000000 4565000000 4286000000 11004000000 10873000000 9864000000 Other Income/(Expense) <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In all periods, other income/(expense) includes currency transaction gains/losses on non-operating monetary assets and liabilities and net periodic pension benefit cost/income, excluding the service cost component, which is included in operating expenses on the accompanying statements of income. In 2023, other income/(expense) includes $46 million of net losses on investments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, other income/(expense) includes $161 million of net losses on investments, $67 million of net gains on derivative instruments to address certain foreign currency risks, and $26 million of losses on the early extinguishment of debt (Note 10).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, other income/(expense) includes $767 million of losses on the early extinguishment of debt (Note 10), $36 million of financing costs associated with obtaining bridge financing commitments in connection with the agreement to acquire PPD (Note 2), offset in part by $66 million of net gains on investments. The company had a cash outlay of $36 million in 2021 associated with obtaining the bridge financing commitments, included in other financing activities, net, in the accompanying statement of cash flows.</span></div> -46000000 -161000000 67000000 -26000000 -767000000 36000000 66000000 36000000 Stock-based Compensation Expense <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has stock-based compensation plans for its key employees, directors and others. These plans permit the grant of a variety of stock and stock-based awards, including restricted stock units, stock options or performance-based shares, as determined by the compensation committee of the company’s Board of Directors or, for certain non-officer grants, by the company’s employee equity committee, which consists of its chief executive officer. The company generally issues new shares of its common stock to satisfy option exercises and restricted unit vesting. Grants of stock options and restricted units generally </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide that in the event of both a change in control of the company and a qualifying termination of an option or unit holder’s employment, all options and service-based restricted unit awards held by the recipient become immediately vested (unless an employment or other agreement with the employee provides for different treatment).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate is calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes option pricing model are as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected stock price volatility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected annual dividend</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average per share grant-date fair values of options granted during 2023, 2022 and 2021 were $159.32, $135.07 and $123.97, respectively. The total intrinsic value of options exercised during the same periods was $320 million, $336 million and $501 million, respectively. The intrinsic value is the difference between the market value of the shares on the exercise date and the exercise price of the option.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the company’s option activity for the year ended December 31, 2023 is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining contractual term <br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate intrinsic <br/>value <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">546.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218.82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/expired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">543.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and unvested expected to vest at December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercisable at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">635 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, there was $162 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to be recognized through 2027 with a weighted average amortization period of 2.2 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share/Unit Awards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the company’s restricted unit activity for the year ended December 31, 2023 is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Units<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>average<br/>grant-date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495.39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480.45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unvested at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average per share grant-date fair values of restricted units granted during 2022 and 2021 were $520.83 and $444.61, respectively. The total fair value of shares vested during 2023, 2022 and 2021 was $207 million, $163 million and $151 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, there was $179 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is expected to be recognized through 2027 with a weighted average amortization period of 1.9 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qualifying employees are eligible to participate in an employee stock purchase plan sponsored by the company. Shares may be purchased under the program at 95% of the fair market value at the end of the purchase period and the shares purchased are not subject to a holding period. Shares are purchased through payroll deductions of up to 10% of each participating employee’s qualifying gross wages. The company issued 0.1 million, 0.2 million and 0.1 million shares, respectively, of its common stock in 2023, 2022 and 2021 under the employee stock purchase plan.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate is calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share/Unit Awards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.</span></div> P3Y P5Y P7Y P10Y <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes option pricing model are as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected stock price volatility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected annual dividend</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.25 0.26 0.26 0.042 0.020 0.008 P4Y8M12D P4Y8M12D P4Y3M18D 0.003 0.002 0.002 159.32 135.07 123.97 320000000 336000000 501000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the company’s option activity for the year ended December 31, 2023 is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining contractual term <br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate intrinsic <br/>value <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">546.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218.82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/expired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">543.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and unvested expected to vest at December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercisable at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">635 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5600000 359.27 700000 546.94 1000000.0 218.82 300000 543.25 5000000.0 401.30 P3Y10M24D 714000000 4800000 396.20 P3Y10M24D 712000000 2800000 316.88 P2Y8M12D 635000000 162000000 P2Y2M12D P3Y P4Y <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the company’s restricted unit activity for the year ended December 31, 2023 is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Units<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>average<br/>grant-date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495.39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480.45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unvested at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 700000 495.39 400000 545.73 400000 480.45 100000 528.59 600000 533.65 520.83 444.61 207000000 163000000 151000000 179000000 P1Y10M24D 0.95 0.10 100000 200000 100000 Pension and Other Postretirement Benefit Plans <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">401(k) Savings Plan and Other Defined Contribution Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s 401(k) savings and other defined contribution plans cover the majority of the company’s eligible U.S. and certain non-U.S. employees. Contributions to the plans are made by both the employee and the company. Company contributions are based on the level of employee contributions, and are based on formulas determined by the company. In 2023, 2022 and 2021, the company charged to expense $468 million, $402 million and $299 million, respectively, related to its defined contribution plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Benefit Pension Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined. Contributions to the plans included in the following table are estimated at between $30 million and $50 million for 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated benefit obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in projected benefit obligations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation at beginning of year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan participants' contributions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(447)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation at end of year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,069 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in fair value of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employer contributions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan participants' contributions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">947 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts recognized in balance sheet</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liability</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amount recognized</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts recognized in accumulated other comprehensive items</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net actuarial loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amount recognized</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For domestic pension plans, actuarial losses experienced in 2023 were driven by decreases in the weighted average discount rates used to determine the projected benefit obligation, as well as differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns. For non-U.S. pension plans, actuarial losses experienced in 2023 were principally driven by decreases in the weighted average discount rates used to determine the projected benefit obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For domestic pension plans, actuarial gains experienced in 2022 were driven by increases in the weighted average discount rates used to determine the projected benefit obligation, as well as differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns. For non-U.S. pension plans, actuarial gains experienced in 2022 were principally driven by increases in the weighted average discount rates used to determine the projected benefit obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2023 and 2022 and are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average assumptions used to determine projected benefit obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate for determining benefit obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate for cash balance plans</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average rate of increase in employee compensation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year, as presented in the following table:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average assumptions used to determine net benefit cost (income)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate - service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate - interest cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average rate of increase in employee compensation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected long-term rate of return on assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with projected benefit obligations in excess of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with accumulated benefit obligations in excess of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement date used to determine benefit information is December 31 for all plan assets and benefit obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic pension benefit cost (income) includes the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Components of net benefit cost (income)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1257">Interest cost on benefit obligation</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1264">Expected return on plan assets</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1271">Amortization of actuarial net loss</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1278">Amortization of prior service cost (benefit)</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1285">Settlement/curtailment loss (gain)</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are estimated using the same assumptions used in determining the company’s benefit obligation at December 31, 2023. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029-2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Domestic Pension Plan Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-U.S. Pension Plan Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds, </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">multi-asset funds, alternative investments and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 30% - 90% for fixed income funds, 0% - 40% for multi-asset funds, 0% - 4% for alternative investments, 0% - 4% for real estate funds and 0% - 45% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the company’s plan assets at December 31, 2023 and 2022, by asset category are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.420%"></td><td style="width:0.1%"></td></tr><tr style="height:41pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not subject to leveling (a)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Domestic pension plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International equity funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total domestic pension plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">947 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">947 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. pension plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Multi-asset funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alternative investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Real estate funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash / money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-U.S. pension plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. </span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.420%"></td><td style="width:0.1%"></td></tr><tr style="height:41pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not subject to leveling (a)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Domestic pension plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International equity funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total domestic pension plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. pension plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Multi-asset funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash / money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-U.S. pension plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. </span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables above present the fair value of the company’s plan assets in accordance with the fair value hierarchy (Note 14). Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. The fair value amounts of these investments presented in the above tables are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension plan assets. These investments were also redeemable at the balance sheet date or within limited time restrictions.</span></div> 468000000 402000000 299000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Benefit Pension Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits.</span></div>The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined.<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Domestic Pension Plan Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-U.S. Pension Plan Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds, </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">multi-asset funds, alternative investments and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 30% - 90% for fixed income funds, 0% - 40% for multi-asset funds, 0% - 4% for alternative investments, 0% - 4% for real estate funds and 0% - 45% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments.</span></div> 30000000 50000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated benefit obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in projected benefit obligations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation at beginning of year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan participants' contributions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(447)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation at end of year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,069 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in fair value of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employer contributions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan participants' contributions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">947 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts recognized in balance sheet</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liability</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amount recognized</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts recognized in accumulated other comprehensive items</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net actuarial loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amount recognized</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1005000000 995000000 1166000000 1016000000 995000000 1260000000 1069000000 1552000000 0 0 15000000 51000000 0 0 26000000 34000000 47000000 27000000 42000000 20000000 0 0 37000000 31000000 0 0 9000000 9000000 -42000000 210000000 -65000000 447000000 79000000 82000000 25000000 19000000 0 0 -57000000 100000000 1005000000 995000000 1221000000 1069000000 937000000 1226000000 868000000 1302000000 0 0 15000000 14000000 84000000 -212000000 29000000 -347000000 5000000 5000000 36000000 36000000 0 0 37000000 31000000 0 0 9000000 9000000 79000000 82000000 25000000 19000000 0 0 49000000 -96000000 947000000 937000000 944000000 868000000 -58000000 -58000000 -277000000 -201000000 0 0 65000000 81000000 6000000 6000000 11000000 11000000 52000000 52000000 331000000 271000000 -58000000 -58000000 -277000000 -201000000 -217000000 -200000000 -151000000 -74000000 0 0 -5000000 -4000000 217000000 200000000 146000000 70000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2023 and 2022 and are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average assumptions used to determine projected benefit obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate for determining benefit obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate for cash balance plans</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average rate of increase in employee compensation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year, as presented in the following table:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average assumptions used to determine net benefit cost (income)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate - service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate - interest cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average rate of increase in employee compensation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected long-term rate of return on assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.0482 0.0501 0.0347 0.0391 0.0476 0.0496 0.0206 0.0219 0.0264 0.0278 0.0362 0.0100 0.0065 0.0501 0.0270 0.0233 0.0395 0.0136 0.0080 0.0277 0.0273 0.0230 0.0625 0.0475 0.0425 0.0433 0.0233 0.0202 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with projected benefit obligations in excess of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1752000000 1636000000 1352000000 1296000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with accumulated benefit obligations in excess of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1695000000 1583000000 1349000000 1294000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic pension benefit cost (income) includes the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Components of net benefit cost (income)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1257">Interest cost on benefit obligation</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1264">Expected return on plan assets</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1271">Amortization of actuarial net loss</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1278">Amortization of prior service cost (benefit)</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1285">Settlement/curtailment loss (gain)</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 26000000 34000000 27000000 47000000 27000000 23000000 42000000 20000000 11000000 59000000 45000000 40000000 37000000 26000000 19000000 0 -4000000 -7000000 -2000000 -7000000 -12000000 0 0 0 -1000000 -1000000 0 0 0 0 -1000000 2000000 0 -12000000 -14000000 -10000000 33000000 32000000 31000000 Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029-2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 81000000 52000000 79000000 55000000 80000000 59000000 79000000 60000000 79000000 65000000 374000000 354000000 0.10 0.10 0.80 0 0.25 0.30 0.90 0 0.40 0 0.04 0 0.04 0 0.45 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the company’s plan assets at December 31, 2023 and 2022, by asset category are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.420%"></td><td style="width:0.1%"></td></tr><tr style="height:41pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not subject to leveling (a)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Domestic pension plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International equity funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total domestic pension plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">947 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">947 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. pension plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Multi-asset funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alternative investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Real estate funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash / money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-U.S. pension plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. </span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.420%"></td><td style="width:0.1%"></td></tr><tr style="height:41pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not subject to leveling (a)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Domestic pension plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International equity funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total domestic pension plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. pension plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Multi-asset funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash / money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-U.S. pension plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. </span></td></tr></table></div> 93000000 0 0 0 93000000 93000000 0 0 0 93000000 739000000 0 0 0 739000000 22000000 0 0 0 22000000 947000000 0 0 0 947000000 7000000 0 0 0 7000000 346000000 9000000 0 0 337000000 66000000 0 0 0 66000000 184000000 0 0 0 184000000 1000000 0 0 0 1000000 333000000 0 333000000 0 0 1000000 0 0 0 1000000 6000000 4000000 0 0 2000000 944000000 13000000 333000000 0 598000000 89000000 0 0 0 89000000 91000000 0 0 0 91000000 739000000 0 0 0 739000000 18000000 0 0 0 18000000 937000000 0 0 0 937000000 8000000 0 0 0 8000000 299000000 0 0 0 299000000 56000000 0 0 0 56000000 190000000 0 0 0 190000000 306000000 0 306000000 0 0 9000000 4000000 0 0 5000000 868000000 4000000 306000000 0 558000000 Income Taxes<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income before provision for income taxes are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,431 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,340 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,867 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,298 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,835 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,841 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the provision for income taxes are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred income tax provision (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,300)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(997)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statutory federal income tax rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes at statutory rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,645 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases (decreases) resulting from:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign rate differential</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Excess tax benefits from stock options and restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (reversal of) tax reserves, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intra-entity transfers</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange loss on inter-company debt refinancing</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (reversal of) valuation allowances, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Withholding taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax return reassessments and settlements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income taxes, net of federal tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, the company released valuation allowances of $32 million in jurisdictions where the deferred tax assets are now expected to be realized. In 2023 the company also recorded a tax benefit of $127 million for U.S. tax credits and the revaluation of net operating loss carryforwards due to higher tax rates as a result of its tax return resubmissions, a $91 million tax benefit, net of related tax expenses, from a foreign exchange loss on an intercompany debt refinancing transaction, and $233 million of tax benefits resulting from intra-entity transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the company settled an IRS audit relating to the 2017 and 2018 tax years. The company recorded a $208 million net tax benefit primarily from this settlement and related impacts, which resulted in a decrease in the company’s unrecognized tax benefits of $658 million. The company recorded $49 million of charges for expired tax credits and other related components of the settlement. The company recorded a charge of $395 million to establish a valuation allowance against certain U.S. foreign tax credits which the company believes will more likely than not expire unutilized. The company also recorded $101 million of additional net unrecognized tax benefit liabilities related to other tax audits.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the company recorded a $188 million income tax benefit related to the deferred tax implications of an intra-entity transfer of assets. Also in 2021, the company recorded a $96 million income tax benefit related to a capital loss resulting from certain intra-entity transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company generally receives a tax deduction upon the exercise of non-qualified stock options by employees, or the vesting of restricted stock units held by employees, for the difference between the exercise price and the market price of the underlying common stock on the date of exercise. The company uses the incremental tax benefit approach for utilization of tax attributes. These excess tax benefits reduce the tax provision. In 2023, 2022 and 2021, the company's tax provision was reduced by $69 million, $80 million and $124 million, respectively, of such benefits. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax asset/(liability) in the accompanying balance sheet consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax asset/(liability)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss and credit carryforwards</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,385 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,951 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserves and accruals</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory basis difference</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development and other capitalized costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (gains) losses on hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets/(liabilities), net before valuation allowance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(662)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets/(liabilities), net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,091)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,984)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company estimates the degree to which tax assets, losses and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2023, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the valuation allowance are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions (reductions) charged to income tax provision, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions due to acquisitions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation and other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, the company had net federal, state and non-U.S. net operating loss carryforwards of $70 million, $93 million and $1.42 billion, respectively. Use of the carryforwards is limited based on the future income of certain subsidiaries. Of the federal net operating loss carryforwards, $30 million expire in the years 2024 through 2037, and the remainder do not expire. Of the state net operating loss carryforwards, $83 million expire in the years 2024 through 2042, and the remainder do not expire. Of the net non-U.S. net operating loss carryforwards, $435 million expire in the years 2026 through 2043, and the remainder do not expire.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, the company had foreign tax credit carryforwards of $648 million and deferred interest carryforwards of $753 million. The foreign tax credit carryforwards will expire in the years 2025 through 2032. Of the deferred interest carryforwards, $149 million expire in the years 2025 through 2033 and the remainder do not expire.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal taxes have been recorded on approximately $34 billion of undistributed foreign earnings as of December 31, 2023. A provision has not been made for certain U.S. state income taxes or additional non-U.S. taxes that would be due when cash is repatriated to the U.S. as the company’s undistributed foreign earnings are intended to be reinvested outside of the U.S. indefinitely. The determination of the amount of the unrecognized deferred tax liability related to the undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed. The company’s intent is to only make distributions from non-U.S. subsidiaries in the future when they can be made at no net tax cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the company had $0.54 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions due to acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions of current year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Closure of tax years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the unrecognized tax benefits are classified as long-term liabilities. The company does not expect its unrecognized tax benefits to change significantly over the next twelve months.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, the company’s unrecognized tax benefits decreased by $12 million as a result of uncertain tax positions relating to foreign tax positions and decreased $19 million relating to U.S. federal and state tax positions. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the company’s unrecognized tax benefits increased by $143 million as a result of uncertain tax positions relating to foreign tax positions and decreased $610 million relating to U.S. federal and state tax positions which included $658 million from the settlement of the IRS audit of the 2017 and 2018 tax years. The company also assumed $15 million of uncertain tax benefits as part of the acquisition of PPD.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the company’s unrecognized tax benefits increased by $80 million as a result of uncertain tax positions relating to foreign tax positions and decreased $75 million relating to U.S. federal and state tax positions. The company also assumed $26 million of uncertain tax benefits as part of the acquisition of PPD. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company classified interest and penalties related to unrecognized tax benefits as income tax expense. The total amount of interest and penalties related to uncertain tax positions and recognized in the balance sheet as of December 31, 2023 and 2022 was $95 million and $74 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company conducts business globally and, as a result, Thermo Fisher or one or more of its subsidiaries files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the company is subject to examination by taxing authorities throughout the world, including such major jurisdictions as Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, the United Kingdom and the United States. With few exceptions, the company is no longer subject to U.S. state and local or non-U.S. income tax examinations for years before 2012 and no longer subject to U.S. federal income tax examinations for years before 2019.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income before provision for income taxes are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,431 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,340 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,867 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,298 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,835 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,841 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2431000000 3859000000 3340000000 3867000000 3976000000 5501000000 6298000000 7835000000 8841000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the provision for income taxes are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred income tax provision (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,300)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(997)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 228000000 813000000 446000000 1206000000 633000000 1148000000 150000000 254000000 160000000 1584000000 1700000000 1754000000 -551000000 -611000000 -227000000 -647000000 -314000000 -399000000 -102000000 -72000000 -19000000 -1300000000 -997000000 -645000000 284000000 703000000 1109000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statutory federal income tax rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes at statutory rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,645 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases (decreases) resulting from:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign rate differential</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Excess tax benefits from stock options and restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (reversal of) tax reserves, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intra-entity transfers</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange loss on inter-company debt refinancing</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (reversal of) valuation allowances, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Withholding taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax return reassessments and settlements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income taxes, net of federal tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.21 0.21 0.21 1323000000 1645000000 1857000000 -223000000 -329000000 -255000000 276000000 202000000 315000000 113000000 96000000 76000000 108000000 149000000 119000000 -69000000 -80000000 -124000000 13000000 -544000000 -17000000 -233000000 -18000000 -284000000 -112000000 0 0 -32000000 344000000 36000000 33000000 84000000 164000000 -187000000 -210000000 1000000 70000000 111000000 82000000 -28000000 -45000000 7000000 284000000 703000000 1109000000 -32000000 -127000000 -91000000 -233000000 -208000000 -658000000 49000000 395000000 101000000 188000000 96000000 -69000000 -80000000 -124000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax asset/(liability) in the accompanying balance sheet consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax asset/(liability)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss and credit carryforwards</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,385 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,951 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserves and accruals</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory basis difference</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development and other capitalized costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (gains) losses on hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets/(liabilities), net before valuation allowance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(662)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets/(liabilities), net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,091)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,984)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company estimates the degree to which tax assets, losses and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2023, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the valuation allowance are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions (reductions) charged to income tax provision, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions due to acquisitions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation and other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4286000000 4277000000 2385000000 1951000000 157000000 140000000 299000000 259000000 275000000 364000000 753000000 445000000 380000000 220000000 -66000000 -199000000 329000000 435000000 226000000 -662000000 1317000000 1322000000 1091000000 1984000000 1322000000 968000000 933000000 -32000000 344000000 24000000 4000000 14000000 30000000 23000000 -4000000 -19000000 1317000000 1322000000 968000000 70000000 93000000 1420000000 30000000 83000000 435000000 648000000 753000000 149000000 34000000000 540000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions due to acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions of current year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Closure of tax years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 572000000 1124000000 1091000000 0 15000000 26000000 4000000 104000000 32000000 34000000 24000000 60000000 43000000 659000000 5000000 6000000 4000000 27000000 21000000 32000000 53000000 540000000 572000000 1124000000 -12000000 -19000000 143000000 -610000000 -658000000 15000000 80000000 -75000000 26000000 95000000 74000000 Earnings per Share <div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:57.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Thermo Fisher Scientific Inc.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted average shares</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plus effect of: stock options and restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average shares</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.45 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.63 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.46 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Antidilutive stock options excluded from diluted weighted average shares</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:57.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Thermo Fisher Scientific Inc.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted average shares</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plus effect of: stock options and restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average shares</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.45 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.63 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.46 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Antidilutive stock options excluded from diluted weighted average shares</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5995000000 6950000000 7725000000 386000000 392000000 394000000 2000000 2000000 3000000 388000000 394000000 397000000 15.52 17.75 19.62 15.45 17.63 19.46 2000000 2000000 1000000 Debt and Other Financing Arrangements <div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective interest rate at December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.797% 2-Year Senior Notes, Due 10/18/2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.215% 3-Year Senior Notes, Due 10/18/2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.953% 3-Year Senior Notes, Due 8/10/2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000% 3-Year Senior Notes due 12/5/2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.80% 5-Year Senior Notes, Due 11/21/2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective interest rate at December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.77% 5-Year Senior Notes, Due 9/6/2028 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.750% 7-Year Senior Notes, Due 10/15/2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000% 5-Year Senior Notes due 1/31/2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.08 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60% 10-Year Senior Notes, Due 10/1/2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.977% 7-Year Senior Notes, Due 8/10/2030</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.00% 10-Year Senior Notes, Due 10/15/2031</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.95% 10-Year Senior Notes, Due 11/21/2032 </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.086% 10-Year Senior Notes, Due 8/10/2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,656 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.200% 10-Year Senior Notes due 1/31/2034</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50% 12-Year Senior Notes, due 9/6/2035 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80% 20-Year Senior Notes, Due 10/15/2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.404% 20-Year Senior Notes, due 8/10/2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.02% 20-Year Senior Notes, due 9/6/2043 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.30% 30-Year Senior Notes, Due 2/1/2044</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.10% 30-Year Senior Notes, Due 8/15/2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total borrowings at par value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total borrowings at carrying value</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,727 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,278 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Short-term obligations and current maturities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1941"><span style="-sec-ix-hidden:f-1942">Long-term obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,308 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,909 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SOFR - Secured Overnight Financing Rate</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EURIBOR - Euro Interbank Offered Rate</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt issuance costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 14 for fair value information pertaining to the company’s long-term borrowings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the annual repayment requirements for debt obligations are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance Lease Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,604 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,028 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to available borrowings under the company’s revolving credit agreements, discussed below, the company had unused lines of credit of $69 million as of December 31, 2023. These unused lines of credit generally provide for short-term unsecured borrowings at various interest rates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Facilities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term SOFR, a EURIBOR-based rate (for funds drawn in euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of December 31, 2023, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest is payable quarterly on the floating rate senior notes, annually on the euro-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the U.S. dollar, euro-denominated fixed rate senior notes and yen-denominated private placement notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest, together with swap breakage costs payable to holders of yen-denominated private placement notes who have entered into cross-currency swap agreements. The company is subject to certain affirmative and negative covenants under the indentures and note purchase agreement governing the senior notes, the most restrictive of which limits the ability of the company to pledge certain property and assets as security under borrowing arrangements. The company was in compliance with all covenants at December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 the company completed the full allocation of an amount equal to the net proceeds from the 0.000% senior notes due 2025 to finance or refinance, in whole or in part, certain COVID-19 response projects.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the company redeemed all of its 3.650% Senior Notes due 2025. In connection with the redemption, the company incurred $26 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the company redeemed some of its existing senior notes. In connection with these redemptions, the company incurred $767 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income. Upon redemption of the senior notes, the company terminated the related fixed to floating rate interest rate swap arrangements and received $22 million, included in other financing activities, net, in the accompanying statement of cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the following notes outstanding as of December 31, 2023, included in the table above (collectively, the “Euronotes”) in registered public offerings: the 0.00% Senior Notes due 2025, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are consolidated in the financial statements of the company.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective interest rate at December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.797% 2-Year Senior Notes, Due 10/18/2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.215% 3-Year Senior Notes, Due 10/18/2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.953% 3-Year Senior Notes, Due 8/10/2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000% 3-Year Senior Notes due 12/5/2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.80% 5-Year Senior Notes, Due 11/21/2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective interest rate at December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.77% 5-Year Senior Notes, Due 9/6/2028 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.750% 7-Year Senior Notes, Due 10/15/2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000% 5-Year Senior Notes due 1/31/2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.08 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60% 10-Year Senior Notes, Due 10/1/2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.977% 7-Year Senior Notes, Due 8/10/2030</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.00% 10-Year Senior Notes, Due 10/15/2031</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.95% 10-Year Senior Notes, Due 11/21/2032 </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.086% 10-Year Senior Notes, Due 8/10/2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,656 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.200% 10-Year Senior Notes due 1/31/2034</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50% 12-Year Senior Notes, due 9/6/2035 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80% 20-Year Senior Notes, Due 10/15/2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.404% 20-Year Senior Notes, due 8/10/2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.02% 20-Year Senior Notes, due 9/6/2043 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.30% 30-Year Senior Notes, Due 2/1/2044</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.10% 30-Year Senior Notes, Due 8/15/2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total borrowings at par value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total borrowings at carrying value</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,727 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,278 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Short-term obligations and current maturities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1941"><span style="-sec-ix-hidden:f-1942">Long-term obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,308 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,909 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SOFR - Secured Overnight Financing Rate</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EURIBOR - Euro Interbank Offered Rate</span></div> 0 310000000 0.0035 P1Y6M 0 1000000000 0.0039 P2Y 0 500000000 0.00797 P2Y 0 1350000000 0.0020 P2Y 0 1819000000 0.00000 P2Y 0 589000000 0.0075 P8Y 0.0093 1104000000 1071000000 0.0053 P3Y 0 500000000 0.01215 P3Y 0.0142 2500000000 2500000000 0.00125 P5Y6M 0.0041 883000000 857000000 0.0200 P10Y 0.0210 706000000 686000000 0.00853 P3Y 0.0105 158000000 170000000 0.00000 P4Y 0.0015 607000000 589000000 0.0320 P3Y 0.0339 552000000 535000000 0.0140 P8Y6M 0.0153 773000000 749000000 0.04953 P3Y 0.0519 600000000 0 0.05000 P3Y 0.0500 1000000000 0 0.0145 P10Y 0.0165 552000000 535000000 0.0175 P7Y 0.0197 662000000 642000000 0.01054 P5Y 0.0118 205000000 221000000 0.0480 P5Y 0.0500 600000000 600000000 0.0050 P8Y6M 0.0077 883000000 857000000 0.0077 P5Y 0.0090 206000000 0 0.01375 P12Y 0.0146 662000000 642000000 0.01750 P7Y 0.0189 700000000 700000000 0.05000 P5Y 0.0500 1000000000 0 0.0195 P12Y 0.0208 773000000 749000000 0.0260 P10Y 0.0274 900000000 900000000 0.01279 P7Y 0.0144 33000000 36000000 0.04977 P7Y 0.0512 750000000 0 0.0080 P9Y 0.0089 1932000000 1873000000 0.00875 P12Y 0.0113 993000000 963000000 0.0200 P10Y 0.0223 1200000000 1200000000 0.02375 P12Y 0.0255 662000000 642000000 0.0149 P10Y 0.0160 45000000 48000000 0.0495 P10Y 0.0509 600000000 600000000 0.05086 P10Y 0.0520 1000000000 0 0.01125 P12Y 0.0120 1656000000 1606000000 0.05200 P10Y 0.0520 500000000 0 0.0365 P12Y 0.0376 828000000 803000000 0.0150 P12Y 0.0158 152000000 0 0.02875 P20Y 0.0294 773000000 749000000 0.0150 P20Y 0.0173 993000000 963000000 0.0280 P20Y 0.0290 1200000000 1200000000 0.01625 P20Y 0.0177 1380000000 1339000000 0.02069 P20Y 0.0213 104000000 111000000 0.05404 P20Y 0.0550 600000000 0 0.0202 P20Y 0.0206 206000000 0 0.0530 P30Y 0.0537 400000000 400000000 0.0410 P30Y 0.0423 750000000 750000000 0.01875 P30Y 0.0198 1104000000 1071000000 0.0200 P30Y 0.0207 828000000 803000000 0.02382 P30Y 0.0243 236000000 254000000 77000000 79000000 35028000000 34561000000 113000000 112000000 188000000 171000000 34727000000 34278000000 190000000 210000000 3609000000 5579000000 31308000000 28909000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the annual repayment requirements for debt obligations are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance Lease Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,604 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,028 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3604000000 5000000 2356000000 13000000 2925000000 12000000 2020000000 10000000 2451000000 8000000 21672000000 142000000 35028000000 190000000 69000000 5000000000 3.5 0 P397D P183D 1 0.00000 0.03650 -26000000 -767000000 22000000 0.0000 0.0080 0.01125 0.01625 0.0200 Leases <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessee, the company leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers, and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally for 1 to 10 years) or have options to terminate the arrangement within 1 year. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has guaranteed the residual value of three leased operating facilities with lease terms ending in 2024, 2025 and 2028. The company has agreed with the lessor to comply with certain financial covenants consistent with its other debt arrangements (Note 10). The aggregate maximum guarantee under these three lease arrangements is $147 million. Operating lease ROU assets and lease liabilities for these lease arrangements are recorded on the consolidated balance sheet as of December 31, 2023, but exclude any amounts for residual value guarantees.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessee, the consolidated financial statements include the following relating to operating leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statement of income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statement of cash flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance sheet</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1999"><span style="-sec-ix-hidden:f-2000">ROU assets - included in other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2003"><span style="-sec-ix-hidden:f-2004">Operating lease liabilities - included in other accrued expenses</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2007"><span style="-sec-ix-hidden:f-2008">Operating lease liabilities - included in other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remaining operating lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs arising from finance leases, short-term leases, and sublease income are not material. See Note 10 for additional information relating to finance leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, future payments of operating lease liabilities are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:84.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2024"><span style="-sec-ix-hidden:f-2025">Total operating lease liability</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,507 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessor, operating leases, sales-type leases and direct financing leases are not material.</span></div> P1M P30Y P1Y P10Y P1Y 3 3 147000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessee, the consolidated financial statements include the following relating to operating leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statement of income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statement of cash flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance sheet</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1999"><span style="-sec-ix-hidden:f-2000">ROU assets - included in other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2003"><span style="-sec-ix-hidden:f-2004">Operating lease liabilities - included in other accrued expenses</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2007"><span style="-sec-ix-hidden:f-2008">Operating lease liabilities - included in other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remaining operating lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 355000000 351000000 254000000 115000000 109000000 66000000 410000000 289000000 288000000 234000000 430000000 293000000 1556000000 1593000000 263000000 272000000 1244000000 1313000000 P9Y2M12D P9Y4M24D 0.040 0.032 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, future payments of operating lease liabilities are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:84.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2024"><span style="-sec-ix-hidden:f-2025">Total operating lease liability</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,507 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 294000000 288000000 242000000 172000000 131000000 723000000 1850000000 343000000 1507000000 Commitments and Contingencies<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has entered into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods, services or fixed assets and to pay royalties that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable at any time without penalty. The aggregate amount of the company’s unconditional purchase obligations totaled $2.53 billion at December 31, 2023, the majority of which are expected to be settled during 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit, Guarantees and Other Commitments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding letters of credit and bank guarantees totaled $315 million at December 31, 2023. Substantially all of these letters of credit and guarantees expire before 2040. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding surety bonds and other guarantees totaled $93 million at December 31, 2023. The expiration of these bonds and guarantees ranges through 2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The letters of credit, bank guarantees and surety bonds principally secure performance obligations, and allow the holder to draw funds up to the face amount of the letter of credit, bank guarantee or surety bond if the applicable business unit does not perform as contractually required.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has funding commitments totaling $164 million at December 31, 2023, related to investments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is a guarantor of pension plan obligations of a divested business. The purchaser of the divested business has agreed to pay for the pension benefits, however the company was required to guarantee payment of these pension benefits should the purchaser fail to do so. The amount of the guarantee at December 31, 2023 was $24 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of businesses of the company, the buyers have assumed certain contractual obligations of such businesses and have agreed to indemnify the company with respect to those assumed liabilities. In the event a third-party to a transferred contract does not recognize the transfer of obligations or a buyer defaults on its obligations under the transferred contract, the company could be liable to the third-party for such obligations. However, in such event, the company would be entitled to seek indemnification from the buyer.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with certain transactions, primarily divestitures, the company has agreed to indemnify the other parties with respect to certain liabilities related to the businesses that were sold or leased properties that were abandoned (e.g., retention of certain environmental, tax, employee and product liabilities). The scope and duration of such indemnity obligations vary from transaction to transaction. Where probable, an obligation for such indemnifications is recorded as a liability. Generally, a maximum obligation cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, historically the company has not made significant payments for these indemnifications.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the company’s efforts to reduce the number of facilities that it occupies, the company has vacated some of its leased facilities or sublet them to third parties. When the company sublets a facility to a third-party, it remains the primary obligor under the master lease agreement with the owner of the facility. As a result, if a third-party vacates the sublet facility, </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the company would be obligated to make lease or other payments under the master lease agreement. The company believes that the financial risk of default by sublessors is individually and in the aggregate not material to the company’s financial position or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of products in the ordinary course of business, the company often makes representations affirming, among other things, that its products do not infringe on the intellectual property rights of others and agrees to indemnify customers against third-party claims for such infringement. The company has not been required to make material payments under such provisions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environmental Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including input from environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At December 31, 2023<span style="-sec-ix-hidden:f-2033">, the company’s total environmental liability was approximately</span> $75 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation and Related Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability, Workers Compensation and Other Personal Injury Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. The range of probable loss for product liability, workers compensation and other personal injury matters of the company’s continuing operations at December 31, 2023, was approximately $222 million to $379 million. The company’s accrual for these matters totaled $224 million at December 31, 2023. The accrual includes estimated defense costs and is gross of estimated amounts due from insurers of $88 million at December 31, 2023 that are included in other assets in the accompanying balance sheet. In addition, as of December 31, 2023, the company had a product liability accrual of $20 million relating to divested businesses.</span></div>Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis. 2530000000 315000000 93000000 164000000 24000000 75000000 222000000 379000000 224000000 88000000 20000000 Comprehensive Income/(Loss) and Shareholders' Equity <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of accumulated other comprehensive items, net of tax are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency<br/>translation<br/>adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized<br/>losses on<br/>hedging<br/>instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension and<br/>other<br/>postretirement<br/>benefit<br/>liability<br/>adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,880)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,099)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss) before reclassifications</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income/(loss)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net other comprehensive income/(loss)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,224)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholders’ Equity</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, the company had reserved 39 million unissued shares of its common stock for possible issuance under stock-based compensation plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in the first quarter of 2024, the company repurchased $3.00 billion of the company's common stock (5.5 million shares).</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of accumulated other comprehensive items, net of tax are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency<br/>translation<br/>adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized<br/>losses on<br/>hedging<br/>instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension and<br/>other<br/>postretirement<br/>benefit<br/>liability<br/>adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,880)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,099)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss) before reclassifications</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income/(loss)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net other comprehensive income/(loss)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,224)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -2880000000 -33000000 -186000000 -3099000000 -69000000 0 -69000000 -138000000 -8000000 -5000000 0 -13000000 -61000000 5000000 -69000000 -125000000 -2941000000 -28000000 -255000000 -3224000000 39000000 3000000000 5500000 Fair Value Measurements and Fair Value of Financial Instruments<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2023. The company’s financial assets and liabilities carried at fair value are primarily comprised of investments in publicly traded securities, insurance contracts, investments in derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Inputs are unobservable data points that are not corroborated by market data. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.713%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.419%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bank time deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2091">Derivative contracts</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.713%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.419%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,082 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent consideration</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions (including assumed balances)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2147"><span style="-sec-ix-hidden:f-2148">Changes in fair value included in earnings</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the aggregate notional value of outstanding derivative contracts. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps designated as net investment hedge - euro</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps designated as net investment hedge - Japanese yen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps designated as net investment hedge - Swiss franc</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2163">Fair value – assets</span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value – liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency exchange contracts (b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) recognized</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value hedging relationships</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedged long-term obligations - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedged long-term obligations - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount reclassified from accumulated other comprehensive items to interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount reclassified from accumulated other comprehensive items to other income/(expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial instruments designated as net investment hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency-denominated debt and other payables</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in currency translation adjustment within other comprehensive items</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(356)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in currency translation adjustment within other comprehensive items</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in interest expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cost of product revenues</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the accompanying statements of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 and Note 10 for additional information on the company’s risk management objectives and strategies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow Hedge Arrangements </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, in connection with the extinguishment of debt (Note 10), the company reclassified $65 million from accumulated other comprehensive income/(loss) to other income/(expense).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Other Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value and fair value of the company’s debt instruments are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,889 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,727 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,268 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,278 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,290 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally developed pricing models and unobservable inputs, which represent level 3 measurements. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.713%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.419%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bank time deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2091">Derivative contracts</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.713%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.419%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,082 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 5021000000 5021000000 0 0 3000000 3000000 0 0 20000000 20000000 0 0 210000000 0 210000000 0 8000000 0 8000000 0 5262000000 5044000000 218000000 0 290000000 0 290000000 0 87000000 0 0 87000000 377000000 0 290000000 87000000 5804000000 5804000000 0 0 25000000 25000000 0 0 12000000 0 12000000 0 162000000 0 162000000 0 79000000 0 79000000 0 6082000000 5829000000 253000000 0 101000000 0 101000000 0 174000000 0 0 174000000 275000000 0 101000000 174000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent consideration</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions (including assumed balances)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2147"><span style="-sec-ix-hidden:f-2148">Changes in fair value included in earnings</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 174000000 317000000 1000000 -18000000 63000000 66000000 25000000 59000000 87000000 174000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the aggregate notional value of outstanding derivative contracts. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps designated as net investment hedge - euro</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps designated as net investment hedge - Japanese yen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps designated as net investment hedge - Swiss franc</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1000000000 900000000 4650000000 1200000000 2500000000 0 1567000000 2434000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2163">Fair value – assets</span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value – liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency exchange contracts (b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span>The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses. 5000000 77000000 287000000 85000000 3000000 2000000 3000000 16000000 8000000 79000000 290000000 101000000 <div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) recognized</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value hedging relationships</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedged long-term obligations - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedged long-term obligations - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount reclassified from accumulated other comprehensive items to interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount reclassified from accumulated other comprehensive items to other income/(expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial instruments designated as net investment hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency-denominated debt and other payables</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in currency translation adjustment within other comprehensive items</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(356)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in currency translation adjustment within other comprehensive items</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in interest expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cost of product revenues</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 77000000 0 0 -81000000 0 0 0 25000000 0 0 -3000000 -4000000 0 0 -3000000 -3000000 -73000000 -356000000 695000000 922000000 -222000000 52000000 71000000 120000000 19000000 8000000 1000000 6000000 12000000 -29000000 102000000 162000000 65000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value and fair value of the company’s debt instruments are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,889 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,727 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,268 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,278 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,290 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally developed pricing models and unobservable inputs, which represent level 3 measurements. 34650000000 32191000000 33889000000 29901000000 0 0 310000000 310000000 77000000 77000000 79000000 79000000 34727000000 32268000000 34278000000 30290000000 Supplemental Cash Flow Information <div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash paid for:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash investing and financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired but unpaid property, plant and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of equity awards exchanged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of acquisition contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease ROU assets obtained in exchange for new finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Declared but unpaid dividends</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of stock upon vesting of restricted stock units</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Excise tax from stock repurchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2260">Restricted cash included in other current assets</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2263">Restricted cash included in other assets</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,097 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,537 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance. <div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash paid for:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash investing and financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired but unpaid property, plant and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of equity awards exchanged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of acquisition contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease ROU assets obtained in exchange for new finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Declared but unpaid dividends</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of stock upon vesting of restricted stock units</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Excise tax from stock repurchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1385000000 667000000 555000000 1482000000 1234000000 2182000000 296000000 393000000 379000000 0 0 43000000 0 0 183000000 2000000 33000000 15000000 137000000 119000000 104000000 234000000 241000000 265000000 28000000 0 0 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2260">Restricted cash included in other current assets</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2263">Restricted cash included in other assets</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,097 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,537 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8077000000 8524000000 6000000 12000000 14000000 1000000 8097000000 8537000000 Restructuring and Other Costs <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and other costs in 2023 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2023, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the company’s workforce.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and other costs in 2022 primarily included impairment of long-lived assets and continuing charges for headcount reductions and facility consolidations in an effort to streamline operations. In 2022, severance actions associated with facility consolidations and cost reduction measures affected less than 2% of the company’s workforce.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and other costs in 2021 primarily included charges for impairments of an acquired technology asset and a tradename asset, and, to a lesser extent, compensation due to employees at acquired businesses on the date of acquisition. In 2021, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 22, 2024, the company has identified restructuring actions that will result in additional charges of approximately $70 million, primarily in 2024, and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and other costs by segment are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as <span style="-sec-ix-hidden:f-2293">restructuring and other costs</span> in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net restructuring charges incurred in 2021 (b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net restructuring charges incurred in 2022 (c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net restructuring charges incurred in 2023 (d) (e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.</span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments. </span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Excludes $46 million of net charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment.</span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes $264 million of net charges, principally $126 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments, $26 million of contract termination costs associated with facility closures in the Laboratory Products and Biopharma Services segment, and $19 million of net charges for pre-acquisition litigation and other matters in the Laboratory Products and Biopharma Services segment.</span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Excludes $93 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $46 million attributable to a noncontrolling interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company expects to pay accrued restructuring costs primarily through 2024.</span></div> 0.05 0.02 0.01 70000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and other costs by segment are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 105000000 30000000 129000000 33000000 1000000 6000000 11000000 68000000 18000000 295000000 12000000 35000000 15000000 3000000 9000000 459000000 114000000 197000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as <span style="-sec-ix-hidden:f-2293">restructuring and other costs</span> in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net restructuring charges incurred in 2021 (b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net restructuring charges incurred in 2022 (c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net restructuring charges incurred in 2023 (d) (e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.</span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments. </span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Excludes $46 million of net charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment.</span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes $264 million of net charges, principally $126 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments, $26 million of contract termination costs associated with facility closures in the Laboratory Products and Biopharma Services segment, and $19 million of net charges for pre-acquisition litigation and other matters in the Laboratory Products and Biopharma Services segment.</span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Excludes $93 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $46 million attributable to a noncontrolling interest.</span></div> 21000000 37000000 40000000 -1000000 17000000 68000000 44000000 41000000 194000000 175000000 60000000 160000000 122000000 35000000 46000000 264000000 126000000 26000000 19000000 93000000 46000000 false false false <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 13, 2023, Michael A. Boxer, our senior vice president, general counsel, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Boxer’s plan is for the exercise of vested stock options and the associated sale of up to 20,566 shares of company common stock through December 13, 2024. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and December 13, 2024.</span></div> December 13, 2023 Michael A. Boxer senior vice president, general counsel true 20566 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2023, Lisa P. Britt, our senior vice president, chief human resources officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Ms. Britt’s plan is for the exercise of vested stock options and the associated sale of up to 14,345 shares of company common stock through November 11, 2024. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and November 12, 2024.</span></div> December 12, 2023 Lisa P. Britt senior vice president, chief human resources officer true 14345 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2023, Marc N. Casper, our chairman, president and chief executive officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Casper’s plan is for the exercise of vested stock options </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the associated sale of up to 202,150 shares of company common stock through November 1, 2024. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and November 4, 2024.</span></div> November 10, 2023 Marc N. Casper chairman, president and chief executive officer true 202150 Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices. Revenues are attributed to countries based on customer location. Includes property, plant and equipment, net, and operating lease ROU assets. Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

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end XML 111 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 112 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 114 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 693 593 1 true 193 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://thermofisher.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://thermofisher.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheet Sheet http://thermofisher.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheet Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheet (Parenthetical) Sheet http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical Consolidated Balance Sheet (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statement of Income Sheet http://thermofisher.com/role/ConsolidatedStatementofIncome Consolidated Statement of Income Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statement of Comprehensive Income Sheet http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome Consolidated Statement of Comprehensive Income Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statement of Comprehensive Income (Parenthetical) Sheet http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncomeParenthetical Consolidated Statement of Comprehensive Income (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statement of Cash Flows Sheet http://thermofisher.com/role/ConsolidatedStatementofCashFlows Consolidated Statement of Cash Flows Statements 8 false false R9.htm 0000009 - Statement - Consolidated Statement of Redeemable Noncontrolling Interest and Equity Sheet http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity Consolidated Statement of Redeemable Noncontrolling Interest and Equity Statements 9 false false R10.htm 0000010 - Statement - Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Parenthetical) Sheet http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquityParenthetical Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Parenthetical) Statements 10 false false R11.htm 0000011 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies Nature of Operations and Summary of Significant Accounting Policies Notes 11 false false R12.htm 0000012 - Disclosure - Acquisitions Sheet http://thermofisher.com/role/Acquisitions Acquisitions Notes 12 false false R13.htm 0000013 - Disclosure - Revenue and Contract-related Balances Sheet http://thermofisher.com/role/RevenueandContractrelatedBalances Revenue and Contract-related Balances Notes 13 false false R14.htm 0000014 - Disclosure - Business Segment and Geographical Information Sheet http://thermofisher.com/role/BusinessSegmentandGeographicalInformation Business Segment and Geographical Information Notes 14 false false R15.htm 0000015 - Disclosure - Other Income/Expense Sheet http://thermofisher.com/role/OtherIncomeExpense Other Income/Expense Notes 15 false false R16.htm 0000016 - Disclosure - Stock-based Compensation Expense Sheet http://thermofisher.com/role/StockbasedCompensationExpense Stock-based Compensation Expense Notes 16 false false R17.htm 0000017 - Disclosure - Pension and Other Postretirement Benefit Plans Sheet http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlans Pension and Other Postretirement Benefit Plans Notes 17 false false R18.htm 0000018 - Disclosure - Income Taxes Sheet http://thermofisher.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 0000019 - Disclosure - Earnings Per Share Sheet http://thermofisher.com/role/EarningsPerShare Earnings Per Share Notes 19 false false R20.htm 0000020 - Disclosure - Debt and Other Financing Arrangements Sheet http://thermofisher.com/role/DebtandOtherFinancingArrangements Debt and Other Financing Arrangements Notes 20 false false R21.htm 0000021 - Disclosure - Leases Sheet http://thermofisher.com/role/Leases Leases Notes 21 false false R22.htm 0000022 - Disclosure - Commitments and Contingencies Sheet http://thermofisher.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 22 false false R23.htm 0000023 - Disclosure - Comprehensive Income and Shareholders Equity Sheet http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquity Comprehensive Income and Shareholders Equity Notes 23 false false R24.htm 0000024 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstruments Fair Value Measurements and Fair Value of Financial Instruments Notes 24 false false R25.htm 0000025 - Disclosure - Supplemental Cash Flow Information Sheet http://thermofisher.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 25 false false R26.htm 0000026 - Disclosure - Restructuring and Other Costs Sheet http://thermofisher.com/role/RestructuringandOtherCosts Restructuring and Other Costs Notes 26 false false R27.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 27 false false R28.htm 9954471 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies Nature of Operations and Summary of Significant Accounting Policies (Policies) Policies http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies 28 false false R29.htm 9954472 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Tables) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables Nature of Operations and Summary of Significant Accounting Policies (Tables) Tables http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies 29 false false R30.htm 9954473 - Disclosure - Acquisitions (Tables) Sheet http://thermofisher.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://thermofisher.com/role/Acquisitions 30 false false R31.htm 9954474 - Disclosure - Revenue and Contract-related Balances (Tables) Sheet http://thermofisher.com/role/RevenueandContractrelatedBalancesTables Revenue and Contract-related Balances (Tables) Tables http://thermofisher.com/role/RevenueandContractrelatedBalances 31 false false R32.htm 9954475 - Disclosure - Business Segment and Geographical Information (Tables) Sheet http://thermofisher.com/role/BusinessSegmentandGeographicalInformationTables Business Segment and Geographical Information (Tables) Tables http://thermofisher.com/role/BusinessSegmentandGeographicalInformation 32 false false R33.htm 9954476 - Disclosure - Stock-based Compensation Expense (Tables) Sheet http://thermofisher.com/role/StockbasedCompensationExpenseTables Stock-based Compensation Expense (Tables) Tables http://thermofisher.com/role/StockbasedCompensationExpense 33 false false R34.htm 9954477 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) Sheet http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables Pension and Other Postretirement Benefit Plans (Tables) Tables http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlans 34 false false R35.htm 9954478 - Disclosure - Income Taxes (Tables) Sheet http://thermofisher.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://thermofisher.com/role/IncomeTaxes 35 false false R36.htm 9954479 - Disclosure - Earnings Per Share (Tables) Sheet http://thermofisher.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://thermofisher.com/role/EarningsPerShare 36 false false R37.htm 9954480 - Disclosure - Debt and Other Financing Arrangements (Tables) Sheet http://thermofisher.com/role/DebtandOtherFinancingArrangementsTables Debt and Other Financing Arrangements (Tables) Tables http://thermofisher.com/role/DebtandOtherFinancingArrangements 37 false false R38.htm 9954481 - Disclosure - Leases (Tables) Sheet http://thermofisher.com/role/LeasesTables Leases (Tables) Tables http://thermofisher.com/role/Leases 38 false false R39.htm 9954482 - Disclosure - Comprehensive Income and Shareholders Equity (Tables) Sheet http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityTables Comprehensive Income and Shareholders Equity (Tables) Tables http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquity 39 false false R40.htm 9954483 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables) Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables Fair Value Measurements and Fair Value of Financial Instruments (Tables) Tables http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstruments 40 false false R41.htm 9954484 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://thermofisher.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://thermofisher.com/role/SupplementalCashFlowInformation 41 false false R42.htm 9954485 - Disclosure - Restructuring and Other Costs (Tables) Sheet http://thermofisher.com/role/RestructuringandOtherCostsTables Restructuring and Other Costs (Tables) Tables http://thermofisher.com/role/RestructuringandOtherCosts 42 false false R43.htm 9954486 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Additional Accounting Policy and Balance Sheet Disclosures (Details) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails Nature of Operations and Summary of Significant Accounting Policies - Additional Accounting Policy and Balance Sheet Disclosures (Details) Details 43 false false R44.htm 9954487 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Inventories (Details) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails Nature of Operations and Summary of Significant Accounting Policies - Inventories (Details) Details http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables 44 false false R45.htm 9954488 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Property, Plant and Equipment (Details) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails Nature of Operations and Summary of Significant Accounting Policies - Property, Plant and Equipment (Details) Details 45 false false R46.htm 9954489 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details) Details 46 false false R47.htm 9954490 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Goodwill (Details) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails Nature of Operations and Summary of Significant Accounting Policies - Goodwill (Details) Details http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables 47 false false R48.htm 9954491 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails Nature of Operations and Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) Details 48 false false R49.htm 9954492 - Disclosure - Acquisitions - Narrative (Details) Sheet http://thermofisher.com/role/AcquisitionsNarrativeDetails Acquisitions - Narrative (Details) Details 49 false false R50.htm 9954493 - Disclosure - Acquisitions - Schedule of Components of Purchase Price (Details) Sheet http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails Acquisitions - Schedule of Components of Purchase Price (Details) Details 50 false false R51.htm 9954494 - Disclosure - Acquisitions - Schedule of Pro Forma Information (Details) Sheet http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails Acquisitions - Schedule of Pro Forma Information (Details) Details 51 false false R52.htm 9954495 - Disclosure - Revenue & Contract-related Balances - Disaggregation of Revenue (Details) Sheet http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails Revenue & Contract-related Balances - Disaggregation of Revenue (Details) Details 52 false false R53.htm 9954496 - Disclosure - Revenue & Contract-related Balances - Revenue Performance Obligations (Details) Sheet http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails Revenue & Contract-related Balances - Revenue Performance Obligations (Details) Details 53 false false R54.htm 9954497 - Disclosure - Revenue & Contract-related Balances - Contract Assets and Liabilities (Details) Sheet http://thermofisher.com/role/RevenueContractrelatedBalancesContractAssetsandLiabilitiesDetails Revenue & Contract-related Balances - Contract Assets and Liabilities (Details) Details 54 false false R55.htm 9954498 - Disclosure - Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details) Sheet http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details) Details 55 false false R56.htm 9954499 - Disclosure - Business Segment and Geographical Information - Schedule of Revenue by Geographical Areas (Details) Sheet http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails Business Segment and Geographical Information - Schedule of Revenue by Geographical Areas (Details) Details 56 false false R57.htm 9954500 - Disclosure - Other Income/Expense (Details) Sheet http://thermofisher.com/role/OtherIncomeExpenseDetails Other Income/Expense (Details) Details http://thermofisher.com/role/OtherIncomeExpense 57 false false R58.htm 9954501 - Disclosure - Stock-based Compensation Expense - Narrative (Details) Sheet http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails Stock-based Compensation Expense - Narrative (Details) Details 58 false false R59.htm 9954502 - Disclosure - Stock-based Compensation Expense - Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model (Details) Sheet http://thermofisher.com/role/StockbasedCompensationExpenseScheduleofWeightedAverageAssumptionsusedintheBlackScholesOptionPricingModelDetails Stock-based Compensation Expense - Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model (Details) Details 59 false false R60.htm 9954503 - Disclosure - Stock-based Compensation Expense - Summary of the Company's Option Activity (Details) Sheet http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails Stock-based Compensation Expense - Summary of the Company's Option Activity (Details) Details 60 false false R61.htm 9954504 - Disclosure - Stock-based Compensation Expense - Summary of the Company's Restricted Unit Activity (Details) Sheet http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails Stock-based Compensation Expense - Summary of the Company's Restricted Unit Activity (Details) Details 61 false false R62.htm 9954505 - Disclosure - Pensions and Other Postretirement Benefit Plans - Narrative (Details) Sheet http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails Pensions and Other Postretirement Benefit Plans - Narrative (Details) Details 62 false false R63.htm 9954506 - Disclosure - Pensions and Other Postretirement Benefit Plans - Reconciliation of Benefit Obligations and Plan Assets (Details) Sheet http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails Pensions and Other Postretirement Benefit Plans - Reconciliation of Benefit Obligations and Plan Assets (Details) Details 63 false false R64.htm 9954507 - Disclosure - Pensions and Other Postretirement Benefit Plans - Actuarial Assumptions (Details) Sheet http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails Pensions and Other Postretirement Benefit Plans - Actuarial Assumptions (Details) Details 64 false false R65.htm 9954508 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation and Fair Value of Plan Assets (Details) Sheet http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation and Fair Value of Plan Assets (Details) Details 65 false false R66.htm 9954509 - Disclosure - Pension and Other Postretirement Benefit Plans - Schedule of Estimated Future Benefit Payments (Details) Sheet http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails Pension and Other Postretirement Benefit Plans - Schedule of Estimated Future Benefit Payments (Details) Details 66 false false R67.htm 9954510 - Disclosure - Pension and Other Postretirement Benefit Plans - Schedule of Fair Value of the Company's Plan Assets (Details) Sheet http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails Pension and Other Postretirement Benefit Plans - Schedule of Fair Value of the Company's Plan Assets (Details) Details 67 false false R68.htm 9954511 - Disclosure - Income Taxes - Components of Income Before Provision for Income Taxes and Provision for Income Taxes (Details) Sheet http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails Income Taxes - Components of Income Before Provision for Income Taxes and Provision for Income Taxes (Details) Details 68 false false R69.htm 9954512 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Details 69 false false R70.htm 9954513 - Disclosure - Income Taxes - Narrative (Details) Sheet http://thermofisher.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 70 false false R71.htm 9954514 - Disclosure - Income Taxes - Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance (Details) Sheet http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails Income Taxes - Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance (Details) Details 71 false false R72.htm 9954515 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Sheet http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Details 72 false false R73.htm 9954516 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) Sheet http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) Details 73 false false R74.htm 9954517 - Disclosure - Debt and Other Financing Arrangements - Schedule of Debt (Details) Sheet http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails Debt and Other Financing Arrangements - Schedule of Debt (Details) Details 74 false false R75.htm 9954518 - Disclosure - Debt and Other Financing Arrangements - Schedule of Annual Repayment Requirements for Debt Obligations (Details) Sheet http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails Debt and Other Financing Arrangements - Schedule of Annual Repayment Requirements for Debt Obligations (Details) Details 75 false false R76.htm 9954519 - Disclosure - Debt and Other Financing Arrangements - Narrative (Details) Sheet http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails Debt and Other Financing Arrangements - Narrative (Details) Details 76 false false R77.htm 9954520 - Disclosure - Leases- Narrative (Details) Sheet http://thermofisher.com/role/LeasesNarrativeDetails Leases- Narrative (Details) Details 77 false false R78.htm 9954521 - Disclosure - Leases - Schedule of Operating Leases (Details) Sheet http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails Leases - Schedule of Operating Leases (Details) Details 78 false false R79.htm 9954522 - Disclosure - Leases - Schedule of Future Payments of Operating Lease Liabilities (Details) Sheet http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails Leases - Schedule of Future Payments of Operating Lease Liabilities (Details) Details 79 false false R80.htm 9954523 - Disclosure - Commitments and Contingencies (Details) Sheet http://thermofisher.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://thermofisher.com/role/CommitmentsandContingencies 80 false false R81.htm 9954524 - Disclosure - Comprehensive Income and Shareholders' Equity (Details) Sheet http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails Comprehensive Income and Shareholders' Equity (Details) Details http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityTables 81 false false R82.htm 9954525 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) Details 82 false false R83.htm 9954526 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Rollforward of the Fair Value of Investments (Details) Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails Fair Value Measurements and Fair Value of Financial Instruments - Rollforward of the Fair Value of Investments (Details) Details 83 false false R84.htm 9954527 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Aggregate Notional Value and Fair Value of Derivative Instruments (Details) Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Aggregate Notional Value and Fair Value of Derivative Instruments (Details) Details 84 false false R85.htm 9954528 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Derivative Instruments, Gain (Loss) Recognized (Details) Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Derivative Instruments, Gain (Loss) Recognized (Details) Details 85 false false R86.htm 9954529 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of the Company's Debt Instruments (Details) Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of the Company's Debt Instruments (Details) Details 86 false false R87.htm 9954530 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Disclosures (Details) Sheet http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Disclosures (Details) Details 87 false false R88.htm 9954531 - Disclosure - Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Details 88 false false R89.htm 9954532 - Disclosure - Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) Sheet http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) Details 89 false false R90.htm 9954533 - Disclosure - Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) Sheet http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1 Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) Details 90 false false All Reports Book All Reports tmo-20231231.htm tmo-20231231.xsd tmo-20231231_cal.xml tmo-20231231_def.xml tmo-20231231_lab.xml tmo-20231231_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 117 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tmo-20231231.htm": { "nsprefix": "tmo", "nsuri": "http://thermofisher.com/20231231", "dts": { "inline": { "local": [ "tmo-20231231.htm" ] }, "schema": { "local": [ "tmo-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "tmo-20231231_cal.xml" ] }, "definitionLink": { "local": [ "tmo-20231231_def.xml" ] }, "labelLink": { "local": [ "tmo-20231231_lab.xml" ] }, "presentationLink": { "local": [ "tmo-20231231_pre.xml" ] } }, "keyStandard": 557, "keyCustom": 36, "axisStandard": 40, "axisCustom": 1, "memberStandard": 75, "memberCustom": 99, "hidden": { "total": 30, "http://fasb.org/us-gaap/2023": 23, "http://xbrl.sec.gov/ecd/2023": 3, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 693, "entityCount": 1, "segmentCount": 193, "elementCount": 1070, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 2104, "http://xbrl.sec.gov/dei/2023": 86, "http://xbrl.sec.gov/ecd/2023": 24 }, "report": { "R1": { "role": "http://thermofisher.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://thermofisher.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://thermofisher.com/role/ConsolidatedBalanceSheet", "longName": "0000003 - Statement - Consolidated Balance Sheet", "shortName": "Consolidated Balance Sheet", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R4": { "role": "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical", "longName": "0000004 - Statement - Consolidated Balance Sheet (Parenthetical)", "shortName": "Consolidated Balance Sheet (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R5": { "role": "http://thermofisher.com/role/ConsolidatedStatementofIncome", "longName": "0000005 - Statement - Consolidated Statement of Income", "shortName": "Consolidated Statement of Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R6": { "role": "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome", "longName": "0000006 - Statement - Consolidated Statement of Comprehensive Income", "shortName": "Consolidated Statement of Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R7": { "role": "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncomeParenthetical", "longName": "0000007 - Statement - Consolidated Statement of Comprehensive Income (Parenthetical)", "shortName": "Consolidated Statement of Comprehensive Income (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://thermofisher.com/role/ConsolidatedStatementofCashFlows", "longName": "0000008 - Statement - Consolidated Statement of Cash Flows", "shortName": "Consolidated Statement of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncreaseDecreaseInDeferredIncomeTaxes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R9": { "role": "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity", "longName": "0000009 - Statement - Consolidated Statement of Redeemable Noncontrolling Interest and Equity", "shortName": "Consolidated Statement of Redeemable Noncontrolling Interest and Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-32", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-32", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquityParenthetical", "longName": "0000010 - Statement - Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Parenthetical)", "shortName": "Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies", "longName": "0000011 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies", "shortName": "Nature of Operations and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://thermofisher.com/role/Acquisitions", "longName": "0000012 - Disclosure - Acquisitions", "shortName": "Acquisitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://thermofisher.com/role/RevenueandContractrelatedBalances", "longName": "0000013 - Disclosure - Revenue and Contract-related Balances", "shortName": "Revenue and Contract-related Balances", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://thermofisher.com/role/BusinessSegmentandGeographicalInformation", "longName": "0000014 - Disclosure - Business Segment and Geographical Information", "shortName": "Business Segment and Geographical Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://thermofisher.com/role/OtherIncomeExpense", "longName": "0000015 - Disclosure - Other Income/Expense", "shortName": "Other Income/Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://thermofisher.com/role/StockbasedCompensationExpense", "longName": "0000016 - Disclosure - Stock-based Compensation Expense", "shortName": "Stock-based Compensation Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlans", "longName": "0000017 - Disclosure - Pension and Other Postretirement Benefit Plans", "shortName": "Pension and Other Postretirement Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://thermofisher.com/role/IncomeTaxes", "longName": "0000018 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://thermofisher.com/role/EarningsPerShare", "longName": "0000019 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://thermofisher.com/role/DebtandOtherFinancingArrangements", "longName": "0000020 - Disclosure - Debt and Other Financing Arrangements", "shortName": "Debt and Other Financing Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://thermofisher.com/role/Leases", "longName": "0000021 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://thermofisher.com/role/CommitmentsandContingencies", "longName": "0000022 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquity", "longName": "0000023 - Disclosure - Comprehensive Income and Shareholders Equity", "shortName": "Comprehensive Income and Shareholders Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstruments", "longName": "0000024 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://thermofisher.com/role/SupplementalCashFlowInformation", "longName": "0000025 - Disclosure - Supplemental Cash Flow Information", "shortName": "Supplemental Cash Flow Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://thermofisher.com/role/RestructuringandOtherCosts", "longName": "0000026 - Disclosure - Restructuring and Other Costs", "shortName": "Restructuring and Other Costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-684", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-684", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies)", "shortName": "Nature of Operations and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Tables)", "shortName": "Nature of Operations and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R30": { "role": "http://thermofisher.com/role/AcquisitionsTables", "longName": "9954473 - Disclosure - Acquisitions (Tables)", "shortName": "Acquisitions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://thermofisher.com/role/RevenueandContractrelatedBalancesTables", "longName": "9954474 - Disclosure - Revenue and Contract-related Balances (Tables)", "shortName": "Revenue and Contract-related Balances (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationTables", "longName": "9954475 - Disclosure - Business Segment and Geographical Information (Tables)", "shortName": "Business Segment and Geographical Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://thermofisher.com/role/StockbasedCompensationExpenseTables", "longName": "9954476 - Disclosure - Stock-based Compensation Expense (Tables)", "shortName": "Stock-based Compensation Expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R34": { "role": "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables", "longName": "9954477 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)", "shortName": "Pension and Other Postretirement Benefit Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://thermofisher.com/role/IncomeTaxesTables", "longName": "9954478 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R36": { "role": "http://thermofisher.com/role/EarningsPerShareTables", "longName": "9954479 - Disclosure - Earnings Per Share (Tables)", "shortName": "Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R37": { "role": "http://thermofisher.com/role/DebtandOtherFinancingArrangementsTables", "longName": "9954480 - Disclosure - Debt and Other Financing Arrangements (Tables)", "shortName": "Debt and Other Financing Arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://thermofisher.com/role/LeasesTables", "longName": "9954481 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityTables", "longName": "9954482 - Disclosure - Comprehensive Income and Shareholders Equity (Tables)", "shortName": "Comprehensive Income and Shareholders Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables", "longName": "9954483 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R41": { "role": "http://thermofisher.com/role/SupplementalCashFlowInformationTables", "longName": "9954484 - Disclosure - Supplemental Cash Flow Information (Tables)", "shortName": "Supplemental Cash Flow Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R42": { "role": "http://thermofisher.com/role/RestructuringandOtherCostsTables", "longName": "9954485 - Disclosure - Restructuring and Other Costs (Tables)", "shortName": "Restructuring and Other Costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R43": { "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails", "longName": "9954486 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Additional Accounting Policy and Balance Sheet Disclosures (Details)", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Additional Accounting Policy and Balance Sheet Disclosures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R44": { "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "longName": "9954487 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Inventories (Details)", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails", "longName": "9954488 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R46": { "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails", "longName": "9954489 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details)", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R47": { "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "longName": "9954490 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Goodwill (Details)", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-22", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-31", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R48": { "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails", "longName": "9954491 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "longName": "9954492 - Disclosure - Acquisitions - Narrative (Details)", "shortName": "Acquisitions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R50": { "role": "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "longName": "9954493 - Disclosure - Acquisitions - Schedule of Components of Purchase Price (Details)", "shortName": "Acquisitions - Schedule of Components of Purchase Price (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-133", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R51": { "role": "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails", "longName": "9954494 - Disclosure - Acquisitions - Schedule of Pro Forma Information (Details)", "shortName": "Acquisitions - Schedule of Pro Forma Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-187", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-187", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R52": { "role": "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails", "longName": "9954495 - Disclosure - Revenue & Contract-related Balances - Disaggregation of Revenue (Details)", "shortName": "Revenue & Contract-related Balances - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-195", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R53": { "role": "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails", "longName": "9954496 - Disclosure - Revenue & Contract-related Balances - Revenue Performance Obligations (Details)", "shortName": "Revenue & Contract-related Balances - Revenue Performance Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-7", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-7", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R54": { "role": "http://thermofisher.com/role/RevenueContractrelatedBalancesContractAssetsandLiabilitiesDetails", "longName": "9954497 - Disclosure - Revenue & Contract-related Balances - Contract Assets and Liabilities (Details)", "shortName": "Revenue & Contract-related Balances - Contract Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:ContractWithCustomerAssetNetNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R55": { "role": "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "longName": "9954498 - Disclosure - Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details)", "shortName": "Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R56": { "role": "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails", "longName": "9954499 - Disclosure - Business Segment and Geographical Information - Schedule of Revenue by Geographical Areas (Details)", "shortName": "Business Segment and Geographical Information - Schedule of Revenue by Geographical Areas (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:NoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R57": { "role": "http://thermofisher.com/role/OtherIncomeExpenseDetails", "longName": "9954500 - Disclosure - Other Income/Expense (Details)", "shortName": "Other Income/Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GainLossOnInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GainLossOnInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R58": { "role": "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "longName": "9954501 - Disclosure - Stock-based Compensation Expense - Narrative (Details)", "shortName": "Stock-based Compensation Expense - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R59": { "role": "http://thermofisher.com/role/StockbasedCompensationExpenseScheduleofWeightedAverageAssumptionsusedintheBlackScholesOptionPricingModelDetails", "longName": "9954502 - Disclosure - Stock-based Compensation Expense - Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model (Details)", "shortName": "Stock-based Compensation Expense - Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R60": { "role": "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails", "longName": "9954503 - Disclosure - Stock-based Compensation Expense - Summary of the Company's Option Activity (Details)", "shortName": "Stock-based Compensation Expense - Summary of the Company's Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-22", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-22", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R61": { "role": "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails", "longName": "9954504 - Disclosure - Stock-based Compensation Expense - Summary of the Company's Restricted Unit Activity (Details)", "shortName": "Stock-based Compensation Expense - Summary of the Company's Restricted Unit Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-22", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R62": { "role": "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "longName": "9954505 - Disclosure - Pensions and Other Postretirement Benefit Plans - Narrative (Details)", "shortName": "Pensions and Other Postretirement Benefit Plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R63": { "role": "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails", "longName": "9954506 - Disclosure - Pensions and Other Postretirement Benefit Plans - Reconciliation of Benefit Obligations and Plan Assets (Details)", "shortName": "Pensions and Other Postretirement Benefit Plans - Reconciliation of Benefit Obligations and Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-268", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-268", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R64": { "role": "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "longName": "9954507 - Disclosure - Pensions and Other Postretirement Benefit Plans - Actuarial Assumptions (Details)", "shortName": "Pensions and Other Postretirement Benefit Plans - Actuarial Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-268", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-268", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R65": { "role": "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails", "longName": "9954508 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation and Fair Value of Plan Assets (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation and Fair Value of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R66": { "role": "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "longName": "9954509 - Disclosure - Pension and Other Postretirement Benefit Plans - Schedule of Estimated Future Benefit Payments (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Schedule of Estimated Future Benefit Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-268", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-268", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R67": { "role": "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "longName": "9954510 - Disclosure - Pension and Other Postretirement Benefit Plans - Schedule of Fair Value of the Company's Plan Assets (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Schedule of Fair Value of the Company's Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-268", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-314", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R68": { "role": "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails", "longName": "9954511 - Disclosure - Income Taxes - Components of Income Before Provision for Income Taxes and Provision for Income Taxes (Details)", "shortName": "Income Taxes - Components of Income Before Provision for Income Taxes and Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R69": { "role": "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails", "longName": "9954512 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R70": { "role": "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "longName": "9954513 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "tmo:EffectiveIncomeTaxRateReconciliationForeignExchangeLossOnDebtRefinancingNetOfExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R71": { "role": "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails", "longName": "9954514 - Disclosure - Income Taxes - Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance (Details)", "shortName": "Income Taxes - Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-21", "name": "tmo:DeferredTaxLiabilitiesDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "tmo:DeferredTaxLiabilitiesDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R72": { "role": "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails", "longName": "9954515 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-22", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R73": { "role": "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails", "longName": "9954516 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "shortName": "Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R74": { "role": "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "longName": "9954517 - Disclosure - Debt and Other Financing Arrangements - Schedule of Debt (Details)", "shortName": "Debt and Other Financing Arrangements - Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R75": { "role": "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails", "longName": "9954518 - Disclosure - Debt and Other Financing Arrangements - Schedule of Annual Repayment Requirements for Debt Obligations (Details)", "shortName": "Debt and Other Financing Arrangements - Schedule of Annual Repayment Requirements for Debt Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R76": { "role": "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "longName": "9954519 - Disclosure - Debt and Other Financing Arrangements - Narrative (Details)", "shortName": "Debt and Other Financing Arrangements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R77": { "role": "http://thermofisher.com/role/LeasesNarrativeDetails", "longName": "9954520 - Disclosure - Leases- Narrative (Details)", "shortName": "Leases- Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-21", "name": "tmo:LesseeOperatingLeaseNumberOfLeasesWithGuaranteedResidualValue", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "tmo:LesseeOperatingLeaseNumberOfLeasesWithGuaranteedResidualValue", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R78": { "role": "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails", "longName": "9954521 - Disclosure - Leases - Schedule of Operating Leases (Details)", "shortName": "Leases - Schedule of Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R79": { "role": "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails", "longName": "9954522 - Disclosure - Leases - Schedule of Future Payments of Operating Lease Liabilities (Details)", "shortName": "Leases - Schedule of Future Payments of Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R80": { "role": "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "longName": "9954523 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-7", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-7", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R81": { "role": "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "longName": "9954524 - Disclosure - Comprehensive Income and Shareholders' Equity (Details)", "shortName": "Comprehensive Income and Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R82": { "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "longName": "9954525 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-625", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-625", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R83": { "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails", "longName": "9954526 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Rollforward of the Fair Value of Investments (Details)", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Rollforward of the Fair Value of Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-633", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-634", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R84": { "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "longName": "9954527 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Aggregate Notional Value and Fair Value of Derivative Instruments (Details)", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Aggregate Notional Value and Fair Value of Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-646", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-646", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R85": { "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "longName": "9954528 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Derivative Instruments, Gain (Loss) Recognized (Details)", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Derivative Instruments, Gain (Loss) Recognized (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-677", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-677", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R86": { "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails", "longName": "9954529 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of the Company's Debt Instruments (Details)", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of the Company's Debt Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R87": { "role": "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails", "longName": "9954530 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Disclosures (Details)", "shortName": "Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Disclosures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R88": { "role": "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails", "longName": "9954531 - Disclosure - Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "shortName": "Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } }, "R89": { "role": "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails", "longName": "9954532 - Disclosure - Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details)", "shortName": "Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-1", "name": "tmo:RestructuringAndRelatedCostPercentageOfTotalWorkforceEliminated", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "tmo:RestructuringAndRelatedCostPercentageOfTotalWorkforceEliminated", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true, "unique": true } }, "R90": { "role": "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1", "longName": "9954533 - Disclosure - Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details)", "shortName": "Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-22", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-32", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tmo-20231231.htm", "unique": true } } }, "tag": { "tmo_A1.45SeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "A1.45SeniorNotesDue2027Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.450% Notes due 2027", "verboseLabel": "1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)", "label": "1.45% Senior Notes Due 2027 [Member]", "documentation": "1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r50", "r1121" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, less allowances of $193 and $189", "verboseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r431", "r432" ] }, "us-gaap_AccrualForEnvironmentalLossContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccrualForEnvironmentalLossContingencies", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental liability", "label": "Accrual for Environmental Loss Contingencies", "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies." } } }, "auth_ref": [ "r499", "r1090", "r1221", "r1222", "r1272", "r1277" ] }, "us-gaap_AccrualForEnvironmentalLossContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccrualForEnvironmentalLossContingenciesDisclosureAbstract", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrual for Environmental Loss Contingencies Disclosure [Abstract]", "label": "Accrual for Environmental Loss Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and other postretirement benefit liability adjustment", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r10", "r30", "r64", "r1240", "r1241", "r1242" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r103", "r307", "r897" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized losses on hedging instruments", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r326", "r336", "r337", "r769", "r1082", "r1240" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r335", "r336", "r826", "r828", "r829", "r830", "r831", "r833" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income/(loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r63", "r64", "r206", "r316", "r892", "r936", "r940" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r335", "r336", "r826", "r828", "r829", "r830", "r831", "r833" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Items", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r6", "r30", "r64", "r779", "r782", "r863", "r931", "r932", "r1240", "r1241", "r1242", "r1250", "r1251", "r1252" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation adjustment", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r8", "r30", "r64", "r336", "r337", "r828", "r829", "r830", "r831", "r833", "r1240" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average amortization period", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r228" ] }, "us-gaap_AcquisitionRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquisitionRelatedCostsMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-recurring Pro Forma Adjustments, Transaction Costs", "label": "Acquisition-related Costs [Member]", "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information)." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r1178" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in excess of par value", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r198" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in Excess of Par Value", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r709", "r710", "r711", "r955", "r1250", "r1251", "r1252", "r1315", "r1346" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r1184" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r1184" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r1184" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r1184" ] }, "us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForChangeInAccountingPrincipleAxis", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Accounting Principle, Type [Axis]", "label": "Change in Accounting Principle, Type [Axis]", "documentation": "Information by type of change in accounting principle. Excludes change from amendment to accounting standards." } } }, "auth_ref": [ "r363", "r364", "r365", "r366", "r941" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Adjustments to Additional Paid in Capital, Other", "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r133", "r134", "r672" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1148", "r1160", "r1170", "r1196" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r1151", "r1163", "r1173", "r1199" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r1184" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AllCurrenciesDomain", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r1191" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r1155", "r1164", "r1174", "r1191", "r1200", "r1204", "r1212" ] }, "tmo_AllOtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "AllOtherCountriesMember", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "All Other Countries [Member]", "documentation": "All Other Countries" } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1210" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable Allowances", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r317", "r433", "r452" ] }, "us-gaap_AlternativeInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AlternativeInvestment", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments measured at NAV", "label": "Alternative Investment", "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund." } } }, "auth_ref": [ "r798", "r807" ] }, "tmo_AlternativeInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "AlternativeInvestmentsMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alternative investments", "label": "Alternative Investments [Member]", "documentation": "Alternative Investments [Member]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of acquisition-related intangible assets", "negatedLabel": "Amortization of acquisition-related intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r17", "r95", "r100" ] }, "tmo_AnalyticalInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "AnalyticalInstrumentsMember", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Analytical Instruments", "label": "Analytical Instruments [Member]", "documentation": "Analytical Instruments Segment" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive stock options excluded from diluted weighted averages shares (shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r390" ] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asia-Pacific", "label": "Asia Pacific [Member]" } } }, "auth_ref": [ "r1348", "r1349", "r1350", "r1351" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r270", "r311", "r354", "r401", "r416", "r422", "r441", "r508", "r509", "r511", "r512", "r513", "r515", "r517", "r519", "r520", "r765", "r770", "r812", "r886", "r998", "r1121", "r1137", "r1284", "r1285", "r1327" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r302", "r321", "r354", "r441", "r508", "r509", "r511", "r512", "r513", "r515", "r517", "r519", "r520", "r765", "r770", "r812", "r1121", "r1284", "r1285", "r1327" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r178" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets [Abstract]", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "tmo_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://thermofisher.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1142", "r1143", "r1156" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://thermofisher.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r1142", "r1143", "r1156" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://thermofisher.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r1142", "r1143", "r1156" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1207" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1208" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1203" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1203" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1203" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1203" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1203" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r1203" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r676", "r677", "r678", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r700", "r701", "r702", "r703", "r704" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1206" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1205" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1204" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r1204" ] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and improvements", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r757", "r1108", "r1111" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r141", "r143", "r757", "r1108", "r1111" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r757" ] }, "us-gaap_BusinessAcquisitionProFormaInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationAbstract", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Pro Forma Information [Abstract]", "label": "Business Acquisition, Pro Forma Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]", "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]", "documentation": "Schedule of the nature and amount of any material, nonrecurring adjustments directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information)." } } }, "auth_ref": [ "r37" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://thermofisher.com/role/AcquisitionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Pro Forma Information", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r1233", "r1234" ] }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill recorded", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes." } } }, "auth_ref": [ "r152" ] }, "tmo_BusinessAcquisitionSharePriceExpected": { "xbrltype": "perShareItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "BusinessAcquisitionSharePriceExpected", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected price per share (dollars per share)", "label": "Business Acquisition, Share Price, Expected", "documentation": "Business Acquisition, Share Price, Expected" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income attributable to Thermo Fisher Scientific Inc.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r755", "r756" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r755", "r756" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total purchase price", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r2", "r3", "r24" ] }, "us-gaap_BusinessCombinationConsiderationTransferredAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredAbstract", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Price", "label": "Business Combination, Consideration Transferred [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of equity awards exchanged", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": [ "r2", "r3" ] }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt settled", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": [ "r2", "r3", "r150", "r762" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r4", "r151", "r763" ] }, "us-gaap_BusinessCombinationPriceOfAcquisitionExpected": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationPriceOfAcquisitionExpected", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected acquisition price", "label": "Business Combination, Price of Acquisition, Expected", "documentation": "Purchase price of expected business acquisition prior to consideration being transferred. Excludes asset acquisition." } } }, "auth_ref": [ "r1224" ] }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pro forma losses", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r142" ] }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pro forma revenues", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r142" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "crdr": "credit", "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance lease liabilities", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "documentation": "Amount of lease obligation assumed in business combination." } } }, "auth_ref": [ "r145" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r145" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "crdr": "debit", "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r145" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "crdr": "credit", "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Contract liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r145" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r145" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred tax assets (liabilities)", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r145" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Definite-lived intangible assets:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r144", "r145" ] }, "tmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetTangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetTangibleAssets", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net tangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Tangible Assets", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Tangible Assets" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "crdr": "credit", "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt", "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r145" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r145" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r144", "r145" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total net assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r145" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Assets Acquired [Abstract]", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]" } } }, "auth_ref": [] }, "tmo_BusinessCombinationRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "BusinessCombinationRedeemableNoncontrollingInterest", "crdr": "credit", "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Redeemable noncontrolling interest", "label": "Business Combination, Redeemable noncontrolling interest", "documentation": "Redeemable noncontrolling interest assumed in a business combination" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r140" ] }, "tmo_BusinessesSoldMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "BusinessesSoldMember", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Businesses Sold", "label": "Businesses Sold [Member]", "documentation": "Businesses Sold" } } }, "auth_ref": [] }, "currency_CHF": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "CHF", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross-currency interest rate swaps designated as net investment hedge - Swiss franc", "label": "Switzerland, Francs" } } }, "auth_ref": [] }, "tmo_CSLMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "CSLMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lengnau biologics manufacturing facility", "label": "CSL [Member]", "documentation": "CSL" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired but unpaid property, plant and equipment", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r75", "r76", "r77" ] }, "tmo_CapitalLossMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "CapitalLossMember", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Loss", "label": "Capital Loss [Member]", "documentation": "Capital Loss" } } }, "auth_ref": [] }, "us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAcquiredInExcessOfPaymentsToAcquireBusiness", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash acquired", "label": "Cash Acquired in Excess of Payments to Acquire Business", "documentation": "The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r72", "r305", "r1076" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r73" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows", "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year", "totalLabel": "Cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r72", "r221", "r351" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "(Decrease) increase in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r5", "r221" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r165" ] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r218" ] }, "us-gaap_CashSurrenderValueFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashSurrenderValueFairValueDisclosure", "crdr": "debit", "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance contracts", "label": "Cash Surrender Value, Fair Value Disclosure", "documentation": "Fair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI)." } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingPrincipleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleMember", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Accounting Principle, Type [Domain]", "label": "Change in Accounting Principle, Type [Domain]", "documentation": "Change in accounting principle. Excludes change from amendment to accounting standards." } } }, "auth_ref": [ "r363", "r364", "r365", "r366", "r941" ] }, "us-gaap_ChangeInAccountingPrincipleOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleOtherMember", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Accounting Principle, Other", "label": "Change in Accounting Principle, Other [Member]", "documentation": "Change in accounting principle, classified as other. Excludes change from amendment to accounting standards." } } }, "auth_ref": [ "r1228", "r1229", "r1230", "r1231", "r1253" ] }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedged long-term obligations - included in other income/(expense)", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement." } } }, "auth_ref": [ "r265" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r1182" ] }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Benefit Obligations and Plan Assets", "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans." } } }, "auth_ref": [ "r44" ] }, "tmo_ChargeForExpiredTaxCreditsDueToAuditSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "ChargeForExpiredTaxCreditsDueToAuditSettlement", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charge for expired tax credits", "label": "Charge for Expired Tax Credits due to Audit Settlement", "documentation": "Charge for Expired Tax Credits due to Audit Settlement" } } }, "auth_ref": [] }, "tmo_ChargesForCashCompensationDueToEmployeesOfAcquiredBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "ChargesForCashCompensationDueToEmployeesOfAcquiredBusinesses", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Cash compensation charges", "label": "Charges For Cash Compensation Due To Employees Of Acquired Businesses", "documentation": "Charges For Cash Compensation Due To Employees Of Acquired Businesses" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r294", "r313", "r314", "r315", "r354", "r380", "r384", "r387", "r389", "r395", "r396", "r441", "r508", "r511", "r512", "r513", "r519", "r520", "r552", "r553", "r555", "r558", "r564", "r812", "r947", "r948", "r949", "r950", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r985", "r1007", "r1027", "r1051", "r1052", "r1053", "r1054", "r1055", "r1220", "r1246", "r1254" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1183" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r1183" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper Programs", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r239", "r1128", "r1129", "r1130", "r1133" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r58", "r188", "r889", "r984" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r237", "r492", "r494", "r1059", "r1276" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r110", "r1060" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unissued shares of common stock (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r59" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends declared per common share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r243" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity", "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, $1.00 par value", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1124", "r1125", "r1126", "r1128", "r1129", "r1130", "r1133", "r1250", "r1251", "r1315", "r1343", "r1346" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, $1 Par Value - Par Value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r197" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, $1 Par Value - Shares Authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r197", "r985" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, $1 Par Value - Shares Issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r197" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r31", "r197", "r985", "r1004", "r1346", "r1347" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $1 par value, 1,200,000,000 shares authorized; 442,188,634 and 440,668,112 shares issued", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r197", "r891", "r1121" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r1188" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r1187" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r1189" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r1186" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets (Liabilities) [Abstract]", "label": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]", "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income attributable to Thermo Fisher Scientific Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r65", "r331", "r333", "r342", "r882", "r906" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r14", "r155", "r160", "r331", "r333", "r341", "r881", "r905" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r160", "r261", "r331", "r333", "r340", "r880", "r904" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r358", "r403", "r414", "r415", "r416", "r417", "r418", "r420", "r424", "r508", "r509", "r510", "r511", "r513", "r514", "r516", "r518", "r519", "r1284", "r1285" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r358", "r403", "r414", "r415", "r416", "r417", "r418", "r420", "r424", "r508", "r509", "r510", "r511", "r513", "r514", "r516", "r518", "r519", "r1284", "r1285" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r156", "r1083" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "tmo_ConsumablesMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "ConsumablesMember", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consumables", "label": "Consumables [Member]", "documentation": "Consumable, single-use products" } } }, "auth_ref": [] }, "tmo_ContingentConsiderationLiabilitiesFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "ContingentConsiderationLiabilitiesFairValueDisclosures", "crdr": "credit", "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Contingent Consideration Liabilities, Fair Value Disclosures", "documentation": "Fair value of contingent consideration liability." } } }, "auth_ref": [] }, "tmo_ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "ContingentConsiderationMember", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration", "label": "Contingent Consideration [Member]", "documentation": "Contingent Consideration [Member]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://thermofisher.com/role/RevenueandContractrelatedBalancesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Contract-related Balances", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r1289" ] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/RevenueContractrelatedBalancesContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract assets, net", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r566", "r568", "r587" ] }, "us-gaap_ContractWithCustomerAssetNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetNoncurrent", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent contract assets, net", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent." } } }, "auth_ref": [ "r566", "r568", "r587" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/RevenueContractrelatedBalancesContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r566", "r567", "r587" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent contract liabilities", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r566", "r567", "r587" ] }, "tmo_CorEvitasLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "CorEvitasLLCMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CorEvitas, LLC", "label": "CorEvitas, LLC [Member]", "documentation": "CorEvitas, LLC" } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r41", "r415", "r416", "r417", "r418", "r424", "r1257" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenues", "negatedTerseLabel": "Cost of goods and services sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r213", "r872" ] }, "tmo_CostOfRevenuesCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "CostOfRevenuesCharges", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cost of revenues adjustments", "label": "Cost Of Revenues Charges", "documentation": "Certain charges to cost of revenues primarily for 1) the sale of inventories revalued at fair value at the date of acquisition and 2) accelerated depreciation at facilities closing due to facility consolidations." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs and operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r210" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and operating expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Costs", "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation." } } }, "auth_ref": [ "r107", "r235", "r236" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CrossCurrencyInterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CrossCurrencyInterestRateContractMember", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross-currency interest rate swaps - designated as net investment hedges", "label": "Cross Currency Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates." } } }, "auth_ref": [ "r1293", "r1314" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CurrencyAxis", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]" } } }, "auth_ref": [ "r1322" ] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1236", "r1249", "r1310" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-U.S.", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1236", "r1249" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Current income tax provision", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r257", "r740", "r748", "r1249" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current income tax provision", "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1236", "r1249", "r1310" ] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r149" ] }, "tmo_DebtCovenantMinimumConsolidatedInterestCoverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "DebtCovenantMinimumConsolidatedInterestCoverageRatio", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum consolidated net interest coverage ratio", "label": "Debt, Covenant, Minimum Consolidated Interest Coverage Ratio", "documentation": "Minimum permitted Consolidated Interest Coverage Ratio (the ratio of Consolidated EBITDA to Consolidated Interest Expense) as defined in the debt or line of credit facility agreements." } } }, "auth_ref": [] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term obligations and current maturities of long-term obligations", "verboseLabel": "Less: Short-term obligations and current maturities", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r312" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Debt and Other Financing Arrangements", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r238", "r352", "r521", "r527", "r528", "r529", "r530", "r531", "r532", "r537", "r544", "r545", "r547" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r47", "r193", "r194", "r271", "r273", "r358", "r522", "r523", "r524", "r525", "r526", "r528", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r543", "r840", "r1091", "r1092", "r1093", "r1094", "r1095", "r1247" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total borrowings at par value", "totalLabel": "Total borrowings at par value", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r47", "r273", "r548" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r535", "r811", "r1092", "r1093" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r55", "r184", "r550", "r840" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r55", "r523" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r358", "r522", "r523", "r524", "r525", "r526", "r528", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r543", "r546", "r840", "r1091", "r1092", "r1093", "r1094", "r1095", "r1247" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r56", "r358", "r522", "r523", "r524", "r525", "r526", "r528", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r543", "r840", "r1091", "r1092", "r1093", "r1094", "r1095", "r1247" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption price", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r40" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r56", "r118", "r119", "r183", "r184", "r187", "r189", "r241", "r242", "r358", "r522", "r523", "r524", "r525", "r526", "r528", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r543", "r546", "r840", "r1091", "r1092", "r1093", "r1094", "r1095", "r1247" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unamortized discount", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": [ "r183", "r184", "r185", "r186", "r187", "r1287" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1249", "r1309", "r1310" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unamortized debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r185", "r1287" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-U.S.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r257", "r1249", "r1309" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred income tax provision (benefit)", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r17", "r257", "r291", "r747", "r748", "r1249" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax provision (benefit)", "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r723", "r724", "r887" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1249", "r1309", "r1310" ] }, "us-gaap_DeferredTaxAssetDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetDomain", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Asset [Domain]", "label": "Deferred Tax Asset [Domain]", "documentation": "Identification of the deferred tax asset for which a valuation reserve exists." } } }, "auth_ref": [ "r136" ] }, "us-gaap_DeferredTaxAssetInterestCarryforward": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetInterestCarryforward", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred interest", "label": "Deferred Tax Asset, Interest Carryforward", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward." } } }, "auth_ref": [ "r1308" ] }, "tmo_DeferredTaxAssetInterestCarryforwardMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "DeferredTaxAssetInterestCarryforwardMember", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Interest Carryforward", "label": "Deferred Tax Asset, Interest Carryforward [Member]", "documentation": "Deferred Tax Asset, Interest Carryforward" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development and other capitalized costs", "label": "Deferred Tax Assets, in Process Research and Development", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r139", "r1308" ] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory basis difference", "label": "Deferred Tax Assets, Inventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r139", "r1308" ] }, "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets/(liabilities), net before valuation allowance", "label": "Deferred Tax Assets (Liabilities) Before Valuation Allowance", "documentation": "For entities that net deferred tax assets and tax liabilities, represents the unclassified net amount of deferred tax assets, before any related valuation allowance, and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities. A temporary difference is a difference between the tax basis of an asset or liability and its carrying amount in the financial statements prepared in accordance with generally accepted accounting principles that will reverse in ensuing periods." } } }, "auth_ref": [] }, "tmo_DeferredTaxAssetsLiabilitiesHedgingTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "DeferredTaxAssetsLiabilitiesHedgingTransactions", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized (gains) losses on hedging instruments", "label": "Deferred Tax Assets (Liabilities), Hedging Transactions", "documentation": "Amount before allocation of valuation allowances of deferred tax asset (liability) attributable to unrealized losses (gains) from hedging transactions." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r139", "r1308" ] }, "us-gaap_DeferredTaxAssetsOtherTaxCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOtherTaxCarryforwards", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss and credit carryforwards", "label": "Deferred Tax Assets, Other Tax Carryforwards", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other." } } }, "auth_ref": [ "r139", "r1308" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs." } } }, "auth_ref": [ "r139", "r1308" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reserves and accruals", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r139", "r1308" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r736" ] }, "tmo_DeferredTaxAssetsValuationAllowanceIncreaseChargedToIncomeTaxProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "DeferredTaxAssetsValuationAllowanceIncreaseChargedToIncomeTaxProvision", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions (reductions) charged to income tax provision, net", "label": "Deferred Tax Assets Valuation Allowance, Increase Charged To Income Tax Provision", "documentation": "Amount of increase in deferred tax valuation allowance resulting from amounts charged to income tax expense." } } }, "auth_ref": [] }, "tmo_DeferredTaxAssetsValuationAllowanceIncreaseDecreaseResultingFromCurrencyTranslationAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "DeferredTaxAssetsValuationAllowanceIncreaseDecreaseResultingFromCurrencyTranslationAndOther", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation and other", "label": "Deferred Tax Assets Valuation Allowance, Increase (Decrease) Resulting From Currency Translation And Other", "documentation": "Amount of increase (decrease) in deferred tax valuation allowance resulting from currency translation and other." } } }, "auth_ref": [] }, "tmo_DeferredTaxAssetsValuationAllowanceIncreaseResultingfromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "DeferredTaxAssetsValuationAllowanceIncreaseResultingfromAcquisition", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions due to acquisitions", "label": "Deferred Tax Assets Valuation Allowance, Increase Resulting from Acquisition", "documentation": "Amount of increase in deferred tax valuation allowance resulting from acquisitions." } } }, "auth_ref": [] }, "tmo_DeferredTaxImplicationsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "DeferredTaxImplicationsMember", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Implications", "label": "Deferred Tax Implications [Member]", "documentation": "Deferred Tax Implications" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Deferred tax assets/(liabilities), net", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r135", "r1307" ] }, "tmo_DeferredTaxLiabilitiesDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization", "crdr": "credit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Depreciation and amortization", "label": "Deferred Tax Liabilities, Depreciation and Amortization", "documentation": "The amount as of the balance sheet date of the estimated future tax effects attributable to the difference between the tax basis of long-lived assets, including property, plant and equipment and intangible assets, and the basis of long-lived assets computed in accordance with generally accepted accounting principles. The basis difference, whether due to impairment charges or other reasons, will increase future taxable income when it reverses." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated benefit obligation", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level." } } }, "auth_ref": [ "r623" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "crdr": "debit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net amount recognized", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r11", "r64", "r1295" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts recognized in accumulated other comprehensive items", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "crdr": "credit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net actuarial loss", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": [ "r64", "r635" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "crdr": "debit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior service credits", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r64", "r635" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual return on plan assets", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses." } } }, "auth_ref": [ "r605", "r1106" ] }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Actuarial (gains) losses", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": [ "r598" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of actuarial net loss", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r592", "r630", "r656", "r1106", "r1107" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "crdr": "debit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of prior service cost (benefit)", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r592", "r631", "r657", "r1106", "r1107" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "crdr": "debit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net amount recognized", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r123", "r124" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts recognized in balance sheet", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "crdr": "debit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent assets", "label": "Assets for Plan Benefits, Defined Benefit Plan", "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r269", "r590", "r591", "r613", "r997", "r1106", "r1336" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate for determining benefit obligation", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r637" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average rate of increase in employee compensation", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r638" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest crediting rate for cash balance plans", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate", "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate." } } }, "auth_ref": [ "r640" ] }, "tmo_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRateServiceCost": { "xbrltype": "percentItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRateServiceCost", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate - service cost", "label": "Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate Service Cost", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine service cost component of net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected long-term rate of return on assets", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r639", "r661" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average rate of increase in employee compensation", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r638" ] }, "tmo_DefinedBenefitPlanAssumptionsUsedCalculatingPeriodicBenefitCostDiscountRateInterestCost": { "xbrltype": "percentItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingPeriodicBenefitCostDiscountRateInterestCost", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate - interest cost", "label": "Defined Benefit Plan Assumptions Used Calculating Periodic Benefit Cost Discount Rate Interest Cost", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine interest cost component of net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Projected benefit obligation at beginning of year", "periodEndLabel": "Projected benefit obligation at end of year", "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r593" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Benefits paid", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r600", "r664" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan participants' contributions", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation." } } }, "auth_ref": [ "r597" ] }, "us-gaap_DefinedBenefitPlanBusinessCombinationsAndAcquisitionsBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBusinessCombinationsAndAcquisitionsBenefitObligation", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Defined Benefit Plan, Benefit Obligation, Business Combination", "documentation": "Amount of increase in benefit obligation of defined benefit plan from business combination." } } }, "auth_ref": [ "r602" ] }, "us-gaap_DefinedBenefitPlanBusinessCombinationsAndAcquisitionsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBusinessCombinationsAndAcquisitionsPlanAssets", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Defined Benefit Plan, Plan Assets, Business Combination", "documentation": "Amount of increase in plan assets of defined benefit plan from business combination." } } }, "auth_ref": [ "r610" ] }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "documentation": "Information by defined benefit plan asset investment." } } }, "auth_ref": [ "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r642", "r1104", "r1105", "r1106" ] }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash / money market funds", "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested." } } }, "auth_ref": [ "r1104" ] }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in projected benefit obligations", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of plan assets", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contributions", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r607", "r617", "r660", "r1104", "r1105", "r1106", "r1107" ] }, "us-gaap_DefinedBenefitPlanDerivativeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDerivativeMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative funds", "label": "Defined Benefit Plan, Derivative [Member]", "documentation": "Financial instrument or other contract with one or more underlyings, notional amount or payment provision or both; can be settled net by means outside contract or delivery of asset; and with minimal or no initial net investment, in which defined benefit plan asset is invested." } } }, "auth_ref": [ "r1104" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payments [Abstract]", "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029-2033", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r624" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r624" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r624" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year." } } }, "auth_ref": [ "r624" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year." } } }, "auth_ref": [ "r624" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year." } } }, "auth_ref": [ "r624" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated contributions to plan", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r625", "r1107" ] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r592", "r629", "r655", "r1106", "r1107" ] }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value of plan assets at beginning of year", "periodEndLabel": "Fair value of plan assets at end of year", "terseLabel": "Fair value of plan assets", "label": "Defined Benefit Plan, Plan Assets, Amount", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": [ "r604", "r615", "r617", "r618", "r1104", "r1105", "r1106" ] }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Currency translation and other", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r599" ] }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanFundedStatusOfPlan", "crdr": "debit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Funded status", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status." } } }, "auth_ref": [ "r590", "r613", "r1106" ] }, "us-gaap_DefinedBenefitPlanInformationAboutPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanInformationAboutPlanAssetsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Information about Plan Assets [Abstract]", "label": "Defined Benefit Plan, Information about Plan Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest costs", "verboseLabel": "Interest cost on benefit obligation", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r592", "r596", "r628", "r654", "r1106", "r1107" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net periodic benefit cost (income)", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r626", "r652", "r1106", "r1107" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Net Periodic Benefit Cost (Income) [Abstract]", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible List]", "label": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes amortization of gain (loss) component of net periodic benefit (cost) credit for defined benefit plan." } } }, "auth_ref": [ "r626", "r652" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible List]", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes amortization of prior service cost (credit) component of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r626", "r652" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible List]", "label": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes expected return (loss) on plan asset component of net periodic benefit (cost) credit for defined benefit plan." } } }, "auth_ref": [ "r626", "r652" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible List]", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes interest cost component of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r626", "r652" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementAndCurtailmentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementAndCurtailmentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible List]", "label": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes settlement and curtailment gain (loss) component of net periodic benefit (cost) credit for defined benefit plan." } } }, "auth_ref": [ "r626", "r1298" ] }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of plan assets", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets", "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r649", "r1106" ] }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Projected benefit obligation", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r649", "r1106" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension plans with accumulated benefit obligations in excess of plan assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated benefit obligation", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r649", "r650", "r1106" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of plan assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r649", "r650", "r1106" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Benefits paid", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r609", "r1300" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan participants' contributions", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets." } } }, "auth_ref": [ "r608" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation and other", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan." } } }, "auth_ref": [ "r606" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Target allocations for investments", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": [ "r614", "r1106" ] }, "us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension plans with projected benefit obligations in excess of plan assets", "label": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanRealEstateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanRealEstateMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real estate funds", "label": "Defined Benefit Plan, Real Estate [Member]", "documentation": "Property composed of building, land and land improvement; in which defined benefit plan asset is invested." } } }, "auth_ref": [ "r1104", "r1106" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1", "crdr": "credit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlement/curtailment loss (gain)", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment." } } }, "auth_ref": [ "r1292", "r1294", "r1299" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service costs", "verboseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r594", "r627", "r653", "r1106", "r1107" ] }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Settlements", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement." } } }, "auth_ref": [ "r595" ] }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanSettlementsPlanAssets", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Settlements", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract." } } }, "auth_ref": [ "r612" ] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Assumptions Used to Determine Benefit Obligation [Abstract]", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost (Income) [Abstract]", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan expense", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r665" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation of property, plant and equipment", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r17", "r102" ] }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": [ "r772" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative contracts", "verboseLabel": "Fair value \u2013 assets", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r322", "r323", "r811", "r967", "r968", "r969", "r970", "r971", "r973", "r974", "r975", "r976", "r977", "r991", "r992", "r1041", "r1044", "r1045", "r1046", "r1047", "r1048", "r1081", "r1126", "r1344" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r975", "r977", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r999", "r1000", "r1001", "r1002", "r1014", "r1015", "r1016", "r1017", "r1020", "r1021", "r1022", "r1023", "r1041", "r1042", "r1045", "r1047", "r1124", "r1126" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Included in interest expense", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r1313" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r169", "r171", "r172", "r174", "r975", "r977", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r999", "r1000", "r1001", "r1002", "r1014", "r1015", "r1016", "r1017", "r1020", "r1021", "r1022", "r1023", "r1041", "r1042", "r1045", "r1047", "r1081", "r1124", "r1126" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r32", "r169", "r172" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r32", "r169", "r172", "r174", "r176", "r177", "r773" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r773" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative contracts", "verboseLabel": "Fair value \u2013 liabilities", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r322", "r323", "r811", "r967", "r968", "r969", "r970", "r973", "r974", "r975", "r976", "r977", "r999", "r1001", "r1002", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1081", "r1344" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r772" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1311", "r1312" ] }, "us-gaap_DerivativesAndFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesAndFairValueTextBlock", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments", "label": "Derivatives and Fair Value [Text Block]", "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities." } } }, "auth_ref": [ "r264", "r266" ] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Contracts", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r32", "r161", "r162", "r167", "r175", "r357" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives designated as hedging instruments", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r32" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product technology", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r259" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r586", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r586", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://thermofisher.com/role/RevenueandContractrelatedBalancesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1290" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpense" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation Expense", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r670", "r675", "r705", "r706", "r708", "r1115" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends declared", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r243" ] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Declared but unpaid dividends", "label": "Dividends Payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r194", "r195", "r272", "r1134", "r1337" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1142", "r1143", "r1156" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1142", "r1143", "r1156", "r1192" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1177" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference [Text Block]", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r1140" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "tmo_DomesticNOLExpiresMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "DomesticNOLExpiresMember", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic NOL Expires", "label": "Domestic NOL Expires [Member]", "documentation": "Domestic NOL Expires" } } }, "auth_ref": [] }, "us-gaap_DomesticPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticPlanMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic Plan", "label": "Domestic Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1301", "r1302", "r1303" ] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "EUR", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross-currency interest rate swaps designated as net investment hedge - euro", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share attributable to Thermo Fisher Scientific Inc.", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic Earnings Per Share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r343", "r367", "r368", "r369", "r370", "r371", "r377", "r380", "r387", "r388", "r389", "r393", "r795", "r796", "r883", "r907", "r1085" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted Earnings Per Share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r343", "r367", "r368", "r369", "r370", "r371", "r380", "r387", "r388", "r389", "r393", "r795", "r796", "r883", "r907", "r1085" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r80", "r81" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://thermofisher.com/role/EarningsPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r376", "r390", "r391", "r392" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange rate effect on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1318" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statutory federal income tax rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r356", "r726", "r750" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationFdiiAmount", "crdr": "credit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign-derived intangible income", "label": "Effective Income Tax Rate Reconciliation, FDII, Amount", "documentation": "Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)." } } }, "auth_ref": [ "r1305" ] }, "tmo_EffectiveIncomeTaxRateReconciliationForeignExchangeLossOnDebtRefinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationForeignExchangeLossOnDebtRefinancing", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange loss on inter-company debt refinancing", "label": "Effective Income Tax Rate Reconciliation, Foreign Exchange Loss On Debt Refinancing", "documentation": "Effective Income Tax Rate Reconciliation, Foreign Exchange Loss On Debt Refinancing" } } }, "auth_ref": [] }, "tmo_EffectiveIncomeTaxRateReconciliationForeignExchangeLossOnDebtRefinancingNetOfExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationForeignExchangeLossOnDebtRefinancingNetOfExpenses", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax benefit from foreign exchange loss on an intercompany debt refinancing transaction", "label": "Effective Income Tax Rate Reconciliation, Foreign Exchange Loss On Debt Refinancing, Net Of Expenses", "documentation": "Effective Income Tax Rate Reconciliation, Foreign Exchange Loss On Debt Refinancing, Net Of Expenses" } } }, "auth_ref": [] }, "tmo_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesAmount", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Withholding taxes", "label": "Effective Income Tax Rate Reconciliation, Foreign Withholding Taxes Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign withholding taxes." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationGiltiAmount", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global intangible low-taxed income", "label": "Effective Income Tax Rate Reconciliation, GILTI, Amount", "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)." } } }, "auth_ref": [ "r1305" ] }, "tmo_EffectiveIncomeTaxRateReconciliationProvisionForReversalOfTaxReservesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationProvisionForReversalOfTaxReservesNet", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for (reversal of) tax reserves, net", "label": "Effective Income Tax Rate Reconciliation, Provision For (Reversal Of) Tax Reserves, Net", "documentation": "Effective Income Tax Rate Reconciliation, Provision For (Reversal Of) Tax Reserves, Net" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess tax benefits from stock options and restricted stock units", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1225", "r1305" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and employee benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r53" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r707" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average amortization period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r707" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1139" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1139" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1139" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1217" ] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsLineItems", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listings [Line Items]", "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsTable", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listings [Table]", "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1139" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1139" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1139" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1139" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1218" ] }, "us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]", "label": "Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes accrual for environmental loss contingency." } } }, "auth_ref": [ "r498", "r1090" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r31", "r297", "r335", "r336", "r337", "r359", "r360", "r361", "r364", "r372", "r374", "r394", "r445", "r451", "r565", "r709", "r710", "r711", "r743", "r744", "r777", "r779", "r780", "r781", "r782", "r784", "r794", "r826", "r828", "r829", "r830", "r831", "r833", "r863", "r931", "r932", "r933", "r955", "r1027" ] }, "us-gaap_EquityFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityFundsMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity funds", "label": "Equity Funds [Member]", "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments." } } }, "auth_ref": [ "r1293" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r411", "r437", "r1239", "r1258" ] }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFVNINoncurrent", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of investments", "label": "Equity Securities, FV-NI, Noncurrent", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent." } } }, "auth_ref": [ "r810" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost method investments", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r436" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r1185" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r1148", "r1160", "r1170", "r1196" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r1145", "r1157", "r1167", "r1193" ] }, "tmo_EuroCommercialPaperProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "EuroCommercialPaperProgramMember", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro Commercial Paper Program", "label": "Euro Commercial Paper Program [Member]", "documentation": "Borrowings under the company's euro commercial paper program" } } }, "auth_ref": [] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]" } } }, "auth_ref": [ "r1348", "r1349", "r1350", "r1351" ] }, "tmo_EuropeanViralVectorManufacturingBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "EuropeanViralVectorManufacturingBusinessMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "European Viral Vector Business", "label": "European Viral Vector Manufacturing Business [Member]", "documentation": "European Viral Vector Manufacturing Business" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r1191" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r800", "r801", "r805" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r800", "r801", "r805" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r178", "r181", "r182" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r535", "r617", "r618", "r619", "r620", "r621", "r622", "r801", "r865", "r866", "r867", "r1092", "r1093", "r1104", "r1105", "r1106" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r180", "r267" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r800", "r801", "r802", "r803", "r806" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueHedgingMember", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedging", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": [ "r164" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r535", "r617", "r622", "r801", "r865", "r1104", "r1105", "r1106" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r535", "r617", "r622", "r801", "r866", "r1092", "r1093", "r1104", "r1105", "r1106" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r535", "r617", "r618", "r619", "r620", "r621", "r622", "r801", "r867", "r1092", "r1093", "r1104", "r1105", "r1106" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r34" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": [ "r34", "r180" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Rollforward of the Fair Value of Investments", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r34", "r180" ] }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measured at Net Asset Value Per Share", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "documentation": "Fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r617", "r798", "r806" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Changes in fair value included in earnings", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r804" ] }, "tmo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuancesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuancesNet", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions (including assumed balances)", "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances, Net", "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances, Net" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r179" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r34" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r535", "r617", "r618", "r619", "r620", "r621", "r622", "r865", "r866", "r867", "r1092", "r1093", "r1104", "r1105", "r1106" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r799", "r806" ] }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)." } } }, "auth_ref": [ "r804" ] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r168", "r170", "r176" ] }, "tmo_FederalAndStateMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "FederalAndStateMember", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal and State", "label": "Federal and State [Member]", "documentation": "Federal and State [Member]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r847", "r858" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029 and thereafter", "label": "Finance Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r858" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r858" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r858" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r858" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r858" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r858" ] }, "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease liability." } } }, "auth_ref": [ "r848" ] }, "us-gaap_FinancialGuaranteeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialGuaranteeMember", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Obligation Guarantee", "label": "Financial Guarantee [Member]", "documentation": "An agreement (contract) that requires the guarantor to make payments to the guaranteed party based on another entity's failure to pay specified obligations, such as debt, to a lender." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails_1": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r309", "r472" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029 and thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r230" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r230" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r230" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r230" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r230" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r469", "r471", "r472", "r474", "r873", "r877" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]", "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails_1": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Definite-lived intangible assets, gross", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r229", "r877" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r873" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r96", "r99" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Estimated future amortization expense of definite-lived intangible assets", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r229", "r873" ] }, "us-gaap_FixedIncomeFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FixedIncomeFundsMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed income funds", "label": "Fixed Income Funds [Member]", "documentation": "Investment that pools funds from investors to invest in a combination of underlying investments, primarily fixed income investments." } } }, "auth_ref": [ "r1293" ] }, "tmo_FloatingRate2YearSeniorNotesDue2023Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "FloatingRate2YearSeniorNotesDue2023Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)", "label": "Floating Rate 2 Year Senior Notes Due 2023 [Member]", "documentation": "Floating Rate 2 Year Senior Notes Due 2023" } } }, "auth_ref": [] }, "tmo_FloatingRateSOFR03518MonthSeniorNotesDue2023Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "FloatingRateSOFR03518MonthSeniorNotesDue2023Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023", "label": "Floating Rate SOFR +0.35% 18 Month Senior Notes Due 2023 [Member]", "documentation": "Floating Rate SOFR +0.35% 18 Month Senior Notes Due 2023" } } }, "auth_ref": [] }, "tmo_FloatingRateSOFR039SeniorNotesDue2023Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "FloatingRateSOFR039SeniorNotesDue2023Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023", "label": "Floating Rate SOFR +0.39% Senior Notes Due 2023 [Member]", "documentation": "Floating Rate SOFR +0.39% Senior Notes Due 2023" } } }, "auth_ref": [] }, "tmo_FloatingRateSOFR053SeniorNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "FloatingRateSOFR053SeniorNotesDue2024Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024", "label": "Floating Rate SOFR +0.53% Senior Notes Due 2024 [Member]", "documentation": "Floating Rate SOFR +0.53% Senior Notes Due 2024" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non- U.S.", "label": "Foreign Tax Authority [Member]", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "tmo_ForeignCountryNolExpiresMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "ForeignCountryNolExpiresMember", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion of Non- U.S. with expiration dates", "label": "Foreign Country NOL Expires [Member]", "documentation": "Portion of Non- U.S. with expiration dates" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency transaction gains (losses)", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r818", "r820", "r822", "r824", "r1024" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Translation", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r817" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeContractMember", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency exchange contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r1081", "r1104", "r1119" ] }, "us-gaap_ForeignPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignPlanMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Plan", "label": "Foreign Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1301", "r1302", "r1303" ] }, "tmo_ForeignTaxCreditCarryforwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "ForeignTaxCreditCarryforwardsMember", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Tax Credit Carryforwards", "label": "Foreign Tax Credit Carryforwards [Member]", "documentation": "Foreign Tax Credit Carryforwards" } } }, "auth_ref": [] }, "tmo_ForeignTaxPositionsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "ForeignTaxPositionsMember", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Foreign Tax Positions [Member]", "documentation": "Foreign Tax Positions [Member]" } } }, "auth_ref": [] }, "tmo_ForeigncurrencydenominateddebtMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "ForeigncurrencydenominateddebtMember", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency-denominated debt", "label": "Foreign currency-denominated debt [Member]", "documentation": "Foreign currency-denominated debt [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1152", "r1164", "r1174", "r1200" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1152", "r1164", "r1174", "r1200" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1152", "r1164", "r1174", "r1200" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r1152", "r1164", "r1174", "r1200" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r1152", "r1164", "r1174", "r1200" ] }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net gains on derivative instruments", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments." } } }, "auth_ref": [ "r169", "r173" ] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnInvestments", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on investments", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r216", "r1219" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on early extinguishment of debt", "verboseLabel": "Loss on early extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r17", "r112", "r113" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r308", "r457", "r878", "r1089", "r1121", "r1261", "r1268" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r460", "r1089" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r456", "r468", "r1089" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related Intangible Assets", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r21" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r464" ] }, "us-gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillGross", "crdr": "debit", "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill, Gross", "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r459", "r466", "r1089" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r1089" ] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finalization of purchase price allocations for 2022 acquisitions", "label": "Goodwill, Purchase Accounting Adjustments", "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r1", "r1267" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GovernmentAssistancePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentAssistancePolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Government Assistance", "label": "Government Assistance [Policy Text Block]", "documentation": "Disclosure of accounting policy for government assistance." } } }, "auth_ref": [ "r835", "r836" ] }, "us-gaap_GuaranteeObligationsByNatureAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteeObligationsByNatureAxis", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Guarantor Obligations, Nature [Axis]", "label": "Guarantor Obligations, Nature [Axis]", "documentation": "Information by nature of guarantee." } } }, "auth_ref": [ "r504", "r505", "r506", "r507" ] }, "us-gaap_GuaranteeObligationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteeObligationsLineItems", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Guarantor Obligations [Line Items]", "label": "Guarantor Obligations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r504", "r505", "r506", "r507" ] }, "us-gaap_GuaranteeObligationsMaximumExposure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteeObligationsMaximumExposure", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum guarantee under lease arrangements", "label": "Guarantor Obligations, Maximum Exposure, Undiscounted", "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions." } } }, "auth_ref": [ "r505" ] }, "us-gaap_GuaranteeObligationsNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteeObligationsNatureDomain", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Guarantor Obligations, Nature [Domain]", "label": "Guarantor Obligations, Nature [Domain]", "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees." } } }, "auth_ref": [ "r504", "r505", "r506", "r507" ] }, "us-gaap_GuaranteeTypeOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteeTypeOtherMember", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Residual Value Guarantee", "label": "Guarantee Type, Other [Member]", "documentation": "Agreement that requires the guarantor to make payments to a guaranteed party in compensation for that party's or parties' loss or injury, classified as other." } } }, "auth_ref": [] }, "us-gaap_GuaranteesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteesAbstract", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Guarantees [Abstract]", "label": "Guarantees [Abstract]" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r32", "r773" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r32" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r32" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1142", "r1143", "r1156" ] }, "us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use." } } }, "auth_ref": [ "r475" ] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of intangible assets", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r17", "r38" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of long-lived assets", "label": "Impairment, Long-Lived Asset, Held-for-Use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r17", "r101", "r234" ] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of disposal group", "label": "Impairment of Long-Lived Assets to be Disposed of", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": [ "r17", "r232" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r355", "r749" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-U.S.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r355", "r749" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes", "terseLabel": "Income before income taxes", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r401", "r415", "r421", "r424", "r909", "r1086" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Income From Continuing Operations Before Income Taxes [Abstract]", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Equity in earnings/(losses) of unconsolidated entities", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r17", "r208", "r276", "r408", "r437", "r899" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r476", "r483", "r1010" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r483", "r1010" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r27" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority, Name [Axis]", "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r27" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority, Name [Domain]", "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://thermofisher.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r356", "r718", "r727", "r734", "r738", "r745", "r751", "r752", "r753", "r952" ] }, "us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits reclassed to accrued income taxes in connection with IRS settlement", "label": "Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority", "documentation": "The amount of the additional liability or refund received or expected based on a final settlement with a taxing authority." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 }, "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails", "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Provision for income taxes", "totalLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r279", "r292", "r373", "r374", "r409", "r725", "r746", "r910" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r334", "r721", "r722", "r734", "r735", "r737", "r739", "r946" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for (reversal of) valuation allowances, net", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r1305" ] }, "us-gaap_IncomeTaxReconciliationDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationDispositionOfAssets", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intra-entity transfers", "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory." } } }, "auth_ref": [ "r1305" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign rate differential", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r1305" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes at statutory rate", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r726" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1305" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State income taxes, net of federal tax", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r1305" ] }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxContingencies", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Provision for (reversal of) tax reserves, net", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies." } } }, "auth_ref": [ "r1305" ] }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxCredits", "crdr": "credit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [ "r1305" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Research credits and incentives", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r1305" ] }, "us-gaap_IncomeTaxReconciliationTaxSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxSettlements", "crdr": "debit", "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax return reassessments and settlements", "negatedTerseLabel": "Tax return reassessments and settlements", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements." } } }, "auth_ref": [ "r1305" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r71", "r74" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r16" ] }, "tmo_IncreaseDecreaseInContractWithCustomerAssetsAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "IncreaseDecreaseInContractWithCustomerAssetsAndLiabilities", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Contract assets/liabilities", "label": "Increase (Decrease) In Contract With Customer Assets And Liabilities", "documentation": "Increase (Decrease) In Contract With Customer Assets And Liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in deferred income taxes", "label": "Increase (Decrease) in Deferred Income Taxes", "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities, excluding the effects of acquisitions:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plus effect of: stock options and restricted stock units (shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r381", "r382", "r383", "r389", "r674" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r470", "r473" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r231" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r97", "r231" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r1155", "r1164", "r1174", "r1191", "r1200", "r1204", "r1212" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1210" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r1144", "r1216" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r1144", "r1216" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r1144", "r1216" ] }, "tmo_InstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "InstrumentsMember", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Instruments", "label": "Instruments [Member]", "documentation": "Instruments (longer-lived products)" } } }, "auth_ref": [] }, "tmo_InsuranceContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "InsuranceContractsMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance contracts", "label": "Insurance Contracts [Member]", "documentation": "Insurance Contracts" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Acquisition-related intangible assets", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r308" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related intangible assets, net", "totalLabel": "Acquisition-related intangible assets", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r94", "r98" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r185", "r278", "r338", "r405", "r839", "r1011", "r1135", "r1345" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r42" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r345", "r348", "r350" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swaps - fair value hedges", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r1073", "r1131", "r1132" ] }, "tmo_InternationalEquityFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "InternationalEquityFundsMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International equity funds", "label": "International Equity Funds [Member]", "documentation": "International Equity Funds" } } }, "auth_ref": [] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntersegmentEliminationMember", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intersegment Eliminations", "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": [ "r403", "r414", "r415", "r416", "r417", "r418", "r420", "r424" ] }, "tmo_IntraEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "IntraEntityAxis", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intra-Entity [Axis]", "label": "Intra-Entity [Axis]", "documentation": "Intra-Entity" } } }, "auth_ref": [] }, "tmo_IntraEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "IntraEntityDomain", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intra-Entity [Domain]", "label": "Intra-Entity [Domain]", "documentation": "Intra-Entity [Domain]" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r227", "r1078" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r319", "r1077", "r1121" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r281", "r304", "r318", "r453", "r454", "r455", "r871", "r1084" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r227", "r1080" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r227", "r1079" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r215", "r404" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r908", "r942", "r943", "r944", "r945", "r1034", "r1035" ] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r800" ] }, "currency_JPY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "JPY", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross-currency interest rate swaps designated as net investment hedge - Japanese yen", "label": "Japan, Yen" } } }, "auth_ref": [] }, "us-gaap_LIFOMethodRelatedItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LIFOMethodRelatedItemsAbstract", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LIFO Method Inventories [Abstract]", "label": "LIFO Method Related Items [Abstract]" } } }, "auth_ref": [] }, "tmo_LaboratoryProductsandServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "LaboratoryProductsandServicesMember", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory Products and Biopharma Services", "label": "Laboratory Products and Services [Member]", "documentation": "Laboratory Products and Services Segment" } } }, "auth_ref": [] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r1291" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://thermofisher.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Leases", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1325" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r851" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r851" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r850" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://thermofisher.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Payments of Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1326" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r858" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029 and thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r858" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r858" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r858" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r858" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r858" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r858" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r858" ] }, "tmo_LesseeOperatingLeaseNumberOfLeasesWithGuaranteedResidualValue": { "xbrltype": "integerItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "LesseeOperatingLeaseNumberOfLeasesWithGuaranteedResidualValue", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leased operating facilities", "label": "Lessee, Operating Lease, Number Of Leases With Guaranteed Residual Value", "documentation": "Lessee, Operating Lease, Number Of Leases With Guaranteed Residual Value" } } }, "auth_ref": [] }, "tmo_LesseeOperatingLeaseOptiontoTerminateTerm": { "xbrltype": "durationItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "LesseeOperatingLeaseOptiontoTerminateTerm", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to terminate, term", "label": "Lessee, Operating Lease, Option to Terminate, Term", "documentation": "Term of lessee's operating lease if an option to terminate is available and executed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining lease term", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1323" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options to extend, renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1324" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://thermofisher.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r845" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, redeemable noncontrolling interest and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r202", "r275", "r895", "r1121", "r1248", "r1259", "r1316" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, redeemable noncontrolling interest and equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r54", "r303", "r354", "r441", "r508", "r509", "r511", "r512", "r513", "r515", "r517", "r519", "r520", "r766", "r770", "r771", "r812", "r1121", "r1284", "r1327", "r1328" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r178" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities [Abstract]", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "tmo_LifeSciencesSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "LifeSciencesSolutionsMember", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Life Sciences Solutions", "label": "Life Sciences Solutions [Member]", "documentation": "Life Sciences Solutions Segment" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings outstanding", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r47", "r273", "r1338" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r51" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused lines of credit", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r51" ] }, "tmo_LisaP.BrittMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "LisaP.BrittMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Lisa P. Britt [Member]", "documentation": "Lisa P. Britt" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total borrowings at carrying value", "verboseLabel": "Carrying value", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r47", "r273", "r534", "r549", "r1092", "r1093", "r1338" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term obligations", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r47", "r888" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029 and thereafter", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r19", "r358", "r1288" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r19", "r358", "r539" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r19", "r358", "r539" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r19", "r358", "r539" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r19", "r358", "r539" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r19", "r358", "r539" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r56" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r56", "r111" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r495", "r496", "r497", "r503", "r1278", "r1279" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r495", "r496", "r497", "r503", "r1278", "r1279" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r495", "r496", "r497", "r503", "r1278", "r1279" ] }, "us-gaap_LossContingencyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAbstract", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency [Abstract]", "label": "Loss Contingency [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss accrual", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r495", "r1223" ] }, "tmo_LossContingencyAccrualProductLiabilityGrossDivestedBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "LossContingencyAccrualProductLiabilityGrossDivestedBusiness", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undiscounted product liability accrual", "label": "Loss Contingency Accrual, Product Liability, Gross, Divested Business", "documentation": "The estimated aggregate undiscounted amount of the accrual for damages arising from third-party use of product(s) or process(es) of divested businesses as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyEstimateOfPossibleLoss", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range of probable loss", "label": "Loss Contingency, Estimate of Possible Loss", "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date." } } }, "auth_ref": [ "r496", "r497", "r502", "r503" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNatureDomain", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r495", "r496", "r497", "r503", "r1278", "r1279" ] }, "us-gaap_LossContingencyReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyReceivable", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated amounts due from insurers", "label": "Loss Contingency, Receivable", "documentation": "Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable." } } }, "auth_ref": [ "r1282" ] }, "us-gaap_LossOnContractTermination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossOnContractTermination", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on contract termination", "label": "Loss on Contract Termination", "documentation": "The loss recognized on termination of a contract." } } }, "auth_ref": [ "r870" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and Equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "tmo_MarcN.CasperMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "MarcN.CasperMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Marc N. Casper [Member]", "documentation": "Marc N. Casper" } } }, "auth_ref": [] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reconciling Items", "label": "Segment Reconciling Items [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r90" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r496", "r497", "r500", "r501", "r668", "r869", "r928", "r976", "r977", "r1032", "r1036", "r1038", "r1039", "r1049", "r1070", "r1071", "r1088", "r1096", "r1114", "r1123", "r1286", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334" ] }, "tmo_MaximumPeriodToMaturityAllowedUnderProgram": { "xbrltype": "durationItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "MaximumPeriodToMaturityAllowedUnderProgram", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum period prior to maturity", "label": "Maximum Period to Maturity Allowed Under Program", "documentation": "Maximum maturity period allowed under U.S. commercial paper program" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r1183" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r1183" ] }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "presentation": [ "http://thermofisher.com/role/Acquisitions" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings." } } }, "auth_ref": [ "r192", "r258" ] }, "tmo_MesaBiotechMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "MesaBiotechMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mesa Biotech", "label": "Mesa Biotech [Member]", "documentation": "Mesa Biotech" } } }, "auth_ref": [] }, "tmo_MichaelA.BoxerMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "MichaelA.BoxerMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Michael A. Boxer [Member]", "documentation": "Michael A. Boxer" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r496", "r497", "r500", "r501", "r668", "r869", "r928", "r976", "r977", "r1032", "r1036", "r1038", "r1039", "r1049", "r1070", "r1071", "r1088", "r1096", "r1114", "r1123", "r1286", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r62", "r274", "r354", "r441", "r508", "r511", "r512", "r513", "r519", "r520", "r812", "r894", "r987" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Contributions from (distributions to) noncontrolling interests", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r243" ] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestLineItems", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Line Items]", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest, noncontrolling owners", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage, parent", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestTable", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r62", "r154", "r157", "r212" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r1203" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1293" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1211" ] }, "tmo_MultiassetFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "MultiassetFundsMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Multi-asset funds", "label": "Multi-asset Funds [Member]", "documentation": "Multi-asset Funds" } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r1184" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r347" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r347" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r221", "r222", "r223" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r209", "r223", "r277", "r301", "r329", "r332", "r337", "r354", "r363", "r367", "r368", "r369", "r370", "r373", "r374", "r385", "r401", "r415", "r421", "r424", "r441", "r508", "r509", "r511", "r512", "r513", "r515", "r517", "r519", "r520", "r796", "r812", "r902", "r1006", "r1025", "r1026", "r1086", "r1135", "r1284" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Less: net (losses) income attributable to noncontrolling interests and redeemable noncontrolling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r159", "r262", "r329", "r332", "r373", "r374", "r901", "r1242" ] }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Net income/(loss)", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest." } } }, "auth_ref": [ "r212" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Thermo Fisher Scientific Inc.", "terseLabel": "Net income", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r344", "r367", "r368", "r369", "r370", "r377", "r378", "r386", "r389", "r401", "r415", "r421", "r424", "r1086" ] }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Net income/(loss)", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity." } } }, "auth_ref": [ "r48", "r262", "r263" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedging", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r166" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r295", "r296", "r297", "r298", "r299", "r362", "r363", "r364", "r365", "r366", "r369", "r375", "r393", "r434", "r435", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r478", "r709", "r710", "r711", "r741", "r742", "r743", "r744", "r758", "r759", "r760", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r808", "r809", "r813", "r814", "r815", "r816", "r837", "r838", "r841", "r842", "r843", "r844", "r859", "r860", "r861", "r862", "r863", "r874", "r875", "r876", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items." } } }, "auth_ref": [ "r78", "r295", "r296", "r297", "r298", "r299", "r362", "r363", "r364", "r365", "r366", "r369", "r375", "r393", "r434", "r435", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r478", "r709", "r710", "r711", "r741", "r742", "r743", "r744", "r758", "r759", "r760", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r808", "r809", "r813", "r814", "r815", "r816", "r837", "r838", "r841", "r842", "r843", "r844", "r859", "r860", "r861", "r862", "r863", "r874", "r875", "r876", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r1183" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r1152", "r1164", "r1174", "r1191", "r1200" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1181" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1180" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r1191" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1211" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1211" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing and financing activities", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "tmo_NoncontrollingInterestContributionFromDistributionsToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "NoncontrollingInterestContributionFromDistributionsToNoncontrollingInterests", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions from (distributions to) noncontrolling interests", "label": "Noncontrolling interest, contribution from (distributions to) noncontrolling interests", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders net of decreases in noncontrolling interest balance from payment of dividends or other distributions." } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Recognition upon acquisition", "label": "Noncontrolling Interest, Increase from Business Combination", "documentation": "Amount of increase in noncontrolling interest from a business combination." } } }, "auth_ref": [ "r29", "r120", "r146" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r153", "r565", "r1250", "r1251", "r1252", "r1346" ] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-lived Assets", "label": "Long-Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": [ "r429" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives not designated as hedging instruments", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r32" ] }, "us-gaap_NonrecurringAdjustmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrecurringAdjustmentAxis", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrecurring Adjustment [Axis]", "label": "Nonrecurring Adjustment [Axis]", "documentation": "Information about material and nonrecurring adjustment directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information)." } } }, "auth_ref": [ "r37" ] }, "us-gaap_NonrecurringAdjustmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrecurringAdjustmentDomain", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrecurring Adjustment [Domain]", "label": "Nonrecurring Adjustment [Domain]", "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information)." } } }, "auth_ref": [ "r37" ] }, "srt_NorthAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NorthAmericaMember", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "North America", "label": "North America [Member]" } } }, "auth_ref": [ "r1348", "r1349", "r1350", "r1351" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1256" ] }, "tmo_OlinkHoldingABMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "OlinkHoldingABMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Olink Holding AB", "label": "Olink Holding AB [Member]", "documentation": "Olink Holding AB" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income", "verboseLabel": "Subtotal reportable segments", "terseLabel": "Consolidated operating income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r401", "r415", "r421", "r424", "r1086" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r852", "r1120" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total operating lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r847" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities - current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r847" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r848" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities - noncurrent", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r847" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r848" ] }, "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease liability." } } }, "auth_ref": [ "r848" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r849", "r854" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r846" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r848" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r857", "r1120" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining operating lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r856", "r1120" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NOL carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r138" ] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Line Items]", "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Table]", "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r137" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Reportable Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r414", "r415", "r416", "r417", "r418", "r424" ] }, "us-gaap_OrderOrProductionBacklogMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrderOrProductionBacklogMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Backlog", "label": "Order or Production Backlog [Member]", "documentation": "Orders, production or production backlog arising from contracts such as purchase or sales orders acquired in a business combination." } } }, "auth_ref": [ "r148" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of Operations and Summary of Significant Accounting Policies", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r191", "r224", "r225", "r260" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r320", "r1121" ] }, "us-gaap_OtherAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Other Assets, Fair Value Disclosure", "documentation": "Fair value portion of other assets." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r310" ] }, "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery, equipment and leasehold improvements", "label": "Other Capitalized Property Plant and Equipment [Member]", "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized." } } }, "auth_ref": [ "r233" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and other postretirement benefit liability adjustments:", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains and losses on hedging instruments:", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation adjustment:", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation adjustment (net of tax provision (benefit) of $(134), $173 and $231)", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r9", "r206", "r819", "r821", "r825" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncomeParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Tax provision (benefit) on currency translation adjustment", "label": "OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax", "documentation": "Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r7", "r12", "r819", "r823", "r832" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income/(loss) before reclassifications", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r46", "r64", "r336", "r826", "r829", "r833", "r1240" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedLabel": "Reclassification adjustment for losses included in net income (net of tax benefit of $2, $1 and $17)", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r324", "r327" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount reclassified from accumulated other comprehensive items to interest expense", "negatedLabel": "Amount reclassified from accumulated other comprehensive items to interest expense", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r289", "r324", "r327" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncomeParenthetical" ], "lang": { "en-us": { "role": { "negatedLabel": "Tax benefit on reclassification adjustment for losses on hedging instruments recognized in net income", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r325" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income/(loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r31", "r46", "r330", "r333", "r339", "r826", "r827", "r833", "r879", "r903", "r1240", "r1241" ] }, "tmo_OtherComprehensiveIncomeLossNetOfTaxIncludingRedeemableAndNonRedeemableNCI": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "OtherComprehensiveIncomeLossNetOfTaxIncludingRedeemableAndNonRedeemableNCI", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Total other comprehensive income/(loss)", "label": "Other Comprehensive Income (Loss) Net of Tax Including Redeemable and NonRedeemable NCI", "documentation": "Other Comprehensive Income (Loss) Net of Tax Including Redeemable and NonRedeemable NCI" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income/(loss):", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedLabel": "Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $(22), $9 and $11)", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax", "documentation": "Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r11", "r206" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncomeParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, Tax", "documentation": "Amount, before reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r11", "r12", "r261" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $1, $3 and $6)", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax", "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r13", "r206", "r245", "r328" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncomeParenthetical" ], "lang": { "en-us": { "role": { "negatedLabel": "Tax benefit on amortization of net loss and prior service benefit included in net periodic pension cost", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax", "documentation": "Amount of tax (expense) benefit for reclassification adjustment from accumulated other comprehensive (income) loss of defined benefit plan." } } }, "auth_ref": [ "r12", "r261" ] }, "tmo_OtherDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "OtherDebtMember", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Debt", "label": "Other Debt [Member]", "documentation": "Other Debt" } } }, "auth_ref": [] }, "us-gaap_OtherExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherExpenseMember", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Expense", "label": "Other Expense [Member]", "documentation": "Primary financial statement caption encompassing other expense." } } }, "auth_ref": [ "r42" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Income and Expenses [Abstract]", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpense" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income/Expense", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r244", "r251" ] }, "us-gaap_OtherIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets", "label": "Other Intangible Assets, Net", "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued expenses", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r53", "r1121" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r57" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other non-cash expenses", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r223" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other income/(expense)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r217" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1183" ] }, "tmo_OtherRegionsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "OtherRegionsMember", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other regions", "label": "Other Regions [Member]", "documentation": "All geographical regions not separately disclosed" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1150", "r1162", "r1172", "r1198" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r1153", "r1165", "r1175", "r1201" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r1153", "r1165", "r1175", "r1201" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "tmo_PPDIncMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "PPDIncMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PPD", "label": "PPD, Inc [Member]", "documentation": "PPD, Inc" } } }, "auth_ref": [] }, "tmo_PPDSNBLKKMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "PPDSNBLKKMember", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PPD-SNBL K.K.", "label": "PPD-SNBL K.K. [Member]", "documentation": "PPD-SNBL K.K. (Consolidated subsidiary with a noncontrolling interest)" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParentMember", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Total Thermo Fisher Scientific Inc. Shareholders\u2019 Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r1179" ] }, "tmo_PaymentGuaranteesInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "PaymentGuaranteesInvestmentsMember", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Payment Guarantees, Investments [Member]", "documentation": "Payment Guarantees, Investments" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other investing activities, net", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1226", "r1243" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of company common stock", "terseLabel": "Purchases of company common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r69" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r482", "r1245" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r69" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash outlay", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r68" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r66", "r761" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisitions, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r66" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r220" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r1182" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1182" ] }, "us-gaap_PensionAndOtherPostretirementBenefitContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitContributions", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Contributions to retirement plans", "terseLabel": "Cash contributions to retirement plans", "label": "Payment for Pension and Other Postretirement Benefits", "documentation": "Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree." } } }, "auth_ref": [ "r15" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlans" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and Other Postretirement Benefit Plans", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r589", "r614", "r616", "r622", "r641", "r643", "r644", "r645", "r646", "r647", "r662", "r663", "r665", "r1106" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "crdr": "credit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Current liability", "label": "Liability, Defined Benefit Plan, Current", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current." } } }, "auth_ref": [ "r194", "r590", "r591", "r613", "r1106" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Noncurrent liabilities", "label": "Liability, Defined Benefit Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": [ "r195", "r590", "r591", "r613", "r1106" ] }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementPlansPolicy", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and Other Postretirement Benefit Plans", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived." } } }, "auth_ref": [ "r20", "r22", "r23", "r33", "r129" ] }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Plans, Defined Benefit", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r590", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r639", "r640", "r642", "r645", "r648", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r665", "r666", "r669", "r1106", "r1107", "r1111", "r1112", "r1113" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1181" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r1191" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r1184" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1180" ] }, "tmo_PeproTechIncMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "PeproTechIncMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PeproTech", "label": "PeproTech, Inc. [Member]", "documentation": "PeproTech, Inc." } } }, "auth_ref": [] }, "us-gaap_PercentageOfLIFOInventory": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PercentageOfLIFOInventory", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of LIFO inventory", "label": "Percentage of LIFO Inventory", "documentation": "The percentage of LIFO (last in first out) inventory to total inventory as of the balance sheet date if other than 100 percent." } } }, "auth_ref": [] }, "us-gaap_PerformanceGuaranteeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceGuaranteeMember", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Guarantee", "label": "Performance Guarantee [Member]", "documentation": "An agreement (contract) that requires the guarantor to make payments to a guaranteed party based on another entity's failure to perform under an obligating agreement. This may include the issuance of a performance standby letter of credit which requires the guarantor to make payments if a specified party fails to perform under a nonfinancial contractual obligation." } } }, "auth_ref": [] }, "us-gaap_PlanAssetCategoriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanAssetCategoriesDomain", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "documentation": "Defined benefit plan asset investment." } } }, "auth_ref": [ "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r642", "r1104", "r1105", "r1106" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, $100 Par Value - Par Value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r196", "r552" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, $100 Par Value - Shares Authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r196", "r985" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, $100 Par Value - Shares Issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r196", "r552" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $100 par value, 50,000 shares authorized; none issued", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r196", "r890", "r1121" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Presentation", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1237" ] }, "us-gaap_ProceedsFromHedgeFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromHedgeFinancingActivities", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from interest rate swap", "label": "Proceeds from Hedge, Financing Activities", "documentation": "The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations." } } }, "auth_ref": [ "r349", "r1244" ] }, "us-gaap_ProceedsFromIssuanceOfCommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommercialPaper", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of commercial paper", "label": "Proceeds from Issuance of Commercial Paper", "documentation": "The cash inflow from borrowing by issuing commercial paper." } } }, "auth_ref": [ "r67" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of debt", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r67", "r947" ] }, "tmo_ProceedsFromPaymentsForCrossCurrencyInterestRateSwapInterestSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "ProceedsFromPaymentsForCrossCurrencyInterestRateSwapInterestSettlements", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from cross-currency interest rate swap interest settlements", "label": "Proceeds From (Payments For) Cross-Currency Interest Rate Swap Interest Settlements", "documentation": "The cash inflow (outflow) provided by (paid for) cross-currency interest rate swap interest rate settlements, which are classified as investing activities, for hedging instruments designated as net investment hedges." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities, net", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r1227", "r1244" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of property, plant and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r219" ] }, "tmo_ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Liability, Workers Compensation and Other Personal Injury Matters", "label": "Product Liability, Workers Compensation and Other Personal Injury Matters [Member]", "documentation": "Amount charged to earnings in the current period for product liability, workers compensation and other personal injury matters." } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenues", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r1097" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r426", "r872", "r922", "r923", "r924", "r925", "r926", "r927", "r1074", "r1097", "r1122", "r1235", "r1280", "r1281", "r1290", "r1340" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r426", "r872", "r922", "r923", "r924", "r925", "r926", "r927", "r1074", "r1097", "r1122", "r1235", "r1280", "r1281", "r1290", "r1340" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 }, "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows", "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome", "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r301", "r329", "r332", "r346", "r354", "r363", "r373", "r374", "r401", "r415", "r421", "r424", "r441", "r508", "r509", "r511", "r512", "r513", "r515", "r517", "r519", "r520", "r764", "r767", "r768", "r796", "r812", "r884", "r900", "r954", "r1006", "r1025", "r1026", "r1086", "r1117", "r1118", "r1136", "r1242", "r1284" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r18" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, at cost", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r233", "r306", "r898" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r18", "r885", "r898", "r1121" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r18", "r284", "r290", "r896" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r18" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r233" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful lives", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r1179" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r1179" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r496", "r497", "r500", "r501", "r614", "r668", "r701", "r702", "r703", "r868", "r869", "r928", "r976", "r977", "r1032", "r1036", "r1038", "r1039", "r1049", "r1070", "r1071", "r1088", "r1096", "r1114", "r1123", "r1126", "r1271", "r1286", "r1330", "r1331", "r1332", "r1333", "r1334" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r496", "r497", "r500", "r501", "r614", "r668", "r701", "r702", "r703", "r868", "r869", "r928", "r976", "r977", "r1032", "r1036", "r1038", "r1039", "r1049", "r1070", "r1071", "r1088", "r1096", "r1114", "r1123", "r1126", "r1271", "r1286", "r1330", "r1331", "r1332", "r1333", "r1334" ] }, "us-gaap_RealEstateFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateFundsMember", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real estate funds", "label": "Real Estate Funds [Member]", "documentation": "Investments in funds that invest in commercial or residential real estate." } } }, "auth_ref": [] }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Contract-related Balances", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized." } } }, "auth_ref": [ "r92" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amounts reclassified from accumulated other comprehensive income/(loss)", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r46", "r64", "r336", "r826", "r831", "r833", "r1240" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r1145", "r1157", "r1167", "r1193" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable noncontrolling interest", "periodStartLabel": "Redeemable noncontrolling interest, beginning balance", "periodEndLabel": "Redeemable noncontrolling interest, ending balance", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r114", "r115", "r116", "r117" ] }, "tmo_RedeemableNoncontrollingInterestRollForward": { "xbrltype": "stringItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "RedeemableNoncontrollingInterestRollForward", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Noncontrolling Interest [Roll Forward]", "label": "Redeemable Noncontrolling Interest [Roll Forward]", "documentation": "Redeemable Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfCommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfCommercialPaper", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of commercial paper", "label": "Repayments of Commercial Paper", "documentation": "The cash outflow due to repaying amounts borrowed by issuing commercial paper." } } }, "auth_ref": [ "r70" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r70", "r950" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r190", "r717", "r1335" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r716" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r1146", "r1158", "r1168", "r1194" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r1147", "r1159", "r1169", "r1195" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r1154", "r1166", "r1176", "r1202" ] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in other current assets", "label": "Restricted Cash and Cash Equivalents, Current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r72", "r305", "r351" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Restricted Cash and Cash Equivalents, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage, classified as current." } } }, "auth_ref": [ "r351" ] }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "crdr": "debit", "calculation": { "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in other assets", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r72", "r280", "r351" ] }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage, classified as noncurrent." } } }, "auth_ref": [ "r351" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "tmo_RestructuringAndOtherCostsIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "RestructuringAndOtherCostsIncomeNet", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and other costs", "negatedLabel": "Restructuring and other costs", "label": "Restructuring And Other Costs (Income) Net", "documentation": "Amount of restructuring charges, remediation costs and assets impairment loss; and, in some periods, may also include gains and losses on the sale of businesses, product lines and real estate." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCosts" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Other Costs", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r479", "r480", "r482", "r485", "r491" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future restructuring costs", "label": "Restructuring and Related Cost, Expected Cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r481", "r484", "r488", "r490" ] }, "tmo_RestructuringAndRelatedCostPercentageOfTotalWorkforceEliminated": { "xbrltype": "percentItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "RestructuringAndRelatedCostPercentageOfTotalWorkforceEliminated", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eliminated workforce percentage", "label": "Restructuring and Related Cost, Percentage of Total Workforce Eliminated", "documentation": "The maximum number of positions eliminated in connection with restructuring plans during the period as a percentage of the company's total workforce." } } }, "auth_ref": [] }, "tmo_RestructuringAndRelatedCostsNonCashCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "RestructuringAndRelatedCostsNonCashCosts", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-cash restructuring costs", "label": "Restructuring and Related Costs, Non-Cash Costs", "documentation": "Restructuring and other costs which consist principally of gains and losses resulting from changes in estimates for significant litigation-related matters, and, in some periods, may also include gains and losses on the sale of businesses, product lines and real estate, and asset impairment charges." } } }, "auth_ref": [] }, "tmo_RestructuringAndRelatedCostsNonCashCostsAmountAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "RestructuringAndRelatedCostsNonCashCostsAmountAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Loss attributable to noncontrolling interest", "label": "Restructuring and Related Costs, Non-Cash Costs, Amount Attributable To Noncontrolling Interest", "documentation": "Restructuring and Related Costs, Non-Cash Costs, Amount Attributable To Noncontrolling Interest" } } }, "auth_ref": [] }, "tmo_RestructuringAndRelatedCostsNonCashCostsPreAcquisitionLitigationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "RestructuringAndRelatedCostsNonCashCostsPreAcquisitionLitigationCosts", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-acquisition litigation costs", "label": "Restructuring and Related Costs, Non-Cash Costs, Pre-Acquisition Litigation Costs", "documentation": "Restructuring and Related Costs, Non-Cash Costs, Pre-Acquisition Litigation Costs" } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Net restructuring charges incurred", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r17", "r486", "r488", "r1273" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r481", "r482", "r483", "r484", "r488", "r489", "r490" ] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r482", "r487" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveRollForward", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveTranslationAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveTranslationAdjustment", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "verboseLabel": "Currency translation", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve." } } }, "auth_ref": [ "r1274", "r1275" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r199", "r243", "r893", "r935", "r940", "r951", "r986", "r1121" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r297", "r359", "r360", "r361", "r364", "r372", "r374", "r445", "r451", "r709", "r710", "r711", "r743", "r744", "r777", "r780", "r781", "r784", "r794", "r931", "r933", "r955", "r1346" ] }, "us-gaap_RetirementPlanSponsorLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanSponsorLocationAxis", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Axis]", "label": "Retirement Plan Sponsor Location [Axis]", "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r638", "r639", "r640", "r642", "r645", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r1301", "r1302", "r1303" ] }, "us-gaap_RetirementPlanSponsorLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanSponsorLocationDomain", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Domain]", "label": "Retirement Plan Sponsor Location [Domain]", "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r638", "r639", "r640", "r642", "r645", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r1301", "r1302", "r1303" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r590", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r639", "r640", "r642", "r645", "r648", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r665", "r666", "r667", "r669", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r590", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r639", "r640", "r642", "r645", "r648", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r665", "r666", "r667", "r669", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails", "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r402", "r403", "r414", "r419", "r420", "r426", "r428", "r430", "r585", "r586", "r872" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r293", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r1072" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://thermofisher.com/role/RevenueandContractrelatedBalances" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue and Contract-related Balances", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r293", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r588" ] }, "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuePerformanceObligationDescriptionOfTiming", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Performance Obligation, Description of Timing", "label": "Revenue, Performance Obligation, Description of Timing", "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service." } } }, "auth_ref": [ "r570" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction price allocated to remaining performance obligation", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r287" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected timing of satisfaction of remaining performance obligation", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r288" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r288" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationPercentage", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligation percentage", "label": "Revenue, Remaining Performance Obligation, Percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue." } } }, "auth_ref": [ "r1232" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease ROU assets obtained in exchange for new finance lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r855", "r1120" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease ROU assets obtained in exchange for new operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r855", "r1120" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1211" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1211" ] }, "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Benefit Obligation and Fair Value of Plan Assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1106", "r1296", "r1297" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Change in Each Component of Accumulated Other Comprehensive Items", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r64", "r1319", "r1321" ] }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of the Company's Plan Assets", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall." } } }, "auth_ref": [ "r246" ] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Actuarial Assumptions", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": [ "r636" ] }, "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Projected Benefit Obligation and Fair Value of Plan Assets", "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1106", "r1296" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r141", "r143", "r757" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://thermofisher.com/role/AcquisitionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Purchase Price", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r141", "r143" ] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Value and Fair Value of the Company's Debt Instruments", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Cash Flow Disclosures", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://thermofisher.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of the Provision for Income Taxes", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r254" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://thermofisher.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r253" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r20", "r125", "r126", "r127", "r128" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Instruments, Gain (Loss) Recognized", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r169", "r172", "r773" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Derivative Instruments", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r170" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://thermofisher.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1255" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://thermofisher.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r252" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r354", "r438", "r439", "r440", "r441", "r812" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Schedule of Equity Method Investments [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available." } } }, "auth_ref": [ "r301", "r354", "r438", "r439", "r440", "r441", "r812" ] }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Future Benefit Payments", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter." } } }, "auth_ref": [ "r247" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r800", "r801" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r96", "r99", "r873" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquisition-related Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r96", "r99" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r1089" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r1089", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270" ] }, "us-gaap_ScheduleOfGuaranteeObligationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGuaranteeObligationsTable", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Guarantor Obligations [Table]", "label": "Schedule of Guarantor Obligations [Table]", "documentation": "Tabular disclosure about the type or nature of guarantees, for example performance, indemnification, payment and other guarantees, and related information such as term, origin and purpose, triggering event, maximum exposure, and carrying value. Represents the guarantor's disclosures which include the information about each guarantee, or each group of similar guarantees, even if the likelihood of the guarantor's need to make any payments under the guarantee is remote. This excludes disclosures for product warranties." } } }, "auth_ref": [ "r504", "r505", "r506", "r507" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://thermofisher.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Income Before Provision for Income Taxes", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1249" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Acquisition-related Intangible Assets", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": [ "r39", "r231" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r49", "r203", "r204", "r205" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Annual Repayment Requirements for Debt Obligations", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Benefit Costs", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r248" ] }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]", "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items." } } }, "auth_ref": [ "r78", "r79", "r82", "r83" ] }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Aggregate Notional Value of Outstanding Derivative Contracts", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": [ "r163" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r43", "r268", "r1339" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r481", "r482", "r483", "r484", "r488", "r489", "r490" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Other Costs by Segment", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r104", "r106", "r108" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Company's Accrued Restructuring Balance", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r105", "r109" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue by Geographical Areas", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r91", "r211" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r91", "r207" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r87", "r88", "r89", "r93" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r87", "r88", "r89", "r93" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r671", "r673", "r676", "r677", "r678", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r700", "r701", "r702", "r703", "r704" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of the Company's Restricted Unit Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r131" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of the Company's Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r35", "r36", "r131" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r250" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-term Debt [Table]", "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r52" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r99" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1138" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1141" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r398", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r430", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r484", "r490", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r1089", "r1235", "r1340" ] }, "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentExpenditureAdditionToLongLivedAssets", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditures", "label": "Segment, Expenditure, Addition to Long-Lived Assets", "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets." } } }, "auth_ref": [ "r412", "r1087" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails", "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r428", "r429", "r969", "r972", "r974", "r1033", "r1037", "r1040", "r1050", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1075", "r1098", "r1126", "r1290", "r1340" ] }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentOperatingActivitiesDomain", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities [Domain]", "label": "Operating Activities [Domain]", "documentation": "Operations of an entity including continuing and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Business Segment and Geographical Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r397", "r398", "r399", "r400", "r401", "r413", "r418", "r422", "r423", "r424", "r425", "r426", "r427", "r430" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "tmo_SellingGeneralAndAdministrativeChargesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SellingGeneralAndAdministrativeChargesNet", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Selling, general and administrative expenses adjustments", "label": "Selling General And Administrative Charges Net", "documentation": "Certain charges/credits to selling, general and administrative expenses principally associated with acquisition accounting." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r214" ] }, "tmo_SeniorNotes0.125Due2025Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes0.125Due2025Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.125% Notes due 2025", "verboseLabel": "0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)", "label": "Senior Notes 0.125% Due 2025 [Member]", "documentation": "Senior Notes 0.125% Due 2025 [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes0.500Due2028Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes0.500Due2028Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.500% Notes due 2028", "verboseLabel": "0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)", "label": "Senior Notes 0.500% Due 2028 [Member]", "documentation": "Senior Notes 0.500% Due 2028 [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes0.75Due2024Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes0.75Due2024Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.750% Notes due 2024", "verboseLabel": "0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)", "label": "Senior Notes 0.75% Due 2024 [Member]", "documentation": "Senior Notes 0.75% Due 2024 [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes0.77Due2028Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes0.77Due2028Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.77% 5-Year Senior Notes, Due 9/6/2028 (yen-denominated)", "label": "Senior Notes 0.77% Due 2028 [Member]", "documentation": "Senior Notes 0.77% Due 2028" } } }, "auth_ref": [] }, "tmo_SeniorNotes0.875Due2031Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes0.875Due2031Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.875% Notes due 2031", "verboseLabel": "0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)", "label": "Senior Notes 0.875% Due 2031 [Member]", "documentation": "Senior Notes 0.875% Due 2031 [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes0000Due2023Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes0000Due2023Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)", "label": "Senior Notes 0.000% Due 2023 [Member]", "documentation": "Senior Notes 0.000% Due 2023" } } }, "auth_ref": [] }, "tmo_SeniorNotes0000Due2025Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes0000Due2025Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)", "label": "Senior Notes 0.000% Due 2025 [Member]", "documentation": "Senior Notes 0.000% Due 2025" } } }, "auth_ref": [] }, "tmo_SeniorNotes0797Due2023Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes0797Due2023Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.797% 2-Year Senior Notes, Due 10/18/2023", "label": "Senior Notes 0.797% Due 2023 [Member]", "documentation": "Senior Notes 0.797% Due 2023" } } }, "auth_ref": [] }, "tmo_SeniorNotes080Due2030Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes080Due2030Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)", "label": "Senior Notes 0.80% Due 2030 [Member]", "documentation": "Senior Notes 0.80% Due 2030" } } }, "auth_ref": [] }, "tmo_SeniorNotes0853Due2025Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes0853Due2025Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated)", "label": "Senior Notes 0.853% Due 2025 [Member]", "documentation": "Senior Notes 0.853% Due 2025" } } }, "auth_ref": [] }, "tmo_SeniorNotes1.375Due2028Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes1.375Due2028Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.375% Notes due 2028", "verboseLabel": "1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)", "label": "Senior Notes 1.375% Due 2028 [Member]", "documentation": "Senior Notes 1.375% Due 2028 [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes1.40Due2026Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes1.40Due2026Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.400% Notes due 2026", "verboseLabel": "1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)", "label": "Senior Notes 1.40% Due 2026 [Member]", "documentation": "1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes1.500Due2039Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes1.500Due2039Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.500% Notes due 2039", "verboseLabel": "1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)", "label": "Senior Notes 1.500% Due 2039 [Member]", "documentation": "Senior Notes 1.500% Due 2039 [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes1.50Due2035Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes1.50Due2035Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.50% 12-Year Senior Notes, due 9/6/2035 (yen-denominated)", "label": "Senior Notes 1.50% Due 2035 [Member]", "documentation": "Senior Notes 1.50% Due 2035" } } }, "auth_ref": [] }, "tmo_SeniorNotes1.875Due2049Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes1.875Due2049Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.875% Notes due 2049", "verboseLabel": "1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)", "label": "Senior Notes 1.875% Due 2049 [Member]", "documentation": "Senior Notes 1.875% Due 2049 [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes1.95Due2029Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes1.95Due2029Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.950% Notes due 2029", "verboseLabel": "1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)", "label": "Senior Notes 1.95% Due 2029 [Member]", "documentation": "1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes1054Due2027Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes1054Due2027Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)", "label": "Senior Notes 1.054% Due 2027 [Member]", "documentation": "Senior Notes 1.054% Due 2027" } } }, "auth_ref": [] }, "tmo_SeniorNotes1125Due2033Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes1125Due2033Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)", "label": "Senior Notes 1.125% Due 2033 [Member]", "documentation": "Senior Notes 1.125% Due 2033" } } }, "auth_ref": [] }, "tmo_SeniorNotes1215Due2024Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes1215Due2024Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.215% 3-Year Senior Notes, Due 10/18/2024", "label": "Senior Notes 1.215% Due 2024 [Member]", "documentation": "Senior Notes 1.215% Due 2024" } } }, "auth_ref": [] }, "tmo_SeniorNotes1279Due2029Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes1279Due2029Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)", "label": "Senior Notes 1.279% Due 2029 [Member]", "documentation": "Senior Notes 1.279% Due 2029" } } }, "auth_ref": [] }, "tmo_SeniorNotes149Due2032Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes149Due2032Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)", "label": "Senior Notes 1.49% Due 2032 [Member]", "documentation": "Senior Notes 1.49% Due 2032" } } }, "auth_ref": [] }, "tmo_SeniorNotes1625Due2041Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes1625Due2041Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)", "label": "Senior Notes 1.625% Due 2041 [Member]", "documentation": "Senior Notes 1.625% Due 2041" } } }, "auth_ref": [] }, "tmo_SeniorNotes1750Due2028Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes1750Due2028Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.750% 7-Year Senior Notes, Due 10/15/2028", "label": "Senior Notes 1.750% Due 2028 [Member]", "documentation": "Senior Notes 1.750% Due 2028" } } }, "auth_ref": [] }, "tmo_SeniorNotes175Due2027Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes175Due2027Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.750% Notes due 2027", "verboseLabel": "1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)", "label": "Senior Notes 1.75% Due 2027 [Member]", "documentation": "Senior Notes 1.75% Due 2027" } } }, "auth_ref": [] }, "tmo_SeniorNotes2.60Due2029Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes2.60Due2029Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.60% 10-Year Senior Notes, Due 10/1/2029", "label": "Senior Notes 2.60% Due 2029 [Member]", "documentation": "Senior Notes 2.60% Due 2029 [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes2.875Due2037Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes2.875Due2037Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.875% Notes due 2037", "verboseLabel": "2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)", "label": "Senior Notes 2.875% Due 2037 [Member]", "documentation": "2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes2000Due2031Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes2000Due2031Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.00% 10-Year Senior Notes, Due 10/15/2031", "label": "Senior Notes 2.000% Due 2031 [Member]", "documentation": "Senior Notes 2.000% Due 2031" } } }, "auth_ref": [] }, "tmo_SeniorNotes200Due2025Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes200Due2025Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.000% Notes due 2025", "verboseLabel": "2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)", "label": "Senior Notes 2.00% Due 2025 [Member]", "documentation": "2.00% 10-Year Senior Notes, Due 4/15/2025 (euro denominated) [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes200Due2051Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes200Due2051Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)", "label": "Senior Notes 2.00% Due 2051 [Member]", "documentation": "Senior Notes 2.00% Due 2051" } } }, "auth_ref": [] }, "tmo_SeniorNotes202Due2043Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes202Due2043Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.02% 20-Year Senior Notes, due 9/6/2043 (yen-denominated)", "label": "Senior Notes 2.02% Due 2043 [Member]", "documentation": "Senior Notes 2.02% Due 2043" } } }, "auth_ref": [] }, "tmo_SeniorNotes2069Due2042Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes2069Due2042Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)", "label": "Senior Notes 2.069% Due 2042 [Member]", "documentation": "Senior Notes 2.069% Due 2042" } } }, "auth_ref": [] }, "tmo_SeniorNotes2375Due2032Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes2375Due2032Member", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.375% Notes due 2032", "verboseLabel": "2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)", "label": "Senior Notes 2.375% Due 2032 [Member]", "documentation": "Senior Notes 2.375% Due 2032" } } }, "auth_ref": [] }, "tmo_SeniorNotes2382Due2052Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes2382Due2052Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)", "label": "Senior Notes 2.382% Due 2052 [Member]", "documentation": "Senior Notes 2.382% Due 2052" } } }, "auth_ref": [] }, "tmo_SeniorNotes2800Due2041Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes2800Due2041Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.80% 20-Year Senior Notes, Due 10/15/2041", "label": "Senior Notes 2.800% Due 2041 [Member]", "documentation": "Senior Notes 2.800% Due 2041" } } }, "auth_ref": [] }, "tmo_SeniorNotes3.65Due2025Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes3.65Due2025Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes 3.65% Due 2025 [Member]", "label": "Senior Notes 3.65% Due 2025 [Member]", "documentation": "3.65% 10-Year Senior Notes, Due 12/15/2025 [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes3200Due2026Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes3200Due2026Member", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "3.200% Notes due 2026", "label": "Senior Notes 3.200% Due 2026 [Member]", "documentation": "Senior Notes 3.200% Due 2026" } } }, "auth_ref": [] }, "tmo_SeniorNotes320Due2026Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes320Due2026Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)", "label": "Senior Notes 3.20% Due 2026 [Member]", "documentation": "Senior Notes 3.20% Due 2026" } } }, "auth_ref": [] }, "tmo_SeniorNotes3650Due2034Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes3650Due2034Member", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "3.650% Notes due 2034", "label": "Senior Notes 3.650% Due 2034 [Member]", "documentation": "Senior Notes 3.650% Due 2034" } } }, "auth_ref": [] }, "tmo_SeniorNotes365Due2034Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes365Due2034Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)", "label": "Senior Notes 3.65% Due 2034 [Member]", "documentation": "Senior Notes 3.65% Due 2034" } } }, "auth_ref": [] }, "tmo_SeniorNotes4.10Due2047Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes4.10Due2047Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.10% 30-Year Senior Notes, Due 8/15/2047", "label": "Senior Notes 4.10% Due 2047 [Member]", "documentation": "4.10% 30-Year Senior Notes, Due 8/15/2047 [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes48Due2027Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes48Due2027Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.80% 5-Year Senior Notes, Due 11/21/2027", "label": "Senior Notes 4.8% Due 2027 [Member]", "documentation": "Senior Notes 4.8% Due 2027" } } }, "auth_ref": [] }, "tmo_SeniorNotes4953Due2026Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes4953Due2026Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.953% 3-Year Senior Notes, Due 8/10/2026", "label": "Senior Notes 4.953% Due 2026 [Member]", "documentation": "Senior Notes 4.953% Due 2026" } } }, "auth_ref": [] }, "tmo_SeniorNotes495Due2032Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes495Due2032Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.95% 10-Year Senior Notes, Due 11/21/2032", "label": "Senior Notes 4.95% Due 2032 [Member]", "documentation": "Senior Notes 4.95% Due 2032" } } }, "auth_ref": [] }, "tmo_SeniorNotes4977Due2030Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes4977Due2030Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.977% 7-Year Senior Notes, Due 8/10/2030", "label": "Senior Notes 4.977% Due 2030 [Member]", "documentation": "Senior Notes 4.977% Due 2030" } } }, "auth_ref": [] }, "tmo_SeniorNotes5.000Due2026Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes5.000Due2026Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.000% 3-Year Senior Notes due 12/5/2026", "label": "Senior Notes 5.000% Due 2026 [Member]", "documentation": "Senior Notes 5.000% Due 2026" } } }, "auth_ref": [] }, "tmo_SeniorNotes5.000Due2029Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes5.000Due2029Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.000% 5-Year Senior Notes due 1/31/2029", "label": "Senior Notes 5.000% Due 2029 [Member]", "documentation": "Senior Notes 5.000% Due 2029" } } }, "auth_ref": [] }, "tmo_SeniorNotes5.200Due2034Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes5.200Due2034Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.200% 10-Year Senior Notes due 1/31/2034", "label": "Senior Notes 5.200% Due 2034 [Member]", "documentation": "Senior Notes 5.200% Due 2034" } } }, "auth_ref": [] }, "tmo_SeniorNotes5086Due2033Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes5086Due2033Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.086% 10-Year Senior Notes, Due 8/10/2033", "label": "Senior Notes 5.086% Due 2033 [Member]", "documentation": "Senior Notes 5.086% Due 2033" } } }, "auth_ref": [] }, "tmo_SeniorNotes530Due2044Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes530Due2044Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.30% 30-Year Senior Notes, Due 2/1/2044", "label": "Senior Notes 5.30% Due 2044 [Member]", "documentation": "5.30% 30-Year Senior Notes, Due 2/1/2044 [Member]" } } }, "auth_ref": [] }, "tmo_SeniorNotes5404Due2043Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SeniorNotes5404Due2043Member", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.404% 20-Year Senior Notes, due 8/10/2043", "label": "Senior Notes 5.404% Due 2043 [Member]", "documentation": "Senior Notes 5.404% Due 2043" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period." } } }, "auth_ref": [ "r143" ] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service revenues", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r1097" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1115" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date", "documentation": "Discount rate from fair value on purchase date that participants pay for shares." } } }, "auth_ref": [ "r130" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Units, Additional Disclosures [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r693" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r693" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r691" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r691" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested, beginning balance (shares)", "periodEndLabel": "Unvested, ending balance (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r688", "r689" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested Restricted Units [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested, weighted average grant-date fair value, beginning (in dollars per share)", "periodEndLabel": "Unvested, weighted average grant-date fair value, ending (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r688", "r689" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r692" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of shares vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r695" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r692" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseScheduleofWeightedAverageAssumptionsusedintheBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual dividend", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r702" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseScheduleofWeightedAverageAssumptionsusedintheBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected stock price volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r701" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseScheduleofWeightedAverageAssumptionsusedintheBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r703" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r671", "r673", "r676", "r677", "r678", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r700", "r701", "r702", "r703", "r704" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payroll deductions", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": [ "r130" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Additional Disclosures [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r682" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r682" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r695" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Canceled/expired (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r1304" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canceled/expired (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r1304" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r684" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r694" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r130" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (shares)", "periodEndLabel": "Outstanding, ending balance (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r680", "r681" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning of period (in dollars per share)", "periodEndLabel": "Outstanding, end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r680", "r681" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r696" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and unvested expected to vest (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r696" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and unvested expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r696" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r676", "r677", "r678", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r700", "r701", "r702", "r703", "r704" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r685" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r684" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation Expense", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r670", "r679", "r698", "r699", "r700", "r701", "r704", "r712", "r713", "r714", "r715" ] }, "tmo_ShareRepurchaseProgramExciseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "ShareRepurchaseProgramExciseTax", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity", "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Excise tax from stock repurchases", "terseLabel": "Excise tax from stock repurchases", "label": "Share Repurchase Program, Excise Tax", "documentation": "Share Repurchase Program, Excise Tax" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1116" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseScheduleofWeightedAverageAssumptionsusedintheBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life of options (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r700" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r130" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r130" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r249" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r696" ] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Financing [Line Items]", "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r52" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r50" ] }, "tmo_SpecialtyDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SpecialtyDiagnosticsMember", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Specialty Diagnostics", "label": "Specialty Diagnostics [Member]", "documentation": "Specialty Diagnostics Segment" } } }, "auth_ref": [] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyPolicy", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Warranty Obligations", "label": "Standard Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": [ "r1283" ] }, "us-gaap_StandbyLettersOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandbyLettersOfCreditMember", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of Credit / Bank Guarantees", "label": "Standby Letters of Credit [Member]", "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation." } } }, "auth_ref": [ "r0", "r1282", "r1341", "r1342" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "tmo_StateNOLExpiresMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "StateNOLExpiresMember", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State NOL Expires", "label": "State NOL Expires [Member]", "documentation": "State NOL Expires" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r300", "r398", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r430", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r477", "r484", "r490", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r1089", "r1235", "r1340" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r294", "r313", "r314", "r315", "r354", "r380", "r384", "r387", "r389", "r395", "r396", "r441", "r508", "r511", "r512", "r513", "r519", "r520", "r552", "r553", "r555", "r558", "r564", "r812", "r947", "r948", "r949", "r950", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r985", "r1007", "r1027", "r1051", "r1052", "r1053", "r1054", "r1055", "r1220", "r1246", "r1254" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r31", "r60", "r297", "r335", "r336", "r337", "r359", "r360", "r361", "r364", "r372", "r374", "r394", "r445", "r451", "r565", "r709", "r710", "r711", "r743", "r744", "r777", "r779", "r780", "r781", "r782", "r784", "r794", "r826", "r828", "r829", "r830", "r831", "r833", "r863", "r931", "r932", "r933", "r955", "r1027" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails", "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r428", "r429", "r969", "r972", "r974", "r1033", "r1037", "r1040", "r1050", "r1058", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1075", "r1098", "r1126", "r1290", "r1340" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r359", "r360", "r361", "r394", "r872", "r942", "r966", "r978", "r979", "r980", "r981", "r982", "r983", "r985", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r999", "r1000", "r1001", "r1002", "r1003", "r1005", "r1008", "r1009", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1027", "r1127" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOperatingActivitiesSegmentAxis", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities [Axis]", "label": "Operating Activities [Axis]", "documentation": "Information by continuing and discontinuing operations." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r359", "r360", "r361", "r394", "r872", "r942", "r966", "r978", "r979", "r980", "r981", "r982", "r983", "r985", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r999", "r1000", "r1001", "r1002", "r1003", "r1005", "r1008", "r1009", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1027", "r1127" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r1149", "r1161", "r1171", "r1197" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of stock upon vesting of restricted stock units", "label": "Stock Issued", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r75", "r76", "r77" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued under ESPP (shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r31", "r196", "r197", "r243" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares under employees' and directors' stock plans (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r31", "r196", "r197", "r243" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r31", "r196", "r197", "r243", "r685" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares under stock plans", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r132", "r196", "r197", "r243" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Thermo Fisher Scientific Inc. shareholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r197", "r200", "r201", "r226", "r987", "r1004", "r1028", "r1029", "r1121", "r1137", "r1248", "r1259", "r1316", "r1346" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Thermo Fisher Scientific Inc. shareholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r153", "r154", "r158", "r297", "r298", "r336", "r359", "r360", "r361", "r364", "r372", "r445", "r451", "r565", "r709", "r710", "r711", "r743", "r744", "r777", "r779", "r780", "r781", "r782", "r784", "r794", "r826", "r828", "r833", "r863", "r932", "r933", "r953", "r987", "r1004", "r1028", "r1029", "r1056", "r1136", "r1248", "r1259", "r1316", "r1346" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Equity:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Income and Shareholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r240", "r353", "r551", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r785", "r1030", "r1031", "r1057" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r834", "r864" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r834", "r864" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r834", "r864" ] }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "presentation": [ "http://thermofisher.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Unrecognized Tax Benefits", "label": "Summary of Income Tax Contingencies [Table Text Block]", "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r28", "r255", "r256" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information [Abstract]", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "tmo_SuretyBondsAndOtherGuaranteesMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "SuretyBondsAndOtherGuaranteesMember", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surety Bonds and Other Guarantees", "label": "Surety Bonds and Other Guarantees [Member]", "documentation": "Surety Bonds and Other Guarantees" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r1190" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforward", "label": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r138" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Axis]", "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r137" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward, Name [Domain]", "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r137" ] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodAxis", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Period [Axis]", "label": "Tax Period [Axis]", "documentation": "Information about the period subject to enacted tax laws." } } }, "auth_ref": [] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodDomain", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Period [Domain]", "label": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": [] }, "tmo_TaxYears20252033Member": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "TaxYears20252033Member", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Years 2025-2033", "label": "Tax Years 2025-2033 [Member]", "documentation": "Tax Years 2025-2033" } } }, "auth_ref": [] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology-Based Intangible Assets", "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r45" ] }, "us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityForeignCurrencyTranslationAdjustments", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income/(loss)", "label": "Temporary Equity, Foreign Currency Translation Adjustments", "documentation": "Adjustments to temporary equity resulting from foreign currency translation adjustments." } } }, "auth_ref": [] }, "tmo_TheBindingSiteGroupMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "TheBindingSiteGroupMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The Binding Site Group", "label": "The Binding Site Group [Member]", "documentation": "The Binding Site Group" } } }, "auth_ref": [] }, "us-gaap_TimeDepositsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimeDepositsAtCarryingValue", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bank time deposits", "label": "Time Deposits, at Carrying Value", "documentation": "Any certificate of deposit or savings account held by a bank or other financial institution for a short-term specified period of time. Because of their short-term, time deposits are considered highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [ "r1238" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1182" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r1189" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tradenames", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r147" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1210" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1212" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://thermofisher.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Stock Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseGrossOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseGrossOfTax", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Included in currency translation adjustment within other comprehensive items", "label": "Derivatives used in Net Investment Hedge, Increase (Decrease), Gross of Tax", "documentation": "Amount, before tax, of increase (decrease) in the cumulative translation adjustment from gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity." } } }, "auth_ref": [ "r1317", "r1320" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1213" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1214" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1212" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1212" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1215" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1213" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r121" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock at Cost (in shares)", "periodStartLabel": "Balance, treasury stock (in shares)", "periodEndLabel": "Balance, treasury stock (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r121" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock at cost, 55,541,290 and 50,157,275 shares", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r61", "r121", "r122" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of company common stock (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r31", "r197", "r243" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of company common stock", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r31", "r121", "r243" ] }, "tmo_U.S.CommercialPaperProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "U.S.CommercialPaperProgramMember", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Commercial Paper Program", "label": "U.S. Commercial Paper Program [Member]", "documentation": "Borrowings under the company's U.S. commercial paper program" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "tmo_USEquityFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "USEquityFundsMember", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. equity funds", "label": "U S Equity Funds [Member]", "documentation": "U.S. Equity Funds" } } }, "auth_ref": [] }, "us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unconditional Purchase Obligations [Abstract]", "label": "Unconditional Purchase Obligations (Excluding Capital Stock Redemptions) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UndistributedEarningsOfForeignSubsidiaries", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undistributed earnings", "label": "Undistributed Earnings of Foreign Subsidiaries", "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile." } } }, "auth_ref": [ "r25", "r26", "r719", "r754" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1209" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r720", "r729" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Reductions for tax positions of prior years", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r730" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Settlements", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": [ "r732" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UTB, interest and penalties", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r728" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions due to acquisitions", "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition", "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions for tax positions of current year", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r731" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions for tax positions of prior years", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r730" ] }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase (decrease) in UTB", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns." } } }, "auth_ref": [ "r1306" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Closure of tax years", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r733" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "crdr": "credit", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unconditional purchase obligations", "label": "Unrecorded Unconditional Purchase Obligation", "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts)." } } }, "auth_ref": [ "r493" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r84", "r85", "r86", "r282", "r283", "r285", "r286" ] }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]", "label": "Valuation Allowance by Deferred Tax Asset [Axis]", "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences." } } }, "auth_ref": [ "r136" ] }, "tmo_ValuationAllowanceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "ValuationAllowanceRollForward", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance [Roll Forward]", "label": "Valuation Allowance [Roll Forward]", "documentation": "Valuation Allowance [Roll Forward]" } } }, "auth_ref": [] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease costs", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r853", "r1120" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted average shares (shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r379", "r389" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r377", "r389" ] }, "tmo_WeightedAverageSharesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://thermofisher.com/20231231", "localname": "WeightedAverageSharesAbstract", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares", "label": "Weighted Average Shares [Abstract]", "documentation": "Weighted Average Shares" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "12", "Subparagraph": "(f)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481410/810-10-15-12" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a-c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481097/715-30-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "60", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "740", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481141/942-740-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "740", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480135/944-740-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "80", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(4)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(a)(b)(c)", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(3)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-12" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-13" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "14", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "15", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "70", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-4" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//230/tableOfContent" }, "r219": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r220": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r221": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r222": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r223": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r224": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r225": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r226": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r227": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r228": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r229": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r230": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r231": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r232": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15" }, "r233": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r234": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r235": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r236": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r237": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r238": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r239": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r240": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r241": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r242": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r243": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r244": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "610", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//610/tableOfContent" }, "r245": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r246": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(d)(5)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r247": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(f)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r248": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r249": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//720/tableOfContent" }, "r252": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r253": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r254": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r255": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r256": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r257": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r258": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r259": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r260": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r261": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r262": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r263": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r264": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r265": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r266": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//820/tableOfContent" }, "r267": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r268": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r269": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r270": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r271": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r272": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r273": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r274": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r275": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r276": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r277": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r278": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-27" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-3" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-54B" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-5" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-21" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-5" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "275", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482094/912-275-50-4" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1009": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1011": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1012": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1013": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1015": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1016": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1018": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1019": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1020": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1021": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1022": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1023": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1024": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1025": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1026": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1027": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1028": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1029": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1030": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r1031": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r1032": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1033": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1034": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r1035": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r1036": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1037": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1038": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1039": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1040": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1041": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r1042": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r1043": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r1044": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r1045": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r1046": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r1047": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r1048": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r1049": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1050": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1051": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r1052": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r1053": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r1054": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r1055": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r1056": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r1057": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r1058": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r1059": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r1060": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r1061": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1062": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1063": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1064": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1065": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1066": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1067": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1068": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1069": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1070": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r1071": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r1072": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r1073": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r1074": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1075": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1076": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r1077": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r1078": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1079": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1080": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1081": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r1082": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r1083": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r1084": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r1085": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r1086": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r1087": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-48" }, "r1088": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r1089": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r1090": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481899/410-30-55-16" }, "r1091": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1092": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r1093": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r1094": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r1095": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r1096": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r1097": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1098": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1099": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1100": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1101": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1102": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1103": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1104": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1105": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1106": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r1107": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18" }, "r1108": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1109": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1110": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1111": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r1112": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r1113": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r1114": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r1115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1116": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1117": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r1118": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r1119": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r1120": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r1121": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r1122": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r1123": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r1124": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r1125": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1126": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r1127": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r1128": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1129": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1130": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1131": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r1132": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r1133": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1134": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2" }, "r1135": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r1136": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r1137": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r1138": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1139": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1140": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r1141": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1142": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1143": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1144": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1145": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1146": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1147": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1148": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1149": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1150": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1151": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1152": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1153": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1154": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1155": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r1156": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1157": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1158": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1159": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1160": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1161": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1162": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1163": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1164": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1165": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1166": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1167": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1168": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1169": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1170": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1171": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1172": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1173": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1174": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1175": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1176": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1177": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1178": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1179": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1180": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1181": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1182": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1183": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1184": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1185": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1186": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1187": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1188": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1189": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1190": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1191": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1192": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1193": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1194": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1195": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1196": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1197": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1198": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1199": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1200": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1201": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1202": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1203": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1204": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1205": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1206": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1207": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1208": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1209": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1210": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1211": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1212": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1213": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1214": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1215": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1216": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1217": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1218": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1219": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1220": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r1221": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1222": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1223": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479455/805-10-15-3" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-7" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-15" }, "r1342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-16" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 118 0000097745-24-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000097745-24-000007-xbrl.zip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